PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Gan, WB; Lichtman, JW				Gan, WB; Lichtman, JW			Synaptic segregation at the developing neuromuscular junction	SCIENCE			English	Article							POSTSYNAPTIC CHANGES; AXON WITHDRAWAL; SKELETAL-MUSCLE; INNERVATION; ELIMINATION; SYNAPSES; INVITRO; MATURATION; DEPRESSION; RECEPTORS	Throughout the developing nervous system, competition between axons causes the permanent removal of some synaptic connections. In mouse neuromuscular junctions at birth, terminal branches of different axons are intermingled. However, during the several weeks after birth, these branches progressively segregated into nonoverlapping compartments before the complete withdrawal of all but one axon. Segregation was caused by selective branch atrophy, detachment, and withdrawal; the axon branches that were nearest to the competitor's branches were removed before the more distant branches were removed. This progression suggests that the signals that mediate the competitive removal of synapses must decrease in potency over short distances.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Lichtman, JW (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave,Box 8108, St Louis, MO 63110 USA.							BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BALICEGORDON RJ, 1993, NEURON, V11, P801, DOI 10.1016/0896-6273(93)90110-D; BALICEGORDON RJ, 1993, J NEUROSCI, V13, P834; BANK M, 1992, J NEUROSCI, V12, P2960, DOI 10.1523/JNEUROSCI.12-08-02960.1992; BRAVIN M, 1995, J COMP NEUROL, V357, P395, DOI 10.1002/cne.903570306; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; Cash S, 1996, NEURON, V16, P745, DOI 10.1016/S0896-6273(00)80095-1; Colman H, 1997, SCIENCE, V275, P356, DOI 10.1126/science.275.5298.356; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; FOREHAND CJ, 1984, J NEUROSCI, V4, P1; GAN WB, 1995, J NEUROSCI, V15, P3243; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; JANSEN JKS, 1990, PROG NEUROBIOL, V34, P39, DOI 10.1016/0301-0082(90)90025-C; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; Penn AA, 1998, SCIENCE, V279, P2108, DOI 10.1126/science.279.5359.2108; PURVES D, 1980, SCIENCE, V210, P153, DOI 10.1126/science.7414326; PURVES D, 1985, PRINCIPLES NEURAL DE; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; RICH MM, 1989, J NEUROSCI, V9, P1781, DOI 10.1523/jneurosci.09-05-01781.1989; RILEY DA, 1977, BRAIN RES, V134, P279, DOI 10.1016/0006-8993(77)91073-3; ROTZLER S, 1991, NATURE, V349, P337, DOI 10.1038/349337a0; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972; YOUNG SR, 1986, J COMP NEUROL, V254, P425, DOI 10.1002/cne.902540402; Zou DJ, 1996, NEURON, V16, P529, DOI 10.1016/S0896-6273(00)80072-0	26	82	86	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1508	1511		10.1126/science.282.5393.1508	http://dx.doi.org/10.1126/science.282.5393.1508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822385				2022-12-28	WOS:000077110800060
J	McHutchison, JG; Gordon, SC; Schiff, ER; Shiffman, ML; Lee, WM; Rustgi, VK; Goodman, ZD; Ling, MH; Cort, S; Albrecht, JK				McHutchison, JG; Gordon, SC; Schiff, ER; Shiffman, ML; Lee, WM; Rustgi, VK; Goodman, ZD; Ling, MH; Cort, S; Albrecht, JK		Hepatitis Interventional Therapy Grp	Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA THERAPY; MULTICENTER TRIAL; VIRAL-HEPATITIS; VIRUS-RNA; HCV RNA; NON-A; METAANALYSIS; MORTALITY; EFFICACY; DURATION	Background Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy. We compared the efficacy and safety of recombinant interferon alfa-2b atone with those of a combination of interferon alfa-2b and ribavirin for the initial treatment of patients with chronic hepatitis C. Methods We randomly assigned 912 patients with chronic hepatitis C to receive standard-dose interferon alfa-2b alone or in combination with ribavirin (1000 or 1200 mg orally per day, depending on body weight) for 24 or 48 weeks. Efficacy was assessed by measurements of serum hepatitis C virus (HCV) RNA and serum aminotransferases and by liver biopsy. Results The rate of sustained virologic response (defined as an undetectable serum HCV RNA level 24 weeks after treatment was completed) was higher among patients who received combination therapy for either 24 weeks (70 of 228 patients, 31 percent) or 48 weeks (87 of 228 patients, 38 percent) than among patients who received interferon alone for either 24 weeks (13 of 231 patients, 6 percent) or 48 weeks (29 of 225 patients, 13 percent) (P<0.001 for the comparison of interferon alone with both 24 weeks and 48 weeks of combination treatment). Among patients with HCV genotype 1 infection, the best response occurred in those who were treated for 48 weeks with interferon and ribavirin. Histologic improvement was more common in patients who were treated with combination therapy for either 24 weeks (57 percent) or 48 weeks (61 percent) than in those who were treated with interferon alone for either 24 weeks (44 percent) or 48 weeks (41 percent). The drug doses had to be reduced and treatment discontinued more often in patients who were treated with combination therapy. Conclusions In patients with chronic hepatitis C, initial therapy with interferon and ribavirin was more effective than treatment with interferon alone. (N Engl J Med 1998;339:1485-92.) (C) 1998, Massachusetts Medical Society.	Scripps Res Inst, Div Gastroenterol Hepatol 203N, La Jolla, CA 92037 USA; William Beaumont Hosp, Royal Oak, MI 48072 USA; Univ Miami, Miami, FL 33152 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Georgetown Univ, Washington, DC USA; Armed Forces Inst Pathol, Washington, DC 20306 USA; Schering Plough Corp, Res Inst, Kenilworth, NJ USA	Scripps Research Institute; Beaumont Health; University of Miami; Virginia Commonwealth University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Georgetown University; United States Department of Defense; Merck & Company; Schering Plough Corporation	McHutchison, JG (corresponding author), Scripps Res Inst, Div Gastroenterol Hepatol 203N, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCRR NIH HHS [MO1-RR00833, 5MO1-RR00082, MO1-RR01066] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066, M01RR000833, M01RR000082] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; [Anonymous], 1997, HEPATOLOGY, V26, pS2; Bodenheimer HC, 1997, HEPATOLOGY, V26, P473, DOI 10.1002/hep.510260231; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; Carithers RL, 1997, HEPATOLOGY, V26, pS83, DOI 10.1002/hep.510260715; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; DETRE KM, 1996, VIRAL HEPATITIS REV, V2, P219; DIBISCEGLIE AM, 1995, ANN INTERN MED, V123, P897, DOI 10.7326/0003-4819-123-12-199512150-00001; Dusheiko G, 1996, J HEPATOL, V25, P591, DOI 10.1016/S0168-8278(96)80225-X; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; GOODMAN ZD, 1995, SEMIN LIVER DIS, V15, P70, DOI 10.1055/s-2007-1007264; HINO K, 1995, DIGEST DIS SCI, V40, P14, DOI 10.1007/BF02063935; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; KLETER GEM, 1993, ANTIMICROB AGENTS CH, V37, P595, DOI 10.1128/AAC.37.3.595; Lau DTY, 1998, GASTROENTEROLOGY, V114, pA1284, DOI 10.1016/S0016-5085(98)85211-6; LIN R, 1995, J HEPATOL, V23, P487, DOI 10.1016/0168-8278(95)80052-2; Lindsay KL, 1996, HEPATOLOGY, V24, P1034; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; McHutchison J, 1998, J HEPATOL, V29, P362, DOI 10.1016/S0168-8278(98)80052-4; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Mutchnick M., 1997, Hepatology, V26, p186A; Ning Q, 1998, J IMMUNOL, V160, P3487; ORITO E, 1995, J MED VIROL, V46, P109, DOI 10.1002/jmv.1890460205; PATTERSON JL, 1990, REV INFECT DIS, V12, P1139; Poynard T, 1996, NEW ENGL J MED, V334, P1143; Poynard T, 1996, HEPATOLOGY, V24, P778; Reichard O, 1998, LANCET, V351, P83, DOI 10.1016/S0140-6736(97)06088-1; Schalm SW, 1997, J HEPATOL, V26, P961, DOI 10.1016/S0168-8278(97)80103-1; SCHVARCZ R, 1995, J MED VIROL, V46, P43, DOI 10.1002/jmv.1890460110; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TINE F, 1991, J HEPATOL, V13, P192, DOI 10.1016/0168-8278(91)90814-R; Tong MJ, 1997, HEPATOLOGY, V26, P1640, DOI 10.1002/hep.510260637; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202	35	2866	2990	1	65	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1998	339	21					1485	1492		10.1056/NEJM199811193392101	http://dx.doi.org/10.1056/NEJM199811193392101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VT	9819446	Green Published			2022-12-28	WOS:000077051800001
J	Cardone, MH; Roy, N; Stennicke, HR; Salvesen, GS; Franke, TF; Stanbridge, E; Frisch, S; Reed, JC				Cardone, MH; Roy, N; Stennicke, HR; Salvesen, GS; Franke, TF; Stanbridge, E; Frisch, S; Reed, JC			Regulation of cell death protease caspase-9 by phosphorylation	SCIENCE			English	Article							CYTOCHROME-C; AKT PROTOONCOGENE; KINASE AKT; KI-RAS; APOPTOSIS; SURVIVAL; ACTIVATION; TRANSFORMATION; MITOCHONDRIA; 3-KINASE	Caspases are intracellular proteases that function as initiators and effectors of apoptosis. The kinase Akt and p21-Ras, an Akt activator, induced phosphorylation of pro-caspase-9 (pro-Casp9) in cells. Cytochrome c-induced proteolytic processing of pro-Casp9 was defective in cytosolic extracts from cells expressing either active Ras or Akt. Akt phosphorylated recombinant Casp9 in vitro on serine-196 and inhibited its protease activity. Mutant pro-Casp9(Ser196Ala) was resistant to Akt-mediated phosphorylation and inhibition in vitro and in cells, resulting in Akt-resistant induction of apoptosis. Thus, caspases can be directly regulated by protein phosphorylation.	Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	Sanford Burnham Prebys Medical Discovery Institute; Massachusetts Institute of Technology (MIT); Columbia University; University of California System; University of California Irvine	Reed, JC (corresponding author), Burnham Inst, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham-inst.org	Roszak, Joanna/F-4003-2010		NCI NIH HHS [CA-69515, CA-69381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069515, P01CA069381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CARDONE MH, UNPUB; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krajewska M, 1997, CANCER RES, V57, P1605; Kuwata H, 1998, BIOCHEM BIOPH RES CO, V245, P764, DOI 10.1006/bbrc.1998.8466; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; RHIM JS, 1994, P NATL ACAD SCI USA, V91, P11874, DOI 10.1073/pnas.91.25.11874; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	33	2601	2717	1	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 13	1998	282	5392					1318	1321		10.1126/science.282.5392.1318	http://dx.doi.org/10.1126/science.282.5392.1318			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812896				2022-12-28	WOS:000076982200045
J	Ishikawa, T; Kajii, S; Matsunaga, K; Hogami, T; Kohtoku, Y; Nagasawa, T				Ishikawa, T; Kajii, S; Matsunaga, K; Hogami, T; Kohtoku, Y; Nagasawa, T			A tough, thermally conductive silicon carbide composite with high strength up to 1600 degrees C in air	SCIENCE			English	Article								A sintered silicon carbide fiber-bonded ceramic, which consists of-a highly ordered, close-packed structure of very fine hexagonal columnar fibers with a thin interfacial carbon Layer between fibers, was synthesized by hot-pressing plied sheets of an amorphous silicon-aluminum-carbon-oxygen fiber prepared from an organosilicon polymer. The interior of the fiber element was composed of sintered beta-silicon carbide crystal without an obvious second phase at the grain boundary and triple points. This material showed high strength lover 600 megapascals in Longitudinal direction), fibrous fracture behavior, excellent high-temperature properties (up to 1600 degrees C in air), and high thermal conductivity (even at temperatures over 1000 degrees C).	Ube Ind Ltd, Corp Res & Dev, Ube, Yamaguchi 755, Japan	Ube Industries Ltd.	Ishikawa, T (corresponding author), Ube Ind Ltd, Corp Res & Dev, 1978-5 Kogushi, Ube, Yamaguchi 755, Japan.							DAVIES IJ, 1997, P 5 JAP INT SAMPE S, P1627; Ifflander K., 1997, CERAMIC ENG SCI P, V18, P625; Ishikawa T, 1998, NATURE, V391, P773, DOI 10.1038/35820; Kingery W.D., 1976, INTRO CERAMICS; Morscher G. N., 1997, CERAM ENG SCI P, V18, P737; RICHERSON DW, 1997, MATER ENGN, V11, P983; Takeda M., 1997, CERAMIC ENG SCI P, V18, P779; Tanaka M., 1993, CERAMIC ENG SCI P, V14, P540; Yamamura T., 1992, Japan Patent, Patent No. 1699835	9	147	152	3	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1295	1297		10.1126/science.282.5392.1295	http://dx.doi.org/10.1126/science.282.5392.1295			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812889				2022-12-28	WOS:000076982200038
J	Fero, ML; Randel, E; Gurley, KE; Roberts, JM; Kemp, CJ				Fero, ML; Randel, E; Gurley, KE; Roberts, JM; Kemp, CJ			The murine gene p27(Kip1) is haplo-insufficient for tumour suppression	NATURE			English	Article							DEPENDENT KINASE INHIBITOR; CELL LUNG-CANCER; P53-DEFICIENT MICE; MOLECULAR ANALYSIS; BREAST-CANCER; CYCLE; MUTATION; RETINOBLASTOMA; TUMORIGENESIS; ACTIVATION	p27(Kip) is a candidate human tumour-suppressor protein, because it is able to inhibit cyclin-dependent kinases and block cell proliferation(1-5). Abnormally low levels of the p27 protein are frequently found in human carcinomas, and these low levels correlate directly with both histological aggressiveness and patient mortality(6-10). However, it has not been possible to establish a causal link between p27 and tumour suppression, because only rare instances of homozygous inactivating mutations of the p27 gene have been found in human tumours(11-14). Thus, p27(Kip1) does not fulfil Knudson's 'two-mutation' criterion for a tumour-suppressor gene(15). Here we show that both p27 nullizygous and p27 heterozygous mice are predisposed to tumours in multiple tissues when challenged with gamma-irradiation or a chemical carcinogen. Therefore p27 is a multiple-tissue tumour suppressor in mice. Molecular analyses of tumours in p27 heterozygous mice show that the remaining wild-type allele is neither mutated nor silenced. Hence, p27 is haplo-insufficient for tumour suppression. The assumption that null mutations in tumour-suppressor genes are recessive excludes those genes that exhibit haplo-insufficiency.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Kemp, CJ (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.			Fero, Matthew/0000-0002-9967-4659	NCI NIH HHS [R01 CA118043, K08 CA071464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA071464, R01CA118043] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER RC, 1989, ACTA ARITH, V53, P217, DOI 10.4064/aa-53-3-217-250; BOUFFLER SD, 1995, CANCER RES, V55, P3883; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hayette S, 1997, LEUKEMIA, V11, P1696, DOI 10.1038/sj.leu.2400814; HU NP, 1994, ONCOGENE, V9, P1021; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAMATA N, 1995, CANCER RES, V55, P2266; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Spirin KS, 1996, CANCER RES, V56, P2400; Stegmaier K, 1996, CANCER RES, V56, P1413; Takeuchi S, 1996, CANCER RES, V56, P738; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5; Yasui W, 1997, JPN J CANCER RES, V88, P625, DOI 10.1111/j.1349-7006.1997.tb00428.x	30	668	681	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1998	396	6707					177	180		10.1038/24179	http://dx.doi.org/10.1038/24179			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823898	Green Accepted			2022-12-28	WOS:000077013300054
J	Margolin, A; Avants, SK; Kleber, HD				Margolin, A; Avants, SK; Kleber, HD			Investigating alternative medicine therapies in randomized controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COCAINE ADDICTION; ACUPUNCTURE; COMPLEMENTARY		Yale Univ, Sch Med, Subst Abuse Ctr, New Haven, CT 06519 USA; Columbia Univ, Ctr Addict & Subst Abuse, New York, NY USA	Yale University; Columbia University	Margolin, A (corresponding author), Yale Univ, Sch Med, Subst Abuse Ctr, 34 Pk St, New Haven, CT 06519 USA.				NIDA NIH HHS [DA00277, DA08513] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008513] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; AVANTS SK, 1995, J SUBST ABUSE TREAT, V12, P195; BORKOVEC TD, 1972, J BEHAV THER EXP PSY, V3, P257, DOI 10.1016/0005-7916(72)90045-6; BREWINGTON V, 1994, J SUBST ABUSE TREAT, V11, P289, DOI 10.1016/0740-5472(94)90040-X; BRUMBAUGH AG, 1995, TRANSFORMATION RECOV; Cassidy C M, 1995, J Altern Complement Med, V1, P19, DOI 10.1089/acm.1995.1.19; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; Cook T.C., 1979, QUASIEXPERIMENTATION; *COUNC SCI MED, 1997, SCI REV ALTERN MED, V1, P2; Culliton P D, 1996, J Altern Complement Med, V2, P149, DOI 10.1089/acm.1996.2.149; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223; KLAJNER F, 1984, ADDICT BEHAV, V9, P41, DOI 10.1016/0306-4603(84)90006-6; KRAMER MS, 1984, JAMA-J AM MED ASSOC, V252, P2739, DOI 10.1001/jama.252.19.2739; Kranz R, 1998, SCHWEIZ MED WSCHR, V128, P616; LEVINE RJ, 1994, PRINCIPLES MED BIO A, V1, P37; LEWITH GT, 1983, PAIN, V16, P111, DOI 10.1016/0304-3959(83)90202-6; LIAO SJ, 1994, PRINCIPLES PRACTICE; MARGOLIN A, 1994, J SUBST ABUSE TREAT, V11, P549, DOI 10.1016/0740-5472(94)90006-X; Margolin A, 1996, J SUBST ABUSE TREAT, V13, P471, DOI 10.1016/S0740-5472(96)00065-7; MARGOLIN A, 1993, AM J CHINESE MED, V21, P103, DOI 10.1142/S0192415X93000133; MARGOLIN A, 1995, AM J CHINESE MED, V23, P105, DOI 10.1142/S0192415X95000146; Meinert CL., 1986, CLIN TRIALS DESIGN C; National Institutes of Health, 1994, ALT MED EXP MED HOR; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; Pocock SJ., 2013, CLIN TRIALS PRACTICA; ROBERTS AH, 1993, CLIN PSYCHOL REV, V13, P373; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Shapiro A, 1984, BEHAV HLTH HDB HLTH, P371; Vickers A, 1997, INT J TECHNOL ASSESS, V13, P111, DOI 10.1017/S0266462300010278; VINCENT C, 1995, J ROY SOC MED, V88, P199; Vincent C, 1990, COMPLEMENT MED RES, V4, P8; Wiseman N, 1985, FUNDAMENTALS CHINESE; Woolf SH, 1997, ARCH FAM MED, V6, P149	35	56	57	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1626	1628		10.1001/jama.280.18.1626	http://dx.doi.org/10.1001/jama.280.18.1626			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	136GX	9820270				2022-12-28	WOS:000076852000036
J	Goodkin, DE				Goodkin, DE			Interferon beta therapy for multiple sclerosis	LANCET			English	Editorial Material									Univ Calif San Francisco, Dept Neurol, MS Ctr, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	Goodkin, DE (corresponding author), Univ Calif San Francisco, Dept Neurol, MS Ctr, San Francisco, CA 94115 USA.							DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Petkau J, 1997, MULT SCLER, V3, P402, DOI 10.1177/135245859700300610; Pozzilli C, 1996, J NEUROL NEUROSUR PS, V61, P251, DOI 10.1136/jnnp.61.3.251; Stone LA, 1997, NEUROLOGY, V49, P862, DOI 10.1212/WNL.49.3.862; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502	8	47	48	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1486	1487		10.1016/S0140-6736(98)00057-9	http://dx.doi.org/10.1016/S0140-6736(98)00057-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820292				2022-12-28	WOS:000076862300002
J	Raju, TNK				Raju, TNK			The Nobel chronicles - 1924: William Einthoven (1860-1927)	LANCET			English	Biographical-Item									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1560	1560		10.1016/S0140-6736(05)60383-2	http://dx.doi.org/10.1016/S0140-6736(05)60383-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820341				2022-12-28	WOS:000076862300074
J	Jones, AM; Im, KH; Savka, MA; Wu, MJ; DeWitt, NG; Shillito, R; Binns, AN				Jones, AM; Im, KH; Savka, MA; Wu, MJ; DeWitt, NG; Shillito, R; Binns, AN			Auxin-dependent cell expansion mediated by overexpressed auxin-binding protein 1	SCIENCE			English	Article							PLASMA-MEMBRANE; MAIZE; PROTOPLASTS; STIMULATION; PLANTS; SITE; WALL	To test the hypothesis that auxin-binding protein 1 (ABP1) is a receptor controlling auxin-mediated plant cell expansion, ABP1 complementary DNAs were expressed in a controllable fashion in tobacco plants and constitutively in maize cell lines. Induction of Arabidopsis ABP1 expression in tobacco leaf strips resulted in an increased capacity for auxin-mediated cell expansion, whereas induction of ABP1 in intact plants resulted in leaves with a normal morphology, but larger cells. Similarly, constitutive expression of maize ABP1 in maize cell lines conferred on them the capacity to respond to auxin by increasing cell size. These results support a role of ABP1 as an auxin receptor controlling plant growth.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; AgrEvo USA, Agr Res Ctr, Pikeville, NC 27863 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania	Jones, AM (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.	alan_jones@unc.edu	Shillito, Ray/AAK-3834-2021	Shillito, Ray/0000-0003-0485-3353	NIGMS NIH HHS [GM7369-06] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; BARBIERBRYGOO H, 1991, PLANT J, V1, P83, DOI 10.1111/j.1365-313X.1991.00083.x; BLATT MR, 1993, ANNU REV PLANT PHYS, V44, P543, DOI 10.1146/annurev.pp.44.060193.002551; BROWN JC, 1994, J BIOL CHEM, V269, P21136; CHU CC, 1975, SCI SINICA, V18, P659; DIEKMANN W, 1995, P NATL ACAD SCI USA, V92, P3425, DOI 10.1073/pnas.92.8.3425; EDGERTON MD, 1994, PHYTOCHEMISTRY, V35, P1111, DOI 10.1016/S0031-9422(00)94807-6; GATZ C, 1992, PLANT J, V2, P397, DOI 10.1046/j.1365-313X.1992.t01-37-00999.x; HARNDEN D, 1995, J PLANT GROWTH REGUL, V14, P109, DOI 10.1007/BF00203122; HEMERLY A, 1995, EMBO J, V14, P3925, DOI 10.1002/j.1460-2075.1995.tb00064.x; JONES AM, 1993, PLANT PHYSIOL, V101, P595, DOI 10.1104/pp.101.2.595; JONES AM, 1989, P NATL ACAD SCI USA, V86, P6153, DOI 10.1073/pnas.86.16.6153; JONES AM, 1994, ANNU REV PLANT PHYS, V45, P393, DOI 10.1146/annurev.pp.45.060194.002141; KAPLAN DR, 1991, BIOSCIENCE, V41, P693, DOI 10.2307/1311764; Keller CP, 1997, PLANT PHYSIOL, V113, P603, DOI 10.1104/pp.113.2.603; KRAMER C, 1993, PLANTA, V190, P454, DOI 10.1007/BF00224783; KUTSCHERA U, 1987, P NATL ACAD SCI USA, V84, P2747, DOI 10.1073/pnas.84.9.2747; NAPIER RM, 1988, PLANTA, V176, P519, DOI 10.1007/BF00397659; Napier RM, 1995, J EXP BOT, V46, P1787, DOI 10.1093/jxb/46.12.1787; RAY PM, 1977, PLANT PHYSIOL, V60, P585, DOI 10.1104/pp.60.4.585; RAY PM, 1992, CURRENT TOPICS PLANT, V11, P18; ROGERS SG, 1986, METHOD ENZYMOL, V118, P627; RUCK A, 1993, PLANT J, V4, P41, DOI 10.1046/j.1365-313X.1993.04010041.x; SHILLITO RD, 1989, BIO-TECHNOL, V7, P581, DOI 10.1038/nbt0689-581; SHIMOMURA S, 1986, J BIOCHEM-TOKYO, V99, P1513, DOI 10.1093/oxfordjournals.jbchem.a135621; TILLMANN U, 1989, EMBO J, V8, P2463, DOI 10.1002/j.1460-2075.1989.tb08381.x	26	216	239	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1114	1117		10.1126/science.282.5391.1114	http://dx.doi.org/10.1126/science.282.5391.1114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804548				2022-12-28	WOS:000076887700048
J	Hagar, RE; Burgstahler, AD; Nathanson, MH; Ehrlich, BE				Hagar, RE; Burgstahler, AD; Nathanson, MH; Ehrlich, BE			Type III InsP(3) receptor channel stays open in the presence of increased calcium	NATURE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; PANCREATIC ACINAR-CELLS; RAT HEPATOCYTES; IDENTIFICATION; TRISPHOSPHATE; OSCILLATIONS; LOCALIZATION; NUCLEOTIDES; CEREBELLUM; RELEASE	The inositol 1,4,5-trisphosphate receptor (InsP(3)R) is the mai(n) calcium(Ca2+) release channel in most tissues. Three isoforms have been identified(1-6), but only types I and II InsP(3)R have been characterized(7,8). Here we examine the functional properties of the type In InsP(3)R because this receptor is restricted to the trigger zone from which Ca2+ waves originate(9-11) and it has distinctive InsP(3)-binding properties(12,13). We find that type III InsP(3)R forms Ca2+ channels with single-channel currents that are similar to those of type I InsP(3)R; however, the open probability of type III InsP(3)R isoform increases monotonically with increased cytoplasmic Ca2+ concentration, whereas the type I isoform has a bell-shaped dependence on cytoplasmic Ca2+. The properties of type III InsP(3)R provide positive feedback as Ca2+ is released; the lack of negative feedback allows complete Ca2+ release from intracellular stores. Thus, activation of type III InsP(3)R in cells that express only this isoform results in a single transient, but global, increase in the concentration of cytosolic Ca2+. The bell-shaped Ca2+-dependence awe of type I InsP(3)R is ideal for supporting Ca2+ oscillations, whereas the properties of type III InsP(3)R are better suited to signal initiation.	Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Dept Med, New Haven, CT 06520 USA; Yale Univ, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Univ Connecticut, Ctr Hlth, Dept Physiol, Farmington, CT 06030 USA	Yale University; Yale University; Yale University; Yale University; University of Connecticut	Hagar, RE (corresponding author), Yale Univ, Dept Pharmacol, 333 Cedar st, New Haven, CT 06520 USA.	rob@hermen.med.yale.edu	/AAX-8408-2021	/0000-0001-9657-9704	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061747, R01DK045710] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK045710-06A2, R01 DK061747, R01 DK061747-01A1, R01 DK045710] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; Bootman MD, 1997, CELL, V91, P367, DOI 10.1016/S0092-8674(00)80420-1; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Cao DR, 1997, J CELL SCI, V110, P497; Cardy TJA, 1997, BIOCHEM J, V328, P785, DOI 10.1042/bj3280785; DeLisle S, 1996, AM J PHYSIOL-CELL PH, V270, pC1255; DIXON CJ, 1990, BIOCHEM J, V269, P499, DOI 10.1042/bj2690499; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Kaftan EJ, 1997, J GEN PHYSIOL, V110, P529, DOI 10.1085/jgp.110.5.529; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; Morgan JM, 1996, PFLUG ARCH EUR J PHY, V431, P697, DOI 10.1007/s004240050054; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; PARKER I, 1996, J PHYSL, V49, P663; Perez PJ, 1997, J BIOL CHEM, V272, P23961, DOI 10.1074/jbc.272.38.23961; PETERSEN CCH, 1991, FEBS LETT, V293, P179, DOI 10.1016/0014-5793(91)81181-7; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591	30	223	225	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 5	1998	396	6706					81	84		10.1038/23954	http://dx.doi.org/10.1038/23954			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136HE	9817204	Green Accepted			2022-12-28	WOS:000076852700058
J	Baird, IM				Baird, IM			Risks of heart-valve abnormalities with appetite suppressants	LANCET			English	Editorial Material											Baird, IM (corresponding author), 1 Fairbourne, Surrey KT11 2BT, England.							Cannistra LB, 1998, NEW ENGL J MED, V339, P771, DOI 10.1056/NEJM199809103391112; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Devereux RB, 1998, NEW ENGL J MED, V339, P765, DOI 10.1056/NEJM199809103391109; GARROW J, 1998, BRIT MED J, V317, P8300; Husten L, 1998, LANCET, V352, P885, DOI 10.1016/S0140-6736(05)60016-5; Jick H, 1998, NEW ENGL J MED, V339, P719, DOI 10.1056/NEJM199809103391102; JOSEFSON D, 1997, BRIT MED J, V315, P1327; Khan MA, 1998, NEW ENGL J MED, V339, P713, DOI 10.1056/NEJM199809103391101; Manson JE, 1996, NEW ENGL J MED, V335, P659, DOI 10.1056/NEJM199608293350910; ROBOLIO PA, 1995, CIRCULATION, V92, P980; Weissman NJ, 1998, NEW ENGL J MED, V339, P725, DOI 10.1056/NEJM199809103391103	11	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1403	1404		10.1016/S0140-6736(05)61258-5	http://dx.doi.org/10.1016/S0140-6736(05)61258-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9807983				2022-12-28	WOS:000076719500003
J	Nygren, E; Wyatt, JC; Wright, P				Nygren, E; Wyatt, JC; Wright, P			Helping clinicians to find data and avoid delays	LANCET			English	Article							MEDICAL RECORD	One major criticism of paper medical records is the time and effort required to find data items or to gain an overview. Computerisation does not necessarily help. To help clinicians find data faster and with less effort, everyone designing and writing in records needs to understand how and why we search records and the design features that make searching easier. This paper describes how clinicians search medical records and how to improve record design, whether on paper or computer, to help clinicians find all the data they need without delay.	UCL, Sch Publ Policy, London WC1H 9EZ, England; Uppsala Univ, Dept Informat Sci, Uppsala, Sweden; Cardiff Univ, Sch Psychol, Cardiff, S Glam, Wales	University of London; University College London; Uppsala University; Cardiff University	Wyatt, JC (corresponding author), UCL, Sch Publ Policy, 29 Tavistock Sq, London WC1H 9EZ, England.	jeremy.wyatt@ucl.ac.uk	Wyatt, Jeremy/F-8160-2010	Wyatt, Jeremy/0000-0001-7008-1473				Berger John, 1980, LOOKING; Dillon A., 1989, Interacting with Computers, V1, P183, DOI 10.1016/0953-5438(89)90025-8; DIXON N, 1980, PRECONSCIOUS PROCESS; Friedman C.P., 1997, EVALUATION METHODS M, P41; FRIES JF, 1974, MED CARE, V12, P871, DOI 10.1097/00005650-197410000-00006; HARTLEY J, 1981, IEEE T PROF COMMUN, V24, P17, DOI 10.1109/TPC.1981.6447818; HARTLEY J, IN PRESS PROCESSING; Kaptelinin V., 1993, P HUM FACT COMP SYST, P183; LJUNGKVIST G, 1976, GRUNDJOURNAL; Norman D. A., 1990, DESIGN EVERYDAY THIN; Nygren E., 1992, CHI '92 Conference Proceedings. ACM Conference on Human Factors in Computing Systems. Striking a Balance, P235, DOI 10.1145/142750.142800; NYGREN E, 1992, COMPUT METH PROG BIO, V39, P1, DOI 10.1016/0169-2607(92)90053-A; NYGREN E, 1996, COMPREHENSIVE SUMMAR, P118; STAGGERS N, 1994, NURS RES, V43, P144; Tognazzini B., 1992, TOG INTERFACE; TUFTE ER, 1990, ENSISIONING INFORMAT; WRIGHT P, 1973, VISIBLE LANG, V7, P351; WRIGHT P, 1995, INFORMATION DESIGN J, V8, P82; Wyatt JC, 1998, LANCET, V352, P1375, DOI 10.1016/S0140-6736(97)08306-2; WYATT JC, 1994, LANCET, V344, P1543, DOI 10.1016/S0140-6736(94)90353-0; [No title captured]	21	71	71	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1462	1466		10.1016/S0140-6736(97)08307-4	http://dx.doi.org/10.1016/S0140-6736(97)08307-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9808009				2022-12-28	WOS:000076719500042
J	Bindman, AB; Osmond, D; Hecht, FM; Lehman, JS; Vranizan, K; Keane, D; Reingold, A				Bindman, AB; Osmond, D; Hecht, FM; Lehman, JS; Vranizan, K; Keane, D; Reingold, A		MESH Study Grp	Multistate evaluation of anonymous HIV testing and access to medical care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NORTH-CAROLINA	Context.-Infection with the human immunodeficiency virus (HIV) is the only infectious disease for which anonymous testing is publicly funded, an exception that has been controversial. Objective.-To assess whether anonymous HIV testing was associated with earlier HIV testing and HIV-related medical care than confidential HIV testing. Design.-Retrospective cohort. Setting.-Arizona, Colorado, Missouri, New Mexico, North Carolina, Oregon, and Texas. Participants.-Probability sample of 835 new acquired immunodeficiency syndrome (AIDS) cases reported to the state health department's HIV/AIDS Reporting System from May 1995 through December 1996. All had responded to the AIDS Patient Survey; 643 had been tested confidentially for HIV, and 192 had been tested anonymously. Main Outcome Measures.-First CD4(+) cell count; number of days from HIV-positive test result to first HIV-related medical care, from first HIV-related medical care to AIDS, and from first HIV-positive test result to AIDS. Results.-Persons tested anonymously sought testing and medical care earlier in the course of HIV disease than did persons tested confidentially. Mean first CD4(+) cell count was 0.427x10(9)/L in persons tested anonymously vs 0.267x10(9)/L in persons tested confidentially. Persons tested anonymously experienced an average of 918 days in HIV-related medical care before an AIDS diagnosis vs 531 days for persons tested confidentially. The mean time from learning they were HIV positive to the diagnosis of AIDS was 1246 days for persons tested anonymously vs 718 days for persons tested confidentially. After adjustment for the subject's age, sex, race/ethnicity, education, income, insurance status, HIV exposure group, whether the respondent had a regular source of care or symptoms at the time of the HIV test, and state residence, anonymous testing remained significantly associated with earlier entry into medical care (P<.001). Conclusion.-Anonymous testing contributes to early HIV testing and medical care.	San Francisco Gen Hosp, Primary Care Res Ctr, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Div Aids, San Francisco, CA 94110 USA; Univ San Francisco, Dept Med, San Francisco, CA 94117 USA; Univ San Francisco, Dept Biostat & Epidemiol, San Francisco, CA 94117 USA; Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Atlanta, GA USA; Univ Calif Berkeley, Dept Epidemiol, Berkeley, CA 94720 USA	San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; University of San Francisco; University of San Francisco; Centers for Disease Control & Prevention - USA; University of California System; University of California Berkeley	Bindman, AB (corresponding author), San Francisco Gen Hosp, Primary Care Res Ctr, Bldg 90,Ward 95,1001 Potrero Ave, San Francisco, CA 94110 USA.			Hecht, Frederick/0000-0002-5782-1171	BHP HRSA HHS [DHHS 282-92-0048] Funding Source: Medline	BHP HRSA HHS		Cunningham WE, 1997, J CLIN EPIDEMIOL, V50, P829, DOI 10.1016/S0895-4356(97)00061-9; FEHRS L, 1988, LANCET, V332, P379; HertzPicciotto I, 1996, AM J PUBLIC HEALTH, V86, P1446, DOI 10.2105/AJPH.86.10.1446; HIRANO D, 1994, AM J PUBLIC HEALTH, V84, P2008, DOI 10.2105/AJPH.84.12.2008; Hoxworth Tamara, 1994, AIDS Public Policy J, V9, P182; Kassler WJ, 1997, J ACQ IMMUN DEF SYND, V14, P281, DOI 10.1097/00042560-199703010-00013; KEGELES SM, 1990, AIDS, V4, P585, DOI 10.1097/00002030-199006000-00016; RICHARDSON L, 1997, NY TIMES        0821; Rosenbaum S, 1997, HEALTH AFFAIR, V16, P90, DOI 10.1377/hlthaff.16.1.90; Steinbrook LD, 1997, NEW ENGL J MED, V337, P779, DOI 10.1056/NEJM199709113371109; WORTLEY PM, 1995, AIDS, V9, P487, DOI 10.1097/00002030-199509050-00011	11	65	66	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	1998	280	16					1416	1420		10.1001/jama.280.16.1416	http://dx.doi.org/10.1001/jama.280.16.1416			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	130YA	9801001	Bronze			2022-12-28	WOS:000076546900036
J	Stratigos, AJ; Arndt, KA; Dover, JS				Stratigos, AJ; Arndt, KA; Dover, JS			Advances in cutaneous aesthetic surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LIPOSUCTION; IMPLANTS; TERM; SKIN		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Dermatol, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Dover, JS (corresponding author), Beth Israel Deaconess Med Ctr, Cosmet Surg & Laser Ctr, 25 Boylston St,Suite 104, Chestnut Hill, MA 02167 USA.							ADAMSON PA, 1990, J OTOLARYNGOL, V19, P267; Bernstein LJ, 1997, DERMATOL SURG, V23, P519, DOI 10.1111/j.1524-4725.1997.tb00677.x; Carruthers A, 1996, J AM ACAD DERMATOL, V34, P788, DOI 10.1016/S0190-9622(96)90016-X; CLARK DP, 1989, J AM ACAD DERMATOL, V21, P992, DOI 10.1016/S0190-9622(89)70288-7; Fitzpatrick RE, 1996, ARCH DERMATOL, V132, P395, DOI 10.1001/archderm.132.4.395; Goldberg DJ, 1998, DERMATOL SURG, V24, P619, DOI 10.1111/j.1524-4725.1998.tb04217.x; Grover R, 1998, BRIT J PLAST SURG, V51, P8, DOI 10.1016/S0007-1226(97)90090-4; Hruza GJ, 1996, ARCH DERMATOL, V132, P451, DOI 10.1001/archderm.132.4.451; Kauvar ANB, 1996, DERMATOL SURG, V22, P343, DOI 10.1111/j.1524-4725.1996.tb00328.x; KELLY K, 1998, LASERS SURG MED S, V10, P38; KLEIN JA, 1990, DERMATOL CLIN, V8, P425, DOI 10.1016/S0733-8635(18)30474-1; Maxwell GP, 1998, PLAST RECONSTR SURG, V101, P189, DOI 10.1097/00006534-199801000-00034; MOLE B, 1992, PLAST RECONSTR SURG, V90, P200, DOI 10.1097/00006534-199290020-00007; Olenius M, 1998, AESTHET PLAST SURG, V22, P97, DOI 10.1007/s002669900172; PINSKI KS, 1992, J DERMATOL SURG ONC, V18, P179, DOI 10.1111/j.1524-4725.1992.tb02795.x; West TB, 1998, DERMATOL SURG, V24, P510, DOI 10.1111/j.1524-4725.1998.tb04198.x; ZUBER M, 1993, NEUROLOGY, V43, P1715, DOI 10.1212/WNL.43.9.1715	17	2	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	1998	280	16					1397	1398		10.1001/jama.280.16.1397	http://dx.doi.org/10.1001/jama.280.16.1397			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130YA	9800989				2022-12-28	WOS:000076546900018
J	Berger, A				Berger, A			Science commentary: Protection against malaria	BRITISH MEDICAL JOURNAL			English	Editorial Material							MEFLOQUINE											Barrett PJ, 1996, BRIT MED J, V313, P525, DOI 10.1136/bmj.313.7056.525; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W	2	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1508	1508		10.1136/bmj.317.7171.1508	http://dx.doi.org/10.1136/bmj.317.7171.1508			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831585	Green Published			2022-12-28	WOS:000077338300037
J	Rubin, P				Rubin, P			Drug treatment during pregnancy	BRITISH MEDICAL JOURNAL			English	Review							FIRST-TRIMESTER; WOMEN; HYPERTENSION; ATENOLOL; EXPOSURE; RISKS; FETUS		Queens Med Ctr, Sch Med, Fac Med & Hlth Sci, Deans Off, Nottingham NG7 2UH, England	University of Nottingham	Rubin, P (corresponding author), Queens Med Ctr, Sch Med, Fac Med & Hlth Sci, Deans Off, Nottingham NG7 2UH, England.							BEROYZ G, 1994, LANCET, V343, P619; BRIGGS GG, 1994, DRUGS PREGNANCY LACT, P808; Butters L, 1990, Midwifery, V6, P146, DOI 10.1016/S0266-6138(05)80172-X; BUTTERS L, 1990, BMJ-BRIT MED J, V301, P587, DOI 10.1136/bmj.301.6752.587; DESWIET M, 1977, NEW ENGL J MED, V297, P1471; Feldkamp M, 1997, JAMA-J AM MED ASSOC, V277, P1193; FITZSIMONS R, 1986, J ALLERGY CLIN IMMUN, V78, P349, DOI 10.1016/S0091-6749(86)80088-4; GINSBERG JS, 1989, THROMB HAEMOSTASIS, V61, P197; GINSBERG JS, 1994, LANCET, V344, P1171; HANRETTY KP, 1995, PRESCRIBING PREGNANC; HANSON JW, 1976, J PEDIATR-US, V89, P662, DOI 10.1016/S0022-3476(76)80414-3; JONES KL, 1989, NEW ENGL J MED, V320, P1661, DOI 10.1056/NEJM198906223202505; KALLEN B, 1983, ACTA PSYCHIAT SCAND, V68, P134, DOI 10.1111/j.1600-0447.1983.tb06991.x; KUHNZ W, 1988, DEV PHARMACOL THERAP, V11, P147, DOI 10.1159/000457682; LAEGREID L, 1989, J PEDIATR-US, V114, P126, DOI 10.1016/S0022-3476(89)80619-5; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LOW LCK, 1978, LANCET, V2, P370; MOISE KJ, 1993, AM J OBSTET GYNECOL, V168, P1350, DOI 10.1016/S0002-9378(11)90763-7; ORME MLE, 1985, BRIT MED J, V291, P918, DOI 10.1136/bmj.291.6500.918; RAMANWILMS L, 1995, OBSTET GYNECOL, V85, P141, DOI 10.1016/0029-7844(94)00341-A; REDMAN CWG, 1976, LANCET, V2, P754; ROSA FW, 1984, AM J OBSTET GYNECOL, V149, P99, DOI 10.1016/0002-9378(84)90308-9; RUBIN PC, 1983, LANCET, V1, P431; RUBIN PC, 1986, BRIT MED J, V292, P81, DOI 10.1136/bmj.292.6513.81; RUBIN PC, 1995, PRECRIBING PREGNANCY, P1; SIBAI BM, 1993, NEW ENGL J MED, V329, P1213, DOI 10.1056/NEJM199310213291701; STUART MJ, 1982, NEW ENGL J MED, V307, P909, DOI 10.1056/NEJM198210073071502; 1976, BMJ, V2, P1155; 1988, LANCET, V2, P1040	29	19	22	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1503	1506		10.1136/bmj.317.7171.1503	http://dx.doi.org/10.1136/bmj.317.7171.1503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831583	Green Published			2022-12-28	WOS:000077338300035
J	Furlan, M; Robles, R; Galbusera, M; Remuzzi, G; Kyrle, PA; Brenner, B; Krause, M; Scharrer, I; Aumann, V; Mittler, U; Solenthaler, M; Lammle, B				Furlan, M; Robles, R; Galbusera, M; Remuzzi, G; Kyrle, PA; Brenner, B; Krause, M; Scharrer, I; Aumann, V; Mittler, U; Solenthaler, M; Lammle, B			Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VONWILLEBRAND-FACTOR; ENDOTHELIAL-CELLS; PLASMA-EXCHANGE; VWF MULTIMERS; PATHOPHYSIOLOGY; ABNORMALITIES; CLEAVAGE; FORMS	Background Thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome are severe microvascular disorders of platelet clumping with similar signs and symptoms. Unusually large multimers of von Willebrand factor, capable of agglutinating circulating platelets under high shear stress, occur in the two conditions. We investigated the prevalence of von Willebrand factor-cleaving protease deficiency in patients with familiar and nonfamilial forms of these disorders. Methods Plasma samples were obtained from 53 patients with thrombotic thrombocytopenic purpura or hemolytic-uremic syndrome. Von Willebrand factor-cleaving protease was assayed in diluted plasma samples with purified normal von Willebrand factor as the substrate. The extent of the degradation of von Willebrand factor was assessed by electrophoresis in sodium dodecyl sulfate-agarose gels and immunoblotting. To determine whether an inhibitor of von Willebrand factor-cleaving protease was present, we measured the protease activity in normal plasma after incubation with plasma from the patients. Results We examined 30 patients with thrombotic thrombocytopenic purpura and 23 patients with the hemolytic-uremic syndrome. Of 24 patients with nonfamilial thrombotic thrombocytopenic purpura, 20 had severe and 4 had moderate protease deficiency during an acute event. An inhibitor found in 20 of these patients was shown to be IgG in five of five tested plasma samples. Of 13 patients with nonfamilial hemolytic-uremic syndrome, 11 had normal levels of activity of von Willebrand factor-cleaving protease during the acute episode, whereas in 2 patients, the activity was slightly decreased. All 6 patients with familial thrombotic thrombocytopenic purpura lacked von Willebrand factor-cleaving protease activity but had no inhibitor, whereas all 10 patients with familial hemolytic-uremic syndrome had normal protease activity. In vitro proteolytic degradation of von Willebrand factor by the protease was studied in 53 patients with familial and 7 patients with nonfamilial hemolytic-uremic syndrome and was normal in all 12 patients. Conclusions Nonfamilial thrombotic thrombocytopenic purpura is due to an inhibitor of von Willebrand factor-cleaving protease, whereas the familial form seems to be caused by a constitutional deficiency of the protease. Patients with the hemolytic-uremic syndrome do not have a deficiency of von Willebrand factor-cleaving protease or a defect in von Willebrand factor that leads to its resistance to protease. (N Engl J Med 1998;339:1578-84.) (C)1998, Massachusetts Medical Society.	Univ Hosp Bern, Inselspital, Cent Hematol Lab, CH-3010 Bern, Switzerland; Mario Negri Inst Pharmacol Res, I-24100 Bergamo, Italy; Gen Hosp, Dept Internal Med 1, Vienna, Austria; Univ Hosp Frankfurt, Frankfurt, Germany; Univ Magdeburg, Childrens Hosp, D-39106 Magdeburg, Germany	University of Bern; University Hospital of Bern; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Otto von Guericke University; University Hospital Magdeburg	Furlan, M (corresponding author), Univ Hosp Bern, Inselspital, Cent Hematol Lab, CH-3010 Bern, Switzerland.		Laemmle, Bernhard/AAJ-1216-2020; Galbusera, Miriam/AAA-7369-2020; Scharrer, Inge/N-2999-2013; Remuzzi, Giuseppe/V-9766-2017	Laemmle, Bernhard/0000-0003-4538-5154; Galbusera, Miriam/0000-0003-2434-7343; Remuzzi, Giuseppe/0000-0002-6194-3446				BELL WR, 1991, NEW ENGL J MED, V325, P398, DOI 10.1056/NEJM199108083250605; BOBBIOPALLAVICINI E, 1994, EUR J HAEMATOL, V52, P222; CHARBA D, 1993, AM J HEMATOL, V42, P268, DOI 10.1002/ajh.2830420306; Chow TW, 1998, AM J HEMATOL, V57, P293, DOI 10.1002/(SICI)1096-8652(199804)57:4<293::AID-AJH5>3.3.CO;2-R; DENT JA, 1990, P NATL ACAD SCI USA, V87, P9508; DENT JA, 1990, P NATL ACAD SCI USA, V87, P6306, DOI 10.1073/pnas.87.16.6306; FRANGOS JA, 1989, AM J PHYSIOL, V256, pH1635, DOI 10.1152/ajpheart.1989.256.6.H1635; Furlan M, 1997, BLOOD, V89, P3097, DOI 10.1182/blood.V89.9.3097; Furlan M, 1998, BLOOD, V91, P2839, DOI 10.1182/blood.V91.8.2839.2839_2839_2846; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Gaddis TG, 1997, AM J HEMATOL, V55, P55, DOI 10.1002/(SICI)1096-8652(199706)55:2<55::AID-AJH1>3.0.CO;2-1; GASSER C, 1955, Schweiz Med Wochenschr, V85, P905; HOFFKES HG, 1995, SEMIN THROMB HEMOST, V21, P161, DOI 10.1055/s-2007-1000391; MOAKE JL, 1984, BLOOD, V64, P592; MOAKE JL, 1985, BLOOD, V65, P1232; MOAKE JL, 1994, LANCET, V343, P393, DOI 10.1016/S0140-6736(94)91227-0; MOAKE JL, 1985, AM J HEMATOL, V20, P73, DOI 10.1002/ajh.2830200110; Moake JL, 1997, SEMIN HEMATOL, V34, P83; MOAKE JL, 1986, J CLIN INVEST, V78, P1456, DOI 10.1172/JCI112736; Moschcowitz E., 1924, P NY PATHOL SOC, V24, P21; PHILLIPS MD, 1993, THROMB HAEMOSTASIS, V69, P1199; Ruggenenti P, 1996, EUR J HAEMATOL, V56, P191; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235	23	1294	1345	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 26	1998	339	22					1578	1584		10.1056/NEJM199811263392202	http://dx.doi.org/10.1056/NEJM199811263392202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZU	9828245				2022-12-28	WOS:000077176100002
J	Leach, RM; Treacher, DF				Leach, RM; Treacher, DF			ABC of oxygen - Oxygen transport - 2. Tissue hypoxia	BRITISH MEDICAL JOURNAL			English	Review									Guys & St Thomas Hosp Trust, Dept Intens Care, London SE1 9RT, England; Guys & St Thomas Hosp Trust, Dept Resp Med, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	Leach, RM (corresponding author), Guys & St Thomas Hosp Trust, Dept Intens Care, London SE1 9RT, England.							Carlet J, 1996, AM J RESP CRIT CARE, V154, P1573; Edwards J. D., 1993, OXYGEN TRANSPORT PRI; LEACH RM, 1992, THORAX, V47, P971, DOI 10.1136/thx.47.11.971	3	92	93	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1370	1373		10.1136/bmj.317.7169.1370	http://dx.doi.org/10.1136/bmj.317.7169.1370			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812940	Green Published			2022-12-28	WOS:000077081600028
J	Sarkar, PS; Chang, HC; Boudi, FB; Reddy, S				Sarkar, PS; Chang, HC; Boudi, FB; Reddy, S			CTG repeats show bimodal amplification in E-coli	CELL			English	Article							ESCHERICHIA-COLI; DISEASE GENES; TRINUCLEOTIDE REPEAT; TRIPLET REPEATS; DNA PALINDROMES; LAGGING-STRAND; IN-VITRO; INSTABILITY; REPLICATION; RECOMBINATION	Trinucleotide repeats in human genetic disorders showing anticipation follow two inheritance patterns as a function of length. Inheritance of 35-50 repeats show incremental changes, white tracts greater than 80 repeats show large saltatory expansions. We describe a bacterial system that recapitulates this striking bimodal pattern of CTG amplification. Incremental expansions predominate in CTG tracts greater than or equal to Okazaki fragment size, while saltatory expansions increase in repeat tracts greater than or equal to Okazaki fragment size. CTG amplification requires loss of SbcC, a protein that modulates cleavage of single-stranded DNA and degradation of duplex DNA from double-strand breaks. These results suggest that noncanonical single strand-containing secondary structures in Okazaki fragments and/or double-strand breaks in repeat tracts are intermediates in CTG amplification.	Univ So Calif, Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA	University of Southern California	Reddy, S (corresponding author), Univ So Calif, Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA.	sitaredd@hsc.usc.edu						Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; BARCELO JM, 1993, HUM MOL GENET, V2, P705, DOI 10.1093/hmg/2.6.705; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BLUMENTHAL AB, 1977, CELL, V12, P183, DOI 10.1016/0092-8674(77)90196-9; BOUDI FB, 1989, HUM GENET, V84, P293; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; DAVIES J, 1992, J MED GENET, V29, P766, DOI 10.1136/jmg.29.11.766; DePamphilis ML, 1995, METHOD ENZYMOL, V262, P628; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; GACY GA, 1995, CELL, V81, P533; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Gourdon G, 1997, NAT GENET, V15, P190, DOI 10.1038/ng0297-190; GREENER A, 1990, STRATEGIES MOL BIOL, V3, P5; HUTCHINSON F, 1996, ESCHERICHIA COLI SAL, V2, P2225; JANSEN G, 1992, NAT GENET, V1, P261, DOI 10.1038/ng0792-261; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; NAOM IS, 1989, NUCLEIC ACIDS RES, V17, P8033, DOI 10.1093/nar/17.20.8033; OKAZAKI R, 1968, P NATL ACAD SCI USA, V59, P598, DOI 10.1073/pnas.59.2.598; Ordway JM, 1996, BIOTECHNIQUES, V21, P609; Pohjanpelto P, 1996, EMBO J, V15, P1193, DOI 10.1002/j.1460-2075.1996.tb00458.x; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; SETLOW P, 1972, J BIOL CHEM, V247, P224; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Trinh T, 1994, FOCUS, V16, P78; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WU CA, 1992, J BIOL CHEM, V267, P4030	36	56	57	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1998	95	4					531	540		10.1016/S0092-8674(00)81620-7	http://dx.doi.org/10.1016/S0092-8674(00)81620-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827805	Bronze			2022-12-28	WOS:000077049400011
J	Patchell, RA; Tibbs, PA; Regine, WF; Dempsey, RJ; Mohiuddin, M; Kryscio, RJ; Markesbery, WR; Foon, KA; Young, B				Patchell, RA; Tibbs, PA; Regine, WF; Dempsey, RJ; Mohiuddin, M; Kryscio, RJ; Markesbery, WR; Foon, KA; Young, B			Postoperative radiotherapy in the treatment of single metastases to the brain - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTRAST-ENHANCED MR; RADIATION-THERAPY; CRANIAL IRRADIATION; RESECTION; FAILURE; MELANOMA; SURGERY; CT	Context.-For the treatment of a single metastasis to the brain, surgical resection combined with postoperative radiotherapy is more effective than treatment with radiotherapy alone. However, the efficacy of postoperative radiotherapy after complete surgical resection has not been established. Objective.-To determine if postoperative radiotherapy resulted in improved neurologic control of disease and increased survival, Design,-Multicenter, randomized, parallel group trial. Setting.-University-affiliated cancer treatment facilities. Patients.-Ninety-five patients who had single metastases to the brain that were treated with complete surgical resections (as verified by postoperative magnetic resonance imaging) between September 1989 and November 1997 were entered into the study. Interventions.-Patients were randomly assigned to treatment with postoperative whole-brain radiotherapy (radiotherapy group, 49 patients) or no further treatment (observation group, 46 patients) for the brain metastasis, with median followup of 48 weeks and 43 weeks, respectively, Main Outcome Measures.-The primary end point was recurrence of tumor in the brain; secondary end points were length of survival, cause of death, and preservation of ability to function independently. Results.-Recurrence of tumor anywhere in the brain was less frequent in the radiotherapy group than in the observation group (9 [18%] of 49 vs 32 [70%] of 46; P<.001). Postoperative radiotherapy prevented brain recurrence at the site of the original metastasis (5 [10%] of 49 vs 21 [46%] of 46; P<.001) and at other sites in the brain (7 [14%] of 49 vs 17 [37] of 46; P<.01), Patients in the radiotherapy group were less likely to die of neurologic causes than patients in the observation group (6 [14%] of 43 who;died vs 17 [44%] of 39; P=.003), There was no significant difference between the 2 groups in overall length of survival or the length of time that patients remained functionally independent. Conclusions.-Patients with cancer and single metastases to the brain who receive treatment with surgical resection and postoperative radiotherapy have fewer recurrences of cancer in the brain and are less likely to die of neurologic causes than similar patients treated with surgical resection alone.	Univ Kentucky, Med Ctr, Dept Neurosurg, Div Neurosurg, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Neurol, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Radiat Med, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Stat, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Internal Med, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Pathol, Lexington, KY 40536 USA; Univ Wisconsin, Sch Med, Dept Neurol Surg, Madison, WI USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Wisconsin System; University of Wisconsin Madison	Patchell, RA (corresponding author), Univ Kentucky, Med Ctr, Dept Neurosurg, Div Neurosurg, 800 Rose St, Lexington, KY 40536 USA.							ARMSTRONG JG, 1994, J CLIN ONCOL, V12, P2340, DOI 10.1200/JCO.1994.12.11.2340; CAIRNCROSS JG, 1980, ANN NEUROL, V7, P529, DOI 10.1002/ana.410070606; COX DR, 1972, J R STAT SOC B, V34, P187; CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627; DAVIS PC, 1991, AM J NEURORADIOL, V12, P293; DEANGELIS LM, 1989, NEUROLOGY, V39, P789, DOI 10.1212/WNL.39.6.789; DEANGELIS LM, 1989, NEUROSURGERY, V24, P798, DOI 10.1227/00006123-198906000-00002; DELATTRE JY, 1988, ARCH NEUROL-CHICAGO, V45, P741, DOI 10.1001/archneur.1988.00520310047016; DOSORETZ DE, 1980, INT J RADIAT ONCOL, V6, P1727, DOI 10.1016/0360-3016(80)90260-6; GAYNOR JJ, 1993, J AM STAT ASSOC, V88, P400, DOI 10.2307/2290318; HAGEN NA, 1990, NEUROLOGY, V40, P158, DOI 10.1212/WNL.40.1.158; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Karnofsky D., 1949, CLIN EVALUATION CHEM, P191; MENDENHALL WM, 1986, INT J RADIAT ONCOL, V12, P741, DOI 10.1016/0360-3016(86)90031-3; Mintz AH, 1996, CANCER, V78, P1470, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1470::AID-CNCR14>3.0.CO;2-X; PATCHELL RA, 1990, NEW ENGL J MED, V322, P494, DOI 10.1056/NEJM199002223220802; RUNGE VM, 1992, JMRI-J MAGN RESON IM, V2, P9, DOI 10.1002/jmri.1880020103; Skibber JM, 1996, ANN SURG ONCOL, V3, P118, DOI 10.1007/BF02305789; SMALLEY SR, 1987, INT J RADIAT ONCOL, V13, P1611, DOI 10.1016/0360-3016(87)90154-4; SZE G, 1990, AM J NEURORADIOL, V11, P785; VECHT CJ, 1993, ANN NEUROL, V33, P583, DOI 10.1002/ana.410330605; WITHERS HR, 1995, INT J RADIAT ONCOL, V31, P353, DOI 10.1016/0360-3016(94)00354-N; YUH WTC, 1992, AM J NEURORADIOL, V13, P335	23	1306	1343	0	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1485	1489		10.1001/jama.280.17.1485	http://dx.doi.org/10.1001/jama.280.17.1485			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809728	Bronze			2022-12-28	WOS:000076757200021
J	Smith-Bindman, R; Kerlikowske, K; Feldstein, VA; Subak, L; Scheidler, J; Segal, M; Brand, R; Grady, D				Smith-Bindman, R; Kerlikowske, K; Feldstein, VA; Subak, L; Scheidler, J; Segal, M; Brand, R; Grady, D			Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ASYMPTOMATIC POSTMENOPAUSAL WOMEN; TRANSVAGINAL SONOGRAPHY; BREAST-CANCER; VAGINAL ULTRASONOGRAPHY; VAGINOSONOGRAPHIC MEASUREMENTS; HISTOPATHOLOGICAL FINDINGS; HISTOLOGICAL-FINDINGS; REPLACEMENT THERAPY; DIAGNOSTIC-VALUE; BLOOD-FLOW	Context.-Postmenopausal vaginal bleeding is a common clinical problem. Endovaginal ultrasound (EVUS) is a noninvasive diagnostic test that may help determine which women should undergo endometrial biopsy. Objective.-To determine the accuracy of EVUS in detecting endometrial disease in postmenopausal women with vaginal bleeding according to hormone replacement use. Data Sources.-Literature search of English-language and non-English-language articles published from 1966 through November 1996 using MEDLINE and by a manual search of bibliographies of published articles, Study Selection.-Studies were included if they prospectively collected EVUS measurements of endometrial thickness prior to obtaining endometrial tissue for histologic evaluation in postmenopausal women with vaginal bleeding. Of 85 studies that included data on EVUS and endometrial histology, 35 were included in the meta-analysis and included 5892 women. Data Extraction.-Articles were reviewed and independently selected and abstracted by 2 reviewers. Disagreement was resolved by consensus. Data Synthesis.-The overall summary mean weighted estimates of sensitivity and specificity were calculated for thresholds of endometrial thickness from 3 to 10 mm, Using a 5-mm threshold to define abnormal endometrial thickening, 96% (95% confidence interval [CI], 94%-98%) of women with cancer had an abnormal EVUS result, whereas 92% (95% CI, 90%-93%) of women with endometrial disease (cancer, polyp, or atypical hyperplasia) had an abnormal result. This did not vary by hormone replacement use. However, the number of women with normal histology who had an abnormal EVUS result did vary by hormone replacement use. In women who were not using hormone replacement therapy, 593 (8%) with normal histological findings had an abnormal EVUS result (specificity, 92%; 95% CI, 90%-94%), whereas 1544 (23%) using hormone replacement therapy had an abnormal EVUS result (specificity, 77%; 95% CI, 75%-79%), For a postmenopausal woman with vaginal bleeding with a 10% pretest probability of endometrial cancer, her probability of cancer is 1% following a normal EVUS result. Conclusion.-Endovaginal ultrasound has a high sensitivity for detecting endometrial cancer and other endometrial disease and can reliably identify postmenopausal women with vaginal bleeding who are highly unlikely to have significant endometrial disease so that endometrial sampling may be unnecessary.	Univ Calif San Francisco, Mt Zion Med Ctr, Dept Radiol, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94115 USA; Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Smith-Bindman, R (corresponding author), Univ Calif San Francisco, Mt Zion Med Ctr, Dept Radiol, 1600 Divisidero St, San Francisco, CA 94115 USA.	Rebecca.Smith-Bindman@Radiology.UCAF.edu						Abu Hmeidan F, 1992, Ultraschall Med, V13, P178; Abu Hmeidan F, 1992, Zentralbl Gynakol, V114, P455; ABUHMEIDAN F, 1991, ZBL GYNAKOL, V113, P707; AITCHISON J, 1964, J ROY STAT SOC B, V26, P462; ALEEM F, 1995, J ULTRAS MED, V14, P139; Aleem F, 1995, J ULTRAS MED, V14, P147; ARCHER DF, 1991, AM J OBSTET GYNECOL, V165, P317, DOI 10.1016/0002-9378(91)90084-5; ARTNER A, 1994, GYNECOL ONCOL, V54, P147, DOI 10.1006/gyno.1994.1184; ATRI M, 1994, RADIOGRAPHICS, V14, P483, DOI 10.1148/radiographics.14.3.8066264; AUSLENDER R, 1993, ULTRASOUND OBST GYN, V3, P426, DOI 10.1046/j.1469-0705.1993.03060426.x; BAKOS O, 1994, MATURITAS, V20, P181, DOI 10.1016/0378-5122(94)90015-9; BATOOL T, 1998, BRIT J OBSTET GYNAEC, V101, P545; BEN BG, 1994, GYNECOL OBSTET INVES, V37, P260; Botsis D., 1992, Clinical and Experimental Obstetrics and Gynecology, V19, P189; BOURNE TH, 1991, GYNECOL ONCOL, V40, P253; BOURNE TH, 1995, ULTRASOUND OBST GYN, V6, P75, DOI 10.1046/j.1469-0705.1995.06020075.x; BOURNE TH, 1990, BRIT MED J, V301, P369, DOI 10.1136/bmj.301.6748.369; BRANDNER P, 1991, GEBURTSH FRAUENHEILK, V51, P734, DOI 10.1055/s-2007-1023824; Brolmann H A, 1993, Ned Tijdschr Geneeskd, V137, P1823; CACCIATORE B, 1994, ACTA OBSTET GYN SCAN, V73, P413, DOI 10.3109/00016349409006254; CASTELOBRANCO C, 1994, MATURITAS, V19, P59, DOI 10.1016/0378-5122(94)90042-6; Cecchini S, 1996, TUMORI, V82, P38, DOI 10.1177/030089169608200107; CHAN FY, 1994, J ULTRAS MED, V13, P623, DOI 10.7863/jum.1994.13.8.623; COHEN I, 1993, J ULTRAS MED, V12, P275, DOI 10.7863/jum.1993.12.5.275; COHEN I, 1994, GYNECOL ONCOL, V52, P185, DOI 10.1006/gyno.1994.1029; CONOSCENTI G, 1995, ULTRASOUND OBST GYN, V6, P108, DOI 10.1046/j.1469-0705.1995.06020108.x; Conoscenti G, 1995, Minerva Ginecol, V47, P293; D'Amelio R, 1994, Minerva Ginecol, V46, P551; DEGENHARDT F, 1991, ULTRASCHALL MED, V12, P119, DOI 10.1055/s-2007-1003981; Dijkhuizen FPHLJ, 1996, OBSTET GYNECOL, V87, P345, DOI 10.1016/0029-7844(95)00450-5; DORUM A, 1993, ACTA OBSTET GYN SCAN, V72, P116, DOI 10.3109/00016349309023423; DUBINSKY TJ, 1995, J ULTRAS MED, V14, P887; DUBINSKY TJ, 1995, J ULTRAS MED, V14, P1; EINERTH Y, 1982, ACTA OBSTET GYN SCAN, V61, P373; EMANUEL MH, 1995, AM J OBSTET GYNECOL, V172, P547, DOI 10.1016/0002-9378(95)90571-5; FELDMAN S, 1994, GYNECOL ONCOL, V55, P56, DOI 10.1006/gyno.1994.1247; FERENCZY A, 1979, OBSTET GYNECOL, V54, P262; FISHER ER, 1995, CANCER-AM CANCER SOC, V75, P1310, DOI 10.1002/1097-0142(19950315)75:6<1310::AID-CNCR2820750613>3.0.CO;2-G; FLEISCHER AC, 1986, J ULTRAS MED, V5, P445; FORNANDER T, 1989, LANCET, V1, P117; GEORGIEV DB, 1994, INT J GYNECOL OBSTET, V47, P147, DOI 10.1016/0020-7292(94)90355-7; GOLDSTEIN SR, 1990, AM J OBSTET GYNECOL, V163, P119, DOI 10.1016/S0002-9378(11)90683-8; GRANBERG S, 1991, AM J OBSTET GYNECOL, V164, P47, DOI 10.1016/0002-9378(91)90622-X; GREDMARK T, 1995, BRIT J OBSTET GYNAEC, V102, P133, DOI 10.1111/j.1471-0528.1995.tb09066.x; GRIMES DA, 1982, AM J OBSTET GYNECOL, V142, P1; GRUNFELD L, 1991, OBSTET GYNECOL, V78, P200; GU CX, 1994, CHUNG HUA FU CHAN KO, V29, P720; GU CX, 1994, CHUNG HUA FU CHAN KO, V29, P761; Gupta JK, 1996, ACTA OBSTET GYN SCAN, V75, P475, DOI 10.3109/00016349609033357; HANGGI W, 1995, ULTRASCHALL MED, V16, P2, DOI 10.1055/s-2007-1003228; Hawwa Z M, 1970, Lahey Clin Found Bull, V19, P61; HULKA CA, 1993, AM J ROENTGENOL, V160, P809, DOI 10.2214/ajr.160.4.8456669; HUNTER RE, 1989, OBSTET GYNECOL, V73, P813; INDMAN PD, 1995, J REPROD MED, V40, P545; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; KARLSSON B, 1994, J ULTRAS MED, V13, P757, DOI 10.7863/jum.1994.13.10.757; KARLSSON B, 1993, GYNECOL ONCOL, V50, P173, DOI 10.1006/gyno.1993.1188; KARLSSON B, 1995, AM J OBSTET GYNECOL, V172, P1488, DOI 10.1016/0002-9378(95)90483-2; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; KLUG PW, 1989, GEBURTSH FRAUENHEILK, V49, P797, DOI 10.1055/s-2008-1036088; KOONINGS PP, 1990, OBSTET GYNECOL, V75, P293; KURJAK A, 1993, AM J OBSTET GYNECOL, V169, P1597, DOI 10.1016/0002-9378(93)90443-M; LAHTI E, 1993, OBSTET GYNECOL, V81, P660; Langer RD, 1997, NEW ENGL J MED, V337, P1792, DOI 10.1056/NEJM199712183372502; LIDOR A, 1986, ACTA OBSTET GYN SCAN, V65, P41; LIPSCOMB GH, 1994, AM J OBSTET GYNECOL, V170, P591, DOI 10.1016/S0002-9378(94)70234-9; Maia H, 1996, INT J GYNECOL OBSTET, V52, P61, DOI 10.1016/0020-7292(95)02577-4; MALINOVA M, 1995, EUR J OBSTET GYN R B, V58, P161, DOI 10.1016/0028-2243(94)01968-1; MALPANI A, 1990, J CLIN ULTRASOUND, V18, P173, DOI 10.1002/jcu.1870180306; Mascaretti G, 1993, Minerva Ginecol, V45, P1; MESTWERDT W, 1983, GYNAKOLOGE, V16, P87; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; NASRI MN, 1991, BRIT J OBSTET GYNAEC, V98, P470, DOI 10.1111/j.1471-0528.1991.tb10342.x; NASRI MN, 1989, BRIT J OBSTET GYNAEC, V96, P1333, DOI 10.1111/j.1471-0528.1989.tb03233.x; NASRI MN, 1991, BRIT J OBSTET GYNAEC, V98, P485, DOI 10.1111/j.1471-0528.1991.tb10346.x; OSMERS R, 1989, GEBURTSH FRAUENHEILK, V49, P262, DOI 10.1055/s-2008-1035751; OSMERS R, 1990, LANCET, V335, P1569, DOI 10.1016/0140-6736(90)91387-P; OSMERS R, 1990, INT J GYNECOL OBSTET, V32, P35, DOI 10.1016/0020-7292(90)90979-U; OSMERS R, 1999, REV FR GYNECOL OBSTE, V87, P309; Pal Attila, 1994, Orvosi Hetilap, V135, P1305; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Persiani P, 1995, Minerva Ginecol, V47, P63; Pertl B, 1996, GYNAKOL GEBURT RUNDS, V36, P14, DOI 10.1159/000272606; POSSATI G, 1994, ANN NY ACAD SCI, V734, P479, DOI 10.1111/j.1749-6632.1994.tb21779.x; PROMER H, 1992, GYNAKOL GEBURT RUNDS, V1, P117; Rayter Z, 1994, Eur J Surg Oncol, V20, P134; Rose PG, 1996, NEW ENGL J MED, V335, P640, DOI 10.1056/NEJM199608293350907; RUDELSTORFER R, 1990, ARCH GYNECOL OBSTET, V248, P37, DOI 10.1007/BF02389588; Salet-Lizee D., 1993, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V22, P593; SCHOENFELD A, 1990, J CLIN ULTRASOUND, V18, P350, DOI 10.1002/jcu.1870180421; SCHRAMM T, 1995, GEBURTSH FRAUENHEILK, V55, P65, DOI 10.1055/s-2007-1022777; SEELBACHGOBEL B, 1995, GEBURTSH FRAUENHEILK, V55, P59, DOI 10.1055/s-2007-1022776; SHIPLEY CF, 1994, J ULTRAS MED, V13, P99; Smith P, 1991, Acta Obstet Gynecol Scand, V70, P591, DOI 10.3109/00016349109007922; STOCK G, 1995, PHILOS QUART, V45, P537, DOI 10.2307/2220325; STOVALL TG, 1989, OBSTET GYNECOL, V73, P405; STOVALL TG, 1991, OBSTET GYNECOL, V77, P954; Taviani A, 1995, Minerva Ginecol, V47, P369; TONGSONG T, 1994, J CLIN ULTRASOUND, V22, P479, DOI 10.1002/jcu.1870220804; TSUDA H, 1995, GYNECOL OBSTET INVES, V40, P271, DOI 10.1159/000292351; TSUDA H, 1995, AM J OBSTET GYNECOL, V172, P1494, DOI 10.1016/0002-9378(95)90484-0; VANDENBOSCH T, 1995, OBSTET GYNECOL, V85, P349, DOI 10.1016/0029-7844(94)00421-9; VandenBosch T, 1996, EUR J OBSTET GYN R B, V64, P91, DOI 10.1016/0301-2115(95)02274-0; VARNER RE, 1991, OBSTET GYNECOL, V78, P195; Volgger B, 1996, GYNAKOL GEBURT RUNDS, V36, P21, DOI 10.1159/000272607; VUOPALA S, 1977, ACTA OBSTET GYNECO S, V70, P22; Weber AM, 1997, AM J OBSTET GYNECOL, V177, P924, DOI 10.1016/S0002-9378(97)70295-3; WEIGEL M, 1990, GEBURTSH FRAUENHEILK, V50, P870, DOI 10.1055/s-2008-1026384; Wolman I, 1996, J CLIN ULTRASOUND, V24, P79, DOI 10.1002/(SICI)1097-0096(199602)24:2<79::AID-JCU5>3.3.CO;2-6; Zacchi V, 1993, Minerva Ginecol, V45, P339; ZALUD I, 1993, J ULTRAS MED, V12, P737, DOI 10.7863/jum.1993.12.12.737; ZANNONI E, 1994, ECO 1994, P27; Zorlu C. Gurkan, 1995, Materia Medica Polona, V27, P23	113	465	484	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1510	1517		10.1001/jama.280.17.1510	http://dx.doi.org/10.1001/jama.280.17.1510			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809732				2022-12-28	WOS:000076757200025
J	Colao, A; Lombardi, G				Colao, A; Lombardi, G			Growth-hormone and prolactin excess	LANCET			English	Article							SLOW-RELEASE LANREOTIDE; LONG-TERM; DOPAMINE AGONISTS; PITUITARY-TUMORS; COLONIC POLYPS; HYPERPROLACTINEMIC HYPOGONADISM; PHARMACOLOGICAL PROPERTIES; ACROMEGALIC PATIENTS; FOLLOW-UP; BONE MASS	The treatment of acromegaly and hyperprolactinaemia has been improved by the availability of effective and well-tolerated slow-release somatostatin analogues and dopamine agonists with long-lasting activity, such as cabergoline. The use of these drugs has extended the possibility of treatment to patients who would have responded poorly to the previously available compounds, such as octreotide or bromocriptine, and to those who were intolerant to pharmacotherapy. Moreover, the improvement in the management of acromegaly has enabled the reversal, at least partly, of cardiomyopathy and sleep apnoea, two important risk factors for morbidity and mortality in these patients.	Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, I-80131 Naples, Italy	University of Naples Federico II	Colao, A (corresponding author), Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, Via S Pansini 5, I-80131 Naples, Italy.	rpivone@tin.it						Abs R, 1998, J CLIN ENDOCR METAB, V83, P374, DOI 10.1210/jc.83.2.374; ALEXANDER L, 1980, CLIN ENDOCRINOL, V12, P71, DOI 10.1111/j.1365-2265.1980.tb03135.x; Andrews David W., 1997, Current Opinion in Oncology, V9, P55; ARON DC, 1995, WESTERN J MED, V162, P340; Barkan A, 1997, J ENDOCRINOL, V155, pS41; Barkan AL, 1997, J CLIN ENDOCR METAB, V82, P3187, DOI 10.1210/jc.82.10.3187; BATES AS, 1993, Q J MED, V86, P293; BENGTSSON BA, 1988, ACTA MED SCAND, V223, P327; BEREZIN M, 1995, J ENDOCRINOL INVEST, V18, P436, DOI 10.1007/BF03349742; Bevan J S, 1992, ENDOCR REV, V13, P221; Biller BMK, 1996, J CLIN ENDOCR METAB, V81, P2338, DOI 10.1210/jc.81.6.2338; BRADA M, 1992, BRIT MED J, V304, P1343, DOI 10.1136/bmj.304.6838.1343; BRIERLE JD, 1996, RAD ONCOLOGY, V41, P55; BRUE T, 1992, J CLIN ENDOCR METAB, V74, P577, DOI 10.1210/jc.74.3.577; BURROW GN, 1981, NEW ENGL J MED, V304, P156, DOI 10.1056/NEJM198101153040306; Caron P, 1997, J CLIN ENDOCR METAB, V82, P18, DOI 10.1210/jc.82.1.18; CHAPMAN IM, 1994, J CLIN ENDOCR METAB, V78, P1312, DOI 10.1210/jc.78.6.1312; CHIODINI PG, 1993, ACTA ENDOCRINOL-COP, V128, P389, DOI 10.1530/acta.0.1280389; CICCARELLI E, 1990, CLIN ENDOCRINOL, V32, P583, DOI 10.1111/j.1365-2265.1990.tb00901.x; Clayton RN, 1997, J ENDOCRINOL, V155, pS23; Colao A, 1997, J CLIN ENDOCR METAB, V82, P3574, DOI 10.1210/jc.82.11.3574; Colao A, 1997, J CLIN ENDOCR METAB, V82, P2777, DOI 10.1210/jc.82.9.2777; Colao A, 1997, CLIN ENDOCRINOL, V47, P23, DOI 10.1046/j.1365-2265.1997.00253.x; Colao A, 1996, EUR J ENDOCRINOL, V135, P548, DOI 10.1530/eje.0.1350548; Colao A, 1997, J CLIN ENDOCR METAB, V82, P518, DOI 10.1210/jc.82.2.518; Colao A, 1998, J CLIN ENDOCR METAB, V83, P2121, DOI 10.1210/jc.83.6.2121; Colao A, 1998, J CLIN ENDOCR METAB, V83, P775, DOI 10.1210/jc.83.3.775; Colao A, 1997, J CLIN ENDOCR METAB, V82, P3308, DOI 10.1210/jc.82.10.3308; Colao A, 1997, J CLIN ENDOCR METAB, V82, P876, DOI 10.1210/jc.82.3.876; CORENBLUM B, 1993, FERTIL STERIL, V59, P671; Costello RT, 1936, AM J PATHOL, V12, P205; CUNNAH D, 1991, CLIN ENDOCRINOL, V34, P231, DOI 10.1111/j.1365-2265.1991.tb00299.x; De Rosa M, 1998, EUR J ENDOCRINOL, V138, P286, DOI 10.1530/eje.0.1380286; DEHERDER WW, 1995, CLIN ENDOCRINOL, V43, P501; DELHOUGNE B, 1995, J CLIN ENDOCR METAB, V80, P3223, DOI 10.1210/jc.80.11.3223; Di Somma C, 1998, J CLIN ENDOCR METAB, V83, P807, DOI 10.1210/jc.83.3.807; EASTMAN RC, 1992, ENDOCRIN METAB CLIN, V21, P693, DOI 10.1016/S0889-8529(18)30209-3; EZZAT S, 1994, J CLIN ENDOCR METAB, V79, P113, DOI 10.1210/jc.79.1.113; EZZAT S, 1994, MEDICINE, V73, P233, DOI 10.1097/00005792-199409000-00001; FAHLBUSCH R, 1993, J ENDOCRINOL INVEST, V16, P449, DOI 10.1007/BF03348882; Fahlbusch R, 1996, METABOLISM, V45, P65, DOI 10.1016/S0026-0495(96)90086-4; Ferrari CI, 1997, CLIN ENDOCRINOL, V46, P409, DOI 10.1046/j.1365-2265.1997.1300952.x; Gillis JC, 1997, DRUGS, V53, P681, DOI 10.2165/00003495-199753040-00009; Giusti M, 1996, J CLIN ENDOCR METAB, V81, P2089, DOI 10.1210/jc.81.6.2089; GREENSPAN SL, 1989, ANN INTERN MED, V110, P526, DOI 10.7326/0003-4819-110-7-526; GROSSMAN A, 1984, BRIT MED J, V288, P1105, DOI 10.1136/bmj.288.6424.1105; HALE R, 1973, LANCET, V2, P581; JACKSON JA, 1986, ANN INTERN MED, V105, P543, DOI 10.7326/0003-4819-105-4-543; JAFFE CA, 1994, DRUGS, V47, P425, DOI 10.2165/00003495-199447030-00004; Jenkins PJ, 1997, CLIN ENDOCRINOL, V47, P17, DOI 10.1046/j.1365-2265.1997.1911029.x; Jenkins PJ, 1996, CLIN ENDOCRINOL, V45, P447, DOI 10.1046/j.1365-2265.1996.8240834.x; JHO HD, 1996, AM ASS NEUROL SURG, V5, P1; JOHNSTON DG, 1984, LANCET, V2, P187; JONES A, 1991, CLIN ENDOCRINOL, V35, P379, DOI 10.1111/j.1365-2265.1991.tb03554.x; KLETZKY OA, 1989, FERTIL STERIL, V51, P269; KLIBANSKI A, 1980, NEW ENGL J MED, V303, P1511, DOI 10.1056/NEJM198012253032605; KLIBANSKI A, 1986, NEW ENGL J MED, V315, P542, DOI 10.1056/NEJM198608283150903; LAMBERTS SWJ, 1995, METABOLISM, V44, P15, DOI 10.1016/0026-0495(95)90305-4; LAMBERTS SWJ, 1991, ENDOCR REV, V12, P450, DOI 10.1210/edrv-12-4-450; Lamberts SWJ, 1996, NEW ENGL J MED, V334, P246, DOI 10.1056/NEJM199601253340408; Lancranjan I, 1996, METABOLISM, V45, P67, DOI 10.1016/S0026-0495(96)90087-6; Liuzzi A, 1996, J ENDOCRINOL INVEST, V19, P196, DOI 10.1007/BF03349866; Lombardi G, 1997, J ENDOCRINOL, V155, pS33; Maor Y, 1997, FERTIL STERIL, V67, P693, DOI 10.1016/S0015-0282(97)81368-4; MELMED S, 1995, J CLIN ENDOCR METAB, V80, P3395, DOI 10.1210/jc.80.12.3395; MELMED S, 1994, AM J MED, V97, P468; Molitch Mark E., 1995, P443; Molitch ME, 1997, J CLIN ENDOCR METAB, V82, P996, DOI 10.1210/jc.82.4.996; NABARRO JDN, 1980, CLIN ENDOCRINOL OXF, V26, P81; RAINS CP, 1995, DRUGS, V49, P255, DOI 10.2165/00003495-199549020-00009; RAJASOORYA C, 1994, CLIN ENDOCRINOL, V41, P95, DOI 10.1111/j.1365-2265.1994.tb03789.x; REDFERN JS, 1995, AM J GASTROENTEROL, V90, P1042; SACCA L, 1994, ENDOCR REV, V15, P555, DOI 10.1210/er.15.5.555; SCHETTINI G, 1990, CLIN ENDOCRINOL, V33, P161, DOI 10.1111/j.1365-2265.1990.tb00479.x; SCHLECHTE J, 1989, J CLIN ENDOCR METAB, V68, P412, DOI 10.1210/jcem-68-2-412; SERRI O, 1994, NEW ENGL J MED, V331, P942, DOI 10.1056/NEJM199410063311412; Sheaves R, 1996, CLIN ENDOCRINOL, V45, P407, DOI 10.1046/j.1365-2265.1996.8370847.x; SHELINE GE, 1984, SECRETORY TUMORS PIT, P93; Shimon I, 1997, J CLIN ENDOCR METAB, V82, P1675, DOI 10.1210/jc.82.6.1675; Soule SG, 1996, CLIN ENDOCRINOL, V44, P711, DOI 10.1046/j.1365-2265.1996.738559.x; STEWART PM, 1993, BRIT MED J, V306, P507, DOI 10.1136/bmj.306.6876.507; StoffelWagner B, 1997, CLIN ENDOCRINOL, V46, P531, DOI 10.1046/j.1365-2265.1997.1430983.x; TURNER TH, 1984, BRIT MED J, V289, P1101, DOI 10.1136/bmj.289.6452.1101; Wass JAH, 1997, J ENDOCRINOL, V155, pS57; WASS JAH, 1993, BRIT MED J, V307, P1505, DOI 10.1136/bmj.307.6918.1505; WEBSTER J, 1994, NEW ENGL J MED, V331, P904, DOI 10.1056/NEJM199410063311403; WEBSTER J, 1992, CLIN ENDOCRINOL, V36, P35, DOI 10.1111/j.1365-2265.1992.tb02900.x; Webster J, 1996, DRUG SAFETY, V14, P228, DOI 10.2165/00002018-199614040-00003; Yamada S, 1996, CLIN ENDOCRINOL, V45, P291, DOI 10.1046/j.1365-2265.1996.8080817.x	89	176	184	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 31	1998	352	9138					1455	1461		10.1016/S0140-6736(98)03356-X	http://dx.doi.org/10.1016/S0140-6736(98)03356-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9808008				2022-12-28	WOS:000076719500041
J	Jiang, Y; Ma, W; Wan, Y; Kozasa, T; Hattori, S; Huang, XY				Jiang, Y; Ma, W; Wan, Y; Kozasa, T; Hattori, S; Huang, XY			The G protein G alpha 12 stimulates Bruton's tyrosine kinase and a rasGAP through a conserved PH/BM domain	NATURE			English	Article							GTPASE-ACTIVATING PROTEIN; BETA-GAMMA-SUBUNITS; RAT-BRAIN; RECEPTOR; PURIFICATION; CASCADE; FAMILY; CELLS	Heterotrimeric guanine-nucleotide-binding proteins (G proteins) are signal transducers that relay messages from many receptors on the cell surface to modulate various cellular processes(1-4). The direct downstream effecters of G proteins consist of the signalling molecules that are activated by their physical interactions with a G alpha or G beta gamma subunit. Effecters that interact directly with G alpha 12 G, proteins have yet to be identified(5,6). Here we show that G alpha 12 binds directly to, and stimulates the activity of, Bruton's tyrosine kinase (Btk) and a Res GTPase-activating protein, Gap1(m), in vitro and in; vivo. G alpha 12 interacts with a conserved domain, composed of the pleckstrin-homology domain and the adjacent Btk motif, that is present in both Btk and Gap1(m). Our results are, to our knowledge, the first to identify direct effecters for G alpha 12 and to show that there is a direct link between heterotrimeric and monomeric G proteins.	Cornell Univ, Coll Med, Dept Physiol, New York, NY 10021 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Natl Inst Neurosci, Div Biochem & Cellular Biol, Tokyo 187, Japan	Cornell University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Center for Neurology & Psychiatry - Japan	Huang, XY (corresponding author), Cornell Univ, Coll Med, Dept Physiol, 1300 York Ave, New York, NY 10021 USA.							Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; BOUME HR, 1990, NATURE, V348, P125; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Harhammer R, 1996, BIOCHEM J, V319, P165, DOI 10.1042/bj3190165; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; MACKAWA M, 1994, MOL CELL BIOL, V14, P6879; MAEKAWA M, 1993, J BIOL CHEM, V268, P22948; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; VIHINEN M, 1995, IMMUNOL TODAY, V16, P460, DOI 10.1016/0167-5699(95)80027-1; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	26	153	156	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1998	395	6704					808	813		10.1038/27454	http://dx.doi.org/10.1038/27454			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AL	9796816				2022-12-28	WOS:000076607400059
J	Cooper, C				Cooper, C			Medical progress in all its gory	LANCET			English	Editorial Material																			0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 3	1998	352	9134					1160	1160		10.1016/S0140-6736(05)79820-2	http://dx.doi.org/10.1016/S0140-6736(05)79820-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798634				2022-12-28	WOS:000076246400075
J	Wolf, PA				Wolf, PA			Prevention of stroke	LANCET			English	Article							CIGARETTE-SMOKING; RISK FACTOR; HOMOCYSTEINE; CHOLESTEROL; DISEASE; TRIAL; MEN		Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Med Ctr, Evans Mem Dept Clin Res, Prevent Med & Epidemiol Sect, Boston, MA USA; Boston Med Ctr, Dept Med, Boston, MA USA	Boston University; Boston Medical Center; Boston Medical Center	Wolf, PA (corresponding author), Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.			Wolf, Philip/0000-0002-3628-301X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL40423, NIH-NO1-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-RO1-NS-17950-17] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Barnett HJM, 1996, NEUROLOGY, V46, P603, DOI 10.1212/WNL.46.3.603; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gillum RF, 1996, AM J EPIDEMIOL, V143, P860, DOI 10.1093/oxfordjournals.aje.a008829; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; Kronmal RA, 1998, STROKE, V29, P887, DOI 10.1161/01.STR.29.5.887; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; PEDERSEN TR, 1994, LANCET, V344, P1383; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Sacco RL, 1997, STROKE, V28, P1507, DOI 10.1161/01.STR.28.7.1507; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; STAESSEN J, 1992, J CARDIOVASC PHARM, V19, P120, DOI 10.1097/00005344-199201000-00017; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025	23	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT	1998	352			3			SIII15	SIII18						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133UP	9803957				2022-12-28	WOS:000076704700005
J	Zachariae, W; Schwab, M; Nasmyth, K; Seufert, W				Zachariae, W; Schwab, M; Nasmyth, K; Seufert, W			Control of cyclin ubiquitination by CDK-regulated binding of Hct1 to the anaphase promoting complex	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; S-PHASE; PROTEOLYSIS; YEAST; PHOSPHORYLATION; REPLICATION; DEGRADATION; EXPRESSION; KINASES; ENTRY	Proteolysis of mitotic cyclins depends on a multisubunit ubiquitin-protein Ligase, the anaphase promoting complex (APC), Proteolysis commences during anaphase, persisting throughout G(1) until it is terminated by-cyclin-dependent kinases (CDKs) as cells enter S phase. Proteolysis of mitotic cyclins in yeast was shown to require association of the APC with the substrate-specific activator Hct1 (also called Cdh1). Phosphorylation of Hct1 by CDKs blocked the Hct1-APC interaction. The mutual inhibition between APC and CDKs explains how cells suppress mitotic CDK activity during G(1) and then establish a period with elevated kinase activity from S phase until anaphase.	Univ Stuttgart, Inst Ind Genet, D-70569 Stuttgart, Germany; Res Inst Mol Pathol, A-1030 Vienna, Austria	University of Stuttgart; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Seufert, W (corresponding author), Univ Stuttgart, Inst Ind Genet, Allmandring 31, D-70569 Stuttgart, Germany.		Seufert, Wolfgang/F-7136-2019	Seufert, Wolfgang/0000-0001-8938-9064; Nasmyth, Kim/0000-0001-7030-4403				Amon A, 1997, EMBO J, V16, P2693, DOI 10.1093/emboj/16.10.2693; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fitzpatrick PJ, 1998, MOL GEN GENET, V258, P437, DOI 10.1007/s004380050753; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Schwab M. M., UNPUB; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SCHWOB E, UNPUB; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SHIRAYAMA M, UNPUB; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Townsley FM, 1998, TRENDS CELL BIOL, V8, P238, DOI 10.1016/S0962-8924(98)01268-9; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Volff JN, 1996, MOL MICROBIOL, V21, P1037, DOI 10.1046/j.1365-2958.1996.761428.x; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; ZACHARIAE W, UNPUB	26	435	445	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1721	1724		10.1126/science.282.5394.1721	http://dx.doi.org/10.1126/science.282.5394.1721			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831566				2022-12-28	WOS:000077246600051
J	Gunnell, DJ; Smith, GD; Holly, JMP; Frankel, S				Gunnell, DJ; Smith, GD; Holly, JMP; Frankel, S			Leg length and risk of cancer in the Boyd Orr cohort	BRITISH MEDICAL JOURNAL			English	Article									Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Bristol, Bristol Royal Infirm, Div Surg, Bristol BS2 8HW, Avon, England	Bristol Royal Infirmary; University of Bristol	Gunnell, DJ (corresponding author), Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.		Gunnell, David/ABE-6653-2020; Davey Smith, George/A-7407-2013	Gunnell, David/0000-0002-0829-6470; Davey Smith, George/0000-0002-1407-8314				ALBANES D, 1988, CANCER RES, V48, P1658; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Frankel S, 1998, BMJ-BRIT MED J, V316, P499, DOI 10.1136/bmj.316.7130.499; Gunnell DJ, 1998, J EPIDEMIOL COMMUN H, V52, P142, DOI 10.1136/jech.52.3.142; Holly J, 1998, LANCET, V351, P1373, DOI 10.1016/S0140-6736(05)79438-1	5	73	74	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1350	1351		10.1136/bmj.317.7169.1350	http://dx.doi.org/10.1136/bmj.317.7169.1350			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812931	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000077081600019
J	Pfeffer, N				Pfeffer, N			Theories in health care and research - Theories of race, ethnicity and culture	BRITISH MEDICAL JOURNAL			English	Article									Univ N London, Sch Community Hlth Psychol & Social Work, Fac Environm & Social Studies, London N5 2AD, England	London Metropolitan University	Pfeffer, N (corresponding author), Univ N London, Sch Community Hlth Psychol & Social Work, Fac Environm & Social Studies, London N5 2AD, England.							Aspinall PJ, 1997, SOC SCI MED, V45, P689, DOI 10.1016/S0277-9536(96)00386-3; Bauman Zygmunt, 1991, MODERNITY HOLOCAUST, P53; BHOPAL RS, 1991, J PUBLIC HEALTH MED, V13, P244; BRAH A, 1996, CARTOGRAPHIES DIASPO, P105; COLEMAN D, 1996, ETHNICITY 1991 CENSU, V1, P10; Foucaults Michel, 1980, HIST SEXUALITY; Gilroy P., 1992, THERE AINT NO BLACK, V2nd ed.; Gilroy P., 1997, IDENTITY DIFFERENCE, P299; Gordon Paul, 1983, CRIT SOC POLICY, V3, P6; GUNARATNAM Y, 1997, DEATH GENDER ETHNICI, P166; McKenzie K, 1996, BRIT MED J, V312, P1054; MCKENZIE KJ, 1994, BRIT MED J, V309, P286, DOI 10.1136/bmj.309.6950.286; SHELDON TA, 1992, J PUBLIC HEALTH MED, V14, P104; Slater David, 1994, RACISM MODERNITY IDE, P87; SMAJE C, 1995, HLTH RACE ETHNICITY, P114; WESTWOOD S, 1994, RACISM MODERNITY IDE, P247; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; Woodward Kathryn, 1997, IDENTITY DIFFERENCE, P35	18	38	39	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1381	1384		10.1136/bmj.317.7169.1381	http://dx.doi.org/10.1136/bmj.317.7169.1381			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	140HH	9812944	Green Published			2022-12-28	WOS:000077081600032
J	Remuzzi, G; Bertani, T				Remuzzi, G; Bertani, T			Pathophysiology of progressive nephropathies	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CONVERTING ENZYME-INHIBITION; LONG-TERM PROGNOSIS; PROTEIN-OVERLOAD PROTEINURIA; PROXIMAL TUBULAR CELLS; FACTOR-KAPPA-B; DIABETIC NEPHROPATHY; ANGIOTENSIN-II; RENAL-DISEASE; GLOMERULAR INJURY; BLOOD-PRESSURE		Mario Negri Inst Pharmacol Res, I-24125 Bergamo, Italy; Osped Riuniti Bergamo, Nephrol Unit, I-24100 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo	Remuzzi, G (corresponding author), Mario Negri Inst Pharmacol Res, Via Gavazzeni 11, I-24125 Bergamo, Italy.		Remuzzi, Giuseppe/V-9766-2017	Remuzzi, Giuseppe/0000-0002-6194-3446				Abbate M, 1998, J AM SOC NEPHROL, V9, P1213; ANDERSON S, 1985, J UROLOGY, V133, P363, DOI 10.1016/S0022-5347(17)48980-4; ANDERSON S, 1986, J CLIN INVEST, V77, P1993, DOI 10.1172/JCI112528; ANDERSON S, 1988, J CLIN INVEST, V82, P1757, DOI 10.1172/JCI113789; ANDERSON S, 1989, KIDNEY INT, V36, P526, DOI 10.1038/ki.1989.227; ANDERSON S, 1985, J CLIN INVEST, V76, P612, DOI 10.1172/JCI112013; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BENIGNI A, 1995, LAB INVEST, V73, P461; BERTANI T, 1986, KIDNEY INT, V30, P488, DOI 10.1038/ki.1986.212; BERTANI T, 1989, LAB INVEST, V60, P196; BIANCONE L, 1994, KIDNEY INT, V45, P451, DOI 10.1038/ki.1994.59; BJORCK S, 1992, BMJ-BRIT MED J, V304, P339, DOI 10.1136/bmj.304.6823.339; BOHLE A, 1991, PATHOL RES PRACT, V187, P251; BOHLEN L, 1994, AM J HYPERTENS, V7, pS84; BOHRER MP, 1977, AM J PHYSIOL, V233, pF13, DOI 10.1152/ajprenal.1977.233.1.F13; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; Breyer JA, 1996, KIDNEY INT, V50, P1651, DOI 10.1038/ki.1996.481; Breyer JA, 1995, J AM SOC NEPHROL, V6, P1523; CAMERON JS, 1978, CLIN NEPHROL, V10, P213; CAMERON JS, 1988, NEPHROTIC SYNDROME, P999; CHANUBIN M, 1932, ARCH INTERN MED, V49, P767; CHURG J, 1970, LANCET, V1, P1299; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DAMICO G, 1992, AM J KIDNEY DIS, V20, P315, DOI 10.1016/S0272-6386(12)70293-7; Eddy AA, 1996, KIDNEY INT, V49, pS49; EDDY AA, 1995, KIDNEY INT, V47, P1546, DOI 10.1038/ki.1995.218; EDDY AA, 1989, AM J PATHOL, V135, P719; Eddy AA, 1996, J AM SOC NEPHROL, V7, P2495; Egido J, 1996, KIDNEY INT, V49, P578, DOI 10.1038/ki.1996.82; FOGO A, 1988, J CLIN INVEST, V82, P322, DOI 10.1172/JCI113590; GINSBERG JM, 1983, NEW ENGL J MED, V309, P1543, DOI 10.1056/NEJM198312223092503; *GRUPP IT STUD EP, 1991, J NEPHROL, V3, P193; Habib R, 1971, Pathol Annu, V6, P417; HAYSLETT JP, 1979, PHYSIOL REV, V59, P137, DOI 10.1152/physrev.1979.59.1.137; HAYSLETT JP, 1969, NEW ENGL J MED, V281, P181, DOI 10.1056/NEJM196907242810402; Hirschberg R, 1996, J CLIN INVEST, V98, P116, DOI 10.1172/JCI118755; Hocher B, 1997, J CLIN INVEST, V99, P1380, DOI 10.1172/JCI119297; JOHNSON HA, 1966, AM J PATHOL, V49, P1; JOHNSON RJ, 1992, HYPERTENSION, V19, P464, DOI 10.1161/01.HYP.19.5.464; KANETO H, 1993, KIDNEY INT, V44, P313, DOI 10.1038/ki.1993.246; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; Lapinski R, 1996, J AM SOC NEPHROL, V7, P653; LEMANN J, 1987, CLIN CHEM, V33, P297; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LEWIS EJ, 1994, NEW ENGL J MED, V330, P152; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; MACKENSENHAEN S, 1988, LAB INVEST, V59, P239; MALLICK NP, 1987, NEPHRON, V46, P113, DOI 10.1159/000184325; MARINIDES GN, 1987, AM J PATHOL, V129, P394; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; Matsusaka T, 1996, J AM SOC NEPHROL, V7, P2025; MCGOVERN VJ, 1964, AUSTRALAS ANN MED, V13, P306; MOGENSEN CE, 1983, PREVENTION TREATMENT, P57; NADASDY T, 1994, RENAL PATHOLOGY CLIN, P330; Nomura A, 1997, AM J PATHOL, V151, P539; Okada H, 1997, AM J PHYSIOL-RENAL, V273, pF563, DOI 10.1152/ajprenal.1997.273.4.F563; Ong A. C. M., 1993, Journal of the American Society of Nephrology, V4, P473; ORISIO S, 1993, KIDNEY INT, V43, P354, DOI 10.1038/ki.1993.53; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; PARK CH, 1984, J CLIN INVEST, V73, P767, DOI 10.1172/JCI111270; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; PICHLER R, 1994, AM J PATHOL, V144, P915; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; REMUZZI A, 1990, J CLIN INVEST, V85, P541, DOI 10.1172/JCI114470; REMUZZI G, 1990, KIDNEY INT, V38, P384, DOI 10.1038/ki.1990.217; RICH AR, 1957, B JOHNS HOPKINS HOSP, V100, P173; RISDON RA, 1968, LANCET, V2, P363; Rodby RA, 1995, AM J KIDNEY DIS, V26, P904, DOI 10.1016/0272-6386(95)90054-3; ROSSING P, 1993, DIABETES, V42, P715, DOI 10.2337/diabetes.42.5.715; ROVIN BH, 1995, KIDNEY INT, V48, P1263, DOI 10.1038/ki.1995.410; Ruggenenti P, 1997, LANCET, V349, P1857; Ruggenenti P, 1998, BRIT MED J, V316, P504, DOI 10.1136/bmj.316.7130.504; Ruggenenti P, 1997, Kidney Int Suppl, V63, pS54; RUILOPE LM, 1990, J HYPERTENS, V8, P525, DOI 10.1097/00004872-199006000-00005; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHMITT H, 1987, PATHOL RES PRACT, V182, P6, DOI 10.1016/S0344-0338(87)80136-X; SCHNAPER HW, 1997, DIS KIDNEY, V2, P1725; SIEGEL NJ, 1974, NEPHRON, V13, P125, DOI 10.1159/000180385; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; TUCKER BJ, 1993, J CLIN INVEST, V92, P686, DOI 10.1172/JCI116638; Wang YP, 1997, J AM SOC NEPHROL, V8, P1537; Wapstra FH, 1996, EXP NEPHROL, V4, P47; WEHRMANN M, 1989, CLIN NEPHROL, V31, P67; WEHRMANN M, 1990, CLIN NEPHROL, V33, P115; WEIDMANN P, 1995, NEPHROL DIAL TRANSPL, V10, P39; Wenzel UO, 1995, AM J KIDNEY DIS, V26, P982, DOI 10.1016/0272-6386(95)90065-9; WHITE RHR, 1970, LANCET, V1, P1353; WOLF G, 1991, CELL REGUL, V2, P219, DOI 10.1091/mbc.2.3.219; WOLF G, 1993, J CLIN INVEST, V92, P1366, DOI 10.1172/JCI116710; YEE J, 1991, SEMIN NEPHROL, V11, P361; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521; Zoja C, 1996, EXP NEPHROL, V4, P213; Zoja C, 1998, EXP NEPHROL, V6, P121; Zoja C, 1998, KIDNEY INT, V53, P1608, DOI 10.1046/j.1523-1755.1998.00905.x; Zoja C, 1997, AM J KIDNEY DIS, V29, P254, DOI 10.1016/S0272-6386(97)90038-X; Zoja C, 1995, AM J KIDNEY DIS, V26, P934, DOI 10.1016/0272-6386(95)90058-6	96	1025	1099	1	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1998	339	20					1448	1456		10.1056/NEJM199811123392007	http://dx.doi.org/10.1056/NEJM199811123392007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VR	9811921				2022-12-28	WOS:000077051700007
J	Itzkowitz, SH				Itzkowitz, SH			Heads or tails in a positive faecal occult blood test	LANCET			English	Editorial Material							NEGATIVE COLONOSCOPY; UPPER ENDOSCOPY; STOOL		Mt Sinai Sch Med, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Itzkowitz, SH (corresponding author), Mt Sinai Sch Med, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA.							CHEN YK, 1993, AM J GASTROENTEROL, V88, P2026; HSIA PC, 1992, AM J GASTROENTEROL, V87, P1571; Rockey DC, 1998, NEW ENGL J MED, V339, P153, DOI 10.1056/NEJM199807163390303; Skoletsky JE, 1998, GASTROENTEROLOGY, V114, pA681, DOI 10.1016/S0016-5085(98)82793-5; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; ZUCKERMAN G, 1992, AM J GASTROENTEROL, V87, P62	7	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1490	1490		10.1016/S0140-6736(05)60324-8	http://dx.doi.org/10.1016/S0140-6736(05)60324-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820295				2022-12-28	WOS:000076862300005
J	Yin, MJ; Yamamoto, Y; Gaynor, RB				Yin, MJ; Yamamoto, Y; Gaynor, RB			The anti-inflammatory agents aspirin and salicylate inhibit the activity of I kappa B kinase-beta	NATURE			English	Article							SODIUM-SALICYLATE; ACTIVATION; ALPHA; PHOSPHORYLATION; IMMUNOSUPPRESSION; GLUCOCORTICOIDS; INDUCTION; PATHWAY; TNF	NF-kappa B comprises a family of cellular transcription factors that are involved in the inducible expression of a variety of cellular genes that regulate the inflammatory response(1,2). NF-kappa B is sequestered in the cytoplasm by inhibitory proteins, I kappa B, which are phosphorylated by a cellular kinase complex known as IKK. IKK is made up of two kinases, IKK-alpha and IKK-beta, which phosphorylate I kappa B, leading to its degradation and translocation of NF-kappa B to the nucleus(3-9). IKK kinase activity is stimulated when cells are exposed to the cytokine TNF-cu or by overexpression of the cellular kinases MEKK1 and NIK10,11. Here we demonstrate that the anti-inflammatory agents aspirin and sodium salicylate specifically inhibit IKK-beta activity in vitro and in vivo. The mechanism of aspirin and sodium salicylate inhibition is due to binding of these agents to IKK-beta to reduce ATP binding. Our results indicate that the anti-inflammatory properties of aspirin and salicylate are mediated in part by their specific inhibition of IKK-beta, thereby preventing activation by NF-kappa B of genes involved in the pathogenesis of the inflammatory response.	Univ Texas, SW Med Ctr, Harold Simmons Canc Ctr, Dept Med,Div Hematol Oncol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Harold Simmons Canc Ctr, Dept Med,Div Hematol Oncol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	gaynor@utsw.swmed.edu						AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; INSEL P, 1996, PHARM BASIS THERAPEU; Kalgutkar AS, 1998, SCIENCE, V280, P1268, DOI 10.1126/science.280.5367.1268; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	26	1340	1402	1	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 5	1998	396	6706					77	80		10.1038/23948	http://dx.doi.org/10.1038/23948			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136HE	9817203				2022-12-28	WOS:000076852700057
J	Miller, FG; Rosenstein, DL; DeRenzo, EG				Miller, FG; Rosenstein, DL; DeRenzo, EG			Professional integrity in clinical research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRIALS	In response to public concern over abuses in human medical experimentation, the dominant approach to the ethics of clinical research during the past 30 years has been regulation, particularly via institutional review board review and approval of scientific protocols and written consent forms. However, the effectiveness of regulatory mechanisms in ensuring the ethical conduct of clinical research is limited. Little attention has been devoted to the nature and role of professional integrity of physician investigators, a conscientious framework for guiding investigators in the socially important but morally complex activity of clinical research. Professional integrity is vital in forging an ethically sound relationship between investigators and patient volunteers, a relationship that differs in important ways from the patient-physician relationship in standard clinical practice. We examine critically 2 models of the moral identity of physician investigators, the investigator as clinician and the investigator as scientist; in neither of these 2 models can the physician investigator eliminate completely the moral conflicts posed by clinical research. The professional integrity of physician investigators depends on a coherent moral identity that is proper to the enterprise of clinical research. The roles of clinician and scientist must be integrated to manage conscientiously the ethical complexity, ambiguity, and tensions between the potentially competing loyalties of science and care of volunteer patients.	Univ Virginia, Sch Med, Dept Med Educ, Charlottesville, VA 22908 USA; Consultat Liaison Serv, Dept Psychiat, Bethesda, MD USA; NIH, Dept Clin Bioeth, Bethesda, MD 20892 USA	University of Virginia; National Institutes of Health (NIH) - USA	Miller, FG (corresponding author), 3910 Underwood St, Chevy Chase, MD 20815 USA.	FGM3910@aol.com						*ADV COMM HUM RAD, 1995, FIN REP, P797; APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; BEECHER HK, 1966, NEW ENGL J MED, V274, P1354, DOI 10.1056/NEJM196606162742405; Carpenter WT, 1997, ARCH GEN PSYCHIAT, V54, P401; DAUGHERTY C, 1995, J CLIN ONCOL, V13, P1062, DOI 10.1200/JCO.1995.13.5.1062; FADEN R, 1986, HIST THEORY INFORMED, P200; Festinger L., 1957, THEORY COGNITIVE DIS, V2; FREEDMAN B, 1996, ETHICS RES INVOLVING, P319; GRINNELL F, 1992, IRB, V12, P1; Haimowitz S, 1997, HASTINGS CENT REP, V27, P9, DOI 10.2307/3527712; hhs, 1979, BELM REP ETH PRINC G; Kass NE, 1996, HASTINGS CENT REP, V26, P25, DOI 10.2307/3528467; Katz Jay, 1993, St Louis Univ Law J, V38, P7; LEVINE RJ, 1986, ETHICS REGULATION CL, P8; Lind S. E, 1996, ETHICS RES INVOLVING, P185; LIPSETT MB, 1982, JAMA-J AM MED ASSOC, V248, P941, DOI 10.1001/jama.248.8.941; MCGINLEY L, 1994, WALL STREET J   0516, pB6; Miller FG, 1998, HEALTH AFFAIR, V17, P264, DOI 10.1377/hlthaff.17.3.264; MILLER FG, 1995, HASTINGS CENT REP, V25, P8, DOI 10.2307/3562107; Miller FG, 1997, BIOL PSYCHIAT, V42, P403, DOI 10.1016/S0006-3223(97)00189-3; *OFF PROT RES RISK, 1994, EV HUM SUBJ PROT SCH; PELLEGRINO ED, 1981, PHILOS BASIS MED PRA, P151; REISER SJ, 1978, MED ETHICS SOCIAL CH; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SCHWARTZ J, 1993, WASH POST       1201, pA4; SCHWARTZ J, 1998, FINAL REPORT ATTORNE; SHORTER E, 1997, HIST PSYCHIATR, P141; Stelfox HT, 1998, NEW ENGL J MED, V338, P101, DOI 10.1056/NEJM199801083380206	28	121	122	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	1998	280	16					1449	1454		10.1001/jama.280.16.1449	http://dx.doi.org/10.1001/jama.280.16.1449			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	130YA	9801009	Bronze			2022-12-28	WOS:000076546900044
J	Shivers, SC; Wang, XN; Li, WG; Joseph, E; Messina, J; Glass, LF; DeConti, R; Cruse, CW; Berman, C; Fenske, NA; Lyman, GH; Reintgen, DS				Shivers, SC; Wang, XN; Li, WG; Joseph, E; Messina, J; Glass, LF; DeConti, R; Cruse, CW; Berman, C; Fenske, NA; Lyman, GH; Reintgen, DS			Molecular staging of malignant melanoma - Correlation with clinical outcome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LYMPH-NODE METASTASES; POLYMERASE CHAIN-REACTION; MONOCLONAL-ANTIBODIES; CUTANEOUS MELANOMA; PROGNOSTIC VALUE; SENTINEL NODE; TUMOR-CELLS; BONE-MARROW; 4 MM; CANCER	Context.-For most solid tumors, the metastatic status of regional lymph nodes is the strongest predictor of relapse and survival. However, routine pathological examination of lymph nodes may underestimate the number of patients with melanoma who have nodal metastases, Objective.-To determine the clinical significance of a highly sensitive molecular assay for occult nodal metastases for the staging of patients with melanoma, Design.-A prospective cohort study of consecutive patients in which lymphatic mapping and sentinel lymph node (SLN) biopsy were performed on 114 melanoma patients with clinical stage I and stage II disease. The SLNs were bivalved, and half of each specimen was submitted for routine pathological examination, The other half was submitted for molecular detection of submicroscopic metastases using a reverse transcriptase-polymerase chain reaction (RT-PCR) assay for tyrosinase messenger RNA as a marker for the presence of melanoma cells. Patient followup averaged 28 months. Setting.-A major university-based melanoma referral center at a National Cancer Institute-designated cancer center. Patients.-A total of 114 patients with newly diagnosed cutaneous malignant melanoma who were at risk for regional nodal metastases, Main Outcome Measure.-Melanoma recurrence and overall survival. Results.-Twenty-three patients (20%) had pathologically positive SLNs, and all of these patients were also RT-PCR positive. Of the 91 pathologically negative patients, 44 were RT-PCR negative and 47 were RT-PCR positive. There was a recurrence rate among 14 (61%) of the 23 patients who were both pathologically and RT-PCR positive and a recurrence rate among 1 (2%) of 44 patients who were both pathologically and RT-PCR negative. For patients who were upstaged by the molecular assay (pathologically negative, RT-PCR positive), there was a recurrence rate among 6 (13%) of 47 patients. The differences in recurrence rates and overall survival between the pathologically negative, RT-PCR-negative and pathologically negative, RT-PCR-positive patient groups were statistically significant (P=.02 for disease-free survival and for overall survival). In both univariate and multivariate regression analyses, the histological and RT-PCR status of the SLNs were the best predictors of disease-free survival. Conclusions.-The use of an RT-PCR assay for detection of submicroscopic melanoma metastases in SLNs improved the prediction of melanoma recurrence and overall survival over routine pathological examination.	Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Cutaneous Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Dept Surg, Tampa, FL 33612 USA; Univ S Florida, Dept Lab Med & Pathol, Tampa, FL 33612 USA; Univ S Florida, Dept Internal Med, Tampa, FL 33612 USA; Univ S Florida, Dept Radiol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Reintgen, DS (corresponding author), Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Cutaneous Oncol Program, 12902 Magnolia dr, Tampa, FL 33612 USA.	doug@moffitt.usf.edu	Shivers, Steve/E-6438-2013; Shivers, Steven/AAE-9288-2022; Lyman, Gary H/K-5227-2019	Shivers, Steve/0000-0001-9538-4016; Lyman, Gary H/0000-0002-0823-8086				Balch CM, 1996, ANN SURG, V224, P255, DOI 10.1097/00000658-199609000-00002; BALCH CM, 1993, ANN SURG, V218, P262, DOI 10.1097/00000658-199309000-00005; BALCH CM, 1992, CUTANEOUS MELANOMA, P188; BERMAN CG, 1992, ANN PLAS SURG, V28, P29, DOI 10.1097/00000637-199201000-00010; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; CHO KH, 1990, CANCER, V66, P765, DOI 10.1002/1097-0142(19900815)66:4<765::AID-CNCR2820660428>3.0.CO;2-M; COCHRAN AJ, 1988, AM J SURG PATHOL, V12, P612, DOI 10.1097/00000478-198808000-00002; COX DR, 1972, J R STAT SOC B, V34, P187; Fields KK, 1996, J CLIN ONCOL, V14, P1868, DOI 10.1200/JCO.1996.14.6.1868; Gershenwald JE, 1998, J CLIN ONCOL, V16, P2253, DOI 10.1200/JCO.1998.16.6.2253; GREENSON JK, 1994, CANCER-AM CANCER SOC, V73, P563, DOI 10.1002/1097-0142(19940201)73:3<563::AID-CNCR2820730311>3.0.CO;2-D; HELLER R, 1993, SEMIN SURG ONCOL, V9, P285; HELLER R, 1991, ARCH SURG-CHICAGO, V126, P1455; Izbicki JR, 1997, NEW ENGL J MED, V337, P1188, DOI 10.1056/NEJM199710233371702; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; KRAG DN, 1995, ARCH SURG-CHICAGO, V130, P654; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; Maehara Y, 1996, SURGERY, V119, P397, DOI 10.1016/S0039-6060(96)80138-3; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Messina J L, 1997, J Fla Med Assoc, V84, P153; MORENO JG, 1992, CANCER RES, V52, P6110; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; MOSS TJ, 1991, NEW ENGL J MED, V324, P219, DOI 10.1056/NEJM199101243240403; Noguchi S, 1996, AM J PATHOL, V148, P649; NORMAN J, 1991, AM J SURG, V162, P432, DOI 10.1016/0002-9610(91)90255-C; REINTGEN D, 1994, ANN SURG, V220, P759, DOI 10.1097/00000658-199412000-00009; REINTGEN DS, 1987, ARCH SURG-CHICAGO, V122, P1338; Roberts WM, 1997, NEW ENGL J MED, V336, P317, DOI 10.1056/NEJM199701303360501; ROSS MI, 1993, SEMIN SURG ONCOL, V9, P219; UREN RF, 1993, J NUCL MED, V34, P1435; VERONESI U, 1988, NEW ENGL J MED, V318, P1159, DOI 10.1056/NEJM198805053181804; WALTS AE, 1988, AM J CLIN PATHOL, V90, P77, DOI 10.1093/ajcp/90.1.77; WANG XN, 1994, ANN SURG, V220, P768, DOI 10.1097/00000658-199412000-00010; WONG JH, 1991, ANN SURG, V214, P637, DOI 10.1097/00000658-199111000-00015; Wood DP, 1997, J CLIN ONCOL, V15, P3451, DOI 10.1200/JCO.1997.15.12.3451	36	264	268	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	1998	280	16					1410	1415		10.1001/jama.280.16.1410	http://dx.doi.org/10.1001/jama.280.16.1410			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130YA	9801000	Bronze			2022-12-28	WOS:000076546900035
J	Jenne, JW				Jenne, JW			Can oral beta(2) agonists cause heart failure?	LANCET			English	Editorial Material							SALBUTAMOL; SALMETEROL				Jenne, JW (corresponding author), 54 PAA-KO Brive, Sandis Pk, NM 87047 USA.							BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; BUNNEY R, 1993, BRIT MED J, V306, P1610, DOI 10.1136/bmj.306.6892.1610-a; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; HIGGINS RM, 1987, LANCET, V2, P863; JENNE JW, 1996, MANUAL ASTHMA MANAGE, P291; KINNEY EL, 1978, JAMA-J AM MED ASSOC, V240, P2247, DOI 10.1001/jama.1978.03290210029010; Mann RD, 1996, J CLIN EPIDEMIOL, V49, P247, DOI 10.1016/0895-4356(95)00555-2; Martin RM, 1998, THORAX, V53, P558, DOI 10.1136/thx.53.7.558; METTAUER B, 1985, AM HEART J, V109, P840, DOI 10.1016/0002-8703(85)90648-9; SACKNER MA, 1975, CHEST, V68, P616, DOI 10.1378/chest.68.5.616; Sitar DS, 1996, CLIN PHARMACOKINET, V31, P246, DOI 10.2165/00003088-199631040-00002; WILSON SR, 1993, THORAX, V48, P886, DOI 10.1136/thx.48.9.886	12	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 3	1998	352	9134					1081	1082		10.1016/S0140-6736(05)79750-6	http://dx.doi.org/10.1016/S0140-6736(05)79750-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798578				2022-12-28	WOS:000076246400003
J	Bignall, J				Bignall, J			Effectiveness or efficiency?	LANCET			English	Editorial Material																			0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					78	78		10.1016/S0140-6736(05)79569-6	http://dx.doi.org/10.1016/S0140-6736(05)79569-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800791				2022-12-28	WOS:000074608600076
J	Westemeier, RL; Brawn, JD; Simpson, SA; Esker, TL; Jansen, RW; Walk, JW; Kershner, EL; Bouzat, JL; Paige, KN				Westemeier, RL; Brawn, JD; Simpson, SA; Esker, TL; Jansen, RW; Walk, JW; Kershner, EL; Bouzat, JL; Paige, KN			Tracking the long-term decline and recovery of an isolated population	SCIENCE			English	Article							ATTWATERS PRAIRIE-CHICKEN; CONSERVATION BIOLOGY; DIRECTIONS	Effects of small population size and reduced genetic variation on the viability of wild animal populations remain controversial. During a 35-year study of a remnant population of greater prairie chickens, population size decreased from 2000 individuals in 1962 to fewer than 50 by 1994. Concurrently, both fitness, as measured by fertility and hatching rates of eggs, and genetic diversity declined significantly. Conservation measures initiated in 1992 with-translocations of birds from Large, genetically diverse populations restored egg viability. Thus, sufficient genetic resources appear to be critical for maintaining populations of greater prairie chickens.	Illinois Nat Hist Survey, Effingham, IL 62401 USA; Illinois Nat Hist Survey, Champaign, IL 61820 USA; Illinois Dept Nat Resources, Newton, IL 62448 USA; Douglas Hart Nat Ctr, Mattoon, IL 61938 USA; Univ Illinois, Dept Nat Resources & Environm Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Ecol Ethol & Evolut, Urbana, IL 61801 USA	Illinois Natural History Survey; Illinois Natural History Survey; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Westemeier, RL (corresponding author), Illinois Nat Hist Survey, Effingham, IL 62401 USA.	j.brawn@uiuc.edu						ALLENDORF F, 1986, CONSERVATION BIOL SC; [Anonymous], 8411 S DAK DEP GAM F; ARTHAUD FL, 1968, THESIS U MISSOURI; BAKER MF, 1953, U KANS MUS NAT HIST, V5; Bouzat JL, 1998, CONSERV BIOL, V12, P836, DOI 10.1046/j.1523-1739.1998.97164.x; Bouzat JL, 1998, AM NAT, V152, P1, DOI 10.1086/286145; CARO TM, 1994, SCIENCE, V263, P485, DOI 10.1126/science.8290956; CAUGHLEY G, 1994, J ANIM ECOL, V63, P215, DOI 10.2307/5542; DROBNEY RD, 1973, THESIS U MISSOURI; Frankham R, 1998, NATURE, V392, P441, DOI 10.1038/33022; Gilpin M.E., 1986, P19; GRANGE WB, 1948, WIS CONSERV DEP PUBL, V328; GROSS ALFRED O., 1928, MEM BOSTON SOC NAT HIST, V6, P491; GROSS AO, 1932, MASS AUDOBON SOC B, V15, P12; GROSS AO, 1930, WIS CONSERV COMM B; Hamerstrom F., 1973, TECHNICAL B DEP NATU, V64; HAMERSTROM F. N., 1939, WILSON BULL, V51, P105; Hedrick PW, 1996, CONSERV BIOL, V10, P1312, DOI 10.1046/j.1523-1739.1996.10051312.x; HORAK GJ, 1985, KANSAS FISH GAME COM, V3; *IL STAT HIST SOC, 1985, 4 ANN ILL HIST S SPR; *ILL AGR STAT SERV, 1997, ILL STAT WAT SURV; *ILL AGR STAT SERV, 1993, ILL STAT WAT SURV; *ILL AGR STAT SERV, 1994, ILL STAT WAT SURV; JOHNSGARD PA, 1983, GROUSE WORLD, P316; JONES DP, 1988, THESIS U MISSOURI; KELLER LF, 1994, NATURE, V372, P356, DOI 10.1038/372356a0; LANDE R, 1988, SCIENCE, V241, P1455, DOI 10.1126/science.3420403; LANDE R, 1995, CONSERV BIOL, V9, P782, DOI 10.1046/j.1523-1739.1995.09040782.x; LOCKART J, 1968, ILL DEP CONSERV TECH; MCDANIEL L, UNPUB; Morrow ME, 1996, WILDLIFE SOC B, V24, P593; Newell J. A., 1987, THESIS MONTANA STATE; OSTERNDORFF EA, 1995, THESIS TEXAS A M U; Peterson MJ, 1996, CONSERV BIOL, V10, P1264, DOI 10.1046/j.1523-1739.1996.10041264.x; Saccheri I, 1998, NATURE, V392, P491, DOI 10.1038/33136; SANDERSON GLEN C., 1966, TRANS ILL STATE ACAD SCI, V59, P326; Schwartz Charles W., 1945, UNIV MISSOURI STUD, V20, P1; SILVY NJ, 1968, THESIS KANSAS STATE; Sisson L., 1976, SHARP TAILED GROUSE; SVEDARSKY WD, 1979, THESIS U N DAKOTA; Toepfer J. E., 1988, THESIS MONTANA STATE; *U MN, 1973, PRAIR CHICK MINN; VANNOORDWIJK AJ, 1981, EVOLUTION, V35, P674, DOI 10.1111/j.1558-5646.1981.tb04929.x; Westemeier RL, 1998, WILSON BULL, V110, P190; Westemeier RL, 1998, J WILDLIFE MANAGE, V62, P854, DOI 10.2307/3802536; WESTEMEIER RL, 1991, WILSON BULL, V103, P717; WESTEMEIER RL, 1995, ILLINOIS NATURAL HIS, V332; WESTEMEIER RL, 1997, ILLINOIS NATURAL HIS, V343; White J., 1978, ILLINOIS NATURAL ARE, V1; Wisdom MJ, 1997, J WILDLIFE MANAGE, V61, P302, DOI 10.2307/3802585; Yeatter Ralph E., 1943, ILLINOIS NAT HIST SURV BULL, V22, P377	52	494	506	2	169	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1695	1698		10.1126/science.282.5394.1695	http://dx.doi.org/10.1126/science.282.5394.1695			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831558				2022-12-28	WOS:000077246600043
J	Thresher, RJ; Vitaterna, MH; Miyamoto, Y; Kazantsev, A; Hsu, DS; Petit, C; Selby, CP; Dawut, L; Smithies, O; Takahashi, JS; Sancar, A				Thresher, RJ; Vitaterna, MH; Miyamoto, Y; Kazantsev, A; Hsu, DS; Petit, C; Selby, CP; Dawut, L; Smithies, O; Takahashi, JS; Sancar, A			Role of mouse cryptochrome blue-light photoreceptor in circadian photoresponses	SCIENCE			English	Article							HUMAN PHOTOLYASE HOMOLOG; DNA PHOTOLYASE; ESCHERICHIA-COLI; SUPRACHIASMATIC NUCLEUS; CRYSTAL-STRUCTURE; RHYTHMS; GENE; PHOTOTRANSDUCTION; EXPRESSION; DROSOPHILA	Cryptochromes are photoactive pigments in the eye that have been proposed to function as circadian photopigments. Mice lacking the cryptochrome 2 blue-light photoreceptor gene (mCry2) were tested for circadian clock-related functions. The mutant mice had a lower sensitivity to acute Light induction of mPer1 in the suprachiasmatic nucleus (SCN) but exhibited normal circadian oscillations of mPer1 and mCry1 messenger RNA in the SCN. Behaviorally, the mutants had an intrinsic circadian period about 1 hour Longer than normal and exhibited high-amplitude phase shifts in response to Light pulses administered at circadian time 17. These data are consistent with the hypothesis that CRY2 protein modulates circadian responses in mice and suggest that cryptochromes have a role in circadian photoreception in mammals.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Northwestern Univ, Natl Sci Fdn Ctr Biol Timing, Howard Hughes Med Inst, Evanston, IL 60208 USA; Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Howard Hughes Medical Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University; Northwestern University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	bsiler.biochem@mhs.unc.edu	Jansen, Heiko T./A-5770-2008; Takahashi, Joseph S./Y-2781-2019; Takahashi, Joseph S/E-8482-2012	Jansen, Heiko T./0000-0003-0178-396X; Takahashi, Joseph S./0000-0003-0384-8878; Takahashi, Joseph S/0000-0003-0384-8878	NIA NIH HHS [P0 AG11412] Funding Source: Medline; NIGMS NIH HHS [GM20069, GM31082] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031082, R01GM031082, R01GM020069, R37GM020069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011412] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS MD, 1995, NATURE, V377, P3; Ahmad M, 1998, NATURE, V392, P720, DOI 10.1038/33701; Ahmad M, 1996, PLANT MOL BIOL, V30, P851, DOI 10.1007/BF00020798; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; ASCHOFF J, 1979, Z TIERPSYCHOL, V49, P225; ASCHOFF J, 1960, COLD SPRING HARB SYM, V25, P11, DOI 10.1101/SQB.1960.025.01.004; Benloucif S, 1997, BRAIN RES, V747, P34, DOI 10.1016/S0006-8993(96)01182-1; Campbell SS, 1998, SCIENCE, V279, P396, DOI 10.1126/science.279.5349.396; DAAN S, 1976, J COMP PHYSIOL, V106, P253, DOI 10.1007/BF01417857; Deng TS, 1997, PLANTA, V202, P502, DOI 10.1007/s004250050155; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDGAR DM, 1991, AM J PHYSIOL, V261, pR928, DOI 10.1152/ajpregu.1991.261.4.R928; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; FOX ME, 1994, MOL CELL BIOL, V14, P8071, DOI 10.1128/MCB.14.12.8071; FRANK KD, 1969, SCIENCE, V163, P688, DOI 10.1126/science.163.3868.688; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HASTINGS JW, 1958, BIOL BULL, V115, P440, DOI 10.2307/1539108; HAYS JB, 1984, MOL CELL BIOL, V9, P767; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; JOHNSON CH, 1989, J BIOL RHYTHM, V4, P417, DOI 10.1177/074873048900400403; Johnson CH, 1996, MOL MICROBIOL, V21, P5, DOI 10.1046/j.1365-2958.1996.00613.x; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Moore RY, 1997, ANNU REV MED, V48, P253, DOI 10.1146/annurev.med.48.1.253; Oren DA, 1996, NEUROSCIENTIST, V2, P207, DOI 10.1177/107385849600200408; Ozer Z, 1995, BIOCHEMISTRY-US, V34, P15886, DOI 10.1021/bi00049a002; PAIETTA J, 1981, P NATL ACAD SCI-BIOL, V78, P5573, DOI 10.1073/pnas.78.9.5573; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PROVENCIO I, 1995, BRAIN RES, V694, P183, DOI 10.1016/0006-8993(95)00694-L; RONNENBERG T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549; RONNENBERG T, 1997, PLANTA, V202, P494; RONNENBERG T, 1988, NATURWISSENSCHAFTEN, V75, P206; ROSENBERG RS, 1991, AM J PHYSIOL, V261, pR491, DOI 10.1152/ajpregu.1991.261.2.R491; SANCAR A, 1984, P NATL ACAD SCI-BIOL, V81, P7397, DOI 10.1073/pnas.81.23.7397; SCHWARTZ WJ, 1990, J NEUROSCI, V10, P3685; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; SOKOLOVE PG, 1978, FDN P, V38, P2589; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; Valentinuzzi VS, 1997, AM J PHYSIOL-REG I, V273, pR1957, DOI 10.1152/ajpregu.1997.273.6.R1957; vanderSpek PJ, 1996, GENOMICS, V37, P177, DOI 10.1006/geno.1996.0539; WICKLAND CR, 1991, AM J PHYSIOL, V261, pR1109, DOI 10.1152/ajpregu.1991.261.5.R1109; WINFREE AT, 1970, J THEOR BIOL, V28, P327, DOI 10.1016/0022-5193(70)90075-5; YAMAMOTO K, 1983, MOL GEN GENET, V192, P282, DOI 10.1007/BF00327679; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zhang Y, 1996, NEUROSCIENCE, V70, P951, DOI 10.1016/0306-4522(95)00408-4; ZIMMERMAN WF, 1971, SCIENCE, V171, P1167, DOI 10.1126/science.171.3976.1167	56	321	330	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1490	1494		10.1126/science.282.5393.1490	http://dx.doi.org/10.1126/science.282.5393.1490			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822380				2022-12-28	WOS:000077110800055
J	Shima, K; Tanji, J				Shima, K; Tanji, J			Role for cingulate motor area cells in voluntary movement selection based on reward	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; RHESUS-MONKEY; PREFRONTAL CORTEX; ACTIVATION; CORTICES; INPUT	Most natural actions are chosen voluntarily from many possible choices, An action is often chosen based on the reward that it is expected to produce. What kind of cellular activity in which area of the cerebral cortex is involved in selecting an action according to the expected reward value? Results of an analysis in monkeys of cellular activity during the performance of reward-based motor selection and the effects of chemical inactivation are presented. We suggest that cells in the rostral cingulate motor area, one of the higher order motor areas in the cortex, play a part in processing the reward information for motor selection.	Tohoku Univ, Sch Med, Dept Physiol, Sendai, Miyagi 980, Japan	Tohoku University	Tanji, J (corresponding author), Tohoku Univ, Sch Med, Dept Physiol, Sendai, Miyagi 980, Japan.							AMARAL DG, 1984, J COMP NEUROL, V230, P465, DOI 10.1002/cne.902300402; BALEYDIER C, 1980, BRAIN, V103, P525, DOI 10.1093/brain/103.3.525; BATES JF, 1993, J COMP NEUROL, V336, P211, DOI 10.1002/cne.903360205; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; JENKINS IH, 1994, J NEUROSCI, V14, P3775; LU MT, 1994, J COMP NEUROL, V341, P375, DOI 10.1002/cne.903410308; MATELLI M, 1991, J COMP NEUROL, V311, P445, DOI 10.1002/cne.903110402; Matsuzaka Y, 1996, J NEUROPHYSIOL, V76, P2327, DOI 10.1152/jn.1996.76.4.2327; MORECRAFT RJ, 1993, J COMP NEUROL, V337, P669, DOI 10.1002/cne.903370411; MORECRAFT RJ, 1992, J COMP NEUROL, V322, P471, DOI 10.1002/cne.903220403; PARTIOT A, 1995, NEUROREPORT, V6, P1397, DOI 10.1097/00001756-199507100-00009; PAUS T, 1993, J NEUROPHYSIOL, V70, P453, DOI 10.1152/jn.1993.70.2.453; Picard N, 1996, CEREB CORTEX, V6, P342, DOI 10.1093/cercor/6.3.342; PLAYFORD ED, 1992, ANN NEUROL, V32, P151, DOI 10.1002/ana.410320206; SHIMA K, 1991, J NEUROPHYSIOL, V65, P188, DOI 10.1152/jn.1991.65.2.188; Van Hoesen G. W. M., 1993, NEUROBIOLOGY CINGULA, P249, DOI DOI 10.1007/978-1-4899-6704-6_9; VOGT BA, 1987, J COMP NEUROL, V262, P271, DOI 10.1002/cne.902620208	18	518	521	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1335	1338		10.1126/science.282.5392.1335	http://dx.doi.org/10.1126/science.282.5392.1335			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812901				2022-12-28	WOS:000076982200050
J	Andersson, DI; Slechta, ES; Roth, JR				Andersson, DI; Slechta, ES; Roth, JR			Evidence that gene amplification underlies adaptive mutability of the bacterial lac operon	SCIENCE			English	Article							EPISOMAL FRAMESHIFT MUTATION; ESCHERICHIA-COLI; REVERSION; RECOMBINATION; CONJUGATION; DELETIONS; MUTANTS; OCCUR; CELLS	Adaptive mutability is the apparent alteration in specificity or rate of mutability seen in bacteria during stress. A model is proposed by which gene amplification during selective growth can give the appearance of adaptive mutability without requiring any change in mutability. The model is based on two assumptions, that a mutant lac locus with residual function allows growth if its copy number is increased, and that true reversion events are made more likely by replication of chromosomes with many copies of the locus. Apparent directed mutability, its recombination requirement, and its apparent independence of cell growth are all accounted for by the model. Evidence is provided far the required residual function and gene amplification.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Swefdish Inst Infect Dis Control, S-10521 Stockholm, Sweden; Uppsala Univ, Dept Microbiol, S-75123 Uppsala, Sweden	Utah System of Higher Education; University of Utah; Swedish Institute for Infectious Disease Control; Uppsala University	Roth, JR (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.	roth@bioscience.utah.edu		Andersson, Dan/0000-0001-6640-2174	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027068] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27068] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RP, 1977, ANNU REV MICROBIOL, V31, P473, DOI 10.1146/annurev.mi.31.100177.002353; [Anonymous], UNPUB; ATKINS JF, 1972, P NATL ACAD SCI USA, V69, P1192, DOI 10.1073/pnas.69.5.1192; BOE L, 1990, MOL MICROBIOL, V4, P597, DOI 10.1111/j.1365-2958.1990.tb00628.x; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; FOSTER PL, 1995, P NATL ACAD SCI USA, V92, P5487, DOI 10.1073/pnas.92.12.5487; FOSTER PL, 1995, J BACTERIOL, V177, P6670, DOI 10.1128/jb.177.22.6670-6671.1995; FOSTER PL, 1992, GENETICS, V131, P783; Foster PL, 1996, GENETICS, V142, P25; FOSTER PL, 1994, SCIENCE, V265, P407, DOI 10.1126/science.8023164; Foster PL, 1997, J BACTERIOL, V179, P1550, DOI 10.1128/jb.179.5.1550-1554.1997; GALITSKI T, 1995, SCIENCE, V268, P421, DOI 10.1126/science.7716546; Galitski T, 1996, GENETICS, V143, P645; HALL BG, 1990, GENETICS, V126, P5; Harris RS, 1996, GENETICS, V142, P681; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kurland C. G., 1996, CELLULAR MOL BIOL, P979; PETERS JE, 1995, J BACTERIOL, V177, P847, DOI 10.1128/jb.177.3.847-850.1995; Peters JE, 1996, J BACTERIOL, V178, P3037, DOI 10.1128/jb.178.11.3037-3043.1996; RADICELLA JP, 1995, SCIENCE, V268, P418, DOI 10.1126/science.7716545; ROSENBERG SM, 1994, SCIENCE, V265, P405, DOI 10.1126/science.8023163; Rosenberg SM, 1998, GENETICS, V148, P1559; ROTH JR, 1996, ESCHERICHIA COLI SAL, P2256; SLECHTA ES, UNPUB; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; TLSTY TD, 1984, CELL, V37, P217, DOI 10.1016/0092-8674(84)90317-9; Torkelson J, 1997, EMBO J, V16, P3303, DOI 10.1093/emboj/16.11.3303; TORKELSON J, 1998, GENETICS, V148, P1453; WHORISKEY SK, 1987, GENE DEV, V1, P227, DOI 10.1101/gad.1.3.227; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976	32	138	144	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 6	1998	282	5391					1133	1135		10.1126/science.282.5391.1133	http://dx.doi.org/10.1126/science.282.5391.1133			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804552				2022-12-28	WOS:000076887700052
J	Lin, JH; Saito, T; Anderson, DJ; Lance-Jones, C; Jessell, TM; Arber, S				Lin, JH; Saito, T; Anderson, DJ; Lance-Jones, C; Jessell, TM; Arber, S			Functionally related motor neuron pool and muscle sensory afferent subtypes defined by coordinate ETS gene expression	CELL			English	Article							CHICK HIND-LIMB; DORSAL-ROOT GANGLIA; TRANSCRIPTION FACTORS; SPINAL-CORD; CELL-DEATH; DIFFERENTIAL EXPRESSION; SYNAPTIC CONNECTIONS; PROJECTION PATTERNS; AXON GUIDANCE; PEA3 GROUP	Motor function depends on the formation of selective connections between sensory and motor neurons and their muscle targets. The molecular basis of the specificity inherent in this sensory-motor circuit remains unclear. We show that motor neuron pools and subsets of muscle sensory afferents can be defined by the expression of ETS genes, notably PEA3 and ER81. There is a matching in PEA3 and ER81 expression by functionally interconnected sensory and motor neurons. ETS gene expression by motor and sensory neurons fails to occur after limb ablation, suggesting that their expression is coordinated by signals from the periphery. ETS genes may therefore participate in the development of selective sensory-motor circuits in the spinal cord.	Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Natl Inst Genet, Mishima, Shizuoka 411, Japan; CALTECH, Pasadena, CA 91125 USA; Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA	Columbia University; Howard Hughes Medical Institute; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; California Institute of Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Jessell, TM (corresponding author), Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA.	tmj1@columbia.edu		Arber, Silvia/0000-0002-6261-250X; Saito, Tetsuichiro/0000-0002-1538-1454; Lin, Jonathan/0000-0002-7438-6941	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025676] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25676] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Appel B, 1995, DEVELOPMENT, V121, P4117; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Caldero J, 1998, J NEUROSCI, V18, P356; Carpenter EM, 1997, DEVELOPMENT, V124, P4505; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; Cohn MJ, 1996, TRENDS GENET, V12, P253, DOI 10.1016/0168-9525(96)10030-5; DAVIS BM, 1989, J COMP NEUROL, V279, P556, DOI 10.1002/cne.902790405; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; Doe CQ, 1996, CURR OPIN NEUROBIOL, V6, P18, DOI 10.1016/S0959-4388(96)80004-3; ECCLES JC, 1957, J PHYSIOL-LONDON, V137, P22, DOI 10.1113/jphysiol.1957.sp005794; Ensini M, 1998, DEVELOPMENT, V125, P969; FRANK E, 1990, J NEUROSCI, V10, P2250; FRANK E, 1993, NEURON, V10, P779, DOI 10.1016/0896-6273(93)90194-V; Frank E, 1988, MESSAGE MIND, P180; FREDETTE BJ, 1994, J NEUROSCI, V14, P7331; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; HOLLYDAY M, 1980, J COMP NEUROL, V194, P143, DOI 10.1002/cne.901940108; HOLLYDAY M, 1990, J COMP NEUROL, V302, P575, DOI 10.1002/cne.903020313; HOLLYDAY M, 1995, J COMP NEUROL, V357, P242, DOI 10.1002/cne.903570205; Hollyday M., 1980, Current Topics in Developmental Biology, V15, P181; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; LAING NG, 1982, DEV BRAIN RES, V5, P181, DOI 10.1016/0165-3806(82)90155-9; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P19, DOI 10.1098/rspb.1981.0080; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P581; LANCEJONES C, 1991, DEV BIOL, V143, P93, DOI 10.1016/0012-1606(91)90057-A; LANCEJONES C, 1979, J MORPHOL, V162, P275; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P371, DOI 10.1113/jphysiol.1978.sp012545; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P391, DOI 10.1113/jphysiol.1978.sp012546; LANDMESSER L, 1986, DEV BIOL, V118, P511, DOI 10.1016/0012-1606(86)90023-0; LANDMESSER LT, 1992, NERVE GROWTH CONE, P373; LEE MT, 1988, J NEUROSCI, V8, P2530; Lefcort F, 1996, J NEUROSCI, V16, P3704; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Matise MP, 1996, DEVELOPMENT, V122, P659; MENDELSON B, 1991, J NEUROSCI, V11, P1390; MU XJ, 1993, J NEUROSCI, V13, P4029; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; OPPENHEIM RW, 1978, BRAIN RES, V154, P148, DOI 10.1016/0006-8993(78)91062-4; Pearson KG., 1997, NEURONS NETWORKS MOT, P225; Romer AS, 1942, J MORPHOL, V71, P251, DOI 10.1002/jmor.1050710203; SAITO T, 1995, MOL CELL NEUROSCI, V6, P280, DOI 10.1006/mcne.1995.1022; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sockanathan S, 1998, CELL, V94, P503, DOI 10.1016/S0092-8674(00)81591-3; Suzuki SC, 1997, MOL CELL NEUROSCI, V9, P433, DOI 10.1006/mcne.1997.0626; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; Tanaka H, 1997, DEV NEUROSCI-BASEL, V19, P106, DOI 10.1159/000111193; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tiret L, 1998, DEVELOPMENT, V125, P279; TOSNEY KW, 1985, DEV BIOL, V109, P193, DOI 10.1016/0012-1606(85)90360-4; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wenner P, 1995, J NEUROSCI, V15, P8191; WHITELAW V, 1983, J NEUROSCI, V3, P1199; WILLIAMS C, 1987, DEV BRAIN RES, V34, P215, DOI 10.1016/0165-3806(87)90210-0; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	59	271	272	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1998	95	3					393	407		10.1016/S0092-8674(00)81770-5	http://dx.doi.org/10.1016/S0092-8674(00)81770-5			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814709	hybrid			2022-12-28	WOS:000076789600012
J	Wasserman, JD; Freeman, M				Wasserman, JD; Freeman, M			An autoregulatory cascade of EGF receptor signaling patterns the Drosophila egg	CELL			English	Article							DORSAL-VENTRAL PATTERN; ALPHA-LIKE PROTEIN; DORSOVENTRAL AXIS; TRANSCRIPTION FACTOR; RHOMBOID GENE; SPITZ GENE; BODY AXES; OOGENESIS; PATHWAY; MELANOGASTER	Intercellular signaling through the EGF receptor (EGFR) patterns the Drosophila egg. The TGF alpha-like ligand Gurken signals from the oocyte to the receptor in the overlying somatic follicle cells. We show that in the dorsal follicle cells this initial paracrine signaling event triggers an autocrine amplification by two other EGFR ligands, Spitz and Vein. Spitz only becomes an effective ligand in the presence of the multitransmembrane domain protein Rhomboid. Consequent high-level EGFR activation leads to localized expression of the diffusible inhibitor Argos, which alters the profile of signaling. This sequential activation, amplification, and local inhibition of the EGFR forms an autoregulatory cascade that leads to the splitting of an initial single peak of signaling into two, thereby patterning the egg.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Freeman, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	MF1@mrc-lmb.cam.ac.uk	Wasserman, JD/AAF-8145-2019; Wasserman, Jonathan D/M-4298-2013	Wasserman, JD/0000-0001-7088-8146; Wasserman, Jonathan D/0000-0001-7088-8146; Freeman, Matthew/0000-0003-0410-5451				BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; Chou TB, 1996, GENETICS, V144, P1673; Deng WM, 1997, DEVELOPMENT, V124, P4639; Dominguez M, 1998, CURR BIOL, V8, P1039, DOI 10.1016/S0960-9822(98)70441-5; Duffy JB, 1998, DEVELOPMENT, V125, P2263; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; FREEMAN M, 1994, MECH DEVELOP, V48, P25, DOI 10.1016/0925-4773(94)90003-5; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Golembo M, 1996, DEVELOPMENT, V122, P3363; Golembo M, 1996, DEVELOPMENT, V122, P223; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Hsu T, 1996, GENE DEV, V10, P1411, DOI 10.1101/gad.10.11.1411; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MAHOWALD AP, 1972, J MORPHOL, V137, P29, DOI 10.1002/jmor.1051370103; Mantrova EY, 1998, GENE DEV, V12, P1166; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; Morimoto AM, 1996, DEVELOPMENT, V122, P3745; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; Musacchio M, 1996, DEV BIOL, V178, P63, DOI 10.1006/dbio.1996.0198; NEUMANSILBERBERG FS, 1994, DEVELOPMENT, V120, P2457; NeumanSilberberg FS, 1996, MECH DEVELOP, V59, P105, DOI 10.1016/0925-4773(96)00567-9; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; NOLL R, 1994, DEVELOPMENT, V120, P2329; PEIFER M, 1993, DEVELOPMENT, V118, P1191; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; Queenan AM, 1997, DEVELOPMENT, V124, P3871; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; RUOHOLABAKER H, 1993, CELL, V73, P953, DOI 10.1016/0092-8674(93)90273-S; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; Sapir A, 1998, DEVELOPMENT, V125, P191; Schnepp B, 1996, GENE DEV, V10, P2302, DOI 10.1101/gad.10.18.2302; Schnorr JD, 1996, GENETICS, V144, P1545; SCHUPBACH T, 1994, CURR OPIN GENET DEV, V4, P502, DOI 10.1016/0959-437X(94)90064-A; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; Simcox AA, 1996, DEV BIOL, V177, P475, DOI 10.1006/dbio.1996.0179; Spradling A.C., 1993, DEV DROSOPHILA MELAN, VI, P1; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TIO M, 1994, MECH DEVELOP, V48, P13, DOI 10.1016/0925-4773(94)90002-7; Twombly V, 1996, DEVELOPMENT, V122, P1555; Wasserman JD, 1997, TRENDS CELL BIOL, V7, P431, DOI 10.1016/S0962-8924(97)01143-4; WIESCHAUS E, 1978, ROUX ARCH DEV BIOL, V184, P75, DOI 10.1007/BF00848670; XU T, 1993, DEVELOPMENT, V117, P1223; Yarnitzky T, 1997, GENE DEV, V11, P2691, DOI 10.1101/gad.11.20.2691; zurLage P, 1997, CURR BIOL, V7, P166, DOI 10.1016/S0960-9822(97)70087-3	51	211	212	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1998	95	3					355	364		10.1016/S0092-8674(00)81767-5	http://dx.doi.org/10.1016/S0092-8674(00)81767-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814706	Green Published, Bronze			2022-12-28	WOS:000076789600009
J	Paneth, N				Paneth, N			Prenatal sonography - safe or sinister?	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED TRIAL; PREGNANCY		Michigan State Univ, Coll Human Med, Dept Epidemiol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University College of Human Medicine	Paneth, N (corresponding author), Michigan State Univ, Coll Human Med, Dept Epidemiol, E Lansing, MI 48824 USA.							BAKKETEIG LS, 1984, LANCET, V2, P207; DUFF GB, 1993, AUST NZ J OBSTET GYN, V33, P374, DOI 10.1111/j.1479-828X.1993.tb02113.x; EIKNES SH, 1984, LANCET, V1, P1347; EWIGMAN BG, 1993, NEW ENGL J MED, V329, P821, DOI 10.1056/NEJM199309163291201; Geerts LTGM, 1996, BRIT J OBSTET GYNAEC, V103, P501, DOI 10.1111/j.1471-0528.1996.tb09796.x; Kieler H, 1997, BRIT J OBSTET GYNAEC, V104, P1267, DOI 10.1111/j.1471-0528.1997.tb10973.x; Kieler H, 1998, EARLY HUM DEV, V50, P233, DOI 10.1016/S0378-3782(97)00097-2; SAARIKEMPPAINEN A, 1990, LANCET, V336, P387, DOI 10.1016/0140-6736(90)91941-3; SALVESEN KA, 1993, BRIT MED J, V307, P1562, DOI 10.1136/bmj.307.6918.1562-a; SALVESEN KA, 1992, LANCET, V339, P85, DOI 10.1016/0140-6736(92)90998-I; SALVESEN KA, 1993, BRIT MED J, V307, P159, DOI 10.1136/bmj.307.6897.159; WALDENSTROM U, 1988, LANCET, V2, P585	12	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					5	6		10.1016/S0140-6736(05)79506-4	http://dx.doi.org/10.1016/S0140-6736(05)79506-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800735				2022-12-28	WOS:000074608600005
J	Strang, J; Sheridan, J				Strang, J; Sheridan, J			Effect of government recommendations on methadone prescribing in southeast England: comparison of 1995 and 1997 surveys	BRITISH MEDICAL JOURNAL			English	Article									Inst Psychiat, Natl Addict Ctr, London SE5 8AF, England; The Maudsley, London SE5 8AF, England	University of London; King's College London	Strang, J (corresponding author), Inst Psychiat, Natl Addict Ctr, De Crespigny Pk,Denmark Hill, London SE5 8AF, England.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725; Sheridan, Janie/0000-0002-0312-3095				*ADV COUNC MIS DRU, 1993, AIDS DRUG MIS UPD RE; *HOM OFF, 1997, STAT MIS DRUGS ADD N; Strang J, 1996, BMJ-BRIT MED J, V313, P270, DOI 10.1136/bmj.313.7052.270; Strang J, 1998, J SUBSTANCE MISUSE, V3, P240; Task Force to Review Services for Drug Misusers, 1996, TASK FORC REV SERV D	5	21	21	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1489	1490		10.1136/bmj.317.7171.1489	http://dx.doi.org/10.1136/bmj.317.7171.1489			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831575	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000077338300024
J	Osborne, CK				Osborne, CK			Drug therapy - Tamoxifen in the treatment of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SURGICAL ADJUVANT BREAST; PIEDMONT-ONCOLOGY-ASSOCIATION; CHEMOTHERAPY PLUS TAMOXIFEN; RANDOMIZED CLINICAL-TRIAL; RECEPTOR-POSITIVE TUMORS; BONE-MINERAL DENSITY; LONG-TERM TAMOXIFEN; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; CHEMOHORMONAL THERAPY		Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Osborne, CK (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NCI NIH HHS [R01 CA30251, P50 CA58183, P30 CA54174] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058183, R01CA030251, P30CA054174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE O, 1992, LANCET, V339, P71; Abram P, 1996, J NATL CANCER I, V88, P1834; Abram P, 1997, J NATL CANCER I, V89, P590; Albain K, 1997, P AN M AM SOC CLIN, V16, p128a; ANDERSSON M, 1991, J NATL CANCER I, V83, P1013, DOI 10.1093/jnci/83.14.1013; ANELLI TFM, 1994, CANCER, V74, P74; ARTEAGA CL, 1991, REGULATORY MECHANISM, P289; ASSIKIS VJ, 1995, INT J GYNECOL OBSTET, V49, P241, DOI 10.1016/0020-7292(95)02387-R; BAGLEY CS, 1987, AM J CLIN ONCOL-CANC, V10, P55, DOI 10.1097/00000421-198702000-00013; BAUM M, 1988, BRIT J CANCER, V57, P608; BEZWODA WR, 1987, CANCER, V60, P1337, DOI 10.1002/1097-0142(19870915)60:6<1337::AID-CNCR2820600629>3.0.CO;2-C; BOCCARDO F, 1990, J CLIN ONCOL, V8, P1310, DOI 10.1200/JCO.1990.8.8.1310; BRATHERTON DG, 1984, BRIT J CANCER, V50, P199, DOI 10.1038/bjc.1984.163; BUCHANAN RB, 1986, J CLIN ONCOL, V4, P1326, DOI 10.1200/JCO.1986.4.9.1326; BUCKLEY MMT, 1989, DRUGS, V37, P451, DOI 10.2165/00003495-198937040-00004; CastiglioneGertsch M, 1997, J CLIN ONCOL, V15, P1385, DOI 10.1200/JCO.1997.15.4.1385; CLARK GM, 1997, P AN M AM SOC CLIN, V16, pA129; Clarke M, 1998, LANCET, V351, P1451; Costantino JP, 1997, J NATL CANCER I, V89, P776, DOI 10.1093/jnci/89.11.776; CRICHLOW RW, 1987, BREAST CANCER DIAGNO, P516; CUMMINGS FJ, 1993, J CLIN ONCOL, V11, P29, DOI 10.1200/JCO.1993.11.1.29; DOMBERNOWSKY P, 1988, ACTA ONCOL, V27, P691, DOI 10.3109/02841868809091771; *EARL BREAST CANC, 1992, LANCET, V339, P1; Ellis PA, 1997, INT J CANCER, V72, P608, DOI 10.1002/(SICI)1097-0215(19970807)72:4<608::AID-IJC10>3.0.CO;2-7; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; FISHER B, 1990, J CLIN ONCOL, V8, P1005, DOI 10.1200/JCO.1990.8.6.1005; FISHER B, 1986, J CLIN ONCOL, V4, P459, DOI 10.1200/JCO.1986.4.4.459; Fisher B, 1997, JNCI-J NATL CANCER I, V89, P1673, DOI 10.1093/jnci/89.22.1673; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FORNANDER T, 1989, LANCET, V1, P117; Gelber RD, 1996, LANCET, V347, P1066, DOI 10.1016/S0140-6736(96)90277-9; Goldhirsch A, 1989, Recent Results Cancer Res, V115, P153; Gorin MB, 1998, AM J OPHTHALMOL, V125, P493, DOI 10.1016/S0002-9394(99)80190-1; Hann LE, 1997, AM J ROENTGENOL, V168, P657, DOI 10.2214/ajr.168.3.9057510; HARD GC, 1993, CANCER RES, V53, P4534; HENDERSON IC, 1987, BREAST DISEASES, P428; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HULL DF, 1983, CANCER RES, V43, P413; INGLE JN, 1986, J CLIN ONCOL, V4, P178, DOI 10.1200/JCO.1986.4.2.178; INGLE JN, 1991, CANCER-AM CANCER SOC, V67, P886, DOI 10.1002/1097-0142(19910215)67:4<886::AID-CNCR2820670405>3.0.CO;2-O; INGLE JN, 1989, CANCER, V63, P1257, DOI 10.1002/1097-0142(19890401)63:7<1257::AID-CNCR2820630705>3.0.CO;2-X; INGLE JN, 1981, NEW ENGL J MED, V304, P16, DOI 10.1056/NEJM198101013040104; Jordan V. C., 1994, LONG TERM TAMOXIFEN, P27; JORDAN VC, 1987, CANCER RES, V47, P4517; JORDAN VC, 1987, CANCER RES, V47, P624; JORDAN VC, 1994, EUR J CANCER, V30A, P1714, DOI 10.1016/0959-8049(94)00349-A; JORDAN VC, 1991, J NATL CANCER I, V83, P1488, DOI 10.1093/jnci/83.20.1488; JORDAN VC, 1994, LONG TERM TAMOXIFEN, P3; KAISERKUPFER MI, 1978, CANCER TREAT REP, V62, P315; KAUFMANN M, 1993, J CLIN ONCOL, V11, P454, DOI 10.1200/JCO.1993.11.3.454; KIANG DT, 1980, CANCER, V45, P1322, DOI 10.1002/1097-0142(19800315)45:6<1322::AID-CNCR2820450609>3.0.CO;2-K; KNIGHT WA, 1980, CLIN ENDOCRINOL META, V9, P361, DOI 10.1016/S0300-595X(80)80038-7; KRISTENSEN B, 1994, J CLIN ONCOL, V12, P992, DOI 10.1200/JCO.1994.12.5.992; Kristensen B, 1996, BREAST CANCER RES TR, V39, P321, DOI 10.1007/BF01806160; LANGANFAHEY SM, 1990, EUR J CANCER, V26, P883, DOI 10.1016/0277-5379(90)90191-U; Levine MN, 1997, THROMB HAEMOSTASIS, V78, P133; LIEN EA, 1991, CANCER RES, V51, P4837; LIPPMAN ME, 1983, BREAST CANCER RES TR, V3, P117, DOI 10.1007/BF01803554; LIPPMAN ME, 1977, NEW ENGL J MED, V296, P154; LODWICK R, 1987, BRIT MED J, V295, P1141, DOI 10.1136/bmj.295.6606.1141-b; LONGSTAFF S, 1989, EUR J CANCER CLIN ON, V25, P1805, DOI 10.1016/0277-5379(89)90351-9; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; LOVE RR, 1991, ARCH INTERN MED, V151, P1842, DOI 10.1001/archinte.151.9.1842; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MANNI A, 1981, CANCER, V48, P873, DOI 10.1002/1097-0142(19810815)48:4<873::AID-CNCR2820480402>3.0.CO;2-1; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; MERCER RJ, 1984, AUST NZ J SURG, V54, P215, DOI 10.1111/j.1445-2197.1984.tb05305.x; Michalets EL, 1998, PHARMACOTHERAPY, V18, P84; MORROW M, 1996, DIS BREAST, P355; MOURIDSEN HT, 1988, ACTA ONCOL, V27, P699, DOI 10.3109/02841868809091772; MUHLEMANN K, 1994, BREAST CANCER RES TR, V30, P201, DOI 10.1007/BF00666064; MUSS HB, 1988, J CLIN ONCOL, V6, P1098, DOI 10.1200/JCO.1988.6.7.1098; MUSS HB, 1994, J CLIN ONCOL, V12, P1630, DOI 10.1200/JCO.1994.12.8.1630; MUSS HB, 1987, J CLIN ONCOL, V5, P1556, DOI 10.1200/JCO.1987.5.10.1556; Nayfield SG, 1996, J CLIN ONCOL, V14, P1018, DOI 10.1200/JCO.1996.14.3.1018; NEMOTO T, 1984, CANCER, V53, P1333, DOI 10.1002/1097-0142(19840315)53:6<1333::AID-CNCR2820530619>3.0.CO;2-7; OSBORNE CK, 1980, CANCER-AM CANCER SOC, V46, P2884, DOI 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U; OSBORNE CK, 1987, EUR J CANCER CLIN ON, V23, P1189; OSBORNE CK, 1985, CANCER RES, V45, P584; Osborne CK, 1996, SCI MED, V3, P32; POTTER GA, 1994, CARCINOGENESIS, V15, P439, DOI 10.1093/carcin/15.3.439; Powles T, 1996, J CLIN ONCOL, V14, P78, DOI 10.1200/JCO.1996.14.1.78; Pritchard KI, 1997, J CLIN ONCOL, V15, P2302, DOI 10.1200/JCO.1997.15.6.2302; Pritchard KI, 1996, J CLIN ONCOL, V14, P2731, DOI 10.1200/JCO.1996.14.10.2731; RAVDIN PM, 1992, J CLIN ONCOL, V10, P1284, DOI 10.1200/JCO.1992.10.8.1284; RAVDIN PM, 1988, CANCER RES, V48, P1026; RIBEIRO G, 1988, BRIT J CANCER, V57, P601, DOI 10.1038/bjc.1988.136; RIBEIRO G, 1985, BRIT J CANCER, V51, P115, DOI 10.1038/bjc.1985.16; RIVKIN SE, 1994, J CLIN ONCOL, V12, P2078, DOI 10.1200/JCO.1994.12.10.2078; ROSSNER S, 1984, ATHEROSCLEROSIS, V52, P339, DOI 10.1016/0021-9150(84)90064-9; Rutqvist LE, 1996, J NATL CANCER I, V88, P1543; RUTQVIST LE, 1991, J NATL CANCER I, V83, P1299, DOI 10.1093/jnci/83.18.1299; RUTQVIST LE, 1993, J NATL CANCER I, V85, P1398, DOI 10.1093/jnci/85.17.1398; SAEZ RA, 1989, BREAST CANC, V1, P163; Shushan A, 1996, AM J OBSTET GYNECOL, V174, P141, DOI 10.1016/S0002-9378(96)70386-1; SMITH IE, 1981, BRIT MED J, V283, P1432, DOI 10.1136/bmj.283.6304.1432; STEWART HJ, 1987, LANCET, V2, P171; Stewart HJ, 1996, BRIT J CANCER, V74, P297, DOI 10.1038/bjc.1996.356; STEWART JF, 1982, CANCER TREAT REP, V66, P1445; SUNDERLAND MC, 1991, J CLIN ONCOL, V9, P1283, DOI 10.1200/JCO.1991.9.7.1283; Tormey DC, 1996, JNCI-J NATL CANCER I, V88, P1828, DOI 10.1093/jnci/88.24.1828; TORMEY DC, 1976, CANCER TREAT REP, V60, P1451; TORMEY DC, 1990, CANCER, V65, P200, DOI 10.1002/1097-0142(19900115)65:2<200::AID-CNCR2820650203>3.0.CO;2-Q; VERCOUTERE AL, 1984, ARCH SURG-CHICAGO, V119, P1301; WATKINS SM, 1988, BRIT J CANCER, V57, P320, DOI 10.1038/bjc.1988.72; WIEBE VJ, 1993, CRIT REV ONCOL HEMAT, V14, P173, DOI 10.1016/1040-8428(93)90008-R; WIEBE VJ, 1992, J CLIN ONCOL, V10, P990, DOI 10.1200/JCO.1992.10.6.990; Wilking N, 1997, DRUG SAFETY, V16, P104, DOI 10.2165/00002018-199716020-00003; Williams JK, 1997, ARTERIOSCL THROM VAS, V17, P403, DOI 10.1161/01.ATV.17.2.403	112	944	990	1	96	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 26	1998	339	22					1609	1618		10.1056/NEJM199811263392207	http://dx.doi.org/10.1056/NEJM199811263392207			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZU	9828250				2022-12-28	WOS:000077176100007
J	Beecham, L				Beecham, L			NHS 1999 cash allocations	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1459	1459						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822420				2022-12-28	WOS:000077202200071
J	Butty, AC; Pryciak, PM; Huang, LS; Herskowitz, I; Peter, M				Butty, AC; Pryciak, PM; Huang, LS; Herskowitz, I; Peter, M			The role of Far1p in linking the heterotrimeric G protein to polarity establishment proteins during yeast mating	SCIENCE			English	Article							MAP KINASE CASCADE; SIGNAL-TRANSDUCTION PATHWAY; PHEROMONE RESPONSE PATHWAY; BETA-GAMMA-SUBUNITS; SACCHAROMYCES-CEREVISIAE; CELL POLARITY; FUNCTIONAL-ANALYSIS; TISSUE POLARITY; BUDDING YEAST; STE5	Heterotrimeric guanosine triphosphate (GTP)-binding proteins (G proteins) determine tissue and cell polarity in a variety of organisms. In yeast, cells orient polarized growth toward the mating partner along a pheromone gradient by a mechanism that requires Far1p and Cdc24p. Far1p bound G beta gamma and interacted with polarity establishment proteins, which organize the actin cytoskeleton. Cells containing mutated Far1p unable to bind G beta gamma or polarity establishment proteins were defective for orienting growth toward their mating partner. In response to pheromones, Far1p moves from the nucleus to the cytoplasm, Thus, Far1p functions as an adaptor that recruits polarity establishment proteins to the site of extracellular signaling marked by G beta gamma to polarize assembly of the cytoskeleton in a morphogenetic gradient.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Univ Massachusetts, Med Ctr, Dept Mol Genet & Microbiol, Shrewsbury, MA 01545 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Swiss Institute Experimental Cancer Research; University of Massachusetts System; University of California System; University of California San Francisco	Peter, M (corresponding author), Swiss Inst Expt Canc Res, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	matthias.peter@isrec.unil.ch	Pryciak, Peter/P-7205-2019; Huang, Linda/C-9903-2014	Pryciak, Peter/0000-0001-9142-1369; Huang, Linda/0000-0002-9033-4391	NIGMS NIH HHS [GM48052, R01 GM057769, F32 GM017494, GM57769] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017494, R01GM057769, R01GM048052] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler PN, 1997, CURR BIOL, V7, P940, DOI 10.1016/S0960-9822(06)00413-1; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; BLONDEL M, UNPUB; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; Chant J, 1996, CURR OPIN CELL BIOL, V8, P557, DOI 10.1016/S0955-0674(96)80035-4; CHENEVERT J, 1994, MOL BIOL CELL, V5, P1169, DOI 10.1091/mbc.5.11.1169; CHENEVERT J, 1994, GENETICS, V136, P1287; CHOI KY, 1994, CELL, V78, P499; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Gartner A, 1998, MOL CELL BIOL, V18, P3681, DOI 10.1128/MCB.18.7.3681; Gho M, 1998, NATURE, V393, P178, DOI 10.1038/30265; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; Harlow E., 1988, ANTIBODIES LAB MANUA; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Huang L., UNPUB; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jaquenoud M, 1998, EMBO J, V17, P5360, DOI 10.1093/emboj/17.18.5360; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; Lyons DM, 1996, MOL CELL BIOL, V16, P4095; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; Pringle JR, 1995, COLD SPRING HARB SYM, V60, P729, DOI 10.1101/SQB.1995.060.01.079; PRINTEN JA, 1994, GENETICS, V138, P609; Pryciak PM, 1996, MOL CELL BIOL, V16, P2614; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Schrick K, 1997, GENETICS, V147, P19; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; SLOAT BF, 1978, SCIENCE, V200, P1171, DOI 10.1126/science.349694; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Valtz N, 1997, METHOD ENZYMOL, V283, P350; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	61	175	177	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1511	1516		10.1126/science.282.5393.1511	http://dx.doi.org/10.1126/science.282.5393.1511			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822386				2022-12-28	WOS:000077110800061
J	Newdick, C				Newdick, C			Primary care groups and the right to prescribe	BRITISH MEDICAL JOURNAL			English	Article									Univ Reading, Dept Law, Reading RG6 6AH, Berks, England	University of Reading	Newdick, C (corresponding author), Univ Reading, Dept Law, Reading RG6 6AH, Berks, England.							*AUD COMM, 1994, PRESCR IMPR RAT PRES, P27; *DEP HLTH, 1995, VAR HLTH WHAT DOH NH; *GEN MED COUNC, 1994, RES CONSTR CONTR PRO; HUNTER DJ, 1992, SOC SCI MED, V35, P557, DOI 10.1016/0277-9536(92)90349-U; Klein RDP, 1996, MANAGING SCARCITY PR; Light DW, 1997, BRIT MED J, V315, P112, DOI 10.1136/bmj.315.7100.112; MOONEY G, 1988, MED ETHICS EC HLTH C; Newdick C, 1998, J Contemp Health Law Policy, V14, P335; NEWDICK C, 1995, WHO SHOULD WE TREAT, P178; Orentlicher David, 1996, Univ Richmond Law Rev, V30, P155; *SECR STAT HLTH, 1997, CMND 3807; *SECR STAT HLTH, 1998, 1 CLASS SERV QUAL NH; Stevens A, 1991, Health Trends, V23, P20; TOWSE A, 1998, GUIDELINES EC EVALUA; WEBSTER C, 1998, NATL HLTH SERVICE PO, P30; WEST P, 1998, MANAGED CARE MODEL U	16	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1361	1364		10.1136/bmj.317.7169.1361	http://dx.doi.org/10.1136/bmj.317.7169.1361			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812936	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000077081600024
J	Studdert, DM; Eisenberg, DM; Miller, FH; Curto, DA; Kaptchuk, TJ; Brennan, TA				Studdert, DM; Eisenberg, DM; Miller, FH; Curto, DA; Kaptchuk, TJ; Brennan, TA			Medical malpractice implications of alternative medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUPUNCTURE; TRIALS; METAANALYSIS; HEALTH; PAIN	Although use of alternative therapies in the United States is widespread and growing, little is known about the malpractice experience of practitioners who deliver these therapies or about the legal principles that govern the relationship between conventional and alternative medicine. Using data from malpractice insurers, we analyzed the claims experience of chiropractors, massage therapists, and acupuncturists for 1990 through 1996, We found that claims against these practitioners occurred less frequently and typically involved injury that was less severe than claims against physicians during the same period. Physicians who may be concerned about their own exposure to liability for referral of patients for alternative treatments can draw some comfort from these findings. However, liability for referral is possible in certain situations and should be taken seriously. Therefore, we review relevant legal principles and case law to understand how malpractice law is likely to develop in this area. We conclude by suggesting some questions for physicians to ask themselves before referring their patients to alternative medicine practitioners.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res,Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Law, Boston, MA 02115 USA; Boston Univ, Sch Law, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston University	Eisenberg, DM (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res,Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.		Studdert, David/AAF-3116-2021	Studdert, David/0000-0003-0585-5537	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U2AR43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baer H A, 1992, Med Anthropol, V13, P369; BIGOS SJ, 1994, CLIN PRACTICE GUIDEL, V14; Blecher MB, 1997, HOSP HEALTH NETWORK, V71, P50; BLECHER MB, 1997, CRAINS CHICAGO  0127, P4; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; COHEN MH, 1996, ARIZ L REV, V38, P83; COVALESKI J, 1997, BESTS REV PC     APR, P61; DUFF C, 1997, WALL STREET J   0414, pB1; EDLIN M, 1997, MANAGED HLTH     JUN, P14; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; *FED CHIR LIC BOAR, 1997, OFF DIR CHIR LIC PRA; FIELDS DH, 1996, NY TIMES        1017, P26; Firshein J, 1995, Bus Health, V13, P28; GONZALES M, 1997, SOCIOECONOMIC CHARAC, P39; GRANDINETTI DA, 1997, MED ECON, V74, P73; Greely H T, 1996, Health Matrix Clevel, V6, P53; HALL MA, 1994, NEW YORK U LAW REV, V69, P693; HILTS PJ, 1996, NY TIMES        0102, P10; HOBSON SM, 1989, INDIANA LAW J, V64, P737; KENT GP, 1988, AM J EPIDEMIOL, V127, P591, DOI 10.1093/oxfordjournals.aje.a114834; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; Miller RH, 1997, HEALTH AFFAIR, V16, P7, DOI 10.1377/hlthaff.16.5.7; MITCHELL BB, 1997, ACUPUNCTURE ORIENTAL; Morreim E. H., 1995, WIDENER LAW S J, V1, P89; *NIH OFF ALT MED, 1998, PROGR AR RES DEV INV; Orentlicher David, 1996, Univ Richmond Law Rev, V30, P155; Pelletier KR, 1997, AM J HEALTH PROMOT, V12, P112, DOI 10.4278/0890-1171-12.2.112; *PHYS INS ASS AM, 1997, PIAA DAT SHAR REP 19; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; WHITAKER B, 1996, NY TIMES        1124, P11; 1997, WALL STREET J   0403, P1; 1991, NCAHF NEWSLETTE 1121, P1; 1996, NATL UNDERWRITE 1126, P18	38	73	73	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1610	1615		10.1001/jama.280.18.1610	http://dx.doi.org/10.1001/jama.280.18.1610			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	136GX	9820265				2022-12-28	WOS:000076852000030
J	Armstrong, N; Sun, Y; Chen, GQ; Gouaux, E				Armstrong, N; Sun, Y; Chen, GQ; Gouaux, E			Structure of a glutamate-receptor ligand-binding core in complex with kainate	NATURE			English	Article							AMPA RECEPTOR; SITE; IDENTIFICATION; DETERMINANTS; DOMAIN; DIFFRACTION; MODULATION; SUBUNIT; REGION	Ionotropic glutamate receptors (iGluRs) mediate excitatory synaptic transmission in vertebrates and invertebrates through ligand-induced opening of transmembrane ion channels. iGluRs are segregated into three subtypes according to their sensitivity to the agonists AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid), kainate (a structural analogue of glutamate) or NMDA (N-methyl-D-aspartate) (Fig.1). iGluRs are important in the development and function of the nervous system, are essential in memory and learning, and are either implicated in or have causal roles in dysfunctions ranging from Alzheimer's, Parkinson's and Huntington's diseases, schizophrenia, epilepsy and Rasmussen's encephalitis to stroke(1,2). Development of iGluR agonists and antagonists has been hampered by a lack of high-resolution structural information. Here we describe the crystal structure of an iGluR ligand-binding region in a complex with the neurotoxin (agonist) kainate. The bilobed structure shows the determinants of receptor-agonist interactions and how ligand-binding specificity and affinity are altered by remote residues and the redox state of the conserved disulphide bond, The structure indicates mechanisms for allosteric effector action and for ligand-induced channel gating. The information provided by this structure will be essential in designing new ligands.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University	Gouaux, E (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.	jeg52@columbia.edu	Gouaux, Eric/Y-4370-2019	Gouaux, Eric/0000-0002-8549-2360				AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHEN GQ, IN PRESS PROTEIN SCI; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; JACOBSON BL, 1992, J MOL BIOL, V223, P27, DOI 10.1016/0022-2836(92)90712-S; Keinanen K, 1997, BIOCHEM SOC T, V25, P835, DOI 10.1042/bst0250835; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; LI F, 1995, MOL PHARMACOL, V47, P148; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paas Y, 1998, TRENDS NEUROSCI, V21, P117, DOI 10.1016/S0166-2236(97)01184-3; Paas Y, 1996, NEURON, V17, P979, DOI 10.1016/S0896-6273(00)80228-7; Partin KM, 1996, J NEUROSCI, V16, P6634, DOI 10.1523/jneurosci.16-21-06634.1996; PARTIN KM, 1995, NEURON, V14, P833, DOI 10.1016/0896-6273(95)90227-9; Read RJ, 1997, METHOD ENZYMOL, V277, P110, DOI 10.1016/S0076-6879(97)77009-5; ROGERS SW, 1994, SCIENCE, V265, P648, DOI 10.1126/science.8036512; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Sun YJ, 1998, J MOL BIOL, V278, P219, DOI 10.1006/jmbi.1998.1675; Sutcliffe MJ, 1996, BIOPHYS J, V70, P1575, DOI 10.1016/S0006-3495(96)79724-2; Swanson GT, 1997, NEURON, V19, P913, DOI 10.1016/S0896-6273(00)80972-1	28	566	578	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 29	1998	395	6705					913	917		10.1038/27692	http://dx.doi.org/10.1038/27692			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804426				2022-12-28	WOS:000076713400060
J	McLellan, F				McLellan, F			"Like hunger, like thirst": patients, journals, and the internet	LANCET			English	Article							WORLD-WIDE-WEB; MEDICAL INFORMATION; HEALTH INFORMATION; NARRATIVES; ILLNESS; QUALITY; ADVICE; CARE		Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	McLellan, F (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 610 Texas Ave, Galveston, TX 77555 USA.			McLellan, Faith/0000-0003-0744-1450				BROWN MS, 1998, MED NET, V4, P17; BYRAM S, 1998, CULTRONIX; ChiLum BI, 1996, JAMA-J AM MED ASSOC, V275, P1361, DOI 10.1001/jama.275.17.1361; Culver JD, 1997, J GEN INTERN MED, V12, P466, DOI 10.1046/j.1525-1497.1997.00084.x; DAVID T, HLTH INFORMATION INT; ENGSTROM P, 1997, MED NET, V3, P1; Frank AW., 2013, WOUNDED STORYTELLER; Glass RM, 1998, JAMA-J AM MED ASSOC, V279, P1309, DOI 10.1001/jama.279.16.1309; GRADY D, 1998, NY TIMES        1229, pD7; GRADY D, 1998, NY TIMES        1117, pD1; HAFNER K, 1996, NEWSWEEK        0527, P77; Hawkins Anne Hunsaker, 1999, RECONSTRUCTING ILLNE; HINNRICHS DLE, 1998, DIANAS STORY; Horton R, 1997, J CLIN EPIDEMIOL, V50, P981, DOI 10.1016/S0895-4356(97)00156-X; HORTON R, 1998, LANCET S, V351, pSL1; Impicciatore P, 1997, BMJ-BRIT MED J, V314, P1875, DOI 10.1136/bmj.314.7098.1875; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P611, DOI 10.1001/jama.279.8.611; Jones AH, 1997, LANCET, V350, P359, DOI 10.1016/S0140-6736(97)07123-7; Kane B, 1998, J AM MED INFORM ASSN, V5, P104, DOI 10.1136/jamia.1998.0050104; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; KATZ J, 1994, NY TIMES        0123; KIRSCHKE D, 1998, UPDATE E HOLLIS; LANDOW GP, 1992, HYPERTEXT CONVERGENC, P3; LUNDBERG GD, 1995, JAMA-J AM MED ASSOC, V274, P655, DOI 10.1001/jama.274.8.655; McLellan MF, 1997, LANCET, V349, P1618, DOI 10.1016/S0140-6736(97)04429-2; MCLELLAN MF, 1997, THESIS U TEXAS MED B; MECKLER L, 1998, CONSUMERS GET HLTH A; MURRAY JH, 1997, HAMLET HOLODECK FUTU, P84; MURRAY P, 1997, MY EXPERIENCE BREAST; Peters R, 1997, JAMA-J AM MED ASSOC, V277, P1258, DOI 10.1001/jama.277.15.1258; Podolsky DK, 1998, GASTROENTEROLOGY, V114, P5, DOI 10.1016/S0016-5085(98)70623-7; Rind DM, 1997, ANN INTERN MED, V127, P138, DOI 10.7326/0003-4819-127-2-199707150-00008; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Singh S, 1998, BRIT MED J, V316, P560, DOI 10.1136/bmj.316.7130.560a; Smith B. H., 1980, NARRATIVE, P209; Smith R, 1998, BMJ-BRIT MED J, V316, P949, DOI 10.1136/bmj.316.7136.949; Sonnenberg FA, 1997, ARCH INTERN MED, V157, P151, DOI 10.1001/archinte.157.2.151; SPIERS J, 1996, SENSE SENSIBILITY HL, P199; Stone J., 1983, JAMA-J AM MED ASSOC, V249, P1741; TODOROV T, 1996, SAIMAGUNDI, V106, P3; Turkle S., 1995, LIFE SCREEN IDENTITY; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209; Wyatt JC, 1997, BRIT MED J, V314, P1879, DOI 10.1136/bmj.314.7098.1879; 1998, HLTH NET FDN CODE CO; 1998, HEART LIGHTS	45	31	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT	1998	352			2			39	43						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PR	9798646				2022-12-28	WOS:000076246600012
J	Gallo, C; Daniele, B; Gaeta, GB; Perrone, F; Pignata, S; D'Alfonso, G; Signoriello, G; Cremona, F; Izzo, F; Parisi, V; Fiore, F; Vallone, P; Monfardini, S; Adinolfi, LE; Ragone, E; Ruggiero, G; Utili, R; Giolitto, G; Giusti, G; Caporaso, N; De Sio, I; Pasquale, G; Piccinino, F; Stanzione, M; Calandra, M; Castellano, L; Blanco, CDV; Colurcio, R; Galanti, B; Russo, M; Palmentieri, B; Persico, M; Budillon, G; Capuano, G; Cimino, L; Pomponi, D; Belli, G; Iannelli, A; Santangelo, ML; Bianco, AR; De Placido, S; Palmieri, G; Castiglione, F; Mazzacca, G; Rispo, A; D'Agostino, L; Mattera, D; Puzziello, A; Cuomo, O; Di Palma, M; Manno, E; Militerno, G; Arena, U; Di Fiore, G; Gentilini, P; Mazzanti, R; Farinati, F; Rinaldi, M; Coviello, A; Elba, S; Manghisi, G; Crispino, B; Laviscio, R; Piai, G; D'Angelo, V; Francica, G; Marone, G; Aiello, A; Ferrau, O; Freni, MA; Aloisio, V; Giorgio, A; Perrotta, A; Felder, M; Zancanella, L; Coolantuono, G; De Sena, G; Guardascione, F; Petrelli, G; Lamorgese, IB; Manzione, L; Pedicini, T; D'Aprile, MD				Gallo, C; Daniele, B; Gaeta, GB; Perrone, F; Pignata, S; D'Alfonso, G; Signoriello, G; Cremona, F; Izzo, F; Parisi, V; Fiore, F; Vallone, P; Monfardini, S; Adinolfi, LE; Ragone, E; Ruggiero, G; Utili, R; Giolitto, G; Giusti, G; Caporaso, N; De Sio, I; Pasquale, G; Piccinino, F; Stanzione, M; Calandra, M; Castellano, L; Blanco, CDV; Colurcio, R; Galanti, B; Russo, M; Palmentieri, B; Persico, M; Budillon, G; Capuano, G; Cimino, L; Pomponi, D; Belli, G; Iannelli, A; Santangelo, ML; Bianco, AR; De Placido, S; Palmieri, G; Castiglione, F; Mazzacca, G; Rispo, A; D'Agostino, L; Mattera, D; Puzziello, A; Cuomo, O; Di Palma, M; Manno, E; Militerno, G; Arena, U; Di Fiore, G; Gentilini, P; Mazzanti, R; Farinati, F; Rinaldi, M; Coviello, A; Elba, S; Manghisi, G; Crispino, B; Laviscio, R; Piai, G; D'Angelo, V; Francica, G; Marone, G; Aiello, A; Ferrau, O; Freni, MA; Aloisio, V; Giorgio, A; Perrotta, A; Felder, M; Zancanella, L; Coolantuono, G; De Sena, G; Guardascione, F; Petrelli, G; Lamorgese, IB; Manzione, L; Pedicini, T; D'Aprile, MD		CLIP Grp	Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial	LANCET			English	Article							ESTROGEN; PLACEBO; RATS	Background Results from small randomised trials on tamoxifen in the treatment of hepatocellular carcinoma (HCC) are conflicting, We studied whether the addition of tamoxifen to best supportive care prolongs survival of patients with HCC. Methods Patients with any stage of HCC were eligible, irrespective of locoregional treatment. Randomisation was centralised, with a minimisation procedure accounting for centre, evidence of disease, and time from diagnosis. Patients were randomly allocated best supportive care alone or in addition to tamoxifen, Tamoxifen was given orally, 40 mg per day, from randomisation until death. Results 496 patients from 30 institutions were randomly allocated treatment from January, 1995, to January, 1997. Information was available for 477 patients. By Sept 15, 1997, 119 (50%) of 240 and 130 (55%) of 237 patients had died in the control and tamoxifen arms, respectively. Median survival was 16 months and 15 months (p=0.54), respectively, No differences were found within subgroups defined by prognostic variables. Relative hazard of death for patients receiving tamoxifen was 1.07 (95% CI 0.83-1.39). Interpretation Our findings show that tamoxifen is not effective in prolonging survival of patients with HCC.	Univ Naples 2, Epidemiol Clin, Cattedra Med, I-80138 Naples, Italy	Universita della Campania Vanvitelli	Gallo, C (corresponding author), Univ Naples 2, Epidemiol Clin, Cattedra Med, Via L Armanni 5, I-80138 Naples, Italy.		persico, marcello/AAB-3562-2019; Signoriello, Giuseppe/AAP-5176-2021; Izzo, Francesco/P-3042-2019; puzziello, alessandro/AAS-1420-2021; D'ANGELO, VALENTINA/AAH-6155-2019; Calandra, Matteo/O-4636-2019; Gallo, Ciro/AAA-9241-2019; Farinati, Fabio/A-8267-2012; Iannelli, Antonio/E-6521-2012	Izzo, Francesco/0000-0003-3093-5408; Gallo, Ciro/0000-0002-7939-3104; Farinati, Fabio/0000-0002-2944-1374; pignata, sandro/0000-0002-8836-2633; Puzziello, Alessandro/0000-0002-1970-7386; Crisanti, Andrea/0000-0002-2406-4426; Piai, Guido/0000-0001-8072-150X				CASTELLS A, 1995, GASTROENTEROLOGY, V109, P917, DOI 10.1016/0016-5085(95)90402-6; CEREZO FJM, 1994, J HEPATOL, V20, P702, DOI 10.1016/S0168-8278(05)80138-2; DEBAC C, 1994, HEPATOLOGY, V20, P1225; ELBA S, 1994, ITAL J GASTROENTEROL, V26, P66; ENGSTROM PF, 1990, CANCER, V65, P2641, DOI 10.1002/1097-0142(19900615)65:12<2641::AID-CNCR2820651207>3.0.CO;2-R; FARINATI F, 1990, J HEPATOL, V11, P297, DOI 10.1016/0168-8278(90)90211-9; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; FRANCAVILLA A, 1989, HEPATOLOGY, V9, P614, DOI 10.1002/hep.1840090417; NAGASUE N, 1995, BRIT J SURG, V82, P542, DOI 10.1002/bjs.1800820435; Pignata S, 1998, EUR J CANCER, V34, P25, DOI 10.1016/S0959-8049(97)00317-1; Pocock SJ., 2013, CLIN TRIALS PRACTICA; SHINOMURA M, 1992, JPN J CANCER RES, V83, P438; Simonetti RG, 1997, ANN ONCOL, V8, P117, DOI 10.1023/A:1008285123736; SUMI C, 1983, J NATL CANCER I, V70, P937; VILLA E, 1995, CANCER RES, V55, P498; YAGER JD, 1980, CANCER RES, V40, P3680	16	188	189	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					17	20						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800740				2022-12-28	WOS:000074608600011
J	Seale, C				Seale, C			Theories and studying the care of dying people	BRITISH MEDICAL JOURNAL			English	Article									Univ London Goldsmiths Coll, Dept Sociol, London SE14 6NW, England	University of London; Goldsmiths University London	Seale, C (corresponding author), Univ London Goldsmiths Coll, Dept Sociol, London SE14 6NW, England.							[Anonymous], YEAR DEATH; Baruch G., 1981, SOCIOLOGY HLTH ILLNE, V3, P275, DOI DOI 10.1111/1467-9566.EP10486851; CARTWRIGHT A, 1990, NATURAL HIST SURVEY; Danforth L.M., 1982, DEATH RITUALS RURAL; Giddens A., 1991, MODERNITY SELF IDENT; Kubler-Ross E., 1970, DEATH DYING; LONG SO, 1982, SOC SCI MED, V16, P2101, DOI 10.1016/0277-9536(82)90259-3; Melzack R, 1989, CHALLENGE PAIN; Metcalf P., 1991, CELEBRATIONS DEATH; Seale C, 1996, AGEING SOC, V16, P75, DOI 10.1017/S0144686X00003147; SEALE C, 1995, SOCIOL HEALTH ILL, V17, P376, DOI 10.1111/1467-9566.ep10933327; SEALE C, 1995, SOCIOLOGY, V29, P597, DOI 10.1177/0038038595029004003; Seale C, 1998, CONSTRUCTING DEATH S; Silverman D., 2015, INTERPRETING QUALITA; SURBONE A, 1992, JAMA-J AM MED ASSOC, V268, P1661	15	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1518	1520		10.1136/bmj.317.7171.1518	http://dx.doi.org/10.1136/bmj.317.7171.1518			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	144WJ	9831588	Green Published			2022-12-28	WOS:000077338300040
J	Murphy, DM; Thomson, DS; Mahoney, TMJ				Murphy, DM; Thomson, DS; Mahoney, TMJ			In situ measurements of organics, meteoritic material, mercury, and other elements in aerosols at 5 to 19 kilometers	SCIENCE			English	Article							CONDENSATION NUCLEI; PARTICLE FORMATION; LOWER STRATOSPHERE; TROPOSPHERE; ORIGIN; METALS; DUST	In situ measurements of the chemical composition of individual aerosol particles at altitudes between 5 and 19 kilometers reveal that upper tropospheric aerosols often contained more organic material than sulfate. Although stratospheric aerosols primarily consisted of sulfuric acid and water, many also contained meteoritic material. Just above the tropopause, small amounts of mercury were found in over half of the aerosol particles that were analyzed. Overall, there was tremendous variety in aerosol composition. One measure of this diversity is that at Least 45 elements were detected in aerosol particles. These results have wide implications for the complexity of aerosol sources and chemistry. They also offer possibilities for understanding the transport of atmospheric aerosols.	NOAA, Aeron Lab, Boulder, CO 80303 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	National Oceanic Atmospheric Admin (NOAA) - USA; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Murphy, DM (corresponding author), NOAA, Aeron Lab, 325 Broadway, Boulder, CO 80303 USA.	murphyd@al.noaa.gov	Murphy, Daniel/J-4357-2012	Murphy, Daniel/0000-0002-8091-7235				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; Biermann UM, 1996, GEOPHYS RES LETT, V23, P1693, DOI 10.1029/96GL01577; BIGG EK, 1970, TELLUS, V22, P550, DOI 10.1111/j.2153-3490.1970.tb00522.x; BROCK CA, 1995, SCIENCE, V270, P1650, DOI 10.1126/science.270.5242.1650; Carslaw KS, 1997, REV GEOPHYS, V35, P125, DOI 10.1029/97RG00078; Chen YL, 1998, GEOPHYS RES LETT, V25, P1391, DOI 10.1029/97GL03261; CHIN M, 1995, J GEOPHYS RES-ATMOS, V100, P8993, DOI 10.1029/95JD00275; DENNING RF, 1989, J GEOPHYS RES-ATMOS, V94, P16757, DOI 10.1029/JD094iD14p16757; DIXON R, UNPUB; FAHEY DW, 1995, SCIENCE, V270, P70, DOI 10.1126/science.270.5233.70; HAYES D, 1980, GEOPHYS RES LETT, V7, P974, DOI 10.1029/GL007i011p00974; Heintzenberg J, 1996, ATMOS RES, V41, P81, DOI 10.1016/0169-8095(95)00042-9; Helmer M, 1998, J GEOPHYS RES-ATMOS, V103, P10913, DOI 10.1029/97JD03075; HERRMANN U, 1978, SPACE SCI, V18, P278; Hofmann DJ, 1998, GEOPHYS RES LETT, V25, P2433, DOI 10.1029/98GL01776; HOFMANN DJ, 1989, J GEOPHYS RES-ATMOS, V94, P11253, DOI 10.1029/JD094iD09p11253; HOFMANN DJ, 1976, J ATMOS SCI, V33, P1782, DOI 10.1175/1520-0469(1976)033<1782:SAMIGT>2.0.CO;2; Houghton J., 1996, SCI CLIMATE CHANGE; HUNTEN DM, 1980, J ATMOS SCI, V37, P1342, DOI 10.1175/1520-0469(1980)037<1342:SADPOM>2.0.CO;2; JONSSON HH, 1995, J ATMOS OCEAN TECH, V12, P115, DOI 10.1175/1520-0426(1995)012<0115:POAFCA>2.0.CO;2; JUNGE CE, 1961, J GEOPHYS RES, V66, P2163, DOI 10.1029/JZ066i007p02163; KANE TJ, 1993, SCIENCE, V259, P1297, DOI 10.1126/science.259.5099.1297; KAUFMANN RL, 1986, PHYSICAL CHEM CHARAC; KENT GS, 1991, J GEOPHYS RES-ATMOS, V96, P5249, DOI 10.1029/89JD03458; KRIEGER A, 1992, GEOPHYS RES LETT, V19, P2301, DOI 10.1029/92GL02633; LOVE SG, 1993, SCIENCE, V262, P550, DOI 10.1126/science.262.5133.550; Middlebrook AM, 1997, AEROSOL SCI TECH, V27, P293, DOI 10.1080/02786829708965475; MILLS MJ, 1996, THESIS U COLORADO BO; MOSSOP SC, 1963, NATURE, V199, P325, DOI 10.1038/199325a0; Murphy DM, 1997, GEOPHYS RES LETT, V24, P3197, DOI 10.1029/97GL03195; MURPHY DM, 1995, AEROSOL SCI TECH, V22, P237, DOI 10.1080/02786829408959743; Novakov T, 1997, J GEOPHYS RES-ATMOS, V102, P30023, DOI 10.1029/97JD02793; PLANE JMC, 1991, INT REV PHYS CHEM, V10, P55, DOI 10.1080/01442359109353254; REILLY P, COMMUNICATION; Rietmeijer FJM, 1997, J GEOPHYS RES-PLANET, V102, P6621, DOI 10.1029/96JE03989; ROSEBURY F, 1964, HDB ELECT TUBE VACUU; RUSSELL JM, 1993, GEOPHYS RES LETT, V20, P719, DOI 10.1029/93GL00497; Schroeder WH, 1998, ATMOS ENVIRON, V32, P809, DOI 10.1016/S1352-2310(97)00293-8; SHEDLOVSKY JP, 1966, TELLUS, V18, P499; SHERIDAN PJ, 1994, GEOPHYS RES LETT, V21, P2587, DOI 10.1029/94GL01387; Slemr F, 1998, ATMOS ENVIRON, V32, P845, DOI 10.1016/S1352-2310(97)00131-3; SLEMR F, 1985, J ATMOS CHEM, V3, P407, DOI 10.1007/BF00053870; Tokos JJS, 1998, ATMOS ENVIRON, V32, P823, DOI 10.1016/S1352-2310(97)00171-4; WATSON JG, 1994, AEROSOL SCI TECH, V21, P1, DOI 10.1080/02786829408959693; Weisenstein DK, 1997, J GEOPHYS RES-ATMOS, V102, P13019, DOI 10.1029/97JD00901; WILSON JC, 1989, J GEOPHYS RES-ATMOS, V94, P16437, DOI 10.1029/JD094iD14p16437; ZHAO JX, 1995, J GEOPHYS RES-ATMOS, V100, P5215, DOI 10.1029/94JD03110; Zieman JJ, 1995, J GEOPHYS RES-ATMOS, V100, P25979, DOI 10.1029/93JD03316	48	491	495	2	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 27	1998	282	5394					1664	1669		10.1126/science.282.5394.1664	http://dx.doi.org/10.1126/science.282.5394.1664			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831550				2022-12-28	WOS:000077246600035
J	Prinz, GA				Prinz, GA			Device physics - Magnetoelectronics	SCIENCE			English	Review							MAGNETORESISTANCE	An approach to electronics is emerging that is based on the up or down spin of the carriers rather than on electrons or holes as in traditional semiconductor electronics. The physical basis for the observed effects is presented, and the initial successful applications of this technology for information storage are reviewed. Additional opportunities for the exploitation of this technology, which are currently under study, are described.	USN, Res Lab, Washington, DC 20375 USA	United States Department of Defense; United States Navy; Naval Research Laboratory	Prinz, GA (corresponding author), USN, Res Lab, Washington, DC 20375 USA.							BAIBICH MN, 1988, PHYS REV LETT, V61, P2472, DOI 10.1103/PhysRevLett.61.2472; DAUGHTON J, 1994, IEEE T MAGN, V30, P4608, DOI 10.1109/20.334164; Dax M., 1997, Semiconductor International, V20, P84; Dong ZW, 1997, APPL PHYS LETT, V71, P1718, DOI 10.1063/1.120014; JULLIERE M, 1975, PHYS LETT A, V54, P225, DOI 10.1016/0375-9601(75)90174-7; MONSMA DJ, 1995, PHYS REV LETT, V74, P5260, DOI 10.1103/PhysRevLett.74.5260; MOODERA JS, 1995, PHYS REV LETT, V74, P3273, DOI 10.1103/PhysRevLett.74.3273; Nitta J, 1997, PHYS REV LETT, V78, P1335, DOI 10.1103/PhysRevLett.78.1335; SCHEUERLEIN RE, 1998, IEEE INT C NONV MEM; Soulen RJ, 1998, SCIENCE, V282, P85, DOI 10.1126/science.282.5386.85; TANG C, 1994, IEEE T MAGN, V30, P3801; 1997, WALL STREET J   1110, pB8	12	3477	3552	7	325	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1660	1663		10.1126/science.282.5394.1660	http://dx.doi.org/10.1126/science.282.5394.1660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831549				2022-12-28	WOS:000077246600034
J	Davidson, JM; Lambert, TW; Goldacre, MJ				Davidson, JM; Lambert, TW; Goldacre, MJ			Career pathways and destinations 18 years on among doctors who qualified in the United Kingdom in 1977: postal questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine the career destinations, by 1995, of doctors who qualified in the United Kingdom in 1977; the relation between their destinations and early career choice; and their intentions regarding retirement age. Design Postal questionnaire. Setting United Kingdom. Subjects All (n = 3135) medical qualifiers of 1977. Main outcome measures Current employment; year by year trends in the percentage of doctors who worked in the NHS, in other medical posts in the United Kingdom, abroad, in non-medical posts, outside medicine, and in part time work; intentions regarding retirement age. Results After about 12 years the distribution of respondents by type of employment and, for women, the percentage of doctors in part time rather than full time medical work, had stabilised. Of all 2997 qualifiers from medical schools in Great Britain, 2399 (80.0% (95% confidence interval 79.5% to 80.6%)) were working in medicine in the NHS in Great Britain 18 years after qualifying. Almost half the women (318/656) worked in the NHS part time. Of 1714 doctors in the NHS, 1125 intended to work in the NHS until normal retirement age, 392 did not, and 197 were undecided. Of the 1548 doctors for whom we had sufficient information, career destinations at 18 years matched the choices made at 1, 3, and 5 years in 58.9% (912), 78.2% (1211), and 86.6% (1341) of cases respectively. Conclusions Planning for the medical workforce needs to be supported by information about doctors' career plans, destinations, and whole time equivalent years of work Postgraduate training needs to take account of doctors' eventual choice of specialty land the timing of this choice).	Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, UK Med Careers Res Grp, Oxford OX3 7LF, England	University of Oxford	Goldacre, MJ (corresponding author), Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, UK Med Careers Res Grp, Oxford OX3 7LF, England.			Lambert, Trevor/0000-0001-9688-3036				*DEP HLTH, 1993, HOSP DOCT TRAIN FUT; Edwards C, 1997, MED EDUC, V31, P237, DOI 10.1111/j.1365-2923.1997.tb02919.x; HOOK EB, 1992, AM J EPIDEMIOL, V135, P1060, DOI 10.1093/oxfordjournals.aje.a116400; Lambert TW, 1998, BRIT MED J, V317, P1429, DOI 10.1136/bmj.317.7170.1429; Lambert TW, 1996, BRIT MED J, V312, P893; PARKHOUSE J, 1988, BRIT MED J, V296, P1651, DOI 10.1136/bmj.296.6637.1651; PARKHOUSE J, 1991, DOCTORS CAREERS AIMS	7	60	60	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1425	1428		10.1136/bmj.317.7170.1425	http://dx.doi.org/10.1136/bmj.317.7170.1425			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822395	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000077202200022
J	Smith, GD; Shipley, M; Leon, DA				Smith, GD; Shipley, M; Leon, DA			Height and mortality from cancer among men: prospective observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADULT HEIGHT		Dept Social Med, Bristol BS8 2PR, Avon, England; UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	Smith, GD (corresponding author), Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.	zetkin@bristol.ac.uk	Davey Smith, George/A-7407-2013; Leon, David A/G-2195-2010	Davey Smith, George/0000-0002-1407-8314; Leon, David A/0000-0001-9747-1762				ALBANES D, 1988, CANCER RES, V48, P1658; Frankel S, 1998, BMJ-BRIT MED J, V316, P499, DOI 10.1136/bmj.316.7130.499; Hebert PR, 1997, CANCER CAUSE CONTROL, V8, P591, DOI 10.1023/A:1018442329319; KRISTAL BS, 1994, MODULATION AGING PRO, P1; LEON DA, 1995, J EPIDEMIOL COMMUN H, V49, P5, DOI 10.1136/jech.49.1.5	5	37	39	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	1998	317	7169					1351	1352		10.1136/bmj.317.7169.1351	http://dx.doi.org/10.1136/bmj.317.7169.1351			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812932	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000077081600020
J	Peschon, JJ; Slack, JL; Reddy, P; Stocking, KL; Sunnarborg, SW; Lee, DC; Russell, WE; Castner, BJ; Johnson, RS; Fitzner, JN; Boyce, RW; Nelson, N; Kozlosky, CJ; Wolfson, MF; Rauch, CT; Cerretti, DP; Paxton, RJ; March, CJ; Black, RA				Peschon, JJ; Slack, JL; Reddy, P; Stocking, KL; Sunnarborg, SW; Lee, DC; Russell, WE; Castner, BJ; Johnson, RS; Fitzner, JN; Boyce, RW; Nelson, N; Kozlosky, CJ; Wolfson, MF; Rauch, CT; Cerretti, DP; Paxton, RJ; March, CJ; Black, RA			An essential role for ectodomain shedding in mammalian development	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-ALPHA; SELECTIN ADHESION MOLECULE; AMYLOID PRECURSOR PROTEIN; SPERM-EGG FUSION; TGF-ALPHA; CONVERTING-ENZYME; FACTOR RECEPTOR; DEFICIENT MICE; TNF-ALPHA	The ectodomains of numerous proteins are released from cells by proteolysis to yield soluble intercellular regulators. The responsible protease, tumor necrosis factor-a converting enzyme (TACE), has been identified only in the case when tumor necrosis factor-alpha (TNF alpha) is released. Analyses of cells lacking this metalloproteinase-disintegrin revealed an expanded role for TACE in the processing of other cell surface proteins, including a TNF receptor, the L-selectin adhesion molecule, and transforming growth factor-alpha (TGF alpha). The phenotype of mice Lacking TACE suggests an essential role for soluble TGF alpha in normal development and emphasizes the importance of protein ectodomain shedding in vivo.	Immunex Res & Dev Corp, Seattle, WA 98101 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Vanderbilt Univ, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA; Pathol Associates Int, Frederick, MD 21701 USA	University of North Carolina; University of North Carolina Chapel Hill; Vanderbilt University; Vanderbilt University	Peschon, JJ (corresponding author), Immunex Res & Dev Corp, 51 Univ St, Seattle, WA 98101 USA.		Russell, William/A-7307-2009		NATIONAL CANCER INSTITUTE [R01CA043793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK053804, R01DK053804] Funding Source: NIH RePORTER; NCI NIH HHS [CA43793] Funding Source: Medline; NIDDK NIH HHS [DK53804] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bennett TA, 1996, J IMMUNOL, V156, P3093; Berkowitz EA, 1996, CELL GROWTH DIFFER, V7, P1271; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1996, BIOCHEM BIOPH RES CO, V225, P400, DOI 10.1006/bbrc.1996.1186; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Ehlers MRW, 1996, BIOCHEMISTRY-US, V35, P9549, DOI 10.1021/bi9602425; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; HARRIS MJ, 1982, ANAT EMBRYOL, V164, P207, DOI 10.1007/BF00318505; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; LEE DC, 1990, HDB EXP PHARM, V95, P611; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; Peschon JJ, 1998, J IMMUNOL, V160, P943; PESCHON JJ, UNPUB; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; ROBERTS SB, 1994, J BIOL CHEM, V269, P3111; RUSSELL WE, 1993, ENDOCRINOLOGY, V133, P1731, DOI 10.1210/en.133.4.1731; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SLACK JL, UNPUB; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Wen CH, 1997, DEVELOPMENT, V124, P4759; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	41	1328	1363	3	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1281	1284		10.1126/science.282.5392.1281	http://dx.doi.org/10.1126/science.282.5392.1281			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812885				2022-12-28	WOS:000076982200034
J	Douglas, C				Douglas, C			Remember them?	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1329	1329		10.1136/bmj.317.7168.1329a	http://dx.doi.org/10.1136/bmj.317.7168.1329a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804746	Green Published			2022-12-28	WOS:000076963800067
J	Roberts, C; Torgerson, D				Roberts, C; Torgerson, D			Understanding controlled trials - Randomisation methods in controlled trials	BRITISH MEDICAL JOURNAL			English	Review									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 6PL, Lancs, England; Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO1 5DD, N Yorkshire, England	University of Manchester; University of York - UK	Roberts, C (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 6PL, Lancs, England.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275				Altman D.G., 1991, PRACTICAL STAT MED R; Pocock SJ., 2013, CLIN TRIALS PRACTICA	2	71	73	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1301	1301		10.1136/bmj.317.7168.1301	http://dx.doi.org/10.1136/bmj.317.7168.1301			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804722	Green Published			2022-12-28	WOS:000076963800031
J	Detels, R; Munoz, A; McFarlane, G; Kingsley, LA; Margolick, JB; Giorgi, J; Scharager, LD; Phair, JP				Detels, R; Munoz, A; McFarlane, G; Kingsley, LA; Margolick, JB; Giorgi, J; Scharager, LD; Phair, JP		Multicenter AIDS Cohort Study Investigators	Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CUBIC MILLIMETER; CONTROLLED TRIAL; MULTICENTER; COHORT; SEROCONVERSION; ZIDOVUDINE; INCUBATION; INDINAVIR; PROTEASE	Context.-Time to development of acquired immunodeficiency syndrome (AIDS) and time to death have been extended with the increased use of combination therapy and protease inhibitors. Cohort studies following up persons with human immunodeficiency virus (HIV) infection in periods characterized by different therapies offer the opportunity to estimate therapy effectiveness at the population level. Objective.-To assess the effectiveness of self-reported, long-term potent antiretroviral therapy in a cohort of 536 men whose duration of HIV infection was known (seroconverters). Design.-Cohort study. The cohort was compared for time to development of AIDS and time to death in 1984 to 1990, 1990 to 1993, 1993 to July 1995, and July 1995 to July 1997 when the major treatments were no therapy, monotherapy, combined therapy, and potent antiretroviral therapy, respectively. Survival analysis methods with time zero set as the date of seroconversion and incorporating staggered entries into each period were used. Mean CD4 cell change, stratified by infection duration, was determined for each period using a random effects model. Setting.-The Multicenter AIDS Cohort Study (MACS) in 4 urban areas (Baltimore, Md; Chicago, III; Los Angeles, Calif; and Pittsburgh, Pa). Participants.-A total of 5622 men who were 18 years or older were enrolled into MACS. Of the 5622, there were 2191 HIV-positive individuals at enrollment. Of the 3431 men who were HIV-negative, 536 were observed to seroconvert and were followed up for up to 13 years. The group of 536 who seroconverted constituted the study population. Main Outcome Measures.-Time from seroconversion to development of AIDS and to death and change in CD4 cell count. Results.-A total of 231 seroconverters developed AIDS, and 200 men died. Using 1990 to 1993 as the reference period, the relative hazard of AIDS was 1.04 (95% confidence interval [GI], 0.73-1.48) during 1993 to July 1995 and 0.35 (95% CI, 0.20-0.61) during July 1995 to July 1997. Relative hazards of death were 0.87 (95% CI, 0.58-1.31) and 0.62 (95% Cl, 0.38-1.01) for the same periods. The relative time (the factor by which times are contracted or expanded) to development of AIDS was 0.97 (95% CI, 0.86-1.09) for 1993 to July 1995 and 1.63 (95% CI, 1.40-1.89) for July 1995 to July 1997. Relative survival time for 1993 to July 1995 was 1.01 (95% CI, 0.91-1.12) and for July 1995 to July 1997 was 1.21 (95% Cl, 1.07-1.36) relative to 1990 to 1993. The rate of CD4 cell count decline in July 1995 to July 1997 was significantly lower (P<.05) compared with the previous 2 periods. Conclusions.-In the calendar period when potent antiretroviral therapy was introduced, the time to development of AIDS and time to death were extended, and rate of CD4 cell count decline was arrested.	Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21218 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA; NIAID, Div AIDS, Bethesda, MD 20892 USA; Northwestern Univ, Sch Med, Chicago, IL USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Northwestern University	Detels, R (corresponding author), Univ Calif Los Angeles, Sch Publ Hlth, POB 951772, Los Angeles, CA 90095 USA.	detels@ucla.edu		Kingsley, Lawrence/0000-0002-7000-8556	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035043, U01AI035042] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Barkan SE, 1998, EPIDEMIOLOGY, V9, P117, DOI 10.1097/00001648-199803000-00004; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P155; CHIASSON MA, 1997, 4 C RETR OPP INF JAN; CHMIEL JS, 1987, AM J EPIDEMIOL, V126, P568, DOI 10.1093/oxfordjournals.aje.a114696; Detels R, 1997, Antivir Ther, V2, P21; DETELS R, 1992, J EPIDEMIOL, V2, pS11; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; GAIL MH, 1995, AIDS CLIN TRIALS, P403; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hills, 1993, STAT MODELS EPIDEMIO; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KINGSLEY LA, 1987, LANCET, V1, P345; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; LEVITT R, 1997, 4 C RETR OPP INF JAN; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; Munoz A, 1996, STAT MED, V15, P2459, DOI 10.1002/(SICI)1097-0258(19961130)15:22<2459::AID-SIM464>3.0.CO;2-Q; Munoz A, 1997, AIDS, V11, pS69; Munoz A, 1996, AM J RESP CRIT CARE, V154, pS234, DOI 10.1164/ajrccm/154.6_Pt_2.S234; MUNOZ A, 1995, AIDS CLIN TRIALS, P423; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Sorvillo F, 1997, J ACQ IMMUN DEF SYND, V15, P179; STEIN D, 1997, 4 C RETR OPP INF JAN; Veugelers PJ, 1998, AM J EPIDEMIOL, V148, P487, DOI 10.1093/oxfordjournals.aje.a009674; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEI LJ, 1992, STAT MED, V11, P1871, DOI 10.1002/sim.4780111409; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	34	582	596	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1497	1503		10.1001/jama.280.17.1497	http://dx.doi.org/10.1001/jama.280.17.1497			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809730	Bronze			2022-12-28	WOS:000076757200023
J	Zwarenstein, M; Schoeman, JH; Vundule, C; Lombard, CJ; Tatley, M				Zwarenstein, M; Schoeman, JH; Vundule, C; Lombard, CJ; Tatley, M			Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis	LANCET			English	Article								Background Tuberculosis is a major public-health problem in South Africa, made worse by poor adherence to and frequent interruption of treatment. Direct observation (DO) of tuberculosis patients taking their drugs is supposed to improve treatment completion and outcome. We compared DO with self-supervision, in which patients on the same drug regimen are not observed taking their pills, to assess the effect of Each on the success of tuberculosis treatment. Methods We undertook an unblinded randomised controlled trial in two communities with large tuberculosis caseloads. The trial included 216 adults who started pulmonary tuberculosis treatment for the first time, or who had a second course of treatment (retreatment patients). No changes to existing treatment delivery were made other than randomisation. Analysis was by intention to treat. Individual patient data from the two communities were combined. Findings Treatment for tuberculosis was more successful among self-supervised patients (60% of patients) than among those on DO (54% of patients, difference between groups 6% [90% CI -5.1 to 17.0]). Retreatment patients had significantly more successful treatment outcomes if self supervised (74% of patients) than an DO (42% of patients, difference between groups 32% [11%-52%]). Interpretation At high rates of treatment interruption, self-supervision achieved equivalent outcomes to clinic DO at lower cost. Self-supervision achieved better outcomes far retreatment patients. Supportive patient-carer relations, rather than the authoritarian surveillance implicit in DO, may improve treatment outcomes and help to control tuberculosis.	S African MRC, Hlth Syst Div, ZA-7505 Tygerberg, South Africa; S African MRC, Ctr Epidemiol Res So Africa, ZA-7505 Tygerberg, South Africa; Dept Hlth, NW Prov, South Africa; Cape Metropolitan Council, Cape Town, South Africa	South African Medical Research Council; South African Medical Research Council	Zwarenstein, M (corresponding author), S African MRC, Hlth Syst Div, POB 19070, ZA-7505 Tygerberg, South Africa.		Tatley, Michael/G-8588-2015; Zwarenstein, Merrick F/P-5210-2014	Tatley, Michael/0000-0003-3121-248X; Zwarenstein, Merrick F/0000-0003-0162-7027				Cameron N, 1996, S AFR MED J, V86, P271; *DEP HLTH, 1996, S AFR TUB CONTR PROG; Department of Health Directorate Epidemiology, 1995, EPIDEMIOLOGICAL COMM, V22, P13; Dick J, 1998, S AFR MED J, V88, P380; DICK J, 1995, CHASEA J COMPR HLTH, V6, P4; DICK J, 1996, TUBERCLE LUNG DIS, V77, P247; Foucault Michel, 1976, BIRTH CLIN; NEWELL DJ, 1992, INT J EPIDEMIOL, V21, P837, DOI 10.1093/ije/21.5.837; SHEINCHUNG C, 1992, DESIGN ANAL BIOAVAIL; Steyn M, 1997, Curationis, V20, P53; VOLMINK J, 1997, INFECT DIS MODULE CO; VOLMINK J, 1997, LANCET, V39, P1399; *W CAP REG SERV CO, 1993, ANN REP DEP HLTH SER; World Health Organization, 1997, WHO REP TUB EP 1997	14	213	219	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 24	1998	352	9137					1340	1343		10.1016/S0140-6736(98)04022-7	http://dx.doi.org/10.1016/S0140-6736(98)04022-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802271				2022-12-28	WOS:000076691700011
J	Christensson, K; Bhat, GJ; Amadi, BC; Eriksson, B; Hojer, B				Christensson, K; Bhat, GJ; Amadi, BC; Eriksson, B; Hojer, B			Randomised study of skin-to-skin versus incubator care for rewarming low-risk hypothermic neonates	LANCET			English	Article									Karolinska Inst, Dept Publ Hlth Sci, Div Int Hlth Care Res, Stockholm, Sweden; Karolinska Hosp, Dept Women & Child Hlth, S-10401 Stockholm, Sweden; Univ Teaching Hosp, Dept Paediat, Lusaka, Zambia; Univ Teaching Hosp, Dept Child Hlth, Lusaka, Zambia; Nord Sch Publ Hlth, Gothenburg, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Zambia; University of Zambia	Christensson, K (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, Div Int Hlth Care Res, Stockholm, Sweden.							CHRISTENSSON K, 1995, J TROP PEDIATRICS, V41, P210, DOI 10.1093/tropej/41.4.210; KARLSSON H, 1996, SKIN SKIN CARE RESUL; Ludington-Hoe S M, 1996, J Obstet Gynecol Neonatal Nurs, V25, P691, DOI 10.1111/j.1552-6909.1996.tb01483.x; REISENFELT T, 1996, ACTA PAEDIAT, V85, P467; *WHO, 1993, WHOFHEMSM932	5	49	50	2	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 3	1998	352	9134					1115	1115		10.1016/S0140-6736(98)00028-2	http://dx.doi.org/10.1016/S0140-6736(98)00028-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798589				2022-12-28	WOS:000076246400014
J	Gratwohl, A; Hermans, J; Goldman, JM; Arcese, W; Carreras, E; Devergie, A; Frassoni, F; Gahrton, G; Kolb, H; Niederwieser, D; Ruutu, T; Vernant, JP; de Witte, T; Apperley, J				Gratwohl, A; Hermans, J; Goldman, JM; Arcese, W; Carreras, E; Devergie, A; Frassoni, F; Gahrton, G; Kolb, H; Niederwieser, D; Ruutu, T; Vernant, JP; de Witte, T; Apperley, J		European Grp Blood Marrow Transplantation	Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation	LANCET			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC-PHASE; INTERFERON-ALPHA; CELLS	Background Transplantation of blood or bone-marrow stem cells is the treatment of choice for selected patients with chronic myeloid leukaemia (CML). Transplantation is used with increasing frequency and success, but remains associated with substantial risks of morbidity and mortality. Other treatments with satisfactory short-term outcome are available. For appropriate counselling of patients, a rapid and simple way to assess risk is needed. Methods Data from 3142 patients (1873 [60%] male, 1269 [40%] female; mean age 34 years, range <1-60 years) treated with allogeneic blood or marrow transplants for CML between 1989 and 1997, reported to the European Group for Blood and Marrow Transplantation (EBMT), were used to develop and test a simple risk score based on previously reported major pretransplant risk factors: histocompatibility, stage of disease at time of transplantation, age and sex of donor and recipient, and time from diagnosis to transplantation. We analysed probabilities of survival, leukaemia-free survival, transplant-related mortality, and relapse incidence with respect to these risk factors. Findings At the time of analysis, 1922 (61%) of the 3142 patients were alive-1567 (65%) of those with HLA-identical sibling donors and 417 (57%) of those with unrelated donors. 1682 (54%) were alive without relapse. 1220 (39%) patients had died, 1013 (83%) of transplant-related causes, 207 (17%) of relapse. 447 (14%) patients had relapsed. The final scoring system was highly predictive for leukaemia-free survival, survival and transplant-related mortality. Survival at 5 years was 72%, 70%, 62%, 48%, 40%, 18%, and 22% for patients with scores 0, 1, 2, 3, 4, 5, and 6, respectively. Risk of transplant-related mortality was 20%, 23%, 31%, 46%, 51%, 71%, and 73%. Data showed the same trends for HLA-identical sibling transplants and unrelated transplants for transplants done in 1989-93 and 1994-96. Interpretation Pretransplant risk factors are cumulative for individual patients with CML having blood or marrow transplantation. A simple system based on five main factors gives adequate risk assessment for counselling of patients and taking decisions.	Kantonsspital, Dept Internal Med, Div Haematol, CH-4031 Basel, Switzerland; Leiden Univ, Dept Med Stat, NL-2300 RA Leiden, Netherlands; Hammersmith Hosp, Royal Postgrad Med Sch, Dept Haematol, London, England; Univ Hosp La Sapienza, Inst Haematol, Rome, Italy; Hosp & Clin, Bone Marrow Transplant Unit, Barcelona, Spain; Hop St Louis, Bone Marrow Transplant Unit, Paris, France; Osped San Martino Genova, Bone Marrow Transplant Unit, Genoa, Italy; Huddinge Univ Hosp, Dept Med, S-14186 Huddinge, Sweden; Univ Munich, Klinikum Grosshadern, Med Klin 3, D-8000 Munich, Germany; Univ Innsbruck, Clin Internal Med, A-6020 Innsbruck, Austria; Univ Helsinki, Cent Hosp, Dept Med, Div Haematol, FIN-00014 Helsinki, Finland; Grp Hosp Pitie Salpetriere, Serv Hematol Clin, F-75634 Paris, France; Univ Nijmegen Hosp, Div Hematol, NL-6500 HB Nijmegen, Netherlands	Kantonsspital Aarau AG (KSA); University of Basel; Leiden University; Leiden University - Excl LUMC; Imperial College London; Sapienza University Rome; University Hospital Sapienza Rome; University of Barcelona; Hospital Clinic de Barcelona; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Genoa; IRCCS AOU San Martino IST; Karolinska Institutet; University of Munich; University of Innsbruck; University of Helsinki; Helsinki University Central Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Radboud University Nijmegen	Gratwohl, A (corresponding author), Kantonsspital, Dept Internal Med, Div Haematol, CH-4031 Basel, Switzerland.	hematology@ubaclu.unibas.ch	de Witte, T.J.M./L-4762-2015; Frassoni, Francesco/K-3971-2018	Frassoni, Francesco/0000-0003-1262-0648; ARCESE, WILLIAM/0000-0001-5697-366X				[Anonymous], 1993, N ENGL J MED, V329, P987; ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; BEELEN DW, 1995, BLOOD, V85, P2981, DOI 10.1182/blood.V85.10.2981.bloodjournal85102981; Carella AM, 1997, HAEMATOLOGICA, V82, P478; CLIFT R, 1989, BONE MARROW TRANSPL, V4, P445; CLIFT RA, 1993, BLOOD, V82, P1954; CORTES JE, 1996, AM J MED, V100, P55; Devergie A, 1997, BONE MARROW TRANSPL, V20, P11, DOI 10.1038/sj.bmt.1700844; Dini G, 1996, BONE MARROW TRANSPL, V18, P80; FEFER A, 1979, NEW ENGL J MED, V300, P333, DOI 10.1056/NEJM197902153000702; GOLDMAN JM, 1993, BLOOD, V82, P2235; GOLDMAN JM, 1986, NEW ENGL J MED, V314, P202, DOI 10.1056/NEJM198601233140403; GRATWOHL A, 1993, BONE MARROW TRANSPL, V12, P509; Gratwohl A, 1997, BONE MARROW TRANSPL, V19, P407, DOI 10.1038/sj.bmt.1700694; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402; Hansen JA, 1998, NEW ENGL J MED, V338, P962, DOI 10.1056/NEJM199804023381405; Hehlmann R, 1996, BONE MARROW TRANSPL, V17, pS21; LEE AJ, 1997, ANN INTERN MED, V127, P1080; Marubini E, 1995, ANAL SURVIVAL DATA C; MCGLAVE PB, 1994, LANCET, V343, P1486, DOI 10.1016/S0140-6736(94)92589-5; Sierra J, 1997, BLOOD, V89, P4226, DOI 10.1182/blood.V89.11.4226; SPECK B, 1984, LANCET, V1, P665; TALPAZ M, 1991, ANN INTERN MED, V114, P532, DOI 10.7326/0003-4819-114-7-532; TURA S, 1994, NEW ENGL J MED, V330, P820; vanRhee F, 1997, BONE MARROW TRANSPL, V20, P553, DOI 10.1038/sj.bmt.1700933	25	492	518	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 3	1998	352	9134					1087	1092		10.1016/S0140-6736(98)03030-X	http://dx.doi.org/10.1016/S0140-6736(98)03030-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798583				2022-12-28	WOS:000076246400008
J	Hill, MD; Hachinski, V				Hill, MD; Hachinski, V			Stroke treatment: time is brain	LANCET			English	Article							ACUTE ISCHEMIC STROKE; PLASMINOGEN-ACTIVATOR; THROMBOLYTIC THERAPY; TEMPERATURE; INFARCTION; SAFETY	Treatments for stroke have traditionally consisted of supportive care and the prevention of complications. The evidence that is accumulating justifies a more aggressive approach. Experimental and clinical data show that there is a variable therapeutic window that may exceed 6-8 h;(1) that stroke units spare lives and reduce disability;(2) and that thrombolysis with recombinant tissue plasminogen activator (rtPA) makes a difference in acute stroke.(3) This article focuses on the ideal treatment of acute ischaemic stroke in the first 24 h.	Univ Toronto, Dept Neurol, Toronto, ON M5B 1W8, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Univ Western Ontario, Dept Neurol Sci, London, ON N6A 3K7, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Western University (University of Western Ontario)	Hill, MD (corresponding author), Univ Toronto, Dept Neurol, Toronto, ON M5B 1W8, Canada.		Hill, Michael D/C-9073-2012	Hill, Michael D/0000-0002-6269-1543				[Anonymous], 1998, JAMA, V279, P1265; [Anonymous], 1986, Arch Neurol, V43, P71; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Boiser JC, 1998, STROKE, V29, P305; Brandt T, 1996, STROKE, V27, P875, DOI 10.1161/01.STR.27.5.875; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; CANDELISE L, 1995, LANCET, V346, P1509; CHAMORRO A, 1995, NEUROLOGY, V45, P861, DOI 10.1212/WNL.45.5.861; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; Chiu D, 1998, STROKE, V29, P18, DOI 10.1161/01.STR.29.1.18; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; Demchuk AM, 1998, STROKE, V29, P273; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; GINSBERG MD, 1995, CEREBROVASCULAR DISEASES, P331; Grond M, 1998, STROKE, V29, P288; GROTTA J, 1997, NEW ENGL J MED, V337, P1309; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HACKE W, 1998, 23 INT JOINT C STROK; Hommel M, 1996, NEW ENGL J MED, V335, P145; HOSSMANN V, 1983, ARCH NEUROL-CHICAGO, V40, P803, DOI 10.1001/archneur.1983.04050120053007; Johnston KC, 1998, STROKE, V29, P447, DOI 10.1161/01.STR.29.2.447; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; Kwiatkowski TG, 1998, STROKE, V29, P288; Leira EC, 1998, STROKE, V29, P320; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MARSH EE, 1989, NEUROLOGY, V39, P1631, DOI 10.1212/WNL.39.12.1631; Read SJ, 1998, STROKE, V29, P312; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Riggs JE, 1996, ARCH NEUROL-CHICAGO, V53, P1306, DOI 10.1001/archneur.1996.00550120118026; Sacchetti ML, 1997, NEUROLOGY, V49, pS70, DOI 10.1212/WNL.49.5_Suppl_4.S70; Sandercock P, 1997, LANCET, V349, P1569; Schwab S, 1997, NEUROLOGY, V48, P762, DOI 10.1212/WNL.48.3.762; Sharafuddin MJA, 1997, J VASC INTERV RADIOL, V8, P939, DOI 10.1016/S1051-0443(97)70690-0; Tanne D, 1998, STROKE, V29, P288; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5; Yoon BW, 1997, ARCH NEUROL-CHICAGO, V54, P741, DOI 10.1001/archneur.1997.00550180055012	36	18	19	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT	1998	352			3			SIII10	SIII14						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133UP	9803956				2022-12-28	WOS:000076704700004
J	MacDowall, P; Kalra, PA; O'Donoghue, DJ; Waldek, S; Mamtora, H; Brown, K				MacDowall, P; Kalra, PA; O'Donoghue, DJ; Waldek, S; Mamtora, H; Brown, K			Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure	LANCET			English	Article							RENAL-ARTERY-STENOSIS; CAPTOPRIL RENOGRAPHY; HYPERTENSION; ISCHEMIA; KIDNEY	Background Renovasular disease commonly affects elderly people. Elderly patients with heart failure are routinely treated with angiotensin-converting-enzyme (ACE) inhibitors, which may increase risk of renal dysfunction, We investigated the frequency of renovascular disease among elderly people with heart failure. Methods From the local population of Salford, UK, we recruited 86 patients with heart failure with a mean age of 77.5 (SD 5.6) years, who were admitted as acute emergencies or who attended general medical clinics. We selected patients by intention to treat with ACE inhibitors. We used captopril renography to screen for renovascular disease, All patients with abnormal renograms underwent magnetic-resonance angiography of the renal arteries as well as 40% of patients with normal renograms as negative controls. Findings Magnetic-resonance angiography showed severe renovascular disease (>50% renal-artery stenosis or occlusion) in 29 (34%) patients. Captopril renography had an estimated sensitivity of 78.8% (95% CI 72.7-97.8) and specificity of 94.3% (67.6-97.3) for detection of renovascular disease. The estimated positive predictive value of captopril renography was 89.7% and the negative predictive value was 87.5%. Patients with renovascular disease had worse renal function (mean creatinine 201 [SD 56] vs 136 [40] mu mol/L, p<0.001), were older (mean age 80.7 [5.6] vs 76.8 [5.3] years, p<0.01), and were more likely than patients without.renovascular disease to have peripheral arterial disease. Interpretation Some elderly patients with occult renovascular disease on ACE inhibitors will be at risk of developing uraemia. Renal function should be closely monitored to detect any deterioration early.	Hope Hosp, Dept Renal Med, Salford M6 8HD, Lancs, England; Hope Hosp, Dept Radiol, Salford M6 8HD, Lancs, England; Hope Hosp, Dept Nucl Med, Salford M6 8HD, Lancs, England		Kalra, PA (corresponding author), Hope Hosp, Dept Renal Med, Salford M6 8HD, Lancs, England.							CONNOLLY JO, 1994, Q J MED, V87, P413; DATSERIS IE, 1994, J NUCL MED, V35, P251; FOMMEI E, 1987, HYPERTENSION, V10, P212, DOI 10.1161/01.HYP.10.2.212; GEYSKES GG, 1988, Q J MED, V66, P203; GEYSKES GG, 1991, AM J HYPERTENS, V4, pS685, DOI 10.1093/ajh/4.12.685S; GRAINGER RG, 1992, DIAGNOSTIC RADIOLOGY, V1; GRENIER N, 1996, AM J ROENTGENOL, V166, P832; HARDING MB, 1992, J AM SOC NEPHROL, V2, P1608; HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706; KALRA PS, 1990, Q J MED, V282, P1013; Kellerman PS, 1996, SEMIN NEPHROL, V16, P33; MACDOWALL P, 1996, NEPHROL DIAL TRANSPL, V11, P1424; MISSOURIS CG, 1994, AM J MED, V96, P10, DOI 10.1016/0002-9343(94)90109-0; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; ROCCATELLO D, 1992, AM J NEPHROL, V12, P406, DOI 10.1159/000168490; SCHILLER NB, 1979, CIRCULATION, V60, P547, DOI 10.1161/01.CIR.60.3.547; SCHWARTZ CJ, 1964, BRIT MED J, V2, P1415, DOI 10.1136/bmj.2.5422.1415; Shanley PF, 1996, SEMIN NEPHROL, V16, P21; Snidow JJ, 1996, RADIOLOGY, V198, P725, DOI 10.1148/radiology.198.3.8628861; Taylor A, 1996, J NUCL MED, V37, P1876; VETROVEC GW, 1989, J INTERVEN CARDIOL, V2, P69; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	22	140	147	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					13	16		10.1016/S0140-6736(97)11060-1	http://dx.doi.org/10.1016/S0140-6736(97)11060-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800739				2022-12-28	WOS:000074608600010
J	Davis, RM				Davis, RM			"Healthy People 2010": national health objectives for the United States	BRITISH MEDICAL JOURNAL			English	Article									Henry Ford Hlth Syst, Ctr Hlth Promot & Dis Prevent, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital	Davis, RM (corresponding author), Henry Ford Hlth Syst, Ctr Hlth Promot & Dis Prevent, 1 Ford Pl 5C, Detroit, MI 48202 USA.							*AUSTR I HLTH WELF, 1997, 1 AIHW DHFS; *AUSTR I HLTH WELF, 1998, 6 AIHW; *COMM DEP HLTH FAM, 1997, NAT HLTH PRIOR AR RE; Commonwealth Department of Human Services and Health. Better Health Outcomes for Australians, 1994, BETT HLTH OUTC AUSTR; *DEP HLTH, 1998, OUR HLTH NAT CONTR H; DOBSON SK, 1994, 1 HLTH DEP W AUSTR; Gabbay J, 1998, BMJ-BRIT MED J, V316, P487, DOI 10.1136/bmj.316.7130.487; *HLTH CAN, 1997, CANADA COMMUNICABLE, V23; *HLTH CAN, 1996, NAT GOALS PREV CONTR; *HLTH TARG IMPL CO, 1988, HLTH AUSTR; *INS I HIGHW SAF, 1998, Q A MOT HELM US LAWS; Maiese DR, 1998, PUBLIC HEALTH REP, V113, P92; *MIN HLTH MIN RESP, 1997, HLTH GOALS BRIT COL; Nutbeam D., 1993, GOALS TARGETS AUSTRA; *PUBL HLTH FDN, 1998, MEAS HLTH OBJ IND 19; *S AUSTR HLTH COMM, 1997, S AUSTR HLTH GOALS T; Secretary of State for Health, 1992, HLTH NAT STRAT HLTH; Stoto MA, 1998, PUBLIC HEALTH REP, V113, P287; U. S. Department of Health and Human Services, 1998, HLTH PEOPL 2010 OBJ; U.S. Department of Health and Human Services, 1991, DHHS PUBL; *US DEP HHS, 1994, 017001004910 US DEP; *US DEP HHS, 1980, PROM HLTH PREV DIS O; *US DEP HHS, 1993, HLTH PEOPL 2000 REV; *US DEP HHS, 1989, PROM HLTH PREV DIS Y; *US DEP HHS, 1995, HLTH PEOPL 2000 COUR; *US DHEW, 1979, DHEW PUBL; *WHO EUR, 1994, HLTH EUR 1993 1994 H; *WHO EUR, 1985, EUR HLTH ALL SER, V1; *WHO EUR, 1998, EURRC4810 WHO REG OF; *WHO EUR, 1993, EUR HLTH ALL SER, V4	30	19	20	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1513	1517		10.1136/bmj.317.7171.1513	http://dx.doi.org/10.1136/bmj.317.7171.1513			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831587	Green Published			2022-12-28	WOS:000077338300039
J	Anderson, BP; Kasevich, MA				Anderson, BP; Kasevich, MA			Macroscopic quantum interference from atomic tunnel arrays	SCIENCE			English	Article							BOSE-EINSTEIN CONDENSATION; WANNIER-STARK LADDERS; DOPPLER LIMIT; SODIUM ATOMS; GAS; TRAP	Interference of atomic de Broglie waves tunneling from a vertical array of macroscopically populated traps has been observed, The traps were Located in the antinodes of an optical standing wave and were Loaded from a Bose-Einstein condensate. Tunneling was induced by acceleration due to gravity, and interference was observed as a train of falling pulses of atoms. In the Limit of weak atomic interactions, the pulse frequency is determined by the gravitational potential energy difference between adjacent potential wells. The effect is closely related to the ac Josephson effect observed in superconducting electronic systems.	Yale Univ, Dept Phys, New Haven, CT 06520 USA	Yale University	Anderson, BP (corresponding author), Yale Univ, Dept Phys, New Haven, CT 06520 USA.		Anderson, Brian P/A-2286-2009	Anderson, Brian P/0000-0002-0442-7867				ANDERSON B, IN PRESS PHYS REV A; Anderson BP, 1996, PHYS REV A, V53, pR3727, DOI 10.1103/PhysRevA.53.R3727; ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; Andrews MR, 1997, SCIENCE, V275, P637, DOI 10.1126/science.275.5300.637; Backhaus S, 1997, SCIENCE, V278, P1435, DOI 10.1126/science.278.5342.1435; BARONE A, 1982, PHYSICS APPL JOSEPHS; Baym G, 1996, PHYS REV LETT, V76, P6, DOI 10.1103/PhysRevLett.76.6; BenDahan M, 1996, PHYS REV LETT, V76, P4508, DOI 10.1103/PhysRevLett.76.4508; BRADLEY CC, 1995, PHYS REV LETT, V75, P1687, DOI 10.1103/PhysRevLett.75.1687; Callaway J., 1991, QUANTUM THEORY SOLID; CHU S, 1985, PHYS REV LETT, V55, P48, DOI 10.1103/PhysRevLett.55.48; DALIBARD J, 1989, J OPT SOC AM B, V6, P2023, DOI 10.1364/JOSAB.6.002023; DAVIS KB, 1995, PHYS REV LETT, V75, P3969, DOI 10.1103/PhysRevLett.75.3969; EMIN D, 1987, PHYS REV B, V36, P7353, DOI 10.1103/PhysRevB.36.7353; Fedichev PO, 1996, PHYS REV LETT, V77, P2921, DOI 10.1103/PhysRevLett.77.2921; Friebel S, 1998, PHYS REV A, V57, pR20, DOI 10.1103/PhysRevA.57.R20; FUKUYAMA H, 1973, PHYS REV B, V8, P5579, DOI 10.1103/PhysRevB.8.5579; GORDON JP, 1980, PHYS REV A, V21, P1606, DOI 10.1103/PhysRevA.21.1606; JAIN AK, 1984, PHYS REP, V109, P309, DOI 10.1016/0370-1573(84)90002-4; JOSEPHSON BD, 1962, PHYS LETT, V1, P251, DOI 10.1016/0031-9163(62)91369-0; LETT PD, 1988, PHYS REV LETT, V61, P169, DOI 10.1103/PhysRevLett.61.169; MASUHARA N, 1988, PHYS REV LETT, V61, P935, DOI 10.1103/PhysRevLett.61.935; Mewes MO, 1997, PHYS REV LETT, V78, P582, DOI 10.1103/PhysRevLett.78.582; MullerSeydlitz T, 1997, PHYS REV LETT, V78, P1038, DOI 10.1103/PhysRevLett.78.1038; Niu Q, 1996, PHYS REV LETT, V76, P4504, DOI 10.1103/PhysRevLett.76.4504; Pereverzev SV, 1997, NATURE, V388, P449, DOI 10.1038/41277; PETRICH W, 1995, PHYS REV LETT, V74, P3352, DOI 10.1103/PhysRevLett.74.3352; RAAB EL, 1987, PHYS REV LETT, V59, P2631, DOI 10.1103/PhysRevLett.59.2631; Siegman A. E., 1986, LASER; SMERZI A, 1987, PHYS REV LETT, V57, P3164; Stamper-Kurn DM, 1998, PHYS REV LETT, V80, P2027, DOI 10.1103/PhysRevLett.80.2027; TAYLOR BN, 1969, REV MOD PHYS, V41, P375, DOI 10.1103/RevModPhys.41.375; UNGAR PJ, 1989, J OPT SOC AM B, V6, P2058, DOI 10.1364/JOSAB.6.002058; WANNIER G, 1961, PHYS REV, V117, P432; Wilkinson SR, 1996, PHYS REV LETT, V76, P4512, DOI 10.1103/PhysRevLett.76.4512; Zapata I, 1998, PHYS REV A, V57, pR28, DOI 10.1103/PhysRevA.57.R28; ZENER C, 1934, P ROYAL SOC, V145, P523, DOI DOI 10.1098/RSPA.1934.0116	37	1151	1187	2	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 27	1998	282	5394					1686	1689		10.1126/science.282.5394.1686	http://dx.doi.org/10.1126/science.282.5394.1686			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831555				2022-12-28	WOS:000077246600040
J	Deng, JS; Gurnis, M; Kanamori, H; Hauksson, E				Deng, JS; Gurnis, M; Kanamori, H; Hauksson, E			Viscoelastic flow in the lower crust after the 1992 Landers, Californial earthquake	SCIENCE			English	Article							28 JUNE 1992; SOUTHERN CALIFORNIA; SLIP EARTHQUAKE; HALF-SPACE; DEFORMATION; FAULT; SEQUENCE; MECHANISMS; STRESS; APRIL	Space geodesy showed that broad-scale postseismic deformation occurred after the 1992 Landers earthquake. Three-dimensional modeling shows that afterslip can only explain one horizontal component of the postseismic deformation, whereas viscoelastic flow can explain the horizontal and near-vertical displacements. The viscosity of a weak, about 10-km-thick Layer, in the Lower crust beneath the rupture zone that controls the rebound is about 10(18) pascal seconds. The viscoelastic behavior of the lower crust may help to explain the extensional structures observed in the Basin and Range province and it may be used for the analysis of earthquake hazard.	CALTECH, Seismol Lab 252 21, Pasadena, CA 91125 USA	California Institute of Technology	Deng, JS (corresponding author), CALTECH, Seismol Lab 252 21, Pasadena, CA 91125 USA.			Hauksson, Egill/0000-0002-6834-5051				AMMON CJ, 1993, GEOPHYS RES LETT, V20, P97, DOI 10.1029/92GL03032; ARROWSMITH JR, 1994, B SEISMOL SOC AM, V84, P511; Bock Y, 1997, J GEOPHYS RES-SOL EA, V102, P18013, DOI 10.1029/97JB01379; BOSL WJ, 1997, EOS, V78, pF491; COTTON F, 1995, GEOPHYS RES LETT, V22, P1921, DOI 10.1029/95GL01773; DZIEWONSKI AM, 1993, PHYS EARTH PLANET IN, V77, P151, DOI 10.1016/0031-9201(93)90095-Q; ERIKSON L, 1986, THESIS STANFORD U; GILBERT LE, 1994, J GEOPHYS RES-SOL EA, V99, P23975, DOI 10.1029/94JB01558; HAUKSSON E, 1994, B SEISMOL SOC AM, V84, P917; HAUKSSON E, 1993, J GEOPHYS RES-SOL EA, V98, P19835, DOI 10.1029/93JB02384; Heki K, 1997, NATURE, V386, P595, DOI 10.1038/386595a0; Jackson DD, 1997, SCIENCE, V277, P1621, DOI 10.1126/science.277.5332.1621; KAUFMAN PS, 1994, J GEOPHYS RES-SOL EA, V99, P15723, DOI 10.1029/94JB00727; MARONE CJ, 1991, J GEOPHYS RES-SOLID, V96, P8441, DOI 10.1029/91JB00275; Massonnet D, 1996, NATURE, V382, P612, DOI 10.1038/382612a0; MELOSH HJ, 1983, J GEOPHYS RES, V88, P515, DOI 10.1029/JB088iB01p00515; NUR A, 1974, SCIENCE, V183, P204, DOI 10.1126/science.183.4121.204; OKADA Y, 1992, B SEISMOL SOC AM, V82, P1018; Peltzer G, 1996, SCIENCE, V273, P1202, DOI 10.1126/science.273.5279.1202; Pollitz FF, 1997, J GEOPHYS RES-SOL EA, V102, P17921, DOI 10.1029/97JB01277; QU J, 1994, B SEISMOL SOC AM, V84, P596; RichardsDinger KB, 1997, J GEOPHYS RES-SOL EA, V102, P15211, DOI 10.1029/97JB00883; RUNDLE JB, 1978, J GEOPHYS RES, V83, P5937, DOI 10.1029/JB083iB12p05937; SAVAGE JC, 1990, J GEOPHYS RES-SOLID, V95, P4873, DOI 10.1029/JB095iB04p04873; Savage JC, 1997, J GEOPHYS RES-SOL EA, V102, P7565, DOI 10.1029/97JB00210; SHEN Z, 1997, EOS T AGU, V78, P477; SHEN ZK, 1994, B SEISMOL SOC AM, V84, P780; SIEH K, 1993, SCIENCE, V260, P171, DOI 10.1126/science.260.5105.171; WALD DJ, 1994, B SEISMOL SOC AM, V84, P668	29	150	167	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1689	1692		10.1126/science.282.5394.1689	http://dx.doi.org/10.1126/science.282.5394.1689			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831556				2022-12-28	WOS:000077246600041
J	Liu, BQ; Peto, R; Chen, ZM; Boreham, J; Wu, YP; Li, JY; Campbell, TC; Chen, JS				Liu, BQ; Peto, R; Chen, ZM; Boreham, J; Wu, YP; Li, JY; Campbell, TC; Chen, JS			Emerging tobacco hazards in China: I. Retrospective proportional mortality study of one million deaths	BMJ-BRITISH MEDICAL JOURNAL			English	Article							REPUBLIC-OF-CHINA; HEPATITIS-B VIRUS; CIGARETTE-SMOKING; HEPATOCELLULAR-CARCINOMA; ESOPHAGEAL CANCER; UNITED-STATES; RISK-FACTORS; LUNG-CANCER; HONG-KONG; SHANGHAI	Objective To assess the hazards at an early phase of the growing epidemic of deaths from tobacco in China Design Smoking habits before 1980 (obtained from family or other informants) of 0.7 million adults who had died of neoplastic, respiratory, or vascular causes were compared with those of a reference group of 0.2 million who had died of other causes. Setting 24 urban and '74 rural areas of China Subjects One million people who had died during 1986-8 and whose families could be interviewed. Main outcome measures Tobacco attributable mortality in middle or old age from neoplastic, respiratory, or vascular disease. Results Among male smokers aged 35-69 there was a 51% (SE 2) excess of neoplastic deaths, a 31% (2) excess of respiratory deaths, and a 15% (2) excess of vascular deaths. All three excesses were significant (P < 0.0001). Among male smokers aged greater than or equal to 70 there was a 39% (3) excess of neoplastic deaths, a 54% (2) excess of respiratory deaths, and a 6% (2) excess of vascular deaths. Fewer women smoked, but those who did had tobacco attributable risks of lung cancer and respiratory disease about the same as men. For both sexes, the lung cancer rates at ages 35-69 were about three times as great in smokers as in non-smokers, but because the rates among non-smokers in different parts of China varied widely the absolute excesses of lung cancer in smokers also varied. Of all deaths attributed to tobacco, 45% were due to chronic obstructive pulmonary disease and 15% to lung cancer; oesophageal cancer, stomach cancer; liver cancer, tuberculosis, stroke, and ischaemic heart disease each caused 5-8%. Tobacco caused about 0.6 million Chinese deaths in 1990 (0.5 million men). This will rise to 0.8 million in 2000 (0.4 million at ages 35-69) or to more if the tobacco attributed fractions increase. Conclusions At current age specific death rates in smokers and non-smokers one in four smokers would be killed by tobacco, but as the epidemic grows this proportion will roughly double. If current smoking uptake rates persist in China (where about two thirds of men but few women become smokers) tobacco will kill about 100 million of the 0.3 billion males now aged 0-29, with half these deaths in middle age and half in old age.	Chinese Acad Med Sci, Natl Canc Inst, Dept Epidemiol, Beijing 100021, Peoples R China; Radcliffe Infirm, Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford OX2 6HE, England; Radcliffe Infirm, Nuffield Dept Clin Med, Epidemiol Studies Unit, Oxford OX2 6HE, England; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Chinese Acad Prevent Med, Inst Nutr & Food Hyg, Beijing 100050, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford; Cornell University; Chinese Center for Disease Control & Prevention; National Institute for Nutrition & Health, Chinese Center for Disease Control & Prevention	Liu, BQ (corresponding author), Chinese Acad Med Sci, Natl Canc Inst, Dept Epidemiol, Chaoyang Dist, Beijing 100021, Peoples R China.	gale.mead@ctsu.ox.ac.uk			NATIONAL CANCER INSTITUTE [R01CA033638] Funding Source: NIH RePORTER; NCI NIH HHS [5R01 CA 33638] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AD HOC COMM HLTH, 1996, TDRGEN961 WHO AD HOC; Armitage P., 1987, STAT METHODS MED RES; CHARLTON A, 1993, SMOKING YOUTH CHINA; Chen ZM, 1997, JAMA-J AM MED ASSOC, V278, P1500, DOI 10.1001/jama.278.18.1500; CHENG KK, 1992, LANCET, V339, P1314, DOI 10.1016/0140-6736(92)91960-G; Deng J, 1985, CHIN J PREV MED, V5, P271; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; Doll R, 1996, BRIT MED BULL, V52, P35, DOI 10.1093/oxfordjournals.bmb.a011531; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; GAO YT, 1988, INT J EPIDEMIOL, V17, P277, DOI 10.1093/ije/17.2.277; GAO YT, 1994, INT J CANCER, V58, P192, DOI 10.1002/ijc.2910580208; GAO YT, 1995, 1995 C INT EP ASS RE, P18; HE Y, IN PRESS CHIN MED J; International Agency for Research on Cancer, 1986, IARC MON EV CARC RIS, V38; LAM KC, 1982, CANCER RES, V42, P5246; Lam TH, 1997, JAMA-J AM MED ASSOC, V278, P1505, DOI 10.1001/jama.278.18.1505; LI JF, 1994, INT J CANCER, V57, P38; LI JY, 1989, INT J CANCER, V43, P755, DOI 10.1002/ijc.2910430502; LI SC, 1985, NEUROLOGY, V35, P1708, DOI 10.1212/WNL.35.12.1708; LIU ZY, 1992, INT J EPIDEMIOL, V21, P197, DOI 10.1093/ije/21.2.197; LU SN, 1988, CANCER-AM CANCER SOC, V62, P2051, DOI 10.1002/1097-0142(19881101)62:9<2051::AID-CNCR2820620930>3.0.CO;2-1; Mackay J, 1995, TOBACCO AND HEALTH, P61; MANTEL N, 1959, J NATL CANCER I, V22, P719; Murray CJL, 1996, GLOBAL BURDEN DIS IN, V1; Niu SR, 1998, BRIT MED J, V317, P1423, DOI 10.1136/bmj.317.7170.1423; PARISH S, 1995, BMJ-BRIT MED J, V311, P471, DOI 10.1136/bmj.311.7003.471; PETO R, 1986, LANCET, V2, P1038; PETO R, 1994, BRIT MED J, V309, P937, DOI 10.1136/bmj.309.6959.937; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; PETO R, 1987, LANCET, V2, P211; Peto R, 1994, MORTALITY TOBACCO DE; Shapiro Sidney, 1979, AM CHINA 30 YEARS PE; Surgeon General, 1989, RED HLTH CONS SMOK 2; WANG YP, 1992, CANCER CAUSE CONTROL, V3, P107, DOI 10.1007/BF00051650; WENG XZ, 1988, REPORT 1984 CHINESE; WENG XZ, 1990, TOBACCO HLTH 1990 GL, P131; *WHO, 1996, WORLD HLTH STAT ANN; World Health Organisation, 1977, INT CLASS DIS 9 REV; XU ZY, 1989, J NATL CANCER I, V81, P1800, DOI 10.1093/jnci/81.23.1800; Yang CH, 1996, PLANT PHYSIOL, V111, P3; Yang G, 1997, REPORT 1996 NATIONWI; YAO LC, 1984, CHIN J EPIDEMIOL, V5, P98; YU JJ, 1990, JAMA-J AM MED ASSOC, V264, P1575, DOI 10.1001/jama.264.12.1575; YU MC, 1987, CANCER RES, V47, P654; Yuan JM, 1996, JAMA-J AM MED ASSOC, V275, P1646, DOI 10.1001/jama.275.21.1646; ZARIDZE D, 1986, IARC SCI PUBLICATION, V74; ZHOU YS, 1990, ATLAS MORTALITY MAIN; ZOLTY B, 1997, TOBACCO HLTH GLOBAL, P441; [No title captured]	52	456	507	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 21	1998	317	7170					1411	1422		10.1136/bmj.317.7170.1411	http://dx.doi.org/10.1136/bmj.317.7170.1411			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822393	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000077202200020
J	Edmondson, P				Edmondson, P			A memorable evening - A doctor's family	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1369	1369		10.1136/bmj.317.7169.1369	http://dx.doi.org/10.1136/bmj.317.7169.1369			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812939	Green Published			2022-12-28	WOS:000077081600027
J	Gumbsch, P; Riedle, J; Hartmaier, A; Fischmeister, HF				Gumbsch, P; Riedle, J; Hartmaier, A; Fischmeister, HF			Controlling factors for the brittle-to-ductile transition in tungsten single crystals	SCIENCE			English	Article							SILICON; CLEAVAGE; MODEL	Materials performance in structural applications is often restricted by a transition from ductile response to brittle fracture with decreasing temperature. This transition is currently viewed as being controlled either by dislocation mobility or by the nucleation of dislocations, Fracture experiments on tungsten single crystals reported here provide evidence for the importance of dislocation nucleation for the fracture toughness in the semibrittle regime. However, it is shown that the transition itself, in general, is controlled by dislocation mobility rather than by nucleation.	Max Planck Inst Met Forsch, D-70174 Stuttgart, Germany	Max Planck Society	Gumbsch, P (corresponding author), Max Planck Inst Met Forsch, Seestr 92, D-70174 Stuttgart, Germany.		Gumbsch, Peter/E-5879-2012; Hartmaier, Alexander/O-2087-2013	Gumbsch, Peter/0000-0001-7995-228X; Hartmaier, Alexander/0000-0002-3710-1169				ARGON AS, 1966, ACTA METALL MATER, V14, P1449, DOI 10.1016/0001-6160(66)90165-9; BERLEC I, 1962, J APPL PHYS, V33, P197, DOI 10.1063/1.1728484; BREDE M, 1988, ACTA METALL MATER, V36, P2003, DOI 10.1016/0001-6160(88)90302-1; Brunner D, COMMUNICATION; Devincre B, 1996, ACTA MATER, V44, P2891, DOI 10.1016/1359-6454(95)00411-4; Ebrahimi F, 1998, ACTA MATER, V46, P1493, DOI 10.1016/S1359-6454(97)00370-4; Hartmaier A, 1997, PHYS STATUS SOLIDI B, V202, pR1, DOI 10.1002/1521-3951(199708)202:2<R1::AID-PSSB99991>3.0.CO;2-J; HIRSCH PB, 1989, P ROY SOC LOND A MAT, V421, P25, DOI 10.1098/rspa.1989.0002; HUANG H, 1994, ACTA METALL MATER, V42, P639, DOI 10.1016/0956-7151(94)90260-7; KHANTHA M, 1994, PHYS REV LETT, V73, P684, DOI 10.1103/PhysRevLett.73.684; KOHLHOFF S, 1991, PHILOS MAG A, V64, P851, DOI 10.1080/01418619108213953; MICHOT G, 1994, MAT SCI ENG A-STRUCT, V176, P99, DOI 10.1016/0921-5093(94)90963-6; RICE JR, 1974, PHILOS MAG, V29, P73, DOI 10.1080/14786437408213555; RIEDLE J, 1994, MATER LETT, V20, P311, DOI 10.1016/0167-577X(94)90036-1; Riedle J, 1996, PHYS REV LETT, V76, P3594, DOI 10.1103/PhysRevLett.76.3594; RIEDLE J, 1995, THESIS U STUTTGART S; ROBERTS SG, 1994, MAT SCI ENG A-STRUCT, V176, P91, DOI 10.1016/0921-5093(94)90962-8; ROBERTS SG, 1996, COMPUTER SIMULATIO E, V308, P409, DOI DOI 10.1007/978-94-011-3546-7; SAMUELS J, 1989, PROC R SOC LON SER-A, V421, P1, DOI 10.1098/rspa.1989.0001; SCHADLER HW, 1964, ACTA METALL MATER, V12, P861, DOI 10.1016/0001-6160(64)90144-0; STJOHN C, 1975, PHILOS MAG, V32, P1193, DOI 10.1080/14786437508228099; Tamura Y., 1972, Transactions of National Research Institute for Metals, V14, P173; ZHOU SJ, 1991, J MATER RES, V6, P1763, DOI 10.1557/JMR.1991.1763; ZIEBART U, 1986, THESIS U STUTTGART S	24	289	291	8	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1293	1295		10.1126/science.282.5392.1293	http://dx.doi.org/10.1126/science.282.5392.1293			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812888				2022-12-28	WOS:000076982200037
J	Nguyen, M; Park, S; Marques, G; Arora, K				Nguyen, M; Park, S; Marques, G; Arora, K			Interpretation of a BMP activity gradient in Drosophila embryos depends on synergistic signaling by two type I receptors, SAX and TKV	CELL			English	Article							SHORT GASTRULATION GENE; DORSAL-VENTRAL PATTERN; DPP RECEPTORS; BETA FAMILY; THICK VEINS; DECAPENTAPLEGIC GENE; CELL FATES; MORPHOGEN; PROTEINS; XENOPUS	Graded activity of the DPP signaling pathway is critical for specification of dorsal embryonic cell fates in Drosophila. We present evidence that a second BMP ligand, SCW, potentiates DPP activity. Using dominant-negative forms of the type I receptors SAX and TKV, we demonstrate that SAX mediates the SCW signal, white TKV is required for both DPP and SCW activity. We find that while DPP/TKV signaling is obligatorily required, SCW/SAX activity is necessary but not sufficient for dorsal patterning. SAX and TKV act synergistically, suggesting a mechanism for integration of the SCW and DPP signals. Further, we show that the extracellular protein SOG can antagonize SCW, thus limiting its ability to augment DPP signaling in a graded manner.	Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Dev Biol, Irvine, CA 92697 USA; CSIC, Inst Cajal, E-28002 Madrid, Spain	University of California System; University of California Irvine; University of California System; University of California Irvine; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Arora, K (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA.				NIGMS NIH HHS [GM55442] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055442] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AONO A, 1995, BIOCHEM BIOPH RES CO, V210, P670, DOI 10.1006/bbrc.1995.1712; ARORA K, 1992, DEVELOPMENT, V114, P1003; ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Burke R, 1996, DEVELOPMENT, V122, P2261; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; GELBART WM, 1989, DEVELOPMENT, V107, P65; Haerry TE, 1998, DEVELOPMENT, V125, P3977; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; LECUIT T, 1996, NATURE, V381, P1387; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Newfeld SJ, 1997, DEVELOPMENT, V124, P3167; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; Parkansky N, 1995, SURF COAT TECH, V76, P197, DOI 10.1016/0257-8972(95)02588-X; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; RAFTERY LA, 1995, GENETICS, V139, P241; RAY RP, 1991, DEVELOPMENT, V113, P35; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Schmidt J, 1995, DEVELOPMENT, V121, P4319; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; Singer MA, 1997, DEVELOPMENT, V124, P79; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; Suzuki A, 1997, BIOCHEM BIOPH RES CO, V232, P153, DOI 10.1006/bbrc.1997.6219; TERRACOL R, 1994, GENETICS, V138, P165; WHARTON KA, 1993, DEVELOPMENT, V117, P807; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; Yu K, 1996, DEVELOPMENT, V122, P4033	47	100	104	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 13	1998	95	4					495	506		10.1016/S0092-8674(00)81617-7	http://dx.doi.org/10.1016/S0092-8674(00)81617-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827802	Bronze			2022-12-28	WOS:000077049400008
J	Sen, J; Goltz, JS; Stevens, L; Stein, D				Sen, J; Goltz, JS; Stevens, L; Stein, D			Spatially restricted expression of pipe in the Drosophila egg chamber defines embryonic dorsal-ventral polarity	CELL			English	Article							HEPARAN-SULFATE 2-SULFOTRANSFERASE; TOLL GENE-PRODUCT; FAINT-LITTLE-BALL; TRANSMEMBRANE PROTEIN; DORSOVENTRAL PATTERN; RECEPTOR HOMOLOG; SERINE PROTEASE; ENCODES; LOCALIZATION; MELANOGASTER	Expression of pipe in the somatic tissue of the Drosophila ovary is required for the formation of embryonic dorsal-ventral polarity. pipe, which encodes an enzyme similar to the glycosaminoglycan-modifying enzyme heparan sulfate 2-O-sulfotransferase, is expressed in a spatially restricted domain of follicle cells on the Ventral side of the egg chamber. Mutations that affect follicular polarity correspondingly alter the spatial pattern of pipe expression. Directed expression of pipe in otherwise pipe mutant females restores embryonic lateral and ventral pattern elements and can orient the dorsal-ventral axis of the embryo. Thus, the localized expression of pipe and the spatially restricted modification of carbohydrate chains play pivotal roles in the mechanisms that establish embryonic pattern and integrate follicular and embryonic polarity.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Stein, D (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	stein@aecom.yu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052761] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52761] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ASHBRUNNER M, 1989, DROSOPHILA LAB MANUA; BEMFIELD M, 1992, ANN REV CELL BIOL, V8, P365; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DeLotto Y, 1998, MECH DEVELOP, V72, P141, DOI 10.1016/S0925-4773(98)00024-0; ENGELS WR, 1986, FOCUS, V8, P6; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; HEINO TI, 1994, DROS INF SERV, V73, P621; HONG CC, 1995, CELL, V82, P785, DOI 10.1016/0092-8674(95)90475-1; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; Konrad KD, 1998, P NATL ACAD SCI USA, V95, P6819, DOI 10.1073/pnas.95.12.6819; Konsolaki M, 1998, GENE DEV, V12, P120, DOI 10.1101/gad.12.1.120; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MOHLER JD, 1977, GENETICS, V85, P259; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; Nilson LA, 1998, CELL, V93, P253, DOI 10.1016/S0092-8674(00)81576-7; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; Queenan AM, 1997, DEVELOPMENT, V124, P3871; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; ROTH S, 1994, DEVELOPMENT, V120, P2245; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; ROTH S, 1993, DEVELOPMENT, V117, P1385; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; Sambrook J., 2002, MOL CLONING LAB MANU; SAVANTBHONSALE S, 1993, GENE DEV, V7, P2548, DOI 10.1101/gad.7.12b.2548; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHNEIDER DS, 1994, DEVELOPMENT, V120, P1243; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SCHUPACH T, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P163; SCHUPBACH T, 1989, GENETICS, V121, P101; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; Spradling A.C., 1993, DEV DROSOPHILA MELAN, VI, P1; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TRIPOULAS NA, 1994, GENETICS, V137, P1027; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wharton K. A., 1992, DROS INFO SERV, V71, P152; Wieschaus E., 1986, P199; Wieschaus E., 1978, WILHELMS ROUXS ARCH, V184, P74; YUE L, 1992, GENE DEV, V6, P2443, DOI 10.1101/gad.6.12b.2443	66	176	179	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 13	1998	95	4					471	481		10.1016/S0092-8674(00)81615-3	http://dx.doi.org/10.1016/S0092-8674(00)81615-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827800	Bronze			2022-12-28	WOS:000077049400006
J	Kemp, M				Kemp, M			Visible viruses	NATURE			English	Article									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.							WILDY P, 1960, VIROLOGY, V12, P204, DOI 10.1016/0042-6822(60)90195-1	1	3	3	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1998	396	6707					123	123		10.1038/24062	http://dx.doi.org/10.1038/24062			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823890				2022-12-28	WOS:000077013300031
J	Treacher, DF; Leach, RM				Treacher, DF; Leach, RM			ABC of oxygen - Oxygen transport - 1. Basic principles	BRITISH MEDICAL JOURNAL			English	Article									Guys & St Thomas Hosp Trust, Dept Intens Care, London, England	Guy's & St Thomas' NHS Foundation Trust	Treacher, DF (corresponding author), Guys & St Thomas Hosp Trust, Dept Intens Care, London, England.								0	51	52	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1302	1306		10.1136/bmj.317.7168.1302	http://dx.doi.org/10.1136/bmj.317.7168.1302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804723	Green Published			2022-12-28	WOS:000076963800032
J	Hesselink, L; Orlov, SS; Liu, A; Akella, A; Lande, D; Neurgaonkar, RR				Hesselink, L; Orlov, SS; Liu, A; Akella, A; Lande, D; Neurgaonkar, RR			Photorefractive materials for nonvolatile volume holographic data storage	SCIENCE			English	Article							LITHIUM-NIOBATE; LINBO3	Optically gated recording and nonvolatile readout in a digital volume holographic data storage system that uses-a pair of mutually incoherent light sources during recording and only one for readout were demonstrated recently. This approach used stoichiometric lithium niobate, which after post-growth processing gave rise to an at least two orders of magnitude improvement in sensitivity over the best materials reported previously. it is also shown that by adding certain dopants (iron and manganese) to near-stoichiometric lithium niobate, the dark storage time and gating efficiency can be increased compared with previous work. The underlying physical mechanisms of gated recording and the effectiveness of the gating process responsible for this manifold improved performance are discussed, and bipolarons and small polarons are identified as the responsible photorefractive species.	Stanford Univ, Stanford, CA 94305 USA; Optitek, Mt View, CA 94043 USA; Rockwell Int Corp, Ctr Sci, Thousand Oaks, CA 91360 USA	Stanford University; Rockwell Collins	Hesselink, L (corresponding author), Stanford Univ, Stanford, CA 94305 USA.							Bai YS, 1997, PHYS REV LETT, V78, P2944, DOI 10.1103/PhysRevLett.78.2944; GARCIACABANES A, 1988, PHYS REV B, V37, P6085, DOI 10.1103/PhysRevB.37.6085; HEANUE JF, 1994, SCIENCE, V265, P749, DOI 10.1126/science.265.5173.749; HESSELINK L, 1996, OPT SOC AM ANN M ROC; HUIGNARD JP, 1988, TOPICS APPL PHYSICS, V61; JERMANN F, 1995, J OPT SOC AM B, V12, P2066, DOI 10.1364/JOSAB.12.002066; KOPPITZ J, 1989, FERROELECTRICS, V92, P233, DOI 10.1080/00150198908211331; Lande D, 1997, OPT LETT, V22, P1722, DOI 10.1364/OL.22.001722; MEHTA A, 1991, J MATER RES, V6, P851, DOI 10.1557/JMR.1991.0851; Mok FH, 1996, OPT LETT, V21, P896, DOI 10.1364/OL.21.000896; Nagels P., 1980, Hall effect and its applications. Proceedings of the commemorative symposium, P253; ORLOV SS, 1997, C LAS EL 97 OPT SOC; SCHIRMER OF, 1991, J PHYS CHEM SOLIDS, V52, P185, DOI 10.1016/0022-3697(91)90064-7; STAEBLER DL, 1974, APPL PHYS LETT, V24, P268, DOI 10.1063/1.1655178; VONDERLINDE D, 1974, APPL PHYS LETT, V25, P155, DOI 10.1063/1.1655420; Zel'dovich B.Y., 1985, PRINCIPLES PHASE CON	16	300	319	2	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1089	1094		10.1126/science.282.5391.1089	http://dx.doi.org/10.1126/science.282.5391.1089			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804540				2022-12-28	WOS:000076887700040
J	Stevens, L				Stevens, L			Twin peaks: Spitz and argos star in patterning of the Drosophila egg	CELL			English	Review							RECEPTOR PATHWAY; VENTRAL ECTODERM; OOGENESIS; ACTIVATION		Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Stevens, L (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							Dominguez M, 1998, CURR BIOL, V8, P1039, DOI 10.1016/S0960-9822(98)70441-5; Freeman M, 1997, DEVELOPMENT, V124, P261; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Golembo M, 1996, DEVELOPMENT, V122, P3363; Golembo M, 1996, DEVELOPMENT, V122, P223; Gonzalez-Reyes A, 1998, DEVELOPMENT, V125, P2837; NeumanSilberberg FS, 1996, MECH DEVELOP, V59, P105, DOI 10.1016/0925-4773(96)00567-9; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; RUOHOLABAKER H, 1993, CELL, V73, P953, DOI 10.1016/0092-8674(93)90273-S; Sapir A, 1998, DEVELOPMENT, V125, P191; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5	14	19	19	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 30	1998	95	3					291	294		10.1016/S0092-8674(00)81759-6	http://dx.doi.org/10.1016/S0092-8674(00)81759-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814698	Bronze			2022-12-28	WOS:000076789600001
J	Mehlen, P; Rabizadeh, S; Snipas, SJ; Assa-Munt, N; Salvesen, GS; Bredesen, DE				Mehlen, P; Rabizadeh, S; Snipas, SJ; Assa-Munt, N; Salvesen, GS; Bredesen, DE			The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis	NATURE			English	Article							COLORECTAL-CARCINOMA; DROSOPHILA HSP27; EXPRESSION; CELLS; PHENOTYPE; GUIDANCE; SYSTEM	The development of colonic carcinoma is associated with the mutation of a specific set of genes(1). One of these, DCC (deleted in colorectal cancer)(2-5), is a candidate tumour-suppressor gene, and encodes a receptor for netrin-1, a molecule involved in axon guidance(6-8). Loss of DCC expression in tumours is not restricted to colon carcinoma(2), and, although there is no increase in the frequency of tumour formation in DCC hemizygous mice(5), reestablishment of DCC expression suppresses tumorigenicity(3,4). However, the mechanism of action of DCC is unknown. Here we show that DCC induces apoptosis in the absence of ligand binding, but blocks apoptosis when engaged by netrin-1. Furthermore, DCC is a caspase substrate, and mutation of the site at which caspase-3 cleaves DCC suppresses the pro-apoptotic effect of DCC completely. These results indicate that DCC may function as a tumour-suppressor protein by inducing apoptosis in settings in which Ligand is unavailable (for example, during metastasis or tumour growth beyond local blood supply) through functional caspase cascades by a mechanism that requires cleavage of DCC at Asp 1,290.	Burnham Inst, Program Aging, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Bredesen, DE (corresponding author), Burnham Inst, Program Aging, La Jolla, CA 92037 USA.							Bennett KL, 1997, J BIOL CHEM, V272, P26940, DOI 10.1074/jbc.272.43.26940; Bredesen DE, 1998, CELL DEATH DIFFER, V5, P365, DOI 10.1038/sj.cdd.4400378; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; BREDESEN DE, 1994, APOPTOSIS, V2, P397; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; Ellerby HM, 1997, J NEUROSCI, V17, P6165; ELLERBY LM, IN PRESS J NEUROCHEM; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Fearon ER, 1996, BBA-REV CANCER, V1288, pM17, DOI 10.1016/0304-419X(96)00023-6; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; MEHLEN P, 1995, J IMMUNOL, V154, P363; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, IN PRESS CELL DEATH; PFLUG BR, 1992, CANCER RES, V52, P5403; RABIZADEH S, 1994, DEV NEUROSCI-BASEL, V16, P207, DOI 10.1159/000112108; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RABIZADEH S, UNPUB CELL; REALE MA, 1994, CANCER RES, V54, P4493; Ruan YL, 1997, J NEUROSCI RES, V50, P383, DOI 10.1002/(SICI)1097-4547(19971101)50:3<383::AID-JNR4>3.0.CO;2-E; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Yang FS, 1998, AM J PATHOL, V152, P379	29	338	350	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1998	395	6704					801	804		10.1038/27441	http://dx.doi.org/10.1038/27441			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AL	9796814				2022-12-28	WOS:000076607400057
J	Ewan, PW				Ewan, PW			Prevention of peanut allergy	LANCET			English	Editorial Material							INFANTS; AGE; SENSITIZATION; AVOIDANCE		Univ Cambridge, Addenbrookes Hosp, Dept Allergy & Clin Immunol, Cambridge CB2 2QQ, England	Addenbrooke's Hospital; University of Cambridge	Ewan, PW (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Allergy & Clin Immunol, Cambridge CB2 2QQ, England.							CANT A, 1985, BRIT MED J, V291, P932, DOI 10.1136/bmj.291.6500.932; Committee on Toxicity of Chemicals in Food, 1998, PEAN ALL; Ewan PW, 1996, BRIT MED J, V312, P1074; HALKEN S, 1992, ALLERGY, V47, P545, DOI 10.1111/j.1398-9995.1992.tb00680.x; HATAHET R, 1994, REV FR ALLERGOL, V34, P377, DOI 10.1016/S0335-7457(05)80243-6; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P59, DOI 10.1111/j.1399-3038.1995.tb00261.x; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Lack G, 1998, J ALLERGY CLIN IMMUN, V101, pS104; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	12	12	12	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					4	5		10.1016/S0140-6736(05)79505-2	http://dx.doi.org/10.1016/S0140-6736(05)79505-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800734				2022-12-28	WOS:000074608600004
J	Himmelstein, DU; Woolhandler, S				Himmelstein, DU; Woolhandler, S			An American view	LANCET			English	Editorial Material									Harvard Univ, Sch Med, Cambridge Hosp, Dept Med, Cambridge, MA 02139 USA	Harvard University; Cambridge Health Alliance; Cambridge Hospital	Himmelstein, DU (corresponding author), Harvard Univ, Sch Med, Cambridge Hosp, Dept Med, Cambridge, MA 02139 USA.								0	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 4	1998	352	9121					54	55		10.1016/S0140-6736(98)05241-6	http://dx.doi.org/10.1016/S0140-6736(98)05241-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800766				2022-12-28	WOS:000074608600049
J	Slaney, G				Slaney, G			Bryan Nicholas Brooke - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1529	1529		10.1136/bmj.317.7171.1529	http://dx.doi.org/10.1136/bmj.317.7171.1529			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831602	Green Published			2022-12-28	WOS:000077338300068
J	Caron, E; Hall, A				Caron, E; Hall, A			Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases	SCIENCE			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; CELL-CYCLE PROGRESSION; ACTIN STRESS FIBERS; COMPLEMENT RECEPTORS; SIGNALING PATHWAY; NADPH OXIDASE; CDC42 GTPASES; MACROPHAGES; ACTIVATION; RAC	The complement and immunoglobulin receptors are the major phagocytic receptors involved during infection. However, only immunoglobulin-dependent uptake results in a respiratory burst and an inflammatory response in macrophages. Rho guanosine triphosphatases (molecular switches that control the organization of the actin cytoskeleton) were found to be essential for-both types of phagocytosis. Two distinct mechanisms of phagocytosis were identified: Type I, used by the immunoglobulin receptor, is mediated by Cdc42 and Rac, and type II, used by the complement receptor, is mediated by Rho. These results suggest a molecular basis for the different biological consequences that are associated with phagocytosis.	UCL, Canc Res Campaign, Oncogene & Signal Transduct Grp, MRC,Lab Mol Cell Biol, London WC1E 6BT, England; UCL, Dept Biochem, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Hall, A (corresponding author), UCL, Canc Res Campaign, Oncogene & Signal Transduct Grp, MRC,Lab Mol Cell Biol, Gower St, London WC1E 6BT, England.	alan.hall@ucl.ac.uk						ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADEREM AA, 1985, J EXP MED, V161, P617, DOI 10.1084/jem.161.3.617; Allen LAH, 1996, CURR OPIN IMMUNOL, V8, P36, DOI 10.1016/S0952-7915(96)80102-6; Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; GREENBERG S, 1991, J IMMUNOL METHODS, V139, P115, DOI 10.1016/0022-1759(91)90358-M; HACKAM DJ, 1998, J BIOL CHEM, V273, P955; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOLZER TJ, 1986, INFECT IMMUN, V51, P514, DOI 10.1128/IAI.51.2.514-520.1986; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KAPLAN G, 1977, SCAND J IMMUNOL, V6, P797, DOI 10.1111/j.1365-3083.1977.tb02153.x; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOSSER DM, 1987, NATURE, V327, P329, DOI 10.1038/327329b0; MOSSER DM, 1985, J IMMUNOL, V135, P2785; Nagata K, 1998, J BIOL CHEM, V273, P15453, DOI 10.1074/jbc.273.25.15453; NEWMAN SL, 1991, J IMMUNOL, V146, P967; NEWMAN SL, 1985, J EXP MED, V161, P1414, DOI 10.1084/jem.161.6.1414; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHLESINGER LS, 1990, J CLIN INVEST, V85, P1304, DOI 10.1172/JCI114568; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; WRIGHT SD, 1983, J EXP MED, V158, P2016, DOI 10.1084/jem.158.6.2016; YAMAMOTO K, 1984, J EXP MED, V159, P405, DOI 10.1084/jem.159.2.405	33	779	796	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1717	1721		10.1126/science.282.5394.1717	http://dx.doi.org/10.1126/science.282.5394.1717			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831565				2022-12-28	WOS:000077246600050
J	Ernst, A; Zibrak, JD				Ernst, A; Zibrak, JD			Current concepts - Carbon monoxide poisoning	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HYPERBARIC-OXYGEN; LIPID-PEROXIDATION; PULSE OXIMETRY; BRAIN; INTOXICATION; TOXICITY; FETAL; RAT; MANAGEMENT; MECHANISM		Beth Israel Deaconess Med Ctr, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Ernst, A (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Pulm & Crit Care Med, W Campus,1 Deaconess Rd, Boston, MA 02215 USA.							Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BECKER LC, 1979, ARCH ENVIRON HEALTH, V34, P274, DOI 10.1080/00039896.1979.10667413; BOGUSZ M, 1975, ARCH TOXICOL, V33, P141, DOI 10.1007/BF00353239; BUCKLEY RG, 1994, ANN EMERG MED, V24, P252, DOI 10.1016/S0196-0644(94)70137-7; BURNEY RE, 1982, ANN EMERG MED, V11, P394, DOI 10.1016/S0196-0644(82)80033-4; CHOI IS, 1983, ARCH NEUROL-CHICAGO, V40, P433, DOI 10.1001/archneur.1983.04050070063016; COBB N, 1991, JAMA-J AM MED ASSOC, V266, P659, DOI 10.1001/jama.266.5.659; Coburn R.F., 1987, HDB PHYSL 3, P439; COBURN RF, 1970, ANN NY ACAD SCI, V174, P11, DOI 10.1111/j.1749-6632.1970.tb49768.x; DEBIAS DA, 1976, ARCH ENVIRON HEALTH, V31, P42, DOI 10.1080/00039896.1976.10667188; ELY EW, 1995, AM J MED, V98, P145; FARROW JR, 1990, J FORENSIC SCI, V35, P1448; FORBES WH, 1945, AM J PHYSIOL, V143, P594, DOI 10.1152/ajplegacy.1945.143.4.594; GEEHR EC, 1989, AM J EMERG MED, V7, P598, DOI 10.1016/0735-6757(89)90282-9; GINSBERG MD, 1976, NEUROLOGY, V26, P15, DOI 10.1212/WNL.26.1.15; GOLDBAUM LR, 1975, AVIAT SPACE ENVIR MD, V46, P1289; Haldane J, 1895, J Physiol, V18, P201; HARDY KR, 1994, J TOXICOL-CLIN TOXIC, V32, P613, DOI 10.3109/15563659409017973; HART IK, 1988, POSTGRAD MED J, V64, P213, DOI 10.1136/pgmj.64.749.213; Hausberg M, 1997, HYPERTENSION, V29, P1114, DOI 10.1161/01.HYP.29.5.1114; HEE J, 1995, PHARMACOL BIOCHEM BE, V52, P195, DOI 10.1016/0091-3057(95)00089-F; Houck Peter M., 1997, Journal of Emergency Medicine, V15, P469, DOI 10.1016/S0736-4679(97)00079-6; ILANO AL, 1990, CHEST, V97, P165, DOI 10.1378/chest.97.1.165; Ischiropoulos H, 1996, J CLIN INVEST, V97, P2260, DOI 10.1172/JCI118667; KALES SN, 1993, AM FAM PHYSICIAN, V48, P1100; LONGO LD, 1977, AM J PHYSIOL, V232, pH324, DOI 10.1152/ajpheart.1977.232.3.H324; MEREDITH T, 1988, BMJ-BRIT MED J, V296, P77, DOI 10.1136/bmj.296.6615.77; MESSIER LD, 1991, J CLIN PSYCHOL, V47, P675, DOI 10.1002/1097-4679(199109)47:5<675::AID-JCLP2270470508>3.0.CO;2-H; MIN SK, 1986, ACTA PSYCHIAT SCAND, V73, P80, DOI 10.1111/j.1600-0447.1986.tb02671.x; MYERS RAM, 1985, ANN EMERG MED, V14, P1163, DOI 10.1016/S0196-0644(85)81022-2; MYERS RAM, 1994, HYPERBARIC MED PRACT, P357; *NAT CTR ENV PUBL, 1990, EPA600890045F NAT CT; *NAT VEH FUEL EM L, 1996, EPA420F96005 NAT VEH; National Center for Health Statistics, 1991, VIT STAT US 1988; NORKOOL DM, 1985, ANN EMERG MED, V14, P1168, DOI 10.1016/S0196-0644(85)81023-4; NORMAN CA, 1990, ANN OCCUP HYG, V34, P335, DOI 10.1093/annhyg/34.4.335; *OSHA, 1996, OSHA FACT SHEET CARB; PACE N, 1950, SCIENCE, V111, P652, DOI 10.1126/science.111.2894.652; RAPHAEL JC, 1989, LANCET, V2, P414; Robkin MA, 1997, INT J DEV BIOL, V41, P283; RODKEY FL, 1974, CLIN CHEM, V20, P83; Roughton FJW, 1944, AM J PHYSIOL, V141, P0017, DOI 10.1152/ajplegacy.1944.141.1.17; SAWA GM, 1981, CAN J NEUROL SCI, V8, P77, DOI 10.1017/S031716710004289X; SEGER D, 1994, ANN EMERG MED, V24, P242, DOI 10.1016/S0196-0644(94)70136-9; SMITH G., 1962, ANN OCCUP HYG, V5, P259; STEWART RD, 1975, ANNU REV PHARMACOL, V15, P409, DOI 10.1146/annurev.pa.15.040175.002205; STEWART RD, 1976, JAMA-J AM MED ASSOC, V235, P398, DOI 10.1001/jama.235.4.398; Thom S R, 1989, Emerg Med Clin North Am, V7, P371; THOM SR, 1992, J APPL PHYSIOL, V73, P1584, DOI 10.1152/jappl.1992.73.4.1584; THOM SR, 1993, TOXICOL APPL PHARM, V123, P234, DOI 10.1006/taap.1993.1242; THOM SR, 1990, J APPL PHYSIOL, V68, P997, DOI 10.1152/jappl.1990.68.3.997; THORN SR, 1995, ANN EMERG MED, V25, P474, DOI 10.1016/S0196-0644(95)70261-X; TIBBLES PM, 1994, ANN EMERG MED, V24, P269, DOI 10.1016/S0196-0644(94)70141-5; Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506; TORNE R, 1991, DERMATOLOGICA, V183, P212, DOI 10.1159/000247672; TOUGER M, 1995, ANN EMERG MED, V25, P481, DOI 10.1016/S0196-0644(95)70262-8; TURINO GM, 1981, CIRCULATION, V63, pA253; *UND HYP MED SOC, 1996, DIR HYP CHAMB US CAN; VEGFORS M, 1991, BRIT J ANAESTH, V66, P625, DOI 10.1093/bja/66.5.625; WILLIAMS J, 1992, Journal of Burn Care and Rehabilitation, V13, P210, DOI 10.1097/00004630-199203000-00006; Wrenn Keith, 1997, Journal of Emergency Medicine, V15, P465, DOI 10.1016/S0736-4679(97)00074-7; ZAGAMI AS, 1993, J NEUROL, V240, P113, DOI 10.1007/BF00858727; ZHANG J, 1992, J CLIN INVEST, V90, P1193, DOI 10.1172/JCI115980; 1996, MMWR MORB MORTAL WKL, V45, P1; 1996, MMWR MORB MORTAL WKL, V45, P1029; 1996, MMWR MORB MORTAL WKL, V45, P265	66	534	557	3	74	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 26	1998	339	22					1603	1608		10.1056/NEJM199811263392206	http://dx.doi.org/10.1056/NEJM199811263392206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZU	9828249				2022-12-28	WOS:000077176100006
J	Jones, D; Gill, PS				Jones, D; Gill, PS			Refugees and primary care: tackling the inequalities	BRITISH MEDICAL JOURNAL			English	Article							HEALTH; STRESS		UCL Royal Free & Univ Coll, Sch Med, Whittington Hosp, Dept Primary Care & Populat Sci, London N19 SNF, England; Univ Birmingham, Dept Gen Practice, Birmingham B15 2TT, W Midlands, England	University of London; University College London; UCL Medical School; University of Birmingham	Jones, D (corresponding author), UCL Royal Free & Univ Coll, Sch Med, Whittington Hosp, Dept Primary Care & Populat Sci, London N19 SNF, England.	d.l.jones@ucl.ac.uk						DICK B, 1984, T ROY SOC TROP MED H, V78, P734, DOI 10.1016/0035-9203(84)90004-X; EISENBRUCH M, 1991, SOC SCI MED, V33, P673, DOI 10.1016/0277-9536(91)90021-4; Gorst-Unsworth C, 1998, BRIT J PSYCHIAT, V172, P90, DOI 10.1192/bjp.172.1.90; GOUGH CB, 1998, 27 LOND STAT OFF; GRANT C, 1995, STATINT OBVIOUS FACT; Hicks C, 1991, Health Serv Manage Res, V4, P89; *HOM DEP, 1998, CM4018; *ISL REF WORK PART, 1992, REP QUEST SURV; JOLY D, 1996, HAVEN HELL ASYLUM PO, P120; Jones D, 1998, BRIT MED J, V316, P1476, DOI 10.1136/bmj.316.7143.1476; KARMI G, 1992, BRIT MED J, V305, P205, DOI 10.1136/bmj.305.6847.205; KARMI G, 1992, REFUGEES N W N E THA; Loizos Peter, 1981, HEART GROWN BITTER C; *LOND REF COUNC, 1997, CRED NAT STUD REF UK; Majeed FA, 1996, BRIT MED J, V313, P669; MERYN S, 1998, BRIT MED J, V316, P1992; MURPHY AW, 1994, IRISH MED J, V87, P174; RAMSAY R, 1993, BRIT J GEN PRACT, V43, P480; *REF HLTH CONS, 1998, PROM HLTH REF; *SECR STAT HLTH, 1997, CM3807; Sinnerbrink I, 1997, J PSYCHOL, V131, P463, DOI 10.1080/00223989709603533; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; TURNBERG L, 1997, HLTH SERVICES LONDON; WOOD JC, 1995, SETTLEMENT REFUGEES; 1993, STATE WORLDS REFUGEE	25	43	43	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1444	1446		10.1136/bmj.317.7170.1444	http://dx.doi.org/10.1136/bmj.317.7170.1444			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	142LP	9822406	Green Published			2022-12-28	WOS:000077202200030
J	Kim, SS; Zhang, WZ; Pinnavaia, TJ				Kim, SS; Zhang, WZ; Pinnavaia, TJ			Ultrastable mesostructured silica vesicles	SCIENCE			English	Article							MESOPOROUS MOLECULAR-SIEVES; ELECTRON-MICROSCOPY; SURFACE PATTERNS; LAMELLAR SILICAS; PHASE-BEHAVIOR; MORPHOGENESIS; MCM-41	A family of mesoporous molecular sieves (denoted MSU-G) with vesiclelike hierarchical structures and unprecedented thermal (1000 degrees C) and hydrothermal stabilities (more than 150 hours at 100 degrees C) associated with high SiO4 cross-linking was prepared through a supramolecular assembly pathway that relies on hydrogen bonding between electrically neutral gemini surfactants of the type CnH2n+1NH(CH2)(2)NH2 and silica precursors derived from tetraethylorthosilicate. The vesicle shells are constructed of one or more undulated silica sheets that are about 3 nanometers thick with mesopores (average diameters from 2.7 to 4.0 nanometers) running both parallel and orthogonal to the silica sheets, which makes the framework structure bicontinuous and highly accessible. Catalytic metal ion centers [for example, Ti(IV) and Al(III)] have been incorporated into the framework with the retention of hierarchical structure.	Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Michigan State Univ, Ctr Fundamental Mat Res, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Pinnavaia, TJ (corresponding author), Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA.							ALFREDSSON V, 1994, J CHEM SOC CHEM COMM, P921, DOI 10.1039/c39940000921; Auguste F, 1997, LANGMUIR, V13, P666, DOI 10.1021/la960683p; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; DUBOIS M, 1991, LANGMUIR, V7, P1352, DOI 10.1021/la00055a011; DUBOIS M, 1993, LANGMUIR, V9, P673, DOI 10.1021/la00027a011; HERRINGTON KL, 1993, J PHYS CHEM-US, V97, P13792, DOI 10.1021/j100153a058; HOFFMANN H, 1992, LANGMUIR, V8, P2629, DOI 10.1021/la00047a011; HUE Q, 1995, SCIENCE, V268, P1324; Huo QS, 1997, CHEM MATER, V9, P14, DOI 10.1021/cm960464p; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Lin HP, 1996, SCIENCE, V273, P765, DOI 10.1126/science.273.5276.765; LINSKER F, 1945, J AM CHEM SOC, V67, P1581, DOI 10.1021/ja01225a054; Mann S, 1997, CHEM MATER, V9, P2300, DOI 10.1021/cm970274u; McGrath KM, 1997, SCIENCE, V277, P552, DOI 10.1126/science.277.5325.552; Oberdisse J, 1998, J PHYS CHEM B, V102, P1102, DOI 10.1021/jp972390q; OGAWA M, 1994, J AM CHEM SOC, V116, P7941, DOI 10.1021/ja00096a079; OLIVER S, 1995, NATURE, V378, P47, DOI 10.1038/378047a0; Ozin GA, 1997, ACCOUNTS CHEM RES, V30, P17, DOI 10.1021/ar960021r; PORTE G, 1992, J PHYS-CONDENS MAT, V4, P8649, DOI 10.1088/0953-8984/4/45/002; Ryoo R, 1997, STUD SURF SCI CATAL, V105, P45; Schacht S, 1996, SCIENCE, V273, P768, DOI 10.1126/science.273.5276.768; Tanev PT, 1996, CHEM MATER, V8, P2068, DOI 10.1021/cm950549a; Tanev PT, 1997, J AM CHEM SOC, V119, P8616, DOI 10.1021/ja970228v; Tanev PT, 1996, SCIENCE, V271, P1267, DOI 10.1126/science.271.5253.1267; Yang H, 1997, NATURE, V386, P692, DOI 10.1038/386692a0; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548	26	496	527	2	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1302	1305		10.1126/science.282.5392.1302	http://dx.doi.org/10.1126/science.282.5392.1302			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812891				2022-12-28	WOS:000076982200040
J	Murley, LL; Grindley, NDF				Murley, LL; Grindley, NDF			Architecture of the gamma delta resolvase synaptosome: Oriented heterodimers identify interactions essential for synapsis and recombination	CELL			English	Article							SITE-SPECIFIC RECOMBINATION; TN3 RESOLVASE; CRYSTAL-STRUCTURE; RES SITES; DNA; PROTEIN; CLEAVAGE; RESIDUES; BINDING; COMPLEX	gamma delta resolvase catalyzes recombination within a complex nucleoprotein structure containing at least 12 resolvase subunits bound to two 114 bp res sites. The 2,3' interaction between resolvase dimers is essential for synapsis and recombination. Using oriented resolvase heterodimers, we have identified half sites of res that must be occupied by a 2,3'-proficient protomer. For synapsis, only four of the eight subunits bound to sites II and III, those at II-L and III-L, require a 2,3'-proficient interface. This 2,3' interaction, apparently between protomers bound to adjacent sites, may nucleate assembly of the core synaptic complex. For recombination, 2,3'-proficient subunits are also required at sites I-R and III-R, suggesting an important communication between the crossover site and the core of the synapse.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Grindley, NDF (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028470, R37GM028470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMEGUID SS, 1984, P NATL ACAD SCI-BIOL, V81, P2001, DOI 10.1073/pnas.81.7.2001; ABREMSKI K, 1983, CELL, V32, P1301, DOI 10.1016/0092-8674(83)90311-2; BEDNARZ AL, 1990, GENE DEV, V4, P2366, DOI 10.1101/gad.4.12b.2366; BOOCOCK MR, 1995, EMBO J, V14, P5129, DOI 10.1002/j.1460-2075.1995.tb00195.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COZZARELLI NR, 1984, COLD SPRING HARB SYM, V49, P383, DOI 10.1101/SQB.1984.049.01.045; GRINDLEY NDF, 1993, SCIENCE, V262, P738, DOI 10.1126/science.8235593; GRINDLEY NDF, 1994, NUCLEIC ACIDS MOL BI, V8, P236; HATFULL GF, 1989, J MOL BIOL, V208, P661, DOI 10.1016/0022-2836(89)90156-3; HATFULL GF, 1986, P NATL ACAD SCI USA, V83, P5429, DOI 10.1073/pnas.83.15.5429; HUGHES RE, 1993, EMBO J, V12, P1447, DOI 10.1002/j.1460-2075.1993.tb05788.x; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; HUGHES RE, 1992, THESIS YALE U NEW HA; LIU T, 1993, J BIOL CHEM, V268, P16309; REED RR, 1984, COLD SPRING HARB SYM, V49, P245, DOI 10.1101/SQB.1984.049.01.028; REED RR, 1981, CELL, V25, P721, DOI 10.1016/0092-8674(81)90179-3; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; RICE PA, 1994, STRUCTURE, V2, P371, DOI 10.1016/S0969-2126(00)00039-3; RICE PA, 1994, EMBO J, V13, P1514, DOI 10.1002/j.1460-2075.1994.tb06413.x; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; SOULTANAS P, 1995, J MOL BIOL, V245, P208, DOI 10.1006/jmbi.1994.0017; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; STARK WM, 1991, EMBO J, V10, P3541, DOI 10.1002/j.1460-2075.1991.tb04918.x; WASSERMAN SA, 1985, SCIENCE, V229, P171, DOI 10.1126/science.2990045; Watson MA, 1996, J MOL BIOL, V257, P317, DOI 10.1006/jmbi.1996.0165; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; ZHOU YH, 1993, CELL, V73, P375, DOI 10.1016/0092-8674(93)90236-J; [No title captured]	29	42	43	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 13	1998	95	4					553	562		10.1016/S0092-8674(00)81622-0	http://dx.doi.org/10.1016/S0092-8674(00)81622-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827807	hybrid			2022-12-28	WOS:000077049400013
J	Sugarman, J; Burk, L				Sugarman, J; Burk, L			Physicians' ethical obligations regarding alternative medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27710 USA; Duke Univ, Ctr Study Aging & Human Dev, Durham, NC 27710 USA; Duke Univ, Dept Philosophy, Durham, NC USA; Duke Univ, Dept Radiol, Durham, NC 27710 USA; Duke Univ, Off Integrat Med Educ, Durham, NC USA	Duke University; Duke University; Duke University; Duke University; Duke University	Sugarman, J (corresponding author), Duke Univ, Med Ctr, Div Gen Internal Med, Box 3040, Durham, NC 27710 USA.			Sugarman, Jeremy/0000-0001-7022-8332				Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Barrett S, 1998, BIOMED ETH, P1; BRATMAN S, 1997, ALTERN THER, V3, P127; CALLAHAN D, 1996, HASTINGS CENT RE NOV, P9; CASSILETH BR, 1991, NEW ENGL J MED, V324, P1180, DOI 10.1056/NEJM199104253241706; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Daly D, 1997, J Altern Complement Med, V3, P405, DOI 10.1089/acm.1997.3.405; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Ernst E, 1998, AM J MED, V104, P170, DOI 10.1016/S0002-9343(97)00397-5; Ernst E, 1996, J MED ETHICS, V22, P197, DOI 10.1136/jme.22.4.197; Halperin E C, 1998, N C Med J, V59, P21; Hufford, 1995, Altern Ther Health Med, V1, P94; Hufford D J, 1997, Altern Ther Health Med, V3, P78; JENIKE MA, 1994, J GERIATR PSYCHIA S1, V7, P1; Kahn J. P., 1998, CONSENT SEEKING JUST; KOTTOW MH, 1992, J MED ETHICS, V18, P18, DOI 10.1136/jme.18.1.18; LYNOE N, 1992, SCAND J SOC MED, V20, P217, DOI 10.1177/140349489202000406; MACK RB, 1998, NC MED J, V59, P24; Macklin R, 1998, KENNEDY INST ETHIC J, V8, P1, DOI 10.1353/ken.1998.0005; Milan FB, 1998, J GEN INTERN MED, V13, P562, DOI 10.1046/j.1525-1497.1998.00168.x; Rosa L, 1998, JAMA-J AM MED ASSOC, V279, P1005, DOI 10.1001/jama.279.13.1005; VONBEHREN D, 1997, ARIZONA HLTH HORIZON, P16; *WORKSH ALT MED, 1995, ALT MED EXP MED HOR	24	37	37	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1623	1625		10.1001/jama.280.18.1623	http://dx.doi.org/10.1001/jama.280.18.1623			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	136GX	9820269				2022-12-28	WOS:000076852000035
J	Howse, M; Bindoff, L; Carmichael, A				Howse, M; Bindoff, L; Carmichael, A			Facial vasculitic rash associated with intravenous immunoglobulin	BRITISH MEDICAL JOURNAL			English	Letter									S Tees Acute Hosp Trust, Middlesbrough TS4 3BW, Cleveland, England		Howse, M (corresponding author), S Tees Acute Hosp Trust, Middlesbrough TS4 3BW, Cleveland, England.			Bindoff, Laurence/0000-0003-0988-276X				Brannagan TH, 1996, NEUROLOGY, V47, P674, DOI 10.1212/WNL.47.3.674; BRUCHA C, 1987, BRIT MED J, V295, P1141; CHANLAM D, 1987, LANCET, V1, P1436; Hashkes PJ, 1996, CLIN EXP RHEUMATOL, V14, P673; Schiavotto C, 1993, Haematologica, V78, P35	5	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1291	1291		10.1136/bmj.317.7168.1291	http://dx.doi.org/10.1136/bmj.317.7168.1291			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804718	Green Published			2022-12-28	WOS:000076963800027
J	Santucci, PA; Haw, J; Trohman, RG; Pinski, SL				Santucci, PA; Haw, J; Trohman, RG; Pinski, SL			Interference with an implantable defibrillator by an electronic antitheft-surveillance device	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARTICLE SURVEILLANCE; CARDIAC-PACEMAKERS; ELECTROMAGNETIC-INTERFERENCE; SYSTEMS; ICD		Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA	Rush University	Santucci, PA (corresponding author), Rush Presbyterian St Lukes Med Ctr, 1753 W Congress Pky, Chicago, IL 60612 USA.							Beaugeard D, 1992, Arch Mal Coeur Vaiss, V85, P1457; DODINOT B, 1993, PACE, V16, P46, DOI 10.1111/j.1540-8159.1993.tb01534.x; Eisenberg E, 1998, J NEUROSURG, V88, P791; Eisenberg E, 1997, J NEUROSURG, V87, P961, DOI 10.3171/jns.1997.87.6.0961; Hayes DL, 1997, NEW ENGL J MED, V336, P1473, DOI 10.1056/NEJM199705223362101; LUCAS EH, 1994, PACE, V17, P2021, DOI 10.1111/j.1540-8159.1994.tb03793.x; Madrid A, 1997, PACE, V20, P212, DOI 10.1111/j.1540-8159.1997.tb04845.x; MARCO D, 1992, PACE, V15, P2016, DOI 10.1111/j.1540-8159.1992.tb03013.x; Mathew P, 1997, PACE, V20, P2857, DOI 10.1111/j.1540-8159.1997.tb05445.x; MORAES JCTD, 1995, ARTIF ORGANS, V19, P238, DOI 10.1111/j.1525-1594.1995.tb02320.x; SCHMITT C, 1991, PACE, V14, P982; Sticherling C, 1997, PACE, V20, P2265, DOI 10.1111/j.1540-8159.1997.tb04246.x	12	45	46	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1998	339	19					1371	1374		10.1056/NEJM199811053391905	http://dx.doi.org/10.1056/NEJM199811053391905			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135BN	9801398				2022-12-28	WOS:000076780200005
J	Duthie, DJR				Duthie, DJR			Heat-related illness	LANCET			English	Editorial Material							HEATSTROKE; HYPERTHERMIA; DANTROLENE; STROKE		Univ Leicester, Glenfield Hosp, Dept Anaesthesia, Leicester L3 9QP, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Duthie, DJR (corresponding author), Univ Leicester, Glenfield Hosp, Dept Anaesthesia, Leicester L3 9QP, Leics, England.							BOUCHAMA A, 1991, CRIT CARE MED, V19, P176, DOI 10.1097/00003246-199102000-00011; Bouchama A, 1996, CRIT CARE MED, V24, P1173, DOI 10.1097/00003246-199607000-00018; Dematte JE, 1998, ANN INTERN MED, V129, P173, DOI 10.7326/0003-4819-129-3-199808010-00001; Epstein Y, 1997, LANCET, V350, P83, DOI 10.1016/S0140-6736(05)61811-9; Farmer JC, 1997, CRIT CARE MED, V25, P1263, DOI 10.1097/00003246-199708000-00003; Hammami MM, 1997, CRIT CARE MED, V25, P1314, DOI 10.1097/00003246-199708000-00017; Hammani MM, 1998, J APPL PHYSIOL, V84, P1615, DOI 10.1152/jappl.1998.84.5.1615; HOPKINS PM, 1991, LANCET, V338, P1491, DOI 10.1016/0140-6736(91)92304-K; LARNER AJ, 1992, LANCET, V339, P182, DOI 10.1016/0140-6736(92)90248-2; Lene B, 1997, JAMA-J AM MED ASSOC, V278, P462; Semenza JC, 1996, NEW ENGL J MED, V335, P84, DOI 10.1056/NEJM199607113350203; SIMON HB, 1993, NEW ENGL J MED, V329, P483; 1998, SCORCHING START 1998	13	10	11	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 24	1998	352	9137					1329	1330		10.1016/S0140-6736(05)60742-8	http://dx.doi.org/10.1016/S0140-6736(05)60742-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802267				2022-12-28	WOS:000076691700007
J	Thorlacius, S; Struewing, JP; Hartge, P; Olafsdottir, GH; Sigvaldason, H; Tryggvadottir, L; Wacholder, S; Tulinius, H; Eyfjord, JE				Thorlacius, S; Struewing, JP; Hartge, P; Olafsdottir, GH; Sigvaldason, H; Tryggvadottir, L; Wacholder, S; Tulinius, H; Eyfjord, JE			Population-based study of risk of breast cancer in carriers of BRCA2 mutation	LANCET			English	Article							ASHKENAZI-JEWISH INDIVIDUALS; OVARIAN-CANCER; GERMLINE MUTATIONS; GENE; FREQUENCY; FAMILIES; ICELAND; JEWS	Background Estimates of an 80-90% risk of breast cancer for carriers of germline mutations in the BRCA1 and BRCA2 genes are based on studies of families at high risk of breast cancer. Risk estimates for a population are possible if the mutation status of a representative sample of that population can be assessed. In Iceland, one common founder BRCA2 mutation occurs in 0.6% of the population. Iceland has a population-based cancer registry and a large collection of pedigrees, and estimation of cancer risk in mutation carriers is therefore possible. Methods We studied 575 breast-cancer patients, 541 women and 34 men unselected for family history of breast cancer. Data on cancer in first-degree relatives were available from the cancer registry. Risk of cancer was estimated by comparing the history of cancer in first-degree relatives of carriers and non-carriers. Findings 56 (10.4%) of the 541 women and 13 (38%) of the 34 men carried the 999del5 mutation. The estimated risk of breast cancer at age 50 for all female carriers of the 999de15 mutation was 17.0% (95% CI 9.1-25.9) and 37.2%(22.4-53.9) at age 70. Interpretation The results of our population-based study show that the mean risk of breast cancer in carriers of mutation in BRCA2 is lower than previously suggested. Individual risk assessment will, however, have to take account of family history.	Iceland Canc Soc, Mol & Cell Biol Res Lab, Reykjavik, Iceland; Iceland Canc Soc, Iceland Canc Registry, Reykjavik, Iceland; NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Eyfjord, JE (corresponding author), Iceland Canc Soc, Mol & Cell Biol Res Lab, Reykjavik, Iceland.	jorunn@krabb.is	Struewing, Jeffery P/I-7502-2013; Struewing, Jeffery P/C-3221-2008	Struewing, Jeffery P/0000-0002-4848-3334; Tryggvadottir, Laufey/0000-0001-8067-9030				Bergthorsson JT, 1998, HUM MUTAT, pS195; BJARNASON O, 1966, CANCER INCIDENCE 5 C, P168; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; EASTON DF, 1995, AM J HUM GENET, V56, P265; Fodor FH, 1998, AM J HUM GENET, V63, P45, DOI 10.1086/301903; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; *IARC, 1997, IARC SCI PUBL, V143, P514; Johannesdottir G, 1996, CANCER RES, V56, P3663; Jonasson JG, 1996, INT J CANCER, V65, P446, DOI 10.1002/(SICI)1097-0215(19960208)65:4<446::AID-IJC9>3.0.CO;2-X; LevyLahad E, 1997, AM J HUM GENET, V60, P1059; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Offit K, 1996, LANCET, V347, P1643, DOI 10.1016/S0140-6736(96)91484-1; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thorlacius S, 1997, AM J HUM GENET, V60, P1079; THORLACIUS S, 1995, LANCET, V346, P544, DOI 10.1016/S0140-6736(95)91383-1; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; TULINIUS H, 1992, J MED GENET, V29, P158, DOI 10.1136/jmg.29.3.158; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	25	273	276	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	1998	352	9137					1337	1339		10.1016/S0140-6736(98)03300-5	http://dx.doi.org/10.1016/S0140-6736(98)03300-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802270				2022-12-28	WOS:000076691700010
J	Scott, K; Zuker, CS				Scott, K; Zuker, CS			Assembly of the Drosophila phototransduction cascade into a signalling complex shapes elementary responses	NATURE			English	Article							PDZ-DOMAIN PROTEIN; SIGNALING COMPLEX; CA2+ CHANNEL; IN-VIVO; TRP; PHOTORECEPTORS; MUTANTS; MORPHOGENESIS; GLYCOPROTEIN; CHAOPTIN	The subcellular compartmentalization of signalling molecules helps to ensure the selective activation of different signal-transduction cascades within a single cell(1). Although there are many examples of compartmentalized signalling molecules, there are few examples of entire signalling cascades being organized as distinct signalling complexes. In Drosophila photoreceptors, the InaD protein, which consists of five PDZ domains, functions as a multivalent adaptor that bring together several components of the phototransduction cascade into a macromolecular complex(2-5). Here we study single-photon responses in several photoreceptor mutant backgrounds, and show that the InaD macromolecular complex is the unit of signalling that underlies elementary responses. We show that the localized activity of this signalling: unit promotes reliable single-photon responses as well as rapid activation and feedback regulation. Finally, we use genetic and electrophysiological tools to illustrate how the assembly of signalling molecules into a transduction complex limits signal amplification in vivo.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Zuker, CS (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.							BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; DELAND MC, 1973, NATURE, V244, P84; FUORTES MGF, 1964, J PHYSIOL-LONDON, V172, P239, DOI 10.1113/jphysiol.1964.sp007415; HARDIE RC, 1995, CELL CALCIUM, V18, P256, DOI 10.1016/0143-4160(95)90023-3; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; JOHNSON EC, 1986, J GEN PHYSIOL, V88, P651, DOI 10.1085/jgp.88.5.651; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Pearn MT, 1996, J BIOL CHEM, V271, P4937; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; Scott K, 1997, TRENDS BIOCHEM SCI, V22, P350, DOI 10.1016/S0968-0004(97)01100-6; Scott K, 1997, CELL, V91, P375, DOI 10.1016/S0092-8674(00)80421-3; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; STIEVE H, 1986, BUMPS ELEMENTARY EXC; Tsunoda S, 1998, CURR OPIN GENET DEV, V8, P419, DOI 10.1016/S0959-437X(98)80112-3; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; YEANDLE S, 1957, THESIS J HOPKINS U; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	21	129	131	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1998	395	6704					805	808		10.1038/27448	http://dx.doi.org/10.1038/27448			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AL	9796815				2022-12-28	WOS:000076607400058
J	Denborough, M				Denborough, M			Malignant hyperthermia	LANCET			English	Article							SUDDEN INFANT DEATH; RYANODINE RECEPTOR GENE; CENTRAL-CORE DISEASE; DANTROLENE SODIUM; SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; RELEASE CHANNEL; HYPERPYREXIA; SUSCEPTIBILITY; CONTRACTURE	A specific inherited muscle membrane disorder predisposes to a variety of clinical problems. The most common is malignant hyperthermia (MH), a dangerous hypermetabolic state after anaesthesia with suxamethonium and/or volatile halogenated anaesthetic agents. MH may also be triggered in susceptible individuals by severe exercise in hot conditions, infections, neuroleptic drugs, and overheating in infants. Inbred pigs have provided a helpful model, and experiments on these animals and in MH-susceptible patients have shown that the essential biochemical abnormality is an increase in calcium ions in the muscle cells. This knowledge has led to a specific muscle test to identify susceptibility to MH and to a specific treatment, dantrolene; and as a result the case-fatality rate in MH has fallen from 70% in the 1970s to 5% today. In pigs susceptibility to MH is caused by a single mutation in the ryanodine receptor (RYR) in skeletal muscle. In man the genetics is more complex and three clinical myopathies that predispose to MH have been defined. By far the most common is inherited as a mendelian dominant characteristic and at present mutations in the human RYR account for no more than 20% of susceptible families.	Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia	Australian National University; John Curtin School of Medical Research	Denborough, M (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia.	M.Denborough@anu.edu.au						AUSTIN KL, 1977, ANAESTH INTENS CARE, V3, P207; BOLES JM, 1982, NOUV PRESSE MED, V11, P674; CAROFF S, 1983, LANCET, V1, P244; COLLINS SP, 1987, INT J BIOCHEM, V19, P819, DOI 10.1016/0020-711X(87)90240-0; COONS DJ, 1982, AM J PSYCHIAT, V139, P944; DELACOUR JL, 1981, NOUV PRESSE MED, V10, P3572; Denborough M, 1996, ANAESTH INTENS CARE, V24, P348, DOI 10.1177/0310057X9602400308; DENBOROUGH MA, 1960, LANCET, V2, P45; DENBOROUGH MA, 1973, BMJ-BRIT MED J, V1, P272, DOI 10.1136/bmj.1.5848.272; DENBOROUGH MA, 1982, LANCET, V2, P1068; DENBOROUGH MA, 1962, BRIT J ANAESTH, V34, P395, DOI 10.1093/bja/34.6.395; DENBOROUGH MA, 1970, LANCET, V1, P1137; DENBOROUGH MA, 1981, MED J AUSTRALIA, V1, P649, DOI 10.5694/j.1326-5377.1981.tb135910.x; DENBOROUGH MA, 1970, LANCET, V1, P1138; DENBOROUGH MA, 1988, BRIT MED J, V296, P1442, DOI 10.1136/bmj.296.6634.1442-a; DENBOROUGH MA, 1982, MED J AUSTRALIA, V1, P204; DENBOROUGH MA, 1996, P 3 INT S MAL HYP TO, P43; DENBOROUGH MA, 1973, INT S MALIGNANT HYPE, P229; DEUFEL T, 1992, AM J HUM GENET, V50, P1151; DOWNEY GP, 1984, AM J MED, V77, P338, DOI 10.1016/0002-9343(84)90716-2; ELLIS FR, 1984, BRIT J ANAESTH, V56, P1267; ELLIS FR, 1988, BRIT J ANAESTH, V60, P28, DOI 10.1093/bja/60.1.28; ELLIS FR, 1971, BRIT J ANAESTH, V43, P721; ELLIS KO, 1972, N-S ARCH PHARMACOL, V274, P107, DOI 10.1007/BF00501011; FOSTER PS, 1989, MUSCLE NERVE, V12, P390, DOI 10.1002/mus.880120509; FUJII J, 1991, SCIENCE, V253, P488; GALLOWAY GJ, 1986, BRIT J ANAESTH, V58, P447, DOI 10.1093/bja/58.4.447; GOEKOOP JG, 1982, LANCET, V2, P49; GORDON RA, 1996, CAN ANAESTH SOC J, V13, P415; HAAN EA, 1990, HUM GENET, V86, P187; HALL LW, 1966, BRIT MED J, V2, P1305, DOI 10.1136/bmj.2.5525.1305; HARRIMAN DG, 1973, Q J MED, V42, P639; HARRISON GG, 1968, BMJ-BRIT MED J, V3, P594, DOI 10.1136/bmj.3.5618.594; HARRISON GG, 1975, BRIT J ANAESTH, V47, P62, DOI 10.1093/bja/47.1.62; Heiman-Patterson T D, 1986, Pediatr Neurol, V2, P175, DOI 10.1016/0887-8994(86)90013-5; HEIMANPATTERSON TD, 1988, MUSCLE NERVE, V11, P453, DOI 10.1002/mus.880110507; ISAACS H, 1970, BRIT MED J, V1, P275, DOI 10.1136/bmj.1.5691.275; ISAACS H, 1992, MUSCLE NERVE, V15, P740, DOI 10.1002/mus.880150619; KALOW W, 1970, LANCET, V2, P895, DOI 10.1016/S0140-6736(70)92069-6; KING JO, 1973, J PEDIATR-US, V83, P37, DOI 10.1016/S0022-3476(73)80309-9; KOLB ME, 1982, ANESTHESIOLOGY, V56, P254, DOI 10.1097/00000542-198204000-00005; KOZAKRIBBENS G, 1994, MINERVA ANESTESIO S3, V60, P177; KRIVOSICHORBER R, 1987, BRIT J ANAESTH, V59, P1554, DOI 10.1093/bja/59.12.1554; Loke J, 1998, AM J MED, V104, P470, DOI 10.1016/S0002-9343(98)00108-9; MACLENNAN DH, 1990, NATURE, V343, P559, DOI 10.1038/343559a0; MAY DC, 1983, ANN INTERN MED, V98, P183, DOI 10.7326/0003-4819-98-2-183; MCCARTHY TV, 1990, NATURE, V343, P562, DOI 10.1038/343562a0; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MOULDS RFW, 1974, BMJ-BRIT MED J, V2, P245, DOI 10.1136/bmj.2.5913.245; ORDING H, 1984, BRIT J ANAESTH, V56, P1183, DOI 10.1093/bja/56.11.1183; ORDING H, 1985, ACTA ANAESTH SCAND, V29, P698, DOI 10.1111/j.1399-6576.1985.tb02283.x; OTSU K, 1992, GENOMICS, V13, P835, DOI 10.1016/0888-7543(92)90163-M; PETERSON DR, 1986, AUST PAEDIATR J, V22, P33; QUANE KA, 1994, HUM MOL GENET, V3, P471, DOI 10.1093/hmg/3.3.471; RANKLEV E, 1985, AM J FOREN MED PATH, V6, P149, DOI 10.1097/00000433-198506000-00007; ROSENBERG H, 1982, P 3 INT S MAL HYP BA, P3; SUTKO JL, 1985, FED PROC, V44, P2984; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	58	171	179	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 3	1998	352	9134					1131	1136		10.1016/S0140-6736(98)03078-5	http://dx.doi.org/10.1016/S0140-6736(98)03078-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798607				2022-12-28	WOS:000076246400043
J	Ham, C				Ham, C			The next 10 years	LANCET			English	Editorial Material									Univ Birmingham, Hlth Serv Management Ctr, Birmingham, W Midlands, England	University of Birmingham	Ham, C (corresponding author), Pk House,40 Edgbaston Pk Rd, Birmingham B15 2RT, W Midlands, England.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					56	57		10.1016/S0140-6736(98)05198-8	http://dx.doi.org/10.1016/S0140-6736(98)05198-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800767				2022-12-28	WOS:000074608600050
J	Sherwood, T				Sherwood, T			Ombudsman's second report, and tobacco	LANCET			English	Editorial Material							SMOKING		Lancet, London WC1B 3SL, England		Sherwood, T (corresponding author), Lancet, London WC1B 3SL, England.							ALDHOUS P, 1998, NEW SCI         0523, P16; BACON F, 1937, ESSAYS 1625; Dyer C, 1998, BRIT MED J, V316, P1555; Horton R, 1998, LANCET, V351, P1450, DOI 10.1016/S0140-6736(05)78867-X; Horton R, 1996, LANCET, V348, P6, DOI 10.1016/S0140-6736(05)64352-8; MCCORMICK J, 1988, LANCET, V1, P649; MCCORMICK J, 1994, LANCET, V344, P52, DOI 10.1016/S0140-6736(94)91071-5; SKRABANEK P, 1992, LANCET, V340, P1208, DOI 10.1016/0140-6736(92)92902-R; SKRABANEK P, 1992, LANCET, V339, P56, DOI 10.1016/0140-6736(92)90179-7; SKRABANEK P, 1989, FOLLIES FALLACIES ME	10	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					7	8		10.1016/S0140-6736(05)79508-8	http://dx.doi.org/10.1016/S0140-6736(05)79508-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800737				2022-12-28	WOS:000074608600007
J	Ramage, M				Ramage, M			Management of sexual problems	BRITISH MEDICAL JOURNAL			English	Article									St Georges Hosp, London, England	St Georges University London	Ramage, M (corresponding author), St Georges Hosp, London, England.							BROWN P, 1989, TREAT YOURSELF SEX; COLE M, 1988, SEX THERAPY BRITAIN; EID JF, 1993, MAKING LOVE AGAIN RE; LITVINOFF S, 1992, RELATE GUIDE LOVING; Masters W., 1970, HUMAN SEXUAL INADEQU; QUILLIAM S, 1997, YOUR SEXUAL SELF; STANLEY E, 1981, BRIT MED J, V282, P1200, DOI 10.1136/bmj.282.6271.1200; ZILBERGELD B, 1986, MEN SEX GUIDE SEXUAL	8	11	12	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1509	1512		10.1136/bmj.317.7171.1509	http://dx.doi.org/10.1136/bmj.317.7171.1509			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831586	Green Published			2022-12-28	WOS:000077338300038
J	Feng, GP; Tintrup, H; Kirsch, J; Nichol, MC; Kuhse, J; Betz, H; Sanes, JR				Feng, GP; Tintrup, H; Kirsch, J; Nichol, MC; Kuhse, J; Betz, H; Sanes, JR			Dual requirement for gephyrin in glycine receptor clustering and molybdoenzyme activity	SCIENCE			English	Article							RAT SPINAL-CORD; TUBULIN LINKER PROTEIN; SUBUNITS; SYNAPSES; MICE; CYTOSKELETON; BIOSYNTHESIS; DEFICIENCY; MUTATIONS; GENES	Glycine receptors are anchored at inhibitory chemical synapses by a cytoplasmic protein, gephyrin. Molecular cloning revealed the similarity of gephyrin to prokaryotic and invertebrate proteins essential for synthesizing a cofactor required for activity of molybdoenzymes. Gene targeting in mice showed that gephyrin is required both for synaptic clustering of glycine receptors in spinal cord and for molybdoenzyme activity in nonneural tissues. The mutant phenotype resembled that of humans with hereditary molybdenum cofactor deficiency and hyperekplexia (a failure of inhibitory neurotransmission), suggesting that gephyrin function may be impaired in both diseases.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	Washington University (WUSTL); Max Planck Society	Sanes, JR (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.	sanesj@thalamus.wustl.edu	Feng, Guoping/Y-2827-2019; Kuhse, Jochen/T-3864-2019					Andrew M, 1997, BRIT J PSYCHIAT, V170, P106, DOI 10.1192/bjp.170.2.106; Aprison M. H., 1990, GLYCINE NEUROTRANSMI, P1; Bechade C, 1996, SEMIN CELL DEV BIOL, V7, P717, DOI 10.1006/scdb.1996.0088; BRUNE W, 1996, AM J HUM GENET, V58, P959; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Johnson J.L, 1995, METABOLIC MOL BASES, V7th edition., P2271, DOI [10.1016/0168-9525(96)81407-7, DOI 10.1016/0168-9525(96)81407-7]; JOHNSON JL, 1991, J INHERIT METAB DIS, V14, P932, DOI 10.1007/BF01800477; Jonas P, 1998, SCIENCE, V281, P419, DOI 10.1126/science.281.5375.419; Kamdar KP, 1997, BIOCHEM SOC T, V25, P778, DOI 10.1042/bst0250778; KIRSCH J, 1995, MOL CELL NEUROSCI, V6, P450, DOI 10.1006/mcne.1995.1033; Kirsch J, 1996, MOL CELL NEUROSCI, V8, P93, DOI 10.1006/mcne.1996.0048; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1993, BRAIN RES, V621, P301, DOI 10.1016/0006-8993(93)90120-C; KIRSCH J, 1995, J NEUROSCI, V15, P4148; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; Nishimaru H, 1996, J PHYSIOL-LONDON, V497, P131, DOI 10.1113/jphysiol.1996.sp021755; PARKS D, 1988, J APPL PHYSIOL, V254, P768; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PFEIFFER F, 1984, P NATL ACAD SCI-BIOL, V81, P7224, DOI 10.1073/pnas.81.22.7224; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; Ramming M, 1997, FEBS LETT, V405, P137, DOI 10.1016/S0014-5793(97)00164-6; Rupar CA, 1996, NEUROPEDIATRICS, V27, P299, DOI 10.1055/s-2007-973798; SANES JR, IN PRESS ANN REV NEU; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; Simon ES, 1997, MOVEMENT DISORD, V12, P221, DOI 10.1002/mds.870120213; STALLMEYER B, 1995, PLANT J, V8, P751, DOI 10.1046/j.1365-313X.1995.08050751.x; TODD AJ, 1995, EUR J NEUROSCI, V7, P1, DOI 10.1111/j.1460-9568.1995.tb01014.x; TRILLER A, 1985, J CELL BIOL, V101, P683, DOI 10.1083/jcb.101.2.683; WATTS RWE, 1965, J LAB CLIN MED, V66, P688; WU WI, 1992, J NEUROSCI, V12, P3935; Yoshida A, 1975, Methods Enzymol, V41, P304	36	322	329	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1321	1324		10.1126/science.282.5392.1321	http://dx.doi.org/10.1126/science.282.5392.1321			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812897				2022-12-28	WOS:000076982200046
J	Owen, DJ; Evans, PR				Owen, DJ; Evans, PR			A structural explanation for the recognition of tyrosine-based endocytotic signals	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; VESICLE FORMATION; CRYSTAL-STRUCTURE; SORTING SIGNALS; INTERNALIZATION; PROTEINS; DOMAIN; MOTIF; ASSOCIATION; REFINEMENT	Many cell surface proteins are marked for endocytosis by a cytoplasmic sequence motif, tyrosine-X-X-(hydrophobic residue), that is recognized by the mu 2 subunit of AP2 adaptors. Crystal structures of the internalization signal binding domain of mu 2 complexed with the internalization signal peptides of epidermal growth factor receptor and the trans-Golgi network protein TGN38 have been determined at 2.7 angstrom resolution, The signal peptides adopted an extended conformation rather than the expected tight turn, Specificity was conferred by hydrophobic pockets that bind the tyrosine and leucine in the peptide. In the crystal, the protein forms dimers that could increase the strength and specificity of binding to dimeric receptors.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Evans, PR (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	pre@mrc-lmb.cam.ac.uk			Medical Research Council [MC_U105178845] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	32	451	462	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 13	1998	282	5392					1327	1332		10.1126/science.282.5392.1327	http://dx.doi.org/10.1126/science.282.5392.1327			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812899	Green Accepted			2022-12-28	WOS:000076982200048
J	Shlay, JC; Chaloner, K; Max, MB; Flaws, B; Reichelderfer, P; Wentworth, D; Hillman, S; Brizz, B; Cohn, DL				Shlay, JC; Chaloner, K; Max, MB; Flaws, B; Reichelderfer, P; Wentworth, D; Hillman, S; Brizz, B; Cohn, DL		Terry Beirn Community Programs Clinical Res AID	Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIABETIC NEUROPATHY; DESIPRAMINE; FLUOXETINE; RAT	Context.-Peripheral neuropathy is common in persons infected with the human immunodeficiency virus (HIV) but few data on symptomatic treatment are available. Objective.-To evaluate the efficacy of a standardized acupuncture regimen (SAR) and amitriptyline hydrochloride for the relief of pain due to HIV-related peripheral neuropathy in HIV-infected patients. Design.-Randomized, placebo-controlled, multicenter clinical trial. Each site enrolled patients into 1 of the following 3 options: (1) a modified double-blind 2 x 2 factorial design of SAR, amitriptyline, or the combination compared with placebo, (2) a modified double-blind design of an SAR vs control points, or (3) a double-blind design of amitriptyline vs placebo. Setting.-Terry Beirn Community Programs for Clinical Research on AIDS (HIV primary care providers) in 10 US cities. Patients.-Patients with HIV-associated, symptomatic, lower-extremity peripheral neuropathy. Of 250 patients enrolled, 239 were in the acupuncture comparison (125 in the factorial option and 114 in the SAR option vs control points option), and 136 patients were in the amitriptyline comparison (125 in the factorial option and 11 in amitriptyline option vs placebo option). Interventions.-Standarized acupuncture regimen vs control points, amitriptyline (75 mg/d) vs placebo, or both for 14 weeks. Main Outcome Measure.-Changes in mean pain scores at 6 and 14 weeks, using a pain scale ranging from 0.0 (no pain) to 1.75 (extremely intense), recorded daily. Results.-Patients in all 4 groups showed reduction in mean pain scores at 6 and 14 weeks compared with baseline values. For both the acupuncture and amitriptyline comparisons, changes in pain score were not significantly different between the 2 groups. At 6 weeks, the estimated difference in pain reduction for patients in the SAR group compared with those in the control points group (a negative value indicates a greater reduction for the "active" treatment) was 0.01 (95% confidence interval [CI], -0.11 to 0.12; P=.88) and for patients in the amitriptyline group vs those in the placebo group was -0.07 (95% CI, -0.22 to 0.08; P = .38). At 14 weeks, the difference for those in the SAR group compared with those in the control points group was -0.08 (95% CI, -0.21 to 0.06; P = .26) and for amitriptyline compared with placebo was 0.00 (95% CI, -0.18 to 0.19; P = .99). Conclusions.-In this study, neither acupuncture nor amitriptyline was more effective than placebo in relieving pain caused by HIV-related peripheral neuropathy.	Denver Community Program Clin Res AIDS, Denver, CO USA; Univ Minnesota, Sch Stat, St Paul, MN 55108 USA; NIAID, NIH, Bethesda, MD 20892 USA; NIDR, NIH, Bethesda, MD 20892 USA; Univ Minnesota, Div Biostat, Minneapolis, MN 55455 USA; Social & Sci Syst Inc, Rockville, MD USA	University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Minnesota System; University of Minnesota Twin Cities; Social & Scientific Systems	Shlay, JC (corresponding author), Denver Publ Hlth, 605 Bannock St, Denver, CO 80204 USA.	jshlay@dhha.org	Chaloner, Kathryn/B-5090-2013					Agresti A, 1996, INTRO CATEGORIAL DAT; ARMINGTON K, 1997, AIDS CARE, V9, P52; Birch S, 1996, J Altern Complement Med, V2, P101, DOI 10.1089/acm.1996.2.101; CHAPMAN CR, 1990, MANAGEMEN TPAIN, P1805; DALAKAS M, 1988, ANN NEUROL, V23, pS28; DEYO RA, 1991, ADULT SPINE PRINCIPL, P1777; FAUCI AS, 1998, HARRISONS PRINCIPLES, P1790; GAW AC, 1975, NEW ENGL J MED, V293, P375, DOI 10.1056/NEJM197508212930803; GRACELY RH, 1978, PAIN, V5, P5, DOI 10.1016/0304-3959(78)90020-9; HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M; HEGARTY A, 1994, SEMIN NEUROL, V14, P213, DOI 10.1055/s-2008-1041080; Jett MF, 1997, PAIN, V69, P161, DOI 10.1016/S0304-3959(96)03231-9; KIEBURTZ Z, 1997, ANN NEUROL, V42, P429; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEBARS D, 1979, PAIN, V6, P283, DOI 10.1016/0304-3959(79)90049-6; LEE PK, 1975, JAMA-J AM MED ASSOC, V232, P1133, DOI 10.1001/jama.232.11.1133; LEWITH GT, 1983, PAIN, V16, P111, DOI 10.1016/0304-3959(83)90202-6; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; MAX MB, 1994, PROG PAIN RES MANAG, V1, P229; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; MAX MB, 1987, NEUROLOGY, V37, P589, DOI 10.1212/WNL.37.4.589; MCQUAY HJ, 1993, ANAESTHESIA, V48, P281, DOI 10.1111/j.1365-2044.1993.tb06943.x; Newshan G, 1998, AIDS, V12, P219; NORTON GR, 1984, CAN J BEHAV SCI, V16, P22, DOI 10.1037/h0080774; OBRIEN PC, 1994, BIOMETRICS, V31, P511; OConnor J, 1981, ACUPUNCTURE COMPREHE; PATEL M, 1989, INT J EPIDEMIOL, V18, P900, DOI 10.1093/ije/18.4.900; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; RICHARDSON PH, 1986, PAIN, V24, P15, DOI 10.1016/0304-3959(86)90023-0; Simpson DM, 1996, NEUROLOGY, V47, P1254, DOI 10.1212/WNL.47.5.1254; SIMPSON DM, 1994, ANN INTERN MED, V121, P769, DOI 10.7326/0003-4819-121-10-199411150-00008; SINDRUP SH, 1990, CLIN PHARMACOL THER, V47, P509, DOI 10.1038/clpt.1990.65; SO YT, 1988, ARCH NEUROL-CHICAGO, V45, P945, DOI 10.1001/archneur.1988.00520330023005; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; THOMSON R, 1982, BRIT J PSYCHIAT, V140, P64, DOI 10.1192/bjp.140.1.64; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; TYOR WR, 1995, J ACQ IMMUN DEF SYND, V9, P379; VINCENT CA, 1986, PAIN, V24, P1, DOI 10.1016/0304-3959(86)90022-9; Vrethem M, 1997, CLIN J PAIN, V13, P313, DOI 10.1097/00002508-199712000-00009	39	202	213	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1590	1595		10.1001/jama.280.18.1590	http://dx.doi.org/10.1001/jama.280.18.1590			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820261	Bronze			2022-12-28	WOS:000076852000026
J	Wilt, TJ; Ishani, A; Stark, G; MacDonald, R; Lau, J; Mulrow, C				Wilt, TJ; Ishani, A; Stark, G; MacDonald, R; Lau, J; Mulrow, C			Saw palmetto extracts for treatment of benign prostatic hyperplasia - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SERENOA-REPENS; DOUBLE-BLIND; CLINICAL-TRIALS; FINASTERIDE; METAANALYSIS; PHYTOTHERAPY; PLACEBO; PERMIXON(R); HYPERTROPHY; EFFICACY	Objective.-To conduct a systematic review and, where possible, quantitative meta-analysis of the existing evidence regarding the therapeutic efficacy and safety of the saw palmetto plant extract, Serenoa repens, in men with symptomatic benign prostatic hyperplasia (BPH). Data Sources.-Studies were identified through the search of MEDLINE (1966-1997), EMBASE, Phytodok, the Cochrane Library, bibliographies of identified trials and review articles, and contact with relevant authors and drug companies, Study Selection.-Randomized trials were included if participants had symptomatic BPH, the intervention was a preparation of S repens alone or in combination with other phytotherapeutic agents, a control group received placebo or other pharmacological therapies for BPH, and the treatment duration was at least 30 days. Data Extraction.-Two investigators for each article (T.J.W,, A.I., G,S., and R.M.) independently extracted key data on design features, subject characteristics, therapy allocation, and outcomes of the studies. Data Synthesis.-A total of 18 randomized controlled trials involving 2939 men met inclusion criteria and were analyzed, Many studies did not report results in a method that permitted meta-analysis. Treatment allocation concealment was adequate in 9 studies; 16 were double-blinded. The mean study duration was 9 weeks (range, 4-48 weeks). As compared with men receiving placebo, men treated with S repens had decreased urinary tract symptom scores (weighted mean difference [WMD], -1.41 points [scale range, 0-19] [95% confidence interval (CI), -2.52 to -0.30] [n = 1 study]), nocturia (WMD, -0.76 times per evening [95% CI, -1.22 to -0.32] [n = 10 studies]), and improvement in self-rating of urinary tract symptoms; risk ratio for improvement (1.72 [:95% CI, 1.21-2.44] [n = 6 studies]), and peak urine flow (WMD, 1.93 mVs [95% CI, 0.72-3.14] [n = 8 studies]). Compared with men receiving finasteride, men treated with S repens had similar improvements in urinary tract symptom scores (WMD, 0.37 international Prostate Symptom Score points [scale range, 0-35] 1:95% CI, -0.45 to 1.19] [n =2 studiesl) and peak urine flow (WMD, -0.74 mL/s [95% CI, -1.66 to 0.18] [n = 2 studies]). Adverse effects due to S repens were mild and infrequent; erectile dysfunction was more frequent with finasteride (4.9%) than with S repens (1.1%; P < .001). Withdrawal rates in men assigned to placebo, S repens, or finasteride were 7%, 9%, and 11%, respectively. Conclusions.-The existing literature on S repens for treatment of BPH is limited in terms of the short duration of studies and variability in study design, use of phytotherapeutic preparations, and reports of outcomes. However, the evidence suggests that S repens improves urologic symptoms and flow measures. Compared with finasteride, S repens produces similar improvement in urinary tract symptoms and urinary flow and was associated with fewer adverse treatment events. Further research is needed using standardized preparations of S repens to determine its long-term effectiveness and ability to prevent BPH complications.	Vet Affairs Med Ctr, Dept Vet Affairs, Cochrane Collaborat Review Grp Prostat Dis & Urol, Coordinating Ctr, Minneapolis, MN 55417 USA; Minneapolis Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis Vet Integrated Serv Network 13, Minneapolis, MN USA; New England Med Ctr, Boston, MA 02111 USA; Dept Vet Affairs, Cochrane Ctr, San Antonio, TX USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Tufts Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Wilt, TJ (corresponding author), Vet Affairs Med Ctr, Dept Vet Affairs, Cochrane Collaborat Review Grp Prostat Dis & Urol, Coordinating Ctr, 111-O,1 Vet Dr, Minneapolis, MN 55417 USA.	wilt.timothy@minneapolis.va.gov						Barry MJ, 1997, JAMA-J AM MED ASSOC, V278, P2178; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; Boccafoschi C, 1983, UROLOGIA, V50, P1257; Boyle P, 1996, UROLOGY, V48, P398, DOI 10.1016/S0090-4295(96)00353-6; BRAECKMAN J, 1997, EUR J CLIN RES, V9, P247; Buck AC, 1996, BRIT J UROL, V78, P325, DOI 10.1046/j.1464-410X.1996.00104.x; CARBIN BE, 1990, BRIT J UROL, V66, P639, DOI 10.1111/j.1464-410X.1990.tb07199.x; Carraro JC, 1996, PROSTATE, V29, P231, DOI 10.1002/(SICI)1097-0045(199610)29:4&lt;231::AID-PROS4&gt;3.0.CO;2-E; CHAMPAULT G, 1984, BRIT J CLIN PHARMACO, V18, P461, DOI 10.1111/j.1365-2125.1984.tb02491.x; Chapple CR, 1996, EUR UROL, V29, P155; CHRISTENSEN MM, 1990, UROL CLIN N AM, V17, P509; COMAR OB, 1986, RIV ITALIANA BIOL ME, V6, P122; CUKIER J, 1985, CR THER PHARM CLIN, V4, P15; DESCOTES JL, 1995, CLIN DRUG INVEST, V9, P291, DOI 10.2165/00044011-199509050-00007; Di Silverio F, 1993, Minerva Urol Nefrol, V45, P143; DICKERSIN K, 1996, BRIT MED J, V12, P944; DISILVERIO F, 1992, EUR UROL, V21, P309; DREIKORN K, 1989, NEW DEV BIOSCIENCES, V5, P109; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Emili E, 1983, UROLOGIA, V50, P1042; Ernst E, 1998, AM J MED, V104, P170, DOI 10.1016/S0002-9343(97)00397-5; GABRIC V, 1987, THERAPIEWOCHE, V37, P1775; Grasso Marco, 1995, Archivos Espanoles de Urologia, V48, P97; GUESS HA, 1992, EPIDEMIOL REV, V14, P131, DOI 10.1093/oxfordjournals.epirev.a036083; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; LAU J, 1996, METAANALYST VERSION; LAVORI PW, 1992, NEUROPSYCHOPHARMACOL, V6, P39; LOBELENZ J, 1992, THERAPEUTIKON, V6, P34; LOWE F, 1998, J UROL S, V159, pA986; Lowe FC, 1996, UROLOGY, V48, P12, DOI 10.1016/S0090-4295(96)00077-5; MANDRESSI S, 1983, UROLOGIA, V50, P752; MARWICK C, 1995, JAMA-J AM MED ASSOC, V273, P607, DOI 10.1001/jama.273.8.607; Mattei F. M., 1990, TW UROL NEPHROL, V2, P346; McConnell JD, 1998, NEW ENGL J MED, V338, P557, DOI 10.1056/NEJM199802263380901; MCCONNELL JD, CLIN PRACTICE GUIDEL, V8; MCGUIRE E, 1987, NIH PUBLICATION, P221; Metzker H, 1996, UROLOGE B, V36, P292, DOI DOI 10.1007/S001310050033; OESTERLING JE, 1995, NEW ENGL J MED, V332, P99, DOI 10.1056/NEJM199501123320207; PERSICHELLI EP, 1986, UROLOGIA, V53, P696; Roehrborn CG, 1996, UROLOGY, V48, P406, DOI 10.1016/S0090-4295(96)00208-7; Roveda S., 1994, Archivio di Medicina Interna, V46, P61; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SEMINO MA, 1992, ARCH ESP UROL, V45, P211; SMITH HR, 1986, BRIT J UROL, V58, P36, DOI 10.1111/j.1464-410X.1986.tb05424.x; Sokeland J, 1997, UROLOGE A, V36, P327, DOI 10.1007/s001200050106; STRAUCH G, 1994, EUR UROL, V26, P247; Tasca A, 1985, Minerva Urol Nefrol, V37, P87; *UPD SOFTW, 1996, REVM COMP PROGR VERS; Wasson JH, 1998, NEW ENGL J MED, V338, P612, DOI 10.1056/NEJM199802263380909; Weisser H, 1997, EUR UROL, V31, P97; 1998, INT MED WORLD REPORT, V13, P8	51	242	251	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1604	1609		10.1001/jama.280.18.1604	http://dx.doi.org/10.1001/jama.280.18.1604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820264				2022-12-28	WOS:000076852000029
J	Ren, ZF; Huang, ZP; Xu, JW; Wang, JH; Bush, P; Siegal, MP; Provencio, PN				Ren, ZF; Huang, ZP; Xu, JW; Wang, JH; Bush, P; Siegal, MP; Provencio, PN			Synthesis of large arrays of well-aligned carbon nanotubes on glass	SCIENCE			English	Article							FIELD-EMISSION	Free-standing aligned carbon nanotubes have previously been grown. above 700 degrees C on mesoporous silica embedded with iron nanoparticles. Here, carbon nanotubes aligned over areas up to several square centimeters were grown on nickel-coated glass below 666 degrees C by plasma-enhanced hot filament chemical vapor deposition. Acetylene gas was used as the carbon source and ammonia gas was used asa catalyst and dilution gas. Nanotubes with controllable diameters from 20 to 400 nanometers and lengths from 0.1 to 50 micrometers were obtained. Using this method, large panels of aligned carbon nanotubes can be made under conditions that are suitable for device fabrication.	SUNY Buffalo, Mat Synth Lab, Dept Phys, Buffalo, NY 14260 USA; SUNY Buffalo, Mat Synth Lab, Dept Chem, Buffalo, NY 14260 USA; SUNY Buffalo, Ctr Adv Photon & Elect Mat, Buffalo, NY 14260 USA; SUNY Buffalo, Instrumentat Ctr, Buffalo, NY 14214 USA; Sandia Natl Labs, Albuquerque, NM 87185 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; United States Department of Energy (DOE); Sandia National Laboratories	Ren, ZF (corresponding author), SUNY Buffalo, Mat Synth Lab, Dept Phys, Nat Sci Complex, Buffalo, NY 14260 USA.		Ren, Zhifeng/B-4275-2014; Han, Jinhua/F-9464-2010					Charlier JC, 1997, SCIENCE, V275, P646, DOI 10.1126/science.275.5300.647; Collins PG, 1997, SCIENCE, V278, P100, DOI 10.1126/science.278.5335.100; DEHEER WA, 1995, SCIENCE, V268, P845, DOI 10.1126/science.268.5212.845; DEHEER WA, 1995, SCIENCE, V270, P1179, DOI 10.1126/science.270.5239.1179; Dillon AC, 1997, NATURE, V386, P377, DOI 10.1038/386377a0; Ebbesen T. W., 1997, CARBON NANOTUBES PRE; Frank S, 1998, SCIENCE, V280, P1744, DOI 10.1126/science.280.5370.1744; HUANG Z, UNPUB; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Journet C, 1997, NATURE, V388, P756, DOI 10.1038/41972; Li WZ, 1996, SCIENCE, V274, P1701, DOI 10.1126/science.274.5293.1701; Liu J, 1998, SCIENCE, V280, P1253, DOI 10.1126/science.280.5367.1253; RINZLER AG, 1995, SCIENCE, V269, P1550, DOI 10.1126/science.269.5230.1550; Terrones M, 1997, NATURE, V388, P52, DOI 10.1038/40369; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Wang QH, 1998, APPL PHYS LETT, V72, P2912, DOI 10.1063/1.121493	16	2326	2550	13	924	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1105	1107		10.1126/science.282.5391.1105	http://dx.doi.org/10.1126/science.282.5391.1105			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804545	Green Submitted			2022-12-28	WOS:000076887700045
J	Thomson, JA; Itskovitz-Eldor, J; Shapiro, SS; Waknitz, MA; Swiergiel, JJ; Marshall, VS; Jones, JM				Thomson, JA; Itskovitz-Eldor, J; Shapiro, SS; Waknitz, MA; Swiergiel, JJ; Marshall, VS; Jones, JM			Embryonic stem cell lines derived from human blastocysts	SCIENCE			English	Article							TELOMERASE ACTIVITY; MOUSE EMBRYOS; CULTURE; ANTIGEN	Human blastocyst-derived, pluripotent cell lines are described that have normal karyotypes, express high levels of telomerase activity, and express cell surface markers that characterize primate embryonic stem cells but do not characterize other early lineages. After undifferentiated proliferation in vitro for 4 to 5 months, these cells still maintained the developmental potential to form trophoblast and derivatives of all three embryonic germ layers, including gut epithelium (endoderm); cartilage, bone, smooth muscle, and striated muscle (mesoderm); and neural epithelium, embryonic ganglia, and stratified squamous epithelium (ectoderm). These cell lines should be useful in human developmental biology, drug discovery, and transplantation medicine.	Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53715 USA; Technion Israel Inst Technol, Fac Med, Dept Gynecol & Obstet, Rambam Med Ctr, IL-31096 Haifa, Israel; Univ Wisconsin, Dept Obstet & Gynecol, Madison, WI 53715 USA	University of Wisconsin System; University of Wisconsin Madison; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Wisconsin System; University of Wisconsin Madison	Thomson, JA (corresponding author), Univ Wisconsin, Wisconsin Reg Primate Res Ctr, 1223 Capitol Court, Madison, WI 53715 USA.							ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ANDREWS PW, 1987, TERATOCARCINOMAS EMB, P207; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Gardner DK, 1998, FERTIL STERIL, V69, P84, DOI 10.1016/S0015-0282(97)00438-X; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Hayflick L, 1961, EXP CELL RES, V25, P581; KANNAGI R, 1983, J BIOL CHEM, V258, P8934; KANNAGI R, 1983, EMBO J, V2, P2355, DOI 10.1002/j.1460-2075.1983.tb01746.x; KLUNG MG, 1996, J CLIN INVEST, V98, P216; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; O'Rahilly R., 1987, DEV STAGES HUMAN EMB; SOLTER D, 1975, P NATL ACAD SCI USA, V72, P5099, DOI 10.1073/pnas.72.12.5099; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; Thomson JA, 1998, CURR TOP DEV BIOL, V38, P133; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; WILES MV, 1991, DEVELOPMENT, V111, P259; Wright WE, 1996, DEV GENET, V18, P173	23	10767	12158	32	1538	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1145	1147		10.1126/science.282.5391.1145	http://dx.doi.org/10.1126/science.282.5391.1145			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804556				2022-12-28	WOS:000076887700056
J	Elad, Y; Nelson, PJ; Meier, DE				Elad, Y; Nelson, PJ; Meier, DE			Jumping to the wrong conclusion	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXTRAPULMONARY TUBERCULOSIS; MANAGEMENT; DIAGNOSIS; IMMUNODEFICIENCY; EPIDEMIOLOGY; INFECTION; AGE		CUNY Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Meier, DE (corresponding author), CUNY Mt Sinai Sch Med, Dept Geriatr & Adult Dev, Box 1070, New York, NY 10029 USA.							*ADV COUNC EL TUB, 1995, MMWR-MORBID MORTAL W, V44, P27; ALVAREZ S, 1987, AM J MED, V82, P602, DOI 10.1016/0002-9343(87)90106-9; BESDINE RW, 1997, GERIATRIC MED, P155; CANTRELL RW, 1975, ARCH OTOLARYNGOL, V101, P53; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; Centers for Disease Control (CDC), 1989, MMWR Morb Mortal Wkly Rep, V38, P269; CHAN CHS, 1995, TUBERCLE LUNG DIS, V76, P290, DOI 10.1016/S0962-8479(05)80026-7; Davies PDO, 1996, DRUG AGING, V8, P436, DOI 10.2165/00002512-199608060-00005; KASSIRER JP, 1989, AM J MED, V86, P433, DOI 10.1016/0002-9343(89)90342-2; KEMP WE, 1995, SOUTHERN MED J, V88, P1221, DOI 10.1097/00007611-199512000-00007; KING D, 1992, J ROY SOC MED, V85, P48; KORZENIEWSKAKOSELA M, 1994, CHEST, V106, P28, DOI 10.1378/chest.106.1.28; LEE KC, 1992, LARYNGOSCOPE, V102, P60; LIAW YS, 1995, J AM GERIATR SOC, V43, P256, DOI 10.1111/j.1532-5415.1995.tb07332.x; MACKAY AD, 1984, Q J MED, V53, P497; SALTZMAN RL, 1987, REV INFECT DIS, V9, P1127; SHAFER RW, 1991, MEDICINE, V70, P384, DOI 10.1097/00005792-199111000-00004; Stead W W, 1989, Semin Respir Infect, V4, P189; STEAD WW, 1987, ANN INTERN MED, V107, P837, DOI 10.7326/0003-4819-107-6-837; STEAD WW, 1985, NEW ENGL J MED, V312, P1483, DOI 10.1056/NEJM198506063122304; TEALE C, 1993, AGE AGEING, V22, P289, DOI 10.1093/ageing/22.4.289; VOYTOVICH AE, 1985, J MED EDUC, V60, P302; WEIR MR, 1985, AM J MED, V79, P467, DOI 10.1016/0002-9343(85)90034-8; WILKINS EGL, 1985, J HYG-CAMBRIDGE, V95, P115, DOI 10.1017/S0022172400062343; WILLIAMSON J, 1964, LANCET, V1, P1117; WILSON LA, 1962, LANCET, V2, P841; 1992, MMWR MORB MORTAL WKL, V41, P61	27	7	7	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1998	339	19					1382	1387		10.1056/NEJM199811053391908	http://dx.doi.org/10.1056/NEJM199811053391908			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135BN	9801401				2022-12-28	WOS:000076780200008
J	Soignet, SL; Maslak, P; Wang, ZG; Jhanwar, S; Calleja, E; Dardashti, LJ; Corso, D; DeBlasio, A; Gabrilove, J; Scheinberg, DA; Pandolfi, PP; Warrell, RP				Soignet, SL; Maslak, P; Wang, ZG; Jhanwar, S; Calleja, E; Dardashti, LJ; Corso, D; DeBlasio, A; Gabrilove, J; Scheinberg, DA; Pandolfi, PP; Warrell, RP			Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANS-RETINOIC ACID; POLYMERASE CHAIN-REACTION; MINIMAL RESIDUAL DISEASE; DIFFERENTIATION THERAPY; CASPASE ACTIVATION; INDUCED APOPTOSIS; CELLS; TRANSCRIPTION; EXPRESSION; GENE	Background Two reports from China have suggested that arsenic trioxide can induce complete remissions in patients with acute promyelocytic leukemia (APL). We evaluated this drug in patients with APL in an attempt to elucidate its mechanism of action. Methods Twelve patients with APL who had relapsed after extensive prior therapy were treated with arsenic trioxide at doses ranging from 0.06 to 0.2 mg per kilogram of body weight per day until visible leukemic cells were eliminated from the bone marrow. Bone marrow mononuclear cells were serially monitored by flow cytometry for immunophenotype, fluorescence in situ hybridization, reverse-transcription-polymerase-chain-reaction (RT-PCR) assay for PML-RAR-alpha: fusion transcripts, and Western blot analysis for expression of the apoptosis-associated proteins caspases 1, 2, and 3. Results Of the 12 patients studied, 11 had a complete remission after treatment that lasted from 12 to 39 days (range of cumulative doses, 160 to 515 mg). Adverse effects were relatively mild and included rash, lightheadedness, fatigue, and musculoskeletal pain. Cells that expressed both CD11b and CD33 (antigens characteristic of mature and immature cells, respectively), and which were found by fluorescence in situ hybridization to carry the t(15;17) translocation, increased progressively in number during treatment and persisted in the early phase of complete remission. Eight of 11 patients who initially tested positive for the PML-RAR-alpha fusion transcript by the RT-PCR assay later tested negative; 3 other patients, who persistently tested positive, relapsed early. Arsenic trioxide induced the expression of the proenzymes of caspase 2 and caspase 3 and activation of both caspase 1 and caspase 3. Conclusions Low doses of arsenic trioxide can induce complete remissions in patients with APL who have relapsed. The clinical response is associated with incomplete cytodifferentiation and the induction of apoptosis with caspase activation in leukemic cells. (C) 1998, Massachusetts Medical Society.	Mem Sloan Kettering Canc Ctr, Dev Chemotherapy Serv, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Div Pharm, New York, NY 10021 USA; Cornell Univ Med Coll, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Warrell, RP (corresponding author), Mem Sloan Kettering Canc Ctr, Dev Chemotherapy Serv, 1275 York Ave, New York, NY 10021 USA.		Roszak, Joanna/F-4003-2010	Maslak, Peter/0000-0003-1949-5819	NATIONAL CANCER INSTITUTE [T32CA009207, R03CA077136] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09207, CA-77136] Funding Source: Medline; FDA HHS [FD-R-001364] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS		Bainbridge WS, 1914, CANC PROBLEM, P271; BIONDI A, 1992, BLOOD, V80, P492; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BURRI C, 1993, CHEMOTHERAPY, V39, P225, DOI 10.1159/000239130; CALLEJA EM, 1998, P AN M AM SOC CLIN, V17, pA218; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chen GQ, 1996, BLOOD, V88, P1052; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; *EUR RET GROUP, 1996, LEUKEMIA, V10, P368; FENAUX P, 1993, BLOOD, V82, P3241; Forkner CE, 1931, J AMER MED ASSOC, V97, P0003, DOI 10.1001/jama.1931.02730010007002; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; Grimwade D, 1996, LEUKEMIA, V10, P61; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Konig A, 1997, BLOOD, V90, P562, DOI 10.1182/blood.V90.2.562.562_562_570; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; Mandelli F, 1997, BLOOD, V90, P1014; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; MILLER WH, 1993, BLOOD, V82, P1689; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet S, 1997, CANCER CHEMOTH PHARM, V40, pS25, DOI 10.1007/s002800051057; Sun H. D., 1992, CHIN J INTEGRAT CHIN, V12, P170; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; Tallman MS, 1997, NEW ENGL J MED, V337, P1639; TERSTAPPEN LWMM, 1990, J LEUKOCYTE BIOL, V48, P138, DOI 10.1002/jlb.48.2.138; Thornberry NA, 1997, BRIT MED BULL, V53, P478; VAHDAT L, 1994, BLOOD, V84, P3843, DOI 10.1182/blood.V84.11.3843.bloodjournal84113843; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wang ZL, 1996, TOXICOL APPL PHARM, V137, P112, DOI 10.1006/taap.1996.0062; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Watson RWG, 1997, FEBS LETT, V412, P603, DOI 10.1016/S0014-5793(97)00779-5; Westervelt P., 1997, Blood, V90, p249B; Yang C. H., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P227; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHANG P, 1996, CHIN J HEMATOL, V17, P58; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	44	1046	1121	1	80	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1998	339	19					1341	1348		10.1056/NEJM199811053391901	http://dx.doi.org/10.1056/NEJM199811053391901			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135BN	9801394				2022-12-28	WOS:000076780200001
J	Mayans, O; van der Ven, PFM; Wilm, M; Mues, A; Young, P; Furst, DO; Wilmanns, M; Gautel, M				Mayans, O; van der Ven, PFM; Wilm, M; Mues, A; Young, P; Furst, DO; Wilmanns, M; Gautel, M			Structural basis for activation of the titin kinase domain during myofibrillogenesis	NATURE			English	Article							GIANT PROTEIN-KINASES; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; TYROSINE KINASE; IMMUNOELECTRON MICROSCOPY; MOLLUSCAN TWITCHIN; PEPTIDE SUBSTRATE; PHOSPHORYLATION; EXPRESSION; MUSCLE	The giant muscle protein titin (connectin) is essential in the temporal and spatial control of the assembly of the highly ordered sarcomeres (contractile units) of striated muscle. Here we present the crystal structure of titin's only catalytic: domain, an autoregulated serine kinase (titin kinase). The structure shows how the active site is inhibited by a tyrosine of the kinase domain. We describe a dual mechanism of activation of titin kinase that consists of phosphorylation of this tyrosine and binding of calcium/calmodulin to the regulatory tail. The serine kinase domain of titin is the first known non-arginine-aspartate kinase to be activated by phosphorylation. The phosphorylated tyrosine is not located in the activation segment, as in other kinases, but in the P + 1 loop, indicating that this tyrosine is a binding partner of the titin kinase substrate. Titin kinase phosphorylates the muscle protein telethonin in early differentiating myocytes, indicating that this kinase may act in myofibrillogenesis.	DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Univ Potsdam, Dept Cell Biol, D-14471 Potsdam, Germany; European Mol Biol Lab, D-69012 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Potsdam; European Molecular Biology Laboratory (EMBL)	Wilmanns, M (corresponding author), DESY, European Mol Biol Lab, Hamburg Outstn, Notkestr 85, D-22603 Hamburg, Germany.	Wilmanns@embl-hamburg.de; Gautel@embl-heidelberg.de	Gautel, Mathias/AAB-9860-2019; Fürst, Dieter O./H-8561-2013; Mayans, Olga/A-3954-2008; Young, Paul/A-4874-2015	Fürst, Dieter O./0000-0001-8805-6444; Young, Paul/0000-0002-1307-0249; Wilm, Matthias/0000-0002-5461-6834; Gautel, Mathias/0000-0003-4027-9803; van der Ven, Peter/0000-0002-9750-8913; Mayans, Olga/0000-0001-6876-8532; Wilmanns, Matthias/0000-0002-4643-5435				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chayen NE, 1997, J APPL CRYSTALLOGR, V30, P198, DOI 10.1107/S0021889896013532; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; ENGELKAMP D, 1992, BIOCHEMISTRY-US, V31, P10258, DOI 10.1021/bi00157a012; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; GAUTEL M, 1995, EUR J BIOCHEM, V230, P752; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HEIERHORST J, 1994, J BIOL CHEM, V269, P21086; HEIERHORST J, 1995, EUR J BIOCHEM, V233, P426, DOI 10.1111/j.1432-1033.1995.426_2.x; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Heierhorst J, 1996, EUR J BIOCHEM, V242, P454, DOI 10.1111/j.1432-1033.1996.454rr.x; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KLEYWEGT GJ, 1994, P CCP4 STUD WEEK 1 M, P56; Kobe B, 1996, EMBO J, V15, P6810, DOI 10.1002/j.1460-2075.1996.tb01072.x; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Maruyama K, 1997, FASEB J, V11, P341, DOI 10.1096/fasebj.11.5.9141500; Mues A, 1998, FEBS LETT, V428, P111, DOI 10.1016/S0014-5793(98)00501-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Obermann WMJ, 1996, J CELL BIOL, V134, P1441, DOI 10.1083/jcb.134.6.1441; OTKINOWSKI Z, 1993, P CCP4 STUD WEEK SER, P56; Sebestyen MG, 1996, J MUSCLE RES CELL M, V17, P343; Song XD, 1996, IEEE T IMAGE PROCESS, V5, P16, DOI 10.1109/83.481667; TAN JL, 1991, J BIOL CHEM, V266, P16044; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Trinick J, 1996, CURR BIOL, V6, P258, DOI 10.1016/S0960-9822(02)00472-4; Valle G, 1997, FEBS LETT, V415, P163, DOI 10.1016/S0014-5793(97)01108-3; VIBERT P, 1993, J MUSCLE RES CELL M, V14, P598, DOI 10.1007/BF00141557; Weijland A, 1996, EUR J BIOCHEM, V240, P756, DOI 10.1111/j.1432-1033.1996.0756h.x; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Young P, 1998, EMBO J, V17, P1614, DOI 10.1093/emboj/17.6.1614; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	47	297	307	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 29	1998	395	6705					863	869		10.1038/27603	http://dx.doi.org/10.1038/27603			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804419				2022-12-28	WOS:000076713400046
J	Dixon, AK; Dendy, P				Dixon, AK; Dendy, P			Spiral CT: how much does radiation dose matter?	LANCET			English	Editorial Material							CONTRAST-ENHANCED CT		Addenbrookes Hosp, Dept Radiol, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Phys Med, Cambridge CB2 2QQ, England; Univ Cambridge, Cambridge CB2 2QQ, England	Addenbrooke's Hospital; University of Cambridge; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	Dixon, AK (corresponding author), Addenbrookes Hosp, Dept Radiol, Hills Rd, Cambridge CB2 2QQ, England.							[Anonymous], 1990, ICRP PUBL; Bearcroft PWP, 1998, EUR J RADIOL, V28, P30, DOI 10.1016/S0720-048X(98)00010-2; Cross JJL, 1998, CLIN RADIOL, V53, P177, DOI 10.1016/S0009-9260(98)80097-4; KALENDER WA, 1990, RADIOLOGY, V176, P181, DOI 10.1148/radiology.176.1.2353088; Kalender WA, 1997, RADIOLOGY P, V205, P471; MAYO JR, 1995, AM J ROENTGENOL, V164, P603, DOI 10.2214/ajr.164.3.7863879; *NAT RAD PROT BOAR, 1993, DOC NRPB, V4, P43; Oliver JH, 1996, RADIOLOGY, V201, P1; Rankin SC, 1998, EUR J RADIOL, V28, P18, DOI 10.1016/S0720-048X(98)00009-6; Rao PM, 1997, RADIOLOGY, V202, P139, DOI 10.1148/radiology.202.1.8988203; Scheck RJ, 1998, BRIT J RADIOL, V71, P734, DOI 10.1259/bjr.71.847.9771384; SHRIMPTON PC, 1995, RADIAT PROT DOSIM, V57, P413; Shrimpton PC, 1991, NRPBR249; SMITH RC, 1995, RADIOLOGY, V194, P789, DOI 10.1148/radiology.194.3.7862980; The Royal College of Radiologists, 1998, MAK BEST US DEP CLIN, V4th; Wade JP, 1997, BRIT J RADIOL, V70, P1146, DOI 10.1259/bjr.70.839.9536906; WAGNER LK, 1994, J VASC INTERV RADIOL, V5, P71, DOI 10.1016/S1051-0443(94)71456-1; [No title captured]	18	56	56	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 3	1998	352	9134					1082	1083		10.1016/S0140-6736(05)79751-8	http://dx.doi.org/10.1016/S0140-6736(05)79751-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798579				2022-12-28	WOS:000076246400004
J	McGonagle, D; Gibbon, W; Emery, P				McGonagle, D; Gibbon, W; Emery, P			Classification of inflammatory arthritis by enthesitis	LANCET			English	Article							SERONEGATIVE SYMMETRICAL SYNOVITIS; TUMOR-NECROSIS-FACTOR; PITTING EDEMA; REACTIVE ARTHRITIS; ANKYLOSING-SPONDYLITIS; RHEUMATOID-ARTHRITIS; ENTHESOPATHY; JOINTS; SPONDYLARTHROPATHY; MEMBRANE	Imaging studies of early synovitis suggest that the first abnormality to appear in swollen joints associated with spondyloarthropathy is an enthesitis (inflammation at sites where ligaments, tendons, or joint capsules are attached to bone). We propose that the synovitis of spondyloarthropathy is secondary to liberation of proinflammatory mediators from the enthesis, whereas the synovitis of rheumatoid arthritis is primary. This suggestion allows a classification of arthritis as either primary synovial (rheumatoid-like) or entheseal (spondyloarthropathy-like) and allows differentiation of presentation of a polyarthritis with a good prognosis (spondyloarthropathy-like), from that with a bad prognosis (rheumatoid arthritis). Pathogenesis of spondyloarthropathy, in particular the part played by HLA-B27 and micro-organisms, should be assessed at the enthesis rather than in the synovium.	Univ Leeds, Dept Rheumatol, Leeds LS1 9NZ, W Yorkshire, England; Leeds Gen Infirm, Dept Radiol, Leeds, W Yorkshire, England	University of Leeds; Leeds General Infirmary; University of Leeds	Emery, P (corresponding author), Univ Leeds, Dept Rheumatol, 36 Clarendon Rd, Leeds LS1 9NZ, W Yorkshire, England.		emery, paul/B-3560-2013					BALL J, 1971, ANN RHEUM DIS, V30, P213, DOI 10.1136/ard.30.3.213; Bhakta BB, 1997, BRIT J RHEUMATOL, V36, P214; CALIN A, 1987, ARTHRITIS RHEUM, V30, P1197, DOI 10.1002/art.1780301021; DOHERTY M, 1994, ATLAS TEST OSTEOARTH, P1; DOUGADOS M, 1991, ARTHRITIS RHEUM, V34, P1218, DOI 10.1002/art.1780341003; FOURNIE B, 1987, REV RHUM, V54, P447; Gerber H F, 1993, Schweiz Rundsch Med Prax, V82, P414; GERSTER JC, 1985, J RHEUMATOL, V12, P310; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HELIWELL P, 1991, BR J RHEUMATOL, V30, P339; HENDERSON B, 1991, CYTOKINE, V3, P246, DOI 10.1016/1043-4666(91)90023-7; HENDERSON B, 1989, CLIN EXP IMMUNOL, V75, P306; Huppertz HI, 1996, BRIT J RHEUMATOL, V35, P1016; JACOBS JC, 1983, ARCH INTERN MED, V143, P103, DOI 10.1001/archinte.143.1.103; Jevtic V, 1996, RADIOLOGE, V36, P624, DOI 10.1007/s001170050120; JEVTIC V, 1995, SKELETAL RADIOL, V24, P351; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KHAN MA, 1990, SEMIN ARTHRITIS RHEU, V20, P107, DOI 10.1016/0049-0172(90)90023-9; LEHTINEN A, 1994, CLIN EXP RHEUMATOL, V12, P143; MAUGARS Y, 1995, J RHEUMATOL, V22, P2135; MCCARTY DJ, 1985, JAMA-J AM MED ASSOC, V254, P2763, DOI 10.1001/jama.254.19.2763; McGonagle D, 1998, ARTHRITIS RHEUM, V41, P694, DOI 10.1002/1529-0131(199804)41:4<694::AID-ART17>3.0.CO;2-#; NAMEY TC, 1976, ARTHRITIS RHEUM-US, V19, P607, DOI 10.1002/art.1780190313; Olivieri I, 1996, ARTHRITIS RHEUM, V39, P1524, DOI 10.1002/art.1780390912; PETTIPHER ER, 1986, P NATL ACAD SCI USA, V83, P8749, DOI 10.1073/pnas.83.22.8749; Reith JD, 1996, AM J SURG PATHOL, V20, P1368, DOI 10.1097/00000478-199611000-00008; RESNICK D, 1983, RADIOLOGY, V146, P1; REVELL PA, 1982, ANN RHEUM DIS, V41, P579, DOI 10.1136/ard.41.6.579; Salvarani C, 1996, ARTHRITIS RHEUM, V39, P73, DOI 10.1002/art.1780390110; SCHAEVERBEKE T, 1995, ANN RHEUM DIS, V54, P681, DOI 10.1136/ard.54.8.681; SCHULZ LC, 1985, RHEUMATOL INT, V5, P21; SCHUMACHER HR, 1988, ARTHRITIS RHEUM, V31, P937; SHICHIKAWA K, 1992, RHEUM DIS CLIN N AM, V18, P203; SIEPER J, 1995, ARTHRITIS RHEUM, V38, P1547, DOI 10.1002/art.1780381105; SIEPER J, 1992, J RHEUMATOL, V19, P1236; SIMPSON J, 1995, J RHEUMATOL, V22, P332; SOAMES RW, 1995, GRAYS ANATOMY, P674; TAYLORROBINSON D, 1992, LANCET, V340, P81, DOI 10.1016/0140-6736(92)90399-N; VANBEUNINGEN HM, 1994, LAB INVEST, V71, P279; VINER NJ, 1991, ARTHRITIS RHEUM, V34, P1151, DOI 10.1002/art.1780340911; Wagner A. D., 1997, Arthritis and Rheumatism, V40, pS62; Watt I, 1997, EUR RADIOL, V7, P344, DOI 10.1007/s003300050165; WORDSWORTH BP, 1990, BRIT J RHEUMATOL, V29, P208	43	356	365	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 3	1998	352	9134					1137	1140		10.1016/S0140-6736(97)12004-9	http://dx.doi.org/10.1016/S0140-6736(97)12004-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798608				2022-12-28	WOS:000076246400044
J	Duley, L				Duley, L		Eclampsia Trial Collaborative Grp	Magnesium sulphate in eclampsia	LANCET			English	Letter									Inst Hlth Sci, Magpie Trial Coordinating Ctr, Oxford OX3 7LF, England	University of Oxford	Duley, L (corresponding author), Inst Hlth Sci, Magpie Trial Coordinating Ctr, Oxford OX3 7LF, England.		Duley, Lelia/E-8107-2015	Duley, Lelia/0000-0001-6721-5178				DULEY L, 1995, LANCET, V345, P1455; DULEY L, 1998, ANTICONVULSANTS WOME; Graham KM, 1998, LANCET, V351, P1061, DOI 10.1016/S0140-6736(05)79030-9; Mittendorf R, 1998, LANCET, V351, P293, DOI 10.1016/S0140-6736(05)78238-6	4	21	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					67	67		10.1016/S0140-6736(05)79550-7	http://dx.doi.org/10.1016/S0140-6736(05)79550-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800779				2022-12-28	WOS:000074608600065
J	Faul, JL; Tormey, W; Tormey, V; Burke, C				Faul, JL; Tormey, W; Tormey, V; Burke, C			High dose inhaled corticosteroids and dose dependent loss of diabetic control	BRITISH MEDICAL JOURNAL			English	Letter									James Connolly Mem Hosp, Dept Resp Med, Dublin 15, Ireland		Faul, JL (corresponding author), James Connolly Mem Hosp, Dept Resp Med, Dublin 15, Ireland.							BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Clark DJ, 1997, THORAX, V52, P55, DOI 10.1136/thx.52.1.55; CONN JW, 1956, METABOLISM, V5, P114; KOENIG RJ, 1976, NEW ENGL J MED, V295, P417, DOI 10.1056/NEJM197608192950804; KRUSZYNSKA YT, 1987, THORAX, V42, P881, DOI 10.1136/thx.42.11.881	5	22	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1491	1491		10.1136/bmj.317.7171.1491	http://dx.doi.org/10.1136/bmj.317.7171.1491			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831576	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000077338300026
J	Chen, JJ; Sun, YN; Nabel, GJ				Chen, JJ; Sun, YN; Nabel, GJ			Regulation of the proinflammatory effects of Fas ligand (CD95L)	SCIENCE			English	Article							CONFER IMMUNE PRIVILEGE; INDUCED APOPTOSIS; GROWTH-FACTOR; ACTIVATION; EXPRESSION; CELLS; NEUTROPHILS; PHOSPHORYLATION; REJECTION; MECHANISM	Fas ligand (CD95L) inhibits T cell function in immune-privileged organs such as the eye and testis, yet in most tissues CD95L expression induces potent inflammatory responses. With a stably transfected colon carcinoma cell Line, CT26-CD95L, the molecular basis for these divergent responses was defined. When injected subcutaneously, rejection of CT26-CD95L was caused by neutrophils activated by CD95L. CT26-CD95L survived in the intraocular space because of the presence of transforming growth factor-beta (TGF-beta), which inhibited neutrophil activation. Providing TGF-beta to subcutaneous sites protected against tumor rejection. Thus, these cytokines together generate a microenvironment that promotes immunologic tolerance, which may aid in the amelioration of allograft rejection.	Univ Michigan, Med Ctr, Dept Internal Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Nabel, GJ (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Howard Hughes Med Inst, 1150 W Med Ctr Dr,4250 Med Sci Res Bldg 1, Ann Arbor, MI 48109 USA.	gnabel@umich.edu						Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Arai H, 1997, NAT MED, V3, P843, DOI 10.1038/nm0897-843; Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Berrou E, 1996, BIOCHEM J, V316, P167, DOI 10.1042/bj3160167; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chen J., UNPUB; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; DAUGHADAY WH, 1991, ENDOCRIN METAB CLIN, V20, P539, DOI 10.1016/S0889-8529(18)30258-5; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Green DR, 1997, P NATL ACAD SCI USA, V94, P5986, DOI 10.1073/pnas.94.12.5986; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HORGAN K, 1998, CURR PROTOC IMMUNOL, V7, P4; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Kang SM, 1997, SCIENCE, V278, P1322, DOI 10.1126/science.278.5341.1322; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; Lee M, 1997, AM J PHYSIOL-LUNG C, V273, pL374, DOI 10.1152/ajplung.1997.273.2.L374; LILES WC, 1995, J IMMUNOL, V155, P2175; LUO Y, 1998, CURR PROTOC IMMUNOL, V3, P20; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; PAZDRAK K, 1995, J IMMUNOL, V155, P4454; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rose DM, 1997, BIOCHEM BIOPH RES CO, V238, P256, DOI 10.1006/bbrc.1997.7271; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; STREILEIN JW, 1992, CURR EYE RES, V11, P41, DOI 10.3109/02713689208999510; Stuart PM, 1997, J CLIN INVEST, V99, P396, DOI 10.1172/JCI119173; VARANI J, 1989, AM J PATHOL, V135, P435; Yang ZY, 1998, SCIENCE, V279, P1034, DOI 10.1126/science.279.5353.1034; Zu YL, 1998, J IMMUNOL, V160, P1982	38	307	324	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1714	1717		10.1126/science.282.5394.1714	http://dx.doi.org/10.1126/science.282.5394.1714			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831564				2022-12-28	WOS:000077246600049
J	Heath, I				Heath, I			A book that changed me - Many patients are struggling too	BRITISH MEDICAL JOURNAL			English	Article																		Schlink Bernhard, 1997, READER	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1449	1449		10.1136/bmj.317.7170.1449	http://dx.doi.org/10.1136/bmj.317.7170.1449			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822408	Green Published			2022-12-28	WOS:000077202200032
J	Ramanan, SV				Ramanan, SV			A memorable patient - A very rare bleeding disorder	BRITISH MEDICAL JOURNAL			English	Article									Univ Connecticut, Storrs, CT 06269 USA	University of Connecticut	Ramanan, SV (corresponding author), Univ Connecticut, Storrs, CT 06269 USA.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1437	1437		10.1136/bmj.317.7170.1437	http://dx.doi.org/10.1136/bmj.317.7170.1437			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822402	Green Published			2022-12-28	WOS:000077202200027
J	Sexton, M; Althuis, MD; Santanello, N; Hyndman, S; Williams, R; Schmeidler, D				Sexton, M; Althuis, MD; Santanello, N; Hyndman, S; Williams, R; Schmeidler, D			Sex differences in the use of asthma drug's: cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							YOUNG-ADULTS; PRESCRIPTION DATABASE; POPULATION; MEDICATIONS; PREDICTORS; CARE	Objectives To assess the use of asthma drugs by men and women with asthma and to identify sex specific predictors for the use of oral steroids. Design Cross sectional study Setting Six general practices in East Anglia. Subjects 103 men and 134 women aged 20-54 with asthma. Main outcome measures Self reported use of beta agonists, inhaled steroids, and oral steroids. Results No sex difference was found in use of beta agonists or inhaled steroids. However a strong association existed between sex and oral steroid use. 40 (30%) women reported using oral steroids compared with nine (9%) men. Women were more than five times (odds ratio = 5.5, 95% confidence interval 2.2 to 13.7) more likely to report use of oral steroids than men after asthma symptoms, age, visits to the general practitioner in previous six months, and time since diagnosis of asthma were controlled for. Women who had visited the general practitioner for asthma one or more times in the previous six months were four times (3.9, 1.6 to 9.5) as likely to report use of oral steroids. In addition, more frequent visits to the general practitioner for asthma were related in a dose-response manner to a greater likelihood of using oral steroids among women after asthma symptoms, age, and time since diagnosis were controlled for. This relation was not observed among men. Conclusion Women used oral steroids more than men. The more frequent consultations with a doctor by women may result in more requests for oral steroids or doctors may preferentially prescribe oral steroids to women.	Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Merck & Co Inc, Merck Res Labs, Epidemiol Res, West Point, PA 19486 USA; Univ Cambridge, Inst Publ Hlth, Dept Community Med, Hlth Serv Res Grp, Cambridge CB2 2SR, England; Univ Leeds, Nuffield Inst Hlth, Leeds LS2 9PL, W Yorkshire, England	University System of Maryland; University of Maryland Baltimore; Merck & Company; University of Cambridge; University of Leeds	Sexton, M (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA.	msexton@epl.umaryland.edu						CHRISCHILLES EA, 1992, J GERONTOL, V47, pM137, DOI 10.1093/geronj/47.5.M137; Gaist D, 1996, BRIT J CLIN PHARMACO, V41, P285, DOI 10.1046/j.1365-2125.1996.03154.x; GERSTMAN BB, 1989, J ALLERGY CLIN IMMUN, V83, P1032, DOI 10.1016/0091-6749(89)90444-2; GRABENSTEIN JD, 1995, MIL MED, V160, P571, DOI 10.1093/milmed/160.11.571; HABBICK B, 1995, CAN MED ASSOC J, V153, P1437; HALLAS J, 1993, J INTERN MED, V234, P65, DOI 10.1111/j.1365-2796.1993.tb00706.x; HAY IFC, 1987, LANCET, V2, P609; Lassila HC, 1996, ANN PHARMACOTHER, V30, P589, DOI 10.1177/106002809603000604; LeSon S, 1996, J ASTHMA, V33, P27, DOI 10.3109/02770909609077760; MCWHORTER WP, 1989, AM REV RESPIR DIS, V139, P721, DOI 10.1164/ajrccm/139.3.721; Murdoch J C, 1980, J R Coll Gen Pract, V30, P593; OSBORNE ML, 1995, J CLIN EPIDEMIOL, V48, P1393, DOI 10.1016/0895-4356(95)00065-8; Rea HH, 1996, CHEST, V110, P1446, DOI 10.1378/chest.110.6.1446; ROBERTS SJ, 1994, BRIT J CLIN PHARMACO, V38, P489, DOI 10.1111/j.1365-2125.1994.tb04389.x; SIBBALD B, 1989, THORAX, V44, P97, DOI 10.1136/thx.44.2.97; Simon GE, 1996, J CLIN EPIDEMIOL, V49, P1067, DOI 10.1016/0895-4356(96)00139-4; SKEGG DCG, 1977, BRIT MED J, V1, P1561, DOI 10.1136/bmj.1.6076.1561; SLY RM, 1994, ANN ALLERGY, V73, P259	18	13	14	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 21	1998	317	7170					1434	1437		10.1136/bmj.317.7170.1434	http://dx.doi.org/10.1136/bmj.317.7170.1434			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822401	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000077202200026
J	Zhu, W; Kochanski, GP; Jin, S				Zhu, W; Kochanski, GP; Jin, S			Low-field electron emission from undoped nanostructured diamond	SCIENCE			English	Article							VAPOR-DEPOSITED DIAMOND; THIN-FILMS; CATHODES; SURFACES; EMITTER; CARBON; STATES	Strong and sustained electron emission at low electric fields was observed in undoped, nanostructured diamond. Electron emission of 10 milliamperes per square centimeter was observed at applied fields of 3 to 5 volts per micrometer, These are the Lowest fields ever reported for any field-emitting material at technologically useful current densities. The emitter consists of a layer of nanometer-size diamond particulates, which is heat-treated in a hydrogen plasma. These emission characteristics are attributed to the particles' high defect density and the low electron affinity of the diamond surface. Such emitters are technologically useful, because they can be easily and economically fabricated on large substrates.	Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T	Zhu, W (corresponding author), Lucent Technol, Bell Labs, 600 Mt Ave, Murray Hill, NJ 07974 USA.							Amaratunga GAJ, 1996, APPL PHYS LETT, V68, P2529, DOI 10.1063/1.116173; BRODIE I, 1992, ADV ELECTRON EL PHYS, V83, P1; Fowler RH, 1928, P R SOC LOND A-CONTA, V119, P173, DOI 10.1098/rspa.1928.0091; Geis MW, 1996, J VAC SCI TECHNOL B, V14, P2060, DOI 10.1116/1.588986; GEIS MW, 1995, APPL PHYS LETT, V67, P1328, DOI 10.1063/1.114529; HE J, 1991, SURF SCI, V246, P348, DOI 10.1016/0039-6028(91)90437-W; HIMPSEL FJ, 1979, PHYS REV B, V20, P624, DOI 10.1103/PhysRevB.20.624; Koizumi S, 1997, APPL PHYS LETT, V71, P1065, DOI 10.1063/1.119729; KUMAR N, 1995, SOLID STATE TECHNOL, V38, P71; Okano K, 1996, NATURE, V381, P140, DOI 10.1038/381140a0; PATE BB, 1981, J VAC SCI TECHNOL, V19, P349, DOI 10.1116/1.571062; SHOVLIN JD, 1994, APPL PHYS LETT, V65, P863, DOI 10.1063/1.112184; Talin AA, 1996, APPL PHYS LETT, V69, P3842, DOI 10.1063/1.117123; VANDERWEIDE J, 1993, APPL PHYS LETT, V62, P1878, DOI 10.1063/1.109639; WANG C, 1991, ELECTRON LETT, V27, P1459, DOI 10.1049/el:19910914; XU NS, 1993, J PHYS D APPL PHYS, V26, P1776, DOI 10.1088/0022-3727/26/10/035; XU NS, 1993, ELECTRON LETT, V29, P1596, DOI 10.1049/el:19931063; YOSHIKAWA M, 1995, APPL PHYS LETT, V67, P694, DOI 10.1063/1.115206; Zhou D, 1997, J APPL PHYS, V82, P4546, DOI 10.1063/1.366190; Zhu W, 1996, J VAC SCI TECHNOL B, V14, P2011, DOI 10.1116/1.588976; ZHU W, 1995, J APPL PHYS, V78, P2707, DOI 10.1063/1.360066; ZHU W, UNPUB	22	369	402	5	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1471	1473		10.1126/science.282.5393.1471	http://dx.doi.org/10.1126/science.282.5393.1471			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822373				2022-12-28	WOS:000077110800048
J	van der Meijden, APM				van der Meijden, APM			Bladder cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TRANSITIONAL-CELL-CARCINOMA; STATES; TRIAL		Bosch Medictr, Dept Urol, NL-5200 ME Hertogenbosch, Netherlands		van der Meijden, APM (corresponding author), Bosch Medictr, Dept Urol, POB 90153, NL-5200 ME Hertogenbosch, Netherlands.	urology.bmc@tip.nl						[Anonymous], 1997, J CLIN PATHOL; AUGUSTINE A, 1988, CANCER RES, V48, P4405; CLAVEL J, 1989, INT J CANCER, V44, P605, DOI 10.1002/ijc.2910440408; Gospodarowicz M K, 1995, Int J Urol, V2 Suppl 2, P41, DOI 10.1111/j.1442-2042.1995.tb00478.x; HALL RR, 1996, NEOADJUVANT CMV CHEM; HAUTMANN RE, 1993, J UROLOGY, V150, P40, DOI 10.1016/S0022-5347(17)35392-2; HERR HW, 1987, J UROLOGY, V138, P1363, DOI 10.1016/S0022-5347(17)43644-5; JENSEN OM, 1990, EUR J CANCER, V26, P1167; Koiso K, 1995, Int J Urol, V2 Suppl 2, P49, DOI 10.1111/j.1442-2042.1995.tb00479.x; Pawinski A, 1996, J UROLOGY, V156, P1934, DOI 10.1016/S0022-5347(01)65396-5; SAROSDY MF, 1995, J UROLOGY, V154, P379, DOI 10.1016/S0022-5347(01)67054-X; SILVERMAN DT, 1989, J NATL CANCER I, V81, P1480, DOI 10.1093/jnci/81.19.1480; SKINNER DG, 1991, J UROLOGY, V145, P459, DOI 10.1016/S0022-5347(17)38368-4; Soloway MS, 1996, J UROLOGY, V156, P363, DOI 10.1016/S0022-5347(01)65851-8; Sternberg C N, 1995, Int J Urol, V2 Suppl 2, P76, DOI 10.1111/j.1442-2042.1995.tb00482.x; STERNBERG CN, 1989, CANCER, V64, P2448, DOI 10.1002/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7; Tannock I F, 1990, Semin Urol, V8, P291; Whitmore WF, 1983, SEMIN UROL, V1, P4	18	44	44	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	1998	317	7169					1366	1369		10.1136/bmj.317.7169.1366	http://dx.doi.org/10.1136/bmj.317.7169.1366			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812938	Green Published			2022-12-28	WOS:000077081600026
J	[Anonymous]				[Anonymous]			Cost of NHS operations varies widely	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	1998	317	7169					1393	1393						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812957				2022-12-28	WOS:000077081600063
J	Alferink, J; Tafuri, A; Vestweber, D; Hallmann, R; Hammerling, GJ; Arnold, B				Alferink, J; Tafuri, A; Vestweber, D; Hallmann, R; Hammerling, GJ; Arnold, B			Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking	SCIENCE			English	Article							P-SELECTIN; IN-VIVO; MICE; INDUCTION; ALLOANTIGENS; RESPONSES; BETA	Self tolerance is acquired by the developing immune system. As reported here, particular properties of the neonatal tissue contribute to this process. Neonatal skin, but not adult skin, was accessible for naive CD8 T cells. In mouse bone marrow chimeras generated at different ages, recent thymic emigrants were tolerized to a skin-expressed major histocompatibility complex class I antigen only during a neonatal period but not during adulthood. Blockade of T cell migration neonatally prevented tolerance induction. Thus, T cell trafficking through nonlymphoid tissues in the neonate is crucial for the establishment of self tolerance to sessile, skin-expressed antigens.	German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany; Univ Munster, Inst Cell Biol, D-48149 Munster, Germany; Univ Erlangen Nurnberg, Inst Expt Med, D-91054 Erlangen, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munster; University of Erlangen Nuremberg	Arnold, B (corresponding author), German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany.		Tafuri, Agostino/AAC-2186-2019	Tafuri, Agostino/0000-0001-7911-9263; alferink, judith/0000-0002-3251-6584; Vestweber, Dietmar/0000-0002-3517-732X				ABRAMOWICZ D, 1990, EUR J IMMUNOL, V20, P1647, DOI 10.1002/eji.1830200805; ALFERINK J, 1995, INT IMMUNOL, V7, P331, DOI 10.1093/intimm/7.2.331; ALFERINK J, UNPUB; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; BREZINSCHEK RI, 1995, J IMMUNOL, V154, P3062; Eppihimer MJ, 1996, CIRC RES, V79, P560, DOI 10.1161/01.RES.79.3.560; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; HALLMANN R, 1995, SCAND J RHEUMATOL, P107; HALSTEAD TE, 1972, TRANSPLANTATION, V14, P339, DOI 10.1097/00007890-197209000-00009; Heath WR, 1998, J EXP MED, V187, P1549, DOI 10.1084/jem.187.10.1549; HUA C, 1986, J IMMUNOL, V136, P1937; KIMPTON WG, 1995, INT IMMUNOL, V7, P1567, DOI 10.1093/intimm/7.10.1567; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MARTIN C, 1994, INT IMMUNOL, V6, P795, DOI 10.1093/intimm/6.6.795; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; Modigliani Y, 1996, IMMUNOL REV, V149, P155, DOI 10.1111/j.1600-065X.1996.tb00903.x; PIGUET PF, 1981, J EXP MED, V154, P581, DOI 10.1084/jem.154.3.581; POWRIE F, 1990, J EXP MED, V172, P1701, DOI 10.1084/jem.172.6.1701; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; Sarzotti M, 1996, SCIENCE, V271, P1726, DOI 10.1126/science.271.5256.1726; SCHOFFEL J, UNPUB; STREILEIN JW, 1991, TRANSPLANTATION, V52, P1, DOI 10.1097/00007890-199107000-00001; WOOD PJ, 1987, J IMMUNOL, V138, P3661	27	104	104	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 13	1998	282	5392					1338	1341		10.1126/science.282.5392.1338	http://dx.doi.org/10.1126/science.282.5392.1338			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812902				2022-12-28	WOS:000076982200051
J	Sereno, PC; Beck, AL; Dutheil, DB; Gado, B; Larsson, HCE; Lyon, GH; Marcot, JD; Rauhut, OWM; Sadleir, RW; Sidor, CA; Varricchio, DD; Wilson, GP; Wilson, JA				Sereno, PC; Beck, AL; Dutheil, DB; Gado, B; Larsson, HCE; Lyon, GH; Marcot, JD; Rauhut, OWM; Sadleir, RW; Sidor, CA; Varricchio, DD; Wilson, GP; Wilson, JA			A long-snouted predatory dinosaur from Africa and the evolution of spinosaurids	SCIENCE			English	Article								Fossils discovered in Lower Cretaceous (Aptian) rocks in the Tenere Desert of central Niger provide new information about spinosaurids, a peculiar group of piscivorous theropod dinosaurs. The remains, which represent a new genus and species, reveal the extreme elongation and transverse compression of the spinosaurid snout. The postcranial bones include blade-shaped vertebral spines that form a low sail over the hips. Phylogenetic analysis suggests that the enlarged thumb claw and robust forelimb evolved during the Jurassic, before the elongated snout and other fish-eating adaptations in the skull. The close phylogenetic relationship between the new African spinosaurid and Baryonyx from Europe provides evidence of dispersal across the Tethys seaway during the Early Cretaceous.	Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA; Museum Natl Hist Nat, Lab Paleontol, F-75005 Paris, France; Inst Rech & Sci Humaine, Niamey, Niger; Univ Illinois, Small Sch Workshop, Chicago, IL 60607 USA; Univ Bristol, Dept Geol, Bristol BS8 1RJ, Avon, England; Univ Illinois, Dept Earth & Environm Sci, Chicago, IL 60607 USA; Old Trail Museum, Choteau, MT 59422 USA; Univ Calif Berkeley, Museum Paleontol, Berkeley, CA 94720 USA	University of Chicago; Museum National d'Histoire Naturelle (MNHN); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Bristol; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of California System; University of California Berkeley	Sereno, PC (corresponding author), Univ Chicago, Dept Organismal Biol & Anat, 1027 E 57th St, Chicago, IL 60637 USA.		Wilson, Jeffrey/C-2737-2008; Marcot, Jonathan/G-2427-2012; Larsson, Hans/AAD-4579-2019; Rauhut, Oliver/AAG-1029-2020; Wilson, Gregory P/A-2363-2009	Larsson, Hans/0000-0002-6377-4770; Rauhut, Oliver/0000-0003-3958-603X; Wilson Mantilla, Gregory/0000-0003-3604-5473; Dutheil, Didier/0000-0002-4856-0918				BOUAZIZ S, 1988, B SOC GEOL FR, P335; Britt B.B., 1991, Brigham Young University Geology Studies, V37, P1; BUFFETAUT E, 1992, NEUES JB GEOLOGIE PA, P88; BUFFETAUT E, 1989, NEUES JB GEOLOGIE PA, P79; Buffetaut E, 1989, TERRA NOVA, V1, P69, DOI 10.1111/j.1365-3121.1989.tb00328.x; CHABLIS S, 1988, THESIS U PARIS; Charig A.J., 1990, P127, DOI 10.1017/CBO9780511608377.012; CHARIG AJ, 1986, NATURE, V324, P359, DOI 10.1038/324359a0; Charig Alan J., 1997, Bulletin of the Natural History Museum Geology Series, V53, P11; de LAPPARENT ALBERT F., 1960, MEM SOC GEOL FRANCE, V88 A, P1; FAURE H, 1966, MEMOIRES BUREAU RECH, V47, P1; GALTON P M, 1982, Geobios (Villeurbanne), V15, P147, DOI 10.1016/S0016-6995(82)80017-X; Galton P.M., 1979, Brigham Young University Geology Studies, V26, P1; GILMORE CW, 1920, US NATL MUS BULL, V110, P1; Greigert J., 1967, MEM BUR RECH GEOL MI, V48, P1; Harland W. B., 1989, GEOLOGIC TIME SCALE; Hu S. y., 1964, Vertebrata Palasiatica, V8, P42; JENSEN JA, 1985, GREAT BASIN NAT, V45, P710; Kellner Alexander W.A., 1996, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V199, P151; Martill DM, 1996, J GEOL SOC LONDON, V153, P5, DOI 10.1144/gsjgs.153.1.0005; MOLINAS E, 1965, RAPP CEA MARSEILLE, P1; Ronquist F, 1997, SYST BIOL, V46, P195, DOI 10.2307/2413643; Russell Dale A., 1996, Bulletin du Museum National d'Histoire Naturelle Section C Sciences de la Terre Paleontologie Geologie Mineralogie, V18, P349; Sereno PC, 1996, SCIENCE, V272, P986, DOI 10.1126/science.272.5264.986; SMITH AG, 1994, ATLAS MESOZOIC CENOZ, P41; Stromer E, 1915, ABHANDLUNGEN KONIGLI, V28, P1; Stromer E., 1934, ABH BAYER AKAD WISS, V22, P1; SWOFFORD DL, 1993, PAUP 3 1; TAQUET P, 1984, CR ACAD SCI II, V299, P217; Taquet P, 1998, CR ACAD SCI II A, V327, P347, DOI 10.1016/S1251-8050(98)80054-2; Taquet P, 1976, CAHIERS PALEONTOLOGI, P1; Viera Luis I., 1995, Munibe (Ciencias Naturales - Natur Zientziak), V47, P57; VONHUENE F, 1926, REV MUSEO PLATA, V29, P35	33	218	229	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1298	1302		10.1126/science.282.5392.1298	http://dx.doi.org/10.1126/science.282.5392.1298			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812890	Green Submitted			2022-12-28	WOS:000076982200039
J	Barnett, HJM; Taylor, W; Eliasziw, M; Fox, AJ; Ferguson, GG; Haynes, RB; Rankin, RN; Clagett, GP; Hachinski, VC; Sackett, DL; Thorpe, KE; Meldrum, HE; Spence, JD				Barnett, HJM; Taylor, W; Eliasziw, M; Fox, AJ; Ferguson, GG; Haynes, RB; Rankin, RN; Clagett, GP; Hachinski, VC; Sackett, DL; Thorpe, KE; Meldrum, HE; Spence, JD		N Amer symptomatic Carotid Endarterectomy Trial	Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL-ISCHEMIA; STROKE; MORTALITY	Background Previous studies have shown that carotid endarterectomy in patients with symptomatic severe carotid stenosis (defined as stenosis of 70 to 99 percent of the luminal diameter) is beneficial up to two years after the procedure. In this clinical trial, we assessed the benefit of carotid endarterectomy in patients with symptomatic moderate stenosis, defined as stenosis of less than 70 percent. We also studied the durability of the benefit of endarterectomy in patients with severe stenosis over eight years of follow-up. Methods Patients who had moderate carotid stenosis and transient ischemic attacks or nondisabling strokes on the same side as the stenosis (ipsilateral) within 180 days before study entry were stratified according to the degree of stenosis (50 to 69 percent or <50 percent) and randomly assigned either to undergo carotid endarterectomy (1108 patients) or to receive medical care alone(1118 patients). The average follow-up was five years, and complete data on outcome events were available for 99.7 percent of the patients. The primary outcome event was any fatal or nonfatal stroke ipsilateral to the stenosis for which the patient underwent randomization. Results Among patients with stenosis of 50 to 69 percent, the five-year rate of any ipsilateral stroke (failure rate) was 15.7 percent among patients treated surgically and 22.2 percent among those treated medically (P=0.045); to prevent one ipsilateral stroke during the five-year period, 15 patients would have to be treated with carotid endarterectomy. Among patients with less than 50 percent stenosis, the failure rate was not significantly lower in the group treated with endarterectomy (14.9 percent) than in the medically treated group (18.7 percent, P=0.16). Among the patients with severe stenosis who underwent endarterectomy, the 30-day rate of death or disabling ipsilateral stroke persisting at 90 days was 2.1 percent; this rate increased to only 6.7 percent at 8 years. Benefit was greatest among men, patients with recent stroke as the qualifying event, and patients with hemispheric symptoms. Conclusions Endarterectomy in patients with symptomatic moderate carotid stenosis of 50 to 69 percent yielded only a moderate reduction in the risk of stroke. Decisions about treatment for patients in this category must take into account recognized risk factors, and exceptional surgical skill is obligatory if carotid endarterectomy is to be performed. Patients with stenosis of less than 50 percent did not benefit from surgery. Patients with severe stenosis (greater than or equal to 70 percent) had a durable benefit from endarterectomy at eight years of follow-up. (N Engl J Med 1998;339:1415-25.) (C) 1998, Massachusetts Medical Society.	John P Robarts Res Inst, London, ON N6A 5K8, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ Western Ontario, Dept Clin Epidemiol & Biostat, London, ON, Canada; Univ Western Ontario, Dept Diagnost Radiol & Nucl Med, London, ON, Canada; Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada; Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75235 USA; Univ Oxford, Nuffield Dept Clin Med, Oxford, England	Western University (University of Western Ontario); McMaster University; McMaster University; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Oxford	Barnett, HJM (corresponding author), John P Robarts Res Inst, POB 5015,100 Perth Dr, London, ON N6A 5K8, Canada.		Buchan, Alastair M/B-9095-2009; Spence, J. David/K-6396-2013	Buchan, Alastair M/0000-0002-2918-5200; Spence, J. David/0000-0001-7478-1098; Haynes, Robert Brian/0000-0002-1453-3196; Thorpe, Kevin/0000-0002-7586-3893; Hershey, Linda/0000-0001-5090-6634	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024456] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS-24456] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNETT H, 1991, ANN R COLL PHYS SURG, V24, P33; Barnett H J, 1997, J Fla Med Assoc, V84, P239; BARNETT HJM, 1990, STROKE, V21, P2; BARNETT HJM, 1991, STROKE, V22, P711, DOI 10.1161/01.STR.22.6.711; BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904; BARNETT HJM, 1984, STROKE, V15, P941, DOI 10.1161/01.STR.15.6.941; BARNETT HJM, 1991, STROKE S11, V24, P33; BROTT T, 1984, STROKE, V15, P950, DOI 10.1161/01.STR.15.6.950; DEHAAN R, 1995, STROKE, V26, P2027, DOI 10.1161/01.STR.26.11.2027; Donnan GA, 1998, LANCET, V351, P1372, DOI 10.1016/S0140-6736(98)22019-8; EASTCOTT HHG, 1954, LANCET, V2, P994; EASTON JD, 1977, STROKE, V8, P565, DOI 10.1161/01.STR.8.5.565; ELIASZIW M, 1994, STROKE, V25, P2445, DOI 10.1161/01.STR.25.12.2445; ELIASZIW M, 1995, STROKE, V26, P1747, DOI 10.1161/01.STR.26.10.1747; Eliasziw M, 1998, CEREBROVASC DIS, V8, P20, DOI 10.1159/000015819; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; FIELDS WS, 1970, J AMER MED ASSOC, V211, P1993, DOI 10.1001/jama.211.12.1993; FOX AJ, 1993, RADIOLOGY, V186, P316, DOI 10.1148/radiology.186.2.8421726; Goldstein LB, 1998, STROKE, V29, P750, DOI 10.1161/01.STR.29.4.750; Harris EK, 1991, SURVIVORSHIP ANAL CL; Huber TS, 1998, STROKE, V29, P1099, DOI 10.1161/01.STR.29.6.1099; KOZAK LJ, 1998, VITAL HLTH STAT, V135, P1; KUCEY DS, IN PRESS J VASC SURG; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; MUURONEN A, 1984, STROKE, V15, P959, DOI 10.1161/01.STR.15.6.959; *N AM SYMPT CAR EN, 1991, STROKE, V22, P816; POKRAS R, 1988, STROKE, V19, P1289, DOI 10.1161/01.STR.19.10.1289; RILES TS, 1994, J VASC SURG, V19, P206, DOI 10.1016/S0741-5214(94)70096-6; ROTHWELL PM, 1994, STROKE, V25, P2435, DOI 10.1161/01.STR.25.12.2435; SALENIUS JP, 1990, J CARDIOVASC SURG, V31, P162; SHAW DA, 1984, J NEUROL SCI, V64, P45, DOI 10.1016/0022-510X(84)90054-6; Slattery J, 1996, LANCET, V347, P1591; SLAVISH LG, 1984, STROKE, V15, P956, DOI 10.1161/01.STR.15.6.956; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; THORPE KE, 1997, 22 INT JOINT C STROK; WARLOW C, 1984, STROKE, V15, P1068, DOI 10.1161/01.STR.15.6.1068; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; WINSLOW CM, 1988, NEW ENGL J MED, V319, P724; Young B, 1996, STROKE, V27, P2216, DOI 10.1161/01.STR.27.12.2216	39	2481	2624	1	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1998	339	20					1415	1425		10.1056/NEJM199811123392002	http://dx.doi.org/10.1056/NEJM199811123392002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VR	9811916				2022-12-28	WOS:000077051700002
J	Ross, GJ; Patrizi, JD				Ross, GJ; Patrizi, JD			Acoustic neuroma (vestibular schwannoma)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									St Francis Med Ctr, Pittsburgh, PA 16201 USA		Ross, GJ (corresponding author), St Francis Med Ctr, Pittsburgh, PA 16201 USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1998	339	20					1440	1440		10.1056/NEJM199811123392005	http://dx.doi.org/10.1056/NEJM199811123392005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VR	9811919				2022-12-28	WOS:000077051700005
J	Eskinazi, DP				Eskinazi, DP			Factors that shape alternative medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Columbia Univ Coll Phys & Surg, Rosenthal Ctr Complementary & Alternat Med, New York, NY 10032 USA	Columbia University	Eskinazi, DP (corresponding author), Columbia Univ Coll Phys & Surg, Rosenthal Ctr Complementary & Alternat Med, 630 W 168th St,Box 75, New York, NY 10032 USA.							*ALT MED PROGR ADV, 1994, TRANSCR ALT MED PROG; BENFIELD H, 1991, HEAVEN EARTH GUIDE C, P5; BENVENISTE J, 1988, NATURE, V334, P291, DOI 10.1038/334291a0; BURKHOLTZ H, 1994, FDA FOLLIES, V12, P110; Chez RA, 1997, AM J OBSTET GYNECOL, V177, P1156, DOI 10.1016/S0002-9378(97)70033-4; Donden Yeshi, 1986, HLTH BALANCE INTRO T; EISENBERG DM, 1993, NEW ENGL J MED, V328, P245; ERNST E, 1996, COMPLEMENTARY MED OB; ESKINAZI D, BOTANICALS ROLE US H; ESKINAZI D, 1996, J ALTERN COMPLEM MED, V2, P1; FUGHBERMAN A, 1996, ALTERNATIVE MED WHAT, P50; JONAS W, 1995, M ALT MED PROGR ADV; Merriam-Webster's, 1993, MERRIAM WEBSTERS COL; *MILB MEM FUND, 1998, ENH ACC ALT MED; *NIH, 1995, ALT MED EXP MED HOR; *ROS CTR COMPL ALT, 1998, INF SHEET WHAT IS CO; SCHIFF M., 1995, MEMORY WATER; Sharma H.M., 1996, FUNDAMENTALS COMPLEM; SIEGFRIED JD, 1998, PHARMA NEWSL     JAN; Wetzel MS, 1998, JAMA-J AM MED ASSOC, V280, P784, DOI 10.1001/jama.280.9.784; WISE TA, 1986, HINDU SYSTEM MED, P1	21	53	53	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1621	1623		10.1001/jama.280.18.1621	http://dx.doi.org/10.1001/jama.280.18.1621			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820268				2022-12-28	WOS:000076852000034
J	Farzadegan, H; Hoover, DR; Astemborski, J; Lyles, CM; Margolick, JB; Markham, RB; Quinn, TC; Vlahov, D				Farzadegan, H; Hoover, DR; Astemborski, J; Lyles, CM; Margolick, JB; Markham, RB; Quinn, TC; Vlahov, D			Sex differences in HIV-1 viral load and progression to AIDS	LANCET			English	Article							MONONUCLEAR CELL COCULTURES; INFECTION; MARKERS; REPLICATION; THERAPY; GROWTH; RNA	Background Plasma HIV-1 RNA measurements are used for initiation of antiretroviral treatments, Whether the viral-load association with prognosis is similar in women and men is unknown. Methods We studied 812 specimens from 650 injection-drug users (IDUs) participating in a continuous observational study of patients based in a community clinic. HIV-1 load was measured by branched-chain DNA on samples from 527 IDUs from the baseline visit, and by reverse-transcriptase PCR and quantitative microculture on samples from 285 IDUs ai a follow-up visit 3 years later. Findings Women had lower median viral-load measurements than men by branched-chain DNA (3365 vs 8907 copies/mL; p=0.001), reverse-transcriptase PCR (45 416 vs 93 130 copies/mL; p=0.02), and quantitative microculture (5 vs 8 infectious units per million peripheral blood mononuclear cells; p=0.015). This association remained even after adjustment for CD4 cell count, race, and drug use within the previous 6 months. Time to AIDS was statistically similar for men and women in a univariate proportional-hazards model and in a model adjusting for CD4 cell count. Proportional-hazards models showed that women with the same viral load as men had a 1.6-fold higher risk of AIDS (95% CI 1.10-2.32); or, equivalently, that women with half the viral load of men had a similar time to AIDS as men. Interpretation Although a biological mechanism remains unclear, these data suggest that current recommendations for HIV-1 viral-load thresholds to initiate antiretroviral therapy should be revised downwards for women.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; NIAID, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Farzadegan, H (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, 615 N Wolfe St,Room E6004, Baltimore, MD 21205 USA.		Quinn, Thomas/A-2494-2010		NIDA NIH HHS [DA04334] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004334, R56DA004334, R37DA004334] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Brancato G, 1997, AM J PUBLIC HEALTH, V87, P1654, DOI 10.2105/AJPH.87.10.1654; Bush CE, 1996, J CLIN MICROBIOL, V34, P970, DOI 10.1128/JCM.34.4.970-972.1996; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; GALAI N, 1995, J ACQ IMMUN DEF SYND, V8, P66; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; Hessol N A, 1996, AIDS, V10 Suppl A, pS69, DOI 10.1097/00002030-199601001-00010; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; MELLORS JW, 1991, J INFECT DIS, V163, P78, DOI 10.1093/infdis/163.1.78; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; PETERSON PK, 1991, J IMMUNOL, V146, P81; PETERSON PK, 1990, AIDS, V4, P869, DOI 10.1097/00002030-199009000-00006; Pezzotti P, 1996, BRIT MED J, V313, P583; SHANKER G, 1994, LYMPHOKINE CYTOK RES, V13, P377; Vlahov D, 1998, JAMA-J AM MED ASSOC, V279, P35, DOI 10.1001/jama.279.1.35; VLAHOV D, 1991, J DRUG ISSUES, V21, P767	17	317	322	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1510	1514		10.1016/S0140-6736(98)02372-1	http://dx.doi.org/10.1016/S0140-6736(98)02372-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820299	hybrid			2022-12-28	WOS:000076862300009
J	Poller, L; Shiach, CR; MacCallum, PK; Johansen, AM; Munster, AM; Magalhaes, A; Jespersen, J				Poller, L; Shiach, CR; MacCallum, PK; Johansen, AM; Munster, AM; Magalhaes, A; Jespersen, J		European Concerted Action Anticoagu	Multicentre randomised study of computerised anticoagulant dosage	LANCET			English	Article							MANAGEMENT; WARFARIN	Background The demand for anticoagulant treatment is increasing. We compared the benefits of computer generated anticoagulaant dosing with traditional dosing decided by experienced medical staff in achieving target international normalised ratios (INRs). Methods In five European centres we randomly assigned 285 patients in the stabilisation period and stabilised patients to the computer-generated-dose group (n=137) or traditional-dose group (n=148). Centres had a specialist interest in oral anticoagulation but no previous experience with computer-generated dosing. The computer program calculated doses and times to next visit. Our main endpoint was time spent in target INR range (Rosendaal method). Findings For all patients combined, computer-generated dosing was significantly beneficial overall in achieving target INR (p=0.004). The mean time within target INR range for all patients and ail ranges was 63.3% (SD 28.0) of days in the computer-generated-dose group compared with 53.2% (27.7) in the traditional-dose group. For the stabilisation patients alone, computer-generated doses led to a non-significant benefit in all INR ranges (p=0.06), whereas in the stable patients the benefit was significant (p=0.02). Interpretation The computer program gave better INR control than the experienced medical staff and at least similar standards to the specialised centres should be generally available. Clinical outcome and cost effectiveness remain to be assessed.	Univ Manchester, Dept Pathol Sci, ECAA Cent Facil, Manchester M13 9PT, Lancs, England; Manchester Royal Infirm, Dept Haematol, Manchester M13 9WL, Lancs, England; St Bartholomews & Royal London Sch Med, MRC, Epidemiol & Med Care Unit, London, England; Aker Sykehus, Dept Med A, Oslo, Norway; Cent Sygehuset, Dept Clin Biochem, Esbjerg, Denmark; Ctr Hosp VN de Gaia, Serv Imunohemoterapia, Vila Nova De Gaia, Portugal	University of Manchester; University of Manchester; University of London; Queen Mary University London	Poller, L (corresponding author), Univ Manchester, Dept Pathol Sci, ECAA Cent Facil, Stopford Bldg, Manchester M13 9PT, Lancs, England.			Munster, Anna-Marie Bloch/0000-0002-3398-3977				AGENO W, 1997, THROMB HAEMOSTASIS, V77, P701; Baglin T, 1998, J CLIN PATHOL, V51, P89, DOI 10.1136/jcp.51.2.89; COLVIN BT, 1990, J CLIN PATHOL, V43, P177; GALVIN M, 1994, P DAWN AC US GROUP M, P1; HIRSH J, 1995, CHEST S, V108, P231; LOELIGER EA, 1984, THROMB HAEMOSTASIS, V54, P514; POLLER L, 1993, J CLIN PATHOL, V46, P299, DOI 10.1136/jcp.46.4.299; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; RYAN PJ, 1989, BRIT MED J, V299, P1207, DOI 10.1136/bmj.299.6709.1207; SMITH SGW, 1989, BRIT MED J, V299, P1529; WILSON R, 1984, BRIT MED J, V289, P422, DOI 10.1136/bmj.289.6442.422	11	175	181	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1505	1509		10.1016/S0140-6736(98)04147-6	http://dx.doi.org/10.1016/S0140-6736(98)04147-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820298				2022-12-28	WOS:000076862300008
J	Jones, VA				Jones, VA			In the same boat	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DISEASE		Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA	Columbia University	Jones, VA (corresponding author), Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA.							Bouma Hessel, 1989, CHRISTIAN FAITH HLTH; Chen C. P. L.-H, 1997, SMJ, V38, P100; DICKENS BM, 1994, ALZ DIS ASSOC DIS, V8, P94, DOI 10.1097/00002093-199408020-00006; Post SG, 1997, JAMA-J AM MED ASSOC, V277, P832, DOI 10.1001/jama.277.10.832; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1537	1538		10.1001/jama.280.17.1537	http://dx.doi.org/10.1001/jama.280.17.1537			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809740				2022-12-28	WOS:000076757200033
J	Nightingale, SL				Nightingale, SL			Emergency contraception kit approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	34	37	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1472	1472		10.1001/jama.280.17.1472-b	http://dx.doi.org/10.1001/jama.280.17.1472-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809716				2022-12-28	WOS:000076757200003
J	Ramsay, DJ; Bowman, MA; Greenman, PE; Jiang, SP; Kushi, LH; Leeman, S; Lin, KM; Moerman, DE; Schnoll, SH; Walker, M; Waternaux, C; Wisneski, LA				Ramsay, DJ; Bowman, MA; Greenman, PE; Jiang, SP; Kushi, LH; Leeman, S; Lin, KM; Moerman, DE; Schnoll, SH; Walker, M; Waternaux, C; Wisneski, LA		NIN Consensus Dev Panel Acupuncture	Acupuncture	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELECTROACUPUNCTURE EA; CHINESE ACUPUNCTURE; POSTOPERATIVE PAIN; NERVE-STIMULATION; SMOKING CESSATION; STROKE PATIENTS; ANALGESIA; MORPHINE; SITES; RATS	Objective.-To provide clinicians, patients, and the general public with a responsible assessment of the use and effectiveness of acupuncture to treat a variety of conditions. Participants.-A nonfederal, nonadvocate, 12-member panel representing the fields of acupuncture, pain, psychology, psychiatry, physical medicine and rehabilitation, drug abuse, family practice, internal medicine, health policy, epidemiology, statistics, physiology, biophysics, and the representatives of the public. In addition, 25 experts from these same fields presented data to the panel and a conference audience of 1200. Presentations and discussions were divided into 3 phases over 2 1/2 days: (1) presentations by investigators working in areas relevant to the consensus questions during a 2-day public session; (2) questions and statements from conference attendees during open discussion periods that were part of the public session; and (3) closed deliberations by the panel during the remainder of the second day and morning of the third. The conference was organized and supported by the Office of Alternative Medicine and the Office of Medical Applications of Research, National institutes of Health, Bethesda, Md. Evidence.-The literature, produced from January 1970 to October 1997, was searched through MEDLINE, Allied and Alternative Medicine, EMBASE, and MANTIS, as well as through a hand search of 9 journals that were not indexed by the National Library of Medicine. An extensive bibliography of 2302 references was provided to the panel and the conference audience. Expert speakers prepared abstracts of their own conference presentations with relevant citations from the literature. Scientific evidence was given precedence over clinical anecdotal experience. Consensus Process.-The panel, answering predefined questions, developed their conclusions based on the scientific evidence presented in the open forum and scientific literature. The panel composed a draft statement, which was read in its entirety and circulated to the experts and the audience for comment. Thereafter, the panel resolved conflicting recommendations and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference. The draft statement was made available on the World Wide Web immediately following its release at the conference and was updated with the panel's final revisions within a few weeks of the conference. The statement is available at http://consensus.nih.gov. Conclusions.-Acupuncture as a therapeutic intervention is widely practiced in the United States. Although there have been many studies of its potential usefulness, many of these studies provide equivocal results because of design, sample size, and other factors. The issue is further complicated by inherent difficulties in the use of appropriate controls, such as placebos and sham acupuncture groups. However, promising results have emerged, for example, showing efficacy of acupuncture in adult postoperative and chemotherapy nausea and vomiting and in postoperative dental pain. There are other situations, such as addiction, stroke rehabilitation, headache, menstrual cramps, tennis elbow, fibromyalgia, myofascial pain, osteoarthritis, low back pain, carpal tunnel syndrome, and asthma, in which acupuncture may be useful as an adjunct treatment or an acceptable alternative or be included in a comprehensive management program. Further research is likely to uncover additional areas where acupuncture interventions will be useful.	Univ Penn Hlth Syst, Dept Family Practice & Community Med, Philadelphia, PA USA; Univ Maryland, College Pk, MD 20742 USA; Michigan State Univ, Coll Osteopath Med, E Lansing, MI 48824 USA; Assoc Asian Pacific Community Hlth Org, Oakland, CA USA; Univ Minnesota, Sch Publ Hlth, Minneapolis, MN 55455 USA; Boston Univ, Sch Med, Dept Pharmacol, Boston, MA 02215 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Harbor Med Ctr, Res Ctr Psychobiol Ethnic, Torrance, CA 90509 USA; Univ Michigan, Dearborn, MI 48128 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Columbia Univ, Div Biostat, New York, NY USA; New York State Psychiat Inst, New York, NY 10032 USA; Amer Wholehealth, Bethesda Ctr, Bethesda, MD USA	University of Pennsylvania; University System of Maryland; University of Maryland College Park; Michigan State University; Michigan State University College of Osteopathic Medicine; University of Minnesota System; University of Minnesota Twin Cities; Boston University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Michigan System; University of Michigan; Virginia Commonwealth University; Columbia University; New York State Psychiatry Institute	Ramsay, DJ (corresponding author), Univ Maryland, College Pk, MD 20742 USA.		bowman, marjorie a/F-7235-2013; Vincent, Charles A/D-1134-2010	bowman, marjorie a/0000-0002-1945-9212; Vincent, Charles A/0000-0003-0270-0222				Asagai Yoshimi, 1994, Laser Therapy, V6, P195; BIRCH S, 1996, ACUPUNCTURE EFFICACY; Bullock M L, 1997, J Altern Complement Med, V3, P31, DOI 10.1089/acm.1997.3.31; BULLOCK ML, 1989, LANCET, V1, P1435; BULLOCK ML, 1987, ALCOHOL CLIN EXP RES, V11, P292, DOI 10.1111/j.1530-0277.1987.tb01310.x; CAHN AM, 1978, LANCET, V1, P182; Cassapakis C., 1995, P 3 S SOC AC RES SEP, P1; Chang FY, 1996, AM J CHINESE MED, V24, P185, DOI 10.1142/S0192415X96000244; CHEN XH, 1992, EUR J PHARMACOL, V211, P203; Cheng X. D., 1997, CHIN J IMMUNOL, V13, P68; CHRISTENSEN PA, 1989, BRIT J ANAESTH, V62, P258, DOI 10.1093/bja/62.3.258; ClavelChapelon F, 1997, PREV MED, V26, P25, DOI 10.1006/pmed.1996.9997; Diehl D L, 1997, J Altern Complement Med, V3, P119, DOI 10.1089/acm.1997.3.119; DU LN, IN PRESS CHIN J IMMU; DUNDEE JW, 1989, J ROY SOC MED, V82, P268, DOI 10.1177/014107688908200508; DUNDEE JW, 1986, BRIT MED J, V293, P583, DOI 10.1136/bmj.293.6547.583; DUNDEE JW, 1991, CLIN PHARMACOL THER, V50, P78, DOI 10.1038/clpt.1991.106; DUNDEE JW, 1989, BRIT J ANAESTH, V63, P612, DOI 10.1093/bja/63.5.612; DUNDEE JW, 1991, POSTGRAD MED J, V67, P47; HAMMERSCHLAG R, 1997, COMPLEMENT THER MED, V5, P133; HAN JS, 1992, NEWS PHYSIOL SCI, V7, P176; HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M; He D, 1997, PREV MED, V26, P208, DOI 10.1006/pmed.1996.0125; HELMS JM, 1996, ACUPUNCTURE ENEGETIC; Hoizey D., 1988, HIST CHINESE MED; Jin HO, 1996, AM J PHYSIOL-GASTR L, V271, pG524, DOI 10.1152/ajpgi.1996.271.3.G524; JOHANSSON K, 1993, NEUROLOGY, V43, P2189, DOI 10.1212/WNL.43.11.2189; Kaptchuk T, 1983, WEB HAS NO WEAVER; KAPTCHUK TJ, IN PRESS B HIST MED; Konefal J., 1995, ALTERNATIVE MED J, V2, P8; Kosten, 1993, AM J ADDICTIONS, V2, P194; Lao L, 1996, J Altern Complement Med, V2, P27, DOI 10.1089/acm.1996.2.27; Lao L, 1996, J Altern Complement Med, V2, P23, DOI 10.1089/acm.1996.2.23; LAO LX, 1995, ORAL SURG ORAL MED O, V79, P423, DOI 10.1016/S1079-2104(05)80121-0; LI YY, 1992, AM J GASTROENTEROL, V87, P1372; LIAO SJ, 1994, PRINCIPLES PRACTICE; Lu Gwei- Djen, 1980, CELESTIAL LANCETS HI; Lytle C D, 1996, J Altern Complement Med, V2, P253, DOI 10.1089/acm.1996.2.253; MARTELETE M, 1985, ACUPUNCTURE ELECTRO, V10, P183, DOI 10.3727/036012985816714432; MITCHELL BB, 1997, ACUPUNCTURE ORIENTAL; Naeser M A, 1996, J Altern Complement Med, V2, P211, DOI 10.1089/acm.1996.2.211; NAESER MA, 1994, ACUPUNCTURE ELECTRO, V19, P227, DOI 10.3727/036012994816357231; NAESER MA, 1927, ACUPUNCT ELECT RES, V19, P22794; Naeser MA, 1996, LASERS SURG MED S, V8, P7; *NIH TECHN ASS, 1996, J ALTERN COMPLEMENT, V2, P1; NORHEIM AJ, 1996, COMPLEMENT THER MED, V4, P8, DOI DOI 10.1016/S0965-2299(96)80049-5; PATEL M, 1989, INT J EPIDEMIOL, V18, P900, DOI 10.1093/ije/18.4.900; Porkert M., 1974, THEORETICAL FDN CHIN; PORTENOY RK, 1993, DRUG THER, V23, P41; SHLAY JC, IN PRESS JAMA; SIMPSON DM, 1991, AIDS, V5, P917, DOI 10.1097/00002030-199108000-00001; SINGH BB, 1997, COMPLEMENT THER MED, V5, P3; SUNG YF, 1977, ANESTH ANALG, V56, P473; Tang NM, 1997, PAIN, V71, P71, DOI 10.1016/S0304-3959(97)03341-1; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; Unschuld Paul O., 1985, MED CHINA HIST IDEAS; VINCENT C, 1995, J ROY SOC MED, V88, P199; Vincent C, 1990, COMPLEMENT MED RES, V4, P8; VINCENT CA, 1986, PAIN, V24, P1, DOI 10.1016/0304-3959(86)90022-9; WHITE AR, 1996, COCHRANE DATABASE SY; YANG QY, 1992, J REPROD MED, V1, P6; YANG SP, 1997, ACTA PHYSL SINICA, V49, P354; YANG SP, 1994, ACUPUNCTURE ELECTRO, V19, P9; YU J, 1995, CHIN J INTEGRATED TR, V1, P13; Zhang Y, 1996, ACUPUNCTURE ELECTRO, V21, P177, DOI 10.3727/036012996816356870; ZHU CB, 1995, ACTA PHARM SINIC, V16, P311; 1996, FED REG, V61, P64616; [No title captured]	68	834	852	8	216	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1518	1524						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809733				2022-12-28	WOS:000076757200026
J	Nichols, J; Zevnik, B; Anastassiadis, K; Niwa, H; Klewe-Nebenius, D; Chambers, I; Scholer, H; Smith, A				Nichols, J; Zevnik, B; Anastassiadis, K; Niwa, H; Klewe-Nebenius, D; Chambers, I; Scholer, H; Smith, A			Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4	CELL			English	Article							MOUSE EGG-CYLINDERS; ES CELLS; GENE-EXPRESSION; DOMAIN; MASS; LINE; DIFFERENTIATION; ESTABLISHMENT; BLASTOCYST; ENHANCER	Oct4 is a mammalian POU transcription factor expressed by early embryo cells and germ cells. We report that the activity of Oct4 is essential for the identity of the pluripotential founder cell population in the mammalian embryo. Oct4-deficient embryos develop to the blastocyst stage, but the inner cell mass cells are not pluripotent. Instead, they are restricted to differentiation along the extraembryonic trophoblast lineage. Furthermore, in the absence of a true inner cell mass, trophoblast proliferation is not maintained in Oct4(-/-) embryos. Expansion of trophoblast precursors is restored, however, by an Oct4 target gene product, fibroblast growth factor-4. Therefore, Oct4 also determines paracrine growth factor signaling from stem cells to the trophectoderm.	Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland; European Mol Biol Lab, D-69117 Heidelberg, Germany	University of Edinburgh; European Molecular Biology Laboratory (EMBL)	Smith, A (corresponding author), Univ Edinburgh, Ctr Genome Res, W Mains Rd,Kings Bldg, Edinburgh EH9 3JQ, Midlothian, Scotland.	Austin.smith@ed.ac.uk	Zevnik, Branko/AAB-7853-2020; Anastassiadis, Konstantinos/A-8944-2010	Zevnik, Branko/0000-0001-7845-9522; Anastassiadis, Konstantinos/0000-0002-9814-0559; Nichols, Jennifer/0000-0002-8650-1388; Smith, Austin/0000-0002-3029-4682; Scholer, Hans/0000-0003-2643-5136; Chambers, Ian/0000-0003-2605-1597				Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; ANSELL JD, 1975, J EMBRYOL EXP MORPH, V33, P177; Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Brook FA, 1997, P NATL ACAD SCI USA, V94, P5709, DOI 10.1073/pnas.94.11.5709; BRULET P, 1980, P NATL ACAD SCI-BIOL, V77, P4113, DOI 10.1073/pnas.77.7.4113; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DIWAN SB, 1976, J NATL CANCER I, V57, P937, DOI 10.1093/jnci/57.4.937; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; GARDNER RL, 1983, INT REV EXP PATHOL, V24, P63; GARDNER RL, 1972, J EMBRYOL EXP MORPH, V28, P279; Gardner RLP., 1975, EARLY DEV MAMMALS, P107; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HANDYSIDE AH, 1984, J EXP ZOOL, V231, P429, DOI 10.1002/jez.1402310317; Hogan B, 1994, MANIPULATING MOUSE E; HOLDENER BC, 1994, DEVELOPMENT, V120, P1335; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; Liu LM, 1996, J BIOL CHEM, V271, P16683, DOI 10.1074/jbc.271.28.16683; MA YG, 1992, DEV BIOL, V154, P45, DOI 10.1016/0012-1606(92)90046-J; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Nichols J, 1996, MECH DEVELOP, V57, P123, DOI 10.1016/0925-4773(96)00531-X; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; NICHOLS J, 1994, EXP CELL RES, V215, P237, DOI 10.1006/excr.1994.1338; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; PAPAIOANNOU VE, 1982, J EMBRYOL EXP MORPH, V68, P199; Pesce M, 1998, MECH DEVELOP, V71, P89, DOI 10.1016/S0925-4773(98)00002-1; Pesce M, 1998, BIOESSAYS, V20, P722, DOI 10.1002/(SICI)1521-1878(199809)20:9&lt;722::AID-BIES5&gt;3.0.CO;2-I; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; ROSSANT J, 1977, J EMBRYOL EXP MORPH, V39, P183; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Saijoh Y, 1996, GENES CELLS, V1, P239, DOI 10.1046/j.1365-2443.1996.d01-237.x; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; SOLTER D, 1975, P NATL ACAD SCI USA, V72, P5099, DOI 10.1073/pnas.72.12.5099; SOLTER D, 1970, NATURE, V227, P503, DOI 10.1038/227503a0; STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883; TARKOWSKI AK, 1967, J EMBRYOL EXP MORPH, V18, P155; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Wilder PJ, 1997, DEV BIOL, V192, P614, DOI 10.1006/dbio.1997.8777; Yeom YI, 1996, DEVELOPMENT, V122, P881; Yuan H., 1996, GENE DEV, V9, P2635	61	2538	2710	3	181	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1998	95	3					379	391		10.1016/S0092-8674(00)81769-9	http://dx.doi.org/10.1016/S0092-8674(00)81769-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814708	Bronze, Green Submitted			2022-12-28	WOS:000076789600011
J	Marrugat, J; Sala, J; Masia, R; Pavesi, M; Sanz, G; Valle, V; Molina, L; Seres, L; Elosua, R				Marrugat, J; Sala, J; Masia, R; Pavesi, M; Sanz, G; Valle, V; Molina, L; Seres, L; Elosua, R		RESCATE Investigators	Mortality differences between men and women following first myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; SEX-DIFFERENCES; CASE-FATALITY; MONICA PROJECT; HEART-DISEASE; OUTCOMES; REGISTER	Context.-Mortality after acute myocardial infarction is worse in women than in men, even after adjustment for comorbidity and age dissimilarities between sexes. Objective.-To assess the influence of sex on survival after acute myocardial infarction. Design.-Inception cohort obtained in a prospective registry of patients with acute myocardial infarction from 1992 through 1994. Setting.-Four teaching hospitals in northeastern Spain. Patients.-All consecutive patients aged 80 years or younger with first acute myocardial infarction. A total of 331 women and 1129 men were included. Main Outcome Measure.-Survival at 28 days and mortality or readmission at 6 months, Results.-Women were older (mean, 68.6 vs 60.1 years), presented more often with diabetes (52.9% vs 23.3%), hypertension (63.9% vs 42.3%), or previous angina (44.6% vs 37.4%), and developed more severe myocardial infarctions than men (acute pulmonary edema or cardiogenic shock occurred in 24.8% of women and 10.5% of men) tall P<.02). Men were more likely than women to receive thrombolytic therapy (41.3% vs 23.9%; P<.001), but rates of percutaneous transluminal angioplasty and coronary artery bypass graft surgery at 28 days were similar among men and women, The 28-day mortality rate was significantly higher among women (18.5% for women, 8.3% for men; P<.001). Revascularization procedures at 6 months were performed in a similar proportion of women and men. However, women had higher 6-month mortality rates (25.8% in women, 10.8% in men; P<.001) and readmission rates (23.3% for women, 12.2% for men; P<.001). After adjustment, women had greater risk of death than men at 28 days (odds ratio [OR], 1.72; 95% confidence interval [CI], 1.12-2.65) and at 6 months (OR, 1.73; 95% ci, 1.18-2.52). Conclusions.-In this study population, women experienced more lethal and severe first acute myocardial infarction than men, regardless of comorbidity, age, or previous angina.	Inst Municipal Invest Med, Unitat Lipids & Epidemiol Cardiovasc, E-08003 Barcelona, Spain; Hosp Clin Barcelona, Inst Cardiovasc Dis, Barcelona, Spain; Hosp Mar, Dept Cardiol, Barcelona, Spain; Hosp Gerona Josep Trueta, Unitat Coronaria, Gerona, Spain; Hosp Germans Trias, Dept Cardiol, Badalona, Spain	University of Barcelona; Hospital Clinic de Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Hospital Germans Trias i Pujol	Marrugat, J (corresponding author), Inst Municipal Invest Med, Unitat Lipids & Epidemiol Cardiovasc, Dr Aiguader 80, E-08003 Barcelona, Spain.		Alonso, Jordi/A-5514-2010	Alonso, Jordi/0000-0001-8627-9636; Marrugat, Jaume/0000-0003-3320-554X				*ACC AHA, 1990, CIRCULATION, V82, P664; BECKER RC, 1994, ANN INTERN MED, V120, P638, DOI 10.7326/0003-4819-120-8-199404150-00003; BOSCH X, 1994, REV ESP CARDIOL S, V47, P926; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; Chambless L, 1997, CIRCULATION, V96, P3849; Chandra NC, 1998, ARCH INTERN MED, V158, P981, DOI 10.1001/archinte.158.9.981; DEMIROVIC J, 1995, AM J CARDIOL, V75, P1096, DOI 10.1016/S0002-9149(99)80737-1; DEVREEDE JJM, 1991, J AM COLL CARDIOL, V18, P698, DOI 10.1016/0735-1097(91)90792-8; EAKER ED, 1993, CIRCULATION, V88, P1999, DOI 10.1161/01.CIR.88.4.1999; Froufe J, 1994, Rev Esp Cardiol, V47 Suppl 1, P27; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; Herman B, 1997, EUR HEART J, V18, P963; HOSMER DW, 1989, APPL LOGISTIC REGRES; Hussain KMA, 1997, AM HEART J, V134, P719, DOI 10.1016/S0002-8703(97)70056-5; JAGLAL SB, 1994, CAN J CARDIOL, V10, P239; JENKINS JS, 1989, AM J CARDIOL, V130, P469; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; MARRUGAT J, 1994, J CLIN EPIDEMIOL, V47, P111, DOI 10.1016/0895-4356(94)90016-7; Marrugat J, 1997, J AM COLL CARDIOL, V30, P1187, DOI 10.1016/S0735-1097(97)00312-4; MAYNARD C, 1996, CIRCULATION S, V94, P1193; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; PEREZ G, 1993, J CLIN EPIDEMIOL, V46, P1173, DOI 10.1016/0895-4356(93)90116-I; Perez G, 1998, INT J EPIDEMIOL, V27, P599, DOI 10.1093/ije/27.4.599; Schwartz LM, 1997, ARCH INTERN MED, V157, P1545, DOI 10.1001/archinte.157.14.1545; Sonke GS, 1996, BRIT MED J, V313, P853; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; VACCARINO V, 1995, CIRCULATION, V91, P1861, DOI 10.1161/01.CIR.91.6.1861	28	170	178	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	1998	280	16					1405	1409		10.1001/jama.280.16.1405	http://dx.doi.org/10.1001/jama.280.16.1405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130YA	9800999	Bronze			2022-12-28	WOS:000076546900034
J	Poungvarin, N				Poungvarin, N			Stroke in the developing world	LANCET			English	Article							INFARCTION; CHINESE		Mahidol Univ, Siriraj Hosp, Fac Med, Dept Med,Div Neurol, Bangkok 10700, Thailand	Mahidol University	Poungvarin, N (corresponding author), Mahidol Univ, Siriraj Hosp, Fac Med, Dept Med,Div Neurol, Bangkok 10700, Thailand.							Allen CMC, 1983, Q J MED, V208, P515; *AS PAC CONS FOR, IN PRESS STROKE; DALAL PM, 1968, BRIT MED J, V3, P769, DOI 10.1136/bmj.3.5621.769; DALAL PM, 1997, J ASSOC PHYSICIAN I, V45, P125; DAVIS PH, 1991, NEUROEPIDEMIOLOGY TR, P27; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; Hacke W, 1997, NEUROLOGY, V49, pS60, DOI 10.1212/WNL.49.5_Suppl_4.S60; HANIP MR, 1996, P 1 MOH AM MIN PUBL; Havlik Richard J., 1992, P262; HU HH, 1992, STROKE, V23, P1237, DOI 10.1161/01.STR.23.9.1237; KAY R, 1992, NEUROLOGY, V42, P985, DOI 10.1212/WNL.42.5.985; *KOR MED INS COOP, 1994, MED INS STAT YB; Korean Neurological Association, 1993, J KOREAN MED SCI, V8, P281; LIM SH, 1996, NEUROL J SE ASIA, V1, P19; MARQUARDSEN J, 1986, STROKE PATHOPHYSIOLO, V1, P31; MARTIN J, 1988, 1 OFF POP CENS SURV; *MIN PUBL HLTH DEP, 1995, ANN REP NAT HLTH STA; *MIN PUBL HLTH DEP, 1996, ANN REP NAT HLTH STA; *MIN PUBL HLTH STA, 1996, ANN REP NAT HLTH STA; *MIN PUBL HLTH STA, 1995, ANN REP NAT HLTH STA; MISBACH J, 1995, STROKE SURVEY JAKART; MORGENSTERN LB, 1997, NEUROLOGY S4, V49, pS60; Nogueira A, 1996, OBES RES, V4, P221; NOGUEIRA A, 1994, J CLIN EPIDEMIOL, V47, P1401; PAN WH, 1995, LANCET, V345, P353, DOI 10.1016/S0140-6736(95)90341-0; *PHIL NEUR ASS, 1993, P 1993 PHIL NEUR ASS; POUNGVARIN N, 1991, BRIT MED J, V302, P1565, DOI 10.1136/bmj.302.6792.1565; POUNGVARIN N, 1989, Journal of the Medical Association of Thailand, V72, P421; POUNGVARIN N, 1991, STROKE, P11; SURTIDENI L, 1995, THESIS U INDONESIA; *TAT SERV LTD DEP, 1997, ANN REP NAT HLTH STA; Venkatesubramanian N, 1994, CEREBROVASC DIS, V4, P250; VIRIYAVEJAKUL A, 1990, CLIN NEUROPHARMACOL, V13, pS26, DOI 10.1097/00002826-199013003-00003; VIRIYAVEJAKUL A, 1983, ASIA PACIFIC C SERIE, V22, P10; Warlow C., 1993, BRAINS DIS NERVOUS S, P197; WARLOW CP, 1996, STROKE PRACTICAL GUI, P632; YIP PK, 1997, STROKE, V28, P88; 1995, HOSP AUTHORITY STAT; 1996, ANN REP NATL HLTH ST; 1994, ANN REPORTS REGISTRY	40	84	87	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT	1998	352			3			SIII19	SIII22						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133UP	9803958				2022-12-28	WOS:000076704700006
J	De Keyser, J				De Keyser, J			Antipyretics in acute ischaemic stroke	LANCET			English	Editorial Material							CEREBRAL-ISCHEMIA; TEMPERATURE		Acad Ziekenhuis, Dept Neurol, NL-9700 RB Groningen, Netherlands	University of Groningen	De Keyser, J (corresponding author), Acad Ziekenhuis, Dept Neurol, NL-9700 RB Groningen, Netherlands.		De Keyser, Jacques/D-3725-2013	De Keyser, Jacques/0000-0002-3394-7757				AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; BEAMER NB, 1995, ANN NEUROL, V37, P800, DOI 10.1002/ana.410370614; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; CASTILLO J, 1994, CEREBROVASC DIS, V4, P56; CHOPP M, 1988, STROKE, V19, P1521, DOI 10.1161/01.STR.19.12.1521; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; TAGI T, 1994, AM J PHYSIOL, V266, pH1770; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013	12	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					6	7						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800736				2022-12-28	WOS:000074608600006
J	Goldstein, DJ; Oz, MC; Rose, EA				Goldstein, DJ; Oz, MC; Rose, EA			Medical progress - Implantable left ventricular assist devices	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TOTAL ARTIFICIAL-HEART; PLATELET-ACTIVATING-FACTOR; END-STAGE CARDIOMYOPATHY; CLINICAL USE; CARDIAC TRANSPLANTATION; DILATED CARDIOMYOPATHY; CIRCULATORY SUPPORT; MECHANICAL SUPPORT; HISTOLOGIC-CHANGES; EXERCISE CAPACITY		Columbia Univ, Columbia Presbyterian Med Ctr, Coll Phys & Surg, Dept Surg,Div Cardiothorac Surg, New York, NY 10032 USA	Columbia University; NewYork-Presbyterian Hospital	Rose, EA (corresponding author), Milstein Hosp, Dept Surg, 177 Ft Washington Ave, New York, NY 10032 USA.		Rose, Eric/AAJ-2281-2020					Allen MD, 1997, WESTERN J MED, V166, P326; AMBROSINO N, 1994, EUR RESPIR J, V7, P17, DOI 10.1183/09031936.94.07010017; Argenziano M, 1998, ANN THORAC SURG, V65, P340, DOI 10.1016/S0003-4975(97)01307-6; ARIA H, 1991, ASAIO T, V37, pM427; BELLAN JA, 1992, AM J PHYSIOL, V263, pH234, DOI 10.1152/ajpheart.1992.263.1.H234; CAMUSSI G, 1987, J EXP MED, V166, P1390, DOI 10.1084/jem.166.5.1390; Catanese KA, 1996, ANN THORAC SURG, V62, P646, DOI 10.1016/S0003-4975(96)00456-0; Chau EMC, 1996, CIRCULATION, V94, P267; Chen JM, 1996, ANN THORAC SURG, V61, P570, DOI 10.1016/0003-4975(95)01031-9; Chen JM, 1996, ANN THORAC SURG, V61, P305, DOI 10.1016/0003-4975(95)01010-6; COPELAND JG, 1986, JAMA-J AM MED ASSOC, V256, P2991; Copeland JG, 1996, J HEART LUNG TRANSPL, V15, P94; Costanzo M R, 1996, Semin Thorac Cardiovasc Surg, V8, P113; Deng MC, 1997, J HEART LUNG TRANSPL, V16, P629; DeRose JJ, 1997, ANN SURG, V226, P461, DOI 10.1097/00000658-199710000-00007; DEVRIES WC, 1984, NEW ENGL J MED, V310, P273, DOI 10.1056/NEJM198402023100501; DUSMAN RE, 1990, CIRCULATION, V82, P51, DOI 10.1161/01.CIR.82.1.51; ElAmir NG, 1996, ASAIO J, V42, P150, DOI 10.1097/00002480-199605000-00006; EMERY RW, 1991, J CARDIAC SURG, V6, P400, DOI 10.1111/j.1540-8191.1991.tb00337.x; ESTRADA-QUINTERO T, 1992, Journal of the American College of Cardiology, V19, p254A; EVANS RW, 1986, JAMA-J AM MED ASSOC, V255, P1892; Fischer SA, 1997, CLIN INFECT DIS, V24, P18, DOI 10.1093/clinids/24.1.18; Foray A, 1996, CIRCULATION, V94, P222; Frazier O H, 1994, Semin Thorac Cardiovasc Surg, V6, P181; FRAZIER OH, 1993, ANN THORAC SURG, V55, P273, DOI 10.1016/0003-4975(93)90536-Q; FRAZIER OH, 1992, ANN THORAC SURG, V53, P1080, DOI 10.1016/0003-4975(92)90393-I; GILLUM RF, 1993, AM HEART J, V126, P1042, DOI 10.1016/0002-8703(93)90738-U; Goldstein D J, 1995, ASAIO J, V41, P873, DOI 10.1097/00002480-199510000-00010; GOLDSTEIN DJ, 1995, ANN THORAC SURG, V59, P1063, DOI 10.1016/0003-4975(95)00086-Z; GRIFFITH BP, 1989, ANN THORAC SURG, V47, P158, DOI 10.1016/0003-4975(89)90258-0; Harper A M, 1996, Clin Transpl, P69; Herrmann M, 1997, CIRCULATION, V95, P814; HO KKL, 1993, J AM COLL CARDIOL  S, V22, P6; Hogness JR, 1991, ARTIFICIAL HEART PRO, P14; Holman WL, 1997, ANN SURG, V225, P695, DOI 10.1097/00000658-199706000-00007; HORVATH CJ, 1988, P NATL ACAD SCI USA, V85, P9219, DOI 10.1073/pnas.85.23.9219; HORVATH CJ, 1991, AM REV RESPIR DIS, V144, P1337, DOI 10.1164/ajrccm/144.6.1337; Howson CP, 1991, ART HEART PROT POL P, P65; JACQUET L, 1991, J THORAC CARDIOV SUR, V101, P256; JAMES KB, 1995, CIRCULATION, V92, P191, DOI 10.1161/01.CIR.92.9.191; JOHNSON KE, 1992, J HEART LUNG TRANSPL, V11, P103; Kannel W B, 1989, Cardiol Clin, V7, P1; KORMOS RL, 1990, ANN THORAC SURG, V49, P261, DOI 10.1016/0003-4975(90)90148-Y; Lee KH, 1996, HEARING RES, V94, P1, DOI 10.1016/0378-5955(95)00220-0; LEVIN HR, 1995, CIRCULATION, V91, P2717, DOI 10.1161/01.CIR.91.11.2717; Levin HR, 1996, J HEART LUNG TRANSPL, V15, P840; LOISANCE DY, 1994, ANN THORAC SURG, V58, P551, DOI 10.1016/0003-4975(94)92254-3; MANDARINO WA, 1995, ASAIO J, V41, pM544, DOI 10.1097/00002480-199507000-00070; Martin J, 1997, ANN THORAC SURG, V63, P1145, DOI 10.1016/S0003-4975(97)00067-2; MASSIE BM, 1990, AM J CARDIOL, V66, P429, DOI 10.1016/0002-9149(90)90698-Z; McCarthy P M, 1994, Semin Thorac Cardiovasc Surg, V6, P174; MCCARTHY PM, 1995, ANN THORAC SURG, V59, P609, DOI 10.1016/0003-4975(94)00953-8; MCLOUGHLIN MP, 1991, TRANSPLANT P, V23, P2693; MEHTA SM, 1995, J HEART LUNG TRANSPL, V14, P585; Moazami N, 1997, ASAIO J, V43, P177; Morrone TM, 1996, J HEART LUNG TRANSPL, V15, P423; Muller J, 1997, CIRCULATION, V96, P542; MUNERETTO C, 1989, ANN THORAC SURG, V47, P151, DOI 10.1016/0003-4975(89)90257-9; Nakatani S, 1996, J AM COLL CARDIOL, V27, P894, DOI 10.1016/0735-1097(95)00555-2; Nakazawa T, 1996, ARTIF ORGANS, V20, P252, DOI 10.1111/j.1525-1594.1996.tb04434.x; NISHIMURA S, 1996, ASAIO J, V42, pM568; OHAR JA, 1993, AM REV RESPIR DIS, V148, P158, DOI 10.1164/ajrccm/148.1.158; OZ MC, 1995, CIRCULATION, V92, P169, DOI 10.1161/01.CIR.92.9.169; OZ MC, 1994, J AM COLL CARDIOL, V24, P1688, DOI 10.1016/0735-1097(94)90175-9; OZ MC, 1995, J CARDIAC SURG, V10, P288, DOI 10.1111/j.1540-8191.1995.tb00613.x; PAE WE, 1981, CHEST, V79, P692, DOI 10.1378/chest.79.6.692; PENNINGTON DG, 1994, J THORAC CARDIOV SUR, V107, P472, DOI 10.1016/S0022-5223(94)70092-3; PENNINGTON DG, 1989, J HEART TRANSPLANT, V8, P116; PENNINGTON DG, 1985, WORLD J SURG, V9, P37, DOI 10.1007/BF01656254; PORTNER PM, 1989, ANN THORAC SURG, V47, P142, DOI 10.1016/0003-4975(89)90256-7; Prendergast TW, 1997, ANN THORAC SURG, V64, P142, DOI 10.1016/S0003-4975(97)00286-5; Rose EA, 1996, ANN THORAC SURG, V61, P399, DOI 10.1016/0003-4975(95)01003-3; ROSE EA, 1994, CIRCULATION, V90, P87; SALAMONSEN RF, 1994, ANAESTH INTENS CARE, V22, P209, DOI 10.1177/0310057X9402200220; SCHEININ SA, 1992, ASAIO J, V38, pM271, DOI 10.1097/00002480-199207000-00035; Schmid C, 1998, ANN THORAC SURG, V65, P1703, DOI 10.1016/S0003-4975(98)00299-9; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; SHAPIRO GC, 1995, J HEART LUNG TRANSPL, V14, P594; SHENKAR R, 1994, AM J RESP CELL MOL, V10, P290, DOI 10.1165/ajrcmb.10.3.8117448; Slater JP, 1996, ANN THORAC SURG, V62, P1321, DOI 10.1016/0003-4975(96)00750-3; Spanier T. B., 1998, Journal of Heart and Lung Transplantation, V17, P83; Spanier T, 1996, J THORAC CARDIOV SUR, V112, P1090, DOI 10.1016/S0022-5223(96)70111-3; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 1983, TRANSPLANT P S1, V15, P2207; 1994, MMWR MORB MORTAL WKL, V43, P77; 1997, MMWR MORB MORTAL WKL, V46, P165; 1996, MMWR MORB MORTAL WKL, V45, P833	88	326	340	0	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1998	339	21					1522	1533		10.1056/NEJM199811193392107	http://dx.doi.org/10.1056/NEJM199811193392107			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VT	9819452				2022-12-28	WOS:000077051800007
J	O'Riordan, JLH				O'Riordan, JLH			Sir John David Nunes Nabarro	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1391	1391		10.1136/bmj.317.7169.1391	http://dx.doi.org/10.1136/bmj.317.7169.1391			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812956				2022-12-28	WOS:000077081600052
J	Anderson, KV				Anderson, KV			Pinning down positional information: Dorsal-ventral polarity in the Drosophila embryo	CELL			English	Review							GENE		Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Anderson, KV (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.							Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; HONG CC, 1995, CELL, V82, P785, DOI 10.1016/0092-8674(95)90475-1; Konsolaki M, 1998, GENE DEV, V12, P120, DOI 10.1101/gad.12.1.120; LeMosy EK, 1998, DEVELOPMENT, V125, P4045; Misra S, 1998, DEVELOPMENT, V125, P1261; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Nilson LA, 1998, CELL, V93, P253, DOI 10.1016/S0092-8674(00)81576-7; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROTH S, 1994, DEVELOPMENT, V120, P2245; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B	13	83	84	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1998	95	4					439	442		10.1016/S0092-8674(00)81610-4	http://dx.doi.org/10.1016/S0092-8674(00)81610-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827795	Bronze			2022-12-28	WOS:000077049400001
J	ter Haar, E; Musacchio, A; Harrison, SC; Kirchhausen, T				ter Haar, E; Musacchio, A; Harrison, SC; Kirchhausen, T			Atomic structure of clathrin: A beta propeller terminal domain joins an alpha zigzag linker	CELL			English	Article							COUPLED RECEPTOR KINASES; COATED VESICLES; HEAVY-CHAIN; G-PROTEIN; LIGHT-CHAINS; ARRESTIN/CLATHRIN INTERACTION; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; SORTING SIGNALS; AP-2 COMPLEXES	Clathrin triskelions form the lattice that organizes recruitment of proteins to coated pits and helps drive Vesiculation of the lipid bilayer. We report the crystal structure at 2.6 Angstrom resolution of a 55 kDa N-terminal fragment from the 190 kDa clathrin heavy chain. The structure comprises the globular "terminal domain" and the linker that joins it to the end of a triskelion leg. The terminal domain is a seven-blade beta propeller, a structure well adapted to interaction with multiple partners, such as the AP-1 and AP-2 sorting adaptor complexes and the nonvisual arrestins. The linker is an alpha-helical zigzag emanating from the propeller domain. We propose that this simple motif may extend into the rest of the clathrin leg.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Kirchhausen, T (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	kirchhausen@crystal.harvard.edu		Musacchio, Andrea/0000-0003-2362-8784	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036548] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM036548, GM36548] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Clairmont KB, 1997, CELL MOL LIFE SCI, V53, P611, DOI 10.1007/s000180050080; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; CROWTHER RA, 1981, J CELL BIOL, V91, P790, DOI 10.1083/jcb.91.3.790; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; Diviani D, 1996, J BIOL CHEM, V271, P5049; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HEUSER J, 1985, J ULTRA MOL STRUCT R, V92, P1, DOI 10.1016/0889-1605(85)90123-5; Huang KM, 1997, J CELL SCI, V110, P899; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; KIRCHHAUSEN T, 1986, J ULTRA MOL STRUCT R, V94, P199, DOI 10.1016/0889-1605(86)90067-4; KIRCHHAUSEN T, 1983, P NATL ACAD SCI-BIOL, V80, P2481, DOI 10.1073/pnas.80.9.2481; KIRCHHAUSEN T, 1984, J CELL BIOL, V99, P1725, DOI 10.1083/jcb.99.5.1725; KIRCHHAUSEN T, 1987, P NATL ACAD SCI USA, V84, P8805, DOI 10.1073/pnas.84.24.8805; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; LEMMON SK, 1991, J CELL BIOL, V112, P65, DOI 10.1083/jcb.112.1.65; LIU SH, 1995, CELL, V83, P257, DOI 10.1016/0092-8674(95)90167-1; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; MURZIN AG, 1992, PROTEINS, V14, P191, DOI 10.1002/prot.340140206; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Saxena K, 1996, BIOCHEMISTRY-US, V35, P15215, DOI 10.1021/bi961616x; SCARMATO P, 1990, J BIOL CHEM, V265, P3661; SCHMID SL, 1982, P NATL ACAD SCI-BIOL, V79, P91, DOI 10.1073/pnas.79.1.91; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Smith CJ, 1998, EMBO J, V17, P4943, DOI 10.1093/emboj/17.17.4943; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; SPRINGER TA, 1998, IN PRESS J MOL BIOL; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; UNGEWICKELL E, 1983, EMBO J, V2, P1401, DOI 10.1002/j.1460-2075.1983.tb01598.x; UNGEWICKELL E, 1981, COLD SPRING HARB SYM, V46, P723, DOI 10.1101/SQB.1982.046.01.069; VIGERS GPA, 1986, EMBO J, V5, P529, DOI 10.1002/j.1460-2075.1986.tb04242.x; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339	75	181	186	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1998	95	4					563	573		10.1016/S0092-8674(00)81623-2	http://dx.doi.org/10.1016/S0092-8674(00)81623-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827808	Green Accepted, Bronze			2022-12-28	WOS:000077049400014
J	Etienne, AS; Maurer, R; Berlie, J; Reverdin, B; Rowe, T; Georgakopoulos, J; Seguinot, V				Etienne, AS; Maurer, R; Berlie, J; Reverdin, B; Rowe, T; Georgakopoulos, J; Seguinot, V			Navigation through vector addition	NATURE			English	Article							PATH INTEGRATION; HOUSE MOUSE; DISTANCE	During short foraging excursions away from their home, central place foragers update their position relative to their point of departure by processing signals generated by locomotion. They therefore can home along a self-generated vector without using learned references, In rodents(1-5) and other mammals(6,7), this path integration process (dead reckoning) can occur on the basis of purely internal signals, such as vestibular(8) or proprioceptive (re)afferences(6). We report here that hamsters are also capable of proceeding to a previously learned feeding site through vector information from locomotion only. The subjects compute(9) the direction and distance to the goal by subtracting their current-position vector from the stored nest-to-goal vector. This computation pertains to locations per se and therefore occurs in absolute space, independently of landmark objects. If available, prominent visual cues merely serve to confirm the path planned through the addition of self-generated vectors, whereas visual as well as nonvisual references confirm that the subject has arrived at the goal site.	Univ Geneva, FPSE, Ethol Lab, CH-1227 Carouge, Switzerland	University of Geneva	Etienne, AS (corresponding author), Univ Geneva, FPSE, Ethol Lab, 54 Route Acacias, CH-1227 Carouge, Switzerland.	Ariane.Etienne@pse.unige.ch; Roland.Maurer@pse.unige.ch						ALYAN S, 1994, ANIM BEHAV, V48, P285, DOI 10.1006/anbe.1994.1242; Alyan SH, 1997, BEHAV PROCESS, V41, P245, DOI 10.1016/S0376-6357(97)00051-X; Benhamou S, 1997, ANIM BEHAV, V54, P321, DOI 10.1006/anbe.1996.0464; CHENG K, 1989, J EXP PSYCHOL ANIM B, V15, P366, DOI 10.1037/0097-7403.15.4.366; COLLETT TS, 1986, J COMP PHYSIOL A, V158, P835, DOI 10.1007/BF01324825; Etienne AS, 1996, J EXP BIOL, V199, P201; ETIENNE AS, 1988, BEHAVIOUR, V106, P81, DOI 10.1163/156853988X00106; ETIENNE AS, 1982, EXPERIENTIA, V38, P553, DOI 10.1007/BF02327044; Etienne AS, 1992, CURRENT DIRECTIONS P, V1, P48, DOI DOI 10.1111/1467-; Gallistel C. R., 1990, ORG LEARNING; MAURER R, 1995, J THEOR BIOL, V175, P457, DOI 10.1006/jtbi.1995.0154; MCNAUGHTON BL, 1991, J COGNITIVE NEUROSCI, V3, P192, DOI 10.1162/jocn.1991.3.2.190; Mittelstaedt H., 1982, P290; POTEGAL M, 1987, COGNITIVE PROCESS, V2, P28; Seguinot V, 1998, ANIM BEHAV, V55, P787, DOI 10.1006/anbe.1997.0662; SEGUINOT V, 1993, J COMP PHYSIOL A, V173, P103; Wiener SI, 1993, MULTISENSORY CONTROL, P427, DOI [10.1093/acprof:oso/9780198547853.003.0208, DOI 10.1093/ACPROF:OSO/9780198547853.003.0208]	17	89	91	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	1998	396	6707					161	164		10.1038/24151	http://dx.doi.org/10.1038/24151			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	139DU	9823894				2022-12-28	WOS:000077013300050
J	Altman, DG				Altman, DG			Confidence intervals for the number needed to treat	BRITISH MEDICAL JOURNAL			English	Article							METAANALYSIS; PREVENTION; THERAPIES; SURGERY; TRIALS		Inst Hlth Sci, Ctr Stat Med, Med Stat Grp, Imperial Canc Res Fund, Oxford OX3 7LF, England	University of Oxford	Altman, DG (corresponding author), Inst Hlth Sci, Ctr Stat Med, Med Stat Grp, Imperial Canc Res Fund, Oxford OX3 7LF, England.							ALTMAN DG, 1989, STATISTICS CONFIDENC, P83; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; Daly LE, 1998, AM J EPIDEMIOL, V147, P783; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; Miller DB, 1997, ARCH INTERN MED, V157, P2045, DOI 10.1001/archinte.157.18.2045; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; SACKETT DL, 1997, EVIDENCE BASED MED P, P208; Sackett DL, 1996, EVIDENCE BASED MED, V1, P164, DOI DOI 10.1136/EBM.1996.1.164; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; TRAMER M, 1995, BRIT J ANAESTH, V75, P556, DOI 10.1093/bja/75.5.556; Tramer MR, 1997, BRIT MED J, V314, P1088, DOI 10.1136/bmj.314.7087.1088	13	666	674	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1309	1312		10.1136/bmj.317.7168.1309	http://dx.doi.org/10.1136/bmj.317.7168.1309			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804726	Green Published			2022-12-28	WOS:000076963800035
J	Shoulson, I				Shoulson, I			Experimental therapeutics of neurodegenerative disorders: Unmet needs	SCIENCE			English	Editorial Material							NEURONAL INTRANUCLEAR INCLUSIONS; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; HUNTINGTONS-DISEASE; CONTROLLED TRIAL; ALPHA-SYNUCLEIN; MUTATION; THERAPY; BRAIN	The experimental therapeutics of neurodegenerative disorders is in its infancy, but neuroprotective strategies are already being applied in healthy persons at high risk of developing disease as well as in patients with manifest illness, Knowledge of etiology and pathogenesis, improved design of clinical trials, the development of biological markers, the advent of genetic animal models, the enhanced identification of susceptibility factors, and more effective drug delivery-such advances have improved the prospects for forestalling onset of illness and clinical decline in the growing numbers of people affected by neurodegenerative disorders.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Neurol, Rochester, NY 14620 USA	University of Rochester	Shoulson, I (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Neurol, Suite 212,1351 Mt Hope Ave, Rochester, NY 14620 USA.							ALBIN RL, 1990, ANN NEUROL, V27, P357, DOI 10.1002/ana.410270403; Andrew SE, 1997, HUM MOL GENET, V6, P2005, DOI 10.1093/hmg/6.12.2005; [Anonymous], 1996, Ann Neurol, V39, P29; [Anonymous], 1996, Ann Neurol, V39, P37; BAR PR, 1997, NEUROPROTECTION CNS; BRAAK H, 1994, NEURODEGENER DIS, P585; CALNE DB, 1993, NEW ENGL J MED, V329, P1021; COTZIAS GC, 1967, NEW ENGL J MED, V276, P374, DOI 10.1056/NEJM196702162760703; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; GREENAMYRE JT, 1994, NEURODEGENER DIS, P685; Gusella JF, 1997, MOL MED, V3, P238, DOI 10.1007/BF03401677; Langer R, 1998, NATURE, V392, P5; LLOYD KG, 1975, J PHARMACOL EXP THER, V195, P453; MARTIN LJ, 1994, AM J PATHOL, V145, P1358; Menkes JH, 1997, MOL GENETIC BASIS NE, P1273; Morrish PK, 1996, BRAIN, V119, P585, DOI 10.1093/brain/119.2.585; *NINDS, 1997, NIH GUIDE, V26; Olanow CW, 1996, NEURODEGENERATION NE; Pardridge WM, 1997, J CEREBR BLOOD F MET, V17, P713, DOI 10.1097/00004647-199707000-00001; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; Pfeiffer RF, 1997, MOVEMENT DISORDERS N, P623; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; PRICE DL, 1995, CURR OPIN NEUROL, V8, P268, DOI 10.1097/00019052-199508000-00004; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; PRICE DL, 1998, NEUROSCI NEWS, V1, P21; Rogers SL, 1998, ARCH INTERN MED, V158, P1021, DOI 10.1001/archinte.158.9.1021; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; SEIBYL JP, 1995, ANN NEUROL, V38, P589, DOI 10.1002/ana.410380407; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Shoulson I, 1998, ANN NEUROL, V44, pS160, DOI 10.1002/ana.410440724; Shoulson I, 1998, ANN NEUROL, V43, P318; SHOULSON I, 1997, NEUROPROTECTION FUND, P457; SLADEK JR, 1988, SCIENCE, V240, P1386, DOI 10.1126/science.3375820; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Uitti RJ, 1996, CNS DRUGS, V5, P369, DOI 10.2165/00023210-199605050-00006; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341	41	68	86	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 6	1998	282	5391					1072	1074		10.1126/science.282.5391.1072	http://dx.doi.org/10.1126/science.282.5391.1072			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804537				2022-12-28	WOS:000076887700037
J	Cook, KA; Dobbs, TE; Hlady, G; Wells, JG; Barrett, TJ; Puhr, ND; Lancette, GA; Bodager, DW; Toth, BL; Genese, CA; Highsmith, AK; Pilot, KE; Finelli, L; Swerdlow, DL				Cook, KA; Dobbs, TE; Hlady, G; Wells, JG; Barrett, TJ; Puhr, ND; Lancette, GA; Bodager, DW; Toth, BL; Genese, CA; Highsmith, AK; Pilot, KE; Finelli, L; Swerdlow, DL			Outbreak of Salmonella serotype hartford infections associated with unpasteurized orange juice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMOLYTIC UREMIC SYNDROME; ESCHERICHIA-COLI O157-H7; PRESSED APPLE CIDER; ODDS RATIO; FRESH	Context.-Acidic foods such as orange juice have been thought to be unlikely vehicles of foodborne illness. Objective.-To investigate an outbreak of Salmonella enterica serotype Hartford (Salmonella Hartford) infections among persons visiting a theme park in Orlando, Fla, in 1995, Design.-Review of surveillance data, matched case-control study, laboratory investigation, and environmental studies. Setting.-General community, Participants.-The surveillance case definition was Salmonella Harfford or Salmonella serogroup C-1 infection in a resident of or a visitor to Orlando in May or June 1995. In the case-control study, case patients were limited to theme park hotel visitors and controls were matched to case patients by age group and hotel check-in date. Main Outcome Measures.-Risk factors for infection and source of implicated food. Results.-Sixty-two case patients from 21 states were identified, Both Salmonella Harfford and Salmonella enterica serotype Gaminara (Salmonella Gaminara) were isolated from stool samples of 1 ill person. Thirty-two case patients and 83 controls were enrolled in the case-control study, Ninety-seven percent of case patients had drunk orange juice in the theme park vs 54% of controls (matched odds ratio, undefined; 95% confidence interval, 5.2 to undefined). The orange juice was unpasteurized and locally produced. Salmonella Gaminara was isolated from 10 of 12 containers of orange juice produced during May and July, indicating ongoing contamination of juice probably because of inadequately sanitized processing equipment. Conclusions.-Unpasteurized orange juice caused an outbreak of salmonellosis in a large Florida theme park. All orange juice was recalled and the processing plant closed, Pasteurization or other equally effective risk-management strategies should be used in the production of all juices.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Bacterial & Mycot Dis, Foodborne & Diarrheal Dis Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Epidem Intelligence Serv, Atlanta, GA 30333 USA; US FDA, SE Reg Lab, Atlanta, GA USA; Florida Dept Hlth, Tallahassee, FL USA; Orange Cty Publ Hlth Unit, Orlando, FL USA; New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; US Food & Drug Administration (FDA); Florida Department of Health; New Jersey Department of Health & Senior Services	Cook, KA (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Bacterial & Mycot Dis, Foodborne & Diarrheal Dis Branch, 1600 Clifton Rd NE,MS A38, Atlanta, GA 30333 USA.		Finelli, Lyn/AAK-2360-2020	Dobbs, Thomas/0000-0001-6199-5337				Altekruse SF, 1997, EMERG INFECT DIS, V3, P285, DOI 10.3201/eid0303.970304; American Public Health Association AWWA, 1992, STAND METH EX WAT WA; Angulo FJ, 1997, AM J PUBLIC HEALTH, V87, P580, DOI 10.2105/AJPH.87.4.580; Attaway J. A., 1972, Proceedings of the Florida State Horticultural Society, V85, P192; BARRETT TJ, 1994, J CLIN MICROBIOL, V32, P3013, DOI 10.1128/JCM.32.12.3013-3017.1994; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; BIRKHEAD GS, 1993, J INFECT DIS, V167, P1228, DOI 10.1093/infdis/167.5.1228; *CDCP, 1995, SALM SURV REP 1993 1; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P4; *CDCP, 1975, MMWR-MORBID MORTAL W, V24, P87; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P975; CHALKER RB, 1988, REV INFECT DIS, V10, P111; Dean A.G., 1994, EPI INFO VERSION 6 W; DUNCAN TG, 1946, AM J PUBLIC HEALTH, V36, P34, DOI 10.2105/AJPH.36.1.34; EISENSTEIN AB, 1963, JAMA-J AM MED ASSOC, V185, P171, DOI 10.1001/jama.1963.03060030029020; Ewing W.H., 1986, EDWARDS EWINGS IDENT; *FL DEP CITR, 1996, STAD PROC CITR PROD; HEDBERG CW, 1996, AM J MED SCI, V311, P23; MALLINSON ET, 1989, AVIAN DIS, V33, P684, DOI 10.2307/1591145; MARTIN D, 1991, EPIDEMIOLOGY, V2, P359, DOI 10.1097/00001648-199109000-00008; MILLARD PS, 1994, JAMA-J AM MED ASSOC, V272, P1592, DOI 10.1001/jama.272.20.1592; Mitscherlich E., 1984, MICROBIAL SURVIVAL E; *NAT COMM CLIN LAB, 1995, PERF STAND ANT DISK; Parish ME, 1998, J FOOD PROTECT, V61, P280, DOI 10.4315/0362-028X-61.3.280; Parish ME, 1997, J FOOD SAFETY, V17, P273, DOI 10.1111/j.1745-4565.1997.tb00194.x; PAVIA AT, 1991, BACTERIAL INFECT HUM, P573; PUTNAM JJ, 1997, FOOD CONSUMPTION PRI; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; SCHMELZER LL, 1967, ARCH ENVIRON HEALTH, V15, P78, DOI 10.1080/00039896.1967.10664879; SINGH BR, 1996, J FOOD SCI TECHNOL I, V32, P504; STEELE BT, 1982, J PEDIATR-US, V101, P963, DOI 10.1016/S0022-3476(82)80021-8; Stephenson J, 1997, JAMA-J AM MED ASSOC, V277, P97, DOI 10.1001/jama.277.2.97; TABERSHAW IR, 1967, ARCH ENVIRON HEALTH, V15, P72, DOI 10.1080/00039896.1967.10664878; U. S. Environmental Protection Agency (USEPA) U. S. Department of Agriculture Department of Health and Human Services, 1997, FOOD SAF FARM TABL N; *US FDA, 1997, FOOD COD 1997 REC US; WELLS JG, 1997, 97 GEN M AM SOC MICR; WILLIAMS R, 1998, FED REGISTER, V63, P24253; 1988, FED REG, V63, P20449	38	116	121	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1504	1509		10.1001/jama.280.17.1504	http://dx.doi.org/10.1001/jama.280.17.1504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809731				2022-12-28	WOS:000076757200024
J	Kiomento, H				Kiomento, H			The intervention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1477	1477		10.1001/jama.280.17.1477	http://dx.doi.org/10.1001/jama.280.17.1477			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809719				2022-12-28	WOS:000076757200007
J	Lou, HC				Lou, HC			Autoregulation of cerebral blood flow and brain lesions in newborn infants	LANCET			English	Editorial Material							INTRAVENTRICULAR HEMORRHAGE; PRETERM INFANTS; AUTO-REGULATION		John F Kennedy Inst, Dept Dev Neurol, DK-2600 Glostrup, Denmark		Lou, HC (corresponding author), John F Kennedy Inst, Dept Dev Neurol, DK-2600 Glostrup, Denmark.							ALS H, 1994, JAMA-J AM MED ASSOC, V272, P853, DOI 10.1001/jama.272.11.853; COURVILLE CB, 1959, J NEUROPATH EXP NEUR, V18, P115, DOI 10.1097/00005072-195901000-00008; DEREUCK J, 1972, ARCH NEUROL-CHICAGO, V27, P229, DOI 10.1001/archneur.1972.00490150037007; FUNATO M, 1992, J PEDIATR-US, V121, P614, DOI 10.1016/S0022-3476(05)81157-6; GUZETTA F, 1986, PEDIATRICS, V78, P995; HAMBLETON G, 1976, ARCH DIS CHILD, V51, P651, DOI 10.1136/adc.51.9.651; LOU HC, 1977, ACTA NEUROL SCAND, V56, P34; MILLIGAN DWA, 1980, LANCET, V1, P896; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PRYDS O, 1989, J PEDIATR-US, V115, P638, DOI 10.1016/S0022-3476(89)80301-4; SKOV L, 1990, Ugeskrift for Laeger, V152, P1646; TSZYCZUK L, 1998, PEDITRICS, V102, P337; TWEED WA, 1983, PEDIATR RES, V17, P246, DOI 10.1203/00006450-198304000-00002; TWEED WA, 1986, PEDIATR RES, V6, P516; Volpe JJ, 1998, ARCH NEUROL-CHICAGO, V55, P297, DOI 10.1001/archneur.55.3.297	15	9	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1406	1406		10.1016/S0140-6736(05)61260-3	http://dx.doi.org/10.1016/S0140-6736(05)61260-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9807985				2022-12-28	WOS:000076719500005
J	Kurada, P; White, K				Kurada, P; White, K			Ras promotes cell survival in Drosophila by downregulating hid expression	CELL			English	Article							PROTEIN TYROSINE KINASE; CENTRAL-NERVOUS-SYSTEM; EGF RECEPTOR; FATE DETERMINATION; SIGNALING PATHWAY; ACTS DOWNSTREAM; DEATH; GENE; APOPTOSIS; MIDLINE		Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	White, K (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.	kwhite@cbrc.mgh.harvard.edu	White, Kristin/D-7936-2013		NIGMS NIH HHS [GM55568, R01 GM055568] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055568] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard JD, 1996, DEVELOPMENT, V122, P1137; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CAMPOS AR, 1992, DEVELOPMENT, V114, P355; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; CLIFFORD RJ, 1989, GENETICS, V123, P771; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; Dong R, 1997, DEV BIOL, V190, P165, DOI 10.1006/dbio.1997.8688; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; GEYER PK, 1993, GENETICS, V133, P265; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; Karim FD, 1998, DEVELOPMENT, V125, P1; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; Miller DT, 1998, DEVELOPMENT, V125, P2327; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PERRIMON N, 1984, GENETICS, V108, P559; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Sawamoto K, 1998, CELL DEATH DIFFER, V5, P262, DOI 10.1038/sj.cdd.4400342; Scholz H, 1997, MECH DEVELOP, V64, P137; Sieff C A, 1994, Curr Opin Hematol, V1, P310; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Stemerdink C, 1997, DEVELOPMENT, V124, P3787; Tio M, 1997, DEVELOPMENT, V124, P343; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131	51	321	320	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1998	95	3					319	329		10.1016/S0092-8674(00)81764-X	http://dx.doi.org/10.1016/S0092-8674(00)81764-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814703	Bronze			2022-12-28	WOS:000076789600006
J	Nathan, DG				Nathan, DG		Natl Inst Hlth Directors Panel Clinical Res	Clinical research - Perceptions, reality, and proposed solutions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INVESTIGATOR; SCIENTIST	Context.-The proportion of investigators applying for clinical research grants from the National Institutes of Health (NIH) who are physicians has declined from 40% 30 years ago to 25% today. Objective.-To recommend NIH policy changes that might encourage physician investigators to undertake careers in clinical research, eg, patient-oriented research, epidemiologic and behavioral studies, outcomes research, and health services research. Participants.-The NIH Director's Panel on Clinical Research comprised 14 physicians from academia and industry, chosen by the director. They met in numerous closed sessions and in 5 public meetings from July 1995 to November 1997. Consensus Process.-In addition to expert opinion and pertinent literature, data sources included the training characteristics of applicants to NIH who were funded or not. Topics considered included financing of clinical research, recruitment, training, and retention of future clinical investigators, conduct of clinical trials, and peer review of clinical research, Consensus was reached and recommendations were made in response to an interim report, widely circulated to the biomedical community, written by members of the panel, which contained preliminary recommendations. Conclusions.-The panel's final recommendations to NIH included maintaining at least the present proportion of NIH funding for clinical research; continuing mentored opportunities in clinical research for medical students; promoting clinical research training by offering didactic courses and grant opportunities in clinical research to nascent investigators emerging from specialty training programs and providing partial salary supper: for mentors; restructuring study sections that review patient-oriented research applications to include more physicians; encouraging clinical investigators and basic scientists to work closely together and weld collaborations between academic clinical investigators and colleagues in pharmaceutical and biotechnology companies; and developing a joint policy between academic health centers and NIH for the support of clinical research and clinical research training.	Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute	Nathan, DG (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA 39542-10, 5 P30 CA 06516-33] Funding Source: Medline; NHLBI NIH HHS [1 P50 HL 54785-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA039542, P30CA006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahrens E.H., 1992, CRISIS CLIN RES OVER; Blumenthal D, 1996, HEALTH AFFAIR, V15, P200, DOI 10.1377/hlthaff.15.2.200; CULLITON BJ, 1995, NAT MED, V1, P281, DOI 10.1038/nm0495-281; EVANS RM, 1993, ED PHYSICIAN SCHOLAR; GILL GN, 1984, AM SCHOLAR, V53, P353; GOLDSTEIN JL, 1986, J CLIN INVEST, V78, P848, DOI 10.1172/JCI112652; Goldstein JL, 1997, J CLIN INVEST, V99, P2803, DOI 10.1172/JCI119470; Iglehart JK, 1997, NEW ENGL J MED, V336, P1827, DOI 10.1056/NEJM199706193362512; Moy E, 1997, JAMA-J AM MED ASSOC, V278, P217, DOI 10.1001/jama.278.3.217; *NIH, 1996, M ADV COMM NIH DIR A; Schrier RW, 1997, ACAD MED, V72, P589, DOI 10.1097/00001888-199707000-00010; Shine KI, 1997, JAMA-J AM MED ASSOC, V278, P245, DOI 10.1001/jama.278.3.245; Shulman LE, 1996, ACAD MED, V71, P362, DOI 10.1097/00001888-199604000-00013; Thompson JN, 1997, JAMA-J AM MED ASSOC, V278, P241, DOI 10.1001/jama.278.3.241; Williams GH, 1997, JAMA-J AM MED ASSOC, V278, P227, DOI 10.1001/jama.278.3.227; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303; [No title captured]	17	182	185	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	1998	280	16					1427	1431		10.1001/jama.280.16.1427	http://dx.doi.org/10.1001/jama.280.16.1427			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130YA	9801003				2022-12-28	WOS:000076546900038
J	Foulkes, WD				Foulkes, WD			BRCA1 and BRCA2: penetrating the clinical arena	LANCET			English	Editorial Material							OVARIAN-CANCER; BREAST; MUTATIONS; CARRIERS; RISK		McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3G 1A4, Canada	McGill University; McGill University	Foulkes, WD (corresponding author), McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada.		Foulkes, William D./AAR-9586-2021	Foulkes, William D./0000-0001-7427-4651				Ansquer Y, 1998, LANCET, V352, P541, DOI 10.1016/S0140-6736(05)79248-5; EASTON DF, 1995, AM J HUM GENET, V56, P265; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Foulkes WD, 1997, CLIN CANCER RES, V3, P2465; Malone KE, 1996, CANCER, V78, P1417, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1417::AID-CNCR7>3.3.CO;2-Q; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; PAGE DL, 1994, CANCER EPIDEM BIOMAR, V3, P101; Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309; Redston M, 1998, NAT GENET, V20, P13, DOI 10.1038/1666; Schubert EK, 1997, AM J HUM GENET, V60, P1031; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Thorlacius S, 1997, AM J HUM GENET, V60, P1079; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	13	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	1998	352	9137					1325	1326		10.1016/S0140-6736(05)60738-6	http://dx.doi.org/10.1016/S0140-6736(05)60738-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802263				2022-12-28	WOS:000076691700003
J	Beecham, L				Beecham, L			JCC is concerned about clinical academic medicine	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1531	1531						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831603				2022-12-28	WOS:000077338300082
J	Jonsson, JS; Gislason, T; Gislason, D; Sigurdsson, JA				Jonsson, JS; Gislason, T; Gislason, D; Sigurdsson, JA			Acute bronchitis and clinical outcome three years later: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							ANTIBIOTICS; ETIOLOGY		Gardabaer Hlth Ctr, IS-210 Gardabaer, Iceland; Vifilsstadir, Dept Pulm, IS-210 Gardabaer, Iceland; Solvangur Hlth Ctr, Dept Family Med, IS-220 Hafnarfjordur, Iceland		Jonsson, JS (corresponding author), Gardabaer Hlth Ctr, Gardatorg 7, IS-210 Gardabaer, Iceland.			Sigurdsson, Johann Agust/0000-0002-5646-6411				Gislason T, 1997, Laeknabladid, V83, P211; GONZALES R, 1995, LANCET, V345, P665, DOI 10.1016/S0140-6736(95)90861-7; Jonsson JS, 1997, SCAND J PRIM HEALTH, V15, P156, DOI 10.3109/02813439709018507; ORR PH, 1993, J FAM PRACTICE, V36, P507; VERHEIJ TJM, 1989, FAM PRACT, V6, P66, DOI 10.1093/fampra/6.1.66	5	18	19	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1433	1433		10.1136/bmj.317.7170.1433	http://dx.doi.org/10.1136/bmj.317.7170.1433			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822398	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000077202200025
J	Oliver, M				Oliver, M			Theories in health care and research - Theories of disability in health practice and research	BRITISH MEDICAL JOURNAL			English	Article							INDEPENDENT RESEARCHER; MYTH		Univ Greenwich, London SE9 2UG, England	University of Greenwich	Oliver, M (corresponding author), Univ Greenwich, London SE9 2UG, England.	MJOliver@gre.ac.uk						ABBERLEY P, 1996, INTERPRETING OFFICIA, P166; Abberley Paul, 1987, DISABIL SOC, V2, P5, DOI DOI 10.1080/02674648766780021; Albrecht Gary, 1992, DISABILITY BUSINESS; ALDERSONP, 1998, BMJ, V316; Barnes C, 1996, DISABIL SOC, V11, P107, DOI 10.1080/09687599650023362; Barnes C., 1997, DOING DISABILITY RES; Barnes C, 1991, DISABLED PEOPLE BRIT; BEGUM N, 1995, CRITICAL PUBLIC HLTH, V6, P30; Bury M, 1996, DISABIL SOC, V11, P111; Bury M., 1996, EXPLORING DIVIDE ILL, P17; Campbell, 1996, DISABILITY POLITICS; Chappel A, 1992, DISABILITY HANDICAP, V7, P1; MARTIN J, 1988, 1 OPCS; OLIVER M, 1996, DISABILITY SOC EMERG, P18; Oliver M., 1996, EXPLORING DIVIDE ILL, P39; Oliver M., 1996, UNDERSTANDING DISABI, DOI 10.1007/978-1-349-24269-6; Oliver Michael, 1997, DOING DISABILITY RES, P15; Oliver Michael, 1990, POLITICS DISABLEMENT; Oliver Michael, 1992, DISABILITY HANDICAP, V7, P101, DOI DOI 10.1080/02674649266780141; Parsons T., 1951, SOCIAL SYSTEM; PECKHAM M, 1995, CONSUMERS RES NHS; SCOTT RA, 1969, MAKING BLIND MEN STU; SHAKESPEARE T, 1996, DISABIL SOC, V11, P114; Shakespeare T., 1995, CRITICAL PUBLIC HLTH, V6, P4, DOI 10.1080/09581599508409047; Sutherland A., 1981, DISABLED WE STAND; Tennant A, 1997, DISABIL REHABIL, V19, P478, DOI 10.3109/09638289709166842; WATSON N, 1995, CRITICAL PUBLIC HLTH, V6, P38; Wood P., 1980, INT CLASSIFICATION I; Zarb G., 1997, DOING DISABILITY RES, P49	29	80	82	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1446	1449		10.1136/bmj.317.7170.1446	http://dx.doi.org/10.1136/bmj.317.7170.1446			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	142LP	9822407	Green Published			2022-12-28	WOS:000077202200031
J	Dudd, SN; Evershed, RP				Dudd, SN; Evershed, RP			Direct demonstration of milk as an element of archaeological economies	SCIENCE			English	Article							CHROMATOGRAPHY MASS-SPECTROMETRY; GAS-CHROMATOGRAPHY; ORGANIC RESIDUES; RATIO; ORIGIN	The stable carbon isotope (delta(13)C) compositions of individual fatty acid components of remnant fats preserved in archaeological pottery vessels show that dairying was a component of archaeological economies. Characteristic delta(13)C values arise from biases in the biosynthetic origins of the C-18:0 fatty acids in milk and adipose fat. Milk and adipose fat from animals raised on similar pastures and fodders have distinct isotopic signatures.	Univ Bristol, Sch Chem, Organ Geochem Unit, Bristol BS8 1TS, Avon, England	University of Bristol	Evershed, RP (corresponding author), Univ Bristol, Sch Chem, Organ Geochem Unit, Bristol BS8 1TS, Avon, England.	r.p.evershed@bristol.ac.uk						BALLS AK, 1937, J BIOL CHEM, V121, P125; Barker G., 1981, LANDSCAPE SOC PREHIS; CHARTERS S, 1993, ARCHAEOMETRY, V35, P211, DOI 10.1111/j.1475-4754.1993.tb01036.x; CHRISTIE WW, 1981, LIPID METABOLISM RUM, P203; CRABTREE P, 1987, EXPEDITION, V28, P59; Deines P, 1980, HDB ENV ISOTOPE GEOC, DOI DOI 10.1016/B978-0-444-41780-0.50015-8; EVERSHED R. P., 1992, P BRIT ACAD, V77, P187; Evershed RP, 1997, NATURWISSENSCHAFTEN, V84, P402, DOI 10.1007/s001140050417; EVERSHED RP, 1995, TETRAHEDRON LETT, V36, P8875, DOI 10.1016/0040-4039(95)01844-8; EVERSHED RP, 1994, ANALYST, V119, P909, DOI 10.1039/an9941900909; EVERSHED RP, 1990, ANALYST, V115, P1339, DOI 10.1039/an9901501339; FRIEDLI H, 1986, NATURE, V324, P237, DOI 10.1038/324237a0; Gouin P., 1990, PALEORIENT, V16, P37, DOI [10.3406/paleo.1990.4531, DOI 10.3406/PALEO.1990.4531]; GUNSTONE FD, 1986, LIPID HDB, P353; HASDORF CA, 1985, NATURE, V315, P489; HERON C, 1993, ARCHAEOLOGICAL METHO, V5, P242; Jones R.E., 1986, 1 BRIT SCH ATH FITCH; LEGGE AJ, 1981, FARMING PRACTICE BRI; McDonald P, 1988, ANIMAL NUTR; PODOLAK J, 1984, ETHNOL SLAV, V16, P49; ROTTLANDER RCA, 1990, ARCHAEO PHYSIKA, V12, P1; Sherratt A. G., 1981, PATTERN OF THE PAST, P261; SHERRIFF BL, 1995, ARCHAEOMETRY, V37, P95; SIMOONS FJ, 1979, ANTHROPOS, V74, P61; WOODBURY SE, 1995, ANAL CHEM, V67, P2685, DOI 10.1021/ac00111a029; [No title captured]	26	209	211	2	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1478	1481		10.1126/science.282.5393.1478	http://dx.doi.org/10.1126/science.282.5393.1478			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	140WA	9822376				2022-12-28	WOS:000077110800051
J	Saal, AE; Hart, SR; Shimizu, N; Hauri, EH; Layne, GD				Saal, AE; Hart, SR; Shimizu, N; Hauri, EH; Layne, GD			Pb isotopic variability in melt inclusions from oceanic island basalts, Polynesia	SCIENCE			English	Article							SOUTH-PACIFIC OCEAN; MANTLE PLUMES; GEOCHEMISTRY; HIMU; METASOMATISM; SYSTEMATICS; OLIVINE; HOTSPOT; ELEMENT; ROCKS	Previous studies have suggested that melting processes are responsible for the trace element variability observed in olivine-hosted basaltic melt inclusions. Melt inclusions from three individual lava samples (two from Mangaia, Cook Islands, and one from Tahaa, Society Islands) have heterogeneous Pb isotopic compositions, even though the erupted Lavas are isotopically homogeneous, The range of Pb isotopic compositions from individual melt inclusions spans 50 percent of the worldwide range observed for ocean island basalts, The melt inclusion data can be explained by two-component mixing for each island. Our data imply that magmas with different isotopic compositions existed in the volcanic plumbing system before or during melt aggregation.	Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA; Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA	Woods Hole Oceanographic Institution; Carnegie Institution for Science	Saal, AE (corresponding author), Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA.		Facility, NENIMF/B-8811-2015					Chauvel C, 1997, CHEM GEOL, V139, P125, DOI 10.1016/S0009-2541(97)00029-6; CHAUVEL C, 1992, EARTH PLANET SC LETT, V110, P99, DOI 10.1016/0012-821X(92)90042-T; DUPUY C, 1992, GEOCHIM COSMOCHIM AC, V56, P2417, DOI 10.1016/0016-7037(92)90198-R; Eiler JM, 1997, GEOCHIM COSMOCHIM AC, V61, P2281, DOI 10.1016/S0016-7037(97)00075-6; GOLDSCHMIDT VM, 1996, VM GOLDSCHM C 1996 H; GURENKO AA, 1995, GEOCHIM COSMOCHIM AC, V59, P2905, DOI 10.1016/0016-7037(95)00184-0; HANNAN BB, 1996, SCIENCE, V272, P991; HART SR, 1992, SCIENCE, V256, P517, DOI 10.1126/science.256.5056.517; Hauri E. H., 1996, J CONF ABSTR, V1, P241; Hauri EH, 1997, CHEM GEOL, V139, P185, DOI 10.1016/S0009-2541(97)00035-1; HAURI EH, 1993, EARTH PLANET SC LETT, V114, P353, DOI 10.1016/0012-821X(93)90036-9; HAURI EH, 1993, NATURE, V365, P221, DOI 10.1038/365221a0; HEMOND C, 1994, CHEM GEOL, V115, P7, DOI 10.1016/0009-2541(94)90143-0; Ionov DA, 1996, CONTRIB MINERAL PETR, V125, P375, DOI 10.1007/s004100050229; Kamenetsky V, 1996, EARTH PLANET SC LETT, V142, P553, DOI 10.1016/0012-821X(96)00115-X; KOGARKO LN, 1995, CONTRIB MINERAL PETR, V121, P267, DOI 10.1007/BF02688242; Lee WJ, 1998, J PETROL, V39, P495, DOI 10.1093/petrology/39.3.495; NAKAMURA Y, 1988, GEOCHIM COSMOCHIM AC, V52, P2909, DOI 10.1016/0016-7037(88)90157-3; SHIMIZU N, 1982, ANNU REV EARTH PL SC, V10, P483, DOI 10.1146/annurev.ea.10.050182.002411; SOBOLEV AV, 1993, NATURE, V363, P151, DOI 10.1038/363151a0; Sun S.S., 1989, GEOL SOC SPECIAL PUB, V42, P313; Woodhead JD, 1996, J VOLCANOL GEOTH RES, V72, P1, DOI 10.1016/0377-0273(96)00002-9; ZINDLER A, 1986, ANNU REV EARTH PL SC, V14, P493, DOI 10.1146/annurev.ea.14.050186.002425	23	176	186	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1481	1484		10.1126/science.282.5393.1481	http://dx.doi.org/10.1126/science.282.5393.1481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822377				2022-12-28	WOS:000077110800052
J	Bader, BL; Rayburn, H; Crowley, D; Hynes, RO				Bader, BL; Rayburn, H; Crowley, D; Hynes, RO			Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins	CELL			English	Article							ENDOTHELIAL GROWTH-FACTOR; CELL-ADHESION; HUMAN CYTOTROPHOBLASTS; ENDOVASCULAR INVASION; VASCULAR DEVELOPMENT; MESODERMAL DEFECTS; TARGETED MUTATIONS; DEFICIENT MICE; BLOOD-VESSELS; ALPHA(V)BETA(3)	alpha v integrins have been implicated in many developmental processes and are therapeutic targets for inhibition of angiogenesis and osteoporosis. Surprisingly, ablation of the gene for the alpha v integrin subunit, eliminating all five alpha v integrins, although causing lethality, allows considerable development and organogenesis including, most notably, extensive vasculogenesis and angiogenesis. Eighty percent of embryos die in midgestation, probably because of placental defects, but all embryos develop normally to E9.5, and 20% are born alive. These liveborn alpha v-null mice consistently exhibit intracerebral and intestinal hemorrhages and cleft palates. These results necessitate reevaluation of the primacy of alpha v integrins in many functions including vascular development, despite reports that blockade of these integrins with antibodies or peptides prevents angiogenesis.	MIT, Howard Hughes Med Inst, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Hynes, RO (corresponding author), MIT, Howard Hughes Med Inst, Ctr Canc Res, Cambridge, MA 02139 USA.	rohynes@mit.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALFANDARI D, 1995, DEV BIOL, V170, P249, DOI 10.1006/dbio.1995.1212; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Breier G, 1996, TRENDS CELL BIOL, V6, P454, DOI 10.1016/0962-8924(96)84935-X; BREUSS JM, 1995, J CELL SCI, V108, P2241; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DAMSKY C, 1993, FASEB J, V7, P1320, DOI 10.1096/fasebj.7.14.8224605; DAMSKY CH, 1994, DEVELOPMENT, V120, P3657; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; DELANNET M, 1994, DEVELOPMENT, V120, P2687; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; FERGUSON MWJ, 1988, DEVELOPMENT, V103, P41; FISHER SJ, 1989, J CELL BIOL, V109, P891, DOI 10.1083/jcb.109.2.891; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; George EL, 1997, BLOOD, V90, P3073, DOI 10.1182/blood.V90.8.3073; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GeorgesLabouesse EN, 1996, DEV DYNAM, V207, P145, DOI 10.1002/(SICI)1097-0177(199610)207:2<145::AID-AJA3>3.0.CO;2-H; Gerber DJ, 1996, P NATL ACAD SCI USA, V93, P14698, DOI 10.1073/pnas.93.25.14698; Goh KL, 1997, DEVELOPMENT, V124, P4309; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HIRSCH E, 1994, DEV DYNAM, V201, P108, DOI 10.1002/aja.1002010203; HodivalaDilke KM, 1997, BLOOD, V90, P2550; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Hynes RO, 1997, THROMB HAEMOSTASIS, V78, P83; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MARINPADILLA M, 1985, J COMP NEUROL, V241, P237, DOI 10.1002/cne.902410210; Martin PT, 1997, DEVELOPMENT, V124, P3909; MCDONALD KA, 1995, J CELL SCI, V108, P2573; MILNER R, 1994, DEVELOPMENT, V120, P3497; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; VAANANEN HK, 1995, J CELL SCI, V108, P2729; Varner JA, 1995, CELL ADHES COMMUN, V3, P367, DOI 10.3109/15419069509081020; VENSTROM K, 1995, MOL BIOL CELL, V6, P419, DOI 10.1091/mbc.6.4.419; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamada S, 1995, CELL ADHES COMMUN, V3, P311, DOI 10.3109/15419069509081016; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; YANG JT, 1995, DEVELOPMENT, V121, P549; YANG JT, 1993, DEVELOPMENT, V119, P1093; Yang JT, 1996, MOL BIOL CELL, V7, P1737, DOI 10.1091/mbc.7.11.1737; Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387; Zhou Y, 1997, J CLIN INVEST, V99, P2152, DOI 10.1172/JCI119388	61	510	535	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1998	95	4					507	519		10.1016/S0092-8674(00)81618-9	http://dx.doi.org/10.1016/S0092-8674(00)81618-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827803	Bronze			2022-12-28	WOS:000077049400009
J	Joseph, KS; Kramer, MS; Marcoux, S; Ohlsson, A; Wen, SW; Allen, A; Platt, R				Joseph, KS; Kramer, MS; Marcoux, S; Ohlsson, A; Wen, SW; Allen, A; Platt, R			Determinants of preterm birth rates in Canada from 1981 through 1983 and from 1992 through 1994	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFANT-MORTALITY; GESTATIONAL-AGE; RECENT TRENDS; EPIDEMIOLOGY; PREMATURITY; FRANCE	Background The rates of preterm birth have increased in many countries, including Canada, over the past 20 years. However, the factors underlying the increase are poorly understood. Methods We used data from the Statistics Canada live-birth and stillbirth data bases to determine the effects of changes in the frequency of multiple births, registration of births occurring very early in gestation, patterns of obstetrical intervention, and use of ultrasonographic dating of gestational age on the rates of preterm birth in Canada from 1981 through 1983 and from 1992 through 1994, All births in 9 of the 12 provinces and territories of Canada were included. Logistic-regression analysis and Poisson regression analysis were used to estimate changes between the two three-year periods, after adjustment for the above-mentioned determinants of the likelihood of preterm births. Results Preterm births increased from 6.3 percent of live births in 1981 through 1983 to 6.8 percent in 1992 through 1994, a relative increase of 9 percent (95 percent confidence interval, 7 to 10 percent). Among singleton births, preterm births increased by 5 percent (95 percent confidence interval, 3 to 6 percent). Multiple births increased from 1.9 percent to 2.1 percent of all live births; the rates of preterm birth among live births resulting from multiple gestation increased by 25 percent (95 percent confidence interval, 21 to 28 percent). Adjustment for the determinants of the likelihood of preterm birth reduced the increase in the rate of preterm birth to 3 percent among all live births and 1 percent among singleton births. Conclusions The recent increase in preterm births in Canada is largely attributable to changes in the frequency of multiple births, obstetrical intervention, and the use of ultrasound-based estimates of gestational age. (N Engl J Med 1998;339:1434-9.) (C) 1998, Massachusetts Medical Society.	Lab Ctr Dis Control, Bur Reprod & Child Hlth, Ottawa, ON K1A OL2, Canada; McGill Univ, Fac Med, Dept Pediat, Montreal, PQ, Canada; McGill Univ, Fac Med, Dept Epidemiol & Biostat, Montreal, PQ, Canada; Univ Laval, Epidemiol Res Grp, Quebec City, PQ, Canada; Womens Coll Hosp, Dept Newborn & Dev Paediat, Toronto, ON M5S 1B2, Canada; Dalhousie Univ, Div Neonatol Perinatal Med, Halifax, NS, Canada	McGill University; McGill University; Laval University; University of Toronto; University Toronto Affiliates; Womens College Hospital; Dalhousie University	Joseph, KS (corresponding author), Lab Ctr Dis Control, Bur Reprod & Child Hlth, Tunneys Pasture AL 060 1E2, Ottawa, ON K1A OL2, Canada.			Platt, Robert/0000-0002-5981-8443; Joseph, K.S./0000-0003-2317-5607				Armitage G, 1994, STAT METHODS MED RES, P93; BERKOWITZ GS, 1993, EPIDEMIOL REV, V15, P414, DOI 10.1093/oxfordjournals.epirev.a036128; BREART G, 1995, PAEDIATR PERINAT EP, V9, P296, DOI 10.1111/j.1365-3016.1995.tb00146.x; CREASY RK, 1990, OBSTET GYNECOL, V76, pS2; Dunn A, 1996, ARCH DIS CHILD-FETAL, V75, pF10, DOI 10.1136/fn.75.1.F10; Fair M, 1993, Health Rep, V5, P281; GOLDENBERG RL, 1989, AM J OBSTET GYNECOL, V160, P462, DOI 10.1016/0002-9378(89)90473-0; *HLTH DIV, 1983, VIT STAT BIRTHS DEAT, V1; *HLTH STAT DIV, 1995, BIRTHS 1992; HOSMER DW, 1989, APPL LOGISTIC REGRES, P131; HOWELL EM, 1994, AM J PUBLIC HEALTH, V845, P8507; Joseph KS, 1997, CAN MED ASSOC J, V157, P535; JOSEPH KS, 1997, CAN MED ASSOC J, V157, P646; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; Millar W J, 1992, Health Rep, V4, P223; MORRISON JC, 1990, OBSTET GYNECOL, V76, pS5; OLSEN P, 1995, AM J EPIDEMIOL, V142, P1184, DOI 10.1093/oxfordjournals.aje.a117577; PAPIERNIK E, 1985, PEDIATRICS, V76, P154; SACHS BP, 1995, OBSTET GYNECOL, V85, P941, DOI 10.1016/0029-7844(95)00056-W; SEPKOWITZ S, 1995, INT J EPIDEMIOL, V24, P583, DOI 10.1093/ije/24.3.583; VENTURA SJ, 1997, MON VITAL STAT REP S, V45; Welsch R, 1980, REGRESSION DIAGNOSTI; ZETTERSTROM R, 1984, ARCH FR PEDIATR, V41, P301; 1994, MMWR MORB MORTAL WKL, V43, P335; 1997, MMWR MORB MORTAL WKL, V46, P121	25	246	249	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1998	339	20					1434	1439		10.1056/NEJM199811123392004	http://dx.doi.org/10.1056/NEJM199811123392004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VR	9811918				2022-12-28	WOS:000077051700004
J	Bensoussan, A; Talley, NJ; Hing, M; Menzies, R; Guo, A; Ngu, M				Bensoussan, A; Talley, NJ; Hing, M; Menzies, R; Guo, A; Ngu, M			Treatment of irritable bowel syndrome with Chinese herbal medicine - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYMPTOMS; CREDIBILITY; CRITIQUE	Context.-Irritable bowel syndrome (IBS) is a common functional bowel disorder for which there is no reliable medical treatment. Objective.-To determine whether Chinese herbal medicine (CHM) is of any benefit in the treatment of IBS, Design.-Randomized, double-blind, placebo-controlled trial conducted during 1996 through 1997, Setting.-Patients were recruited through 2 teaching hospitals and 5 private practices of gastroenterologists, and received CHM in 3 Chinese herbal clinics. Patients.-A total of 116 patients who fulfilled the Rome criteria, an established standard for diagnosis of IBS. Intervention.-Patients were randomly allocated to 1 of 3 treatment groups: individualized Chinese herbal formulations (n = 38), a standard Chinese herbal formulation (n = 43), or placebo (n = 35). Patients received 5 capsules 3 times daily for 16 weeks and were evaluated regularly by a traditional Chinese herbalist and by a gastroenterologist. Patients, gastroenterologists, and herbalists were all blinded to treatment group. Main Outcome Measures.-Change in total bowel symptom scale scores and global improvement assessed by patients and gastroenterologists and change in the degree of interference in life caused by IBS symptoms assessed by patients. Results.-Compared with patients in the placebo group, patients in the active treatment groups (standard and individualized CHM) had significant improvement in bowel symptom scores as rated by patients (P = .03) and by gastroenterologists (P = .001), and significant global improvement as rated by patients (P = .007) and by gastroenterologists (P = .002), Patients reported that treatment significantly reduced the degree of interference with life caused by IBS symptoms (P = .03), Chinese herbal formulations individually tailored to the patient proved no more effective than standard CHM treatment. On follow-up 14 weeks after completion of treatment, only the individualized CHM treatment group maintained improvement. Conclusion.-Chinese herbal formulations appear to offer improvement in symptoms for some patients with IBS.	Univ Western Sydney Macarthur, Fac Hlth, Res Unit Complementary Med, Campbelltown, NSW 2560, Australia; Univ Sydney, Dept Behav Sci, Sydney, NSW 2006, Australia; Nepean Hosp, Dept Med, Sydney, NSW, Australia; Bondi Junct Endoscopy Ctr, Sydney, NSW, Australia; Balmain Chinese Herbal Ctr, Sydney, NSW, Australia; Concord Repatriat Gen Hosp, Gastroenterol Unit, Sydney, NSW, Australia	Western Sydney University; University of Sydney; Nepean Hospital; Concord Repatriation General Hospital	Bensoussan, A (corresponding author), Univ Western Sydney Macarthur, Fac Hlth, Res Unit Complementary Med, POB 555, Campbelltown, NSW 2560, Australia.		Talley, Nicholas J/D-5399-2013	Talley, Nicholas J/0000-0003-2537-3092; Menzies, Ross/0000-0002-7589-960X; Bensoussan, Alan/0000-0002-7433-667X				[Anonymous], 1992, GASTROENTEROL INT; ANTHONY HM, 1998, CLIN RES METHODOLOGY, P108; BENSOUSSAN A, 1993, AM J ACUPUNCT, V19, P357; Bensoussan A, 1996, SAFER CHOICE PRACTIC; BORKOVEC TD, 1972, J BEHAV THER EXP PSY, V3, P257, DOI 10.1016/0005-7916(72)90045-6; CHEN DZ, 1995, NANJING MED U J, V15, P924; DROSSMAN DA, 1993, DIGEST DIS SCI, V38, P1569, DOI 10.1007/BF01303162; HEATON KW, 1992, GASTROENTEROLOGY, V102, P1962, DOI 10.1016/0016-5085(92)90320-X; Hsu H-Y, 1986, 1986 ORIENTAL MATERI; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; KANE JA, 1995, GUT, V36, P146, DOI 10.1136/gut.36.1.146; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; LIU ZK, 1990, CHIN J INTEGRATED TR, V10, P615; PETRIE J, 1985, CLIN EXP RHEUMATOL, V3, P151; SHI ZQ, 1989, CHIN J INTEGRATED TR, V9, P241; Talley N, 1993, GASTROENTEROL INT, V6, P189; TALLEY NJ, 1995, AUST NZ J MED, V25, P302, DOI 10.1111/j.1445-5994.1995.tb01894.x; Talley NJ, 1996, AM J GASTROENTEROL, V91, P277; TALLEY NJ, 1991, GASTROENTEROLOGY, V101, P927, DOI 10.1016/0016-5085(91)90717-Y; Vincent C, 1990, COMPLEMENT MED RES, V4, P8; XU RL, 1995, SHANXI J TRADIT CHIN, V11, P10; YU ZX, 1991, CHIN J INTEGRATED TR, V11, P170	22	278	298	2	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1585	1589		10.1001/jama.280.18.1585	http://dx.doi.org/10.1001/jama.280.18.1585			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820260	Bronze			2022-12-28	WOS:000076852000025
J	Kappos, L; Polman, C; Pozzilli, C; Thompson, A; Dahlke, F; Knight, R; Hern, J; Coleman, R; Gerrie, L; Cooper, G; Moore, J; Boringa, J; van Oosten, B; Ronner, H; Schrijver, H; Truyen, L; Montalban, J; Rio, J; Tintore, M; Jacas, C; Marzo, E; Lechner-Scott, J; Huber, S; Lienert, C; Brunnschweiler, H; Hawkins, S; Droogan, A; McDonnell, G; Duddy, M; McKinstry, S; Altenkirch, H; Baum, K; Einhaupl, K; Marx, P; Poewe, W; Walter, G; Akman, H; Brockmeier, B; Scherer, P; Zschenderlein, R; Schmierer, K; Gelderblom, H; Hartmann, A; Stapf, C; Luschow, A; Mackert, B; Schumacher, H; Masuhr, F; Hempel, T; Zimmermann, R; Munch, M; Francis, D; Heafield, M; Al-Memar, A; Winer, J; Chong, M; Brochet, B; Gayou, A; Auriacombe, S; Dousset, V; Wiles, C; Thomas, F; Pickersgill, T; Hinds, N; Dawson, K; Hughes, T; Hutchinson, M; Murphy, R; Redmond, J; Webb, S; Stoll, G; Jander, S; Hagemann, G; Koller, H; Hanemann, C; Kolmel, H; Reichel, D; Petereit, K; Thieme, A; Khatami, A; Neumann, M; Amaducci, L; Massacesi, L; Siracusa, G; Amato, M; Bartolozzi, L; Repice, A; Minderhoud, J; De Keyser, J; Zorgdrager, A; Zwanikken, C; Poser, S; Polak, T; Gunther, A; Bitsch, A; Borner, T; Weber, F; Wikstrom, J; Farkkila, M; Majuri, H; Sumelahti, M; Telakivi, T; Fredrikson, S; Martin, C; Miller, D; O'Riordan, J; Brex, P; Kapoor, R; Werring, D; Confavreux, C; Brunet, P; Hannoun, D; Brudon, F; Moreau, T; Blanc, S; D'Hooghe, M; Jacobs, K; Lissoir, F; Demonty, L; Comi, G; Colombo, B; Rossi, P; Rodegher, M; Santuccio, G; Martinelli, F; Hohlfeld, R; Walther, E; Goebels, N; Dang, T; Lindert, R; Voltz, R; Cartlidge, N; Bates, D; Moran, G; Pandit, L; Westwood, M; Haller, P; Sommer, J; Bitter, J; Suss, F; Mellies, J; Mucha, P; Lyon-Caen, O; Degos, JD; Roullet, E; Lubetzki, C; Creange, A; Tourbah, A; Pez, D; Lecanuet, P; Nicolt, P; Edan, G; Belliard, S; De Marco, O; Cahagne, V; De Burghgraeve, V; Brunet, I; Fieschi, C; Millefiorini, E; Gasperini, C; Buttinelli, C; Frontini, M; Howell, S; Hadjivassiliou, M; Gibson, A; Graham, A; Harkness, K; Lawden, M; Clanet, M; Wauban, E; Azais-Vuillemin, C; Lau, GKK; Louis, C; Panelius, M; Ruutiainen, J; Eralinna, J; Soilu-Hanninen, M; Gold, R; Hartung, HP; Jung, S; Bayas, A; Flachenecker, P; Weilbach, F; Archelos, J; Kollegger, H; Vass, K; Asenbaum, S; Chatsakos, T; Beckmann, K; Ghazi, M; Wagner, K; Miltenburger, C; McFarland, H; Petkau, J; Sabouraud, O; Toyka, K				Kappos, L; Polman, C; Pozzilli, C; Thompson, A; Dahlke, F; Knight, R; Hern, J; Coleman, R; Gerrie, L; Cooper, G; Moore, J; Boringa, J; van Oosten, B; Ronner, H; Schrijver, H; Truyen, L; Montalban, J; Rio, J; Tintore, M; Jacas, C; Marzo, E; Lechner-Scott, J; Huber, S; Lienert, C; Brunnschweiler, H; Hawkins, S; Droogan, A; McDonnell, G; Duddy, M; McKinstry, S; Altenkirch, H; Baum, K; Einhaupl, K; Marx, P; Poewe, W; Walter, G; Akman, H; Brockmeier, B; Scherer, P; Zschenderlein, R; Schmierer, K; Gelderblom, H; Hartmann, A; Stapf, C; Luschow, A; Mackert, B; Schumacher, H; Masuhr, F; Hempel, T; Zimmermann, R; Munch, M; Francis, D; Heafield, M; Al-Memar, A; Winer, J; Chong, M; Brochet, B; Gayou, A; Auriacombe, S; Dousset, V; Wiles, C; Thomas, F; Pickersgill, T; Hinds, N; Dawson, K; Hughes, T; Hutchinson, M; Murphy, R; Redmond, J; Webb, S; Stoll, G; Jander, S; Hagemann, G; Koller, H; Hanemann, C; Kolmel, H; Reichel, D; Petereit, K; Thieme, A; Khatami, A; Neumann, M; Amaducci, L; Massacesi, L; Siracusa, G; Amato, M; Bartolozzi, L; Repice, A; Minderhoud, J; De Keyser, J; Zorgdrager, A; Zwanikken, C; Poser, S; Polak, T; Gunther, A; Bitsch, A; Borner, T; Weber, F; Wikstrom, J; Farkkila, M; Majuri, H; Sumelahti, M; Telakivi, T; Fredrikson, S; Martin, C; Miller, D; O'Riordan, J; Brex, P; Kapoor, R; Werring, D; Confavreux, C; Brunet, P; Hannoun, D; Brudon, F; Moreau, T; Blanc, S; D'Hooghe, M; Jacobs, K; Lissoir, F; Demonty, L; Comi, G; Colombo, B; Rossi, P; Rodegher, M; Santuccio, G; Martinelli, F; Hohlfeld, R; Walther, E; Goebels, N; Dang, T; Lindert, R; Voltz, R; Cartlidge, N; Bates, D; Moran, G; Pandit, L; Westwood, M; Haller, P; Sommer, J; Bitter, J; Suss, F; Mellies, J; Mucha, P; Lyon-Caen, O; Degos, JD; Roullet, E; Lubetzki, C; Creange, A; Tourbah, A; Pez, D; Lecanuet, P; Nicolt, P; Edan, G; Belliard, S; De Marco, O; Cahagne, V; De Burghgraeve, V; Brunet, I; Fieschi, C; Millefiorini, E; Gasperini, C; Buttinelli, C; Frontini, M; Howell, S; Hadjivassiliou, M; Gibson, A; Graham, A; Harkness, K; Lawden, M; Clanet, M; Wauban, E; Azais-Vuillemin, C; Lau, GKK; Louis, C; Panelius, M; Ruutiainen, J; Eralinna, J; Soilu-Hanninen, M; Gold, R; Hartung, HP; Jung, S; Bayas, A; Flachenecker, P; Weilbach, F; Archelos, J; Kollegger, H; Vass, K; Asenbaum, S; Chatsakos, T; Beckmann, K; Ghazi, M; Wagner, K; Miltenburger, C; McFarland, H; Petkau, J; Sabouraud, O; Toyka, K		Eur Study Grp Interferon Beta-1b Sec	Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis	LANCET			English	Article							STATUS SCALE EDSS; IMPAIRMENT	Background The beneficial effects of interferon beta have only been shown for patients in the relapsing-remitting phase of multiple sclerosis (MS). The role of interferon beta in the treatment of patients who are in the secondary progressive phase of the disease (SP-MS), and for whom no effective drug treatment is available, has not been assessed. Methods In this multicentre, double-masked, randomised, placebo-controlled trial, outpatients with SP-MS having scores of 3.0-6.5 on the Expanded Disability Status Scale (EDSS) received either 8 million IU interferon beta-1b every other day subcutaneously, or placebo, for up to 3 years. The primary outcome was the time to confirmed progression in disability as measured by a 1.0 point increase on the EDSS, sustained for at least 3 months, or a 0.5 point increase if the baseline EDSS was 6.0 or 6.5, A prospectively planned interim analysis of safety and efficacy of the intention-to-treat population was done after all patients had been in the study for at least 2 years. Findings 358 patients with SP-MS were allocated placebo and 360 were allocated interferon beta-1b; 57 patients (31 placebo, 26 interferon beta-1b) were lost to follow-up. There was a highly significant difference in time to confirmed progression of disability in favour of interferon beta-1b (p = 0.0008). Interferon beta-1b delayed progression for 9-12 months in a study period of 2-3 years. The odds ratio for confirmed progression was 0.65 (95% CI 0.52-0.83). This beneficial effect was seen in patients with superimposed relapses and in patients who had only progressive deterioration without relapses. Positive results were also obtained regarding time to becoming wheelchair-bound, relapse rate and severity, number of steroid treatments and hospital admissions, as well as on magnetic resonance imaging variables. The drug was safe and side effects were in line with previous experience with interferon beta-1b. The study was stopped after the interim results gave clear evidence of efficacy. interpretation Treatment with interferon beta-1b delays sustained neurological deterioration in patients with SP-MS. Interferon beta-1b is the first treatment to show a therapeutic effect in patients with SP-MS.	Univ Basel Hosp, Kantonsspital, Dept Neurol, CH-4031 Basel, Switzerland; Schering AG, D-1000 Berlin, Germany	Kantonsspital Aarau AG (KSA); University of Basel; Schering AG	Kappos, L (corresponding author), Univ Basel Hosp, Kantonsspital, Dept Neurol, Petersgraben 4, CH-4031 Basel, Switzerland.	kappos@ubaclu.unibas.ch	D'hooghe, Marie BGJ/G-3423-2013; Pozzilli, Carlo/AAC-3270-2022; Schmierer, Klaus/W-3253-2019; De Keyser, Jacques/D-3725-2013; Lima, Thaísa/AAG-6483-2021; Werring, David J/D-4741-2009; AURIACOMBE, Sophie/T-5596-2019; Edan, Gilles/AAI-5944-2020; Schmierer, Klaus/C-1712-2008; Thompson, Alan J/C-2654-2008; Boneschi, Filippo Martinelli/H-8592-2012; Fredrikson, Sten/AAI-7144-2020; Werring, David/Q-8435-2019; van Oosten, Bob/I-7152-2012; Massacesi, Luca/ABA-9431-2020; Scherer, Philipp E/K-7819-2012	Pozzilli, Carlo/0000-0002-6360-4798; De Keyser, Jacques/0000-0002-3394-7757; Werring, David J/0000-0003-2074-1861; Thompson, Alan J/0000-0002-4333-8496; Werring, David/0000-0003-2074-1861; van Oosten, Bob/0000-0003-4536-6201; Massacesi, Luca/0000-0001-5083-372X; Scherer, Philipp E/0000-0003-0680-3392; Fredrikson, Sten/0000-0002-8042-3286				Carton H, 1998, J NEUROL NEUROSUR PS, V64, P444, DOI 10.1136/jnnp.64.4.444; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Ebers GC, 1997, ANN NEUROL, V42, P986; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; Koch GG, 1988, BIOPHARMACEUTICAL ST, P403; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LECHNERSCOTT J, 1997, J NEUROL S3, V244, P25; LLEONART R, 1990, BIO-TECHNOL, V8, P1263, DOI 10.1038/nbt1290-1263; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Lucchinetti CF, 1996, BRAIN PATHOL, V6, P259, DOI 10.1111/j.1750-3639.1996.tb00854.x; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; NOSEWORTHY JH, 1990, NEUROLOGY, V40, P971, DOI 10.1212/WNL.40.6.971; NOSEWORTHY JH, 1991, LANCET, V337, P441; Petkau J, 1997, MULT SCLER, V3, P402, DOI 10.1177/135245859700300610; PETKAU J, 1996, ADV MS CLIN TRIAL DE, P63; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Rudick R, 1997, ANN NEUROL, V42, P379, DOI 10.1002/ana.410420318; Weinshenker BG, 1996, NEUROLOGY, V46, P1613, DOI 10.1212/WNL.46.6.1613; WEINSHENKER BG, 1987, CAN J NEUROL SCI, V14, P255, DOI 10.1017/S0317167100026573; WILLOUGHBY EW, 1988, NEUROLOGY, V38, P1793, DOI 10.1212/WNL.38.11.1793; WOLINSKY JS, 1990, ANN NEUROL, V27, P591; [No title captured]	22	806	818	0	31	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1491	1497		10.1016/S0140-6736(98)10039-9	http://dx.doi.org/10.1016/S0140-6736(98)10039-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820296	Green Submitted			2022-12-28	WOS:000076862300006
J	Poepping, I; Thalhammer, C; Pilz, B; Luft, FC				Poepping, I; Thalhammer, C; Pilz, B; Luft, FC			Cutting edge of cardiomyopathy	LANCET			English	Article							TRAUMATIC ARTERIOVENOUS-FISTULA		Univ Klinikum Charite, Max Delbruck Ctr Mol Med, Franz Volhard Clin, Berlin, Germany; Humboldt Univ, Fac Med, Berlin, Germany	Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	Thalhammer, C (corresponding author), Franz Volhard Clin, Wiltberg Str 50, D-13122 Berlin, Germany.			Luft, Friedrich/0000-0002-8635-1199				MARIN ML, 1993, J VASC SURG, V18, P299, DOI 10.1016/0741-5214(93)90611-O; ROBBS JV, 1994, BRIT J SURG, V81, P1296, DOI 10.1002/bjs.1800810912; TOUHO H, 1995, NEURORADIOLOGY, V37, P65, DOI 10.1007/BF00588523	3	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1518	1518		10.1016/S0140-6736(98)07303-6	http://dx.doi.org/10.1016/S0140-6736(98)07303-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820301				2022-12-28	WOS:000076862300011
J	Kemp, M				Kemp, M			Vincian velcro	NATURE			English	Article									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	1	1	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1998	396	6706					25	25		10.1038/23832	http://dx.doi.org/10.1038/23832			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136HE	9817199	Bronze			2022-12-28	WOS:000076852700031
J	Cottaris, NP; De Valois, RL				Cottaris, NP; De Valois, RL			Temporal dynamics of chromatic tuning in macaque primary visual cortex	NATURE			English	Article							STRIATE CORTEX; SIMPLE CELLS; MECHANISMS; RETINA; PATHWAY; NEURONS; MONKEY	The ability to distinguish colour from intensity variations is a difficult computational problem for the visual system because each of the three cone photoreceptor types absorb all wavelengths of light, although their peak sensitivities are at relatively short (S cones), medium (M cones), or long (L cones) wavelengths. The first stage in colour processing is the comparison of the outputs of different cone types by spectrally opponent neurons in the retina and upstream in the lateral geniculate nucleus(1-3). Some neurons receive opponent inputs from L and M cones, whereas others receive input from S cones opposed by combined signals from L and M cones. Here we report how the outputs of the L/M- and S-opponent geniculate cell types are combined in time at the next stage of colour processing, in the macaque primary visual cortex (V1). Some V1 neurons respond to a single chromatic region, with either a short (68-95 ms) or a longer (96-135 ms) latency, whereas others respond to two chromatic regions with a difference in latency of 20-30 ms. Across all types, short latency responses are mostly evoked by L/M-opponent inputs whereas longer latency responses are evoked mostly by S-opponent inputs. Furthermore, neurons with late S-cone inputs exhibit dynamic changes in the sharpness of their chromatic tuning over time. We propose that the sparse, S-opponent signal in the lateral geniculate nucleus is amplified in area V1, possibly through recurrent excitatory networks. This results in a delayed, sluggish cortical S-cone signal which is then integrated with L/M-opponent signals to rotate the lateral geniculate nucleus chromatic axes(4-5).	Univ Calif Berkeley, Program Vis Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Cottaris, NP (corresponding author), Univ Calif Berkeley, Program Vis Sci, 3210 Tolman Hall, Berkeley, CA 94720 USA.	nicolas@valois.berkeley.edu						ALBRECHT DG, 1991, VISUAL NEUROSCI, V7, P531, DOI 10.1017/S0952523800010336; Calkins DJ, 1998, J NEUROSCI, V18, P3373; DACEY DM, 1994, NATURE, V367, P731, DOI 10.1038/367731a0; Dacey DM, 1996, P NATL ACAD SCI USA, V93, P582, DOI 10.1073/pnas.93.2.582; DEBOER E, 1968, IEEE T BIO-MED ENG, VBM15, P169, DOI 10.1109/TBME.1968.4502561; DEMONASTERIO FM, 1981, SCIENCE, V213, P1278, DOI 10.1126/science.7268439; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P241, DOI 10.1113/jphysiol.1984.sp015499; DEVALOIS RL, 1966, J OPT SOC AM, V56, P966, DOI 10.1364/JOSA.56.000966; DEVALOIS RL, 1993, VISION RES, V33, P1053, DOI 10.1016/0042-6989(93)90240-W; DEVALOIS RL, UNPUB VISION RES; GEGENFURTNER KR, 1995, VISION RES, V35, P1547, DOI 10.1016/0042-6989(94)00264-M; GIELEN CCAM, 1982, BIOL CYBERN, V44, P211, DOI 10.1007/BF00344277; Hartline HK, 1940, AM J PHYSIOL, V130, P0690, DOI 10.1152/ajplegacy.1940.130.4.690; HAWKEN MJ, 1988, J NEUROSCI, V8, P3541; LENNIE P, 1990, J NEUROSCI, V10, P649; LENNIE P, 1988, CRIT REV NEUROBIOL, V3, P333; LENNIE P, 1984, TRENDS NEUROSCI, V7, P243, DOI 10.1016/S0166-2236(84)80216-7; MACLEOD DIA, 1979, J OPT SOC AM, V69, P1183, DOI 10.1364/JOSA.69.001183; MALPELI JG, 1978, BRAIN RES, V141, P385, DOI 10.1016/0006-8993(78)90211-1; Martin PR, 1997, EUR J NEUROSCI, V9, P1536, DOI 10.1111/j.1460-9568.1997.tb01509.x; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; PUGH M, 1997, SOC NEUR ABSTR, V23, P603; RABIN J, 1994, VISION RES, V34, P2657, DOI 10.1016/0042-6989(94)90222-4; Reid RC, 1997, VISUAL NEUROSCI, V14, P1015, DOI 10.1017/S0952523800011743; Ringach DL, 1997, NATURE, V387, P281, DOI 10.1038/387281a0; STOCKMAN A, 1991, VISION RES, V31, P189, DOI 10.1016/0042-6989(91)90111-H; Tolhurst DJ, 1997, VISUAL NEUROSCI, V14, P293, DOI 10.1017/S0952523800011433	27	144	144	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 29	1998	395	6705					896	900		10.1038/27666	http://dx.doi.org/10.1038/27666			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804422				2022-12-28	WOS:000076713400056
J	Garner, P				Garner, P			What makes DOT work?	LANCET			English	Editorial Material							DIRECTLY OBSERVED THERAPY; TUBERCULOSIS		Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Div, Liverpool L3 5QA, Merseyside, England	Liverpool School of Tropical Medicine; University of Liverpool	Garner, P (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Div, Liverpool L3 5QA, Merseyside, England.		Garner, Paul/HII-5856-2022	Garner, Paul/0000-0002-0607-6941				Chaulk CP, 1998, JAMA-J AM MED ASSOC, V279, P943, DOI 10.1001/jama.279.12.943; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; ElSadr W, 1996, AM J PUBLIC HEALTH, V86, P1146, DOI 10.2105/AJPH.86.8_Pt_1.1146; Garner P, 1997, LANCET, V350, P666, DOI 10.1016/S0140-6736(05)63361-2; VOLMINK J, 1998, COCHRANE LIB CDROM O; *WHO, 1997, WHOTB97220 GLOB TUB	6	28	30	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 24	1998	352	9137					1326	1327		10.1016/S0140-6736(05)60739-8	http://dx.doi.org/10.1016/S0140-6736(05)60739-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802264				2022-12-28	WOS:000076691700004
J	Holland, WW				Holland, WW			Community medicine	LANCET			English	Editorial Material									LSE Hlth, Univ London London Sch Econ & Polit Sci, London WC2A 2AE, England	University of London; London School Economics & Political Science	Holland, WW (corresponding author), LSE Hlth, Univ London London Sch Econ & Polit Sci, Houghton St, London WC2A 2AE, England.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					53	54		10.1016/S0140-6736(98)04263-9	http://dx.doi.org/10.1016/S0140-6736(98)04263-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800765				2022-12-28	WOS:000074608600048
J	Takei, K; Shin, RM; Inoue, T; Kato, K; Mikoshiba, K				Takei, K; Shin, RM; Inoue, T; Kato, K; Mikoshiba, K			Regulation of nerve growth mediated by inositol 1,4,5-trisphosphate receptors in growth cones	SCIENCE			English	Article							ASSISTED LASER INACTIVATION; CELL-ADHESION MOLECULES; NEURITE OUTGROWTH; EXPRESSION; CALCIUM; EXTENSION; MOTILITY; PROTEINS	The inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) acts as a Ca2+ release channel on internal Ca2+ stores. Type 1 IP3R(IP(3)R1) is enriched in growth cones of neurons in chick dorsal root ganglia. Depletion of internal Ca2+ stores and inhibition of IP3 signaling with drugs inhibited neurite extension. Microinjection of. heparin, a competitive IP3R blocker, induced neurite retraction. Acute Localized Loss of function of IP(3)R1 in the growth cone induced by chromophore-assisted Laser inactivation resulted in growth arrest and neurite retraction. IP3-induced Ca2+ release in growth cones appears to have a crucial role in control of nerve growth.	Japan Sci & Technol Corp, ERATO, Calciosignal Net Project, Bunkyo Ku, Tokyo 1130021, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, Tokyo 1080071, Japan; RIKEN, Brain Sci Inst, Wako, Saitama 3510198, Japan	Japan Science & Technology Agency (JST); University of Tokyo; RIKEN	Takei, K (corresponding author), Japan Sci & Technol Corp, ERATO, Calciosignal Net Project, Bunkyo Ku, Tokyo 1130021, Japan.		Inoue, Takafumi/AAM-9533-2020; Mikoshiba, Katsuhiko/N-7943-2015	Inoue, Takafumi/0000-0002-2728-0060; 				AIHARA Y, UNPUB; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; CHANG HY, 1995, NATURE, V376, P686, DOI 10.1038/376686a0; CYPHER C, 1992, Current Opinion in Cell Biology, V4, P4, DOI 10.1016/0955-0674(92)90051-D; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1993, RECEPTOR CHANNEL, V1, P11; GOMEZ TM, 1995, NEURON, V14, P1233, DOI 10.1016/0896-6273(95)90270-8; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOSHIMA Y, 1993, J NEUROSCI, V13, P559; JAY DG, 1990, NATURE, V348, P548, DOI 10.1038/348548a0; JAY DG, 1988, P NATL ACAD SCI USA, V85, P5454, DOI 10.1073/pnas.85.15.5454; KATER SB, 1991, J NEUROSCI, V11, P891; Kuhn TB, 1998, J NEUROSCI, V18, P184; LETOURNEAU PC, 1989, DEVELOPMENT, V105, P505; LIAO JC, 1994, P NATL ACAD SCI USA, V91, P2659, DOI 10.1073/pnas.91.7.2659; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; SILVER RA, 1990, NATURE, V343, P751, DOI 10.1038/343751a0; Sydor AM, 1996, J CELL BIOL, V134, P1197, DOI 10.1083/jcb.134.5.1197; TAKEI K, UNPUB; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VANBERKUM MFA, 1995, NEURON, V14, P43, DOI 10.1016/0896-6273(95)90239-2; Wang FS, 1996, SCIENCE, V273, P660, DOI 10.1126/science.273.5275.660; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	26	154	157	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1705	1708		10.1126/science.282.5394.1705	http://dx.doi.org/10.1126/science.282.5394.1705			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831561				2022-12-28	WOS:000077246600046
J	Andersson, SGE; Zomorodipour, A; Andersson, JO; Sicheritz-Ponten, T; Alsmark, UCM; Podowski, RM; Naslund, AK; Eriksson, AS; Winkler, HH; Kurland, CG				Andersson, SGE; Zomorodipour, A; Andersson, JO; Sicheritz-Ponten, T; Alsmark, UCM; Podowski, RM; Naslund, AK; Eriksson, AS; Winkler, HH; Kurland, CG			The genome sequence of Rickettsia prowazekii and the origin of mitochondria	NATURE			English	Article							STAPHYLOCOCCUS-AUREUS; EVOLUTION; ALIGNMENT; RNA; SYSTEM; GENES	We describe here the complete genome sequence (1,111,523 base pairs) of the obligate intracellular parasite Rickettsia prowarekii, the causative agent of epidemic typhus, This genome contains 834 protein-ooding genes. The functional profiles of these genes show similarities to those of mitochondrial genes: no genes required for anaerobic glycolysis are found in either R. prowazekii or mitochondrial genomes, but a complete set of genes encoding components of the tricarboxyilc acid cycle and the respiratory-chain complex is found in R. prowarekii, In effect, ATP production In Rickettsia Is the same as that in mitochondria. Many genes involved in the biosynthesis and regulation of biosynthesis of amino acids and nucleosides in free-living bacteria are absent front R. prowazekii and mitochondria, Such genes seem to have been replaced by homologues in the nuclear (host) genome, the R. prowarekii genome contains the highest proportion of non-coding DNA (24%) detected so far in a microbial genome, Such non-coding sequences may be degraded remnants of 'neutralized' genes that await elimination from the genome, Phylogenetic analyses Indicate that R. prowazekii is more closely related to mitochondria than is any other microbe studied so far.	Uppsala Univ, Dept Mol Biol, S-75124 Uppsala, Sweden; Univ S Alabama, Dept Microbiol & Immunol, Mobile, AL 36688 USA	Uppsala University; University of South Alabama	Kurland, CG (corresponding author), Uppsala Univ, Dept Mol Biol, S-75124 Uppsala, Sweden.	chuck@xray.bmc.uu.se	Alsmark, Cecilia/AAO-1330-2021; Zomorodipour, Alireza/AAA-9003-2022; Sicheritz-Ponten, Thomas/A-4325-2017	Zomorodipour, Alireza/0000-0003-0671-4779; Podowski, Raf/0000-0001-5500-8913; Sicheritz-Ponten, Thomas/0000-0001-6615-1141				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Andersson B, 1996, ANAL BIOCHEM, V236, P107, DOI 10.1006/abio.1996.0138; Andersson JO, 1997, MICROBIOL-SGM, V143, P2783, DOI 10.1099/00221287-143-8-2783; ANDERSSON SGE, 1995, J BACTERIOL, V177, P4171, DOI 10.1128/jb.177.14.4171-4175.1995; Andersson SGE, 1995, BIOCHEM CELL BIOL, V73, P775, DOI 10.1139/o95-086; Andersson SGE, 1996, J MOL EVOL, V42, P525, DOI 10.1007/BF02352282; Andersson SGE, 1998, TRENDS MICROBIOL, V6, P263, DOI 10.1016/S0966-842X(98)01312-2; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Christie PJ, 1997, J BACTERIOL, V179, P3085, DOI 10.1128/jb.179.10.3085-3094.1997; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; EBELING S, 1991, J BACTERIOL, V173, P6373, DOI 10.1128/jb.173.20.6373-6382.1991; Felsenstein J., 1974, GENETICS, V78, P157; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; GRAY MW, 1989, P NATL ACAD SCI USA, V86, P2267, DOI 10.1073/pnas.86.7.2267; GRAY MW, 1996, EVOLUTION MICROBIAL, P00109; Gross L, 1996, P NATL ACAD SCI USA, V93, P10539, DOI 10.1073/pnas.93.20.10539; HIMMELREICH R, 1996, NUCLEIC ACIDS RES, V3, P109; Koonin EV, 1998, CURR BIOL, V8, pR266, DOI 10.1016/S0960-9822(98)70169-1; KURLAND CG, 1992, BIOESSAYS, V14, P709, DOI 10.1002/bies.950141013; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; LIN WS, 1994, J BACTERIOL, V176, P7005, DOI 10.1128/JB.176.22.7005-7016.1994; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MARGULIS L, 1970, P349; MELLY MA, 1974, INFECT IMMUN, V10, P389, DOI 10.1128/IAI.10.2.389-397.1974; Ohta T, 1972, J Mol Evol, V1, P150, DOI 10.1007/BF01659161; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Ota T, 1971, J Mol Evol, V1, P18, DOI 10.1007/BF01659391; PETERSON PK, 1978, INFECT IMMUN, V19, P943, DOI 10.1128/IAI.19.3.943-949.1978; Sicheritz-Ponten T, 1998, BBA-BIOENERGETICS, V1365, P545, DOI 10.1016/S0005-2728(98)00099-1; Sicheritz-Ponten T, 1997, COMPUT APPL BIOSCI, V13, P621; Sicheritz-Ponten T, 1997, Microb Comp Genomics, V2, P123, DOI 10.1089/omi.1.1997.2.123; Staden R, 1996, MOL BIOTECHNOL, V5, P233, DOI 10.1007/BF02900361; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VIALE AM, 1994, FEBS LETT, V341, P146, DOI 10.1016/0014-5793(94)80446-X; WEISBURG WG, 1989, J BACTERIOL, V171, P4202, DOI 10.1128/JB.171.8.4202-4206.1989; WEISBURG WG, 1985, SCIENCE, V230, P556, DOI 10.1126/science.3931222; WINKLER HH, 1976, J BIOL CHEM, V251, P389; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	47	1266	1897	5	152	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 12	1998	396	6707					133	140		10.1038/24094	http://dx.doi.org/10.1038/24094			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823893	Bronze			2022-12-28	WOS:000077013300041
J	O'Connell, MJ				O'Connell, MJ			Irinotecan for colorectal cancer: a small step forward	LANCET			English	Editorial Material									Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA	Mayo Clinic	O'Connell, MJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA.							Becouarn Y, 1998, SEMIN ONCOL, V25, P23; Bleiberg H, 1998, SEMIN ONCOL, V25, P32	2	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1402	1402		10.1016/S0140-6736(98)00051-8	http://dx.doi.org/10.1016/S0140-6736(98)00051-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9807982				2022-12-28	WOS:000076719500002
J	Oancea, E; Meyer, T				Oancea, E; Meyer, T			Protein kinase C as a molecular machine for decoding calcium and diacylglycerol signals	CELL			English	Article							FLUORESCENT INDICATORS; ACIDIC LIPIDS; CALMODULIN; CELLS; OSCILLATIONS; ACTIVATION; MEMBRANES; BINDING	The specificity of many signal transduction pathways relies on the temporal coordination of different second messenger signals. Here we found a molecular mechanism which guarantees that conventional protein kinase C (PKC) isoforms are sequentially activated by calcium and diacylglycerol signals. Receptor stimuli that triggered repetitive calcium spikes induced a parallel repetitive translocation of GFP-tagged PKC gamma to the plasma membrane. While calcium acted rapidly, diacylglycerol binding to PKC gamma was initially prevented by a pseudosubstrate clamp, which kept the diacylglycerol-binding site inaccessible and delayed calcium- and diacylglycerol-mediated kinase activation. After termination of calcium signals, bound diacylglycerol prolonged kinase activity. The properties of this molecular decoding machine make PKC gamma responsive to persistent diacylglycerol increases combined with high- but not low-frequency calcium spikes.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Meyer, T (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	tobias@cellbio.duke.edu		Meyer, Tobias/0000-0003-4339-3804	NIGMS NIH HHS [GM-51457] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BONI LT, 1985, J BIOL CHEM, V260, P819; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANNUN YA, 1985, J BIOL CHEM, V260, P39; Hurley JH, 1997, CURR OPIN STRUC BIOL, V7, P557, DOI 10.1016/S0959-440X(97)80122-4; KONTOS CD, 1998, IN PRESS MOL CELL BI; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; Mosior M, 1996, BIOCHEMISTRY-US, V35, P1612, DOI 10.1021/bi952031q; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; PEARS CJ, 1991, J CELL SCI, V100, P683; Quest AFG, 1996, ENZYME PROTEIN, V49, P231, DOI 10.1159/000468635; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; SCHNEIDER H, 1992, INT IMMUNOL, V4, P447, DOI 10.1093/intimm/4.4.447; Srinivasan N, 1996, PROTEINS, V26, P217; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Stauffer TP, 1997, J CELL BIOL, V139, P1447, DOI 10.1083/jcb.139.6.1447; Teruel MN, 1997, BIOPHYS J, V73, P1785, DOI 10.1016/S0006-3495(97)78209-2; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252	31	517	526	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1998	95	3					307	318		10.1016/S0092-8674(00)81763-8	http://dx.doi.org/10.1016/S0092-8674(00)81763-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814702	Bronze			2022-12-28	WOS:000076789600005
J	Warlow, CP				Warlow, CP			Epidemiology of stroke	LANCET			English	Article							CAROTID STENOSIS; CASE-FATALITY; MORTALITY; INFARCTION; DISEASE; TRENDS; RISK; COST		Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Warlow, CP (corresponding author), Western Gen Hosp, Dept Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.							Boiten J, 1997, CEREBROVASC DIS, V7, P138, DOI 10.1159/000108179; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; BONITA R, 1993, LANCET, V342, P1470, DOI 10.1016/0140-6736(93)92938-P; Bonita R, 1989, HYPERTENSION S1, V3; Brown RD, 1996, STROKE, V27, P373; *E STROK COR HEART, IN PRESS LANCET; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; FEIGIN VL, 1995, STROKE, V26, P924, DOI 10.1161/01.STR.26.6.924; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; ISARD PA, 1992, CEREBROVASC DIS, V2, P47, DOI 10.1159/000108988; LODDER J, 1990, STROKE, V21, P375, DOI 10.1161/01.STR.21.3.375; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Rose G., 1992, STRATEGY PREVENTIVE; SANDERCOCK PAG, 1989, BRIT MED J, V298, P75, DOI 10.1136/bmj.298.6666.75; STREIFLER JY, 1995, ARCH NEUROL-CHICAGO, V52, P246, DOI 10.1001/archneur.1995.00540270034016; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491; Taylor TN, 1996, STROKE, V27, P1459, DOI 10.1161/01.STR.27.9.1459; TERENT A, 1988, STROKE, V19, P598, DOI 10.1161/01.STR.19.5.598; WARLOW C, 1996, STROKE PRACTICAL GUI; WARLOW CP, IN PRESS J R COLL PH	21	84	85	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT	1998	352			3			SIII1	SIII4						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133UP	9803954				2022-12-28	WOS:000076704700002
J	Healey, PJ; Davis, CL				Healey, PJ; Davis, CL			Transmission of tumours by transplantation	LANCET			English	Editorial Material							GLIOBLASTOMA-MULTIFORME; MALIGNANCY; RECIPIENTS; DONOR		Univ Washington, Med Ctr, Dept Surg & Transplant Serv, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Davis, CL (corresponding author), Univ Washington, Med Ctr, Dept Surg & Transplant Serv, Seattle, WA 98195 USA.							Bresalier RS, 1997, CANCER, V80, P776; COLQUHOUN SD, 1994, TRANSPLANTATION, V57, P970; Detry O, 1997, TRANSPLANT INT, V10, P83, DOI 10.1111/j.1432-2277.1997.tb00544.x; JONAS S, 1996, TRANSPL INT, V9, P83; LEFRANCOIS N, 1987, TRANSPLANT P, V19, P2242; MORSE JHG, 1990, TRANSPLANTATION, V50, P857; ONDA K, 1989, NEUROSURGERY, V25, P533, DOI 10.1227/00006123-198910000-00005; Oudard S, 1997, ANTICANCER RES, V17, P1903; PASQUIER B, 1994, HUM PATHOL, V25, P623, DOI 10.1016/0046-8177(94)90233-X; PENN I, 1993, TRANSPLANT INT, V6, P1; RUIZ JC, 1993, TRANSPLANTATION, V55, P682; *UNOS, 1997, 1997 ANN REP US SCI; VANBERNAL F, 1993, HUM PATHOL, V25, P623; Wallace CJ, 1996, AM J NEURORADIOL, V17, P1929	14	33	36	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					2	3		10.1016/S0140-6736(98)22027-7	http://dx.doi.org/10.1016/S0140-6736(98)22027-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800732				2022-12-28	WOS:000074608600002
J	Akagi, K; Piao, G; Kaneko, S; Sakamaki, K; Shirakawa, H; Kyotani, M				Akagi, K; Piao, G; Kaneko, S; Sakamaki, K; Shirakawa, H; Kyotani, M			Helical polyacetylene synthesized with a chiral nematic reaction field	SCIENCE			English	Article							LIQUID-CRYSTAL SOLVENT; MAGNETIC-FIELD; FILM	Helical polyacetylene was synthesized under an asymmetric reaction field consisting of chiral nematic (N*) Liquid crystals (LCs). The chiral nematic LC was prepared by adding a chiroptical binaphthol derivative as a chiral dopant to a mixture of two nematic LCs. Acetylene polymerizations were carried out using the catalyst titanium tetra-n-butoxide-triethylaluminum dissolved in the chiral nematic LC solvent. The polyacetylene film was shown by scanning electron microscopy to consist of clockwise or counterclockwise helical structure of fibrils. A Cotton effect was observed in the region of the pi --> pi* transition of the polyacetylene chain in circular dichroism spectra. The high electrical conductivities of similar to 1500 to 1800 siemens per centimeter after iodine doping and the chiral helicity of these films may be exploited in electromagnetic and optical applications.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058573, Japan; Univ Tsukuba, Inst Mat Sci, Tsukuba, Ibaraki 3058573, Japan; Natl Inst Mat & Chem Res, Tsukuba, Ibaraki 3050046, Japan	University of Tsukuba; University of Tsukuba; National Institute of Advanced Industrial Science & Technology (AIST)	Akagi, K (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058573, Japan.		Kyotani, Mutsumasa/S-9874-2017; Piao, Guangzhe/M-8797-2016	Kyotani, Mutsumasa/0000-0002-0478-9278; 				AKAGI K, 1989, MOL CRYST LIQ CRYST, V172, P115, DOI 10.1080/00268948908042156; AKAGI K, 1989, SYNTHETIC MET, V28, pD51, DOI 10.1016/0379-6779(89)90673-5; AKAGI K, 1987, POLYM J, V19, P185, DOI 10.1295/polymj.19.185; AKAGI K, 1987, SYNTHETIC MET, V17, P241, DOI 10.1016/0379-6779(87)90744-2; Akagi S., UNPUB; ARAYA K, 1986, SYNTHETIC MET, V14, P199, DOI 10.1016/0379-6779(86)90184-0; Bozovic I., 1987, Modern Physics Letters B, V1, P81, DOI 10.1142/S0217984987000120; NAARMANN H, 1987, SYNTHETIC MET, V22, P1, DOI 10.1016/0379-6779(87)90564-9; Nalwa H.S, 1997, HDB ORGANIC CONDUCTI, V1st ed.; SCHNUR JM, 1993, SCIENCE, V262, P1669, DOI 10.1126/science.262.5140.1669; SHIRAKAWA H, 1971, POLYM J, V2, P231, DOI 10.1295/polymj.2.231; SHIRAKAWA H, 1988, J MACROMOL SCI CHEM, VA25, P643, DOI 10.1080/00222338808053390; Skotheim T.J., 1986, HDB CONDUCTING POLYM; TSUKAMOTO J, 1990, JPN J APPL PHYS 1, V29, P125, DOI 10.1143/JJAP.29.125	14	380	381	5	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1683	1686		10.1126/science.282.5394.1683	http://dx.doi.org/10.1126/science.282.5394.1683			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831554				2022-12-28	WOS:000077246600039
J	Meek, S				Meek, S		SW Region Major Trauma Outcome Study Grp	Lesson of the week - Fractures of the thoracolumbar spine in major trauma patients	BRITISH MEDICAL JOURNAL			English	Review							INJURIES; ETIOLOGY		Royal United Hosp, Emergency Dept, Bath BA1 3NG, Avon, England		Meek, S (corresponding author), Royal United Hosp, Emergency Dept, Bath BA1 3NG, Avon, England.	steve.meek@ruh-bath.swest.nhs.uk						*AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP M, P300; COOPER C, 1995, J TRAUMA, V38, P692, DOI 10.1097/00005373-199505000-00003; DAVIS JW, 1993, J TRAUMA, V34, P342, DOI 10.1097/00005373-199303000-00006; ENDERSON BL, 1990, J TRAUMA, V30, P666, DOI 10.1097/00005373-199006000-00002; FRANKEL HL, 1994, J TRAUMA, V37, P673, DOI 10.1097/00005373-199410000-00024; HOFFMAN JR, 1992, ANN EMERG MED, V21, P1454, DOI 10.1016/S0196-0644(05)80059-9; KUPFERSCHMID JP, 1989, J TRAUMA, V29, P593, DOI 10.1097/00005373-198905000-00009; Meldon SW, 1995, J TRAUMA, V39, P1110, DOI 10.1097/00005373-199512000-00017; REID DC, 1987, J TRAUMA, V27, P980, DOI 10.1097/00005373-198709000-00005; SAMUELS LE, 1993, J TRAUMA, V34, P85, DOI 10.1097/00005373-199301000-00016; TERREGINO CA, 1993, J TRAUMA, V35, P979	11	19	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1442	1443		10.1136/bmj.317.7170.1442	http://dx.doi.org/10.1136/bmj.317.7170.1442			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822404	Green Published			2022-12-28	WOS:000077202200029
J	Ebert, D				Ebert, D			Evolution - Experimental evolution of parasites	SCIENCE			English	Review							SERIAL PASSAGE; CELL-CULTURE; ENCEPHALITIS-VIRUS; BABESIA-BOVIS; DISEASE VIRUS; IN-VITRO; VIRULENCE; SELECTION; ATTENUATION; VACCINE	Serial passage experiments are a form of experimental evolution that is frequently used in applied sciences; for example, in vaccine development. During these experiments, molecular and phenotypic evolution can be monitored in real time, providing insights into the causes and consequences of parasite evolution. Within-host competition generally drives an increase in a parasite's virulence in a new host, whereas the parasite becomes avirulent to its former host, indicating a trade-off between parasite fitnesses on different hosts. Understanding why parasite virulence seldom escalates similarly in natural populations could help us to manage virulence and deal with emerging diseases.	Univ Basel, Inst Zool, CH-4051 Basel, Switzerland	University of Basel	Ebert, D (corresponding author), Univ Basel, Inst Zool, Rheinsprung 9, CH-4051 Basel, Switzerland.	ebert@ubaclu.unibas.ch	Ebert, Dieter/P-6134-2019; Ebert, Dieter/B-5502-2009	Ebert, Dieter/0000-0003-2653-3772; Ebert, Dieter/0000-0003-2653-3772				ADAMS MW, 1971, BIOSCIENCE, V21, P1067, DOI 10.2307/1295991; ANDERSON RM, 1982, PARASITOLOGY, V85, P411, DOI 10.1017/S0031182000055360; Baumann P, 1997, BIOSCIENCE, V47, P12, DOI 10.2307/1313002; BAWDEN FC, 1958, J GEN MICROBIOL, V18, P751, DOI 10.1099/00221287-18-3-751; BERGE TO, 1961, AM J HYG, V73, P209, DOI 10.1093/oxfordjournals.aje.a120178; Brown AJL, 1997, P NATL ACAD SCI USA, V94, P1862, DOI 10.1073/pnas.94.5.1862; BRUGH M, 1991, AVIAN DIS, V35, P824, DOI 10.2307/1591616; BRUMMER E, 1990, MYCOPATHOLOGIA, V109, P13, DOI 10.1007/BF00437001; BULL JJ, 1992, EVOLUTION, V46, P882, DOI 10.1111/j.1558-5646.1992.tb00606.x; BULL JJ, 1991, EVOLUTION, V45, P875, DOI [10.1111/j.1558-5646.1991.tb04356.x, 10.2307/2409695]; BULL JJ, 1994, EVOLUTION, V48, P1423, DOI 10.1111/j.1558-5646.1994.tb02185.x; BURDON JJ, 1981, J APPL ECOL, V18, P649, DOI 10.2307/2402423; CALLOW LL, 1979, INT J PARASITOL, V9, P333, DOI 10.1016/0020-7519(79)90083-3; CAO JX, 1995, J GEN VIROL, V76, P2757, DOI 10.1099/0022-1317-76-11-2757; CARSON CA, 1990, EXP PARASITOL, V70, P404, DOI 10.1016/0014-4894(90)90124-U; CATRENICH CE, 1988, INFECT IMMUN, V56, P3121, DOI 10.1128/IAI.56.12.3121-3125.1988; CHAO L, 1990, NATURE, V348, P454, DOI 10.1038/348454a0; CHIN W, 1968, AM J TROP MED HYG, V17, P355, DOI 10.4269/ajtmh.1968.17.355; CLARIDGE MF, 1982, ENTOMOL EXP APPL, V32, P213, DOI 10.1111/j.1570-7458.1982.tb03208.x; CONTRERAS VT, 1994, MEM I OSWALDO CRUZ, V89, P253, DOI 10.1590/S0074-02761994000200026; CUNFER BM, 1984, ANN APPL BIOL, V104, P61, DOI 10.1111/j.1744-7348.1984.tb05587.x; DAY KP, 1993, P NATL ACAD SCI USA, V90, P8292, DOI 10.1073/pnas.90.17.8292; DEARSLY AL, 1990, PARASITOLOGY, V100, P359, DOI 10.1017/S0031182000078628; DIEZ J, 1990, VIRUS RES, V18, P3, DOI 10.1016/0168-1702(90)90084-O; DIFFLEY P, 1987, AM J TROP MED HYG, V36, P533, DOI 10.4269/ajtmh.1987.36.533; DOBSON C, 1977, INT J PARASITOL, V7, P463, DOI 10.1016/0020-7519(77)90007-8; DONGES J, 1988, PARASITOLOGIE; Ebert D, 1999, EVOLUTION IN HEALTH AND DISEASE, P161; Ebert D, 1997, EVOLUTION, V51, P1828, DOI [10.2307/2411005, 10.1111/j.1558-5646.1997.tb05106.x]; Ebert Dieter, 1996, Trends in Ecology and Evolution, V11, P79, DOI 10.1016/0169-5347(96)81047-0; Ewald PW, 1994, EVOLUTION INFECT DIS; FRY JD, 1990, AM NAT, V136, P569, DOI 10.1086/285116; Groisman EA, 1996, CELL, V87, P791, DOI 10.1016/S0092-8674(00)81985-6; GUTEKUNST DE, 1979, AM J VET RES, V40, P974; GUTHRIE WD, 1974, J ECON ENTOMOL, V67, P605, DOI 10.1093/jee/67.5.605; HARROWER KM, 1977, T BRIT MYCOL SOC, V68, P101, DOI 10.1016/S0007-1536(77)80159-9; Herre EA, 1995, PARASITOLOGY, V111, pS179, DOI 10.1017/S0031182000075880; JAENIKE J, 1978, Evolutionary Theory, V3, P191; JANDA Z, 1968, ARCH GES VIRUSFORSCH, V24, P192, DOI 10.1007/BF01241291; JINKS JL, 1963, HEREDITY, V18, P245, DOI 10.1038/hdy.1963.29; JOHNSTON RE, 1988, VIROLOGY, V162, P437, DOI 10.1016/0042-6822(88)90484-9; KARRON RA, 1988, J INFECT DIS, V157, P338, DOI 10.1093/infdis/157.2.338; KILBOURNE ED, 1960, J EXP MED, V111, P387, DOI 10.1084/jem.111.3.387; KOGUT MH, 1983, PARASITOLOGY, V86, P199, DOI 10.1017/S003118200005037X; KUMAR S, 1987, VIRUS RES, V7, P335, DOI 10.1016/0168-1702(87)90047-5; KURATH G, 1995, RNA, V1, P491; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; LECOMTE V, 1992, PARASITOL RES, V78, P267, DOI 10.1007/BF00931740; LEVIN HB, 1979, MYCOPATHOL MYCOL APP, V41, P177; LEVINE JF, 1990, RES VET SCI, V48, P64, DOI 10.1016/S0034-5288(18)31511-X; LIERSCH S, 1998, P R SOC LONDON B, V265, P1; Lipsitch M, 1997, TRENDS MICROBIOL, V5, P31, DOI 10.1016/S0966-842X(97)81772-6; Mansky LM, 1998, J GEN VIROL, V79, P1337, DOI 10.1099/0022-1317-79-6-1337; MARCHETTE NJ, 1990, AM J TROP MED HYG, V43, P212, DOI 10.4269/ajtmh.1990.43.212; Mel SF, 1996, CELL, V87, P795, DOI 10.1016/S0092-8674(00)81986-8; MUSKETT JC, 1985, VACCINE, V3, P309, DOI 10.1016/S0264-410X(85)90161-6; NI YW, 1992, J GEN VIROL, V73, P3107, DOI 10.1099/0022-1317-73-12-3107; NOVELLA IS, 1995, P NATL ACAD SCI USA, V92, P5841, DOI 10.1073/pnas.92.13.5841; NOWAK MA, 1994, P ROY SOC B-BIOL SCI, V255, P81, DOI 10.1098/rspb.1994.0012; OLMSTED RA, 1984, SCIENCE, V225, P424, DOI 10.1126/science.6204381; PAVAN OH, 1981, ENTOMOPHAGA, V26, P99, DOI 10.1007/BF02371838; Plowright W, 1986, Rev Sci Tech, V5, P897, DOI 10.20506/rst.5.4.271; Proutski V, 1997, J GEN VIROL, V78, P1543, DOI 10.1099/0022-1317-78-7-1543; RUBIN SA, 1993, J VIROL, V67, P548, DOI 10.1128/JVI.67.1.548-552.1993; SABIN AB, 1954, J EXP MED, V99, P551, DOI 10.1084/jem.99.6.551; SMITH JM, 1966, AM NAT, V100, P637, DOI 10.1086/282457; STEVENS NE, 1948, J AM SOC AGRON, V40, P841; Sutherland IA, 1996, EXP PARASITOL, V83, P125, DOI 10.1006/expr.1996.0056; TAKAI S, 1994, VET MICROBIOL, V39, P187, DOI 10.1016/0378-1135(94)90099-X; Theiler M, 1937, J EXP MED, V65, P787, DOI 10.1084/jem.65.6.787; TURNBULL PCB, 1991, VACCINE, V9, P533, DOI 10.1016/0264-410X(91)90237-Z; Turner PE, 1998, EVOLUTION, V52, P315, DOI 10.1111/j.1558-5646.1998.tb01634.x; VIA S, 1990, ANNU REV ENTOMOL, V35, P421, DOI 10.1146/annurev.en.35.010190.002225; WESTROP GD, 1989, J VIROL, V63, P1338, DOI 10.1128/JVI.63.3.1338-1344.1989; WILLIAMS GC, 1991, Q REV BIOL, V66, P1, DOI 10.1086/417048; WONG MM, 1977, J PARASITOL, V63, P872, DOI 10.2307/3279897; WOOLCOCK PR, 1979, VET REC, V105, P30, DOI 10.1136/vr.105.2.30; Zelle MR, 1942, J INFECT DIS, V71, P131, DOI 10.1093/infdis/71.2.131; ZUCKERMAN MA, 1994, J INFECTION, V28, P41, DOI 10.1016/S0163-4453(94)94099-1	79	399	408	1	130	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1432	1435		10.1126/science.282.5393.1432	http://dx.doi.org/10.1126/science.282.5393.1432			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822369				2022-12-28	WOS:000077110800031
J	Lough, M; Cleland, J; Langan, J; Cowley, A; Wade, A				Lough, M; Cleland, J; Langan, J; Cowley, A; Wade, A			Initiating angiotensin converting enzyme inhibitors in mild to moderate heart failure in general practice: randomised, placebo controlled trial	BRITISH MEDICAL JOURNAL			English	Article									Airdrie Hlth Ctr, Airdrie ML6 0JU, Scotland; Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland; Bailleston Hlth Ctr, Glasgow G69 7AD, Lanark, Scotland; Queens Med Ctr, Nottingham NG7 2UH, England; Clydebank Hlth Ctr, Glasgow G81 2TQ, Lanark, Scotland	University of Glasgow; University of Nottingham	Lough, M (corresponding author), Airdrie Hlth Ctr, Monkscourt Ave, Airdrie ML6 0JU, Scotland.		Cleland, John G./AAZ-4185-2020	Cleland, John G./0000-0002-1471-7016				ANDERSON JV, 1987, BRIT HEART J, V57, P578; CLARKE KW, 1994, BRIT HEART J, V71, P584; Cleland JGF, 1996, HEART, V75, P410, DOI 10.1136/hrt.75.4.410; CLELAND JGF, 1995, J HUM HYPERTENS, V9, P435; Houghton AR, 1997, INT J CARDIOL, V59, P7, DOI 10.1016/S0167-5273(96)02904-X; Mair FS, 1996, BRIT J GEN PRACT, V46, P77; McDonagh T. A., 1996, European Heart Journal, V17, P317	7	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1352	1353		10.1136/bmj.317.7169.1352	http://dx.doi.org/10.1136/bmj.317.7169.1352			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812933	Green Published, Green Submitted			2022-12-28	WOS:000077081600021
J	Tu, JV; Hannan, EL; Anderson, GM; Iron, K; Wu, KY; Vranizan, K; Popp, AJ; Grumbach, K				Tu, JV; Hannan, EL; Anderson, GM; Iron, K; Wu, KY; Vranizan, K; Popp, AJ; Grumbach, K			The fall and rise of carotid endarterectomy in the United States and Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREVENTION; STROKE	Background Randomized clinical trials have demonstrated the efficacy of carotid endarterectomy in the prevention of stroke when the procedure is performed in regional centers of surgical excellence. However, the relative effects of these studies on the rates of carotid endarterectomy in the United States and Canada have been unclear. Methods We calculated the annual rate of carotid endarterectomy in the U.S. states of California and New York and in the Canadian province of Ontario from 1983 through 1995. We also studied whether patients in the early 1990s were selectively referred to hospitals with high volumes of procedures and historically low in-hospital mortality rates. Results Rates of carotid endarterectomy fell in all three regions from 1984 to 1989 (from 126 to 66 per 100,000 adults 40 years of age or older in California, from 65 to 40 per 100,000 in New York, and from 40 to 15 per 100,000 in Ontario), after the publication of studies demonstrating that the rates of complications of carotid endarterectomy were unacceptably high. However, the clinical trials of the 1990s, which showed benefit from carotid endarterectomy, were associated with a dramatic resurgence in the rates of the procedure from 1989 to 1995 (from 66 to 99 per 100,000 in California, from 40 to 96 per 100,000 in New York, and from 15 to 38 per 100,000 in Ontario). These increased rates were not associated with proportionally greater numbers of referrals of patients to hospitals with low mortality rates. Conclusions There have been a dramatic fall and a rise in the rates of carotid endarterectomy in both the United States and Canada, which correlate with the publication of first unfavorable and then favorable clinical studies. The absence of selective referral of patients to centers with the lowest mortality rates raises questions about whether the benefits of carotid endarterectomy in the general population are similar to those demonstrated in the clinical trials. (N Engl J Med 1998;339:1441-7.) (C) 1998, Massachusetts Medical Society.	Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Adm, Toronto, ON, Canada; Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; Albany Med Coll, Dept Surg, Albany, NY 12208 USA	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of California System; University of California San Francisco; Albany Medical College	Tu, JV (corresponding author), Inst Clin Evaluat Sci, G106-2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Grumbach, Kevin/L-9222-2016	Tu, Jack/0000-0003-0111-722X				[Anonymous], 1994, STROKE, V25, P2523; BEEBE HG, 1989, CIRCULATION, V79, P472, DOI 10.1161/01.CIR.79.2.472; BROTT T, 1984, STROKE, V15, P950, DOI 10.1161/01.STR.15.6.950; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; Commission on Professional and Hospital Activities, 1992, INT CLASS DIS; EASTCOTT HHG, 1954, LANCET, V2, P994; GILLUM RF, 1995, STROKE, V26, P1724, DOI 10.1161/01.STR.26.9.1724; GOLDSTEIN LB, 1995, STROKE, V26, P1607, DOI 10.1161/01.STR.26.9.1607; Hennekens C.H., 1987, EPIDEMIOLOGY MED; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; *MIN IND SCI TECHN, 1993, CAN CLASS DIAGN THER; MUURONEN A, 1984, STROKE, V15, P959, DOI 10.1161/01.STR.15.6.959; Rosner B., 2011, FUNDAMENTALS BIOSTAT, V7th; *SAS I, 1996, SAS SOFTW COMP PROGR; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TO T, 1996, PATTERNS HLTH CARE O, P85; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WARLOW C, 1984, STROKE, V15, P1068, DOI 10.1161/01.STR.15.6.1068; Wennberg J E, 1984, Health Manage Q, P6, DOI 10.1377/hlthaff.3.2.6; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; WINSLOW CM, 1988, NEW ENGL J MED, V319, P724	22	152	154	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1998	339	20					1441	1447		10.1056/NEJM199811123392006	http://dx.doi.org/10.1056/NEJM199811123392006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VR	9811920				2022-12-28	WOS:000077051700006
J	Ezzo, J; Berman, BM; Vickers, AJ; Linde, K				Ezzo, J; Berman, BM; Vickers, AJ; Linde, K			Complementary medicine and the Cochrane Collaboration	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SYSTEMATIC REVIEWS; CONTROLLED TRIALS; CEREBRAL INSUFFICIENCY; ALTERNATIVE MEDICINE; GINKGO-BILOBA; METAANALYSES; PREVALENCE; ENGLISH; QUALITY; BIAS		Univ Maryland, Sch Med, Complementary Med Program, Baltimore, MD 21207 USA; Res Council Complementary Med, London, England; Tech Univ, Ctr Complementary Med Res, Munich, Germany	University System of Maryland; University of Maryland Baltimore; Technical University of Munich	Ezzo, J (corresponding author), Univ Maryland, Sch Med, Complementary Med Program, Kernan Hosp Mans,2200 Kernan Dr, Baltimore, MD 21207 USA.	jezzo@compmed.ummc.ab.umd.edu		Linde, Klaus/0000-0002-2902-970X				BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; Bero LA, 1997, ANN INTERN MED, V127, P37, DOI 10.7326/0003-4819-127-1-199707010-00007; Callaham ML, 1998, JAMA-J AM MED ASSOC, V280, P254, DOI 10.1001/jama.280.3.254; *COMPL MED FIELD M, 1998, COCHR LIBR; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; Dickersin K, 1998, CLIN OBSTET GYNECOL, V41, P315, DOI 10.1097/00003081-199806000-00012; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1997, SYSTEMATATIC REV, P17; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FISHBAIN DA, 1995, NIH TECHN ASS INT BE; FULDER SJ, 1985, LANCET, V2, P542; HOFMANS EA, 1990, LANCET, V336, P57, DOI 10.1016/0140-6736(90)91574-T; Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; Khan KS, 1996, ARCH INTERN MED, V156, P661, DOI 10.1001/archinte.156.6.661; Kiley R, 1997, J ROY SOC MED, V90, P610, DOI 10.1177/014107689709001105; KLEIJNEN J, 1992, PHARM WEEKBLAD, V14, P316, DOI 10.1007/BF01977620; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352, DOI 10.1111/j.1365-2125.1992.tb05642.x; KNIPSCHILD P, 1993, LANCET, V341, P1135, DOI 10.1016/0140-6736(93)93140-V; LEHMANN HP, 1995, MED DECIS MAKING, V15, P424; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MADDOCKS I, 1985, MED J AUSTRALIA, V142, P547, DOI 10.5694/j.1326-5377.1985.tb113490.x; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5; WOOTTON JC, 1997, J ALTERN COMPLEM MED, V2, P261; 1998, COCHRANE LIBR	30	34	35	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1628	1630		10.1001/jama.280.18.1628	http://dx.doi.org/10.1001/jama.280.18.1628			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820271				2022-12-28	WOS:000076852000037
J	Argiles, A; Mourad, G; Mion, C				Argiles, A; Mourad, G; Mion, C			Seasonal changes in blood pressure in patients with end-stage renal disease treated with hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GEOGRAPHIC VARIATIONS; ENVIRONMENTAL-TEMPERATURE; HYPERTENSION; MORTALITY; SURVIVAL	Background Many factors contribute to the regulation of blood pressure. The role of climate has received relatively little attention. Methods During a four-year period, we determined the influence of climate on blood pressure in 53 patients with end-stage renal disease treated with hemodialysis. For each patient, blood pressure was measured before each of three dialysis treatments per week for an average of 31 months. The dose of dialysis (urea clearance multiplied by the length of dialysis and divided by the distribution volume of urea) and protein catabolism rate were assessed monthly. We then analyzed the monthly mean values for blood pressure, pulse, and body weight in relation to the monthly values for temperature, relative humidity, and atmospheric pressure recorded in Montpellier, France. Results The maximal monthly temperature varied from 10 degrees C in the winter to 31 degrees C in the summer, and the minimal monthly temperature from 1 to 20 degrees C. The mean (+/-SE) systolic and diastolic blood pressure was highest during the winter (153 +/- 3/82 +/- 2 mm Hg) and lowest during the summer (141 +/- 3/75 +/- 2 mm Hg). The seasonal pattern was evident throughout the four-year period. Blood pressure was correlated inversely with monthly maximal temperature (r = -0.65 and P < 0.001 for systolic pressure; r = -0.71 and P < 0.001 for diastolic pressure) and directly with minimal humidity (r = 0.45 and P = 0.002 for systolic pressure; r = 0.43 and P = 0.003 for diastolic pres sure). Changes in protein catabolic rate, weight gain between dialysis sessions, and dialysis dose were not related to changes in blood pressure. Conclusions In patients with end-stage renal disease treated with hemodialysis, blood pressure varies seasonally, with higher values in the winter and lower values in the summer. (C) 1998, Massachusetts Medical Society.	Installat Domicile Epurat Renales, 746 Rue Croix Lavit, F-34192 Montpellier 5, France; Univ Hosp Lapeyronie, Dept Nephrol, Montpellier, France; Inst Genet Humaine, Montpellier, France	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier	Argiles, A (corresponding author), Installat Domicile Epurat Renales, 746 Rue Croix Lavit, F-34192 Montpellier 5, France.			Argiles, Angel/0000-0001-7029-4532				BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919; BRUCE N, 1991, J HYPERTENS, V9, P851, DOI 10.1097/00004872-199109000-00013; CHARRA B, 1983, NEPHRON, V33, P96, DOI 10.1159/000182920; CHARRA B, 1992, KIDNEY INT, V41, P1286, DOI 10.1038/ki.1992.191; CHESTER AC, 1978, T AM SOC ART INT ORG, V24, P36; Cocchi A, 1984, Contrib Nephrol, V41, P288; de Swiet M, 1984, J Hypertens, V2, P501; Degoulet P, 1980, Proc Eur Dial Transplant Assoc, V17, P149; ELFORD J, 1990, BRIT MED J, V300, P291, DOI 10.1136/bmj.300.6720.291; European Dialysis and Transplantation Association, 1992, NEPHROL DIAL TRANSPL, V7, pS20; HUTING J, 1988, NEPHRON, V49, P284, DOI 10.1159/000185077; JENNER DA, 1987, J HYPERTENS, V5, P683; KERR PB, 1992, KIDNEY INT, V41, P1035, DOI 10.1038/ki.1992.157; Kiefe CI, 1997, CIRCULATION, V96, P1082, DOI 10.1161/01.CIR.96.4.1082; Kotchen TA, 1997, CIRCULATION, V96, P1071, DOI 10.1161/01.CIR.96.4.1071; LAZARUS JM, 1975, KIDNEY INT, V7, pS167; LINDNER A, 1974, NEW ENGL J MED, V290, P697, DOI 10.1056/NEJM197403282901301; Luik AJ, 1997, NEPHROL DIAL TRANSPL, V12, P1557; MA KW, 1992, AM J KIDNEY DIS, V19, P505, DOI 10.1016/S0272-6386(12)80827-4; POCOCK SJ, 1980, BRIT MED J, V280, P1243, DOI 10.1136/bmj.280.6226.1243; PRINEAS RJ, 1980, HYPERTENSION, V2, pI18, DOI 10.1161/01.HYP.2.4_Pt_2.I18; Scribner BH, 1997, SEMIN DIALYSIS, V10, P250, DOI 10.1111/j.1525-139X.1997.tb00505.x; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; *USRDS, 1996, AM J KIDNEY DIS S, V28, pS93; VINCENTI F, 1980, AM J MED, V68, P363, DOI 10.1016/0002-9343(80)90104-7	25	113	117	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1998	339	19					1364	1370		10.1056/NEJM199811053391904	http://dx.doi.org/10.1056/NEJM199811053391904			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135BN	9801397	Bronze			2022-12-28	WOS:000076780200004
J	Pearce, JM; Roberts, ADL; Good, M				Pearce, JM; Roberts, ADL; Good, M			Hippocampal lesions disrupt navigation based on cognitive maps but not heading vectors	NATURE			English	Article								Animals can find a hidden goal in several ways. They might use a cognitive map that encodes information about the geometric relationship between the goal and two or more landmarks(1), Alternatively, they might use a heading vector that specifies the direction and distance of the goal from a single landmark(2). Rats with damage to the hippocampus have difficulty in finding a hidden goal(3). Here we determine which of the above strategies is affected by such damage. Rats were required to swim in a water maze to a submerged platform, which was always at the same distance and direction from a landmark The platform and landmark remained in the same place for the four trials of each session, but they were moved to a new position at the start of a session(4). Rats with damage to the hippocampus found the platform more efficiently than did normal rats in the first trial of a session but, in contrast to normal rats, their performance did not improve during a session. Our results indicate that hippocampally damaged rats are able to navigate by means of heading vectors but not cognitive maps.	Cardiff Univ, Sch Psychol, Cardiff CF1 3YG, S Glam, Wales	Cardiff University	Pearce, JM (corresponding author), Cardiff Univ, Sch Psychol, Cardiff CF1 3YG, S Glam, Wales.		Pearce, John/A-1783-2010	Roberts, Amanda/0000-0002-2889-9551				COLLETT TS, 1986, J COMP PHYSIOL A, V158, P835, DOI 10.1007/BF01324825; GALISTEL CR, 1990, ORG LEARNING; JARRARD LE, 1989, J NEUROSCI METH, V29, P251, DOI 10.1016/0165-0270(89)90149-0; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Rescorla R.A., 1972, CLASSICAL CONDITION, P64, DOI DOI 10.1101/GR.110528.110; Roberts ADL, 1998, J EXP PSYCHOL ANIM B, V24, P172, DOI 10.1037/0097-7403.24.2.172	8	187	191	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1998	396	6706					75	77		10.1038/23941	http://dx.doi.org/10.1038/23941			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	136HE	9817202				2022-12-28	WOS:000076852700056
J	Cobey, JC				Cobey, JC			Monitoring of the landmine treaty	LANCET			English	Editorial Material									Surg Off, Washington, DC 20006 USA		Cobey, JC (corresponding author), Surg Off, 2029 K St NW, Washington, DC 20006 USA.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1468	1468		10.1016/S0140-6736(05)61291-3	http://dx.doi.org/10.1016/S0140-6736(05)61291-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9808011				2022-12-28	WOS:000076719500045
J	Gill, PS; Coker, J; Jones, D				Gill, PS; Coker, J; Jones, D			UH Government's immigration proposals disregard human rights	LANCET			English	Editorial Material									Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; Jane Coker & Partners Solicitors, London, England; UCL, Sch Med, London W1N 8AA, England; Royal Free Hosp, Sch Med, Dept Primary Care & Populat Sci, London, England	University of Birmingham; University of London; University College London; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Gill, PS (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.							*HOM DEP, 1998, CM4018; Sinnerbrink I, 1997, J PSYCHOL, V131, P463, DOI 10.1080/00223989709603533	2	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1468	1468		10.1016/S0140-6736(05)61292-5	http://dx.doi.org/10.1016/S0140-6736(05)61292-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	134AJ	9808012				2022-12-28	WOS:000076719500044
J	Marrion, NV; Tavalin, SJ				Marrion, NV; Tavalin, SJ			Selective activation of Ca2+-activated K+ channels by co-localized Ca2+ channels in hippocampal neurons	NATURE			English	Article							CALCIUM-CHANNEL; PYRAMIDAL NEURONS; POTASSIUM CHANNELS; AFTERHYPERPOLARIZATION; DIFFUSION; BRAIN	Calcium entry through voltage-gated calcium channels can activate either large- (BK) or small- (SK) conductance calcium-activated potassium channels. In hippocampal neurons, activation of BK channels underlies the falling phase of an action potential and generation of the fast afterhyperpolarization (AHP)(1,2). In contrast, SK channel activation underlies generation of the slow AHP after a burst of action potentials(3). The source of calcium for BK channel activation is unknown, but the slow AHP is blocked by dihydropyridine antagonists(4,5), indicating that L-type calcium channels provide the calcium for activation of SK channels. It is not understood how this specialized coupling between calcium and potassium channels is achieved, Here we study channel activity in cell-attached patches from hippocampal neurons and report a unique specificity of coupling. L-type channels activate SK channels only, without activating BK channels present in the same patch. The delay between the opening of L-type channels and SK channels indicates that these channels are 50-150 nm apart. In contrast, N-type calcium channels activate BK channels only, with opening of the two channel types being nearly coincident. This temporal association indicates that N and BK channels are very close. Finally, P/Q-type calcium channels do not couple to either SK or BK channels. These data indicate an absolute segregation of coupling between channels, and illustrate the functional importance of submembrane calcium microdomains.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England	Oregon Health & Science University; University of Bristol	Marrion, NV (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA.	N.V.Marrion@bris.ac.uk			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010202] Funding Source: NIH RePORTER; NINDS NIH HHS [F32 NS010202] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHAD JE, 1984, BIOPHYS J, V45, P993, DOI 10.1016/S0006-3495(84)84244-7; Cloues RK, 1997, J NEUROSCI, V17, P6493; Davies PJ, 1996, J PHYSIOL-LONDON, V495, P353, DOI 10.1113/jphysiol.1996.sp021599; ELLIOTT EM, 1995, J NEUROSCI, V15, P6433; Hirschberg B, 1998, J GEN PHYSIOL, V111, P565, DOI 10.1085/jgp.111.4.565; HORN R, 1983, BIOPHYS J, V43, P207, DOI 10.1016/S0006-3495(83)84341-0; IMREDY JP, 1992, NEURON, V9, P197, DOI 10.1016/0896-6273(92)90159-B; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LANCASTER B, 1991, J NEUROSCI, V11, P23; LANCASTER B, 1986, J NEUROPHYSIOL, V55, P1268, DOI 10.1152/jn.1986.55.6.1268; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; Marrion NV, 1996, NEURON, V16, P163, DOI 10.1016/S0896-6273(00)80033-1; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; McDonough SI, 1996, J NEUROSCI, V16, P2612; MILLS LR, 1994, J NEUROSCI, V14, P6815; MOYER JR, 1992, J NEUROPHYSIOL, V68, P2100, DOI 10.1152/jn.1992.68.6.2100; Naraghi M, 1997, J NEUROSCI, V17, P6961; Pineda JC, 1998, J NEUROPHYSIOL, V79, P2522, DOI 10.1152/jn.1998.79.5.2522; RASCOL O, 1991, FUNDAM CLIN PHARM, V5, P299, DOI 10.1111/j.1472-8206.1991.tb00725.x; SAH P, 1995, NEURON, V15, P435, DOI 10.1016/0896-6273(95)90047-0; STORM JF, 1987, J PHYSIOL-LONDON, V385, P733, DOI 10.1113/jphysiol.1987.sp016517; Valiante TA, 1997, J PHYSIOL-LONDON, V499, P121, DOI 10.1113/jphysiol.1997.sp021915; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; YUE DT, 1990, J GEN PHYSIOL, V95, P911, DOI 10.1085/jgp.95.5.911; YUE DT, 1990, SCIENCE, V250, P1735, DOI 10.1126/science.2176745; Zhang L, 1995, J NEUROPHYSIOL, V74, P2225, DOI 10.1152/jn.1995.74.6.2225	26	454	462	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1998	395	6705					900	905		10.1038/27674	http://dx.doi.org/10.1038/27674			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804423				2022-12-28	WOS:000076713400057
J	Neri, P; Morrone, MC; Burr, DC				Neri, P; Morrone, MC; Burr, DC			Seeing biological motion	NATURE			English	Article							POINT-LIGHT DISPLAYS; PERCEPTION; SUMMATION; PATTERNS; NOISE	One of the more stunning examples of the resoucefulness of human vision is the ability to see 'biological motion', which was first shown(1) with an adaptation of earlier cinematic work(2): illumination of only the joints of a walking person is enough to convey a vivid, compelling impression of human animation, although the percept collapses to a jumble of meaningless lights when the walker stands still. The information is sufficient to discriminate the sex and other details of the walker(3,4), and can be interpreted by young infants(5). Here we measure the ability of the visual system to integrate this type of motion information over space and time, and compare this capacity with that for viewing simple translational motion. Sensitivity to biological motion increases rapidly with the number of illuminated joints, far more rapidly than for simple motion. Furthermore, this information is summed over extended temporal intervals of up to 3 seconds (eight times longer than for simple motion). The steepness of the summation curves indicates that the mechanisms that analyse biological motion do not integrate linearly over space and time with constant efficiency, as may occur for other forms of complex motion(6), but instead adapt to the nature of the stimulus.	CNR, Ist Neurofisiol, I-56127 Pisa, Italy; Univ Florence, Dept Psychol, I-50125 Florence, Italy; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	Consiglio Nazionale delle Ricerche (CNR); University of Florence; University of Oxford	Burr, DC (corresponding author), CNR, Ist Neurofisiol, Via S Zeno 51, I-56127 Pisa, Italy.	daye@in.pi.cnr.it	Morrone, Maria Concetta/C-6756-2014; Neri, Peter/G-1066-2012	Morrone, Maria Concetta/0000-0002-1025-0316; Neri, Peter/0000-0003-1981-5309; Burr, David/0000-0003-1541-8832				Barlow H, 1997, J NEUROSCI, V17, P7954; BURR DC, 1981, PROC R SOC SER B-BIO, V211, P321, DOI 10.1098/rspb.1981.0010; Burr DC, 1998, VISION RES, V38, P1731, DOI 10.1016/S0042-6989(97)00346-5; CUTTING JE, 1981, J EXP PSYCHOL HUMAN, V7, P71, DOI 10.1037/0096-1523.7.1.71; CUTTING JE, 1978, BEHAV RES METH INSTR, V10, P91, DOI 10.3758/BF03205105; Dittrich WH, 1996, PERCEPTION, V25, P727, DOI 10.1068/p250727; FOX R, 1982, SCIENCE, V218, P486, DOI 10.1126/science.7123249; Green DM, 1966, SIGNAL DETECTION THE; JOHANSSON G, 1973, PERCEPT PSYCHOPHYS, V14, P201, DOI 10.3758/BF03212378; LAPPIN JS, 1976, VISION RES, V16, P161, DOI 10.1016/0042-6989(76)90093-6; MALONEY RK, 1987, J OPT SOC AM A, V4, P2336, DOI 10.1364/JOSAA.4.002336; Marey Etienne-Jules, 1894, LE MOUVEMENT; MARR D, 1982, PROC R SOC SER B-BIO, V214, P501, DOI 10.1098/rspb.1982.0024; MATHER G, 1992, P ROY SOC B-BIOL SCI, V249, P149, DOI 10.1098/rspb.1992.0097; MATHER G, 1994, P ROY SOC B-BIOL SCI, V258, P273, DOI 10.1098/rspb.1994.0173; MORRONE MC, 1995, NATURE, V376, P507, DOI 10.1038/376507a0; Ullman S., 1983, HUMAN MACHINE VISION, P459; WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828; WATSON AB, 1979, VISION RES, V19, P515, DOI 10.1016/0042-6989(79)90136-6; Wilson HR, 1997, VISION RES, V37, P2325, DOI 10.1016/S0042-6989(97)00104-1	20	225	230	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 29	1998	395	6705					894	896		10.1038/27661	http://dx.doi.org/10.1038/27661			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804421				2022-12-28	WOS:000076713400055
J	Golbe, LI				Golbe, LI			Parkinson's disease: nature meets nurture	LANCET			English	Editorial Material							ALPHA-SYNUCLEIN; FAMILIES		Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Golbe, LI (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08901 USA.							Baba M, 1998, AM J PATHOL, V152, P879; GOLBE LI, 1990, ANN NEUROL, V27, P276, DOI 10.1002/ana.410270309; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Schirmer EC, 1997, P NATL ACAD SCI USA, V94, P13932, DOI 10.1073/pnas.94.25.13932; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tanner CM, 1997, MOVEMENT DISORDERS N, P137; Wisniewski T, 1997, NEUROBIOL DIS, V4, P313, DOI 10.1006/nbdi.1997.0147; WSZOLEK ZK, 1993, NERVENARZT, V64, P331	11	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 24	1998	352	9137					1328	1329		10.1016/S0140-6736(05)60741-6	http://dx.doi.org/10.1016/S0140-6736(05)60741-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802266				2022-12-28	WOS:000076691700006
J	Sablin, EP; Case, RB; Dai, SC; Hart, CL; Ruby, A; Vale, RD; Fletterick, RJ				Sablin, EP; Case, RB; Dai, SC; Hart, CL; Ruby, A; Vale, RD; Fletterick, RJ			Direction determination in the minus-end-directed kinesin motor ncd	NATURE			English	Article							CRYOELECTRON MICROSCOPY; PROTEIN; DROSOPHILA; MICROTUBULES; SEGREGATION; DOMAIN	Motor proteins of the kinesin superfamily transport intracellular cargo along microtubules. Although different kinesin proteins share 30-50% amino-acid identity in their motor catalytic cores, some move to the plus end of microtubules whereas others travel in the opposite direction(1,2). Crystal structures of the Catalytic cores of conventional kinesin (a plus-end-directed motor involved in organelle transport) and ncd (a minus-end-directed motor involved in chromosome segregation) are nearly identical(3,4); therefore, the structural basis for their opposite directions of movement is unknown. Here we show that the ncd 'neck', made up of 13 class-specific residues next to the superfamily-conserved catalytic core, is essential for minus-end-directed motility, as mutagenesis of these neck residues reverses the direction of ncd motion. By solving the 2.5 Angstrom structure of a functional ncd dimer,we show that the ncd neck(a coiled-coil) differs from the corresponding region in the kinesin neck tan interrupted beta-strand)(5,6), although both necks interact with similar elements in the catalytic cores. The distinct neck architectures also confer different symmetries to the ncd and kinesin dimers and position these motors with appropriate directional bias on the microtubule.	Univ Calif San Francisco, Dept Biochem Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Vale, RD (corresponding author), Univ Calif San Francisco, Dept Biochem Biophys, San Francisco, CA 94143 USA.	vale@phy.ucsf.edu						Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HYMAN AA, 1991, J CELL SCI, P125; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	20	178	180	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 22	1998	395	6704					813	816		10.1038/27463	http://dx.doi.org/10.1038/27463			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AL	9796817				2022-12-28	WOS:000076607400060
J	Forrester, JE; Bailar, JC; Esrey, SA; Jose, MV; Castillejos, BT; Ocampo, G				Forrester, JE; Bailar, JC; Esrey, SA; Jose, MV; Castillejos, BT; Ocampo, G			Randomised trial of albendazole and pyrantel in symptomless trichuriasis in children	LANCET			English	Article							ASCARIS-LUMBRICOIDES INFECTIONS; SCHOOL-CHILDREN; TRICHIURA; HOOKWORM; MODELS; GROWTH	Background We aimed to find out whether symptomless infection with Trichuris trichiura is associated with impairment of growth and to assess the effect of a multiple-doses regimen of anthelmintic drugs on the growth of children. Methods In a community based trial, 622 Mexican children were randomly allocated one of three treatment regimens: 3 days of albendazole 400 mg daily (high efficacy); one dose of albendazole 400 mg (moderate efficacy); one dose of pyrantel (pyrantel embonate) 11 mg/kg (low efficacy). Growth was monitored for 12 months. Analyses were by intention to treat. Findings 113 (18%) children were lost to follow-up-34 from the pyrantel group, 45 from the albendazole 400 mg group, and 34 from the albendazole 1200 mg group. Among the 127 children with heavy pretreatment infections, albendazole 1200 mg was better than pyrantel in terms of an increase in arm circumference (mean 0.26 cm, p=0.044), Among the 381 children with low pretreatment levels of infection, changes in weight (mean difference between groups -0.33 kg, p=0.036), arm circumference (-0.18 cm, p=0.0095), and thickness of triceps skinfold (-0.41 mm, p=0.0031) were less in children on albendazole 1200 mg than in those on pyrantel. Interpretation Symptomless trichuriasis impairs growth and albendazole or pyrantel may affect growth, independently of a therapeutic action on parasites. Possible toxic effects of high-dose albendazole require further investigation.	McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ H3A 1A2, Canada; Inst Nacl Salud Publ, Ctr Invest Sobre Enfermedades Infecciosas, Col Sta Maria Ahuacatitlan, Cuernavaca, Morelos, Mexico	McGill University; Instituto Nacional de Salud Publica	Forrester, JE (corresponding author), Tufts Univ, Sch Med, Dept Family Med & Community Hlth, Boston, MA 02111 USA.		José, Marco/AFU-1547-2022; José, Marco V./A-1075-2008	José, Marco/0000-0001-8497-6681; 				Beaver PC, 1984, CLIN PARASITOLOGY, P231; BUNDY DAP, 1985, T ROY SOC TROP MED H, V79, P641, DOI 10.1016/0035-9203(85)90178-6; CLINE BL, 1982, MED CLIN N AM, V66, P721, DOI 10.1016/S0025-7125(16)31418-3; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; GOTTSCHALL DW, 1990, PARASITOL TODAY, V6, P115, DOI 10.1016/0169-4758(90)90228-V; HALL A, 1993, T ROY SOC TROP MED H, V87, P84, DOI 10.1016/0035-9203(93)90435-S; JORDAN MD, 1986, ANTHROPOMETRIC SOFTW; KATZ M, 1982, REV INFECT DIS, V4, P768; LACEY E, 1990, PARASITOL TODAY, V6, P112, DOI 10.1016/0169-4758(90)90227-U; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lohman T. G., 1998, ANTROPOMETRIC STANDA; MARRINER SE, 1986, EUR J CLIN PHARMACOL, V30, P705, DOI 10.1007/BF00608219; MARTIN LK, 1968, AM J TROP MED HYG, V17, P382, DOI 10.4269/ajtmh.1968.17.382; NOKES C, 1992, PARASITOLOGY, V104, P539, DOI 10.1017/S0031182000063800; Reynoldson J. A., 1992, Parasitology Today, V8, P412, DOI 10.1016/0169-4758(92)90193-6; Rosso Del, 1996, CLASS ACTION IMPROVI; SIMEON DT, 1995, J NUTR, V125, P1875, DOI 10.1093/jn/125.7.1875; STEPHENSEON LS, 1987, IMPACT HELMINTH INFE; STEPHENSON LS, 1989, AM J TROP MED HYG, V41, P78, DOI 10.4269/ajtmh.1989.41.78; STEPHENSON LS, 1993, J NUTR, V123, P656, DOI 10.1093/jn/123.4.656; STEPHENSON LS, 1993, J NUTR, V123, P1036; WALKER SP, 1988, EUR J CLIN NUTR, V42, P395; WARREN KS, 1991, LANCET, V338, P686, DOI 10.1016/0140-6736(91)91251-O; WHITTAKER SG, 1991, TOXICOL APPL PHARM, V109, P73, DOI 10.1016/0041-008X(91)90192-H; *WHO, 1992, WHOCDSIPICTD921; ZEGER SL, 1986, BIOMETRICS, V42, P212	26	32	33	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 3	1998	352	9134					1103	1108		10.1016/S0140-6736(97)08325-6	http://dx.doi.org/10.1016/S0140-6736(97)08325-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798586				2022-12-28	WOS:000076246400011
J	Savage, P; Roddie, M; Seckl, MJ				Savage, P; Roddie, M; Seckl, MJ			A 28-year-old woman with a pulmonary embolus	LANCET			English	Article							CHORIOCARCINOMA	In February, 1997, a 28-year-old woman was seen in a casualty department with a 4-month history of a cough producing blood-stained non-purulent sputum and shortness of breath. During the preceding 2 weeks she had had intermittent vaginal bleeding after 3 months without a menstrual period. Her periods were usually regular. She had two children, the youngest being 3 years old. She was considered to have a chest infection and was treated with oral antibiotics. 2 weeks later her symptoms were worse, with increasing shortness of breath and chest pain. She was admitted to hospital with hypoxia, raised venous pressure, right heart strain, and consolidation at the right lung base. Chest radiograph showed areas of consolidation in the right lung. Ventilation/perfusion scans showed normal ventilation but absent perfusion to the entire right lung and multiple small defects in the left lung. Ultrasound examination of the pelvis and leg veins was unremarkable with no enlargement of the uterus or evidence of deep-vein thrombosis. Full blood count and biochemistry were normal. A diagnosis of pulmonary thromboembolism was made and she was anticoagulated with heparin. 3 days later her condition had not improved and a gynaecologist was consulted about her vaginal bleeding.	Charing Cross Hosp, Dept Med Oncol, London W6 8RF, England; Charing Cross Hosp, Dept Radiol, London W6 8RF, England	Imperial College London; Imperial College London	Seckl, MJ (corresponding author), Charing Cross Hosp, Dept Med Oncol, London W6 8RF, England.			Savage, Philip/0000-0002-4792-6869				MEANEY FM, 1997, NEW ENGL J MED, V336, P1422; NEWLANDS ES, 1991, BRIT J OBSTET GYNAEC, V98, P550, DOI 10.1111/j.1471-0528.1991.tb10369.x; SECKL MJ, 1991, LANCET, V338, P1313, DOI 10.1016/0140-6736(91)92603-Y; TIDY JA, 1995, BRIT J OBSTET GYNAEC, V102, P715, DOI 10.1111/j.1471-0528.1995.tb11429.x	4	14	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					30	30		10.1016/S0140-6736(98)05199-X	http://dx.doi.org/10.1016/S0140-6736(98)05199-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800743				2022-12-28	WOS:000074608600014
J	Summerbell, CD; Watts, C; Higgins, JPT; Garrow, JS				Summerbell, CD; Watts, C; Higgins, JPT; Garrow, JS			Randomised controlled trial of novel, simple, and well supervised weight reducing diets in outpatients	BRITISH MEDICAL JOURNAL			English	Article							OBESITY	Objectives To investigate the contribution of novelty and simplicity to compliance with a low energy diet among obese outpatients. Design Three arm randomised trial for 16 weeks. Setting NHS hospital obesity clinic. Subjects 45 patients aged over 17 years with a body mass index > 27 who were not diabetic, pregnant, or lactating. Interventions Conventional 3.4 MJ diet (control), isoenergetic novel diet of milk only, or milk plus one designated food daily. Follow up visit every 4 weeks, Main outcome measure Weight loss. Results Mean weight loss (kg) after 16 weeks on control, milk only, and milk plus diets was 1.7 (95% confidence interval - 0.3 to 3.7), 9.4 (5.9 to 12.9), and 7.0 (2.7 to 11.3) respectively, Weight loss on the novel diets was significantly greater than on the control diet. Conclusions Dietary treatment can achieve as much weight loss in obese outpatients over 16 weeks as has been reported for the most successful drug treatment, but compliance with the prescribed diet is poor unless the diet is novel and simple.	Univ London St Bartholomews Hosp Med Coll, Rank Dept Human Nutr, London EC1M 6BQ, England; Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England	University of London; Queen Mary University London; University of London; University College London	Summerbell, CD (corresponding author), Univ Teesside, Sch Hlth, Middlesbrough TS1 3BA, Cleveland, England.		Summerbell, Carolyn/AAC-3159-2019; Higgins, Julian PT/H-4008-2011	Summerbell, Carolyn/0000-0003-1910-9383; Higgins, Julian PT/0000-0002-8323-2514				BORTZ WM, 1969, AM J MED, V47, P325, DOI 10.1016/0002-9343(69)90159-4; BRAY GA, 1996, CIBA S, V201; Garrow J. S., 1988, OBESITY RELATED DIS; GARROW JS, 1989, INT J OBESITY, V13, P521; Glenny AM, 1997, INT J OBESITY, V21, P715, DOI 10.1038/sj.ijo.0800495; GUYGRAND B, 1989, LANCET, V2, P1142; James WPT, 1997, INT J OBESITY, V21, pS24; Lean MEJ, 1997, INT J OBESITY, V21, pS30; *SCOTT INT GUID NE, 1996, OB SCOTL; Sjostrom L, 1998, LANCET, V352, P167, DOI 10.1016/S0140-6736(97)11509-4; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; WING RR, 1979, INT J OBESITY, V3, P261	12	62	65	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1487	1489		10.1136/bmj.317.7171.1487	http://dx.doi.org/10.1136/bmj.317.7171.1487			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831574	Green Published, Bronze			2022-12-28	WOS:000077338300023
J	Wade, NA; Birkhead, GS; Warren, BL; Charbonneau, TT; French, PT; Wang, L; Baum, JB; Tesoriero, JM; Savicki, R				Wade, NA; Birkhead, GS; Warren, BL; Charbonneau, TT; French, PT; Wang, L; Baum, JB; Tesoriero, JM; Savicki, R			Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VERTICAL TRANSMISSION; PREVENTION; INFECTION; REDUCTION; MACAQUES; AIDS	Background The Pediatric AIDS Clinical Trials Group Protocol 076 reported a reduction in the rate of perinatal transmission of the human immunodeficiency virus (HIV) from 25.5 percent to 8.3 percent with a three-part regimen of zidovudine given ante partum, intra partum, and to the newborn. We examined the effects of abbreviated zidovudine regimens on perinatal HIV transmission using data from the HIV polymerase-chain-reaction (PCR) testing service of the New York State Department of Health. Pregnant women who received abbreviated regimens rather than the recommended regimens did so because of limited prenatal care or by choice. Methods The requisition form used by the PCR testing service included information on the demographic characteristics of the infants and the timing of any perinatal treatment with zidovudine. We also analyzed data on the timing of zidovudine prophylaxis collected by chart review in a subgroup of 454 infants as a means of validating the results in the entire cohort. Results From August 1, 1995, through January 31, 1997, specimens from 939 HIV-exposed infants who were 180 days of age or younger were submitted for PCR testing. The rates of perinatal HIV transmission varied depending on when zidovudine prophylaxis was begun. When treatment was begun in the prenatal period, the rate of HIV transmission was 6.1 percent (95 percent confidence interval, 4.1 to 8.9 percent); when begun intra partum, the rate was 10.0 percent (3.3 to 21.8 percent); when begun within the first 48 hours of life, the rate was 9.3 percent (4.1 to 17.5 percent); and when begun on day 3 of life or later, the rate was 18.4 percent (7.7 to 34.3 percent). In the absence of zidovudine prophylaxis, the rate of HIV transmission was 26.6 percent (21.1 to 32.7 percent). Conclusions These results confirm the efficacy of zidovudine prophylaxis and suggest that there are reductions in the rates of perinatal transmission of HIV even with the use of abbreviated regimens that are begun intra partum or in the first 48 hours of life. (N Engl J Med 1998;339:1409-14.) (C) 1998, Massachusetts Medical Society.	New York State Dept Hlth, AIDS Inst, Albany, NY 12237 USA; New York State Dept Hlth, Wadsworth Lab, Albany, NY 12237 USA; New York State Dept Hlth, Prevent Med Residency Program, Albany, NY 12237 USA; SUNY Albany, Sch Publ Hlth, Dept Epidemiol, Albany, NY 12222 USA	State University of New York (SUNY) System; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Wade, NA (corresponding author), New York State Dept Hlth, AIDS Inst, Empire State Plaza,Corning Tower,Rm 412, Albany, NY 12237 USA.		Birkhead, Guthrie/AAG-9058-2019	Birkhead, Guthrie/0000-0002-6511-6560				Bottiger D, 1997, AIDS, V11, P157, DOI 10.1097/00002030-199702000-00004; Charbonneau TT, 1997, AIDS PATIENT CARE ST, V11, P227, DOI 10.1089/apc.1997.11.227; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; Cornfield J, 1961, B INT STAT I, V38, P97; FISCUS SA, 1997, 4 C RETR OPP INF WAS, P134; MANTEL N, 1959, J NATL CANCER I, V22, P719; *PHS TASK FORC, 1998, MMWR-MORBID MORTAL W, V47, P30; *SAS I, 1995, SAS VERS 6 11; SCOTT GB, 1995, PEDIATRICS, V95, P303; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; *US PUBL HLTH SERV, 1995, MMWR-MORBID MORTAL W, V44, P1; US Public Health Service, 1994, MMWR-MORBID MORTAL W, V43, P1; VANROMPAY KKA, 1995, ANTIMICROB AGENTS CH, V39, P125, DOI 10.1128/AAC.39.1.125; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; 1995, MMWR MORB MORTAL WKL, V44, P929; 1997, INT J GYNECOL OBSTET, V57, P73; 1998, MMWR MORB MORTAL WKL, V47, P211; 1998, MMWR MORB MORTAL WKL, V47, P151	19	388	400	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1998	339	20					1409	1414		10.1056/NEJM199811123392001	http://dx.doi.org/10.1056/NEJM199811123392001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VR	9811915				2022-12-28	WOS:000077051700001
J	Bove, G; Nilsson, N				Bove, G; Nilsson, N			Spinal manipulation in the treatment of episodic tension-type headache - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Episodic tension-type headache is common and is often treated using manual therapies. Few data exist for the efficacy of these interventions. Objective.-To determine the effects of spinal manipulation therapy on adults with episodic tension-type headache. Design.-Randomized controlled trial lasting 19 weeks. Setting.-Outpatient facility of a National Health Service-funded chiropractic research institution in Denmark. Participants.-Volunteer sample of 26 men and 49 women aged 20 to 59 years who met the diagnostic criteria for episodic tension-type headache as defined by the International Headache Society, Intervention.-Participants were randomized into 2 groups, 1 receiving soft tissue therapy and spinal manipulation (the manipulation group), and the other receiving soft tissue therapy and a placebo laser treatment (the control group). All participants received 8 treatments over 4 weeks; all treatments were performed by the same chiropractor, Main Outcome Measures.-Daily hours of headache, pain intensity per episode, and daily analgesic use, as recorded in diaries. Results.-Based on intent-to-treat analysis, no significant differences between the manipulation and control groups were observed in any of the 3 outcome measures, However, by week 7, each group experienced significant reductions in mean daily headache hours (manipulation group, reduction from 2.8 to 1.5 hours; control group, reduction from 3.4 to 1.9 hours) and mean number of analgesics per day (manipulation group, reduction from 0.66 to 0.38; control group, reduction from 0.82 to 0.59). These changes were maintained through the observation period. Headache pain intensity was unchanged for the duration of the trial. Conclusion.-As an isolated intervention, spinal manipulation does not seem to have a positive effect on episodic tension-type headache.	Odense Univ, Ctr Biomech, Dept Anat & Cell Biol, DK-5220 Odense M, Denmark	University of Southern Denmark	Nilsson, N (corresponding author), Odense Univ, Ctr Biomech, Dept Anat & Cell Biol, Campusvej 55, DK-5220 Odense M, Denmark.							Bergmann TF, 1993, CHIROPRACTIC TECHNIQ; BOGDUK N, 1987, PATIENT MANAGE, V11, P163; BOLINE PD, 1995, J MANIP PHYSIOL THER, V18, P148; GAM AN, 1993, PAIN, V52, P63, DOI 10.1016/0304-3959(93)90114-5; HOYT WH, 1979, J AM OSTEOPATH ASSOC, V78, P322; LEWIT K, 1971, EUR NEUROL, V5, P365, DOI 10.1159/000114092; Nilsson N, 1997, J Manipulative Physiol Ther, V20, P326; NILSSON N, 1995, J MANIP PHYSIOL THER, V18, P435; NILSSON N, 1995, CERVICOGENIC HEADACH; OLESEN J, 1988, Cephalalgia, V8, P1; Pfaffenrath V, 1990, Funct Neurol, V5, P159; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; Schwartz BS, 1998, JAMA-J AM MED ASSOC, V279, P381, DOI 10.1007/s11916-010-0146-2; Turk Z, 1987, MANUAL MED, V3, P15; VERNON H, 1982, J MANIP PHYSIOL THER, V5, P109; [No title captured]; [No title captured]	17	94	94	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1576	1579		10.1001/jama.280.18.1576	http://dx.doi.org/10.1001/jama.280.18.1576			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820258	Bronze			2022-12-28	WOS:000076852000023
J	Showalter, MR				Showalter, MR			Detection of centimeter-sized meteoroid impact events in Saturn's F ring	SCIENCE			English	Article							B-RING; SPOKES; PLANETARY; EVOLUTION; SATELLITES	Voyager images reveal that three prominent clumps in Saturn's F ring were short-lived, appearing rapidly and then spreading and decaying in brightness over periods of similar to 2 weeks. These features arise from hypervelocity impacts by similar to 10-centimeter meteoroids into F ring bodies. Future ring observations of these impact events could constrain the centimeter-sized component of the meteoroid population, which is otherwise unmeasurable but plays an import ant role in the evolution of rings and surfaces in the outer solar system. The F ring's numerous other trumps are much longer lived and appear to be unrelated to impacts.	Stanford Univ, Space Telecommun & Radiosci Lab, Stanford, CA 94305 USA	Stanford University	Showalter, MR (corresponding author), NASA, Ames Res Ctr, Moffett Field, CA 94035 USA.							Bosh AS, 1996, SCIENCE, V272, P518, DOI 10.1126/science.272.5261.518; Burns J.A., 1984, IAU COLLO Q 75 PLANE, P200; Cuzzi JN, 1998, ICARUS, V132, P1, DOI 10.1006/icar.1997.5863; CUZZI JN, 1988, ICARUS, V74, P284, DOI 10.1016/0019-1035(88)90043-7; CUZZI JN, 1990, ICARUS, V84, P467, DOI 10.1016/0019-1035(90)90049-F; DERMOTT SF, 1981, NATURE, V290, P454, DOI 10.1038/290454a0; DOYLE LR, 1989, ICARUS, V80, P104, DOI 10.1016/0019-1035(89)90163-2; Durisen RH, 1996, ICARUS, V124, P220, DOI 10.1006/icar.1996.0200; GEHRELS T, 1980, SCIENCE, V207, P434, DOI 10.1126/science.207.4429.434; GOERTZ CK, 1983, ICARUS, V53, P219, DOI 10.1016/0019-1035(83)90143-4; GRUN E, 1983, ICARUS, V54, P227, DOI 10.1016/0019-1035(83)90194-X; Grun E., 1984, ADV SPACE RES, V4, P143, DOI [10.1016/0273-1177(84)90019-X, DOI 10.1016/0273-1177(84)90019-X]; Hall DT, 1996, SCIENCE, V272, P516, DOI 10.1126/science.272.5261.516; HILL JR, 1982, J GEOPHYS RES-SPACE, V87, P7413, DOI 10.1029/JA087iA09p07413; HUMES DH, 1980, J GEOPHYS RES-SPACE, V85, P5841, DOI 10.1029/JA085iA11p05841; KOLVOORD RA, 1990, NATURE, V345, P695, DOI 10.1038/345695a0; MORFILL GE, 1983, ICARUS, V55, P439, DOI 10.1016/0019-1035(83)90114-8; MORFILL GE, 1983, ICARUS, V53, P230, DOI 10.1016/0019-1035(83)90144-6; POLLACK JB, 1980, J ATMOS SCI, V37, P868, DOI 10.1175/1520-0469(1980)037<0868:SBNPOS>2.0.CO;2; POULET F, 1997, B AM ASTRON SOC, V29, P1001; RODDIER C, 1996, 6515 IAU; SHOWALTER MR, 1992, ICARUS, V100, P394, DOI 10.1016/0019-1035(92)90107-I; SHOWALTER MR, 1982, ICARUS, V52, P526, DOI 10.1016/0019-1035(82)90013-6; SHOWALTER MR, 1997, B AM ASTRON SOC, V29, P999; SHOWALTER MR, 1994, B AM ASTRON SOC, V26, P1150; SMITH BA, 1981, SCIENCE, V212, P163, DOI 10.1126/science.212.4491.163; SMITH BA, 1982, SCIENCE, V215, P504, DOI 10.1126/science.215.4532.504; SYNNOTT SP, 1983, ICARUS, V53, P156, DOI 10.1016/0019-1035(83)90029-5; TAGGER M, 1991, ICARUS, V91, P297, DOI 10.1016/0019-1035(91)90026-P	29	41	41	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1099	1102		10.1126/science.282.5391.1099	http://dx.doi.org/10.1126/science.282.5391.1099			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804543				2022-12-28	WOS:000076887700043
J	Higgs, DR				Higgs, DR			Do LCRs open chromatin domains?	CELL			English	Review							LOCUS ACTIVATION REGION; BETA-GLOBIN LOCUS; GENE; TRANSCRIPTION; REPLICATION; MICE		John Radcliffe Hosp, MRC, Mol Haematol Unit, Inst Mol Med, Oxford OX3 9DS, England	University of Oxford	Higgs, DR (corresponding author), John Radcliffe Hosp, MRC, Mol Haematol Unit, Inst Mol Med, Oxford OX3 9DS, England.							ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Grosveld F, 1998, SEMIN HEMATOL, V35, P105; Higgs DR, 1998, SEMIN HEMATOL, V35, P93; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Reik A, 1998, MOL CELL BIOL, V18, P5992, DOI 10.1128/MCB.18.10.5992; STALDER J, 1980, CELL, V20, P451, DOI 10.1016/0092-8674(80)90631-5; Stamatoyannopolous G., 1994, MOL BASIS BLOOD DIS, P107; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749	17	85	91	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 30	1998	95	3					299	302		10.1016/S0092-8674(00)81761-4	http://dx.doi.org/10.1016/S0092-8674(00)81761-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814700	Bronze			2022-12-28	WOS:000076789600003
J	Treloar, SA; Do, KA; Martin, NG				Treloar, SA; Do, KA; Martin, NG			Genetic influences on the age at menopause	LANCET			English	Editorial Material							TWIN		PO Royal Brisbane Hosp, Queensland Inst Med Res, Cooperat Res Ctr Discovery Genes Common Human Dis, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	Treloar, SA (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Cooperat Res Ctr Discovery Genes Common Human Dis, Brisbane, Qld 4029, Australia.			Martin, Nicholas/0000-0003-4069-8020				Faddy MJ, 1996, HUM REPROD, V11, P1484; GOSDEN RG, 1987, HUM REPROD, V2, P617, DOI 10.1093/oxfordjournals.humrep.a136601; MARTIN NG, 1978, HEREDITY, V40, P97, DOI 10.1038/hdy.1978.10; Martin NG, 1997, AM J MED GENET, V69, P114, DOI 10.1002/(SICI)1096-8628(19970303)69:1<114::AID-AJMG23>3.0.CO;2-R; NEALE MC, 1992, NATO ASI SERIES; Snieder H, 1998, J CLIN ENDOCR METAB, V83, P1875, DOI 10.1210/jc.83.6.1875; TRELOAR AE, 1967, INT J FERTIL, V12, P77; TRELOAR SA, 1990, AM J HUM GENET, V47, P137; TRELOAR SA, 1992, AM J OBSTET GYNECOL, V167, P82, DOI 10.1016/S0002-9378(11)91632-9	9	77	79	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 3	1998	352	9134					1084	1085		10.1016/S0140-6736(05)79753-1	http://dx.doi.org/10.1016/S0140-6736(05)79753-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798581				2022-12-28	WOS:000076246400006
J	Lees, KR				Lees, KR			If I had a stroke ...	LANCET			English	Article							ACUTE ISCHEMIC STROKE; INFARCTION	... I will aim to bypass my family doctor and organise Immediate transport to hospital. The options for acute treatment may be limited, but there is no disadvantage to early specialist attention and investigation. I will choose a hospital that has an expressed interest in stroke, and preferably an acute-stroke unit. Specialist stroke care reduces disability and mortality,(1) and uncertainty over: the contribution of acute care is now diminishing.(2)	Univ Glasgow, Western Infirm, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Lees, KR (corresponding author), Univ Glasgow, Western Infirm, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland.							Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Bath FJ, 1997, CEREBROVASC DIS, V7, P205, DOI 10.1159/000108192; Diener HC, 1998, CEREBROVASC DIS, V8, P172, DOI 10.1159/000015847; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Dyker AG, 1997, BMJ-BRIT MED J, V314, P1584, DOI 10.1136/bmj.314.7094.1584; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Grotta J, 1997, STROKE, V28, P2338, DOI 10.1161/01.STR.28.12.2338; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Lees KR, 1998, LANCET, V351, P1447, DOI 10.1016/S0140-6736(05)78865-6; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Muir K, 1997, LANCET, V350, P1476, DOI 10.1016/S0140-6736(05)64242-0; Ronning OM, 1998, STROKE, V29, P58, DOI 10.1161/01.STR.29.1.58; Sandercock P, 1997, LANCET, V349, P1569; Squire IB, 1996, CEREBROVASC DIS, V6, P156, DOI 10.1159/000108016; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WAHLGREN NG, 1994, CEREBROVASC DIS, V4, P204, DOI 10.1159/000108483; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5; Weir CJ, 1997, BMJ-BRIT MED J, V314, P1303, DOI 10.1136/bmj.314.7090.1303; WEIR CJ, 1994, LANCET, V344, P999, DOI 10.1016/S0140-6736(94)91648-9	19	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT	1998	352			3			SIII28	SIII30						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133UP	9803960				2022-12-28	WOS:000076704700008
J	Vuadens, P; Bogousslavsky, J				Vuadens, P; Bogousslavsky, J			Diagnosis as a guide to stroke therapy	LANCET			English	Article							ACUTE ISCHEMIC STROKE; MAGNETIC-RESONANCE ANGIOGRAPHY; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE-PROFESSIONALS; SPECIAL-WRITING-GROUP; VASCULAR TERRITORIES; HEMORRHAGIC STROKE; HEMISPHERIC STROKE; CAROTID-ARTERY; MANAGEMENT		CHU Vaudois, Dept Neurol, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Bogousslavsky, J (corresponding author), CHU Vaudois, Dept Neurol, CH-1011 Lausanne, Switzerland.							Aboderin I, 1996, J INTERN MED, V240, P173, DOI 10.1046/j.1365-2796.1996.39861000.x; Adams HP, 1996, STROKE, V27, P1711; ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; BAMFORD JM, 1996, MEASUREMENT NEUROLOG, P303; BESSON G, 1995, STROKE, V26, P1205, DOI 10.1161/01.STR.26.7.1205; Bogousslavsky J, 1996, CEREBROVASC DIS, V6, P315; BOGOUSSLAVSKY J, 1991, CEREBROVASC DIS, V1, P61, DOI 10.1159/000108899; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; DAMASIO H, 1983, ARCH NEUROL-CHICAGO, V40, P138, DOI 10.1001/archneur.1983.04050030032005; DEBRAY JM, 1995, CEREBROVASC DIS, V5, P414, DOI 10.1159/000107895; EDWARDS DF, 1995, STROKE, V26, P1852, DOI 10.1161/01.STR.26.10.1852; Ferro JM, 1996, STROKE, V27, P2225, DOI 10.1161/01.STR.27.12.2225; FISHER M, 1995, JAMA-J AM MED ASSOC, V274, P908; GHIKA JA, 1990, ARCH NEUROL-CHICAGO, V47, P1097, DOI 10.1001/archneur.1990.00530100063014; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; KASTE M, 1995, STROKE, V26, P249, DOI 10.1161/01.STR.26.2.249; Kothari R, 1997, STROKE, V28, P1871, DOI 10.1161/01.STR.28.10.1871; LEYS D, 1992, STROKE, V23, P317, DOI 10.1161/01.STR.23.3.317; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Nendaz M, 1997, EUR NEUROL, V37, P199, DOI 10.1159/000117442; ORGOGOZO JM, 1992, STROKE, V23, P1678, DOI 10.1161/01.STR.23.11.1678; ROSEN B R, 1989, Magnetic Resonance Quarterly, V5, P263; ROTHER J, 1995, J NEUROL, V242, P430, DOI 10.1007/BF00873545; ROTHER J, 1993, STROKE, V24, P1310, DOI 10.1161/01.STR.24.9.1310; Siewert B, 1997, STROKE, V28, P1211, DOI 10.1161/01.STR.28.6.1211; TEASDALE G, 1974, LANCET, V2, P81; VANNINEN RI, 1993, STROKE, V24, P1310; Von Kummer Rudiger, 1997, Stroke, V28, P270; VONKUMMER R, 1995, EARLY CT DIAGNOSIS H; WARRACH S, 1996, J CEREB BLOOD FLOW M, V16, P53; Worthy SA, 1997, NEURORADIOLOGY, V39, P122, DOI 10.1007/s002340050378	32	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT	1998	352			3			SIII5	SIII9						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133UP	9803955				2022-12-28	WOS:000076704700003
J	Amores, A; Force, A; Yan, YL; Joly, L; Amemiya, C; Fritz, A; Ho, RK; Langeland, J; Prince, V; Wang, YL; Westerfield, M; Ekker, M; Postlethwait, JH				Amores, A; Force, A; Yan, YL; Joly, L; Amemiya, C; Fritz, A; Ho, RK; Langeland, J; Prince, V; Wang, YL; Westerfield, M; Ekker, M; Postlethwait, JH			Zebrafish hox clusters and vertebrate genome evolution	SCIENCE			English	Article							FUNCTIONAL EVOLUTION; GENE; ORGANIZATION; EXPRESSION; TRANSCRIPTION; DROSOPHILA; TETRAPODS; COMPLEX	HOX genes specify cell fate in the anterior-posterior axis of animal embryos. Invertebrate chordates have one HOX cluster, but mammals have four, suggesting that cluster duplication facilitated the evolution of vertebrate body Plans. This report shows that zebrafish have seven hox clusters. Phylogenetic analysis and genetic mapping suggest a chromosome doubling event, probably by whole genome duplication, after the divergence of ray-finned and lobe-finned fishes but before the teleost radiation. Thus, teleosts, the most species-rich group of vertebrates, appear to have more copies of;these developmental regulatory genes than do mammals, despite Less complexity in the anterior-posterior axis.	Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA; Ottawa Civic Hosp, Loeb Inst Med Res, Ottawa, ON K1Y 4E9, Canada; Boston Univ, Sch Med, Ctr Human Genet, Boston, MA 02118 USA; Emory Univ, Dept Biol, Atlanta, GA 30322 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Chicago, Chicago, IL 60637 USA; Kalamazoo Coll, Dept Biol, Kalamazoo, MI 49006 USA	University of Oregon; University of Ottawa; Ottawa Hospital Research Institute; Boston University; Emory University; Princeton University; University of Chicago; Kalamazoo College	Ekker, M (corresponding author), Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA.		Yan, Yi/GSO-3046-2022	Prince, Victoria/0000-0001-5810-7300; Amores, Angel/0000-0002-9307-3609	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD022486] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR010715] Funding Source: NIH RePORTER; NCRR NIH HHS [R01RR10715] Funding Source: Medline; NICHD NIH HHS [P01HD22486] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; Allendorf F.W., 1984, P1; AMEMIYA C, UNPUB; Aparicio S, 1997, NAT GENET, V16, P79, DOI 10.1038/ng0597-79; Bailey WJ, 1997, MOL BIOL EVOL, V14, P843, DOI 10.1093/oxfordjournals.molbev.a025825; BUTH DG, 1991, CYPRINID FISHES SYST, P00083; CANTATORE P, 1994, J MOL EVOL, V39, P589, DOI 10.1007/BF00160404; Dickman S, 1997, SCIENCE, V275, P1568, DOI 10.1126/science.275.5306.1568; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; EIKEN HG, 1987, BIOCHEM BIOPH RES CO, V149, P1165, DOI 10.1016/0006-291X(87)90530-4; FERRIS SD, 1979, J MOL EVOL, V12, P267, DOI 10.1007/BF01732026; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; Kmita-Cunisse M, 1998, P NATL ACAD SCI USA, V95, P3030, DOI 10.1073/pnas.95.6.3030; Kourakis MJ, 1997, DEV BIOL, V190, P284, DOI 10.1006/dbio.1997.8689; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Misof BY, 1996, MOL PHYLOGENET EVOL, V5, P309, DOI 10.1006/mpev.1996.0026; Misof BY, 1996, J EXP ZOOL, V274, P193, DOI 10.1002/(SICI)1097-010X(19960215)274:3&lt;193::AID-JEZ6&gt;3.0.CO;2-J; NJOLSTAD P R, 1989, Gene (Amsterdam), V73, P33; NJOLSTAD PR, 1988, NUCLEIC ACIDS RES, V16, P9097, DOI 10.1093/nar/16.19.9097; NJOLSTAD PR, 1990, EMBO J, V9, P515, DOI 10.1002/j.1460-2075.1990.tb08138.x; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; PRINCE V, 1997, DEVELOPMENT, V125, P393; Prince VE, 1998, DEVELOPMENT, V125, P407; RUNSTADLER JA, 1991, NUCLEIC ACIDS RES, V19, P5434, DOI 10.1093/nar/19.19.5434; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sordino P, 1996, MECH DEVELOP, V59, P165, DOI 10.1016/0925-4773(96)00587-4; vanderHoeven F, 1996, MECH DEVELOP, V54, P9, DOI 10.1016/0925-4773(95)00455-6; Zhang JZ, 1996, GENETICS, V142, P295	30	1417	1485	3	188	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1711	1714		10.1126/science.282.5394.1711	http://dx.doi.org/10.1126/science.282.5394.1711			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831563				2022-12-28	WOS:000077246600048
J	Hu, FB; Stampfer, MJ; Manson, JE; Rimm, EB; Colditz, GA; Rosner, BA; Speizer, FE; Hennekens, CH; Willett, WC				Hu, FB; Stampfer, MJ; Manson, JE; Rimm, EB; Colditz, GA; Rosner, BA; Speizer, FE; Hennekens, CH; Willett, WC			Frequent nut consumption and risk of coronary heart disease in women: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIETARY-FAT; PLASMA-CHOLESTEROL; HEALTH; ATHEROSCLEROSIS; LIPOPROTEINS; ALMONDS; WALNUTS; ACIDS; MEN	Objective To examine the relation between nut consumption and risk of coronary heart disease in a cohort of women from the Nurses' Health Study. Design Prospective cohort study Setting Nurses' Health Study. Subjects 86 016 women from 34 to 59 years of age without previously diagnosed coronary heart disease, stroke, or cancer at baseline in 1980. Main outcome measures Major coronary heart disease including non-fatal myocardial infarction and fatal coronary heart disease. Results 1255 major coronary disease events (861 cases of non-fatal myocardial infarction and 394 cases of fatal coronary heart disease) occurred during 14 years of follow up. After adjusting far age, smoking, and other known risk factors for coronary heart disease, women who ate more than five units of nuts tone unit equivalent to 1 oz of nuts) a week (frequent consumption) had a significantly lower risk of total coronary heart disease (relative risk 0.65, 95% confidence interval 0.47 to 0.89, P for trend = 0.0009) than women who never ate nuts or who ate less than one unit a month (rare consumption). The magnitude of risk reduction was similar for both fatal coronary heart disease (0.61, 0.35 to 1.05, P for trend = 0.007) and non-fatal myocardial infarction (0.68, 0.47 to 1.00, P for trend = 0.04), Further adjustment for intakes of dietary fats, fibre, vegetables, and fruits did not alter these results. The inverse association persisted in subgroups stratified by levels of smoking, use of alcohol, use of multivitamin and vitamin E supplements, body mass index, exercise, and intake of vegetables or fruits. Conclusions Frequent nut consumption was associated with a reduced risk of both fatal coronary heart disease and non-fatal myocardial infarction. These data, and these from other epidemiological and clinical studies, support a role for nuts in reducing the risk of coronary heart disease.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Hu, FB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.	Frank.Hu@channing.harvard.edu	Colditz, Graham/A-3963-2009; Hu, Frank/C-1919-2013	Colditz, Graham/0000-0002-7307-0291; 	NCI NIH HHS [CA40356, R01 CA040356] Funding Source: Medline; NHLBI NIH HHS [R01 HL034594, HL24074, HL34594] Funding Source: Medline; NIDDK NIH HHS [T32 DK007703, P30 DK046200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007703, P30DK046200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBEY M, 1994, AM J CLIN NUTR, V59, P995, DOI 10.1093/ajcn/59.5.995; ALDERSON LM, 1986, ARTERIOSCLEROSIS, V6, P465, DOI 10.1161/01.ATV.6.5.465; Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; Colditz GA, 1997, J WOMENS HEALTH, V6, P49, DOI 10.1089/jwh.1997.6.49; COOKE JP, 1993, ARCH INTERN MED, V153, P896, DOI 10.1001/archinte.1993.00410070076013; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DOLECEK TA, 1992, P SOC EXP BIOL MED, V200, P177, DOI 10.3181/00379727-200-43413; Dreher ML, 1996, NUTR REV, V54, P241, DOI 10.1111/j.1753-4887.1996.tb03941.x; FRASER GE, 1994, AM J CLIN NUTR, V59, p1117S, DOI 10.1093/ajcn/59.5.1117S; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; GABH Rose, 1982, WHO MONOGRAPH SERIES; GRUNDY SM, 1990, J LIPID RES, V31, P1149; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; KRITCHEVSKY D, 1991, INT J TISSUE REACT, V13, P59; OByrne DJ, 1997, LIPIDS, V32, P687, DOI 10.1007/s11745-997-0088-y; PRINEAS RJ, 1993, NEW ENGL J MED, V329, P359; SABATE J, 1993, NEW ENGL J MED, V328, P603, DOI 10.1056/NEJM199303043280902; SABATE J, 1993, EUR J CLIN NUTR, V47, pS71; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SPILLER GA, 1992, J AM COLL NUTR, V11, P126; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; *USDA, 1989, AGR HDB, V8; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011	24	389	404	0	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	1998	317	7169					1341	1345		10.1136/bmj.317.7169.1341	http://dx.doi.org/10.1136/bmj.317.7169.1341			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812929	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000077081600017
J	Ban, C; Yang, W				Ban, C; Yang, W			Crystal structure and ATPase activity of MutL: Implications for DNA repair and mutagenesis	CELL			English	Article							DIRECTED MISMATCH REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GENE; PROTEIN; MUTATIONS; CHAPERONE; RECOMBINATION; REPLICATION	MutL and its homologs are essential for DNA mismatch repair. Mutations in genes encoding human homologs of MutL cause multiorgan cancer susceptibility. We have determined the crystal structure of a 40 kDa N-terminal fragment of E. coli MutL that retains all of the conserved residues in the MutL family. The structure of MutL is homologous to that of an ATPase-containing fragment of DNA gyrase. We have demonstrated that MutL binds and hydrolyzes ATP to ADP and Pi. Mutations in the MutL family that cause deficiencies in DNA mismatch repair and a predisposition to cancer mainly occur in the putative ATP-binding site. We provide evidence that the flexible, yet conserved, loops surrounding this ATP-binding site undergo conformational changes upon ATP hydrolysis thereby modulating interactions between MutL and other components of the repair machinery.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Yang, W (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	wei.yang@nih.gov	Ban, Changill/F-5426-2013; Yang, Wei/D-4926-2011; Yang, Wei/ABB-4785-2020	Yang, Wei/0000-0002-3591-2195; Yang, Wei/0000-0002-3591-2195				Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Aronshtam A, 1996, NUCLEIC ACIDS RES, V24, P2498, DOI 10.1093/nar/24.13.2498; AU KG, 1992, J BIOL CHEM, V267, P12142; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; COOPER DL, 1993, J BIOL CHEM, V268, P11823; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; Evarsson A., 1994, EMBO J, V13, P3669; FENG G, 1995, BIOTECHNIQUES, V19, P956; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Hangaishi A, 1997, BLOOD, V89, P1740, DOI 10.1182/blood.V89.5.1740.1740_1740_1747; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, COLLABORATIVE COMPUT, V4, P59; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Lewis RJ, 1996, EMBO J, V15, P1412, DOI 10.1002/j.1460-2075.1996.tb00483.x; LOEB LA, 1974, CANCER RES, V34, P2311; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pang QS, 1997, MOL CELL BIOL, V17, P4465, DOI 10.1128/MCB.17.8.4465; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Stams T, 1998, SCIENCE, V280, P752, DOI 10.1126/science.280.5364.752; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	44	319	322	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 13	1998	95	4					541	552		10.1016/S0092-8674(00)81621-9	http://dx.doi.org/10.1016/S0092-8674(00)81621-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827806	Bronze			2022-12-28	WOS:000077049400012
J	Worgotter, F; Suder, K; Zhao, YQ; Kerscher, N; Eysel, UT; Funke, K				Worgotter, F; Suder, K; Zhao, YQ; Kerscher, N; Eysel, UT; Funke, K			State-dependent receptive-field restructuring in the visual cortex	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; RELAY CELLS; CATS; MODULATION; ORGANIZATION; MECHANISMS; RESPONSES; DYNAMICS; NEURONS	To extract important information from the environment on a useful timescale, the visual system must be able to adapt rapidly to constantly changing scenes. This requires dynamic control of visual resolution possibly at the level of the responses of single neurons. Individual cells in the visual cortex respond to Light stimuli on particular locations (receptive fields) on the retina, and the structure of these receptive fields can change in different contexts(1-4). Here we show experimentally that the shape of receptive fields in the primary visual cortex of anaesthetized cats undergoes significant modifications, which are correlated with the general state of the brain as assessed by electroencephalography: receptive fields are wider during synchronized states and smaller during non-synchronized states. We also show that cortical receptive fields shrink over time when stimulated with hashing light spots. Finally, by using a network model we account for the changing size of the cortical receptive fields by dynamically rescaling the levels of excitation and inhibition in the visual thalamus and cortex. The observed dynamic changes in the sizes of the cortical receptive field could be a reflection of a process that adapts the spatial resolution within the primary visual pathway to different states of excitability.	Ruhr Univ Bochum, Inst Physiol, D-44780 Bochum, Germany	Ruhr University Bochum	Worgotter, F (corresponding author), Ruhr Univ Bochum, Inst Physiol, D-44780 Bochum, Germany.			Funke, Klaus/0000-0003-2359-8917; Eysel, Ulf/0000-0001-6087-957X				AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; AHLSEN G, 1985, EXP BRAIN RES, V58, P134; BAL T, 1993, J PHYSIOL-LONDON, V468, P669, DOI 10.1113/jphysiol.1993.sp019794; DEANGELIS GC, 1993, J NEUROPHYSIOL, V69, P1091, DOI 10.1152/jn.1993.69.4.1091; ECKHORN R, 1993, BIOL CYBERN, V69, P37, DOI 10.1007/BF00201407; Funke K, 1998, VISUAL NEUROSCI, V15, P711, DOI 10.1017/S0952523898154111; FUNKE K, 1992, BRAIN RES, V573, P217, DOI 10.1016/0006-8993(92)90766-3; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; JAHNSEN H, 1984, J PHYSIOL-LONDON, V349, P205, DOI 10.1113/jphysiol.1984.sp015153; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; LO FS, 1991, EXP BRAIN RES, V83, P317; MCCARLEY RW, 1983, J NEUROPHYSIOL, V50, P7980; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; SAWAI H, 1988, BRAIN RES, V455, P394, DOI 10.1016/0006-8993(88)90102-3; Sherman SM, 1996, J NEUROPHYSIOL, V76, P1367, DOI 10.1152/jn.1996.76.3.1367; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; Steriade M, 1996, SCIENCE, V272, P225, DOI 10.1126/science.272.5259.225; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Timofeev I, 1996, J NEUROPHYSIOL, V76, P4152, DOI 10.1152/jn.1996.76.6.4152; ULRICH DJ, 1991, J NEUROPHYSIOL, V65, P1528; Worgotter F, 1998, J PHYSIOL-LONDON, V509, P797, DOI 10.1111/j.1469-7793.1998.797bm.x; Zipser K, 1996, J NEUROSCI, V16, P7376	23	137	138	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1998	396	6707					165	168		10.1038/24157	http://dx.doi.org/10.1038/24157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823895				2022-12-28	WOS:000077013300051
J	Zaman, MM; Yoshiike, N; Rouf, MA; Haque, S; Chowdhury, AH; Nakayama, T; Tanaka, H				Zaman, MM; Yoshiike, N; Rouf, MA; Haque, S; Chowdhury, AH; Nakayama, T; Tanaka, H			Association of rheumatic fever with serum albumin concentration and body iron stores in Bangladeshi children: case-control study	BRITISH MEDICAL JOURNAL			English	Article									Tokyo Med & Dent Univ, Med Res Inst, Dept Epidemiol, Tokyo 101, Japan; Natl Inst Hlth & Nutr, Div Adult Hlth Sci, Tokyo 162, Japan; Natl Ctr Control Rheumat Fever & Heart Dis, Dhaka 1207, Bangladesh	Tokyo Medical & Dental University (TMDU); National Institute of Health & Nutrition - Japan	Zaman, MM (corresponding author), Natl Ctr Control Rheumat Fever & Heart Dis, Sher e Bangla Nagar, Dhaka 1207, Bangladesh.		NAKAYAMA, Takeo/HCH-0537-2022; Zaman, M Mostafa/H-4163-2019	Zaman, M Mostafa/0000-0002-1736-1342; Nakayama, Takeo/0000-0002-7918-6252				ARYANPURKASHANI I, 1980, AM HEART J, V100, P942, DOI 10.1016/0002-8703(80)90088-5; COBURN AF, 1960, AM J MED SCI, V240, P687; COOPER WC, 1974, AM J CLIN NUTR, V27, P647, DOI 10.1093/ajcn/27.6.647; GIBSON R, 1990, PRINCIPLE NUTR ASSES; Zaman MM, 1998, J TROP PEDIATRICS, V44, P142, DOI 10.1093/tropej/44.3.142	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1287	1288		10.1136/bmj.317.7168.1287	http://dx.doi.org/10.1136/bmj.317.7168.1287			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804715	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000076963800024
J	Rosenthal, PB; Zhang, XD; Formanowski, F; Fitz, W; Wong, CH; Meier-Ewert, H; Skehel, JJ; Wiley, DC				Rosenthal, PB; Zhang, XD; Formanowski, F; Fitz, W; Wong, CH; Meier-Ewert, H; Skehel, JJ; Wiley, DC			Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus	NATURE			English	Article							GP41 TRANSMEMBRANE GLYCOPROTEIN; GP120 ENVELOPE GLYCOPROTEIN; X-RAY-DIFFRACTION; SIALIC-ACID; RECEPTOR DETERMINANT; MEMBRANE-FUSION; HIGH-AFFINITY; HEMAGGLUTININ; PROTEIN; BINDING	The spike glycoproteins of the lipid-enveloped orthomyxoviruses I and paramyxoviruses have three functions: to recognize the receptor on the cell surface, to mediate viral fusion with the cell membrane. and to destroy the receptor. In influenza C virus, a single glycoprotein, the haemagglutinin-esterase-fusion (HEF) protein, possesses all three functions (reviewed in ref, 1). In influenza A and B, the first two activities are mediated by haemagglutinin and the third by a second glycoprotein, neuraminidase. Here we report the crystal structure of the HEF envelope glycoprotein of influenza C virus. We have identified the receptor-binding site and the receptor-destroying enzyme (9-O-acetylesterase) sites, by using receptor analogues. The receptor-binding domain is structurally similar to the sialic acid-binding domain of influenza A haemagglutinin, but binds 9-O-acetylsialic acid. The esterase domain has a structure similar to the esterase from Streptomyces scabies and a brain acetylhydrolase(2,3). The receptor domain is inserted into a surface loop of the esterase domain and the esterase domain is inserted into a surface loop of the stem. The stem domain is similar to that of influenza A haemagglutinin, except that the triple-stranded, alpha-helical bundle diverges at both of its ends, and the amino terminus of HEF2 the fusion peptide, is partially exposed. The segregation of HEF's three functions into structurally distinct domains suggests that the entire stem region, including sequences at the amino and carboxy termini of HEF1 which precede the post-translational cleavage site between HEF1 and HEF2 forms an independent fusion domain which is probably derived from an ancestral membrane fusion protein.	Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Tech Univ Munich, Abt Virol, D-80802 Munich 40, Germany; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Natl Inst Med Res, London NW7 1AA, England	Harvard University; Howard Hughes Medical Institute; Harvard University; Technical University of Munich; Scripps Research Institute; MRC National Institute for Medical Research	Wiley, DC (corresponding author), Harvard Univ, Howard Hughes Med Inst, 7 Divin Ave, Cambridge, MA 02138 USA.			Zhang, Xiaodong/0000-0001-9786-7038				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Eisen MB, 1997, VIROLOGY, V232, P19, DOI 10.1006/viro.1997.8526; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fitz W, 1996, BIOORGAN MED CHEM, V4, P1349, DOI 10.1016/0968-0896(96)00123-X; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; GRIMES J, 1995, NATURE, V373, P167, DOI 10.1038/373167a0; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; HERRLER G, 1991, ADV VIRUS RES, V40, P213; HERRLER G, 1992, J BIOL CHEM, V267, P12501; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POLLARD SR, 1992, EMBO J, V11, P585, DOI 10.1002/j.1460-2075.1992.tb05090.x; ROGERS GN, 1983, NATURE, V304, P76, DOI 10.1038/304076a0; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; Rosenthal PB, 1996, ACTA CRYSTALLOGR D, V52, P1041, DOI 10.1107/S0907444996005021; ROSENTHAL PB, 1996, THESIS HARVARD U; SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; WEI YY, 1995, NAT STRUCT BIOL, V2, P218, DOI 10.1038/nsb0395-218; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; Wyatt R, 1997, J VIROL, V71, P9722, DOI 10.1128/JVI.71.12.9722-9731.1997	30	182	190	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 5	1998	396	6706					92	96		10.1038/23974	http://dx.doi.org/10.1038/23974			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136HE	9817207	Green Published			2022-12-28	WOS:000076852700061
J	Tanaka, T; Saha, SK; Tomomori, C; Ishima, R; Liu, DJ; Tong, KI; Park, H; Dutta, R; Qin, L; Swindells, MB; Yamazaki, T; Ono, AM; Kainosho, M; Inouye, M; Ikura, M				Tanaka, T; Saha, SK; Tomomori, C; Ishima, R; Liu, DJ; Tong, KI; Park, H; Dutta, R; Qin, L; Swindells, MB; Yamazaki, T; Ono, AM; Kainosho, M; Inouye, M; Ikura, M			NMR structure of the histidine kinase domain of the E-coli osmosensor EnvZ	NATURE			English	Article							SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; DNA GYRASE; PROTEIN; BINDING; PROGRAM; MUTANT	Bacteria live in capricious environments, in which they must continuously sense external conditions in order to adjust their shape, motility and physiology(1). The histidine-aspartate phosphorelay signal-transduction system (also known as the two-component system) is important in cellular adaptation to environmental changes in both prokaryotes and lower eukaryotes(2,3). In this system, protein histidine kinases function as sensors and signal transducers, The Escherichia coli osmosensor, EnvZ, is a transmembrane protein with histidine kinase activity in its cytoplasmic region(2). The cytoplasmic region contains two functional domains(4): domain A (residues 223-289) contains the conserved histidine residue (H243), a site of autophosphorylation as well as transphosphorylation to the conserved D55 residue of response regulator OmpR, whereas domain B (residues 290-450) encloses several highly conserved regions (G1, G2, F and N boxes) and is able to phosphorylate H243. Here we present the solution structure of domain B, the catalytic core of EnvZ. This core has a novel protein kinase structure, distinct from the serine/threonine/tyrosine kinase fold, with unanticipated similarities to both heat-shock protein 90 and DNA gyrase B.	Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058577, Japan; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Helix Res Inst Inc, Kisarazu 2920812, Japan; Natl Inst Agrobiol Resources, Tsukuba, Ibaraki 3050856, Japan; Tokyo Metropolitan Univ, Dept Chem, Hachioji, Tokyo 1920397, Japan	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Tsukuba; University of Tsukuba; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institute of Agrobiological Sciences - Japan; Tokyo Metropolitan University	Ikura, M (corresponding author), Ontario Canc Inst, Div Mol & Struct Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	mikura@oci.utor-onto.ca	Qin, Ling/B-3147-2012	Ikura, Mitsuhiko/0000-0002-9524-1303				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barrett JF, 1998, P NATL ACAD SCI USA, V95, P5317, DOI 10.1073/pnas.95.9.5317; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Dutta R, 1996, J BIOL CHEM, V271, P1424, DOI 10.1074/jbc.271.3.1424; DZIEJMAN M, 1995, 2 COMPONENT SIGNAL T, P305; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; Holdgate GA, 1997, BIOCHEMISTRY-US, V36, P9663, DOI 10.1021/bi970294+; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; Mizuno T, 1997, DNA Res, V4, P161, DOI 10.1093/dnares/4.2.161; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; ORENGO CA, 1992, PROTEINS, V14, P139, DOI 10.1002/prot.340140203; OTA IM, 1993, SCIENCE, V262, P366; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; Parkinson J.S., 1995, 2 COMPONENT SIGNAL T, P9; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Soncini FC, 1996, J BACTERIOL, V178, P6796, DOI 10.1128/jb.178.23.6796-6801.1996; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WIRGLERMURPHY SM, 1997, TRENDS BIOCHEM SCI, V22, P172; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286	23	208	213	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1998	396	6706					88	92		10.1038/23968	http://dx.doi.org/10.1038/23968			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136HE	9817206				2022-12-28	WOS:000076852700060
J	Schechter, AN				Schechter, AN			The crisis in clinical research - Endangering the half-century National Institutes of Health Consensus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INVESTIGATOR; SCIENTIST				Schechter, AN (corresponding author), Bldg 10,Room 9N307,10 Ctr Dr, Bethesda, MD 20892 USA.	aschecht@helix.nih.gov		Schechter, Alan N/0000-0002-5235-9408				Ahrens E.H., 1992, CRISIS CLIN RES OVER; Bush, 1945, SCI THE ENDLESS FRON, DOI DOI 10.1016/j.techsoc.2019.03.007; FREDRICKSON DS, 1993, EMERGING POLICIES BI, V3, P1; Gallin JI, 1998, ACAD MED, V73, P460, DOI 10.1097/00001888-199805000-00008; GILL GN, 1984, AM SCHOLAR, V53, P353; Goldstein JL, 1997, J CLIN INVEST, V99, P2803, DOI 10.1172/JCI119470; *I MED, 1998, SCI OPP PUBL NEEDS; Nathan DG, 1998, JAMA-J AM MED ASSOC, V280, P1427, DOI 10.1001/jama.280.16.1427; *NIH, 1997, NIH DIR PAN CLIN RES; Rosenberg SA, 1996, NEW ENGL J MED, V334, P392, DOI 10.1056/NEJM199602083340610; Schrier RW, 1997, ACAD MED, V72, P589, DOI 10.1097/00001888-199707000-00010; Shine KI, 1997, JAMA-J AM MED ASSOC, V278, P245, DOI 10.1001/jama.278.3.245; Shulman LE, 1996, ACAD MED, V71, P362, DOI 10.1097/00001888-199604000-00013; SHULMAN LE, 1996, ACAD MED, V71, P398; Thompson JN, 1997, JAMA-J AM MED ASSOC, V278, P241, DOI 10.1001/jama.278.3.241; TOPPING NH, 1952, JAMA-J AM MED ASSOC, V150, P541, DOI 10.1001/jama.1952.03680060013005; Williams GH, 1997, JAMA-J AM MED ASSOC, V278, P227, DOI 10.1001/jama.278.3.227; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303; [No title captured]	19	64	66	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	1998	280	16					1440	1442		10.1001/jama.280.16.1440	http://dx.doi.org/10.1001/jama.280.16.1440			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130YA	9801006				2022-12-28	WOS:000076546900041
J	Benavente, O; Moher, D; Pham, B				Benavente, O; Moher, D; Pham, B			Carotid endarterectomy for asymptomatic carotid stenosis: a meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To assess the value of carotid endarterectomy for prevention of stroke in patients with asymptomatic carotid stenosis. Design Systematic review and meta-analysis of randomised controlled trials in patients with asymptomatic carotid stenosis in which subjects were allocated to carotid endarterectomy or to medical treatment alone. Subjects Five trials enrolled 2440 patients with stenosis greater than or equal to 50%. Main outcome measures Stroke ipsilateral to the stenosis, all strokes, and perioperative complications (stroke or death). Results In patients who underwent carotid endarterectomy (n = 1215) there was a significant reduction in the odds of ipsilateral stroke plus perioperative stroke or death (odds ratio 0.62; 95% confidence interval 0.44 to 0.86), corresponding to a 2% absolute risk reduction over about 3.1 years. The prevalence of stroke in any location was also reduced (0.68; 0.51 to 0.9) in patients undergoing carotid endarterectomy. During the immediate postoperative period there was an increased prevalence of stroke or death among such patients (4.51; 2.36 to 8.64). Conclusion Carotid endarterectomy in patients with asymptomatic carotid stenosis unequivocally reduces the incidence of ipsilateral stroke, though the absolute benefit is relatively small. Given the modest benefit of surgery for unselected patients with asymptomatic carotid artery stenosis carotid endarterectomy cannot be routinely recommended for these patients pending reliable identification of high risk subgroups, and medical management is a sensible alternative for most patients.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Neurol, San Antonio, TX 78284 USA; Childrens Hosp Eastern Ontario, Thomas C Chalmers Ctr Systemat Reviews, Ottawa, ON K1H 8L1, Canada	University of Texas System; University of Texas Health San Antonio; University of Ottawa; Children's Hospital of Eastern Ontario	Benavente, O (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Neurol, San Antonio, TX 78284 USA.	benavente@uthscsa.edu		Moher, David/0000-0003-2434-4206				[Anonymous], 1995, Lancet, V345, P209; Begg C., 1994, HDB RES SYNTHESIS, P399; CLAGETT GP, 1984, SURGERY, V96, P823; *COCHR COLL, 1998, COHR LIB; DIENER HC, 1991, STROKE, V22, P1229; HALLIDAY AW, 1994, EUR J VASCULAR SURG, V8, P703; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; LAGNEAU P, 1993, J MAL VASCUL, V18, P209; MEISSNER I, 1987, JAMA-J AM MED ASSOC, V258, P2704; NORRIS JW, 1991, STROKE, V22, P1485, DOI 10.1161/01.STR.22.12.1485; *OSTR COLL GROUP, 1991, CONT CLIN TRIALS, V15, P503; PRATI P, 1992, STROKE, V23, P1705, DOI 10.1161/01.STR.23.12.1705; RICCI S, 1991, CEREBROVASC DIS, V23, P1752; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WIEBERS DO, 1992, MAYO CLIN PROC, V67, P513	19	109	114	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 28	1998	317	7171					1477	1480		10.1136/bmj.317.7171.1477	http://dx.doi.org/10.1136/bmj.317.7171.1477			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831572	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000077338300020
J	Gradwell, M				Gradwell, M			A patient who changed my practice? The new Holy Grail	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1502	1502		10.1136/bmj.317.7171.1502	http://dx.doi.org/10.1136/bmj.317.7171.1502			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831582	Green Published			2022-12-28	WOS:000077338300034
J	Niu, SR; Yang, GH; Chen, ZM; Wang, JL; Wang, GH; He, XZ; Schoepff, H; Boreham, J; Pan, HC; Peto, R				Niu, SR; Yang, GH; Chen, ZM; Wang, JL; Wang, GH; He, XZ; Schoepff, H; Boreham, J; Pan, HC; Peto, R			Emerging tobacco hazards in China: 2. Early mortality results from a prospective study	BRITISH MEDICAL JOURNAL			English	Article							SMOKING	Objective To monitor the evolving epidemic of mortality from tobacco in China following the large increase in male cigarette use in recent decades. Design Prospective study of smoking and mortality starting with 224 500 interviewees who should eventually be followed for some decades. Setting 45 nationally representative small urban or rural areas distributed across China. Subjects Male population aged 40 or over in 1991, of whom about 80% were interviewed about smoking, drinking, and medical history. Main outcome measure Cause specific mortality, initially to 1995 but later to continue, with smoker versus non-smoker risk ratios standardised for area, age, and use of alcohol. Results 74% were smokers (73% current, only 1% former), but few of this generation would have smoked substantial numbers of cigarettes since early adult life. Overall mortality is increased among smokers (risk ratio 1.19; 95% confidence interval 1.13 to 1.25, P < 0.0001). Almost all the increased mortality involved neoplastic, respiratory, or vascular disease. The overall risk ratios currently associated with smoking are less extreme in rural areas (1.26, 1.12, or 1.02 respectively for smokers who started before age 20, at 20-24, or at older ages) than in urban areas (1.73, 1.40, or 1.16 respectively). Conclusion This prospective study and the accompanying retrospective study show that by 1990 smoking was already causing about 12% of Chinese male mortality in middle age. This proportion is predicted to rise to about 33% by 2030. Long term continuation of the prospective study (with periodic resurveys) can monitor the evolution of this epidemic.	Chinese Acad Prevent Med, Beijing 100050, Peoples R China; Radcliffe Infirm, Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford OX2 6HE, England; Radcliffe Infirm, Nuffield Dept Clin Med, Epidemiol Studies Unit, Oxford OX2 6HE, England	Chinese Center for Disease Control & Prevention; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Niu, SR (corresponding author), Chinese Acad Prevent Med, 29 Nan Wei Lu, Beijing 100050, Peoples R China.							Chen ZM, 1997, JAMA-J AM MED ASSOC, V278, P1500, DOI 10.1001/jama.278.18.1500; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; Liu BQ, 1998, BMJ-BRIT MED J, V317, P1411, DOI 10.1136/bmj.317.7170.1411; PETO R, 1994, BRIT MED J, V309, P937, DOI 10.1136/bmj.309.6959.937; PETO R, 1987, LANCET, V2, P211; PETO R, 1994, MORTALITY TOBACCO DE; Yang GH., 1991, EXPLORING ADULT MORT	7	152	172	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1423	1424		10.1136/bmj.317.7170.1423	http://dx.doi.org/10.1136/bmj.317.7170.1423			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822394	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000077202200021
J	Paytan, A; Kastner, M; Campbell, D; Thiemens, MH				Paytan, A; Kastner, M; Campbell, D; Thiemens, MH			Sulfur isotopic composition of Cenozoic seawater sulfate	SCIENCE			English	Article							PALEOCENE-EOCENE BOUNDARY; ATMOSPHERIC OXYGEN; GEOCHEMICAL CYCLES; REDOX STABILIZATION; MARINE PRODUCTIVITY; SEDIMENTARY SULFUR; CARBON; OCEANS; RECORD; COLLISION	A continuous seawater sulfate sulfur isotope curve for the Cenozoic with a resolution of similar to 1 million years was generated using marine barite, The sulfur isotopic composition decreased from 19 to 17 per mil between 65 and 55 million years ago, increased abruptly from 17 to 22 per mil between 55 and 45 million years ago, remained nearly constant from 35 to similar to 2 million years ago, and has decreased by 0.8 per mil during the past 2 million years. A comparison between seawater sulfate and marine carbonate carbon isotope records reveals no clear systematic coupling between the sulfur and carbon cycles over one to several millions of years, indicating that changes in the burial rate of pyrite sulfur and organic carbon did not singularly control the atmospheric oxygen content over short time intervals in the Cenozoic. This finding has implications for the modeling of controls on atmospheric oxygen concentration.	Univ Calif San Diego, Scripps Inst Oceanog, Geosci Res Div, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of California System; University of California San Diego	Paytan, A (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Geosci Res Div, 9500 Gilman Dr, La Jolla, CA 92093 USA.	apaytan@ucsd.edu						BAKER PA, 1982, J SEDIMENT PETROL, V52, P71; BECK RA, 1995, GEOLOGY, V23, P387, DOI 10.1130/0091-7613(1995)023<0387:OCEAGW>2.3.CO;2; BECK RA, 1995, NATURE, V373, P55, DOI 10.1038/373055a0; Berger WH, 1989, OCEAN PRODUCTIVITY P; BERKNER LV, 1965, J ATMOS SCI, V22, P225, DOI 10.1175/1520-0469(1965)022<0225:OTOARO>2.0.CO;2; BERNER RA, 1984, GEOCHIM COSMOCHIM AC, V48, P605, DOI 10.1016/0016-7037(84)90089-9; BERNER RA, 1987, AM J SCI, V287, P177, DOI 10.2475/ajs.287.3.177; BERNER RA, 1989, AM J SCI, V289, P333, DOI 10.2475/ajs.289.4.333; BERNER RA, 1989, PALAEOGEOGR PALAEOCL, V75, P97, DOI DOI 10.1016/0031-0182(89)90186-7; Bralower TJ, 1997, GEOLOGY, V25, P963, DOI 10.1130/0091-7613(1997)025<0963:HRROTL>2.3.CO;2; BURDETT JW, 1989, EARTH PLANET SC LETT, V94, P189, DOI 10.1016/0012-821X(89)90138-6; CANDE SC, 1995, J GEOPHYS RES-SOL EA, V100, P6093, DOI 10.1029/94JB03098; Carpenter SJ, 1997, GEOCHIM COSMOCHIM AC, V61, P4831, DOI 10.1016/S0016-7037(97)00361-X; CHAMBERS LA, 1978, GEOMICROBIOL J, V1, P249; CHURCH TM, 1979, MINERALOGICAL SOC AM, V6, P175; CLAYPOOL GE, 1980, CHEM GEOL, V28, P199, DOI 10.1016/0009-2541(80)90047-9; Colman AS, 1997, SCIENCE, V275, P406, DOI 10.1126/science.275.5298.406; Delaney ML, 1988, PALEOCEANOGRAPHY, V3, P137, DOI 10.1029/PA003i002p00137; DELANEY ML, 1989, EARTH PLANET SC LETT, V95, P23, DOI 10.1016/0012-821X(89)90165-9; GAO X, 1993, GEOCHIM COSMOCHIM AC, V57, P3159, DOI 10.1016/0016-7037(93)90300-L; GARRELS RM, 1984, AM J SCI, V284, P989, DOI 10.2475/ajs.284.9.989; GARRELS RM, 1976, AM SCI, V63, P306; HARDIE LA, 1984, AM J SCI, V284, P193, DOI 10.2475/ajs.284.3.193; HOEFS J, 1967, HDB GEOCHEMISTRY, V1; HOLLAND HD, 1973, GEOCHIM COSMOCHIM AC, V37, P2605, DOI 10.1016/0016-7037(73)90268-8; Holland HD., 1984, CHEM EVOLUTION ATMOS; Holser W. T., 1989, EVOLUTION GLOBAL BIO, P21; Holser W. T., 1988, CHEM CYCLES EVOLUTIO, P105; Holser W.T., 1966, CHEM GEOL, V1, P93, DOI [10.1016/0009-2541(66)90011-8., DOI 10.1016/0009-2541(66)90011-8]; HOLSER WT, 1988, PALEOCEANOGRAPHY, V3, P173; JONES TP, 1991, PALAEOGEOGR PALAEOCL, V77, P39; KENNETT JP, 1991, NATURE, V353, P225, DOI 10.1038/353225a0; KOCH PL, 1992, NATURE, V358, P319, DOI 10.1038/358319a0; KUMP LR, 1989, AM J SCI, V289, P390, DOI 10.2475/ajs.289.4.390; KUMP LR, 1986, AM J SCI, V286, P337, DOI 10.2475/ajs.286.5.337; LASAGA AC, 1989, AM J SCI, V289, P411, DOI 10.2475/ajs.289.4.411; Lein A. Y., 1989, EVOLUTION GLOBAL BIO, P65; LEIN AY, 1983, GLOBAL BIOGEOCHEMICA, P95; LINDH TB, 1983, THESIS U MIAMI; LONGINELLI A, 1979, PALAEOGEOGR PALAEOCL, V29, P95, DOI 10.1016/0031-0182(79)90076-2; LORENS RB, 1980, GEOCHIM COSMOCHIM AC, V44, P1265, DOI 10.1016/0016-7037(80)90087-3; MACKENZIE FT, 1993, NATO ASI SER, V14, P1; Miller KG, 1987, PALEOCEANOGRAPHY, V2, P1, DOI 10.1029/PA002i001p00001; NIELSEN H, 1989, EVOLUTION GLOBAL BIO, P57; PAYTAN A, 1993, NATURE, V366, P445, DOI 10.1038/366445a0; PAYTAN A, 1995, THESIS U CALIFORNIA; Perry E., 1974, SEA, V5; Petsch ST, 1998, AM J SCI, V298, P246, DOI 10.2475/ajs.298.3.246; PETSCH ST, IN PRESS GEOCHIM COS; PEUCKEREHRENBRINK B, 1995, EARTH PLANET SC LETT, V130, P155, DOI 10.1016/0012-821X(95)00003-U; RAAB M, 1991, CHEM GEOL, V86, P323, DOI 10.1016/0168-9622(91)90014-N; RAISWELL R, 1986, GEOCHIM COSMOCHIM AC, V50, P1967, DOI 10.1016/0016-7037(86)90252-8; Rau G. H, 1994, CARBON CYCLING GLACI, P307; RAYMO ME, 1988, GEOLOGY, V16, P649, DOI 10.1130/0091-7613(1988)016<0649:IOLCMB>2.3.CO;2; REA DK, 1990, PALAEOGEOGR PALAEOCL, V79, P117, DOI 10.1016/0031-0182(90)90108-J; REES CE, 1978, GEOCHIM COSMOCHIM AC, V42, P377, DOI 10.1016/0016-7037(78)90268-5; ROBINSON JM, 1991, PALAEOGEOGR PALAEOCL, V77, P51; SCHIDLOWSKI M, 1977, J GEOPHYS RES-OC ATM, V82, P2557, DOI 10.1029/JC082i018p02557; SCHIDLOWSKI M, 1981, GEOCHIM COSMOCHIM AC, V45, P589, DOI 10.1016/0016-7037(81)90192-7; SHACKLETON WJ, 1987, MARINE PETROLEUM SOU, P423; Strauss H, 1997, PALAEOGEOGR PALAEOCL, V132, P97, DOI 10.1016/S0031-0182(97)00067-9; STRAUSS H, 1993, PRECAMBRIAN RES, V63, P225, DOI 10.1016/0301-9268(93)90035-Z; Thode H. G., 1965, AAPG MEMOIRS, P367; Thomas E., 1996, Geological Society Special Publication, V101, P401, DOI 10.1144/GSL.SP.1996.101.01.20; VanCappellen P, 1996, SCIENCE, V271, P493, DOI 10.1126/science.271.5248.493; VEIZER J, 1980, GEOCHIM COSMOCHIM AC, V44, P579, DOI 10.1016/0016-7037(80)90250-1; WALKER JCG, 1986, MAR GEOL, V70, P159, DOI 10.1016/0025-3227(86)90093-9; WATSON A, 1978, BIOSYSTEMS, V10, P293, DOI 10.1016/0303-2647(78)90012-6; ZACHOS JC, 1994, PALEOCEANOGRAPHY, V9, P353, DOI 10.1029/93PA03266	69	289	296	3	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1459	1462		10.1126/science.282.5393.1459	http://dx.doi.org/10.1126/science.282.5393.1459			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822370				2022-12-28	WOS:000077110800045
J	Morell, RJ; Kim, HJ; Hood, LJ; Goforth, L; Friderici, K; Fisher, R; Van Camp, G; Berlin, CI; Oddoux, C; Ostrer, H; Keats, B; Friedman, TB				Morell, RJ; Kim, HJ; Hood, LJ; Goforth, L; Friderici, K; Fisher, R; Van Camp, G; Berlin, CI; Oddoux, C; Ostrer, H; Keats, B; Friedman, TB			Mutations in the connexin 26 gene (GJB2) among Ashkenazi Jews with nonsyndromic recessive deafness	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							JEWISH POPULATION; HEARING IMPAIRMENT; PREVALENCE; EMISSIONS; FREQUENCY	Background Mutations in the GJB2 gene cause one form of nonsyndromic recessive deafness. Among Mediterranean Europeans, more than 80 percent of cases of nonsyndromic recessive deafness result from inheritance of the 30delG mutant allele of GJB2. We assessed the contribution of mutations in GJB2 to the prevalence of the condition among Ashkenazi Jews. Methods We tested for mutations in GJB2 in DNA samples from three Ashkenazi Jewish families with nonsyndromic recessive deafness, from Ashkenazi Jewish persons seeking carrier testing for other conditions, and from members of other ethnic groups. The hearing of persons who were heterozygous for mutations in GJB2 was assessed by means of pure-tone audiometry, measurement of middle-ear immittance, and recording of otoacoustic emissions. Results Two frame-shift mutations in GJB2, 167delT and 30delG, were observed in the families with nonsyndromic recessive deafness. In the Ashkenazi Jewish population the prevalence of heterozygosity for 167delT, which is rare in the general population, was 4.03 percent (95 percent confidence interval, 2.5 to 6.0 percent), and for 30delG the prevalence was 0.73 percent (95 percent confidence interval, 0.2 to 1.8 percent). Genetic-linkage analysis showed conservation of the haplotype for 167delT but the existence of several haplotypes for 30delG. Audiologic examination of carriers of the mutant alleles who had normal hearing revealed subtle differences in their otoacoustic emissions, suggesting that the expression of mutations in GJB2 may be semidominant. Conclusions The high frequency of carriers of mutations in GJB2(4.76 percent) predicts a prevalence of 1 deaf person among 1765 people, which may account for the majority of cases of nonsyndromic recessive deafness in the Ashkenazi Jewish population. Conservation of the haplotype flanking the 167delT mutation suggests that this allele has a single origin, whereas the multiple haplotypes with the 30delG mutation suggest that this site is a hot spot for recurrent mutations. (N Engl J Med 1998;339:1500-5.) (C) 1998, Massachusetts Medical Society.	NIDCD, Genet Mol Lab, NIH, Rockville, MD 20850 USA; Louisiana State Univ, Med Ctr, Dept Otorhinolaryngol & Biocommun, Kresge Hearing Res Lab, New Orleans, LA USA; Michigan State Univ, Coll Human Med, Dept Pediat & Human Dev, E Lansing, MI 48824 USA; Univ Antwerp, Dept Med Genet, Antwerp, Belgium; NYU Med Ctr, Dept Pediat, Human Genet Program, New York, NY 10016 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Louisiana State University System; Michigan State University; Michigan State University College of Human Medicine; University of Antwerp; New York University	Morell, RJ (corresponding author), NIDCD, Genet Mol Lab, NIH, 5 Res Ctr,Rm 2A19, Rockville, MD 20850 USA.		Van Camp, Guy/F-3386-2013; Morell, Robert James/Q-2042-2019	Van Camp, Guy/0000-0001-5105-9000; Morell, Robert/0000-0003-1537-7356	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000039] Funding Source: NIH RePORTER; NIDCD NIH HHS [Z01 DC 00039-01] Funding Source: Medline; PHS HHS [P0100379] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anderson H, 1968, Acta Otolaryngol, V65, P535; BERLIN CI, 1995, HEARING RES, V87, P96, DOI 10.1016/0378-5955(95)00082-F; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; BROWNSTEIN Z, 1991, AM J MED GENET, V41, P306, DOI 10.1002/ajmg.1320410309; Carrasquillo MM, 1997, HUM MOL GENET, V6, P2163, DOI 10.1093/hmg/6.12.2163; CHUNG C S, 1970, American Journal of Human Genetics, V22, P630; COLLET L, 1990, HEARING RES, V43, P251, DOI 10.1016/0378-5955(90)90232-E; COSTEFF H, 1980, AM J HUM GENET, V32, P64; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; Estivill X, 1998, LANCET, V351, P394, DOI 10.1016/S0140-6736(97)11124-2; FEINMESSER M, 1990, J LARYNGOL OTOL, V104, P675, DOI 10.1017/S0022215100113593; Fraser G R, 1971, Otolaryngol Clin North Am, V4, P227; HOOD LJ, 1998, OTOACOUSTIC EMISSION, P137; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KEMP DT, 1978, J ACOUST SOC AM, V64, P1386, DOI 10.1121/1.382104; Konigsmark B.W., 1976, GENETIC METABOLIC DE; Kronn D, 1998, ARCH INTERN MED, V158, P777, DOI 10.1001/archinte.158.7.777; KRONN D, 1995, AM J HUM GENET, V57, P1250; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Liu XZ, 1997, ANN OTO RHINOL LARYN, V106, P220, DOI 10.1177/000348949710600307; MEREDITH R, 1992, J AUDIOL MED, V1, P11; MEULENBELT I, 1995, AM J HUM GENET, V57, P1252; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; MOTULSKY AG, 1995, NAT GENET, V9, P99, DOI 10.1038/ng0295-99; Nance W E, 1980, Birth Defects Orig Artic Ser, V16, P263; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; RISCH N, 1995, NAT GENET, V9, P152, DOI 10.1038/ng0295-152; TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI, P188; VanCamp G, 1997, AM J HUM GENET, V60, P758; VANCAMP G, 1998, HEREDITARY HEARING L; Zbar RIS, 1998, OTOLARYNG HEAD NECK, V118, P333, DOI 10.1016/S0194-5998(98)70311-0; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	32	411	450	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1998	339	21					1500	1505		10.1056/NEJM199811193392103	http://dx.doi.org/10.1056/NEJM199811193392103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VT	9819448				2022-12-28	WOS:000077051800003
J	Ait-Si-Ali, S; Ramirez, S; Barre, FX; Dkhissi, F; Magnaghi-Jaulin, L; Girault, JA; Robin, P; Knibiehler, M; Pritchard, LL; Ducommun, B; Trouche, D; Harel-Bellan, A				Ait-Si-Ali, S; Ramirez, S; Barre, FX; Dkhissi, F; Magnaghi-Jaulin, L; Girault, JA; Robin, P; Knibiehler, M; Pritchard, LL; Ducommun, B; Trouche, D; Harel-Bellan, A			Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A	NATURE			English	Article							CREB-BINDING-PROTEIN; TRANSCRIPTION FACTOR; COACTIVATOR; P300; DIFFERENTIATION; PRODUCT	Transforming viral proteins such as E1A force cells through the restriction point of the cell cycle into S phase by forming complexes with two cellular proteins(1-3): the retinoblastoma protein (Rb)(4) a transcriptional co-repressor(5), and CBP/p300 (ref. 6), a transcriptional co-activator(7-9). These two proteins locally influence chromatin structure: Rb recruits a histone deacetylase(10-12) whereas CBP is a histone acetyltransferase(13,14). Progression through the restriction point is triggered by phosphorylation of Rb, leading to disruption of Rb-associated repressive complexes and allowing the activation of S-phase genes(15). Here we show that CBP, like Rb, is controlled by phosphorylation at the G1/S boundary, increasing its histone acetyltransferase activity. This enzymatic activation is mimicked by E1A.	CNRS, UPR 9079, Lab Oncogenese Differenciat & Transduct Signal, F-94801 Villejuif, France; Coll France, INSERM, U114, F-75005 Paris, France; Univ Toulouse 3, CNRS, UPR 9062, IPBS, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Harel-Bellan, A (corresponding author), CNRS, UPR 9079, Lab Oncogenese Differenciat & Transduct Signal, IFC-01, F-94801 Villejuif, France.	ahbellan@vjf.cnrs.fr	Girault, Jean-Antoine/F-7518-2013; Trouche, Didier/B-2854-2008; Harel-Bellan, Annick/M-9795-2015; Barre, François-Xavier/F-6767-2019; DUCOMMUN, Bernard/B-3208-2008; Ramirez-Clavijo, Sandra/G-5268-2016	Girault, Jean-Antoine/0000-0002-7900-1705; Harel-Bellan, Annick/0000-0002-2339-153X; DUCOMMUN, Bernard/0000-0002-7126-8368; Trouche, Didier/0000-0003-1398-6481; Ramirez-Clavijo, Sandra/0000-0003-0336-5614				Ait-Si-Ali S, 1998, NUCLEIC ACIDS RES, V26, P3869, DOI 10.1093/nar/26.16.3869; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DYSON N, 1992, CANCER SURV, V12, P161; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Groisman R, 1996, J BIOL CHEM, V271, P5258; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEINBERG RA, 1992, CANCER SURV, V12, P43; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389	30	256	261	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	1998	396	6707					184	186		10.1038/24190	http://dx.doi.org/10.1038/24190			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823900				2022-12-28	WOS:000077013300056
J	Mayatepek, E; Flock, B				Mayatepek, E; Flock, B			Leukotriene C-4-synthesis deficiency: a new inborn error of metabolism linked to a fatal developmental syndrome	LANCET			English	Article							CENTRAL NERVOUS-SYSTEM; C-4 SYNTHASE; CYSTEINYL-LEUKOTRIENES; HUMAN-LEUKOCYTES; 5-LIPOXYGENASE; GLUTATHIONE; PROTEIN; PURIFICATION; CONVERSION; PRODUCTS	Background Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent lipid mediators derived from arachidonic acid in the 5-lipoxygenase pathway that exert profound biological effects. We investigated synthesis and metabolism of leukotrienes in an infant who presented with muscular hypotonia, psychomotor retardation, failure to thrive, and microcephaly. The course of the disease was rapidly progressive and the infant died aged 6 months. Methods Cysteinyl leukotrienes and LTB4 were analysed in cerebrospinal fluid, plasma, urine, and stimulated monocytes by EIA. We measured [H-3]-LTC4 formation from [H-3]-LTA(4) in monocytes and platelets by radio-high-pressure liquid chromatography. Findings Concentrations of LTC4 and its metabolites were below the detection limit in the cerebrospinal fluid, plasma and urine. LTC4 could not be generated in stimulated monocytes, whereas LTB4 synthesis was increased. [H-3]LTC4 could not be made from [H-3]-LTA(4) in the patient's monocytes or platelets. Interpretation In this patient, inability to synthesise LTC4 suggests a deficiency of LTC4 synthase. This defect is a new inborn error of human eicosanoid metabolism and may be associated with the clinical disorder. Leukotriene analysis should be done in all patients with neurological symptoms who are candidates for metabolic diseases.	Heidelberg Univ, Childrens Hosp, Dept Gen Paediat, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Mayatepek, E (corresponding author), Heidelberg Univ, Childrens Hosp, Dept Gen Paediat, Neuenheimer Feld 150, D-69120 Heidelberg, Germany.	ertan_mayatepek@ukl.uni-heidelberg.de						ANTOINE C, 1991, BIOCHIM BIOPHYS ACTA, V1075, P162, DOI 10.1016/0304-4165(91)90247-E; Bigby TD, 1996, MOL MED, V2, P637, DOI 10.1007/BF03401647; BROCK TG, 1994, J BIOL CHEM, V269, P22059; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; GEROZISSIS K, 1986, EUR J PHARMACOL, V121, P313; HYNES N, 1991, BRAIN RES, V553, P4, DOI 10.1016/0006-8993(91)90222-H; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; Jakobsson PJ, 1996, J BIOL CHEM, V271, P22203, DOI 10.1074/jbc.271.36.22203; KEPPLER D, 1988, ANN NY ACAD SCI, V524, P68, DOI 10.1111/j.1749-6632.1988.tb38531.x; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; LEE CW, 1983, IMMUNOLOGY, V48, P27; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LINDGREN JA, 1984, P NATL ACAD SCI-BIOL, V81, P6212, DOI 10.1073/pnas.81.19.6212; MAYATEPEK E, 1994, PEDIATR RES, V35, P307, DOI 10.1203/00006450-199403000-00005; MAYATEPEK E, 1993, J CLIN INVEST, V91, P881, DOI 10.1172/JCI116309; MAYATEPEK E, 1994, PEDIATR RES, V37, P1; PACEASCIAK CR, 1986, BIOCHEM BIOPH RES CO, V140, P857, DOI 10.1016/0006-291X(86)90713-8; PALMER MR, 1980, NEUROSCI LETT, V18, P173, DOI 10.1016/0304-3940(80)90322-5; PENROSE JF, 1992, P NATL ACAD SCI USA, V89, P11603, DOI 10.1073/pnas.89.23.11603; RADMARK O, 1980, BIOCHEM BIOPH RES CO, V96, P1679, DOI 10.1016/0006-291X(80)91367-4; RADMARK O, 1984, J BIOL CHEM, V259, P2339; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Scoggan KA, 1997, J BIOL CHEM, V272, P10182; SIMMET T, 1988, BRAIN RES, V456, P344, DOI 10.1016/0006-8993(88)90237-5; SPECTOR R, 1986, BIOCHEM PHARMACOL, V35, P2849, DOI 10.1016/0006-2952(86)90475-2; WILLIAMS JD, 1984, J IMMUNOL, V132, P3034; YOSHIMOTO T, 1988, J CLIN INVEST, V81, P866, DOI 10.1172/JCI113396	28	31	78	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 7	1998	352	9139					1514	1517		10.1016/S0140-6736(98)01186-6	http://dx.doi.org/10.1016/S0140-6736(98)01186-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820300				2022-12-28	WOS:000076862300010
J	Shukla, VK; Prakash, A; Tripathi, BD; Reddy, DCS; Singh, S				Shukla, VK; Prakash, A; Tripathi, BD; Reddy, DCS; Singh, S			Biliary heavy metal concentrations in carcinoma of the gall bladder: case-control study	BRITISH MEDICAL JOURNAL			English	Article									Banaras Hindu Univ, Inst Med Sci, Dept Surg, Varanasi 221005, Uttar Pradesh, India; Banaras Hindu Univ, Inst Med Sci, Dept Community Med, Varanasi 221005, Uttar Pradesh, India; Banaras Hindu Univ, Fac Sci, Dept Bot, Varanasi 221005, Uttar Pradesh, India	Banaras Hindu University (BHU); Banaras Hindu University (BHU); Banaras Hindu University (BHU)	Shukla, VK (corresponding author), Banaras Hindu Univ, Inst Med Sci, Dept Surg, Varanasi 221005, Uttar Pradesh, India.			Tripathi, Brahma Dutt/0000-0002-3888-0379; Shukla, Vijay/0000-0002-2585-3478				KJELLSTROM T, 1979, ENVIRON HEALTH PERSP, V28, P199, DOI 10.2307/3428921; KRISHNAMURTI CR, 1990, TOXIC METALS INDIAN, P75; Leonard A., 1983, P INT C HEAV MET ENV, P700; *ROYAL COMM ENV PO, 1983, COMM8852; SHUKLA VK, 1985, J SURG ONCOL, V28, P32, DOI 10.1002/jso.2930280109	5	37	37	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1288	1289		10.1136/bmj.317.7168.1288	http://dx.doi.org/10.1136/bmj.317.7168.1288			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804716	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000076963800025
J	van der Windt, DAWM; Koes, BW; Deville, W; Boeke, AJP; de Jong, BA; Bouter, LM				van der Windt, DAWM; Koes, BW; Deville, W; Boeke, AJP; de Jong, BA; Bouter, LM			Effectiveness of corticosteroid injections versus physiotherapy for treatment of painful stiff shoulder in primary care: randomised trial	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; CLINICAL-TRIALS; STEROID INJECTIONS; DISORDERS; MANAGEMENT; CAPSULITIS; PLACEMENT; ACCURACY	Objective to compare the effectiveness of corticosteroid injections with physiotherapy for the treatment of painful stiff shoulder. Design Randomised trial. Setting 40 general practices. Subjects 109 patients consulting general practitioners for shoulder pain were enrolled in the trial. Interventions Patients were randomly allocated to 6 weeks of treatment either with corticosteroid injections (53) or physiotherapy (56). Main outcome measures Outcome assessments were carried out 3, 7, 13, 26, and 52 weeks after randomisation; some of the assessments were done by an observer blind to treatment allocation. Primary outcome measures were the success of treatment as measured by scores on scales measuring improvement in the main complaint and pain, and improvement in scores on a scale measuring shoulder disability. Results At 7 weeks 40 (77%) out of 52 patients seared with injections were considered to be treatment successes compared with 26 (46%) out of 56 treated with physiotherapy (difference between groups 31%, 95% confidence interval 14% to 48%). The difference in improvement favoured those treated dth corticosteroids in nearly all outcome measures; these differences were statistically significant At 26 and 52 weeks differences between the groups were comparatively small. Adverse reactions wee generally mild However among women receiving treatment with corticosteroids adverse reactions were mure troublesome: facial flushing was reported by 9 women and irregular menstrual bleeding by 6, 2 of whom were postmenopausal. Conclusions The beneficial effects of corticosteroid injections administered by general practitioners for treatment of painful stiff shoulder are superior to those of physiotherapy. The differences between the intervention groups were mainly the result of the comparatively faster relief of symptoms that occurred in patients treated with injections. Adverse reactions were generally mild but doctors should be aware of the potential side effects of injections of triamcinolone, particularly in women.	Free Univ Amsterdam, Fac Med, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Rehabil Med, NL-1105 AZ Amsterdam, Netherlands; Vrije Univ, Fac Med, Dept Gen Practice, Amsterdam, Netherlands; Vrije Univ, Fac Med, Dept Epidemiol & Biostat, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	van der Windt, DAWM (corresponding author), Free Univ Amsterdam, Fac Med, Inst Res Extramural Med, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.		Deville, Walter/B-5160-2013; Koes, Bart w/K-4614-2016	Koes, Bart w/0000-0002-0450-9969; Bouter, Lex/0000-0002-2659-5482				Bakker JF, 1990, HUISARTS WETENSCHAP, V33, P196; BULGEN DY, 1984, ANN RHEUM DIS, V43, P353, DOI 10.1136/ard.43.3.353; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; Croft P, 1996, BRIT MED J, V313, P601; CROFT P, 1993, EPIDEMIOLOGY RHEUMAT, P375; DACRE JE, 1989, ANN RHEUM DIS, V48, P322, DOI 10.1136/ard.48.4.322; DEWOLF AN, 1994, VADEMECUM, V12, P7; Eustace JA, 1997, ANN RHEUM DIS, V56, P59, DOI 10.1136/ard.56.1.59; Green S, 1998, BRIT MED J, V316, P354, DOI 10.1136/bmj.316.7128.354; HEEMSKERK MAM, 1997, NED TIJDSCHR FYSIOTH, V107, P146; JACOBS LGH, 1991, BRIT MED J, V302, P1498, DOI 10.1136/bmj.302.6791.1498; JONES A, 1993, BRIT MED J, V307, P1329, DOI 10.1136/bmj.307.6915.1329; LAMBERTS H, 1991, REASON ENCOUNTER E 1; LEE PN, 1974, ANN RHEUM DIS, V33, P116, DOI 10.1136/ard.33.2.116; LEE YJ, 1991, STAT MED, V10, P1595, DOI 10.1002/sim.4780101011; NORUSIS MJ, 1992, SPSS PC PLUS ADV STA; Van der Heijden G.J.M.G., 1996, SHOULDER DISORDER TR, P79; van der Windt DAWM, 1998, ANN RHEUM DIS, V57, P82, DOI 10.1136/ard.57.2.82; vanderHeijden GJMG, 1997, BRIT MED J, V315, P25, DOI 10.1136/bmj.315.7099.25; vanderHeijden GJMG, 1996, BRIT J GEN PRACT, V46, P309; vanderWindt DAWM, 1996, BRIT J GEN PRACT, V46, P519; VANDERWINDT DAWM, 1995, ANN RHEUM DIS, V54, P959, DOI 10.1136/ard.54.12.959; White AET, 1996, J ORTHOP RHEUMATOL, V9, P37; Winters JC, 1997, BRIT MED J, V314, P1320, DOI 10.1136/bmj.314.7090.1320	24	178	178	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1292	1296		10.1136/bmj.317.7168.1292	http://dx.doi.org/10.1136/bmj.317.7168.1292			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804720	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000076963800029
J	Shyng, SL; Nichols, CG				Shyng, SL; Nichols, CG			Membrane phospholipid control of nucleotide sensitivity of K-ATP channels	SCIENCE			English	Article							POTASSIUM CHANNELS; SULFONYLUREA RECEPTOR; STOICHIOMETRY; SUBUNIT; MUSCLE	Adenosine triphosphate (ATP)-sensitive potassium (K-ATP) channels couple cell metabolism to electrical activity. Phosphatidylinositol phosphates (PIPs) profoundly antagonized ATP inhibition of K-ATP channels when applied to inside-out membrane patches. It is proposed that membrane-incorporated pips can bind to positive charges in the cytoplasmic region of the channel's K(ir)6.2 subunit, stabilizing the open state of the channel and antagonizing the inhibitory effect of ATP. The tremendous effect of pips on ATP sensitivity suggests that in vivo alterations of membrane PIP levels will have substantial effects on K-ATP channel activity and hence on the gain of metabolism-excitation coupling.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Nichols, CG (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	cnichols@cellbio.wustl.edu	Nichols, Colin/D-6336-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045742] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45742] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; CANNELL MB, 1991, BIOPHYS J, V60, P1156, DOI 10.1016/S0006-3495(91)82151-8; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; DEUTSCH N, 1994, J GEN PHYSIOL, V104, P773, DOI 10.1085/jgp.104.4.773; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FINDLAY I, 1991, FEBS LETT, V279, P95, DOI 10.1016/0014-5793(91)80259-6; Hilgemann DW, 1997, ANNU REV PHYSIOL, V59, P193, DOI 10.1146/annurev.physiol.59.1.193; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0	16	482	483	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1138	1141		10.1126/science.282.5391.1138	http://dx.doi.org/10.1126/science.282.5391.1138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804554				2022-12-28	WOS:000076887700054
J	Hiraoka, N; Allen, E; Apel, IJ; Gyetko, MR; Weiss, SJ				Hiraoka, N; Allen, E; Apel, IJ; Gyetko, MR; Weiss, SJ			Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins	CELL			English	Article							PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; HUMAN STROMELYSIN-3; PROGELATINASE-A; SNAKE-VENOM; TNF-ALPHA; ANGIOGENESIS; MIGRATION; MICE	During angiogenesis, endothelial cells penetrate fibrin barriers via undefined proteolytic mechanisms. We demonstrate that the fibrinolytic plasminogen activator (PA)-plasminogen system is not required for this process, since tissues isolated from PA- or plasminogen-deficient mice successfully neovascularize fibrin gels. By contrast, neovessel formation, in vitro and in vivo, is dependent on fibrinolytic, endothelial cell-derived matrix metalloproteinases (MMP). MMPs directly regulate this process as invasion-incompetent cells penetrate fibrin barriers when transfected with the most potent fibrinolytic metalloproteinase identified in endothelium, membrane type-1 MMP (MT1-MMP). Membrane display of MT1-MMP is required, as invasion-incompetent cells expressing a fibrinolytically active, transmembrane-deleted form of MT1-MMP remain noninvasive. These observations identify a PA-independent fibrinolytic pathway wherein tethered MMPs function as pericellular fibrinolysins during the neovascularization process.	Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Ann Arbor Vet Affairs Med Ctr, Dept Internal Med, Div Pulm Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan	Weiss, SJ (corresponding author), Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.	sjweiss@umich.edu			NCI NIH HHS [CA71699] Funding Source: Medline; NHLBI NIH HHS [HL54216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071699] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Bini A, 1996, BIOCHEMISTRY-US, V35, P13056, DOI 10.1021/bi960730c; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Botos I, 1996, P NATL ACAD SCI USA, V93, P2749, DOI 10.1073/pnas.93.7.2749; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWN LF, 1993, AM J PATHOL, V142, P273; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; Bugge TH, 1997, BLOOD, V90, P4522; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Carmeliet P, 1997, J CLIN INVEST, V99, P200, DOI 10.1172/JCI119148; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453; DVORAK HF, 1987, LAB INVEST, V57, P673; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Itoh T, 1998, CANCER RES, V58, P1048; Kitching AR, 1997, J EXP MED, V185, P963, DOI 10.1084/jem.185.5.963; Koolwijk P, 1996, J CELL BIOL, V132, P1177, DOI 10.1083/jcb.132.6.1177; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; Mudgett JS, 1998, ARTHRITIS RHEUM-US, V41, P110, DOI 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; NOMURA H, 1995, CANCER RES, V55, P3263; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; PLOPLIS V, 1995, CIRCULATION, V92, P2582; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sabapathy KT, 1997, J CELL BIOL, V137, P953, DOI 10.1083/jcb.137.4.953; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schuster V, 1997, BLOOD, V90, P958, DOI 10.1182/blood.V90.3.958.958_958_966; Senger DR, 1996, AM J PATHOL, V149, P1; Ueno H, 1997, CANCER RES, V57, P2055; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Xiao Q, 1997, P NATL ACAD SCI USA, V94, P10335, DOI 10.1073/pnas.94.19.10335; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730	58	616	643	0	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 30	1998	95	3					365	377		10.1016/S0092-8674(00)81768-7	http://dx.doi.org/10.1016/S0092-8674(00)81768-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814707	Bronze			2022-12-28	WOS:000076789600010
J	Nakashima, AK; Horsley, R; Frey, RL; Sweeney, PA; Weber, JT; Fleming, PL				Nakashima, AK; Horsley, R; Frey, RL; Sweeney, PA; Weber, JT; Fleming, PL			Effect of HIV reporting by name on use of HIV testing in publicly funded counseling and testing programs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	125th Annual Meeting of the American-Public-Health-Association	NOV 09-13, 1997	INDIANAPOLIS, INDIANA	Amer Public Hlth Assoc, Natl Assoc Publ Hlth Policy, APHA, Med Care Sect			UNITED-STATES; NORTH-CAROLINA; EPIDEMIC	Context.-Policies requiring confidential reporting by name to state health departments of persons infected with the human immunodeficiency virus (HIV) have potential to cause some of them to avoid HIV testing. Objective.-To describe trends in use of HIV testing services at publicly funded HIV counseling and testing sites before and after the implementation of HIV reporting policies, Design and Setting.-Analysis of service provision data from 6 state health departments (Louisiana, Michigan, Nebraska, Nevada, New Jersey, and Tennessee) 12 months before and 12 months after HIV reporting was introduced. Main Outcome Measure.-Percent change in numbers of persons tested at publicly funded HIV counseling and testing sites after implementation of confidential HIV reporting by risk group. Results.-No significant declines in the total number of HIV tests provided at counseling and testing sites in the months immediately after implementation of HIV reporting occurred in any state, other than those expected from trends present before HIV reporting. Increases occurred in Nebraska(l5.8%), Nevada (48.4%), New Jersey (21.3%), and Tennessee (62.8%). Predicted decreases occurred in Louisiana (10.5%) and Michigan (2.0%), In all areas, testing of at-risk heterosexuals increased in the year after HIV reporting was implemented (Louisiana, 10.5%; Michigan, 225.1%; Nebraska, 5.7%; Nevada, 303.3%; New Jersey, 462.9%; Tennessee, 603.8%). Declines in testing occurred among men who have sex with men in Louisiana (4.3%) and Tennessee (4.1%) after HIV reporting; testing increased for this group in Michigan (5.3%), Nebraska (19.6%), Nevada (12.5%), and New Jersey (22.4%). Among injection drug users, testing declined in Louisiana (15%), Michigan (34.3%), and New Jersey (0.6%) and increased in Nebraska (1.7%), Nevada (18.9%), and Tennessee (16.6%). Conclusions.-Confidential HIV reporting by name did not appear to affect use of HIV testing in publicly funded counseling and testing programs.	Ctr Dis Control, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Nakashima, AK (corresponding author), Ctr Dis Control, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, 1600 Clifton Rd,MS E-47, Atlanta, GA 30333 USA.							*AIDS ACT FDN, 1993, SHOULD HIV TEST RES; *AM CIV LIB UN, 1997, HIV SURV NAM REP PUB; Burris S, 1997, AIDS PUBLIC POLICY J, V12, P66; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P45; *CDCP, 1998, HIV COUNS TEST PUBL; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P861; *CDCP, 1997, 9 CDCP, P32; *CDCP, 1994, HIV COUNC TEST REF S; Diggle PJ, 1994, ANAL LONGITUDINAL DA; FEHRS LJ, 1988, LANCET, V2, P379; Forbes Anna, 1996, AIDS Policy Law, VBonus Report, P1; FORDYCE EJ, 1989, JAMA-J AM MED ASSOC, V262, P349, DOI 10.1001/jama.1989.03430030037014; FRANCIS DP, 1993, J ACQ IMMUN DEF SYND, V6, P285; Gostin LO, 1997, NEW ENGL J MED, V337, P1162, DOI 10.1056/NEJM199710163371611; Hecht F. M., 1997, JGIM, V12, P108; HertzPicciotto I, 1996, AM J PUBLIC HEALTH, V86, P1446, DOI 10.2105/AJPH.86.10.1446; HIRANO D, 1994, AM J PUBLIC HEALTH, V84, P2008, DOI 10.2105/AJPH.84.12.2008; Hoxworth Tamara, 1994, AIDS Public Policy J, V9, P182; Irwin KL, 1996, AIDS, V10, P1707, DOI 10.1097/00002030-199612000-00016; JOHNSON WD, 1988, 4 INT C AIDS JUN 14; Kassler WJ, 1997, J ACQ IMMUN DEF SYND, V14, P281, DOI 10.1097/00042560-199703010-00013; KEGELES SM, 1990, AIDS, V4, P585, DOI 10.1097/00002030-199006000-00016; KEGELES SM, 1989, JAMA-J AM MED ASSOC, V261, P1275, DOI 10.1001/jama.1989.03420090039012; LEHMAN JS, 1998, 12 INT C AIDS JUL 2; MYERS T, 1993, AM J PUBLIC HEALTH, V83, P701, DOI 10.2105/AJPH.83.5.701; PETERSON DR, 1996, 11 INT C AIDS JUL 11; PHILLIPS KA, 1994, J ACQ IMMUN DEF SYND, V7, P403; *SAS I INC, 1996, SAS STAT SOFTW CHANG, P36; THALL PF, 1990, BIOMETRICS, V46, P657, DOI 10.2307/2532086; Weber JT, 1997, AIDS EDUC PREV, V9, P79	31	42	43	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	1998	280	16					1421	1426		10.1001/jama.280.16.1421	http://dx.doi.org/10.1001/jama.280.16.1421			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	130YA	9801002	Bronze			2022-12-28	WOS:000076546900037
J	Winstanley, P				Winstanley, P			Albendazole for mass treatment of asymptomatic trichuris infections	LANCET			English	Editorial Material									Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England	University of Liverpool	Winstanley, P (corresponding author), Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England.							BUNDY DAP, 1989, ADV PARASIT, V28, P107; Chan MS, 1997, PARASITOL TODAY, V13, P438, DOI 10.1016/S0169-4758(97)01144-7; Cooper ES, 1995, T ROY SOC TROP MED H, V89, P653, DOI 10.1016/0035-9203(95)90430-1; DOLLERY C, 1991, THERAPEUTIC DRUGS, pA31; Hall A, 1997, PARASITOL TODAY, V13, P411, DOI 10.1016/S0169-4758(97)01136-8; HORTON RJ, 1989, T ROY SOC TROP MED H, V83, P97, DOI 10.1016/0035-9203(89)90724-4; *WHO, WHOCDSIPICTD921	7	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 3	1998	352	9134					1080	1081		10.1016/S0140-6736(98)00027-0	http://dx.doi.org/10.1016/S0140-6736(98)00027-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798577				2022-12-28	WOS:000076246400002
J	Tsai, HM; Lian, ECY				Tsai, HM; Lian, ECY			Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMOLYTIC-UREMIC SYNDROME; VONWILLEBRAND-FACTOR; ENDOTHELIAL-CELLS; NORMAL PLASMA; SHEAR-STRESS; FACTOR-VIII; CLEAVAGE; PROTEOLYSIS; PLATELETS	Background Thrombotic thrombocytopenic purpura is a potentially fatal disease characterized by widespread platelet thrombi in the microcirculation. In the normal circulation, von Willebrand factor is cleaved by a plasma protease. We explored the hypothesis that a deficiency of this protease predisposes patients with thrombotic thrombocytopenic purpura to platelet thrombosis. Methods We studied the activity of von Willebrand factor-cleaving protease and sought inhibitors of this protease in plasma from patients with acute thrombotic thrombocytopenic purpura, patients with other diseases, and normal control subjects. We also investigated the effect of shear stress on the ristocetin cofactor activity of purified von Willebrand factor in the cryosupernatant fraction of the plasma samples. Results Thirty-nine samples of plasma from 37 patients with acute thrombotic thrombocytopenic purpura had severe deficiency of von Willebrand factor-cleaving protease. No deficiency was detected in 16 samples of plasma from patients with thrombotic thrombocytopenic purpura in remission or in 74 plasma samples from normal subjects, randomly selected hospitalized patients or outpatients, or patients with hemolysis, thrombocytopenia, or thrombosis from other causes. Inhibitory activity against the protease was detected in 26 of the 39 plasma samples (67 percent) obtained during the acute phase of the disease. The inhibitors were IgG antibodies. Shear stress increased the ristocetin cofactor activity of von Willebrand factor in the cryosupernatant of plasma samples obtained during the acute phase, but decreased the activity in cryosupernatant of plasma from normal subjects. Conclusions Inhibitory antibodies against von Willebrand factor-cleaving protease occur in patients with acute thrombotic thrombocytopenic purpura, A deficiency of this protease is likely to have a critical role in the pathogenesis of platelet thrombosis in this disease. (N Engl J Med 1998;339:1585-94.) (C)1998, Massachusetts Medical Society.	Montefiore Med Ctr, Div Hematol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Univ Miami, Ctr Thrombosis & Hemostasis, Miami, FL 33152 USA; Univ Miami, Sylvester Canc Ctr, Miami, FL 33152 USA; Vet Affairs Med Ctr, Miami, FL 33125 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Miami; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Tsai, HM (corresponding author), Montefiore Med Ctr, Div Hematol, 111 E 210th St, Bronx, NY 10467 USA.				NHLBI NIH HHS [R01 HL062136-01, R01 HL062136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASADA Y, 1985, THROMB RES, V38, P469, DOI 10.1016/0049-3848(85)90180-X; BAEHR G, 1936, T ASSOC AM PHYSICIAN, V51, P43; Bell WR, 1997, SEMIN HEMATOL, V34, P134; BURNS ER, 1982, BLOOD, V60, P1030; Chow TW, 1998, AM J HEMATOL, V57, P293, DOI 10.1002/(SICI)1096-8652(199804)57:4<293::AID-AJH5>3.3.CO;2-R; CONSONNI R, 1994, BRIT J HAEMATOL, V87, P321, DOI 10.1111/j.1365-2141.1994.tb04916.x; DENT JA, 1990, P NATL ACAD SCI USA, V87, P9508; DENT JA, 1990, P NATL ACAD SCI USA, V87, P6306, DOI 10.1073/pnas.87.16.6306; Furlan M, 1997, BLOOD, V89, P3097, DOI 10.1182/blood.V89.9.3097; Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Hymes KB, 1997, SEMIN HEMATOL, V34, P117; JOSEPH G, 1994, AM J HEMATOL, V47, P189, DOI 10.1002/ajh.2830470308; KELTON JG, 1992, BLOOD, V80, P2246; Kroll MH, 1996, BLOOD, V88, P1525; Kwaan HC, 1997, SEMIN HEMATOL, V34, P159; Mitra D, 1997, BLOOD, V89, P1224, DOI 10.1182/blood.V89.4.1224; MIURA M, 1984, AM J HEMATOL, V17, P307, DOI 10.1002/ajh.2830170311; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; MOAKE JL, 1989, AM J MED, V87, P9; Moschcowitz E., 1924, P NY PATHOL SOC, V24, P21; NEAME PB, 1980, SEMIN THROMB HEMOST, V6, P416, DOI 10.1055/s-2007-1005113; Nichols W C, 1995, Blood, V86, P2461; NICHOLS WC, 1994, BLOOD, V83, P3225; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; SIDDIQUI FA, 1985, J CLIN INVEST, V76, P1330, DOI 10.1172/JCI112107; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; TANDON NN, 1994, BRIT J HAEMATOL, V88, P816, DOI 10.1111/j.1365-2141.1994.tb05122.x; TOROK TJ, 1995, AM J HEMATOL, V50, P84, DOI 10.1002/ajh.2830500203; Tsai HM, 1997, BLOOD, V89, P1954, DOI 10.1182/blood.V89.6.1954; TSAI HM, 1989, BLOOD, V73, P2074; TSAI HM, 1994, BLOOD, V83, P2171; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235	33	1300	1356	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 26	1998	339	22					1585	1594		10.1056/NEJM199811263392203	http://dx.doi.org/10.1056/NEJM199811263392203			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZU	9828246	Green Accepted, Bronze			2022-12-28	WOS:000077176100003
J	Hazelrigg, T				Hazelrigg, T			The destinies and destinations of RNAs	CELL			English	Review							ACTIN MESSENGER-RNA; PAIR-RULE TRANSCRIPTS; BINDING PROTEIN; XENOPUS OOCYTES; TRANSLATIONAL REGULATION; DROSOPHILA EMBRYOS; INTRACELLULAR-LOCALIZATION; ASYMMETRIC LOCALIZATION; ENDOPLASMIC-RETICULUM; NUCLEAR EXPORT		Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Hazelrigg, T (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.							Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; BARBARESE E, 1995, J CELL SCI, V108, P2781; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; BASSELL GJ, 1994, J CELL BIOL, V126, P863, DOI 10.1083/jcb.126.4.863; Bassell GJ, 1998, J NEUROSCI, V18, P251; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Broadus J, 1998, NATURE, V391, P792, DOI 10.1038/35861; Carson JH, 1997, CELL MOTIL CYTOSKEL, V38, P318, DOI 10.1002/(SICI)1097-0169(1997)38:4<318::AID-CM2>3.0.CO;2-#; Chicurel ME, 1998, NATURE, V392, P730, DOI 10.1038/33719; Cooperstock RL, 1997, SEMIN CELL DEV BIOL, V8, P541, DOI 10.1006/scdb.1997.0179; Dahanukar A, 1996, GENE DEV, V10, P2610, DOI 10.1101/gad.10.20.2610; Davis I, 1997, SEMIN CELL DEV BIOL, V8, P91, DOI 10.1006/scdb.1996.0126; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; Deshler JO, 1997, SCIENCE, V276, P1128, DOI 10.1126/science.276.5315.1128; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; ELISHA Z, 1995, EMBO J, V14, P5109, DOI 10.1002/j.1460-2075.1995.tb00193.x; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; Etkin LD, 1997, SCIENCE, V276, P1092, DOI 10.1126/science.276.5315.1092; Femino A, 1998, SCIENCE, V280, P585, DOI 10.1126/science.280.5363.585; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; Forbes A, 1998, DEVELOPMENT, V125, P679; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; FrancisLang H, 1996, EMBO J, V15, P640, DOI 10.1002/j.1460-2075.1996.tb00396.x; Fuerstenberg S, 1998, INT J DEV BIOL, V42, P379; Gautreau D, 1997, DEVELOPMENT, V124, P5013; Gavis ER, 1996, DEVELOPMENT, V122, P2791; Gavis ER, 1997, TRENDS CELL BIOL, V7, P485, DOI 10.1016/S0962-8924(97)01162-8; Gunkel N, 1998, GENE DEV, V12, P1652, DOI 10.1101/gad.12.11.1652; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; Iida T, 1998, P NATL ACAD SCI USA, V95, P11274, DOI 10.1073/pnas.95.19.11274; Ikenishi K, 1998, DEV GROWTH DIFFER, V40, P1; Kawasaki I, 1998, CELL, V94, P635, DOI 10.1016/S0092-8674(00)81605-0; KIMHA J, 1995, CELL, V81, P403, DOI 10.1016/0092-8674(95)90393-3; Kislauskis Edward H., 1992, Current Opinion in Cell Biology, V4, P975, DOI 10.1016/0955-0674(92)90128-Y; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; KLOC M, 1995, DEVELOPMENT, V121, P287; Kloc M, 1998, MECH DEVELOP, V73, P95, DOI 10.1016/S0925-4773(98)00041-0; Knowles RB, 1997, P NATL ACAD SCI USA, V94, P14804, DOI 10.1073/pnas.94.26.14804; Knowles RB, 1996, J NEUROSCI, V16, P7812; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; Lantz VA, 1998, J CELL BIOL, V140, P897, DOI 10.1083/jcb.140.4.897; LATHAM VM, 1994, J CELL BIOL, V126, P1211, DOI 10.1083/jcb.126.5.1211; LEHMANN R, 1995, CELL, V83, P353, DOI 10.1016/0092-8674(95)90111-6; LINK W, 1995, P NATL ACAD SCI USA, V92, P5734, DOI 10.1073/pnas.92.12.5734; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; LUND E, 1998, IN PRESS SCIENCE; LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6; Macdonald PM, 1998, MOL CELL BIOL, V18, P3788, DOI 10.1128/MCB.18.7.3788; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MACDONALD PM, 1995, P NATL ACAD SCI USA, V92, P10787, DOI 10.1073/pnas.92.23.10787; Macdonald PM, 1996, CURR OPIN GENET DEV, V6, P403, DOI 10.1016/S0959-437X(96)80060-8; Macdonald PM, 1997, RNA, V3, P1413; MERMALL V, 1994, NATURE, V369, P560, DOI 10.1038/369560a0; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; Mowry KL, 1996, P NATL ACAD SCI USA, V93, P14608, DOI 10.1073/pnas.93.25.14608; Muslimov IA, 1998, J CELL BIOL, V141, P1601, DOI 10.1083/jcb.141.7.1601; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Oleynikov Y, 1998, TRENDS CELL BIOL, V8, P381, DOI 10.1016/S0962-8924(98)01348-8; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Schnapp BJ, 1997, SEMIN CELL DEV BIOL, V8, P529, DOI 10.1006/scdb.1997.0178; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; SCHWARTZ SP, 1992, P NATL ACAD SCI USA, V89, P11895, DOI 10.1073/pnas.89.24.11895; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Steward O, 1997, NEURON, V18, P9, DOI 10.1016/S0896-6273(01)80041-6; Steward O, 1998, NEURON, V21, P741, DOI 10.1016/S0896-6273(00)80591-7; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Styhler S, 1998, DEVELOPMENT, V125, P1569; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; Swalla BJ, 1996, DEV GENET, V19, P258, DOI 10.1002/(SICI)1520-6408(1996)19:3<258::AID-DVG9>3.0.CO;2-8; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; Theurkauf WE, 1998, DEVELOPMENT, V125, P3655; Tomancak P, 1998, DEVELOPMENT, V125, P1723; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; WILKIE G, 1998, VISUALIZING MNRA IN; Zhang J, 1998, CELL, V94, P515, DOI 10.1016/S0092-8674(00)81592-5; Zhang J, 1996, DEVELOPMENT, V122, P4119	87	85	84	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1998	95	4					451	460		10.1016/S0092-8674(00)81613-X	http://dx.doi.org/10.1016/S0092-8674(00)81613-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827798	hybrid			2022-12-28	WOS:000077049400004
J	Kasschau, KD; Carrington, JC				Kasschau, KD; Carrington, JC			A counterdefensive strategy of plant viruses: Suppression of posttranscriptional gene silencing	CELL			English	Article							TOBACCO ETCH POTYVIRUS; HELPER COMPONENT-PROTEINASE; LONG-DISTANCE MOVEMENT; PATHOGEN-DERIVED RESISTANCE; TO-CELL MOVEMENT; TRANSGENIC PLANTS; GENOME AMPLIFICATION; PROTEOLYTIC ACTIVITIES; RNA DEGRADATION; X RNA	Posttranscriptional gene silencing (PTGS) in plants inactivates some aberrant or highly expressed RNAs in a sequence-specific manner in the cytoplasm. A silencing mechanism similar to PTGS appears to function as an adaptive antiviral response. We demonstrate that the P1/HC-Pro polyprotein encoded by tobacco etch virus functions as a suppressor of PTGS. A locus comprised of a highly expressed P-glucuronidase (GUS) transgene was shown to exhibit PTGS. Genetic crosses and segregation analyses revealed that a P1/HC-Pro transgene suppressed PIGS of the GUS sequence. Nuclear transcription assays indicated that the silencing suppression activity of P1/HC-Pro was at the posttranscriptional level. These data reveal that plant viruses can condition enhanced susceptibility within a host through interdiction of a potent defense response.	Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	Washington State University	Carrington, JC (corresponding author), Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA.	carrington@wsu.edu	Carrington, James C/A-4656-2012	Carrington, James C/0000-0003-3572-129X	NIAID NIH HHS [AI27832, AI43288] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027832, R01AI027832, R01AI043288, R21AI043288] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Kaff NS, 1998, SCIENCE, V279, P2113, DOI 10.1126/science.279.5359.2113; Angell SM, 1997, EMBO J, V16, P3675, DOI 10.1093/emboj/16.12.3675; Baulcombe DC, 1996, PLANT CELL, V8, P1833, DOI 10.1105/tpc.8.10.1833; BRIGNETI G, 1998, IN PRESS EMBO J, V17; CARRINGTON JC, 1990, EMBO J, V9, P1347, DOI 10.1002/j.1460-2075.1990.tb08249.x; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; CARRINGTON JC, 1993, J VIROL, V67, P6995, DOI 10.1128/JVI.67.12.6995-7000.1993; COX KH, 1988, PLANT MOL BIOL PRACT, P1; CRONIN S, 1995, PLANT CELL, V7, P549, DOI 10.1105/tpc.7.5.549; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; Depicker A, 1997, CURR OPIN CELL BIOL, V9, P373, DOI 10.1016/S0955-0674(97)80010-5; DING SW, 1995, EMBO J, V14, P5762, DOI 10.1002/j.1460-2075.1995.tb00265.x; DOLJA VV, 1992, P NATL ACAD SCI USA, V89, P10208, DOI 10.1073/pnas.89.21.10208; DOUGHERTY WG, 1994, MOL PLANT MICROBE IN, V7, P544, DOI 10.1094/MPMI-7-0554; DOUGHERTY WG, 1995, CURR OPIN CELL BIOL, V7, P399, DOI 10.1016/0955-0674(95)80096-4; English JJ, 1996, PLANT CELL, V8, P179, DOI 10.1105/tpc.8.2.179; FEINBERG AP, 1983, ANAL BIOCHEM, V257, P8569; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Goodwin J, 1996, PLANT CELL, V8, P95, DOI 10.1105/tpc.8.1.95; HEHL R, 1990, PLANT CELL, V2, P709, DOI 10.1105/tpc.2.8.709; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; KASSCHAU KD, 1995, VIROLOGY, V209, P268, DOI 10.1006/viro.1995.1254; Kasschau KD, 1997, VIROLOGY, V228, P251, DOI 10.1006/viro.1996.8368; KJERTRUP S, 1998, PLANT J, V14, P91; KLEIN PG, 1994, VIROLOGY, V204, P759, DOI 10.1006/viro.1994.1591; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; KUMAGAI MH, 1995, P NATL ACAD SCI USA, V92, P1679, DOI 10.1073/pnas.92.5.1679; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LINDBO JA, 1992, MOL PLANT MICROBE IN, V5, P144, DOI 10.1094/MPMI-5-144; LINDBO JA, 1992, VIROLOGY, V189, P725, DOI 10.1016/0042-6822(92)90595-G; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; Matthews REF., 2002, PLANT VIROLOGY; MEINS F, 1995, CURR TOP MICROBIOL, V197, P105; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Pruss G, 1997, PLANT CELL, V9, P859, DOI 10.1105/tpc.9.6.859; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; Rojas MR, 1997, VIROLOGY, V237, P283, DOI 10.1006/viro.1997.8777; Ruiz F, 1998, MOL BIOL CELL, V9, P931, DOI 10.1091/mbc.9.4.931; Ruiz MT, 1998, PLANT CELL, V10, P937, DOI 10.1105/tpc.10.6.937; Schaad MC, 1997, J VIROL, V71, P8624, DOI 10.1128/JVI.71.11.8624-8631.1997; Schob H, 1997, MOL GEN GENET, V256, P581, DOI 10.1007/s004380050604; SCHOLTHOF HB, 1995, VIROLOGY, V213, P425, DOI 10.1006/viro.1995.0015; Shi XM, 1997, VIROLOGY, V231, P35, DOI 10.1006/viro.1997.8488; SMITH HA, 1994, PLANT CELL, V6, P1441, DOI 10.1105/tpc.6.10.1441; Tanzer MM, 1997, PLANT CELL, V9, P1411, DOI 10.1105/tpc.9.8.1411; VANCE VB, 1991, VIROLOGY, V182, P486, DOI 10.1016/0042-6822(91)90589-4; VERCHOT J, 1995, J VIROL, V69, P3668, DOI 10.1128/JVI.69.6.3668-3674.1995; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438	52	629	699	2	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1998	95	4					461	470		10.1016/S0092-8674(00)81614-1	http://dx.doi.org/10.1016/S0092-8674(00)81614-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827799	Bronze			2022-12-28	WOS:000077049400005
J	King, AJ; Sun, HY; Diaz, B; Barnard, D; Miao, WY; Bagrodia, S; Marshall, MS				King, AJ; Sun, HY; Diaz, B; Barnard, D; Miao, WY; Bagrodia, S; Marshall, MS			The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338	NATURE			English	Article							SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; ACTIVATION; RAS; CASCADE; ERK	The pathway involving the signalling: protein p21(Ras) propagates a range of extracellular signals from receptors on the cell membrane to the cytoplasm and nucleus(1). The Ras proteins regulate many effecters, including members of the Raf family of protein kinases. Ras-dependent activation of Raf-1 at the plasma membrane involves phosphorylation events, protein-protein interactions and structural changes(2-8). Phosphorylation of serine residues 338 or 339 in the catalytic domain of Raf-1 regulates its activation in response to Ras, Src and epidermal growth factor(9,10). Here we show that the p21-activated protein kinase Pak3 phosphorylates Raf-1 on serine 338 in vitro and in vivo. The p21-activated protein kinases are regulated by the Rho-family GTPases Rac and Cdc42 (ref, 11). Our results indicate that signal transduction through Raf-1 depends on both Ras and the activation of the Pak pathway. As guanine-nucleotide-exchange activity on Rac can be stimulated by a Ras-dependent phosphatidylinositol-3-OH kinase(12,13), a mechanism could exist through which one Ras effector pathway can be influenced by another.	Indiana Univ, Sch Med, Dept Med, Div Hematol Oncol, Bloomington, IN 47405 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Bloomington, IN 47405 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Cornell Univ, Dept Pharmacol, Sect Mol & Cell Biol, Ithaca, NY 14853 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Cornell University	Marshall, MS (corresponding author), Indiana Univ, Sch Med, Dept Med, Div Hematol Oncol, Bloomington, IN 47405 USA.	mmarsha@.iupui.edu						BADRODIA S, 1995, J BIOL CHEM, V270, P22731; BARNARD D, IN PRESS ONCOGENE; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; ESCHENBRUCH M, 1982, ANAL BIOCHEM, V125, P96, DOI 10.1016/0003-2697(82)90387-6; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Rooney RD, 1996, J BIOL CHEM, V271, P21498, DOI 10.1074/jbc.271.35.21498; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454	22	365	375	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	1998	396	6707					180	183		10.1038/24184	http://dx.doi.org/10.1038/24184			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823899				2022-12-28	WOS:000077013300055
J	Alderson, P; Goodey, C				Alderson, P; Goodey, C			Theories in health care and research - Theories of consent	BRITISH MEDICAL JOURNAL			English	Article									Univ London, Inst Educ, Social Sci Res Unit, London WC1H 0NS, England	University of London; University College London; UCL Institute of Education	Alderson, P (corresponding author), Univ London, Inst Educ, Social Sci Res Unit, London WC1H 0NS, England.			Alderson, Priscilla/0000-0003-4002-4501				Alderson P, 1998, BRIT MED J, V317, P1007, DOI 10.1136/bmj.317.7164.1007; Alderson P, 1996, HLTH CARE CHOICES MA; Alderson P., 1990, CHOOSING CHILDREN PA; Alderson P., 1993, CHILDRENS CONSENT SU; [Anonymous], 1986, HIST THEORY INFORM C; Gillon R., 1994, PHILOS MED ETHICS; Kennedy I., 1988, TREAT ME RIGHT; Mitscherlich A., 1949, DOCTORS INFAMY STORY, pxxiii; MONTGOMERY J, 1997, HLTH CARE LAW; OLIVER M, 1998, IN PRESS BMJ; *WORLD MED ASS, 1989, WORLD MED ASS HDB DE; Yiannis GABRIEL, 1995, UNMANAGEABLE CONSUME	12	40	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1313	1315		10.1136/bmj.317.7168.1313	http://dx.doi.org/10.1136/bmj.317.7168.1313			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804727	Green Published			2022-12-28	WOS:000076963800036
J	Ford, R; Durcan, G; Warner, L; Hardy, P; Muijen, M				Ford, R; Durcan, G; Warner, L; Hardy, P; Muijen, M			One day survey by the Mental Health Act Commission of acute adult psychiatric inpatient wards in England and Wales	BRITISH MEDICAL JOURNAL			English	Article								Objectives To provide (via the Mental Health Act Commission's "national visit") empirical evidence on ward occupancy levels, use of the Mental Health Act 1983, nurse staffing, and care of female patients on acute adult psychiatric wards. Design One day survey of a stratified random sample. Settings 119/250 (47%) acute adult psychiatric inpatient units in England and Wales. Subjects End sample of 263 acute psychiatric inpatient wards. Main outcome measures Ward occupancy rates; number of patients detained under the Mental Health Act and proportion "absent without leave"; nurse staffing levels, skill mix, and vacancies; proportion of women with self contained, women-only facilities. Results Mean ward occupancy was 99% (95% confidence interval 97% to 102%). A ward mean of 30% (28% to 32%) of patients were detained under the Mental Health Act; of all detained patients, 1% (1% to 2%) were absent without leave. A ward mean of 0.3 (0.29 to 0.31) nurses were on duty per patient at the time of the visit An estimated ward mean of 31% (30% to 32%) of nurse staffing may have been through casual contracts-higher in inner (48% (43% to 53%)) and outer London (45% (41% to 48%)). On 26% (21% to 32%) of wards, there were no nurses interacting with patients. A ward mean of 36% (30% to 41%) of female patients had self contained, women-only facilities. Conclusions Attention should focus on improving the quality of acute inpatient psychiatric care as well as of community care.	Sainsbury Ctr Mental Hlth, London SE1 1LB, England		Ford, R (corresponding author), Sainsbury Ctr Mental Hlth, London SE1 1LB, England.							Audit Commission, 1994, FIND PLAC REV MENT H; BLOMCOOPER L, 1995, FALLING SHADOW ONE P; *DEP HLTH, 1996, INP FORM DET HOSP ME; *DEP HLTH, 1996, SPECTR CAR LOC SERV; Department of Health, 1996, HLTH PERS SOC SERV S; HOWLAND G, 1996, IHSM HLTH SOCIAL SER; Hurst K, 1995, J Nurs Manag, V3, P43, DOI 10.1111/j.1365-2834.1995.tb00065.x; Moore C, 1998, Nurs Times, V94, P54; *ROYAL COLL PSYCH, 1997, JUST BRICKS MORT REP; Shepherd G, 1997, BRIT MED J, V314, P262, DOI 10.1136/bmj.314.7076.262; SNELL J, 1997, HLTH SERVICE J, V107, P26	11	46	46	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1279	1283		10.1136/bmj.317.7168.1279	http://dx.doi.org/10.1136/bmj.317.7168.1279			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804713	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000076963800022
J	Horwich, A; Huddart, R; Dearnaley, D				Horwich, A; Huddart, R; Dearnaley, D			Markers and management of germ-cell tumours of the testes	LANCET			English	Review							MEDICAL-RESEARCH-COUNCIL; LYMPH-NODE DISSECTION; I TESTICULAR TERATOMA; RANDOMIZED TRIAL; CYTOGENETIC ANALYSIS; CLINICAL STAGE; TUMORS; CANCER; ETOPOSIDE; CISPLATIN		Royal Marsden NHS Trust, Acad Unit Radiotherapy & Oncol, Sutton SM2 5PT, Surrey, England; Inst Canc Res, Sutton SM2 5PT, Surrey, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK	Horwich, A (corresponding author), Royal Marsden NHS Trust, Acad Unit Radiotherapy & Oncol, Downs Rd, Sutton SM2 5PT, Surrey, England.		Dearnaley, David P/J-2318-2014	Dearnaley, David P/0000-0002-3954-2806; huddart, robert/0000-0003-3604-1990				[Anonymous], 1997, J Clin Oncol, V15, P594; ATKIN NB, 1983, CANCER GENET CYTOGEN, V10, P199, DOI 10.1016/0165-4608(83)90125-5; BAJORIN DF, 1993, J CLIN ONCOL, V11, P598, DOI 10.1200/JCO.1993.11.4.598; BOSL GJ, 1994, J NATL CANCER I, V86, P349, DOI 10.1093/jnci/86.5.349; BROUN ER, 1992, ANN INTERN MED, V117, P124, DOI 10.7326/0003-4819-117-2-124; CULLEN MH, 1996, TESTICULAR CANC INVE, P181; Dearnaley DP, 1998, P AN M AM SOC CLIN, V17, p309a; DEJONG B, 1990, CANCER GENET CYTOGEN, V48, P143, DOI 10.1016/0165-4608(90)90115-Q; deWit R, 1997, J CLIN ONCOL, V15, P1837, DOI 10.1200/JCO.1997.15.5.1837; DONOHUE JP, 1993, BRIT J UROL, V71, P326, DOI 10.1111/j.1464-410X.1993.tb15952.x; EINHORN LH, 1977, ANN INTERN MED, V87, P293, DOI 10.7326/0003-4819-87-3-293; FORMAN D, 1992, BRIT J CANCER, V65, P255, DOI 10.1038/bjc.1992.51; FOSSA SD, 1996, P AN M AM SOC CLIN, V15, P239; FREEDMAN LS, 1987, LANCET, V2, P294; GIACCHETTI S, 1993, INT J RADIAT ONCOL, V27, P3, DOI 10.1016/0360-3016(93)90414-Q; HAY JH, 1984, BRIT J RADIOL, V57, P597, DOI 10.1259/0007-1285-57-679-597; Hernes EH, 1996, EUR UROL, V30, P349; HORWICH A, 1994, RADIOTHER ONCOL, V30, P193, DOI 10.1016/0167-8140(94)90457-X; HORWICH A, 1994, EUR J CANCER, V30A, P1607, DOI 10.1016/0959-8049(94)00329-4; HORWICH A, 1992, EUR J CANCER, V28A, P1307, DOI 10.1016/0959-8049(92)90505-V; Horwich A, 1997, J CLIN ONCOL, V15, P1844, DOI 10.1200/JCO.1997.15.5.1844; HORWICH A, 1995, BRIT J CANCER, V71, P901, DOI 10.1038/bjc.1995.175; HORWICH A, 1996, TESTICULAR CANC INVE, P1; Kaye SB, 1998, J CLIN ONCOL, V16, P692, DOI 10.1200/JCO.1998.16.2.692; Khoo V S, 1997, Clin Oncol (R Coll Radiol), V9, P252, DOI 10.1016/S0936-6555(97)80011-8; LASSEN U, 1997, P AN M AM SOC CLIN, V16, pA321; MEAD GM, 1992, J CLIN ONCOL, V10, P85, DOI 10.1200/JCO.1992.10.1.85; MOLLER H, 1993, EUR J CANCER, V29A, P672, DOI 10.1016/S0959-8049(05)80344-2; MOTZER RJ, 1994, J CLIN ONCOL, V12, P2277, DOI 10.1200/JCO.1994.12.11.2277; OLIVER RTD, 1994, INT J RADIAT ONCOL, V29, P3, DOI 10.1016/0360-3016(94)90219-4; PECKHAM MJ, 1985, LANCET, V1, P8; PECKHAM MJ, 1983, BRIT J CANCER, V47, P613, DOI 10.1038/bjc.1983.99; PIZZOCARO G, 1987, INT J ANDROL, V10, P269, DOI 10.1111/j.1365-2605.1987.tb00193.x; READ G, 1992, J CLIN ONCOL, V10, P1762, DOI 10.1200/JCO.1992.10.11.1762; Read G, 1993, Clin Oncol (R Coll Radiol), V5, P364, DOI 10.1016/S0936-6555(05)80087-1; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; Saxman SB, 1998, J CLIN ONCOL, V16, P702, DOI 10.1200/JCO.1998.16.2.702; SCHMOLL HJ, 1996, TESTICULAR CANC INVE, P255; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Summersgill B, 1998, BRIT J CANCER, V77, P305, DOI 10.1038/bjc.1998.47; Summersgill BM, 1998, GERM CELL TUMOURS IV, P87; WILLIAMS SD, 1987, NEW ENGL J MED, V316, P1435, DOI 10.1056/NEJM198706043162302; Zagars GK, 1996, TESTICULAR CANC INVE, P99	44	19	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 7	1998	352	9139					1535	1538		10.1016/S0140-6736(98)04251-2	http://dx.doi.org/10.1016/S0140-6736(98)04251-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820318				2022-12-28	WOS:000076862300039
J	Morris, AAM; Rodger, IW				Morris, AAM; Rodger, IW			Leukotrienes and the brain	LANCET			English	Editorial Material							ACID		Royal Victoria Infirm, Dept Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Merck Frosst Ctr Therapeut Res, Dept Pharmacol, Kirkland, PQ, Canada	Newcastle University - UK; Merck & Company	Morris, AAM (corresponding author), Royal Victoria Infirm, Dept Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.							Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Goldhill J, 1997, AM J PHYSIOL-GASTR L, V272, pG1135, DOI 10.1152/ajpgi.1997.272.5.G1135; KIESEL L, 1991, P NATL ACAD SCI USA, V88, P8801, DOI 10.1073/pnas.88.19.8801; Lammers CH, 1996, J NEUROCHEM, V66, P147; LINDGREN JA, 1984, P NATL ACAD SCI-BIOL, V81, P6212, DOI 10.1073/pnas.81.19.6212; MAYATEPEK E, 1994, PEDIATR RES, V35, P307, DOI 10.1203/00006450-199403000-00005; MIYAMOTO T, 1987, FEBS LETT, V216, P123, DOI 10.1016/0014-5793(87)80769-X; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; YOKIMOZO T, 1997, NATURE, V387, P620	9	12	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1487	1488		10.1016/S0140-6736(05)60322-4	http://dx.doi.org/10.1016/S0140-6736(05)60322-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820293				2022-12-28	WOS:000076862300003
J	Caruso, F; Caruso, RA; Mohwald, H				Caruso, F; Caruso, RA; Mohwald, H			Nanoengineering of inorganic and hybrid hollow spheres by colloidal templating	SCIENCE			English	Article							MULTILAYER FILMS; PARTICLES; SILICA; ADSORPTION; POLYELECTROLYTE; GOLD; NANOPARTICLES; MICROSPHERES; CARBONATE; HEMATITE	Hollow silica and silica-polymer spheres with diameters between 720 and 1000 nanometers were fabricated by consecutively assembling silica nanoparticles and polymer onto colloids and subsequently removing the templated colloid either by calcination or decomposition upon exposure to solvents. Scanning and transmission electron microscopy images demonstrate that the wall thickness of the hollow spheres can be readily controlled by varying the number of nanoparticle-polymer deposition cycles, and the size and shape are determined by the morphology of the templating colloid. The hollow spheres produced are envisioned to have applications in areas ranging from medicine to pharmaceutics to materials science.	Max Planck Inst Colloids & Interfaces, D-12489 Berlin, Germany; Max Planck Inst Colloids & Interfaces, D-14513 Teltow, Germany	Max Planck Society; Max Planck Society	Caruso, F (corresponding author), Max Planck Inst Colloids & Interfaces, Rudower Chaussee 5, D-12489 Berlin, Germany.	caruso@mpikg.fta-berlin.de	Caruso, Frank/A-9587-2011; Möhwald, Helmuth/B-8265-2014; Caruso, Rachel/E-2353-2013	Caruso, Frank/0000-0002-0197-497X; Caruso, Rachel/0000-0003-4922-2256				Bamnolker H, 1997, J MATER SCI LETT, V16, P1412, DOI 10.1023/A:1018565428355; Caruso F, 1997, LANGMUIR, V13, P3427, DOI 10.1021/la9608223; Caruso F, 1998, J AM CHEM SOC, V120, P8523, DOI 10.1021/ja9815024; Caruso F., UNPUB; CAUSO F, 1998, J PHYS CHEM B, V102, P2011; Correa-Duarte MA, 1998, CHEM PHYS LETT, V286, P497, DOI 10.1016/S0009-2614(98)00012-8; Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232; DECHER G, 1991, MAKROMOL CHEM-M SYMP, V46, P321, DOI 10.1002/masy.19910460145; Donath E, 1998, ANGEW CHEM INT EDIT, V37, P2202, DOI 10.1002/(SICI)1521-3773(19980904)37:16<2201::AID-ANIE2201>3.0.CO;2-E; GARG A, 1988, J COLLOID INTERF SCI, V126, P243, DOI 10.1016/0021-9797(88)90118-X; Giersig M, 1997, ADV MATER, V9, P570, DOI 10.1002/adma.19970090712; Giersig M, 1997, BER BUNSEN PHYS CHEM, V101, P1617, DOI 10.1002/bbpc.19971011110; KAWAHASHI N, 1991, J COLLOID INTERF SCI, V143, P103, DOI 10.1016/0021-9797(91)90442-B; KAWAHASHI N, 1990, J COLLOID INTERF SCI, V138, P534, DOI 10.1016/0021-9797(90)90235-G; Keller SW, 1995, J AM CHEM SOC, V117, P12879, DOI 10.1021/ja00156a034; KLEINFELD ER, 1994, SCIENCE, V265, P370, DOI 10.1126/science.265.5170.370; Liu YL, 1997, ANGEW CHEM INT EDIT, V36, P2114, DOI 10.1002/anie.199721141; Liz-Marzan LM, 1996, CHEM COMMUN, P731, DOI 10.1039/cc9960000731; Liz-Marzan LM, 1996, LANGMUIR, V12, P4329, DOI 10.1021/la9601871; LVOV Y, 1995, J AM CHEM SOC, V117, P6117, DOI 10.1021/ja00127a026; Lvov Y, 1997, LANGMUIR, V13, P6195, DOI 10.1021/la970517x; MARGEL S, 1984, J POLYM SCI POL CHEM, V22, P145, DOI 10.1002/pol.1984.170220115; Milton K, 1969, SCATTERING LIGHT OTH SCATTERING LIGHT OTH, P414; OHMORI M, 1992, J COLLOID INTERF SCI, V150, P594, DOI 10.1016/0021-9797(92)90229-F; PHILIPSE AP, 1994, LANGMUIR, V10, P92, DOI 10.1021/la00013a014; Sukhorukov GB, 1996, THIN SOLID FILMS, V284, P220, DOI 10.1016/S0040-6090(95)08309-X; Sukhorukov GB, 1998, POLYM ADVAN TECHNOL, V9, P759, DOI 10.1002/(SICI)1099-1581(1998100)9:10/11<759::AID-PAT846>3.0.CO;2-Q; VonKlitzing R, 1996, MACROMOLECULES, V29, P6901; WALSH D, 1995, NATURE, V377, P320, DOI 10.1038/377320a0	29	3872	4028	62	2267	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 6	1998	282	5391					1111	1114		10.1126/science.282.5391.1111	http://dx.doi.org/10.1126/science.282.5391.1111			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804547				2022-12-28	WOS:000076887700047
J	Hardy, J; Gwinn-Hardy, K				Hardy, J; Gwinn-Hardy, K			Genetic classification of primary neurodegenerative disease	SCIENCE			English	Review							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID-BETA-PROTEIN; PROGRESSIVE SUPRANUCLEAR PALSY; AMYOTROPHIC-LATERAL-SCLEROSIS; STRAUSSLER-SCHEINKER DISEASE; CREUTZFELDT-JAKOB DISEASE; MACHADO-JOSEPH DISEASE; TRANSGENIC MICE; PRION PROTEIN; SPINOCEREBELLAR ATAXIA	During the past 10 years (the "decade of the brain"), some of the genetic causes of many of the primary neurodegenerative diseases, which include Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, and many ataxic syndromes, have been found. These breakthroughs mean that for many of these diseases we now know the initiating trigger as well as the final outcome. These diseases have many pathological mechanisms in common, and there may be relatively few pathways to neuronal death seen in these disorders. Thus, treatment strategies developed for a particular disease may be found to have efficacy in more than one disorder.	Mayo Clin Jacksonville, Dept Pharmacol, Jacksonville, FL 32224 USA; Mayo Clin Jacksonville, Dept Neurol, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic	Hardy, J (corresponding author), Mayo Clin Jacksonville, Dept Pharmacol, Jacksonville, FL 32224 USA.	hardy@mayo.edu	Gwinn, Katrina A/C-2508-2009; Hardy, John/C-2451-2009	Hardy, John/0000-0002-3122-0423; Gwinn, Katrina/0000-0002-8277-651X				Abdullah AAR, 1998, HUM MOL GENET, V7, P379, DOI 10.1093/hmg/7.3.379; Alzheimer A., 1907, ALLGEMEINE Z PSYCHIA, V64, P146, DOI DOI 10.1002/CA.980080612; BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Bielschowsky M., 1903, NEUROL CENTRALBL, V22, P997; BINGHAM PM, 1995, NAT GENET, V9, P191, DOI 10.1038/ng0295-191; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BROWN J, 1995, HUM MOL GENET, V4, P1625, DOI 10.1093/hmg/4.9.1625; Buchman VL, 1998, NAT NEUROSCI, V1, P101, DOI 10.1038/349; BUEESCHERRER V, 1995, AM J PATHOL, V146, P924; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Clark HB, 1997, J NEUROSCI, V17, P7385; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crook R, 1998, NAT MED, V4, P452, DOI 10.1038/nm0498-452; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Davies SW, 1998, LANCET, V351, P131, DOI 10.1016/S0140-6736(97)08360-8; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; FARRER M, IN PRESS HUM MOL GEN; FEANY MB, 1995, AM J PATHOL, V146, P1388; Flanigan K, 1996, AM J HUM GENET, V59, P392; Foster NL, 1997, ANN NEUROL, V41, P706, DOI 10.1002/ana.410410606; Fox NC, 1997, J MAGN RESON IMAGING, V7, P1069, DOI 10.1002/jmri.1880070620; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gasser T, 1998, NAT GENET, V18, P262, DOI 10.1038/ng0398-262; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; GOLDMAN JE, 1983, SCIENCE, V221, P1082, DOI 10.1126/science.6308771; GRAHAM DI, 1997, GREENFIELDS NEUROPAT; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HARDING AE, 1993, ADV NEUROL, V61, P1; HARDY J, 1993, LANCET, V342, P737; HOLBERG M, 1998, HUM MOL GENET, V7, P913; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1992, NAT GENET, V1, P68, DOI 10.1038/ng0492-68; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; IKEDA K, 1994, NEUROSCI LETT, V174, P157, DOI 10.1016/0304-3940(94)90010-8; IWATSUBO T, 1994, ACTA NEUROPATHOL, V88, P129; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1998, NAT GENET, V6, P9; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; Kwok JBJ, 1997, NEUROREPORT, V8, P1537, DOI 10.1097/00001756-199704140-00043; LANTOS PL, 1994, NEUROSCI LETT, V172, P77, DOI 10.1016/0304-3940(94)90666-1; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEE CS, 1995, NEUROLOGY, V45, P435, DOI 10.1212/WNL.45.3.435; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Lewy F.H., 2017, HDB NEUROLOGIE, V3, P920; Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216; LYNCH T, 1994, NEUROLOGY, V44, P1878, DOI 10.1212/WNL.44.10.1878; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MAZZIOTA JC, 1992, NEW ENGL J MED, V49, P148; MAZZIOTTA JC, 1987, NEW ENGL J MED, V316, P357, DOI 10.1056/NEJM198702123160701; MCGEER PL, 1977, ARCH NEUROL-CHICAGO, V34, P33, DOI 10.1001/archneur.1977.00500130053010; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; NAGAFUCHI S, 1998, NAT GENET, V6, P14; Nissl F., 1892, ALLG Z PSYCHIAT, V48, P197; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; OWEN F, 1989, LANCET, V1, P51; Oyama F, 1998, J NEUROCHEM, V71, P313; PAKKENBERG B, 1991, J NEUROL NEUROSUR PS, V54, P30, DOI 10.1136/jnnp.54.1.30; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Piccardo P, 1998, NEUROBIOL AGING, V19, pS172; Pick A, 1906, MON PSYCHIATR NEUROL, V19, P97; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; RANUM LPW, 1994, NAT GENET, V8, P280, DOI 10.1038/ng1194-280; Reiman EM, 1996, NEW ENGL J MED, V334, P752, DOI 10.1056/NEJM199603213341202; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; Shoulson I, 1998, SCIENCE, V282, P1072, DOI 10.1126/science.282.5391.1072; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; SORBI S, 1995, ANN NEUROL, V38, P124, DOI 10.1002/ana.410380120; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; STEELE JC, 1972, BRAIN, V95, P693; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; YAMADA T, 1992, NEUROSCI LETT, V135, P99, DOI 10.1016/0304-3940(92)90145-W; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	100	291	313	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 6	1998	282	5391					1075	1079		10.1126/science.282.5391.1075	http://dx.doi.org/10.1126/science.282.5391.1075			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804538				2022-12-28	WOS:000076887700038
J	Ghosh, A; Kolodkin, AL				Ghosh, A; Kolodkin, AL			Specification of neuronal connectivity: ETS marks the spot	CELL			English	Review							PATHWAY SELECTION; AXON GUIDANCE; SPINAL-CORD; CHICK; MOTONEURONS; EMBRYOS; WINGS		Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Ghosh, A (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.							EISEN JS, 1991, SCIENCE, V252, P569, DOI 10.1126/science.1708527; FERNS MJ, 1993, J NEUROSCI, V13, P2463, DOI 10.1523/JNEUROSCI.13-06-02463.1993; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P19, DOI 10.1098/rspb.1981.0080; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P581; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P371, DOI 10.1113/jphysiol.1978.sp012545; LANDMESSER L, 1986, DEV BIOL, V118, P511, DOI 10.1016/0012-1606(86)90023-0; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; PHELAN KA, 1990, J NEUROSCI, V10, P2699; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wenner P, 1995, J NEUROSCI, V15, P8191	13	15	15	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 30	1998	95	3					303	306		10.1016/S0092-8674(00)81762-6	http://dx.doi.org/10.1016/S0092-8674(00)81762-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814701	Bronze			2022-12-28	WOS:000076789600004
J	Stevenson, JC				Stevenson, JC			Management of corticosteroid-induced osteoporosis	LANCET			English	Editorial Material							BONE LOSS; FRACTURES; THERAPY; ASTHMA		St Marys Hosp, Imperial Coll, Sch Med, Wynn Inst Endocrinol & Metab Med,Rosen Labs, London W2 1PG, England	Imperial College London	Stevenson, JC (corresponding author), St Marys Hosp, Imperial Coll, Sch Med, Wynn Inst Endocrinol & Metab Med,Rosen Labs, Praed St, London W2 1PG, England.							Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603; ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; DEMPSTER DW, 1983, CALCIFIED TISSUE INT, V35, P410, DOI 10.1007/BF02405069; Eastell R, 1998, J INTERN MED, V244, P271, DOI 10.1046/j.1365-2796.1998.00408.x; Gonnelli S, 1997, CALCIFIED TISSUE INT, V61, P382, DOI 10.1007/s002239900352; HALL GM, 1994, ARTHRITIS RHEUM, V37, P1499, DOI 10.1002/art.1780371014; LUENGO M, 1991, THORAX, V46, P803, DOI 10.1136/thx.46.11.803; REID IR, 1996, ARCH INTERN MED, V156, P1373; Roux C, 1998, J CLIN ENDOCR METAB, V83, P1128, DOI 10.1210/jc.83.4.1128; Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502; SAITO JK, 1995, CALCIFIED TISSUE INT, V57, P115, DOI 10.1007/BF00298431; SAMBROOK P, 1990, J BONE MINER RES, V5, P1211	12	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 24	1998	352	9137					1327	1328		10.1016/S0140-6736(05)60740-4	http://dx.doi.org/10.1016/S0140-6736(05)60740-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802265				2022-12-28	WOS:000076691700005
J	Wyatt, JC; Wright, P				Wyatt, JC; Wright, P			Design should help use of patients' data	LANCET			English	Article							CLINICAL-DATA SYSTEMS; ACCURACY; RECORDS; ERRORS; CARE	Checklists and other tools help doctors to use published evidence in clinical practice. Two other important sources of evidence, however, are the patient and his or her medical record. This series aims to advance the practice of evidence-based medicine by helping in redesign of medical records, drawing on insights from psychology, information design, and medical informatics; and by promoting changes analogous to those occurring in the medical literature. The four papers look at: the uses of medical records and importance of organising them so doctors can use the data they contain; different methods doctors use to search for data and how design of records can help or hinder these approaches; how we interpret data once found, and how record formatting assists this process; and the issues raised by computerisation of records.	UCL, Sch Publ Policy, London WC1H 9EZ, England; Cardiff Univ, Sch Psychol, Cardiff, S Glam, Wales	University of London; University College London; Cardiff University	Wyatt, JC (corresponding author), UCL, Sch Publ Policy, 29 Tavistock Sq, London WC1H 9EZ, England.	jeremy.wyatt@ucl.ac.uk	Wyatt, Jeremy/F-8160-2010	Wyatt, Jeremy/0000-0001-7008-1473				EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; FERNOW LC, 1978, MED CARE, V16, P476, DOI 10.1097/00005650-197806000-00004; FLETCHER RH, 1974, NEW ENGL J MED, V290, P829, DOI 10.1056/NEJM197404112901505; FRIES JF, 1974, MED CARE, V12, P871, DOI 10.1097/00005650-197410000-00006; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; Nelder JA, 1997, BRIT MED J, V314, P831, DOI 10.1136/bmj.314.7083.831; POWSNER SM, 1994, LANCET, V344, P386, DOI 10.1016/S0140-6736(94)91406-0; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SLESS D, 1998, INFORMATION DESIGN J, V9, P3; WAINER H, 1984, AM STAT, V38, P137, DOI 10.2307/2683253; WEED LL, 1968, NEW ENGL J MED, V278, P593, DOI 10.1056/NEJM196803142781105; WONG ET, 1983, JAMA-J AM MED ASSOC, V250, P2510, DOI 10.1001/jama.250.18.2510; WYATT JC, 1994, LANCET, V344, P1682, DOI 10.1016/S0140-6736(94)90463-4; WYATT JC, 1994, LANCET, V344, P1609, DOI 10.1016/S0140-6736(94)90409-X; WYATT JC, 1994, LANCET, V344, P1543, DOI 10.1016/S0140-6736(94)90353-0; [No title captured]; [No title captured]; [No title captured]; [No title captured]	20	63	63	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 24	1998	352	9137					1375	1378		10.1016/S0140-6736(97)08306-2	http://dx.doi.org/10.1016/S0140-6736(97)08306-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802289				2022-12-28	WOS:000076691700048
J	Krumholz, HM				Krumholz, HM			Time to focus on the more typical heart-failure patients	LANCET			English	Editorial Material									Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA	Yale University; Yale University	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Dept Med, 333 Cedar St, New Haven, CT 06520 USA.		, Harlan/AAI-2875-2020					HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706; LUCHI RJ, 1991, J AM GERIATR SOC, V39, P810, DOI 10.1111/j.1532-5415.1991.tb02705.x; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; *US DEPT HHS, 1994, MORB MORT CHARTB CAR; WEI JY, 1992, NEW ENGL J MED, V327, P1735, DOI 10.1056/NEJM199212103272408; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	6	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					3	4		10.1016/S0140-6736(05)79504-0	http://dx.doi.org/10.1016/S0140-6736(05)79504-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800733				2022-12-28	WOS:000074608600003
J	Beecham, L				Beecham, L			New guidance on PCGs expected in December	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1531	1531						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831603				2022-12-28	WOS:000077338300079
J	Maron, BJ; Mitten, MJ; Quandt, EF; Zipes, DP				Maron, BJ; Mitten, MJ; Quandt, EF; Zipes, DP			Competitive athletes with cardiovascular disease - The case of Nicholas Knapp	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LEFT-VENTRICULAR HYPERTROPHY; SUDDEN-DEATH; CARDIOVERTER-DEFIBRILLATOR; YOUNG-ADULTS; CARDIOMYOPATHY; ECHOCARDIOGRAPHY; ABNORMALITIES; ARRHYTHMIAS; PATTERNS		Minneapolis Heart Inst, Minneapolis, MN 55407 USA; S Texas Coll Law, Houston, TX 77002 USA; Kelley Drye & Warren, Chicago, IL 60606 USA; Indiana Univ, Sch Med, Indianapolis, IN 46202 USA	Minneapolis Heart Institute Foundation; Indiana University System; Indiana University-Purdue University Indianapolis	Maron, BJ (corresponding author), Minneapolis Heart Inst, Minneapolis, MN 55407 USA.			Zipes, Douglas/0000-0001-7141-6829				BENSON DW, 1983, AM J CARDIOL, V52, P65, DOI 10.1016/0002-9149(83)90070-X; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; FAN W, 1994, AM J CARDIOL, V74, P687, DOI 10.1016/0002-9149(94)90310-7; JONES CJ, 1992, BUFFALO LAW REV, V40, P113; KLUES HG, 1995, J AM COLL CARDIOL, V26, P1699, DOI 10.1016/0735-1097(95)00390-8; Liberthson RR, 1996, NEW ENGL J MED, V334, P1039, DOI 10.1056/NEJM199604183341607; MARON BJ, 1983, AM J CARDIOL, V51, P189, DOI 10.1016/S0002-9149(83)80034-4; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; Maron BJ, 1994, J AM COLL CARDIOL, V24, P845; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; MIROWSKI M, 1980, NEW ENGL J MED, V303, P322, DOI 10.1056/NEJM198008073030607; MITTEN MJ, 1994, J AM COLL CARDIOL, V24, P861, DOI 10.1016/0735-1097(94)90840-0; Mitten MJ, 1998, MARQUETTE SPORTS LAW, V8, P189; Mitten MJ, 1992, NEB L REV, V71, P987; *NAT COLL ATHL ASS, 1997, 1997 98 NCAA SPORTS, P14; SPIRITO P, 1986, J AM COLL CARDIOL, V8, P537, DOI 10.1016/S0735-1097(86)80180-2; TYE L, 1996, BOSTON GLOBE    0801, P49; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; ZIPES DP, 1994, J AM COLL CARDIOL, V24, P892, DOI 10.1016/0735-1097(94)90847-8; ZIPES DP, 1995, CIRCULATION, V92, P59, DOI 10.1161/01.CIR.92.1.59	22	74	75	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 26	1998	339	22					1632	1635		10.1056/NEJM199811263392211	http://dx.doi.org/10.1056/NEJM199811263392211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZU	9828254				2022-12-28	WOS:000077176100011
J	Benbow, A; Maresh, M				Benbow, A; Maresh, M			Reducing maternal mortality: reaudit of recommendations in reports of confidential inquiries into maternal deaths	BRITISH MEDICAL JOURNAL			English	Article									St Marys Hosp, Royal Coll Obstetricians & Gynaecologists, Clin Audit Unit, Manchester M13 0JH, Lancs, England	University of Manchester	Maresh, M (corresponding author), St Marys Hosp, Royal Coll Obstetricians & Gynaecologists, Clin Audit Unit, Manchester M13 0JH, Lancs, England.							*DEP HLTH, 1994, REP CONF ENQ MAT DEA; Hibbard B, 1994, Health Trends, V26, P26; PATEL N, 1992, MATERNAL MORTALITY W; *ROYAL COLL OBST G, 1994, DER STAND MAT MORT R; WATERSTONE M, 1998, BR J OBSTET GYNA S17, V105, P35	5	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1431	1432		10.1136/bmj.317.7170.1431	http://dx.doi.org/10.1136/bmj.317.7170.1431			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822397	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000077202200024
J	Pishvaee, B; Payne, GS				Pishvaee, B; Payne, GS			Clathrin coats - Threads laid bare	CELL			English	Review							LIGHT-CHAINS; ARRESTIN/CLATHRIN INTERACTION; TRIMERIZATION; LOCALIZATION; DOMAIN		Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pishvaee, B (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.							Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chu DS, 1996, J BIOL CHEM, V271, P33123, DOI 10.1074/jbc.271.51.33123; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Huang KM, 1997, J CELL SCI, V110, P899; KAY BK, 1998, IN PRESS PROT SCI; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; KIRCHHAUSEN T, 1993, J BIOL CHEM, V268, P10268; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; LIU SH, 1995, CELL, V83, P257, DOI 10.1016/0092-8674(95)90167-1; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; Pishvaee B, 1997, EMBO J, V16, P2227, DOI 10.1093/emboj/16.9.2227; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Smith CJ, 1998, EMBO J, V17, P4943, DOI 10.1093/emboj/17.17.4943; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; UNGEWICKELL E, 1991, J BIOL CHEM, V266, P12710; Ybe JA, 1998, EMBO J, V17, P1297, DOI 10.1093/emboj/17.5.1297	20	33	34	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1998	95	4					443	446		10.1016/S0092-8674(00)81611-6	http://dx.doi.org/10.1016/S0092-8674(00)81611-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827796	Bronze			2022-12-28	WOS:000077049400002
J	Kondziolka, D; Lunsford, LD; McLaughlin, MR; Flickinger, JC				Kondziolka, D; Lunsford, LD; McLaughlin, MR; Flickinger, JC			Long-term outcomes after radiosurgery for acoustic neuromas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GAMMA-KNIFE RADIOSURGERY; STEREOTAXIC RADIOSURGERY; HEARING PRESERVATION; VESTIBULAR SCHWANNOMA; SURGICAL-MANAGEMENT; TUMORS; SURGERY; NEUROPATHIES; NEURINOMA	Background Stereotactic radiosurgery is the principal alternative to microsurgical resection for acoustic neuromas (vestibular schwannomas). The goals of radiosurgery are the long-term prevention of tumor growth, maintenance of neurologic function, and prevention of new neurologic deficits. Although acceptable short-term outcomes have been reported, long-term outcomes have not been well documented. Methods We evaluated 162 consecutive patients who underwent radiosurgery for acoustic neuromas between 1987 and 1992 by means of serial imaging tests, clinical evaluations, and a survey between 5 and 10 years after the procedure. The average dose of radiation to the tumor margin was 16 Gy, and the mean transverse diameter of the tumor was 22 mm (range, 8 to 39). Resection had been performed previously in 42 patients (26 percent); in 13 patients the tumor represented a recurrence of disease after a previous total resection. Facial function was normal in 76 percent of the patients before radiosurgery, and 20 percent had useful hearing. Results The rate of tumor control (with no resection required) was 98 percent. One hundred tumors (62 percent) became smaller, 53 (33 percent) remained unchanged in size, and 9 (6 percent) became slightly larger. Resection was performed in four patients (2 percent) within four years after radiosurgery. Normal facial function was preserved in 79 percent of the patients after five years (House-Brackmann grade 1), and normal trigeminal function was preserved in 73 percent. Fifty-one percent of the patients had no change in hearing ability, No new neurologic deficits appeared more than 28 months after radiosurgery. An outcomes questionnaire was returned by 115 patients (77 percent of the 149 patients still living). Fifty-four of these patients (47 percent) were employed at the time of radiosurgery, and 37 (69 percent) remained so. Radiosurgery was believed to have been successful by all 30 patients who had undergone surgery previously and by 81 (95 percent) of the 85 who had not. Thirty-six of the 115 patients (31 percent) described at least one complication, which resolved in 56 percent of those cases. Conclusions Radiosurgery can provide long-term control of acoustic neuromas while preserving neurologic function. (N Engl J Med 1998;339:1426-33.) (C) 1998, Massachusetts Medical Society.	Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Radiat Oncol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kondziolka, D (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Suite B-400,200 Lothrop St, Pittsburgh, PA 15213 USA.		Lunsford, L. Dade/AHI-7993-2022	Flickinger, John/0000-0001-6900-1384	NINDS NIH HHS [K08 NS 017293] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEDERSON JB, 1991, NEUROSURGERY, V28, P646, DOI 10.1227/00006123-199105000-00002; CERULLO LJ, 1993, SURG NEUROL, V39, P485, DOI 10.1016/0090-3019(93)90036-Z; Flickinger JC, 1996, RADIOTHER ONCOL, V41, P215, DOI 10.1016/S0167-8140(96)01831-2; FLICKINGER JC, 1993, RADIOTHER ONCOL, V27, P91, DOI 10.1016/0167-8140(93)90127-T; FLICKINGER JC, 1990, INT J RADIAT ONCOL, V18, P1495, DOI 10.1016/0360-3016(90)90326-F; FLICKINGER JC, 1991, CANCER, V67, P345, DOI 10.1002/1097-0142(19910115)67:2<345::AID-CNCR2820670205>3.0.CO;2-M; Flickinger JC, 1996, INT J RADIAT ONCOL, V36, P275, DOI 10.1016/S0360-3016(96)00335-5; FOOTE RL, 1995, INT J RADIAT ONCOL, V32, P1153, DOI 10.1016/0360-3016(94)00454-S; GARDNER G, 1988, ANN OTO RHINOL LARYN, V97, P55, DOI 10.1177/000348948809700110; Gormley WB, 1997, NEUROSURGERY, V41, P50, DOI 10.1097/00006123-199707000-00012; HOUSE JW, 1985, OTOLARYNG HEAD NECK, V93, P146, DOI 10.1177/019459988509300202; KONDZIOLKA D, 1992, NEUROSURGERY, V30, P402, DOI 10.1227/00006123-199203000-00015; KONDZIOLKA D, 1997, TECH NEUROSURG, V3, P154; LALWANI AK, 1995, AM J OTOL, V16, P758; LINSKEY ME, 1991, AM J NEURORADIOL, V12, P1165; LINSKEY ME, 1993, J NEUROSURG, V78, P645, DOI 10.3171/jns.1993.78.4.0645; LINSKEY ME, 1993, INT J RADIAT ONCOL, V25, P227, DOI 10.1016/0360-3016(93)90343-T; Lunsford L D, 1993, Clin Neurosurg, V40, P475; Mazzoni A, 1996, SKULL BASE SURG, V6, P105, DOI 10.1055/s-2008-1058651; NOREN G, 1983, NEUROSURGERY, V13, P12, DOI 10.1227/00006123-198307000-00003; OGUNRINDE OK, 1994, J NEUROSURG, V80, P1011, DOI 10.3171/jns.1994.80.6.1011; OGUNRINDE OK, 1994, SKULL BASE SURG, V4, P87, DOI 10.1055/s-2008-1058976; OGUNRINDE OK, 1995, ARCH NEUROL-CHICAGO, V52, P73, DOI 10.1001/archneur.1995.00540250077016; POLLOCK BE, 1995, NEUROSURGERY, V36, P215, DOI 10.1227/00006123-199501000-00036; POLLOCK BE, 1995, NEUROSURGERY, V36, P427; POST KD, 1995, J NEUROSURG, V83, P191, DOI 10.3171/jns.1995.83.2.0191; Rowed DW, 1997, J NEUROSURG, V86, P456, DOI 10.3171/jns.1997.86.3.0456; SAMII M, 1992, NEUROSURGERY, V31, P615; Samii M, 1997, NEUROSURGERY, V40, P11, DOI 10.1097/00006123-199701000-00002; SHELTON C, 1991, LARYNGOSCOPE, V101, P925; Slatterly W, 1997, AM J OTOL, V18, P796; Slattery WH, 1997, AM J OTOL, V18, P596; THOMAS HAL, 1992, CAN MED ASSOC J, V147, P859; Wiegand DA, 1996, LARYNGOSCOPE, V106, P58, DOI 10.1097/00005537-199601000-00012; WIEGAND DA, 1989, LARYNGOSCOPE, V99, P179	35	543	550	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1998	339	20					1426	1433		10.1056/NEJM199811123392003	http://dx.doi.org/10.1056/NEJM199811123392003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VR	9811917				2022-12-28	WOS:000077051700003
J	Beecham, L				Beecham, L			Doctor Patient Partnership tackles men's health	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1325	1325						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804740				2022-12-28	WOS:000076963800064
J	Davey, G				Davey, G			Still life and the rounding of consciousness	LANCET			English	Article											Davey, G (corresponding author), 21 Springfield Rd, Teddington TW11 9AP, Middx, England.							BONKIN B, 1998, CAMI CAMBRIDGE ALUMN; Byatt A.S., 1993, PASSIONS MIND; Byatt A. S., 1985, STILL LIFE; Byatt A. S., 1981, VIRGIN GARDEN; Byatt A.S., 1996, BABEL TOWER; Calman K, 1996, LANCET, V347, P1499, DOI 10.1016/S0140-6736(96)90665-0; WEATHERALL DJ, 1994, BRIT MED J, V309, P1671, DOI 10.1136/bmj.309.6970.1671	7	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1544	1547		10.1016/S0140-6736(98)05458-0	http://dx.doi.org/10.1016/S0140-6736(98)05458-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820320				2022-12-28	WOS:000076862300041
J	Jones, EG; Pons, TP				Jones, EG; Pons, TP			Thalamic and brainstem contributions to large-scale plasticity of primate somatosensory cortex	SCIENCE			English	Article							MASSIVE CORTICAL REORGANIZATION; FREQUENCY-DISCRIMINATION TASK; ADULT FLYING-FOX; RECEPTIVE-FIELDS; MACAQUE MONKEYS; REPRESENTATIONAL PLASTICITY; FUNCTIONAL REORGANIZATION; SOMATOTOPIC ORGANIZATION; CHRONIC DEAFFERENTATION; DIGIT DENERVATION	After long-term denervation of an upper limb in macaque monkeys, the representation of the face in somatosensory cortex expands over many millimeters into the silenced representation of the hand. Various brainstem and cortical mechanisms have been proposed to explain this phenomenon, Reorganization in the thalamus has been Largely ignored, In monkeys with deafferented upper Limbs for 12 to 20 years, it was found that the brainstem cuneate and the thalamic ventral posterior nuclei had undergone severe transneuronal atrophy, and physiological mapping in the thalamus revealed that the face and trunk representations were adjoined white the normally small representation of the lower face had expanded comparable to the expansion in cortex. Reorganization of brainstem and thalamic nuclei associated with slow transneuronal atrophy is likely to be a progressive process, When coupled with divergence of ascending connections, it is likely to make a substantial contribution to representational changes in cortex.	Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA; Wake Forest Univ, Sch Med, Dept Neurosurg, Winston Salem, NC 27157 USA	University of California System; University of California Davis; Wake Forest University	Jones, EG (corresponding author), Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021377, R01NS035246] Funding Source: NIH RePORTER; NIMH NIH HHS [MH53369] Funding Source: Medline; NINDS NIH HHS [NS21377, NS35246] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLOWAY KD, 1991, EXP BRAIN RES, V85, P598; ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; BURTON H, 1995, J COMP NEUROL, V355, P508, DOI 10.1002/cne.903550404; CALFORD MB, 1988, NATURE, V332, P446, DOI 10.1038/332446a0; CALFORD MB, 1991, J NEUROPHYSIOL, V65, P178, DOI 10.1152/jn.1991.65.2.178; CALFORD MB, 1991, SOMATOSENS MOT RES, V8, P249, DOI 10.3109/08990229109144748; CAMPBELL AW, 1905, HISTOLOGICAL STUDIES, P86; Churchill JD, 1998, EXP BRAIN RES, V118, P189, DOI 10.1007/s002210050271; Cowan W. M., 1970, CONT RES METHODS NEU, P217, DOI 10.1007/978-3-642-85986-1_11; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; DEFELIPE J, 1986, J NEUROSCI, V6, P3749, DOI 10.1523/jneurosci.06-12-03749.1986; DOSTROVSKY JO, 1976, EXP NEUROL, V52, P480, DOI 10.1016/0014-4886(76)90219-3; DYKES RW, 1984, J NEUROPHYSIOL, V52, P1066, DOI 10.1152/jn.1984.52.6.1066; Ergenzinger ER, 1998, NAT NEUROSCI, V1, P226, DOI 10.1038/673; Florence SL, 1995, J NEUROSCI, V15, P8083; GARRAGHTY PE, 1994, SOMATOSENS MOT RES, V11, P109, DOI 10.3109/08990229409028864; GARRAGHTY PE, 1991, NEUROREPORT, V2, P747, DOI 10.1097/00001756-199112000-00004; Huntley GW, 1997, CEREB CORTEX, V7, P143, DOI 10.1093/cercor/7.2.143; JAIN N, 1995, J NEUROPHYSIOL, V73, P1537, DOI 10.1152/jn.1995.73.4.1537; Jones E.G., 1994, Cerebral Cortex, V10, P61; JONES EG, 1982, J NEUROPHYSIOL, V48, P521, DOI 10.1152/jn.1982.48.2.521; JONES EG, 1993, CEREB CORTEX, V3, P361, DOI 10.1093/cercor/3.5.361-a; JONES EG, 1982, J NEUROPHYSIOL, V48, P545, DOI 10.1152/jn.1982.48.2.545; JONES EG, 1997, P NATL ACAD SCI USA, V94, P11007; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.neuro.14.1.137; KALASKA J, 1982, BRAIN RES, V236, P35, DOI 10.1016/0006-8993(82)90032-4; Knecht S, 1996, BRAIN, V119, P1213, DOI 10.1093/brain/119.4.1213; KOLARIK RC, 1994, J NEUROSCI, V14, P4269; LENZ FA, 1994, J NEUROPHYSIOL, V72, P1570, DOI 10.1152/jn.1994.72.4.1570; LOEWY AD, 1973, J COMP NEUROL, V147, P497, DOI 10.1002/cne.901470405; LOMBARD MC, 1979, ADV PAIN RES THER, V3, P767; LUND JP, 1994, SCIENCE, V265, P546, DOI 10.1126/science.8036500; Manger PR, 1997, J NEUROSCI, V17, P6338; MANGER PR, 1996, P R SOC LONDON B, V263, P939; MELZACK R, 1990, TRENDS NEUROSCI, V13, P92; MILLAR J, 1976, EXP NEUROL, V50, P658, DOI 10.1016/0014-4886(76)90035-2; MOUNTCASTLE VB, 1952, J COMP NEUROL, V97, P409, DOI 10.1002/cne.900970302; NICOLELIS MAL, 1993, NATURE, V361, P533, DOI 10.1038/361533a0; Parker JL, 1998, J NEUROSCI, V18, P548; PETTIT MJ, 1993, SCIENCE, V262, P2054, DOI 10.1126/science.8266104; POGGIO GF, 1963, J NEUROPHYSIOL, V26, P775, DOI 10.1152/jn.1963.26.5.775; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; PONS TP, 1987, SOMATOSENS MOT RES, V4, P309, DOI 10.3109/07367228709144612; POWELL TPS, 1967, NATURE, V215, P425, DOI 10.1038/215425a0; RAMACHANDRAN VS, 1992, SCIENCE, V258, P1159, DOI 10.1126/science.1439826; RAMACHANDRAN VS, 1993, P NATL ACAD SCI USA, V90, P10420; Rasmusson D, 1996, J COMP NEUROL, V364, P92; RAUSELL E, 1992, P NATL ACAD SCI USA, V89, P2571, DOI 10.1073/pnas.89.7.2571; RAUSELL E, 1991, J NEUROSCI, V11, P210; RAUSELL E, 1995, J NEUROSCI, V15, P4270; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1015, DOI 10.1152/jn.1992.67.5.1015; RECANZONE GH, 1992, CEREB CORTEX, V2, P181, DOI 10.1093/cercor/2.3.181; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; RHOADES RW, 1987, J NEUROPHYSIOL, V57, P1577, DOI 10.1152/jn.1987.57.5.1577; Sherrington C, 1939, SELECTED WRITINGS C, P31; Shin HC, 1995, NEUROREPORT, V7, P33, DOI 10.1097/00001756-199512000-00007; SRETAVAN DW, 1986, J NEUROSCI, V6, P234; Taub E, 1980, BEHAV PSYCHOL REHABI, P371; WALL PD, 1971, NATURE, V232, P542, DOI 10.1038/232542a0; WOODS TM, 1998, NEUR ABSTR, V24, P1512; Xerri C, 1998, J NEUROPHYSIOL, V79, P2119, DOI 10.1152/jn.1998.79.4.2119	62	187	194	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1121	1125		10.1126/science.282.5391.1121	http://dx.doi.org/10.1126/science.282.5391.1121			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804550				2022-12-28	WOS:000076887700050
J	Regamey, N; Tamm, M; Wernli, M; Witschi, A; Thiel, G; Cathomas, G; Erb, P				Regamey, N; Tamm, M; Wernli, M; Witschi, A; Thiel, G; Cathomas, G; Erb, P			Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; DNA-SEQUENCES; ANTIBODIES; IDENTIFICATION; MALIGNANCIES; ANTIGEN; FORMS; KSHV; RISK	Background Human herpesvirus 8 (HHV-8) has been detected in all forms of Kaposi's sarcoma, including transplantation-associated Kaposi's sarcoma. To investigate the possibility of transmission of HHV-8 through allografts, we measured the seroprevalence of HHV-8 before and after renal transplantation. Methods Using an enzyme-linked immunosorbent assay with the recombinant HHV-8 protein orf 65.2, we analyzed serum samples from 220 renal-transplant recipients for the presence of antibodies to HHV-8 on the day of transplantation and one year later. Positive results were confirmed by an indirect immunofluorescence assay that detects antibodies to latent antigen and by Western blotting. Follow-up lasted at least four years. Results The seroprevalence of HHV-8 in graft recipients increased from 6.4 percent on the day of transplantation to 17.7 percent one year after transplantation. Seroconversion occurred within the first year after transplantation in 25 patients, and Kaposi's sarcoma developed in 2 of them within 26 months after transplantation. Sequential serum samples were obtained from 10 of the patients with seroconversion, and in 8 of these patients, IgM antibodies to HHV-8 appeared within three months after transplantation. In the case of six patients who seroconverted, serum samples from the donors were available, and five (83 percent) tested positive for HHV-8. In a control group of eight patients who were seronegative at the time of transplantation and who received allografts from HHV-8-negative donors, none seroconverted within the year after transplantation. Conclusions HHV-8 is transmitted through renal allografts and is a risk factor for transplantation-associated Kaposi's sarcoma. (C) 1998, Massachusetts Medical Society.	Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland; Univ Basel Hosp, Dept Internal Med, Div Nephrol, CH-4031 Basel, Switzerland; Univ Zurich Hosp, Inst Pathol, CH-8091 Zurich, Switzerland	University of Basel; University of Basel; University of Zurich; University Zurich Hospital	Erb, P (corresponding author), Univ Basel, Inst Med Microbiol, Peterspl 10, CH-4003 Basel, Switzerland.							al-Sulaiman M H, 1994, Transplant Sci, V4, P46; Blackbourn DJ, 1997, AIDS, V11, P249, DOI 10.1097/00002030-199702000-00016; Cathomas G, 1996, J CLIN PATHOL, V49, P631, DOI 10.1136/jcp.49.8.631; Cathomas G, 1997, TRANSPLANTATION, V64, P175, DOI 10.1097/00007890-199707150-00033; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Farge D, 1993, Eur J Med, V2, P339; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Kedes DH, 1996, NAT MED, V2, P1041; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Lin SF, 1997, J VIROL, V71, P3069, DOI 10.1128/JVI.71.4.3069-3076.1997; Martin JN, 1998, NEW ENGL J MED, V338, P948, DOI 10.1056/NEJM199804023381403; Moore PS, 1996, AIDS, V10, P175, DOI 10.1097/00002030-199602000-00007; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Parravicini C, 1997, BLOOD, V90, P2826; PENN I, 1991, TRANSPLANT P, V23, P1101; Penn I, 1995, TRANSPLANTATION, V60, P1485, DOI 10.1097/00007890-199560120-00020; Penn I, 1996, TRANSPLANT P, V28, P876; QUNIBI W, 1988, AM J MED, V84, P225, DOI 10.1016/0002-9343(88)90418-4; Regamey N, 1998, J CLIN MICROBIOL, V36, P1784, DOI 10.1128/JCM.36.6.1784-1786.1998; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SHMUELI D, 1989, TRANSPLANT P, V21, P3209; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; Whitby D, 1998, J NATL CANCER I, V90, P395, DOI 10.1093/jnci/90.5.395	25	220	228	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1998	339	19					1358	1363		10.1056/NEJM199811053391903	http://dx.doi.org/10.1056/NEJM199811053391903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135BN	9801396				2022-12-28	WOS:000076780200003
J	Tao, YZ; Olson, NH; Xu, W; Anderson, DL; Rossmann, MG; Baker, TS				Tao, YZ; Olson, NH; Xu, W; Anderson, DL; Rossmann, MG; Baker, TS			Assembly of a tailed bacterial virus and its genome release studied in three dimensions	CELL			English	Article							HERPES-SIMPLEX VIRUS; BACILLUS-SUBTILIS; 3-DIMENSIONAL RECONSTRUCTION; CRYOELECTRON MICROSCOPY; BACTERIOPHAGE PHI-29; 13-FOLD SYMMETRY; DNA; PROTEIN; MATURATION; CONNECTOR	We present the first three-dimensional reconstruction of a prolate, tailed phage, and its empty prohead precursor by cryo-electron microscopy. The head-tail connector, the central component of the DNA packaging machine, is visualized for the first time in situ within the Bacillus subtilis dsDNA phage phi 29. The connector, with 12- or 13-fold symmetry, appears to fit loosely into a pentameric vertex of the head, a symmetry mismatch that may be required to rotate the connector to package DNA. The prolate head of phi 29 has 10 hexameric units in its cylindrical equatorial region, and 11 pentameric and 20 hexameric units comprise icosahedral end-caps with T=3 quasi-symmetry. Reconstruction of an emptied phage particle shows that the connector and neck/tail assembly undergo significant conformational changes upon ejection of DNA.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Chinese Acad Sci, Inst Biophys, Beijing 100101, Peoples R China; Univ Minnesota, Dept Microbiol & Oral Sci, Minneapolis, MN 55455 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Chinese Academy of Sciences; Institute of Biophysics, CAS; University of Minnesota System; University of Minnesota Twin Cities	Baker, TS (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.			, Timothy/0000-0001-6543-8968	NIAID NIH HHS [P01 AI035212] Funding Source: Medline; NIDCR NIH HHS [R01 DE003606, DE03606] Funding Source: Medline; NIGMS NIH HHS [R01 GM033050, GM33050, R37 GM033050] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE003606, R01DE003606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033050, R01GM033050] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI U, 1974, Journal of Supramolecular Structure, V2, P253, DOI 10.1002/jss.400020218; ANDERSON DL, 1966, J BACTERIOL, V91, P2081, DOI 10.1128/JB.91.5.2081-2089.1966; Anderson Dwight, 1993, P859; Baker TS, 1996, CURR OPIN STRUC BIOL, V6, P585, DOI 10.1016/S0959-440X(96)80023-6; Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; Belnap DM, 1996, J MOL BIOL, V259, P249, DOI 10.1006/jmbi.1996.0317; BJORNSTI MA, 1983, J VIROL, V45, P383, DOI 10.1128/JVI.45.1.383-396.1983; BOOY FP, 1991, CELL, V64, P1007, DOI 10.1016/0092-8674(91)90324-R; CARAZO JM, 1986, J MOL BIOL, V192, P853, DOI 10.1016/0022-2836(86)90033-1; CARRASCOSA JL, 1981, VIROLOGY, V111, P401, DOI 10.1016/0042-6822(81)90343-3; CARRASCOSA JL, 1982, J MOL BIOL, V154, P311, DOI 10.1016/0022-2836(82)90066-3; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; Caston JR, 1997, J CELL BIOL, V138, P975, DOI 10.1083/jcb.138.5.975; Cerritelli ME, 1997, CELL, V91, P271, DOI 10.1016/S0092-8674(00)80409-2; CONWAY JF, 1995, J MOL BIOL, V253, P86, DOI 10.1006/jmbi.1995.0538; DOKLAND T, 1993, J MOL BIOL, V233, P682, DOI 10.1006/jmbi.1993.1545; Dokland T, 1997, NATURE, V389, P308, DOI 10.1038/38537; DRYDEN KA, 1993, J CELL BIOL, V122, P1023, DOI 10.1083/jcb.122.5.1023; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; Fuller SD, 1996, J STRUCT BIOL, V116, P48, DOI 10.1006/jsbi.1996.0009; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Grimes S, 1997, J MOL BIOL, V266, P901, DOI 10.1006/jmbi.1996.0843; Guasch A, 1998, J MOL BIOL, V281, P219, DOI 10.1006/jmbi.1998.1928; Guo PX, 1998, MOL CELL, V2, P149, DOI 10.1016/S1097-2765(00)80124-0; GUO PX, 1991, VIROLOGY, V183, P366, DOI 10.1016/0042-6822(91)90149-6; GUO PX, 1986, P NATL ACAD SCI USA, V83, P3505, DOI 10.1073/pnas.83.10.3505; HAGEN EW, 1976, J VIROL, V19, P501, DOI 10.1128/JVI.19.2.501-517.1976; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; Hendrix RW, 1998, CELL, V94, P147, DOI 10.1016/S0092-8674(00)81413-0; ILAG LL, 1995, STRUCTURE, V3, P353, DOI 10.1016/S0969-2126(01)00167-8; LEPAULT J, 1987, EMBO J, V6, P1507, DOI 10.1002/j.1460-2075.1987.tb02393.x; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; OLSON NH, 1989, ULTRAMICROSCOPY, V30, P281, DOI 10.1016/0304-3991(89)90057-0; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; REILLY BE, 1977, J VIROL, V24, P363, DOI 10.1128/JVI.24.1.363-377.1977; ROSSMANN MG, 1994, PROTEIN SCI, V3, P1712, DOI 10.1002/pro.5560031010; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ThumanCommike PA, 1996, J MOL BIOL, V260, P85, DOI 10.1006/jmbi.1996.0383; TOSI M, 1973, J VIROL, V12, P1548, DOI 10.1128/JVI.12.6.1548-1559.1973; Trus BL, 1996, J MOL BIOL, V263, P447, DOI 10.1016/S0022-2836(96)80018-0; TSUPRUN V, 1994, BIOPHYS J, V66, P2139, DOI 10.1016/S0006-3495(94)81009-4; WICHITWECHKARN J, 1989, NUCLEIC ACIDS RES, V17, P3459, DOI 10.1093/nar/17.9.3459; Zhang F, 1998, MOL CELL, V2, P141, DOI 10.1016/S1097-2765(00)80123-9; Zhou ZH, 1998, P NATL ACAD SCI USA, V95, P2778, DOI 10.1073/pnas.95.6.2778	44	184	192	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 30	1998	95	3					431	437		10.1016/S0092-8674(00)81773-0	http://dx.doi.org/10.1016/S0092-8674(00)81773-0			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814712	Green Accepted, Bronze			2022-12-28	WOS:000076789600015
J	John, TJ; Samuel, R; Balraj, V; John, R				John, TJ; Samuel, R; Balraj, V; John, R			Disease surveillance at district level: a model for developing countries	LANCET			English	Article								For over a decade we have maintained within a district of 5 million people, a system of prompt reporting of cases of childhood vaccine-preventable diseases, encephalitis, meningitis, hepatitis, and rabies; together with a sentinel laboratory surveillance of cholera, typhoid fever, malaria, HIV infection and antimicrobial-resistance patterns of selected pathogens. The system combined government and private sectors, with every hospital enrolled and participating. Reports were scanned daily on a computer for any clustering of cases. Interventions included investigations, immunisation, antimicrobial treatment, health education, and physical rehabilitation of children with paralysis. All vaccine-preventable diseases have declined markedly, whilst malaria and HIV infections have increased steadily. Annual expense was less than one US cent per head. The reasons for the success and sustainability of this model include simplicity or reporting procedure, low budget, private-sector participation, personal rapport with people in the network, regular feedback of information through a monthly bulletin, and the visible interventions consequent upon reporting. This district-level disease surveillance model is replicable in developing countries for evaluating polio eradication efforts, monitoring immunisation programmes, detecting outbreaks of old or new diseases, and for evaluating control measures.	Christian Med Coll & Hosp, Dept Clin Virol, Vellore 632004, Tamil Nadu, India	Christian Medical College & Hospital (CMCH) Vellore	John, TJ (corresponding author), Christian Med Coll & Hosp, Dept Clin Virol, Vellore 632004, Tamil Nadu, India.			John, Rohan/0000-0001-7946-3013				JOHN TJ, 1993, REV MED VIROL, V3, P149, DOI 10.1002/rmv.1980030305; KUMAR S, 1994, LANCET, V344, P941, DOI 10.1016/S0140-6736(94)92280-2; SANCHEZ A, 1995, EMERG INFECT DIS, V1, P96, DOI 10.3201/eid0103.950307	3	50	51	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					58	61						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800768				2022-12-28	WOS:000074608600051
J	Hasenclever, D; Diehl, V				Hasenclever, D; Diehl, V		Int Prognostic Factors Project Adv Hodgkins Dis	A prognostic score for advanced Hodgkin's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POOR-RISK PATIENTS; DIRECTLY PREDICTIVE EQUATION; COMBINATION CHEMOTHERAPY; STAGE-IV; MOPP/ABVD CHEMOTHERAPY; SALVAGE CHEMOTHERAPY; MVPP CHEMOTHERAPY; INTENSIVE THERAPY; INITIAL TREATMENT; MEDIASTINAL BULK	Background Two thirds of patients with advanced Hodgkin's disease are cured with current approaches to treatment. Prediction of the outcome is important to avoid overtreating some patients and to identify others in whom standard treatment is likely to fail. Methods Data were collected from 25 centers and study groups on a total of 5141 patients treated with combination chemotherapy for advanced Hodgkin's disease, with or without radiotherapy. The data included the outcome and 19 demographic and clinical characteristics at diagnosis. The end point was freedom from progression of disease. Complete data were available for 1618 patients; the final Cox model was fitted to these data. Data from an additional 2643 patients were used for partial validation. Results The prognostic score was defined as the number of adverse prognostic factors present at diagnosis. Seven factors had similar independent prognostic effects: a serum albumin level of less than 4 g per deciliter, a hemoglobin level of less than 10.5 g per deciliter, male sex, an age of 45 years or older, stage IV disease (according to the Ann Arbor classification), leukocytosis (a white-cell count of at least 15,000 per cubic millimeter), and lymphocytopenia (a lymphocyte count of less than 600 per cubic millimeter, a count that was less than 8 percent of the white-cell count, or both). The score predicted the rate of freedom from progression of disease as follows: 0, or no factors (7 percent of the patients), 84 percent; 1 (22 percent of the patients), 77 percent; 2 (29 percent of the patients), 67 percent; 3 (23 percent of the patients), 60 percent; 4 (12 percent of the patients), 51 percent; and 5 or higher (7 percent of the patients), 42 percent. Conclusions The prognostic score we developed may be useful in designing clinical trials;for the treatment of advanced Hodgkin's disease and in making individual therapeutic decisions, but a distinct group of patients at very high risk could not be identified on the basis of routinely documented demographic and clinical characteristics. (N Engl J Med 1998;339: 1506-14.) (C) 1998, Massachusetts Medical Society.	Univ Leipzig, IMISE, D-04103 Leipzig, Germany; Univ Cologne, Clin Internal Med 1, Cologne, Germany	Leipzig University; University of Cologne	Hasenclever, D (corresponding author), Univ Leipzig, IMISE, Liebigstr 27, D-04103 Leipzig, Germany.							ANDERSON H, 1985, CLIN RADIOL, V36, P449, DOI 10.1016/S0009-9260(85)80183-5; ANDERSON H, 1991, ANN ONCOL, V2, P49, DOI 10.1093/annonc/2.suppl_2.49; ASSOULINE D, 1993, P AN M AM SOC CLIN, V12, P381; Bjorkholm M, 1995, ANN ONCOL, V6, P895; BONADONNA G, 1991, ANN ONCOL, V2, P9, DOI 10.1093/annonc/2.suppl_1.9; BRUSAMOLINO E, 1989, HAEMATOLOGICA, V74, P173; BRUSAMOLINO E, 1994, ANN ONCOL, V5, pS53, DOI 10.1093/annonc/5.suppl_2.S53; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; CARDE P, 1995, LEUKEMIA LYMPHOMA, V15, P31, DOI 10.3109/10428199509052703; Carella AM, 1996, LEUKEMIA LYMPHOMA, V21, P63, DOI 10.3109/10428199609067581; Diehl V, 1995, ANN ONCOL, V6, P901, DOI 10.1093/oxfordjournals.annonc.a059357; Federico M, 1996, LEUKEMIA, V10, pS69; Ferme C, 1997, CANCER-AM CANCER SOC, V80, P1124; FERME C, 1993, INT J RADIAT ONCOL, V26, P397, DOI 10.1016/0360-3016(93)90956-V; FERME C, 1995, ANN ONCOL, V6, P543, DOI 10.1093/oxfordjournals.annonc.a059242; FERME C, 1991, EUR J HAEMATOL, V46, P306; GAUSE A, 1992, ANN ONCOL, V3, pS49, DOI 10.1093/annonc/3.suppl_4.S49; GISSELBRECHT C, 1995, LEUKEMIA LYMPHOMA, V15, P23, DOI 10.3109/10428199509052700; Glick JH, 1998, J CLIN ONCOL, V16, P19, DOI 10.1200/JCO.1998.16.1.19; Glimelius B, 1996, LEUKEMIA LYMPHOMA, V21, P71, DOI 10.3109/10428199609067582; GOBBI PG, 1988, LANCET, V1, P675, DOI 10.1016/S0140-6736(88)91477-8; GOBBI PG, 1994, HAEMATOLOGICA, V79, P241; GOBBI PG, 1989, HAEMATOLOGICA, V74, P29; GOBBI PG, 1986, HAEMATOLOGICA, V71, P95; GOBBI PG, 1985, CANCER, V55, P389, DOI 10.1002/1097-0142(19850115)55:2<389::AID-CNCR2820550216>3.0.CO;2-F; GOBBI PG, 1993, J CLIN ONCOL, V11, P712, DOI 10.1200/JCO.1993.11.4.712; GORSCHLUTER M, 1995, ANN ONCOL, V6, P477, DOI 10.1093/oxfordjournals.annonc.a059218; HANCOCK BW, 1994, ANN ONCOL, V5, pS117, DOI 10.1093/annonc/5.suppl_2.S117; HANCOCK BW, 1992, J CLIN ONCOL, V10, P1252, DOI 10.1200/JCO.1992.10.8.1252; HASEGAWA G, 1995, NEFROLOGIA, V15, P1; Hasenclever D, 1996, ANN ONCOL, V7, P95; HENRYAMAR M, 1990, C INSERM, V196, P169; HILL M, 1995, J CLIN ONCOL, V13, P387, DOI 10.1200/JCO.1995.13.2.387; Holte H, 1996, ACTA ONCOL, V35, P73, DOI 10.3109/02841869609098523; HOPPER KD, 1991, INVEST RADIOL, V26, P1101, DOI 10.1097/00004424-199112000-00015; Horning SJ, 1996, ANN ONCOL, V7, P105; HORNING SJ, 1992, ANN ONCOL, V3, P747, DOI 10.1093/oxfordjournals.annonc.a058333; HUDSON BV, 1987, CLIN RADIOL, V38, P257, DOI 10.1016/S0009-9260(87)80060-0; Kaplan HS, 1980, HODGKINS DIS; Lee SM, 1997, BRIT J CANCER, V75, P110, DOI 10.1038/bjc.1997.18; LONGO DL, 1992, J CLIN ONCOL, V10, P210, DOI 10.1200/JCO.1992.10.2.210; LONGO DL, 1986, J CLIN ONCOL, V4, P1295, DOI 10.1200/JCO.1986.4.9.1295; LOTAN C, 1996, ANN ONCOL, V7, P114; MACLENNAN KA, 1983, CLIN RADIOL, V34, P491, DOI 10.1016/S0009-9260(83)80146-9; MUNKER R, 1995, J CLIN ONCOL, V13, P403, DOI 10.1200/JCO.1995.13.2.403; PFREUNDSCHUH MG, 1994, J CLIN ONCOL, V12, P580, DOI 10.1200/JCO.1994.12.3.580; PIZZOLO G, 1990, BRIT J HAEMATOL, V75, P282, DOI 10.1111/j.1365-2141.1990.tb02664.x; PROCTOR SJ, 1991, EUR J CANCER, V27, P624, DOI 10.1016/0277-5379(91)90231-2; PROCTOR SJ, 1992, LEUKEMIA LYMPHOMA, V7, P17, DOI 10.3109/10428199209061558; PROCTOR SJ, 1993, LEUKEMIA, V7, P1911; RADFORD JA, 1995, J CLIN ONCOL, V13, P2379, DOI 10.1200/JCO.1995.13.9.2379; RANSON MR, 1991, ANN ONCOL, V2, P423, DOI 10.1093/oxfordjournals.annonc.a057978; REECE DE, 1994, BLOOD, V83, P1193; Schmitz N., 1995, Blood, V86, p439A; Simmonds PD, 1997, ANN ONCOL, V8, P259, DOI 10.1023/A:1008282020341; SOMERS R, 1994, J CLIN ONCOL, V12, P279, DOI 10.1200/JCO.1994.12.2.279; Specht, 1996, Semin Radiat Oncol, V6, P146; SPECHT L, 1988, EUR J HAEMATOL, V41, P359; SPECHT L, 1991, CANCER TREAT REV, V18, P21, DOI 10.1016/0305-7372(91)90003-I; STRAUS DJ, 1990, J CLIN ONCOL, V8, P1173, DOI 10.1200/JCO.1990.8.7.1173; STRAUS DJ, 1995, LEUKEMIA LYMPHOMA, V15, P41, DOI 10.3109/10428199509052704; TRUMPER L, 1994, ANN ONCOL, V5, pS93, DOI 10.1093/annonc/5.suppl_1.S93; TUBIANA M, 1971, CANCER RES, V31, P1801; Uziely B, 1990, Leuk Lymphoma, V1, P123, DOI 10.3109/10428199009042469; WAGSTAFF J, 1986, HEMATOL ONCOL, V4, P135, DOI 10.1002/hon.2900040206	65	1223	1285	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1998	339	21					1506	1514		10.1056/NEJM199811193392104	http://dx.doi.org/10.1056/NEJM199811193392104			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VT	9819449				2022-12-28	WOS:000077051800004
J	Graham, BS				Graham, BS			Science, medicine, and the future - Infection with HIV-1	BRITISH MEDICAL JOURNAL			English	Review							SIMIAN IMMUNODEFICIENCY VIRUS; TYPE-1 INFECTION; RHESUS-MONKEYS; VIRAL LOAD; T-CELLS; RESPONSES; MACAQUES; VIREMIA; RESISTANCE; VACCINES		Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA	Vanderbilt University	Graham, BS (corresponding author), Vanderbilt Univ, Sch Med, A-4103 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	Barney.Graham@mcmail.vanderbilt.edu	Graham, Barney S./AAC-5898-2019	Graham, Barney S./0000-0001-8112-0853	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045210] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-45210] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balter M, 1998, SCIENCE, V280, P1856, DOI 10.1126/science.280.5371.1856; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; CLERICI M, 1994, JAMA-J AM MED ASSOC, V271, P42, DOI 10.1001/jama.271.1.42; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; Ferrari G, 1997, P NATL ACAD SCI USA, V94, P1396, DOI 10.1073/pnas.94.4.1396; Finzi D, 1998, CELL, V93, P665, DOI 10.1016/S0092-8674(00)81427-0; Fleury S, 1998, NAT MED, V4, P794, DOI 10.1038/nm0798-794; Fowke KR, 1996, LANCET, V348, P1347, DOI 10.1016/S0140-6736(95)12269-2; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; GRAHAM BS, 1995, NEW ENGL J MED, V333, P1331, DOI 10.1056/NEJM199511163332007; GRAHAM BS, IN PRESS TXB AIDS ME; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Joag SV, 1997, J VIROL, V71, P4016, DOI 10.1128/JVI.71.5.4016-4023.1997; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lafeuillade A, 1997, J INFECT DIS, V176, P804, DOI 10.1086/517307; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998; Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PINTO LA, 1995, J CLIN INVEST, V96, P867, DOI 10.1172/JCI118133; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; Schwartz DH, 1997, J INFECT DIS, V176, P1168, DOI 10.1086/514109; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; YASUTOMI Y, 1993, J VIROL, V67, P1707, DOI 10.1128/JVI.67.3.1707-1711.1993; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	37	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1297	1301		10.1136/bmj.317.7168.1297	http://dx.doi.org/10.1136/bmj.317.7168.1297			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804721	Green Published			2022-12-28	WOS:000076963800030
J	Lewis, G; Sloggett, A				Lewis, G; Sloggett, A			Suicide, deprivation, and unemployment: record linkage study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RATES	Objectives To investigate the association between suicide and socioeconomic status, unemployment, and chronic illness. Design Longitudinal study. Setting England and Wales. Subjects Individuals from the Office for National Statistics longitudinal study for whom 1981 census data were available. The longitudinal study is a representative 1% sample of the population of England and Wales in which census variables are linked to mortality data. Main outcome measures Suicide and undetermined deaths occurring between 1983 and 1992. Odds ratios estimated with logistic regression adjusted for attrition of cohort members. Results There was a strong independent association between suicide and individuals who were unemployed (odds ratio 2.6; 95% confidence interval 2.0 to 3.4) and permanently sick (2.5; 1.6 to 4.0), Those without access to a car had an increased risk (1.3; 1.0 to 1.5), but other measures of socioeconomic status were not associated with suicide. Conclusions The association between suicide and unemployment is more important than the association with other socioeconomic measures. Although some potentially important confounders were not adjusted for, the findings support the idea that unemployment or lack of job security increases the risk of suicide and that social and economic policies that reduce unemployment will also reduce the rate of suicide.	Cardiff Univ, Div Psychol Med, Cardiff CF4 4XN, S Glam, Wales; Univ London London Sch Hyg & Trop Med, Ctr Populat Studies, London WC1E 7HT, England	Cardiff University; University of London; London School of Hygiene & Tropical Medicine	Lewis, G (corresponding author), Cardiff Univ, Div Psychol Med, Cardiff CF4 4XN, S Glam, Wales.	wpcghl@cardiff.ac.uk	Lewis, Glyn/E-9944-2012	Lewis, Glyn/0000-0001-5205-8245				BANKS MH, 1982, PSYCHOL MED, V12, P789, DOI 10.1017/S0033291700049096; Charlton J., 1992, Population Trends, P10; Charlton J., 1993, POPULATION TRENDS, V71, P34; FOX AJ, 1982, LONGITUDINAL STUDY S, V1; Giddens Anthony, 1978, DURKHEIM; Goldblatt P, 1990, LONGITUDINAL STUDY M; HOLDING TA, 1978, BRIT J PSYCHIAT, V133, P542, DOI 10.1192/bjp.133.6.542; KREITMAN N, 1991, J EPIDEMIOL COMMUN H, V45, P195, DOI 10.1136/jech.45.3.195; KREITMAN N, 1976, BRIT J PREV SOC MED, V30, P86; LAST JM, 1988, DICT EPIDEMIOLOGY, P1; Lewis G, 1998, LANCET, V352, P605, DOI 10.1016/S0140-6736(98)04494-8; MARZUK PM, 1992, ARCH GEN PSYCHIAT, V49, P451; MOSER KA, 1984, LANCET, V2, P1324; PLATT S, 1984, SOC SCI MED, V19, P93, DOI 10.1016/0277-9536(84)90276-4; SAINSBURY P, 1986, SUICIDE, P17; *STAT, 1995, STAT STAT SOFTW 4 0; WARR P, 1985, PSYCHOL MED, V15, P795, DOI 10.1017/S003329170000502X; Warr P., 1987, WORK UNEMPLOYMENT ME, P1; Weich S, 1998, J EPIDEMIOL COMMUN H, V52, P8, DOI 10.1136/jech.52.1.8	19	232	235	0	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 7	1998	317	7168					1283	1286		10.1136/bmj.317.7168.1283	http://dx.doi.org/10.1136/bmj.317.7168.1283			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	138GP	9804714	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000076963800023
J	Tamura, M; Itoh, Y; Oasa, Y; Nakajima, T				Tamura, M; Itoh, Y; Oasa, Y; Nakajima, T			Isolated and companion young brown dwarfs in the taurus and chamaeleon molecular clouds	SCIENCE			English	Article							CHAMELEON DARK CLOUDS; STELLAR POPULATION; PLEIADES CLUSTER; STARS; PHOTOMETRY; DISCOVERY; MODEL	Infrared imaging observations have detected a dozen faint young stellar objects (YSOs) in the Taurus and Chamaeleon molecular clouds whose near-infrared colors are similar to those of classical T Tauri stars (TTS). They are around four magnitudes fainter than low-luminosity YSOs in Taurus detected in earlier surveys and as much as eight magnitudes fainter than typical TTS. The extreme faintness of the objects and their lower luminosity relative to previously identified brown dwarfs in the Pleiades indicate that these faint YSOs are very young brown dwarfs on the order of 1 million years old.	Natl Astron Observ, Tokyo 1818588, Japan; Univ Tokyo, Tokyo 1818588, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); University of Tokyo	Tamura, M (corresponding author), Natl Astron Observ, Osawa 2-21-1, Tokyo 1818588, Japan.			Itoh, Yoichi/0000-0002-3231-1159				Adams FC, 1998, ASTR SOC P, V134, P3; BEICHMAN CA, 1986, ASTROPHYS J, V307, P337, DOI 10.1086/164421; BERTOUT C, 1988, ASTROPHYS J, V330, P350, DOI 10.1086/166476; BESSELL MS, 1991, ASTRON J, V101, P662, DOI 10.1086/115714; Burrows A, 1997, ASTROPHYS J, V491, P856, DOI 10.1086/305002; COHEN M, 1979, ASTROPHYS J SUPPL S, V41, P743, DOI 10.1086/190641; COMERON F, 1993, ASTROPHYS J, V416, P185, DOI 10.1086/173225; DANTONA F, 1994, ASTROPHYS J SUPPL S, V90, P467, DOI 10.1086/191867; Delfosse X, 1997, ASTRON ASTROPHYS, V327, pL25; ELIAS JH, 1978, ASTROPHYS J, V224, P857, DOI 10.1086/156436; GARDNER JP, 1993, ASTROPHYS J, V415, pL9, DOI 10.1086/187020; GAUVIN LS, 1992, ASTROPHYS J, V385, P217, DOI 10.1086/170929; Itoh Y, 1996, ASTROPHYS J, V465, pL129, DOI 10.1086/310154; ITOH Y, 1998, THESIS U TOKYO; ITOH Y, UNPUB; JONES TJ, 1981, MON NOT R ASTRON SOC, V197, P413, DOI 10.1093/mnras/197.2.413; Kirkpatrick JD, 1997, ASTROPHYS J, V476, P311, DOI 10.1086/303613; KOORNNEEF J, 1983, ASTRON ASTROPHYS, V128, P84; Kulkami SR, 1997, SCIENCE, V276, P1350, DOI 10.1126/science.276.5317.1350; Marcy GW, 1996, ASTROPHYS J, V464, pL147, DOI 10.1086/310096; MAYOR RM, 1995, NATURE, V378, P355; Meyer MR, 1997, ASTRON J, V114, P288, DOI 10.1086/118474; NAKAJIMA T, 1995, NATURE, V378, P463, DOI 10.1038/378463a0; NEUHAUSER R, 1995, ASTRON ASTROPHYS, V295, pL5; Nordh L, 1996, ASTRON ASTROPHYS, V315, pL185; OASA Y, UNPUB; OPPENHEIMER BR, 1995, SCIENCE, V270, P1478, DOI 10.1126/science.270.5241.1478; Osorio MRZ, 1997, ASTRON ASTROPHYS, V317, P164; Osorio MRZ, 1997, ASTRON ASTROPHYS, V323, P105; REBOLO R, 1995, NATURE, V377, P129, DOI 10.1038/377129a0; REBOLO R, 1998, ASP C SERIES, V134, P115; STRINGFELLOW GS, 1991, ASTROPHYS J, V375, pL21, DOI 10.1086/186079; STROM KM, 1989, ASTRON J, V97, P1451, DOI 10.1086/115085; STROM KM, 1995, ASTROPHYS J, V438, P813, DOI 10.1086/175125; Tamura M, 1998, ASTR SOC P, V134, P338	35	46	46	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1095	1097		10.1126/science.282.5391.1095	http://dx.doi.org/10.1126/science.282.5391.1095			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804541				2022-12-28	WOS:000076887700041
J	Yeshurun, Y; Carrasco, M				Yeshurun, Y; Carrasco, M			Attention improves or impairs visual performance by enhancing spatial resolution	NATURE			English	Article							TEXTURE SEGMENTATION; SELECTIVE ATTENTION; NEURAL MECHANISMS; AREAS V1; SEARCH; ECCENTRICITY; VISION; CORTEX; SIZE; V2	Covert attention, the selective processing of visual information at a given location in the absence of eye movements, improves performance in several tasks, such as visual search and detection of luminance and vernier targets(1-6). An important unsettled issue is whether this improvement is due to a reduction in noise (internal or external)(6-9), a change in decisional criteria(10,11), or signal enhancement(3,5,12). Here we show that attention can affect performance by signal enhancement. For a texture segregation task in which performance is actually diminished when spatial resolution is too high, we observed that attention improved performance at peripheral locations where spatial resolution was too low, but impaired performance at central locations where spatial resolution was too high(4-12). The counterintuitive impairment of performance that we found at the central retinal locations appears to have only one possible explanation: attention enhances spatial resolution,	NYU, Dept Psychol, New York, NY 10003 USA	New York University	Carrasco, M (corresponding author), NYU, Dept Psychol, 6 Washington Pl, New York, NY 10003 USA.	marisa@psych.nyu.edu	Yeshurun, Yaffa/AAC-9164-2021	Yeshurun, Yaffa/0000-0003-0513-9290	NATIONAL EYE INSTITUTE [R01EY016200] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY016200] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Balz GW, 1997, VISION RES, V37, P1499, DOI 10.1016/S0042-6989(96)00296-9; Carrasco M, 1998, J EXP PSYCHOL HUMAN, V24, P673, DOI 10.1037/0096-1523.24.2.673; CHEAL ML, 1992, ACTA PSYCHOL, V81, P243, DOI 10.1016/0001-6918(92)90020-E; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DeValois RL, 1988, SPATIAL VISION; DUNCAN J, 1992, J EXP PSYCHOL HUMAN, V18, P578, DOI 10.1037/0096-1523.18.2.578; Graham N.V.S, 1989, VISUAL PATTERN ANAL; Gurnsey R, 1996, J EXP PSYCHOL HUMAN, V22, P738; Joffe KM, 1995, SPATIAL VISION, V9, P325, DOI 10.1163/156856895X00034; Jonides J., 1981, ATTENTION PERFORM, P187, DOI DOI 10.1037/0096-1523.29.5.835; Joseph JS, 1997, NATURE, V387, P805, DOI 10.1038/42940; JULESZ B, 1981, NATURE, V290, P91, DOI 10.1038/290091a0; KEHRER L, 1989, Spatial Vision, V4, P45, DOI 10.1163/156856889X00040; KINCHLA RA, 1992, ANNU REV PSYCHOL, V43, P711, DOI 10.1146/annurev.ps.43.020192.003431; Lee DK, 1997, VISION RES, V37, P2409, DOI 10.1016/S0042-6989(97)00055-2; Lu ZL, 1998, VISION RES, V38, P1183, DOI 10.1016/S0042-6989(97)00273-3; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24, DOI 10.1152/jn.1997.77.1.24; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; Morgan MJ, 1998, Q J EXP PSYCHOL-A, V51, P347, DOI 10.1080/713755766; Morikawa K, 1997, INVEST OPHTH VIS SCI, V38, P2986; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; NAKAYAMA K, 1989, VISION RES, V29, P1631, DOI 10.1016/0042-6989(89)90144-2; PALMER J, 1994, VISION RES, V34, P1703, DOI 10.1016/0042-6989(94)90128-7; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; SHAW ML, 1984, ATTENTION PERFORM, V10, P109; Sperling G., 1986, HDB PERCEPTION PERFO, V1, P1; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; WOLFE JM, 1994, PSYCHON B REV, V1, P202, DOI 10.3758/BF03200774; Yeshurun Y, 1999, VISION RES, V39, P293, DOI 10.1016/S0042-6989(98)00114-X	30	470	473	3	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 5	1998	396	6706					72	75		10.1038/23936	http://dx.doi.org/10.1038/23936			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	136HE	9817201	Green Accepted			2022-12-28	WOS:000076852700055
J	Seigneur, M; Bidnenko, V; Ehrlich, SD; Michel, B				Seigneur, M; Bidnenko, V; Ehrlich, SD; Michel, B			RuvAB acts at arrested replication forks	CELL			English	Article							ESCHERICHIA-COLI K-12; DOUBLE-STRAND BREAKS; JUNCTION-SPECIFIC ENDONUCLEASE; STABLE DNA-REPLICATION; HOLLIDAY JUNCTIONS; RECBCD ENZYME; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; SUBSTRATE-SPECIFICITY; HELICASE ACTIVITY	Replication arrest leads to the occurrence of DNA double-stranded breaks (DSB). We studied the mechanism of DSB formation by direct measure of the amount of in vivo linear DNA in Escherichia coli cells that lack the RecBCD recombination complex and by genetic means. The RuvABC proteins, which catalyze migration and cleavage of Holliday junctions, are responsible for the occurrence of DSBs at arrested replication forks. In cells proficient for RecBC, RuvAB is uncoupled from RuvC and DSBs may be prevented. This may be explained if a Holliday junction forms upon replication fork arrest, by annealing of the two nascent strands. RecBCD may act on the double-stranded tail prior to the cleavage of the RuvAB-bound junction by RuvC to rescue the blocked replication fork without breakage.	INRA, F-78352 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay	Michel, B (corresponding author), INRA, F-78352 Jouy En Josas, France.	bmichel@biotec.jouy.inra.fr	Ehrlich, S./Y-2423-2019	Ehrlich, S./0000-0002-7563-4046; Bidnenko, Vladimir/0000-0002-0070-4839				Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; ASAI T, 1994, CELL, V78, P1051, DOI 10.1016/0092-8674(94)90279-8; BAKER TA, 1983, J BACTERIOL, V156, P970, DOI 10.1128/JB.156.2.970-974.1983; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Bennett RJ, 1996, P NATL ACAD SCI USA, V93, P12217, DOI 10.1073/pnas.93.22.12217; BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1994, J BIOL CHEM, V269, P5195; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; Bentley NJ, 1997, BIOL CHEM, V378, P1267; Bierne H, 1997, EMBO J, V16, P3332, DOI 10.1093/emboj/16.11.3332; Bierne H, 1997, MOL MICROBIOL, V24, P1225, DOI 10.1046/j.1365-2958.1997.4381795.x; Birren B, 1993, PULSE FIELD GEL ELEC; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Boudsocq F, 1997, J MOL BIOL, V270, P201, DOI 10.1006/jmbi.1997.1098; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; CLERGET M, 1991, NEW BIOL, V3, P780; COLASANTI J, 1987, MOL GEN GENET, V209, P382, DOI 10.1007/BF00329669; CONDRA JH, 1982, J GEN MICROBIOL, V128, P613; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Davies AA, 1998, CURR BIOL, V8, P725, DOI 10.1016/S0960-9822(98)70282-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; Eggleston AK, 1997, CELL, V89, P607, DOI 10.1016/S0092-8674(00)80242-1; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; Gordon GS, 1997, CELL, V90, P1113, DOI 10.1016/S0092-8674(00)80377-3; Hargreaves D, 1998, NAT STRUCT BIOL, V5, P441, DOI 10.1038/nsb0698-441; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; Jones JM, 1997, EMBO J, V16, P6886, DOI 10.1093/emboj/16.22.6886; KoffelSchwartz N, 1996, P NATL ACAD SCI USA, V93, P7805, DOI 10.1073/pnas.93.15.7805; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LANE HED, 1975, J MOL BIOL, V97, P99; Leach DRF, 1997, MOL MICROBIOL, V26, P597, DOI 10.1046/j.1365-2958.1997.6071957.x; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LLOYD RG, 1996, ESCHERICHIA COLI SAL, P2236; LOUARN JM, 1991, J BACTERIOL, V173, P5097, DOI 10.1128/jb.173.16.5097-5104.1991; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MONK M, 1972, J BACTERIOL, V109, P971, DOI 10.1128/JB.109.3.971-978.1972; MOSIG G, 1995, FEMS MICROBIOL REV, V17, P83, DOI 10.1111/j.1574-6976.1995.tb00190.x; MYERS RS, 1994, ANNU REV GENET, V28, P49, DOI 10.1146/annurev.ge.28.120194.000405; OSSANNA N, 1989, J BACTERIOL, V171, P303, DOI 10.1128/jb.171.1.303-307.1989; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; Rice DW, 1997, CURR OPIN STRUC BIOL, V7, P798, DOI 10.1016/S0959-440X(97)80149-2; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; SARGENTINI NJ, 1986, RADIAT RES, V107, P58, DOI 10.2307/3576850; Saveson CJ, 1997, GENETICS, V146, P457; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; SKARSTAD K, 1993, J BACTERIOL, V175, P5505, DOI 10.1128/JB.175.17.5505-5509.1993; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sorokin A, 1996, GENOME RES, V6, P448, DOI 10.1101/gr.6.5.448; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; TorresRamos CA, 1997, J BIOL CHEM, V272, P25445, DOI 10.1074/jbc.272.41.25445; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; UZEST M, 1995, MOL MICROBIOL, V17, P1177, DOI 10.1111/j.1365-2958.1995.mmi_17061177.x; WANG TCV, 1983, J BACTERIOL, V156, P1093, DOI 10.1128/JB.156.3.1093-1098.1983; WANG TCV, 1986, J BACTERIOL, V165, P1023, DOI 10.1128/jb.165.3.1023-1025.1986; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; Whitby MC, 1996, J MOL BIOL, V264, P878, DOI 10.1006/jmbi.1996.0684; YANCEYWRONA JE, 1992, NUCLEIC ACIDS RES, V20, P6713, DOI 10.1093/nar/20.24.6713; Yu X, 1997, J MOL BIOL, V266, P217, DOI 10.1006/jmbi.1996.0799; ZIEG J, 1978, J BACTERIOL, V134, P958, DOI 10.1128/JB.134.3.958-966.1978; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	81	465	468	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 30	1998	95	3					419	430		10.1016/S0092-8674(00)81772-9	http://dx.doi.org/10.1016/S0092-8674(00)81772-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814711	Bronze			2022-12-28	WOS:000076789600014
J	Menegon, A; Board, PG; Blackburn, AC; Mellick, GD; Le Couteur, DG				Menegon, A; Board, PG; Blackburn, AC; Mellick, GD; Le Couteur, DG			Parkinson's disease, pesticides, and glutathione transferase polymorphisms	LANCET			English	Article							S-TRANSFERASE; ASSOCIATION; BRAIN; CDNA; GENE; METABOLITES; CLONING	Background Parkinson's disease is thought to be secondary to the presence of neurotoxins, and pesticides have been implicated as possible causative agents. Glutathione transferases (GST) metabolise xenobiotics, including pesticides. Therefore, we investigated the role of GST polymorphisms in the pathogenesis of idiopathic Parkinson's disease. Methods We genotyped by PCR polymorphisms in four GST classes (GSTM1, GSTT1, GSTP1, and GSTZ1) in 95 Parkinson's disease patients and 95 controls. We asked all patients for information about pesticide exposure. Findings The distribution of the GSTP1 genotypes differed significantly between patients and controls who had been exposed to pesticides (controls vs patients: AA 14 [54%] of 26 vs seven [18%] of 39; AB 11 [42%] of 26 vs 22 [56%] of 39; BE 1 [4%] of 26 vs six [15%] of 39; AC 0 vs four [10%] of 39, p=0.009). No association was found with any of the other GST polymorphisms. Pesticide exposure and a positive family history were risk factors for Parkinson's disease. Interpretation GSTP1-1, which is expressed in the blood-brain barrier, may influence response to neurotoxins and explain the susceptibility of some people to the parkinsonism-inducing effects of pesticides.	Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Canberra, ACT 2601, Australia; Univ Sydney, Canberra Hosp, Canberra Clin Sch, Dept Pharmacol, Canberra, ACT, Australia; Univ Sydney, Canberra Hosp, Canberra Clin Sch, Dept Med, Canberra, ACT, Australia; Univ Queensland, Princess Alexandra Hosp, Dept Med, Woolloongabba, Qld, Australia	Australian National University; John Curtin School of Medical Research; Australian National University; Canberra Hospital; University of Sydney; Australian National University; Canberra Hospital; University of Sydney; University of Queensland	Board, PG (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Canberra, ACT 2601, Australia.		Mellick, George D./A-7650-2010; Blackburn, Anneke C/B-3670-2011	Mellick, George D./0000-0002-7211-4651; Blackburn, Anneke C/0000-0002-6589-0142; Le Couteur, David/0000-0002-4227-5817				AliOsman F, 1997, J BIOL CHEM, V272, P10004; ANDERS MW, 1988, CRC CR REV TOXICOL, V18, P311, DOI 10.3109/10408448809037470; Baez S, 1997, BIOCHEM J, V324, P25, DOI 10.1042/bj3240025; Bandmann O, 1997, LANCET, V350, P1136, DOI 10.1016/S0140-6736(97)03495-8; Board PG, 1997, BIOCHEM J, V328, P929; BOARD PG, 1989, ANN HUM GENET, V53, P205, DOI 10.1111/j.1469-1809.1989.tb01786.x; BOCCHETTA A, 1986, LANCET, V2, P1163; CALNE DB, 1992, ANN NEUROL S, V32, P125; CARDER PJ, 1990, NEUROPATH APPL NEURO, V16, P293, DOI 10.1111/j.1365-2990.1990.tb01264.x; CHENEVIXTRENCH G, 1995, CARCINOGENESIS, V16, P1655, DOI 10.1093/carcin/16.7.1655; DIILIO C, 1995, TOXICOL LETT, V76, P173, DOI 10.1016/0378-4274(94)03210-X; DiIlio C, 1996, BIOCHEM PHARMACOL, V52, P43, DOI 10.1016/0006-2952(96)00137-2; HA X, 1997, BIOCHEM BIOPH RES CO, V238, P397; Harries LW, 1997, CARCINOGENESIS, V18, P641, DOI 10.1093/carcin/18.4.641; Harris MJ, 1998, PHARMACOGENETICS, V8, P27, DOI 10.1097/00008571-199802000-00004; HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539; HO SC, 1989, NEUROLOGY, V39, P1314, DOI 10.1212/WNL.39.10.1314; JOHNSON JA, 1993, J NEUROSCI, V13, P2013; LeCouteur DG, 1997, MOVEMENT DISORD, V12, P760, DOI 10.1002/mds.870120523; MATTHIAS C, 1988, PHARMACOGENETICS, V8, P1; McCann SJ, 1997, J NEUROL SCI, V153, P50, DOI 10.1016/S0022-510X(97)00179-2; PEMBLE S, 1994, BIOCHEM J, V300, P271, DOI 10.1042/bj3000271; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; SENANAYAKE N, 1995, HUM EXP TOXICOL, V14, P600, DOI 10.1177/096032719501400708; SIAN J, 1994, ANN NEUROL, V36, P356, DOI 10.1002/ana.410360306; TANNER CM, 1989, TRENDS NEUROSCI, V12, P49, DOI 10.1016/0166-2236(89)90135-5; TISON F, 1994, MOVEMENT DISORD, V9, P117, DOI 10.1002/mds.870090128; WILCE MCJ, 1993, BIOCHIM BIOPHYS ACTA, V1205, P1; ZIMNIAK P, 1994, EUR J BIOCHEM, V224, P893, DOI 10.1111/j.1432-1033.1994.00893.x	30	244	248	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 24	1998	352	9137					1344	1346		10.1016/S0140-6736(98)03453-9	http://dx.doi.org/10.1016/S0140-6736(98)03453-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802272				2022-12-28	WOS:000076691700012
J	van Gijn, J; Dennis, MS				van Gijn, J; Dennis, MS			Issues and answers in stroke care	LANCET			English	Article							RANDOMIZED CONTROLLED TRIAL; WHITE-MATTER; MANAGEMENT; COMMUNITY; DEMENTIA; ASPIRIN; LESIONS; RISK	In this section we address three aspects of stroke care that are important yet could not be reviewed in depth. The first is the organisation of stroke care (stroke units), in the acute phase as well as in the rehabilitation phase. The type of stroke services that hospitals provide varies considerably from place to place. To some extent this reflects differences in local conditions and needs, but at least there is now good evidence that hospital-based stroke services need to be organised. Which proportion of stroke patients needs formal rehabilitation depends on case-mix, with age and severity of stroke being the main factors. A rough estimate is that 20% of patients die within 30 days, and that 40-60% of survivors remain functionally dependent at the end of that period. The second issue is that of vascular cognitive impairment and its prevention. The increasing sensitivity of neuro-imaging techniques has revived the notion of chronic ischaemia as a cause of mental decline. The intellectual changes are mostly mild but the high prevalence makes this disorder a major health problem. Lastly, cost-effectiveness of hospital care for stroke patients is a controversial issue, given the great variation across Europe in the proportion of stroke admissions.	Univ Utrecht, Dept Neurol, NL-3508 GA Utrecht, Netherlands; Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	Utrecht University; University of Edinburgh	van Gijn, J (corresponding author), Univ Utrecht, Dept Neurol, POB 85500, NL-3508 GA Utrecht, Netherlands.							Algra A, 1996, J NEUROL NEUROSUR PS, V60, P197, DOI 10.1136/jnnp.60.2.197; ASPLUND K, 1993, CEREBROVASC DIS, V3, P34, DOI 10.1159/000108747; Asplund K, 1996, CEREBROVASC DIS, V6, P66, DOI 10.1159/000108000; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Asplund K, 1997, STROKE, V28, P2139, DOI 10.1161/01.STR.28.11.2139; BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; Bowler JV, 1997, ARCH NEUROL-CHICAGO, V54, P697, DOI 10.1001/archneur.1997.00550180021007; BRETELER MMB, 1994, NEUROLOGY, V44, P1246, DOI 10.1212/WNL.44.7.1246; DEGROOT JC, 1997, CEREBROVASC DIS S4, V7, P66; Dennis M, 1997, BRIT MED J, V314, P1071, DOI 10.1136/bmj.314.7087.1071; DEPIPPO KL, 1994, NEUROLOGY, V44, P1655, DOI 10.1212/WNL.44.9.1655; Forster A, 1996, BRIT MED J, V312, P1642, DOI 10.1136/bmj.312.7047.1642; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660; Indredavik B, 1997, STROKE, V28, P1861, DOI 10.1161/01.STR.28.10.1861; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LEYS D, 1994, VASCULAR DEMENTIA; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Martin PJ, 1997, QJM-INT J MED, V90, P759; MATHEW P, 1995, J NEUROL NEUROSUR PS, V59, P287, DOI 10.1136/jnnp.59.3.287; NORRIS JW, 1982, LANCET, V1, P328; Norton B, 1996, BRIT MED J, V312, P13, DOI 10.1136/bmj.312.7022.13; Pasquier F, 1997, J NEUROL, V244, P135, DOI 10.1007/s004150050064; PROHOVNIK I, 1996, VASCULAR DEMENTIA CU; Ronning OM, 1998, STROKE, V29, P586, DOI 10.1161/01.STR.29.3.586; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; VANSWIETEN JC, 1991, BRAIN, V114, P761; WARDLAW JM, 1998, STROKE MODULE COCHRA; WARLOW C, 1996, STROKE PRACTICAL GUI; WHURR R, 1992, EUR J DISORDER COMM, V27, P1	30	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT	1998	352			3			SIII23	SIII27						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133UP	9803959				2022-12-28	WOS:000076704700007
J	Verma, L; Macdonald, F; Leedham, P; McConachie, M; Dhanjal, S; Hulten, M				Verma, L; Macdonald, F; Leedham, P; McConachie, M; Dhanjal, S; Hulten, M			Rapid and simple prenatal DNA diagnosis of Down's syndrome	LANCET			English	Article							POLYMERASE CHAIN-REACTION; ANEUPLOIDIES; PCR; MARKERS	Background Prenatal diagnosis of chromosomal abnormality requires cytogenetic analysis of amniotic fetal cells. The necessary culture time delays diagnosis, is expensive, and requires substantial scientific expertise. In a masked prospective study, we investigated the feasibility of PCR amplification of chromosome 21 markers for the prenatal diagnosis of Down's syndrome. Methods The study population consisted of 2167 pregnant women, undergoing amniocentesis for prenatal diagnosis. In this cohort at least 1.5 mL amniotic fluid was available surplus to the requirements for traditional diagnostic methods. DNA was extracted from the surplus amniotic fluid and amplified in fluorescence-based PCR reactions, with three small-tandem-repeat markers located on chromosome 21. The products of the reactions were analysed on a DNA sequencer to identify the presence of two or three copies of chromosome 21. Findings In 2083 (97.4%) of 2139 samples of amniotic fluid that were not macroscopically blood-stained, two DNA markers gave an informative and correct result, identifying 2053 fetuses as normal and 30 as having trisomy 21 Down's syndrome (as confirmed by cytogenetic analysis). An extra marker was informative in 32 of 41 other clear samples. Thus a total of 99.6% informative results was achieved with these three markers. Macroscopically bloodstained samples (28 [1.3%]) were unsuitable for DNA testing. They gave a typical but non-informative result. There were no false-positive or false-negative results. Interpretation The PCR-based DNA diagnostic test has great potential for improved prenatal diagnosis of Down's syndrome, with the advantage that results may be available within a day.	Birmingham Heartlands Hosp, Reg Genet Serv, LSF Res Unit, Birmingham B9 5ST, W Midlands, England	Heart of England NHS Foundation Trust; University of Birmingham	Hulten, M (corresponding author), Univ Warwick, Dept Biol Sci, Mol Med Res Ctr, Coventry CV4 7AL, W Midlands, England.	ceht@dna.bio.warwick.ac.uk						ADINOLFI M, 1995, BIOESSAYS, V17, P661, DOI 10.1002/bies.950170712; Bianchi DW, 1997, AM J HUM GENET, V61, P822, DOI 10.1086/514885; Bosch A, 1996, EUR J HUM GENET, V4, P135; Falconer C, 1997, J MED GENET, V34, pSP67; Gardner RJM, 1996, CHROMOSOME ABNORMALI, V2nd; Goldberg JD, 1997, AM J HUM GENET, V61, P806, DOI 10.1086/514889; Leschot NJ, 1997, EUR J HUM GENET, V5, P1; LUBIN MB, 1991, MOL CELL PROBE, V5, P307, DOI 10.1016/0890-8508(91)90054-N; MANSFIELD ES, 1993, HUM MOL GENET, V2, P43, DOI 10.1093/hmg/2.1.43; MCINNIS MG, 1993, GENOMICS, V16, P562, DOI 10.1006/geno.1993.1231; Nakamura A, 1997, J BIOCHEM-TOKYO, V122, P872; Pertl B, 1996, HUM GENET, V98, P55, DOI 10.1007/s004390050159; PERTL B, 1994, LANCET, V343, P1197, DOI 10.1016/S0140-6736(94)92404-X; SHARMA V, 1992, HUM MOL GENET, V1, P67, DOI 10.1093/hmg/1.1.67-a; SPATHAS DH, 1994, PRENATAL DIAG, V14, P1049, DOI 10.1002/pd.1970141107; *UK NAT EXT QUAL A, 1996, CLIN CYTOGENET; WARBURTON D, 1991, AM J HUM GENET, V49, P995; WARD BE, 1993, AM J HUM GENET, V52, P854; Winsor EJT, 1996, PRENATAL DIAG, V16, P49, DOI 10.1002/(SICI)1097-0223(199601)16:1<49::AID-PD808>3.3.CO;2-L	19	95	134	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 4	1998	352	9121					9	12		10.1016/S0140-6736(97)11090-X	http://dx.doi.org/10.1016/S0140-6736(97)11090-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800738				2022-12-28	WOS:000074608600009
J	Volta, U; De Franceschi, L; Lari, F; Molinaro, N; Zoli, M; Bianchi, FB				Volta, U; De Franceschi, L; Lari, F; Molinaro, N; Zoli, M; Bianchi, FB			Coeliac disease hidden by cryptogenic hypertransaminasaemia	LANCET			English	Article							ADULT CELIAC-DISEASE; GLUTEN-FREE DIET; ANTIBODIES; GLIADIN; ENTEROPATHY; LIVER	Background Hypertransaminasaemia of unknown, cryptogenic, origin occasionally has been found to be the only sign of coeliac disease. Raised concentrations of transaminases, or aminotransferases, have been retrospectively observed in about a half of patients with coeliac disease who are on a gluten-containing diet. We aimed to establish the overall prevalence of coeliac disease among patients with cryptogenic hypertransaminasaemia. Methods Of the 600 consecutive patients referred to our outpatient clinic for liver disease due to raised serum transaminases from September, 1995, to June, 1997, 55 were classified as having cryptogenic hypertransaminasaemia after the exclusion of every known cause of liver disease. These patients were tested by indirect immunofluorescence for IgA to endomysium and for IgA and IgG to gliadin. Findings Five patients were positive for both IgA to endomysium and IgG to gliadin, whereas IgA to gliadin was only found in four patients. IgG to gliadin was also present in another patient who was not positive for antibodies to endomysium. The six antibody-positive patients had duodenal biopsy that showed a subtotal villous atrophy consistent with coeliac disease in the five patients with antibodies to endomysium. The patient with only IgG to gliadin had a normal small-intestine mucosa. None of the five patients with coeliac disease had gastrointestinal symptoms. Liver biopsy samples were taken from three of the five patients with flat mucosa and showed a histological picture of nonspecific reactive hepatitis. Transaminase concentrations reverted to normal within 6 months in four patients with coeliac disease who followed a strict gluten-free diet. Interpretation Our results show that about 9% of patients with cryptogenic hypertransaminasaemia are affected by symptom-free coeliac disease. Gluten-sensitive enteropathy and antibody screening for coeliac disease by means of antibodies to endomysium and gliadin should be considered in these patients.	Univ Bologna, SOrsola Malpighi Policlin, Dept Internal Med Cardioangiol Hepatol, I-40138 Bologna, Italy	University of Bologna	Volta, U (corresponding author), Univ Bologna, SOrsola Malpighi Policlin, Dept Internal Med Cardioangiol Hepatol, Via Massarenti 9, I-40138 Bologna, Italy.			De Franceschi, Lucia/0000-0003-1257-8101; Volta, Umberto/0000-0003-3405-3808				BARDELLA MT, 1995, HEPATOLOGY, V22, P833, DOI 10.1002/hep.1840220322; Bode S, 1996, SCAND J GASTROENTERO, V31, P54, DOI 10.3109/00365529609031627; Bonamico M, 1986, Minerva Pediatr, V38, P959; BRAZIER F, 1994, EUR J GASTROEN HEPAT, V6, P183, DOI 10.1097/00042737-199402000-00016; CACCIARI E, 1985, LANCET, V1, P1469; CORAZZA G, 1992, GASTROENTEROLOGY, V103, P1517, DOI 10.1016/0016-5085(92)91172-Z; CORAZZA GR, 1995, SCAND J GASTROENTERO, V30, P153, DOI 10.3109/00365529509093254; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; Hadjivassiliou M, 1996, LANCET, V347, P369, DOI 10.1016/S0140-6736(96)90540-1; HAGANDER B, 1977, LANCET, V2, P270; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; JACOBSEN MB, 1990, SCAND J GASTROENTERO, V25, P656, DOI 10.3109/00365529008997589; LEONARDI S, 1990, J PEDIATR GASTR NUTR, V11, P404, DOI 10.1097/00005176-199010000-00021; LINDGREN S, 1994, SCAND J GASTROENTERO, V29, P661, DOI 10.3109/00365529409092489; MCFARLANE XA, 1995, GUT, V36, P710, DOI 10.1136/gut.36.5.710; MEYERS S, 1981, GUT, V22, P61, DOI 10.1136/gut.22.1.61; POLLOCK DJ, 1977, HISTOPATHOLOGY, V1, P421, DOI 10.1111/j.1365-2559.1977.tb01681.x; ROY-CHOUDHURY D, 1966, Scandinavian Journal of Gastroenterology, V1, P57; SHER KS, 1994, DIGESTION, V55, P243, DOI 10.1159/000201155; TRIER JS, 1991, NEW ENGL J MED, V325, P1709, DOI 10.1056/NEJM199112123252406; VAJRO P, 1993, J PEDIATR-US, V122, P416, DOI 10.1016/S0022-3476(05)83430-4; VOLTA U, 1985, GUT, V26, P667, DOI 10.1136/gut.26.7.667; VOLTA U, 1995, DIGEST DIS SCI, V40, P1902, DOI 10.1007/BF02208653; VOLTA U, 1992, LANCET, V339, P242, DOI 10.1016/0140-6736(92)90040-A	24	166	171	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 4	1998	352	9121					26	29		10.1016/S0140-6736(97)11222-3	http://dx.doi.org/10.1016/S0140-6736(97)11222-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800742				2022-12-28	WOS:000074608600013
J	Eysenbach, G; Diepgen, TL				Eysenbach, G; Diepgen, TL			Towards quality management of medical information on the Internet: evaluation, labelling, and filtering of information	BRITISH MEDICAL JOURNAL			English	Article							WORLD-WIDE-WEB		Univ Hosp Erlangen, Dept Dermatol, Unit Med Informat Epidemiol & Publ Hlth, D-91052 Erlangen, Germany	University of Erlangen Nuremberg	Eysenbach, G (corresponding author), Univ Hosp Erlangen, Dept Dermatol, Unit Med Informat Epidemiol & Publ Hlth, Hartmannstr 14, D-91052 Erlangen, Germany.		Eysenbach, Gunther/AAJ-7158-2020	Eysenbach, Gunther/0000-0001-6479-5330				Ambre J, 1997, WHITE PAPER CRITERIA; APPLEYARD RJ, 1997, AM MED INF ASS ANN F; Coiera E, 1996, BMJ-BRIT MED J, V312, P3, DOI 10.1136/bmj.312.7022.3; *COLL CRIT APPR ME, 1997, MED PICS EL RAT VOC; Culver JD, 1997, J GEN INTERN MED, V12, P466, DOI 10.1046/j.1525-1497.1997.00084.x; Dearlove OR, 1997, BRIT MED J, V315, P491, DOI 10.1136/bmj.315.7106.491a; deBousingen DD, 1997, LANCET, V350, P874, DOI 10.1016/S0140-6736(05)62059-4; deBousingen DD, 1996, LANCET, V348, P1440; Donabedian A, 1980, EXPLORATIONS QUALITY, V1; Eysenbach G, 1998, JAMA-J AM MED ASSOC, V280, P1333, DOI 10.1001/jama.280.15.1333; GARFIELD E, 1976, NATURE, V264, P609, DOI 10.1038/264609a0; HernandezBorges AA, 1997, PEDIATRICS, V100, DOI 10.1542/peds.100.2.e8; Huberman BA, 1998, SCIENCE, V280, P95, DOI 10.1126/science.280.5360.95; Impicciatore P, 1997, BMJ-BRIT MED J, V314, P1875, DOI 10.1136/bmj.314.7098.1875; *INT ORG STAND, 1994, 175 ISO TC; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P611, DOI 10.1001/jama.279.8.611; KRAUSKOPF T, 1996, WORLD WIDE WEB J, V1, P45; MALET G, 1997, MED MATRIX CODE COND; MCNAB A, 1997, ARIADNE         0518, P9; MILLER J, 1996, WORLD WIDE WEB J, V1, P23; NIGEL G, 1997, LANCET, V349, P1679; Resnick P, 1996, COMMUN ACM, V39, P87, DOI 10.1145/236156.236175; RESNICK P, 1997, SCI AM, V3, P106; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Weisbord SD, 1997, NEW ENGL J MED, V337, P825, DOI 10.1056/NEJM199709183371205; Wyatt JC, 1997, BRIT MED J, V314, P1879, DOI 10.1136/bmj.314.7098.1879	26	287	296	2	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1496	1500		10.1136/bmj.317.7171.1496	http://dx.doi.org/10.1136/bmj.317.7171.1496			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831581	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000077338300030
J	Sun, G; Dilcher, DL; Zheng, SL; Zhou, ZK				Sun, G; Dilcher, DL; Zheng, SL; Zhou, ZK			In search of the first flower: A Jurassic angiosperm, Archaefructus, from northeast China	SCIENCE			English	Article							FOSSIL FLOWERS; REPRODUCTIVE STRUCTURES; NEW-JERSEY; PLANT; EVOLUTION; AFFINITY; POLLEN; ORIGIN	Angiosperm fruiting, axes were discovered from the Upper Jurassic of China. Angiosperms are defined by carpels enclosing ovules, a character demonstrated in this fossil. This feature is Lacking in other fossils reported to be earliest angiosperms. The fruits are small follicles formed from conduplicate carpels helically arranged. Adaxial elongate stigmatic crests are conspicuous on each carpel. The basal one-third of the axes bore deciduous organs of uncertain affinities. No scars of subtending floral organs are present to define the individual fertile parts as floral units, but the Leaf-Like structures subtending each axis define them as flowers. These fruiting axes have primitive characters and characters not considered primitive.	Acad Sinica, Nanjing Inst Geol & Palaeontol, Nanjing 210008, Peoples R China; Univ Florida, Florida Museum Nat Hist, Gainesville, FL 32611 USA; Shenyang Inst Geol & Mineral Resources, Shenyang 110032, Peoples R China; Acad Sinica, Kunming Inst Bot, Kunming 650204, Peoples R China	Chinese Academy of Sciences; State University System of Florida; University of Florida; Chinese Academy of Sciences; Kunming Institute of Botany, CAS	Sun, G (corresponding author), Acad Sinica, Nanjing Inst Geol & Palaeontol, Nanjing 210008, Peoples R China.		Zhou, Zhekun/G-5281-2011	Zhou, Zhekun/0000-0002-0710-2128				AXELROD DI, 1959, SCIENCE, V130, P203, DOI 10.1126/science.130.3369.203; BURGER D, 1990, REV PALAEOBOT PALYNO, V65, P153, DOI 10.1016/0034-6667(90)90066-R; Cao ZY, 1998, CHINESE SCI BULL, V43, P230, DOI 10.1007/BF02898918; Chen P., 1980, B NANJING I GEOL PAL, V1, P22; Chen PJ, 1998, NATURE, V391, P147, DOI 10.1038/34356; CORNET B, 1989, Palaeontographica Abteilung B Palaeophytologie, V213, P37; CORNET B, 1986, EVOL THEOR, V7, P231; CORNET B, 1992, REV PALAEOBOT PALYNO, V71, P269, DOI 10.1016/0034-6667(92)90167-F; Cornet B., 1993, MOD GEOL, V19, P81; CRANE PR, 1993, NATURE, V366, P631, DOI 10.1038/366631a0; CRANE PR, 1985, ANN MO BOT GARD, V72, P716, DOI 10.2307/2399221; Crane PR, 1996, INT J PLANT SCI, V157, pS50, DOI 10.1086/297403; CREPET WL, 1992, P NATL ACAD SCI USA, V89, P8986, DOI 10.1073/pnas.89.19.8986; CRONGUIST A, 1981, INTEGRATED SYSTEM CL; DILCHER DL, 1995, MONOG SYST BOTAN, V53, P187; DILCHER DL, 1996, 6 C LAT BOT MAR DEL, P29; Doyle J.A., 1976, ORIGIN EARLY EVOLUTI, P139; Doyle J.A., 1984, P 27 INT GEOL C PAL, V2, P23; DOYLE JA, 1986, BOT REV, V52, P1; Duan SY, 1998, SCI CHINA SER D, V41, P14, DOI 10.1007/BF02932415; Endress P. K., 1994, DIVERSITY EVOLUTIONA; ENDRESS PK, 1986, PLANT SYST EVOL, V152, P1, DOI 10.1007/BF00985348; FRIIS E, 1996, PROG BOT, V57, P253; Friis EM, 1997, EVOLUTION DIVERSIFIC, P121; FRIIS EM, 1987, ORIGINS ANGIOSPERMS, P145; Gandolfo MA, 1998, AM J BOT, V85, P964, DOI 10.2307/2446363; HERENDEEN PS, 1994, PLANT SYST EVOL, V189, P29, DOI 10.1007/BF00937576; Hickey Leo J., 1996, P176, DOI 10.1007/978-0-585-23095-5_8; Hill CR, 1996, CRETACEOUS RES, V17, P27, DOI 10.1006/cres.1996.0003; HOU LH, 1995, NATURE, V377, P616, DOI 10.1038/377616a0; Ji Q., 1996, CHINESE GEOL, V233, P30; Keller JA, 1996, AM J BOT, V83, P528, DOI 10.2307/2446221; KRASSILOV V, 1982, Palaeontographica Abteilung B Palaeophytologie, V181, P1; Krassilov VA, 1997, ANGIOSPERM ORIGINS M; Labandeira CC, 1998, SCIENCE, V280, P57, DOI 10.1126/science.280.5360.57; NIXON KC, 1993, AM J BOT, V80, P616, DOI 10.2307/2445430; Ren D, 1998, SCIENCE, V280, P85, DOI 10.1126/science.280.5360.85; SMITH PE, 1995, CAN J EARTH SCI, V32, P1426, DOI 10.1139/e95-115; SUN G, 1996, PALEOBOTANIST, V45, P393; SUN G, 1993, SCI CHINA SER B, V36, P253; Takhtajan A., 1987, BIOGEOGRAPHICAL EVOL, P26; Taylor David Winship, 1996, P116, DOI 10.1007/978-0-585-23095-5_6; TAYLOR DW, 1992, PLANT SYST EVOL, V180, P137, DOI 10.1007/BF00941148; TAYOR TN, 1993, BIOL EVOLUTION FOSSI; Unwin DM, 1998, NATURE, V391, P119, DOI 10.1038/34279; Vakhrameev V.A., 1991, JURASSIC CRETACEOUS	46	320	394	1	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1692	1695		10.1126/science.282.5394.1692	http://dx.doi.org/10.1126/science.282.5394.1692			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831557				2022-12-28	WOS:000077246600042
J	Gueugniaud, PY; Mols, P; Goldstein, P; Pham, E; Dubien, PY; Deweerdt, C; Vergnion, M; Petit, P; Carli, P				Gueugniaud, PY; Mols, P; Goldstein, P; Pham, E; Dubien, PY; Deweerdt, C; Vergnion, M; Petit, P; Carli, P		European Epinephrine Study Grp	A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL BLOOD-FLOW; CARDIOPULMONARY-RESUSCITATION; LIFE-SUPPORT; SWINE MODEL; VASOPRESSIN; ALGORITHM; PERFUSION; PRESSURE; DOGS	Background Clinical trials have not shown a benefit of high doses of epinephrine in the management of cardiac arrest. We conducted a prospective, multicenter, randomized study comparing repeated high doses of epinephrine with repeated standard doses in cases of out-of-hospital cardiac arrest. Methods Adult patients who had cardiac arrest outside the hospital were enrolled if the cardiac rhythm continued to be ventricular fibrillation despite the administration of external electrical shocks, or if they had asystole or pulseless electrical activity at the time epinephrine was administered. We randomly assigned 3327 patients to receive up to 15 high doses (5 mg each) or standard doses (1 mg each) of epinephrine according to the current protocol for advanced cardiac life support. Results In the high-dose group, 40.4 percent of 1677 patients had a return of spontaneous circulation, as compared with 36.4 percent of 1650 patients in the standard-dose group (P = 0.02); 26.5 percent of the patients in the high-dose group and 23.6 percent of those in the standard-dose group survived to be admitted to the hospital (P = 0.05); 2.3 percent of the patients in the high-dose group and 2.8 percent in the standard-dose group survived to be discharged from the hospital (P = 0.34). There was no significant differ ence in neurologic status according to treatment among those discharged. High-dose epinephrine improved the rate of successful resuscitation in patients with asystole, but not in those with ventricular fibrillation. Conclusions In our study, long-term survival after cardiac arrest outside the hospital was no better with repeated high doses of epinephrine than with repeated standard doses. (N Engl J Med 1998;339:1595-601.) (C)1998, Massachusetts Medical Society.	Univ Lyon 1, Hop Edouard Herriot, Serv Aide Med Urgente Lyons, Dept Anesthesiol & Emergency Med Syst, F-69365 Lyon, France; CHU St Pierre, Serv Aide Med Urgente Brussels, Dept Emergency Med & Emergency Med Syst, Brussels, Belgium; Ctr Hosp Reg & Univ Lille, Serv Aide Med Urgente Lille, Dept Anesthesiol & Emergency Med Syst, F-59037 Lille, France; Univ Lyon 1, Med Serv, Dept Comp & Stat, F-69365 Lyon, France; Hop Edouard Herriot, Dept Pharmaceut, Lyon, France; Ctr Hosp Reg Citadelle, Serv Mobile Urgence & Reanimat, Dept Emergency Med, Liege, Belgium; CHU Necker, Serv Aide Med Urgence Paris, Dept Anesthesiol & Emergency Med Syst, Paris, France	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite de Lille - ISITE; CHU Lille; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Gueugniaud, PY (corresponding author), Hop Edouard Herriot, Dept Anesthesiol 7, Pavillon 1,Pl Arsonval, F-69437 Lyon, France.							ABRAMSON NS, 1991, NEW ENGL J MED, V324, P1225; ABRAMSON NS, 1986, NEW ENGL J MED, V314, P397; ABRAMSON NS, 1995, ANN EMERG MED, V25, P130; *AM HEART ASS, 1992, JAMA-J AM MED ASSOC, V268, P2205; BARTON CW, 1990, ANN EMERG MED, V19, P490; BROWN CG, 1987, AM J EMERG MED, V5, P362, DOI 10.1016/0735-6757(87)90382-2; BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; BROWN CG, 1986, ANN EMERG MED, V15, P1138, DOI 10.1016/S0196-0644(86)80853-8; BRUNETTE DD, 1990, ANN EMERG MED, V19, P8, DOI 10.1016/S0196-0644(05)82130-4; CALLAHAM M, 1992, JAMA-J AM MED ASSOC, V268, P2667, DOI 10.1001/jama.268.19.2667; CARLI PA, 1993, TXB TRAUMA ANESTHESI, P199; CHAMBERLAIN D, 1992, RESUSCITATION, V24, P111, DOI 10.1016/0300-9572(92)90016-6; CHOUX C, 1995, RESUSCITATION, V29, P3, DOI 10.1016/0300-9572(94)00810-3; Chugh SS, 1997, CIRCULATION, V96, P2453; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; Fisher LD., 1997, BIOMETRICS, V53, P1182; GOETTING MG, 1989, CRIT CARE MED, V17, P1258, DOI 10.1097/00003246-198912000-00004; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GUEUGNIAUD PY, 1989, RESUSCITATION, V17, pS79, DOI 10.1016/0300-9572(89)90093-2; Kloeck W, 1997, RESUSCITATION, V34, P109, DOI 10.1016/S0300-9572(97)01100-3; KOSCOVE EM, 1988, JAMA-J AM MED ASSOC, V259, P3031, DOI 10.1001/jama.259.20.3031; KOSNIK JW, 1985, ANN EMERG MED, V14, P204, DOI 10.1016/S0196-0644(85)80440-6; Levine RL, 1997, NEW ENGL J MED, V337, P301, DOI 10.1056/NEJM199707313370503; LINDNER KH, 1991, ACTA ANAESTH SCAND, V35, P253, DOI 10.1111/j.1399-6576.1991.tb03283.x; LINDNER KH, 1995, CIRCULATION, V91, P215, DOI 10.1161/01.CIR.91.1.215; Lindner KH, 1997, LANCET, V349, P535, DOI 10.1016/S0140-6736(97)80087-6; Lindner KH, 1996, ANN INTERN MED, V124, P1061, DOI 10.7326/0003-4819-124-12-199606150-00006; LINDNER KH, 1991, AM J EMERG MED, V9, P27, DOI 10.1016/0735-6757(91)90008-8; MARTIN D, 1990, ANN EMERG MED, V19, P322, DOI 10.1016/S0196-0644(05)82055-4; NIEMANN JT, 1992, NEW ENGL J MED, V327, P1075; PARADIS NA, 1991, JAMA-J AM MED ASSOC, V265, P1139, DOI 10.1001/jama.265.9.1139; Plaisance P, 1997, CIRCULATION, V95, P955; SAFAR P, 1986, CIRCULATION, V74, P138; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; WEAVER WD, 1991, NEW ENGL J MED, V325, P1437, DOI 10.1056/NEJM199111143252008	37	227	233	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 26	1998	339	22					1595	1601		10.1056/NEJM199811263392204	http://dx.doi.org/10.1056/NEJM199811263392204			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZU	9828247	Bronze			2022-12-28	WOS:000077176100004
J	Davis, GL; Esteban-Mur, R; Rustgi, V; Hoefs, J; Gordon, SC; Trepo, C; Shiffman, ML; Zeuzem, S; Craxi, A; Ling, MH; Albrecht, J				Davis, GL; Esteban-Mur, R; Rustgi, V; Hoefs, J; Gordon, SC; Trepo, C; Shiffman, ML; Zeuzem, S; Craxi, A; Ling, MH; Albrecht, J		Int Hepatitis Interventional Therapy Grp	Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; SUSTAINED RESPONSE; ALPHA THERAPY; VIRUS-RNA; FOLLOW-UP; HCV RNA; TRIAL; RETREATMENT; METAANALYSIS	Background Interferon alfa is the only effective treatment for patients with chronic hepatitis C. Forty percent of patients have an initial response to this therapy, but most subsequently relapse. We compared the effect of interferon alone with that of interferon plus oral ribavirin for relapses of chronic hepatitis C. Methods We studied 345 patients with chronic hepatitis C who relapsed after interferon treatment. A total of 173 patients were randomly assigned to receive standard-dose recombinant interferon alfa-2b concurrently with ribavirin (1000 to 1200 mg orally per day, depending on body weight) for six months, and 172 patients were assigned to receive interferon and placebo. Results At the completion of treatment, serum levels of hepatitis C virus (HCV) RNA were undetectable in 141 of the 173 patients who were treated with interferon and ribavirin and in 80 of the 172 patients who were treated with interferon alone (82 percent vs. 47 percent, P<0.001). Serum HCV RNA levels remained undetectable 24 weeks after the end of treatment in 84 patients (49 percent) in the combination-therapy group, but in only 8 patients (5 percent) in the interferon group (P<0.001). Sustained normalization of serum alanine aminotransferase concentrations and histologic improvement were highly correlated with virologic response. Base-line serum HCV RNA levels of 2 x 10(6) copies per milliliter or less were associated with higher rates of response in both treatment groups. Viral genotypes other than type 1 were associated with sustained responses only in the combination-therapy group. Combined therapy caused a predictable fall in hemoglobin concentrations but otherwise had a safety profile similar to that of interferon alone. Conclusions In patients with chronic hepatitis C who relapse after treatment with interferon, therapy with interferon and oral ribavirin results in higher rates of sustained virologic, biochemical, and histologic response than treatment with interferon alone. (N Engl J Med 1998;339:1493-9.) (C) 1998, Massachusetts Medical Society.	Univ Florida, Coll Med, Sect Hepatobiliary Dis, Gainesville, FL 32610 USA; Hosp Gen Valle Hebron, Barcelona, Spain; Inova Inst Res & Educ, Falls Church, VA USA; Univ Calif Irvine, Orange, CA 92668 USA; William Beaumont Hosp, Royal Oak, MI 48072 USA; Hop Hotel Dieu, F-69288 Lyon, France; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Univ Frankfurt Klinikum, D-6000 Frankfurt, Germany; Policlin P Giaccone, Palermo, Italy; Schering Plough Corp, Res Inst, Kenilworth, NJ USA	State University System of Florida; University of Florida; Hospital Universitari Vall d'Hebron; University of California System; University of California Irvine; Beaumont Health; CHU Lyon; Virginia Commonwealth University; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Merck & Company; Schering Plough Corporation	Davis, GL (corresponding author), Univ Florida, Coll Med, Sect Hepatobiliary Dis, Box 100214, Gainesville, FL 32610 USA.		Zeuzem, Stefan/AAE-7435-2019; Craxi, Antonio/K-9529-2016	esteban, rafael/0000-0001-5280-392X; Craxi, Antonio/0000-0002-4480-9544	NCRR NIH HHS [5MO1-RR00082] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000082] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBER MS, 1997, PROG NONLIN, V26, P1; Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; [Anonymous], 1997, HEPATOLOGY, V26, pS2; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Bodenheimer HC, 1997, HEPATOLOGY, V26, P473, DOI 10.1002/hep.510260231; Bonkovsky HL, 1996, DIGEST DIS SCI, V41, P149, DOI 10.1007/BF02208597; BRILLANTI S, 1994, GASTROENTEROLOGY, V107, P812, DOI 10.1016/0016-5085(94)90131-7; Carithers RL, 1997, HEPATOLOGY, V26, pS83, DOI 10.1002/hep.510260715; Chemello L, 1995, J HEPATOL, V23, P8; DAVIS GL, 1994, J HEPATOL, V21, P1, DOI 10.1016/S0168-8278(94)80128-2; Davis GL, 1997, HEPATOLOGY, V26, pS122, DOI 10.1002/hep.510260721; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DETRE KM, 1996, VIRAL HEPATITIS REV, V2, P219; DI BA, 1989, NEW ENGL J MED, V321, P1506; DIBISCEGLIE AM, 1992, HEPATOLOGY, V16, P649, DOI 10.1002/hep.1840160307; Dusheiko G, 1997, HEPATOLOGY, V26, pS112, DOI 10.1002/hep.510260720; Dusheiko G, 1996, J HEPATOL, V25, P591, DOI 10.1016/S0168-8278(96)80225-X; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; Fuschi P., 1997, Journal of Hepatology, V26, P192; Hawkins A, 1997, J CLIN MICROBIOL, V35, P187, DOI 10.1128/JCM.35.1.187-192.1997; Keeffe EB, 1997, HEPATOLOGY, V26, pS101, DOI 10.1002/hep.510260718; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KORETZ RL, 1993, ANN INTERN MED, V119, P110, DOI 10.7326/0003-4819-119-2-199307150-00003; LAU JYN, 1993, LANCET, V342, P504; Le X., 1996, Hepatology, V24, p536A; LIN R, 1995, J HEPATOL, V23, P487, DOI 10.1016/0168-8278(95)80052-2; Lindsay KL, 1997, HEPATOLOGY, V26, pS71, DOI 10.1002/hep.510260713; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; MARCELLIN P, 1993, J INFECT DIS, V167, P780, DOI 10.1093/infdis/167.3.780; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; MATTSON L, 1993, LIVER, V13, P274; PATTERSON JL, 1990, REV INFECT DIS, V12, P1139; Picciotto A., 1996, Hepatology, V24, p273A; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Poynard T, 1996, NEW ENGL J MED, V334, P1143; Poynard T, 1996, HEPATOLOGY, V24, P778; Reichard O, 1998, LANCET, V351, P83, DOI 10.1016/S0140-6736(97)06088-1; REICHARD O, 1995, HEPATOLOGY, V21, P918, DOI 10.1016/0270-9139(95)90234-1; SCHVARCZ R, 1995, J MED VIROL, V46, P43, DOI 10.1002/jmv.1890460110; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Shiffman ML, 1996, HEPATOLOGY, V24, P21, DOI 10.1002/hep.510240105; SHINDO M, 1995, ANN INTERN MED, V122, P586, DOI 10.7326/0003-4819-122-8-199504150-00005; TINE F, 1991, J HEPATOL, V13, P192, DOI 10.1016/0168-8278(91)90814-R; TOYODA H, 1994, AM J GASTROENTEROL, V89, P1453	45	1102	1131	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1998	339	21					1493	1499		10.1056/NEJM199811193392102	http://dx.doi.org/10.1056/NEJM199811193392102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VT	9819447	Green Published			2022-12-28	WOS:000077051800002
J	Beard, K; Forrester, E; Lee, A; Burns, H; Brodie, MJ				Beard, K; Forrester, E; Lee, A; Burns, H; Brodie, MJ			Systems and strategies for managing the drugs budget in Glasgow	BRITISH MEDICAL JOURNAL			English	Article							PHARMACOECONOMICS		Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland; Victoria Infirm, NHS Trust, Dept Geriatr Med, Glasgow G41 3DX, Lanark, Scotland; Glasgow Royal NHS Trust, Dept Clin Pharmacol, Glasgow G42 9TY, Lanark, Scotland; Glasgow Royal NHS Trust, Area Drug Informat Ctr, Glasgow G42 9TY, Lanark, Scotland; Greater Glasgow Hlth Board, Glasgow G3 8YU, Lanark, Scotland	University of Glasgow	Brodie, MJ (corresponding author), Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland.							Bastida JL, 1997, LANCET, V350, P679, DOI 10.1016/S0140-6736(05)63509-X; CHRISTIE B, 1997, SCOTSMAN        1023, P24; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; WALLEY T, 1994, PHARMACOECONOMICS, V5, P93, DOI 10.2165/00019053-199405020-00003; Walley T, 1997, BRIT J CLIN PHARMACO, V43, P343, DOI 10.1046/j.1365-2125.1997.00574.x	5	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1378	1381		10.1136/bmj.317.7169.1378	http://dx.doi.org/10.1136/bmj.317.7169.1378			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812943	Green Published			2022-12-28	WOS:000077081600031
J	Carmi, I; Kopczynski, JB; Meyer, BJ				Carmi, I; Kopczynski, JB; Meyer, BJ			The nuclear hormone receptor SEX-1 is an X-chromosome signal that determines nematode sex	NATURE			English	Article							LIGAND-BINDING DOMAIN; CAENORHABDITIS-ELEGANS; DOSAGE COMPENSATION; CRYSTAL-STRUCTURE; RETINOIC ACID; C-ELEGANS; GENE; IDENTIFICATION; TRANSCRIPTION; SUPERFAMILY	Organisms in many phyla determine sexual fate by distinguishing one X chromosome from two. Here we use the model organism Caenorhabditis elegans to dissect such an X-chromosome-counting mechanism in molecular detail. In this nematode, several genes on the X chromosome called X signal elements communicate X-chromosome dose by controlling the activity of the sex-determination gene xol-1 (refs 1, 2), xol-1 specifies male (XO) fate when active and hermaphrodite (XX) fate when inactive(3,4). The only X signal element described so far represses xol-1 post-transcriptionally, but xol-1 is repressed in XX animals by transcriptional and post-transcriptional mechanisms(2). Here we identify a nuclear-hormone-receptor homologue, SEX-1, that regulates the transcription of xol-1. We show that sex-1 is vital to X-chromosome counting: changing sex-1 gene dose in XX or XO embryos causes sexual transformation and death from inadequate dosage compensation (the hermaphrodite-specific process that equalizes X-gene expression between the sexes(5)). The SEX-1 protein acts directly on xol-1, associating with its promoter in vivo and repressing xol-1 transcription in XX embryos. Thus, xol-1 is the direct molecular target of the primary sex-determination signal, and the dose of a nuclear hormone receptor helps to communicate X-chromosome number to determine nematode sex.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Meyer, BJ (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.			Meyer, Barbara/0000-0002-6530-4588	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030702] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM030702] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERIB CC, 1994, GENETICS, V138, P1105; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRENNER S, 1974, GENETICS, V77, P71; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; HODGKIN J, 1994, DEVELOPMENT, V120, P3681; HODGKIN J, 1995, GENETICS, V141, P527; KOSTROUCH Z, 1995, P NATL ACAD SCI USA, V92, P156, DOI 10.1073/pnas.92.1.156; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MENEELY PM, 1984, GENETICS, V106, P29; MEYER BJ, 1997, C ELEGANS, V2, P209; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2; Nicoll M, 1997, NATURE, V388, P200, DOI 10.1038/40645; PLENEFISCH JD, 1989, GENETICS, V121, P57; Ramkissoon Y, 1996, CURR OPIN GENET DEV, V6, P316, DOI 10.1016/S0959-437X(96)80008-6; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; STONE BL, 1993, CELL, V75, P307, DOI 10.1016/0092-8674(93)80072-M; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WILLIAMS BD, 1992, GENETICS, V131, P609	26	113	123	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1998	396	6707					168	173		10.1038/24164	http://dx.doi.org/10.1038/24164			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823896				2022-12-28	WOS:000077013300052
J	Burger, RL; Gordon, RB				Burger, RL; Gordon, RB			Early central Andean metalworking from Mina Perdida, Peru	SCIENCE			English	Article							NATIVE COPPER; HUMANITYS INTRODUCTION; METALLURGY	Copper and gold artifacts in contexts dated to similar to 3120 to 3020 carbon-14 years before the present (similar to 1410 to 1090 calendar years B.C.) recovered in excavations at Mina Perdida, Lurin Valley, Peru, show that artisans hammered native metals into thin foils, in some cases with intermediate anneals, They gilded copper artifacts by attaching gold foil. The artifacts show that fundamental elements of the Andean metallurgical tradition were developed before the Chavin horizon, and that on the Peruvian coast the working of native copper preceded the production of smelted copper objects.	Yale Univ, Museum Nat Hist, New Haven, CT 06520 USA; Yale Univ, Dept Anthropol, New Haven, CT 06520 USA; Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Burger, RL (corresponding author), Yale Univ, Museum Nat Hist, POB 208277, New Haven, CT 06520 USA.	richard.burger@yale.edu; robert.gordon@yale.edu						ALVA W, 1992, ORO ANTIGUO PERU, P17; BURGER R, 1991, J FIELD ARCHAEOL, V18, P30; BURGER R, 1992, CHAVIN ORIGINS ANDEA, P99; BURGER R, 1998, RES ANTHR AESTHETICS, V33, P32; Burger R. L, 1996, ANDEAN ART DUMBARTON, P45; CAMUS F, 1996, SOC EC GEOLOGISTS SP, V5, P1; CRADDOCK PT, 1987, ARCHAEOMETRY, V29, P187, DOI 10.1111/j.1475-4754.1987.tb00411.x; CRADDOCK PT, 1995, EARLY METAL MINING P, P94; Graffam G., 1994, GEOSCIENCE MAN, V33, P75; GROSSMAN JW, 1992, ARCHAEOLOGY, V24, P1072; Hauptmann A., 1992, ARCHAEOMATERIALS, V6, P1; HIRAO Y, 1992, ARCHAEOLOGY NATURAL, V25, P13; LECHTMAN H, 1993, TECHNOLOGIES POWER, P244; MADDIN R, 1980, J ARCHAEOL SCI, V7, P211, DOI 10.1016/S0305-4403(80)80025-2; Muhly J., 1980, COMING AGE IRON, P267; ONUKI Y, 1995, KUNTUR WASI CERRO BL, P210; PATTERSON T, 1983, INVESTIGATIONS ANDEA, P73; PETERSEN U, COMMUNICATION; PETERSEN U, 1996, MAGMATIC TECTONIC CO; Ramsey CB, 1995, RADIOCARBON, V37, P425, DOI 10.1017/S0033822200030903; RAPP G, 1988, BEGINNING USE METALS, pCH2; RYE D, COMMUNICATION; SHIMADA I, 1994, GEOSCIENCE MAN, V33, P41; SMITH CS, 1981, SEARCH STRUCTURE, P78; STULVER M, 1986, RADIOCARBON, V28, P805; THORPE SJ, 1984, MICROBEAM ANAL 1984, P227; TYLECOTE RF, 1992, HIST METALLURGY, P1; WAYMAN ML, 1985, CIM BULL, V78, P75; WAYMAN ML, 1985, CIM BULL, V78, P67	29	24	27	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1108	1111		10.1126/science.282.5391.1108	http://dx.doi.org/10.1126/science.282.5391.1108			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	136YY	9804546				2022-12-28	WOS:000076887700046
J	Rougier, P; Van Cutsem, E; Bajetta, E; Niederle, N; Possinger, K; Labianca, R; Navarro, M; Morant, R; Bleiberg, H; Wils, J; Awad, L; Herait, P; Jacques, C				Rougier, P; Van Cutsem, E; Bajetta, E; Niederle, N; Possinger, K; Labianca, R; Navarro, M; Morant, R; Bleiberg, H; Wils, J; Awad, L; Herait, P; Jacques, C			Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer	LANCET			English	Article							PHASE-II; HEPATIC METASTASES; PROGNOSTIC FACTORS; 24-HOUR INFUSION; 5-FLUOROURACIL; CARCINOMA; CHEMOTHERAPY; LEUCOVORIN	Background In phase II trials, irinotecan is active in patients with advanced colorectal cancer, but the survival and clinical benefit of irinotecan compared with second-line fluorouracil by continuous infusion is not known. Methods 267 patients who had failed to respond to first-line fluorouracil, or whose disease had progressed after treatment with first-line fluorouracil were randomly allocated irinotecan 300-350 mg/m(2) infused once every 3 weeks or fluorouracil by continuous infusion. Treatment was given until disease progression, unacceptable toxic effects, or the patient refused to continue treatment. The primary endpoint was survival, while progression-free survival, response rate, symptom-free survival, adverse events, and quality of life (QoL) were secondary endpoints. Findings 133 patients were randomly allocated irinotecan and 134 were allocated fluorouracil by continuous infusion. Patients treated with irinotecan lived for Significantly longer than patients on fluorouracil (p=0.035). Survival at 1 year was increased from 32% in the fluorouracil group to 45% in the irinotecan group. Median survival was 10.8 months in the irinotecan group and 8.5 months in the fluorouracil group. Median progression-free survival was longer with irinotecan (4.2 vs 2.9 months for irinotecan vs fluorouracil, respectively; p=0.030). The median pain-free survival was 10.3 months and 8.5 months (p=0.06) for irinotecan and fluorouracil, respectively. Both treatments were equally well tolerated. QoL was similar in both groups. Interpretation Compared with fluorouracil by continuous infusion second-line irinotecan significantly improved survival in patients with advanced colorectal cancer.	Inst Gustave Roussy, Villejuif, France; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; Natl Canc Inst, I-20133 Milan, Italy; Kliniburn Leverkusen, Leverkusen, Germany; Med Klin 2, Berlin, Germany; San Carlo Borromeo Hosp, Milan, Italy; Inst Catala Oncol, Barcelona, Spain; Kantonsspital, St Gallen, Switzerland; Inst Jules Bordet, B-1000 Brussels, Belgium; St Laurentus Hosp, Roermond, Netherlands; Rhone Poulenc Rorer, Res & Dev, Antony, France	UNICANCER; Gustave Roussy; KU Leuven; University Hospital Leuven; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Hamburg; University Medical Center Hamburg-Eppendorf; San Carlo Borromeo Hospital; Catalan Institute of Oncology; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen; Institut Jules Bordet; Sanofi-Aventis	Rougier, P (corresponding author), Hop Ambroise Pare, F-92104 Boulogne, France.		Van+Cutsem, Eric/ABE-1762-2021; Labianca, Roberto/N-1847-2016	Labianca, Roberto/0000-0001-7149-822X				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; ARDALAN B, 1991, J CLIN ONCOL, V9, P625, DOI 10.1200/JCO.1991.9.4.625; CUNNINGHAM D, 1993, EUR J CANCER, V29A, P2077, DOI 10.1016/0959-8049(93)90036-F; deGramont A, 1997, J CLIN ONCOL, V15, P808, DOI 10.1200/JCO.1997.15.2.808; DIEHR P, 1995, MED CARE, V33, pAS164; Ducreux M., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P408; FINDLAY M, 1994, ANN ONCOL, V5, P239, DOI 10.1093/oxfordjournals.annonc.a058800; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; HANSEN R, 1989, J SURG ONCOL, V40, P177, DOI 10.1002/jso.2930400309; IZZO J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P217; JAGER E, 1995, EUR J CANCER, V31, P10; KEMENY N, 1989, CANCER, V63, P742, DOI 10.1002/1097-0142(19890215)63:4<742::AID-CNCR2820630423>3.0.CO;2-T; *NORD GASTR TUM AD, 1993, J CLIN ONCOL, V10, P904; Pitot HC, 1997, J CLIN ONCOL, V15, P2910, DOI 10.1200/JCO.1997.15.8.2910; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; ROUGIER P, 1995, BRIT J SURG, V82, P1397, DOI 10.1002/bjs.1800821034; Rougier P, 1997, J CLIN ONCOL, V15, P251, DOI 10.1200/JCO.1997.15.1.251; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752; SCHMOLL HJ, 1996, IS THERE SECOND LINE; Sobrero AF, 1997, J CLIN ONCOL, V15, P368, DOI 10.1200/JCO.1997.15.1.368; VANCUTSEM E, 1997, P AN M AM SOC CLIN, V16, pA268; VONHOFF DD, 1997, P AN M AM SOC CLIN, V16, pA228; WEH HJ, 1994, ANN ONCOL, V5, P233, DOI 10.1093/oxfordjournals.annonc.a058799	23	820	834	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 31	1998	352	9138					1407	1412		10.1016/S0140-6736(98)03085-2	http://dx.doi.org/10.1016/S0140-6736(98)03085-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9807986				2022-12-28	WOS:000076719500006
J	Chen, J; Lee, KH; Steinhauer, DA; Stevens, DJ; Skehel, JJ; Wiley, DC				Chen, J; Lee, KH; Steinhauer, DA; Stevens, DJ; Skehel, JJ; Wiley, DC			Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation	CELL			English	Article							VIRUS HEMAGGLUTININ; MEMBRANE-FUSION; HYDROPHOBIC CORE; ENVELOPE GLYCOPROTEIN; ATOMIC-STRUCTURE; HIV-1 GP41; PH; ACTIVATION; INHIBITION; VIRULENCE	The membrane fusion potential of influenza HA, like many viral membrane-fusion glycoproteins, is generated by proteolytic cleavage of a biosynthetic precursor. The three-dimensional structure of ectodomain of the precursor HA0 has been determined and compared with that of cleaved HA. The cleavage site is a prominent surface loop adjacent to a novel cavity; cleavage results in structural rearrangements in which the nonpolar amino acids near the new amino terminus bury ionizable residues in the cavity that are implicated in the low-pH-induced conformational change. Amino acid insertions at the cleavage site in HAs of virulent avian viruses and those of viruses isolated from the recent severe outbreak of influenza in humans in Hong Kong would extend this surface loop, facilitating intracellular cleavage.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Childrens Hosp, Dept Med, Mol Med Lab, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Natl Inst Med Res, London NW7 1AA, England	Harvard University; Harvard University; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; MRC National Institute for Medical Research	Wiley, DC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	dcwadmin@crystal.harvard.edu						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BODIAN DL, 1993, BIOCHEMISTRY-US, V32, P2967, DOI 10.1021/bi00063a007; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DESHPANDE KL, 1987, P NATL ACAD SCI USA, V84, P36, DOI 10.1073/pnas.84.1.36; GarciaMoreno B, 1997, BIOPHYS CHEM, V64, P211, DOI 10.1016/S0301-4622(96)02238-7; GARTEN W, 1989, VIROLOGY, V172, P25, DOI 10.1016/0042-6822(89)90103-7; GERMINO J, 1984, P NATL ACAD SCI-BIOL, V81, P4692, DOI 10.1073/pnas.81.15.4692; GETHING MJ, 1989, CURR TOP MEMBR TRANS, V32, P337; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAY AJ, 1989, CONCEPTS VIRAL PATHO, V3, P361; Hoffman LR, 1997, J VIROL, V71, P8808, DOI 10.1128/JVI.71.11.8808-8820.1997; KAWAOKA Y, 1984, VIROLOGY, V139, P303, DOI 10.1016/0042-6822(84)90376-3; KAWAOKA Y, 1989, J VIROL, V63, P3296, DOI 10.1128/JVI.63.8.3296-3300.1989; KHATCHIKIAN D, 1989, NATURE, V340, P156, DOI 10.1038/340156a0; KIDO H, 1992, J BIOL CHEM, V267, P13573; Klenk H D, 1988, Adv Virus Res, V34, P247, DOI 10.1016/S0065-3527(08)60520-5; Klenk Hans-Dieter, 1994, Trends in Microbiology, V2, P39, DOI 10.1016/0966-842X(94)90123-6; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; KLENK HD, 1993, VIRUS STRATEGIES MOL, P195; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAZAROWITZ SG, 1975, VIROLOGY, V68, P440, DOI 10.1016/0042-6822(75)90285-8; MAEDA T, 1980, FEBS LETT, V122, P283, DOI 10.1016/0014-5793(80)80457-1; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; OHUCHI M, 1989, VIROLOGY, V168, P274, DOI 10.1016/0042-6822(89)90267-5; ORLICH M, 1994, VIROLOGY, V204, P462, DOI 10.1006/viro.1994.1555; Perdue ML, 1997, VIRUS RES, V49, P173, DOI 10.1016/S0168-1702(97)01468-8; ROSENTHAL PB, 1998, IN PRESS NATURE; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; Steinhauer D. A., 1992, Seminars in Virology, V3, P91; STEINHAUER DA, 1995, J VIROL, V69, P6643, DOI 10.1128/JVI.69.11.6643-6651.1995; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; STITES WE, 1991, J MOL BIOL, V221, P7, DOI 10.1016/0022-2836(91)80195-Z; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Turk D., 1992, THESIS TU MUENCHEN; VEY M, 1992, VIROLOGY, V188, P408, DOI 10.1016/0042-6822(92)90775-K; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; WATOWICH SJ, 1994, STRUCTURE, V2, P719, DOI 10.1016/S0969-2126(00)00073-3; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WEBSTER RG, 1987, CELL, V50, P665, DOI 10.1016/0092-8674(87)90321-7; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WEIS WI, 1990, EMBO J, V9, P17, DOI 10.1002/j.1460-2075.1990.tb08075.x; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; *WHO, 1998, WKLY EPIDEMIOL REC, V73, P56; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	58	379	401	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1998	95	3					409	417		10.1016/S0092-8674(00)81771-7	http://dx.doi.org/10.1016/S0092-8674(00)81771-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814710	Bronze			2022-12-28	WOS:000076789600013
J	Rudick, RA				Rudick, RA			A 29-year-old man with multiple sclerosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MAGNETIC-RESONANCE SPECTROSCOPY; APPEARING WHITE-MATTER; PLACEBO-CONTROLLED TRIAL; PROTON NMR-SPECTROSCOPY; INTERFERON-BETA; DOUBLE-BLIND; DISEASE PROGRESSION; VIRAL-INFECTIONS; IMAGING LESIONS; T-CELLS		Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Ohio State Univ, Cleveland, OH USA	Cleveland Clinic Foundation; University System of Ohio; Ohio State University	Rudick, RA (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							ALTER M, 1994, NEUROLOGY, V44, P1537; ANDERSEN O, 1993, J NEUROL, V240, P417, DOI 10.1007/BF00867354; ANDERSON DW, 1992, ANN NEUROL, V31, P333, DOI 10.1002/ana.410310317; ARNOLD DL, 1994, ANN NEUROL, V36, P76, DOI 10.1002/ana.410360115; BRUHN H, 1992, ANN NEUROL, V32, P140, DOI 10.1002/ana.410320205; Calabresi PA, 1997, ANN NEUROL, V41, P669, DOI 10.1002/ana.410410517; CANNIZZARO LA, 1994, CYTOGENET CELL GENET, V66, P244, DOI 10.1159/000133703; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; DAVIES SEC, 1995, J NEUROCHEM, V64, P742; DeStefano N, 1997, NEUROLOGY, V49, P1138, DOI 10.1212/WNL.49.4.1138; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Duquette P, 1996, NEUROLOGY, V47, P889; Durelli L, 1996, NEUROLOGY, V47, P123, DOI 10.1212/WNL.47.1.123; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; EBERS GC, 1995, NATURE, V377, P150, DOI 10.1038/377150a0; Filippi M, 1998, ANN NEUROL, V43, P809, DOI 10.1002/ana.410430616; FILIPPI M, 1994, NEUROLOGY, V44, P635, DOI 10.1212/WNL.44.4.635; Fu L, 1998, BRAIN, V121, P103, DOI 10.1093/brain/121.1.103; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; GOODKIN DE, IN PRESS NEUROLOGY; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; HUSTED CA, 1994, ANN NEUROL, V36, P157, DOI 10.1002/ana.410360207; Jacobs L D, 1995, Mult Scler, V1, P118; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; Johnson KP, 1998, NEUROLOGY, V50, P701, DOI 10.1212/WNL.50.3.701; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; KINKEL RP, 1996, CONNS CURRENT THERAP, P883; Kuokkanen S, 1996, NAT GENET, V13, P477, DOI 10.1038/ng0896-477; LAROCCA NG, 1995, NATL MULTIPLE SCLERO, P1; Leppert D, 1996, ANN NEUROL, V40, P846, DOI 10.1002/ana.410400606; LU HT, 1995, J EXP MED, V182, P1517, DOI 10.1084/jem.182.5.1517; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Matthews PM, 1996, BRAIN, V119, P715, DOI 10.1093/brain/119.3.715; McFarland H F, 1996, Mult Scler, V2, P198; MCFARLAND HF, 1992, ANN NEUROL, V32, P758, DOI 10.1002/ana.410320609; MILLAR JHD, 1967, LANCET, V2, P429; MILLIGAN NM, 1987, J NEUROL NEUROSUR PS, V50, P511, DOI 10.1136/jnnp.50.5.511; Munschauer FE, 1997, CLIN THER, V19, P868, DOI 10.1016/S0149-2918(97)80041-0; Narayana PA, 1998, ANN NEUROL, V43, P56, DOI 10.1002/ana.410430112; Narayanan S, 1997, ANN NEUROL, V41, P385, DOI 10.1002/ana.410410314; NORONHA A, 1993, J NEUROIMMUNOL, V46, P145, DOI 10.1016/0165-5728(93)90244-S; Pan JW, 1996, MAGNET RESON MED, V36, P72, DOI 10.1002/mrm.1910360113; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; Petajan JH, 1996, ANN NEUROL, V39, P432, DOI 10.1002/ana.410390405; POSER S, 1979, J NEUROL SCI, V40, P159, DOI 10.1016/0022-510X(79)90201-6; RAINE CS, 1994, J NEUROPATH EXP NEUR, V53, P328, DOI 10.1097/00005072-199407000-00002; Rep MHG, 1996, J NEUROIMMUNOL, V67, P111; Rooney WD, 1997, MULT SCLER, V3, P231, DOI 10.1177/135245859700300403; ROSE AS, 1968, NEUROLOGY, V18, P1; RUDICK RA, 1990, POSTGRAD MED, V88, P197; RUDICK RA, 1987, SEMIN NEUROL, V7, P150, DOI 10.1055/s-2008-1041415; Rudick RA, 1998, NEUROLOGY, V50, P1266, DOI 10.1212/WNL.50.5.1266; RUDICK RA, 1992, CLEV CLIN J MED, V59, P267, DOI 10.3949/ccjm.59.3.267; Rudick RA, 1997, NEW ENGL J MED, V337, P1604, DOI 10.1056/NEJM199711273372207; RUDICK RA, 1986, ARCH NEUROL-CHICAGO, V43, P578, DOI 10.1001/archneur.1986.00520060042015; RUDICK RA, IN PRESS J NEUROIMMU; RUNMARKER B, 1994, J NEUROL, V241, P597, DOI 10.1007/BF00920623; SADOVNICK AD, 1995, NEUROL CLIN, V13, P99, DOI 10.1016/S0733-8619(18)30063-X; SADOVNICK AD, 1994, ANN NEUROL, V36, pS194, DOI 10.1002/ana.410360806; Schiepers C, 1997, MULT SCLER, V3, P8, DOI 10.1177/135245859700300102; Schnorpfeil F, 1997, Electromyogr Clin Neurophysiol, V37, P207; SCHUMACHER GA, 1965, ANN NY ACAD SCI, V122, P552; SIBLEY WA, 1985, LANCET, V1, P1313; Simon JH, 1998, ANN NEUROL, V43, P79, DOI 10.1002/ana.410430114; Simon JH, 1998, NEUROLOGY, V50, pA192; Simon JH, 1997, JMRI-J MAGN RESON IM, V7, P29, DOI 10.1002/jmri.1880070106; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; Sriram S, 1998, NEUROLOGY, V50, P571, DOI 10.1212/WNL.50.2.571; STONE LA, 1995, ANN NEUROL, V37, P611, DOI 10.1002/ana.410370511; Stuve O, 1996, ANN NEUROL, V40, P853, DOI 10.1002/ana.410400607; THOMPSON AJ, 1991, ANN NEUROL, V29, P53, DOI 10.1002/ana.410290111; THOMPSON AJ, 1989, NEUROLOGY, V39, P969, DOI 10.1212/WNL.39.7.969; Tourbah A, 1996, J NEURORADIOLOGY, V23, P49; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; TRAUGOTT U, 1983, J NEUROIMMUNOL, V4, P201, DOI 10.1016/0165-5728(83)90036-X; WEINSHENKER BG, 1994, ANN NEUROL, V36, pS6, DOI 10.1002/ana.410360704; WEINSHENKER BG, 1991, BRAIN, V114, P1045, DOI 10.1093/brain/114.2.1045	78	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	1998	280	16					1432	1439		10.1001/jama.280.16.1432	http://dx.doi.org/10.1001/jama.280.16.1432			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130YA	9801004				2022-12-28	WOS:000076546900039
J	Visser, L; Stricker, B; Hoogendoorn, M; Vinks, A				Visser, L; Stricker, B; Hoogendoorn, M; Vinks, A			Do not give paraffin to packers	LANCET			English	Article									Hague Hosp Cent Pharm, NL-2504 AC The Hague, Netherlands; Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Bronovo Hosp, The Hague, Netherlands	Erasmus University Rotterdam; Haaglanden Medical Center; Bronovo Hospital	Visser, L (corresponding author), Hague Hosp Cent Pharm, POB 43100, NL-2504 AC The Hague, Netherlands.		Visser, Loes Ellen/GLS-7819-2022	Visser, Loes Ellen/0000-0002-1421-6246; Vinks, Alexander/0000-0003-4224-2967				ELLENHORN MJ, 1997, ELLENHORNS MED TOXIC, P380; LANCASHIRE MJR, 1988, BRIT MED J, V296, P1035, DOI 10.1136/bmj.296.6628.1035; WHITE N, 1988, NATURE, V335, P19, DOI 10.1038/335019a0	3	25	25	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 24	1998	352	9137					1352	1352		10.1016/S0140-6736(98)08302-0	http://dx.doi.org/10.1016/S0140-6736(98)08302-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802274				2022-12-28	WOS:000076691700014
J	Kissane, DW; Street, A; Nitschke, P				Kissane, DW; Street, A; Nitschke, P			Seven deaths in Darwin: case studies under the Rights of the Terminally Ill Act, Northern Territory, Australia	LANCET			English	Article							PHYSICIAN-ASSISTED SUICIDE; NETHERLANDS; EUTHANASIA; ATTITUDES; DESIRE; LIFE	Background During the 9 months between July, 1996, and March, 1997, the provision of euthanasia for the terminally ill was legal in the Northern Territory of Australia. Seven patients made formal use of the Rights of the Terminally III (ROTI) Act;(1) four died under the Act. We report their clinical details and the decision-making process required by the Act. Methods We taped in-depth interviews with the general practitioner who provided euthanasia. Further information was available from public texts created by patients, the media, and the coroner. Findings All seven patients had cancer, most at advanced stages. Three were socially isolated. Symptoms of depression were common. Having met criteria of the Act, some patients deferred their decision for a time before proceeding with euthanasia. Medical opinions about the terminal nature of illness differed. Interpretation Provision of opinions about the terminal nature of illness and the mental health of the patient, as required by the ROTI Act, created problematic gatekeeping roles for the doctors involved.	Univ Melbourne, Ctr Palliat Care, Kew, Vic 3101, Australia; La Trobe Univ, Sch Nursing Victoria, Bundoora, Vic 3083, Australia; Darwin Gen Practice, Darwin, NT, Australia	University of Melbourne; La Trobe University	Kissane, DW (corresponding author), Univ Melbourne, Ctr Palliat Care, 104 Studley Pk Rd, Kew, Vic 3101, Australia.		Street, Annette/I-5188-2012	Street, Annette/0000-0002-5376-8588; Kissane, David/0000-0002-5930-4573				Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; DENT RB, 1997, COMMUNICATION   0921; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Ganzini L, 1996, AM J PSYCHIAT, V153, P1469; Hooper SC, 1996, MED J AUSTRALIA, V165, P416, DOI 10.5694/j.1326-5377.1996.tb138576.x; MCCARTHY M, 1994, LANCET, V344, P1494; MCLAUGHLN M, 1996, ROAD NOWHERE; MILLS J, 1997, COMMUNICATION   0101; Owen C., 1994, PSYCHO-ONCOLOGY, V3, P1, DOI [10.1002/pon.2960030103, DOI 10.1002/PON.2960030103]; Owen C., 1992, PSYCHO-ONCOLOGY, V1, P79, DOI [10.1002/pon.2960010205, DOI 10.1002/PON.2960010205]; RYAN C, 1996, AUSTRALAS PSYCHIATRY, V4, P307; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; WILKINSON P, 1995, EUTHANASIA	17	110	110	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 3	1998	352	9134					1097	1102		10.1016/S0140-6736(98)05406-3	http://dx.doi.org/10.1016/S0140-6736(98)05406-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798585				2022-12-28	WOS:000076246400010
J	Godber, G				Godber, G			The hospital surveys, 1942-44	LANCET			English	Editorial Material											Godber, G (corresponding author), 21 Almoners Ave, Cambridge CB1 4NZ, England.								0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					49	50		10.1016/S0140-6736(98)02245-4	http://dx.doi.org/10.1016/S0140-6736(98)02245-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800762				2022-12-28	WOS:000074608600045
J	Pouria, S; de Andrade, A; Barbosa, J; Cavalcanti, RL; Barreto, VTS; Ward, CJ; Preiser, W; Poon, GK; Neild, GH; Codd, GA				Pouria, S; de Andrade, A; Barbosa, J; Cavalcanti, RL; Barreto, VTS; Ward, CJ; Preiser, W; Poon, GK; Neild, GH; Codd, GA			Fatal microcystin intoxication in haemodialysis unit in Caruaru, Brazil	LANCET			English	Article							CYANOBACTERIAL TOXINS	Background After a drought in February, 1996, all 126 patients in a haemodialysis unit in Caruaru, north-east Brazil, developed signs and symptoms of acute neurotoxicity and subacute hepatotoxicity following the use of water from a lake with massive growth of cyanobacteria (blue-green algae). 60 patients died. Methods Besides recording clinical details and outcome at follow-up, we arranged laboratory, radiological, and histological investigations on the patients and toxicological studies of serum and haemodialysis water filters. Findings The acute presentation was with malaise, myalgia and weakness, nausea and vomiting, and tender hepatomegaly, with a range of neurological symptoms from tinnitus, vertigo, headaches, and deafness to blindness and convulsions. Liver injury ranged from abnormal liver-function test results to rapidly progressive and fatal hepatic failure, Biochemical investigations revealed gross hyperbilirubinaemia, abnormal liver enzyme activities, and hypertriglyceridaemia, but there was no evidence of haemolysis or microangiopathy. Histology revealed a novel acute toxic hepatitis with diffuse panlobular hepatocyte necrosis, neutrophil infiltration, canalicular cholestasis, and regenerative multinucleate hepatocytes. Samples of serum, dialysis filters, and water-treatment columns contained microcystins, the highly toxic low-molecular-weight hepatotoxins produced by cyanobacteria. Interpretation Cyanobacteria present water-borne hazards to health via drinking water and recreational water. Haemodialysis presents an additional high-risk exposure route: when they enter directly into the circulation, microcystins can lead to fatal clinical syndromes ranging from acute neurotoxic illness to subacute liver failure.	UCL, Sch Med, Inst Urol & Nephrol, London W1N 8AA, England; Univ Fed Pernambuco, Hosp Clin, Recife, PE, Brazil; Hosp Barao Lucena, Recife, PE, Brazil; Univ Dundee, Dept Biol Sci, Dundee DD1 4HN, Scotland; UCL, Sch Med, Dept Virol, London W1N 8AA, England; Adv Bioanalyt Serv Inc, Ithaca, NY USA	University of London; University College London; UCL Medical School; Universidade Federal de Pernambuco; University of Dundee; University of London; University College London; UCL Medical School	Neild, GH (corresponding author), Middlesex Hosp, Inst Urol & Nephrol, London W1N 8AA, England.	g.neild@ucl.ac.uk	Neild, Guy/K-2513-2013; Preiser, Wolfgang/J-4875-2016	Preiser, Wolfgang/0000-0002-0254-7910; ward, clive/0000-0001-7093-5109				AZEVEDO SMF, 1996, P 4 S BRAZ SOC TOX, P83; BARRETO V, 1996, HEPATOLOGY S, V24, P2; CARMICHAEL WW, 1985, CRIT REV ENV CONTR, V15, P275, DOI 10.1080/10643388509381734; Carmichael WW, 1996, HARMFUL ALGAE NEWS, V15, P11; CARMICHAEL WW, 1996, P 4 S BRAZ SOC TOX, P83; Codd GA, 1995, WATER SCI TECHNOL, V32, P149, DOI 10.1016/0273-1223(95)00692-3; CODD GA, 1996, PROGR RES 4 S SOC BR, P87; Codd GA., 1994, REV MED MICROBIOL, V5, P256, DOI [DOI 10.1097/00013542-199410000-00005, 10.1097/00013542-199410000-00005]; ELDER GH, 1993, LANCET, V341, P1519, DOI 10.1016/0140-6736(93)90643-U; FALCONER IR, 1983, MED J AUSTRALIA, V1, P511, DOI 10.5694/j.1326-5377.1983.tb136192.x; JACKSON ARB, 1984, VET PATHOL, V21, P102, DOI 10.1177/030098588402100117; Jochimsen EM, 1998, NEW ENGL J MED, V338, P873, DOI 10.1056/NEJM199803263381304; Lawton Linda A., 1995, Natural Toxins, V3, P50, DOI 10.1002/nt.2620030110; POON GK, 1993, J CHROMATOGR, V628, P215, DOI 10.1016/0021-9673(93)80005-S; Sivonen Kaarina, 1996, Phycologia, V35, P12, DOI 10.2216/i0031-8884-35-6S-12.1; TURNER PC, 1990, BRIT MED J, V300, P1440, DOI 10.1136/bmj.300.6737.1440; Ueno Y, 1996, CARCINOGENESIS, V17, P1317, DOI 10.1093/carcin/17.6.1317; Ward CJ, 1997, FEMS MICROBIOL LETT, V153, P465, DOI 10.1016/S0378-1097(97)00290-5; *WHO, 1997, WORK M CHEM SUBST DR; YU SZ, 1997, PRIMARY LIVER CANC, P30	20	572	641	6	130	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					21	26		10.1016/S0140-6736(97)12285-1	http://dx.doi.org/10.1016/S0140-6736(97)12285-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800741				2022-12-28	WOS:000074608600012
J	Lucas, A; Morley, R; Cole, TJ				Lucas, A; Morley, R; Cole, TJ			Randomised trial of early diet in preterm babies and later intelligence quotient	BRITISH MEDICAL JOURNAL			English	Article							BREAST-MILK; CHILDREN; SUPPLEMENTATION; STIMULATION; JAMAICAN; INFANTS; WEIGHT	Objectives To determine whether perinatal nutrition influences cognitive function at 71/2-8 years in children born preterm. Design Randomised, blinded nutritional intervention trial. Blinded follow up at 71/2-8 years. Setting Intervention phase in two neonatal units; follow up in a clinic or school setting. Subjects 424 preterm infants who weighed under 1850 g at birth; 360 of those who survived were tested at 71/2-8 years. Interventions Standard infant formula versus nutrient enriched preterm formula randomly assigned as sole diet (trial A) or supplements to maternal milk (trial B) fed for a mean of 1 month. Main outcome measures Intelligence quotient (IQ) at 71/2-8 years with abbreviated Weschler intelligence scale for children (revised). Results There was a major sex difference in the impact of diet. At 71/2-8 years boys previously fed standard versus preterm formula as sole diet had a 12.2 point disadvantage (95% confidence interval 3.7 to 20.6; P < 0.01 in verbal IQ. In those with highest intakes of trial diets corresponding figures were 9.5 point disadvantage and 14.4 point disadvantage in overall IQ (1.2 to 17.7; P < 0.05) and verbal IQ (5.7 to 23.2; P < 0.01). Consequently, more infants fed term formula had low verbal IQ(< 85): 31% versus 14% for both sexes (P = 0.02) and 47% versus 13% in boys P = 0.009). There was a higher incidence of cerebral palsy in chose fed term formula; exclusion of such children did not alter the findings. Conclusions Preterm infants are vulnerable to suboptimal early nutrition in terms of their cognitive performance-notably, language based skills-at 71/2-8 years, when cognitive scores are highly predictive of adult ones. Our data on cerebral palsy generate a new hypothesis that suboptimal nutritional management during a critical or plastic early period of rapid brain growth could impair functional compensation in those sustaining an earlier brain insult. Cognitive function, notably in males, may be permanently impaired by suboptimal neonatal nutrition.	Inst Child Hlth, MRC, Childhood Nutr Res Ctr, Clin Trials Grp, London WC1N 1EH, England; MRC, Dunn Nutr Unit, Cambridge CB4 1XJ, England	University of London; University College London	Lucas, A (corresponding author), Inst Child Hlth, MRC, Childhood Nutr Res Ctr, Clin Trials Grp, 30 Guilford St, London WC1N 1EH, England.	A.Lucas@ich.ucl.ac.uk	Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200				COOKE RWI, 1977, EARLY HUM DEV, V1, P145, DOI 10.1016/0378-3782(77)90015-9; Cronbach LJ, 1990, ESSENTIALS PSYCHOL T, P284; Dobbing J., 1981, MOL BASIS NEUROPATHO, P221; FITZHARDINGE PM, 1972, PEDIATRICS, V50, P50; GARDNER JMM, 1994, P NUTR SOC, V53, P241, DOI 10.1079/PNS19940025; Grantham-McGregor S., 1987, Early nutrition and later achievement, P128; GranthamMcGregor SM, 1997, AM J CLIN NUTR, V66, P247, DOI 10.1093/ajcn/66.2.247; GRANTHAMMCGREGOR SM, 1991, LANCET, V338, P1, DOI 10.1016/0140-6736(91)90001-6; HUSAINI MA, 1991, AM J CLIN NUTR, V54, P799, DOI 10.1093/ajcn/54.5.799; Katz H. B., 1980, Nutrition Abstracts and Reviews, A and B, V50, P767; KOLB B, 1990, FUNDAMENTALS NEUROPS, P679; LUCAS A, 1989, ARCH DIS CHILD, V64, P1570, DOI 10.1136/adc.64.11.1570; LUCAS A, 1984, ARCH DIS CHILD, V59, P722, DOI 10.1136/adc.59.8.722; LUCAS A, 1991, CIBA F SYMP, V156, P38; LUCAS A, 1990, LANCET, V335, P1477, DOI 10.1016/0140-6736(90)93026-L; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; MCCALL RB, 1979, HDB INFANT DEV, P707; McNemar Q, 1974, J CONSULT CLIN PSYCH, V42, P145, DOI DOI 10.1037/H0035842; MORLEY R, 1988, ARCH DIS CHILD, V63, P1382, DOI 10.1136/adc.63.11.1382; POLLITT E, 1993, MONOGR SOC RES CHILD, P58; *PSYCH CORP, 1974, PWECHSL INT SCAL CHI; RICHARDSON SA, 1976, PEDIATR RES, V10, P57, DOI 10.1203/00006450-197601000-00011; SMART JL, 1993, P NUTR SOC, V52, P189, DOI 10.1079/PNS19930051; SMART JL, 1977, GENETICS ENV INTELLI, P215; SMART JL, 1986, P 13 C NUTR, P74; [No title captured]	26	453	480	0	24	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1481	1487		10.1136/bmj.317.7171.1481	http://dx.doi.org/10.1136/bmj.317.7171.1481			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831573	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000077338300022
J	Qian, YW; Erikson, E; Maller, JL				Qian, YW; Erikson, E; Maller, JL			Purification and cloning of a protein kinase that phosphorylates and activates the polo-like kinase Plx1	SCIENCE			English	Article							CDC25 PROTEIN; CELL-CYCLE; DNA-REPLICATION; PHOSPHATASE; XENOPUS; EXTRACTS; MITOSIS; CENTROSOME; INITIATION; P34CDC2	The Xenopus polo-like kinase 1 (Plx1) is essential during mitosis for the activation of Cdc25C, for spindle assembly, and for cyclin B degradation. Polo-Like kinases from various organisms are activated by phosphorylation by an unidentified protein kinase. A protein kinase, polo-like kinase kinase 1 or xPlkk1, that phosphorylates and activates Plx1 in vitro was purified to near homogeneity and cloned. Phosphopeptide mapping of Plx1 phosphorylated in vitro by recombinant xPlkk1 or in progesterone-treated oocytes indicates that xPlkk1 may activate Plx1 in vivo. The xPlkk1 protein itself was also activated by phosphorylation on serine and threonine residues, and the kinetics of activation of xPlkk1 in vivo closely paralleled the activation of Plx1. Moreover, microinjection of xPlkk1 into Xenopus oocytes accelerated the timing of activation of Plx1 and the transition from G(2) to M phase of the cell cycle. These results define a protein kinase cascade that regulates several events of mitosis.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA.				NCI NIH HHS [CA46934] Funding Source: Medline; NIGMS NIH HHS [GM26743] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BoucksonCastaing V, 1996, J CELL SCI, V109, P179; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Murphy SM, 1998, J CELL BIOL, V141, P663, DOI 10.1083/jcb.141.3.663; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; QIAN Y, UNPUB; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; YAMASHITA K, 1990, EMBO J, V9, P331	27	106	111	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1701	1704		10.1126/science.282.5394.1701	http://dx.doi.org/10.1126/science.282.5394.1701			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831560				2022-12-28	WOS:000077246600045
J	Lambert, TW; Goldacre, MJ				Lambert, TW; Goldacre, MJ			Career destinations seven years on among doctors who qualified in the United Kingdom in 1988: postal questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							ASCERTAINMENT; PREVALENCE	Objective To report the career choices and career destinations in 1995 of doctors who qualified in the United Kingdom in 1988. Design Postal questionnaire. Setting United Kingdom. Subjects All doctors who qualified in the United Kingdom in 1988. Main outcome measures Current employment. Results Of the 3724 doctors who were sent questionnaires, eight had died and three declined to participate. Of the remaining 3713 doctors, 2885 (77.7%) replied. 16.9% (608/3593; 95% confidence interval 16.1% to 17.8%) of all 1988 qualifiers from medical schools in Great Britain were not working in the NHS in Great Britain in 1995 compared with 17.0% (624/3674; 16.1% to 17.9%) of the 1983 cohort in 1990. The proportion of doctors working in general practice was lower than in previous cohorts. The percentage of women in general practice (44.3% (528/1192)) substantially exceeded that of men (33.1% (443/1340)). 53% (276/522) of the women in general practice and 20% (98/490) of the women in hospital specialties worked part time. Conclusions Concerns about recruitment difficulties in general practice are justified. Women are now entering general practice in greater numbers than men. There is no evidence of a greater exodus from the NHS from the 1988 qualifiers than from earlier cohorts.	Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, UK Med Careers Res Grp, Oxford OX3 7LF, England	University of Oxford	Lambert, TW (corresponding author), Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, UK Med Careers Res Grp, Oxford OX3 7LF, England.			Lambert, Trevor/0000-0001-9688-3036				HOOK EB, 1993, AM J EPIDEMIOL, V137, P1148, DOI 10.1093/oxfordjournals.aje.a116618; HOOK EB, 1992, AM J EPIDEMIOL, V135, P1060, DOI 10.1093/oxfordjournals.aje.a116400; Lambert TW, 1996, BRIT MED J, V313, P19, DOI 10.1136/bmj.313.7048.19; Lambert TW, 1996, BRIT MED J, V312, P893; Medical Workforce Standing Advisory Committee, 1997, 3 DEP HLTH MED WORKF; PARKHOUSE J, 1991, DOCTORS CAREERS AIMS	6	30	30	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1429	1431		10.1136/bmj.317.7170.1429	http://dx.doi.org/10.1136/bmj.317.7170.1429			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822396	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000077202200023
J	Smith, S; Giriat, I; Schmitt, A; de Lange, T				Smith, S; Giriat, I; Schmitt, A; de Lange, T			Tankyrase, a poly(ADP-ribose) polymerase at human telomeres	SCIENCE			English	Article							PROTEINS; TRF1; REPEATS; SITE; DNA	Tankyrase, a protein with homology to ankyrins and to the catalytic domain of poly(adenosine diphosphate-ribose) polymerase (PARP), was identified and localized to human telomeres. Tankyrase binds to the telomeric protein TRF1 (telomeric repeat binding factor-1), a negative regulator of telomere Length maintenance. Like ankyrins, tankyrase contains 24 ankyrin repeats in a domain responsible for its interaction with TRF1. Recombinant tankyrase was found to have PARP activity in vitro, with both TRF1 and tankyrase functioning as accepters for adenosine diphosphate (ADP)-ribosylation. ADP-ribosylation of TRF1 diminished its ability to bind to telomeric DNA in vitro, suggesting that telomere function in human cells is regulated by poly(ADP-ribosyl)ation.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	delange@rockvax.rockefeller.edu	de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X; Smith, Susan/0000-0002-8213-5915	NCI NIH HHS [CA76027] Funding Source: Medline; NIGMS NIH HHS [GM49046] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076027] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049046, R01GM049046] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; BENNETT V, 1992, J BIOL CHEM, V267, P8703; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DOMENIGHINI M, 1994, MOL MICROBIOL, V14, P41, DOI 10.1111/j.1365-2958.1994.tb01265.x; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Oei SL, 1998, BIOCHEMISTRY-US, V37, P1465, DOI 10.1021/bi9727390; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; PURNELL MR, 1980, BIOCHEM J, V185, P775, DOI 10.1042/bj1850775; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; SIMONIN F, 1993, J BIOL CHEM, V268, P8529; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	20	851	910	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1484	1487		10.1126/science.282.5393.1484	http://dx.doi.org/10.1126/science.282.5393.1484			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822378				2022-12-28	WOS:000077110800053
J	Coffey, MC; Strong, JE; Forsyth, PA; Lee, PWK				Coffey, MC; Strong, JE; Forsyth, PA; Lee, PWK			Reovirus therapy of tumors with activated Ras pathway	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; DIFFERENTIAL REGULATION; MESSENGER-RNA; EXPRESSION; CELLS; AMPLIFICATION; AUTOCRINE; INFECTION; CANCER; GENE	Human reovirus requires an activated Res signaling pathway far infection of cultured cells. To investigate whether this property can be exploited for cancer therapy, severe combined immune deficient mice bearing tumors established from v-erbB-transformed murine NIH 3T3 cells or human U87 glioblastoma cells were treated with the virus. A single intratumoral injection of virus resulted in regression of tumors in 65 to 80 percent of the mice. Treatment of immune-competent C3H mice bearing tumors established from ras-transformed C3H-10T1/2 cells also resulted in tumor regression, although a series of injections were required. These results suggest that, with further work, reovirus may have applicability in the treatment of cancer.	Univ Calgary, Hlth Sci Ctr, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Hlth Sci Ctr, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada; Univ Calgary, Hlth Sci Ctr, Dept Oncol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Lee, PWK (corresponding author), Univ Calgary, Hlth Sci Ctr, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada.							Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BOS JL, 1989, CANCER RES, V49, P4682; Chase M, 1998, NAT BIOTECHNOL, V16, P444, DOI 10.1038/nbt0598-444; COFFEY MW, UNPUB; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; HERMANSON M, 1992, CANCER RES, V52, P3213; LECO KJ, 1992, GENE, V117, P209, DOI 10.1016/0378-1119(92)90731-4; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LORENCE RM, 1994, CANCER RES, V54, P6017; LOWE PN, 1994, CELL SIGNAL, V6, P109, DOI 10.1016/0898-6568(94)90067-1; MAMAJIWALLA SN, 1995, ONCOGENE, V11, P377; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7729; NISTER M, 1991, J BIOL CHEM, V266, P16755; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SHERRY B, 1993, J VIROL, V67, P6119, DOI 10.1128/JVI.67.10.6119-6124.1993; STECK PA, 1988, CANCER RES, V48, P5433; Strong JE, 1996, J VIROL, V70, P612, DOI 10.1128/JVI.70.1.612-616.1996; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; STRONG JE, 1993, VIROLOGY, V197, P405, DOI 10.1006/viro.1993.1602; TYLER KL, 1996, FIELDS VIROLOGY, P1597; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899	25	618	674	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1332	1334		10.1126/science.282.5392.1332	http://dx.doi.org/10.1126/science.282.5392.1332			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812900				2022-12-28	WOS:000076982200049
J	Mitchell, TB; Bollinger, JJ; Dubin, DHE; Huang, XP; Itano, WM; Baughman, RH				Mitchell, TB; Bollinger, JJ; Dubin, DHE; Huang, XP; Itano, WM; Baughman, RH			Direct observations of structural phase transitions in planar crystallized ion plasmas	SCIENCE			English	Article							QUADRUPOLE STORAGE RING; LASER-COOLED IONS; WIGNER-CRYSTAL; SYSTEMS	Laser-cooled Be-9(+) ions confined in two-dimensionally extended Lattice planes were directly observed, and the images were used to characterize the structural phases of the ions. Five different stable crystalline phases were observed, and the energetically favored structure could be sensitively tuned by changing the areal density of the confined ions. The experimental results are in good agreement with theoretical predictions for the planar (infinite in two dimensions) one-component plasma. Qualitatively similar structural phase transitions occur, or are predicted to occur, in other experimentally realizable planar systems.	Natl Inst Stand & Technol, Div Time & Frequency, Boulder, CO 80303 USA; Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA; Allied Signal Inc, Res & Technol, Morristown, NJ 07962 USA	National Institute of Standards & Technology (NIST) - USA; University of California System; University of California San Diego	Mitchell, TB (corresponding author), Natl Inst Stand & Technol, Div Time & Frequency, Boulder, CO 80303 USA.	travis.mitchell@nist.gov	Itano, Wayne/AAV-8781-2020; Baughman, Ray Henry/A-8628-2018	Baughman, Ray Henry/0000-0001-5845-5137				Baughman RH, 1998, NATURE, V392, P362, DOI 10.1038/32842; BIRKL G, 1992, NATURE, V357, P310, DOI 10.1038/357310a0; BREWER LR, 1988, PHYS REV A, V38, P859, DOI 10.1103/PhysRevA.38.859; DIEDRICH F, 1987, PHYS REV LETT, V59, P2931, DOI 10.1103/PhysRevLett.59.2931; Drewsen M, 1998, PHYS REV LETT, V81, P2878, DOI 10.1103/PhysRevLett.81.2878; DUBIN DHE, 1990, PHYS REV A, V42, P4972, DOI 10.1103/PhysRevA.42.4972; Ghosh P K, 1995, ION TRAPS; GILBERT SL, 1987, PHYS REV LETT, V59, P2022; Goldoni G, 1996, PHYS REV B, V53, P4591, DOI 10.1103/PhysRevB.53.4591; GRIMES CC, 1979, PHYS REV LETT, V42, P795, DOI 10.1103/PhysRevLett.42.795; Huang XP, 1998, PHYS REV LETT, V80, P73, DOI 10.1103/PhysRevLett.80.73; Huang XP, 1998, PHYS PLASMAS, V5, P1656, DOI 10.1063/1.872834; ICHIMARU S, 1987, PHYS REP, V149, P91, DOI 10.1016/0370-1573(87)90125-6; Itano WM, 1998, SCIENCE, V279, P686, DOI 10.1126/science.279.5351.686; LAKES R, 1987, SCIENCE, V235, P1038, DOI 10.1126/science.235.4792.1038; Mitchell T., UNPUB; NARASIMHAN S, 1995, PHYS REV B, V52, P12291, DOI 10.1103/PhysRevB.52.12291; O'Neil TM, 1998, PHYS PLASMAS, V5, P2163, DOI 10.1063/1.872925; ONEIL TM, 1981, PHYS FLUIDS, V24, P1447, DOI 10.1063/1.863565; Pieper JB, 1996, J VAC SCI TECHNOL A, V14, P519, DOI 10.1116/1.580118; RAFAC R, 1991, P NATL ACAD SCI USA, V88, P483, DOI 10.1073/pnas.88.2.483; RAHMAN A, 1986, PHYS REV LETT, V57, P1133, DOI 10.1103/PhysRevLett.57.1133; ROBERSON CW, 1988, NONNEUTRAL PLASMA PH; SCHIFFER JP, 1993, PHYS REV LETT, V70, P818, DOI 10.1103/PhysRevLett.70.818; Schmidt M, 1997, PHYS REV E, V55, P7228, DOI 10.1103/PhysRevE.55.7228; TAN JN, 1995, PHYS REV LETT, V75, P4198, DOI 10.1103/PhysRevLett.75.4198; Valtchinov VI, 1997, PHYS REV E, V56, P4351, DOI 10.1103/PhysRevE.56.4351; VANHORN HM, 1991, SCIENCE, V252, P384, DOI 10.1126/science.252.5004.384; VANWINKLE DH, 1986, PHYS REV A, V34, P562, DOI 10.1103/PhysRevA.34.562; WAKI I, 1992, PHYS REV LETT, V68, P2007, DOI 10.1103/PhysRevLett.68.2007; WINELAND DJ, 1978, PHYS REV LETT, V40, P1639, DOI 10.1103/PhysRevLett.40.1639; WINELAND DJ, 1987, PHYS REV LETT, V59, P2935, DOI 10.1103/PhysRevLett.59.2935	32	186	186	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1290	1293		10.1126/science.282.5392.1290	http://dx.doi.org/10.1126/science.282.5392.1290			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812887	Green Submitted			2022-12-28	WOS:000076982200036
J	Rebolo, R; Osorio, MRZ; Madruga, S; Bejar, VJS; Arribas, S; Licandro, J				Rebolo, R; Osorio, MRZ; Madruga, S; Bejar, VJS; Arribas, S; Licandro, J			Discovery of a low-mass brown dwarf companion of the young nearby star G 196-3	SCIENCE			English	Article							SEQUENCE; CANDIDATES; EMISSION; PLEIADES; TRACKS; FIELD; DENIS	A substellar-mass object in orbit at about 300 astronomical units from the young low-mass star G 196-3 was detected by direct imaging. Optical and infrared photometry and low- and intermediate-resolution spectroscopy of the faint companion, hereafter referred to as G 196-3B, confirm its cool atmosphere and allow its mass to be estimated at 25(-10)(+15) Jupiter masses. The separation between the objects and their mass ratio suggest the fragmentation of a collapsing cloud as the most Likely origin for G 196-3B, but alternatively it could have originated from a protoplanetary disc that has been dissipated. Whatever the formation process was, the young age of the primary star (about 100 million years) demonstrates that substellar companions can form on short time scales.	Inst Astrofis Canarias, E-38200 Tenerife, Canary Islands, Spain	Instituto de Astrofisica de Canarias	Rebolo, R (corresponding author), Inst Astrofis Canarias, E-38200 Tenerife, Canary Islands, Spain.		Arribas, Santiago/F-9277-2015; Rebolo, Rafael/S-1563-2019; Licandro, Javier/L-7667-2014; Zapatero Osorio, Maria Rosa/C-2744-2017; Béjar, Victor J. Sánchez/AAA-2094-2019; Madruga, Santiago/I-2085-2015	Arribas, Santiago/0000-0001-7997-1640; Licandro, Javier/0000-0002-9214-337X; Zapatero Osorio, Maria Rosa/0000-0001-5664-2852; Béjar, Victor J. Sánchez/0000-0002-5086-4232; Madruga, Santiago/0000-0002-9996-1287; Rebolo, Rafael/0000-0003-3767-7085				Artymowicz P, 1998, ASTR SOC P, V134, P152; Baraffe I, 1998, ASTRON ASTROPHYS, V337, P403; BARAFFE I, 1995, ASTROPHYS J, V446, pL35, DOI 10.1086/187924; BASRI G, IN PRESS ASTROPHYS J; BEICHMAN C, 1998, VER LOW MASS STARS B; Bessell MS, 1998, ASTRON ASTROPHYS, V333, P231; Bodenheimer P, 1998, ASTR SOC P, V134, P115; BRUHWEILER F, 1997, B AM ASTRON SOC, V191; Burrows A, 1997, ASTROPHYS J, V491, P856, DOI 10.1086/305002; Burrows A, 1998, ASTR SOC P, V134, P354; CHABRIER G, 1996, IN PRESS ASTROPHYS J, V459, pL91; DANTONA F, 1994, ASTROPHYS J SUPPL S, V90, P467, DOI 10.1086/191867; Delfosse X, 1997, ASTRON ASTROPHYS, V327, pL25; HEMPELMANN A, 1995, ASTRON ASTROPHYS, V294, P515; KIRKPATRICK D, IN PRESS ASTROPHYS J; Lampton M, 1997, ASTROPHYS J SUPPL S, V108, P545, DOI 10.1086/312965; Marcy G, 1998, NATURE, V391, P127, DOI 10.1038/34298; MARTIN EL, 1994, ASTROPHYS J, V436, P262, DOI 10.1086/174900; Martin EL, 1997, ASTRON ASTROPHYS, V327, pL29; Martin EL, 1996, ASTROPHYS J, V469, P706, DOI 10.1086/177817; MARTIN EL, 1998, IN PRESS ASTROPHYS J, V499, P661; NAKAJIMA T, 1995, NATURE, V378, P463, DOI 10.1038/378463a0; Oppenheimer BR, 1998, ASTROPHYS J, V502, P932, DOI 10.1086/305928; OPPENHEIMER BR, 1995, SCIENCE, V270, P1478, DOI 10.1126/science.270.5241.1478; PAVLENKO YV, 1998, VERY LOW MASS STARS; Polomski E, 1997, ASTROPHYS J, V486, P179, DOI 10.1086/304495; PROSSER CF, 1991, ASTRON J, V101, P1361, DOI 10.1086/115772; Randich S, 1996, ASTRON ASTROPHYS, V305, P785; RUIZ MR, 1997, IN PRESS ASTROPHYS J, V491, pL107; Saumon D, 1996, ASTROPHYS J, V460, P993, DOI 10.1086/177027; Schultz AB, 1998, ASTROPHYS J, V492, pL181, DOI 10.1086/311103; TINNEY CG, IN PRESS ASTRON ASTR	33	136	136	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1309	1312		10.1126/science.282.5392.1309	http://dx.doi.org/10.1126/science.282.5392.1309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812893				2022-12-28	WOS:000076982200042
J	Tucker, AS; Matthews, KL; Sharpe, PT				Tucker, AS; Matthews, KL; Sharpe, PT			Transformation of tooth type induced by inhibition of BMP signaling	SCIENCE			English	Article							TISSUES; HOX11; GENE	Mammalian dentitions are highly patterned, with different types of teeth positioned in different regions of the jaws. BMP4 is an early oral epithelial protein signal that directs odontogenic gene expression in mesenchyme cells of the developing mandibular arch, BMP4 was shown to inhibit expression of the homeobox gene Barx-1 and to restrict expression to the proximal, presumptive molar mesenchyme of mouse embryos at embryonic day 10, The inhibition of BMP signaling early in mandible development by the action of exogenous Noggin protein resulted in ectopic Barx-1 expression in the distal, presumptive incisor mesenchyme and a transformation of tooth identity from incisor to molar.	Guys Kings & St Thomas Sch Dent, Guys Hosp, Dept Craniofacial Dev, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Sharpe, PT (corresponding author), Guys Kings & St Thomas Sch Dent, Guys Hosp, Dept Craniofacial Dev, London SE1 9RT, England.		Tucker, Abigail S/K-1788-2016	Tucker, Abigail S/0000-0001-8871-6094; Sharpe, Paul/0000-0003-2116-9561	Medical Research Council [G9800001] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		DEAR TN, 1995, DEVELOPMENT, V121, P2909; Ferguson CA, 1998, GENE DEV, V12, P2636, DOI 10.1101/gad.12.16.2636; Grigoriou M, 1998, DEVELOPMENT, V125, P2063; Houzelstein D, 1997, MECH DEVELOP, V65, P123, DOI 10.1016/S0925-4773(97)00065-8; Kantaputra P N, 1992, Clin Dysmorphol, V1, P128; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; RAJU K, 1993, MECH DEVELOP, V44, P51, DOI 10.1016/0925-4773(93)90016-Q; Thomas BL, 1998, EUR J ORAL SCI, V106, P48, DOI 10.1111/j.1600-0722.1998.tb02153.x; Thomas BL, 1997, DEVELOPMENT, V124, P4811; TISSIERSETA JP, 1995, MECH DEVELOP, V51, P3, DOI 10.1016/0925-4773(94)00343-L; Tucker AS, 1998, DEV DYNAM, V212, P533, DOI 10.1002/(SICI)1097-0177(199808)212:4<533::AID-AJA6>3.3.CO;2-I; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	14	333	356	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1136	1138		10.1126/science.282.5391.1136	http://dx.doi.org/10.1126/science.282.5391.1136			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804553				2022-12-28	WOS:000076887700053
J	Cunningham, D; Pyrhonen, S; James, RD; Punt, CJA; Hickish, TF; Heikkila, R; Johannesen, TB; Starkhammar, H; Topham, CA; Awad, L; Jacques, C; Herait, P				Cunningham, D; Pyrhonen, S; James, RD; Punt, CJA; Hickish, TF; Heikkila, R; Johannesen, TB; Starkhammar, H; Topham, CA; Awad, L; Jacques, C; Herait, P			Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer	LANCET			English	Article							QUALITY-OF-LIFE; PHASE-II TRIAL; HEPATIC METASTASES; CHEMOTHERAPY	Background In phase II studies, irinotecan is active in metastatic colorectal cancer, but the overall benefit has not been assessed in a randomised clinical trial. Methods Patients with proven metastatic colorectal cancer, which had progressed within 6 months of treatment with fluorouracil, were randomly assigned either 300-350 mg/m(2) irinotecan every 3 weeks with supportive care or supportive care alone, in a 2:1 ratio. Findings 189 patients were allocated irinotecan and supportive care and 90 supportive care alone. The mean age of the participants was 58.8 years; 181 (65%) were men and 98 (35%) were women. WHO performance status was 0 in 79 (42%) patients, 1 in 77 (41%) patients, and 2 in 32 (17%) patients. Tumour-related symptoms were present in 134 (71%) patients and weight loss of more than 5% was seen in 15 (8%) patients. With a median follow-up of 13 months, the overall survival was significantly better in the irinotecan group (p=0.0001), with 36.2% 1-year survival in the irinotecan group versus 13.8% in the supportive-care group. The survival benefit, adjusted for prognostic factors in a multivariate analysis, remained significant (p=0.001), Survival without performance-status deterioration (p=0.0001), without weight loss of more than 5% (p=0.018), and pain-free survival (p=0.003) were significantly better in the patients given irinotecan. In a quality-of-life analysis, all significant differences, except on diarrhoea score, were in favour of the irinotecan group. Interpretation Our study shows that despite the side-effects of treatment, patients who have metastatic colorectal cancer, and for whom fluorouracil has failed, have a longer survival, fewer tumour-related symptoms, and a better quality of life when treated with irinotecan than with supportive care alone.	Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England; Royal Marsden Hosp Chelsea, London, England; Univ Helsinki Hosp, Helsinki, Finland; Christie Hosp, Manchester, Lancs, England; Univ Nijmegen Hosp, NL-6500 HB Nijmegen, Netherlands; Royal Bournemouth Hosp, Dorset, England; Poole Hosp, Dorset, England; Cent Hosp Rogaland, Stavanger, Norway; Univ Tromso Hosp, N-9012 Tromso, Norway; Linkoping Univ Hosp, S-58185 Linkoping, Sweden; St Lukes Hosp, Guildford, Surrey, England; Rhone Poulenc Rorer, Res & Dev, Antony, France	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of Helsinki; Helsinki University Central Hospital; Christie NHS Foundation Trust; Christie Hospital; Radboud University Nijmegen; Poole Hospital; UiT The Arctic University of Tromso; University Hospital of North Norway; Linkoping University; Sanofi-Aventis	Cunningham, D (corresponding author), Royal Marsden Hosp, Dept Med, Downs Rd, Sutton SM2 5PT, Surrey, England.			Cunningham, David/0000-0001-5158-1069; Hickish, Tamas/0000-0001-6770-7279				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; COHEN AM, 1997, CANC PRINCIPLES PRAC, P1145; CREEMERS GJ, 1994, CANCER TREAT REV, V20, P73, DOI 10.1016/0305-7372(94)90011-6; Earlam S, 1996, J CLIN ONCOL, V14, P171, DOI 10.1200/JCO.1996.14.1.171; FAGES B, 1997, P AN M AM SOC CLIN, V16, pA288; GLIMELIUS B, 1992, J CLIN ONCOL, V10, P904, DOI 10.1200/JCO.1992.10.6.904; GLIMELIUS B, 1994, CANCER, V73, P556, DOI 10.1002/1097-0142(19940201)73:3<556::AID-CNCR2820730310>3.0.CO;2-8; KEMENY N, 1989, CANCER, V63, P742, DOI 10.1002/1097-0142(19890215)63:4<742::AID-CNCR2820630423>3.0.CO;2-T; MARSONI S, 1987, CANC TREAT REP, V71, P7180; National Cancer Institute, 1988, GUID REP ADV DRUG RE; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; Pitot HC, 1997, J CLIN ONCOL, V15, P2910, DOI 10.1200/JCO.1997.15.8.2910; ROSS P, 1996, ANN ONCOL, V7, P34; Rothenberg ML, 1996, J CLIN ONCOL, V14, P1128, DOI 10.1200/JCO.1996.14.4.1128; ROUGIER P, 1995, BRIT J SURG, V82, P1397, DOI 10.1002/bjs.1800821034; Rougier P, 1997, J CLIN ONCOL, V15, P251, DOI 10.1200/JCO.1997.15.1.251; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752; VANCUTSEM E, 1997, P AN M AM SOC CLIN, V16, pA268	18	1035	1055	8	25	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1413	1418		10.1016/S0140-6736(98)02309-5	http://dx.doi.org/10.1016/S0140-6736(98)02309-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9807987				2022-12-28	WOS:000076719500007
J	Poynard, T; Marcellin, P; Lee, SS; Niederau, C; Minuk, GS; Ideo, G; Bain, V; Heathcote, J; Zeuzem, S; Trepo, C; Albrecht, J				Poynard, T; Marcellin, P; Lee, SS; Niederau, C; Minuk, GS; Ideo, G; Bain, V; Heathcote, J; Zeuzem, S; Trepo, C; Albrecht, J		Int Hepatitis Interventional Therapy Grp (IHIT	Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus	LANCET			English	Article							NON-B-HEPATITIS; HCV RNA; NON-A; LIVER; METAANALYSIS; MORTALITY; DURATION; THERAPY; ALFA-2B	Background Only 15-20% of patients with chronic hepatitis C achieve a sustained virological response with interferon therapy. The aim of this study was to compare the efficacy and safety of interferon alpha 2b in combination with oral ribavirin with interferon alone, for treatment of chronic infection with hepatitis C virus (HCV). Methods 832 patients aged 18 years or more with chronic HCV who had not been treated with interferon or ribavirin, were enrolled and randomly allocated one of three regimens: 3 mega units (MU) interferon alpha 2b three times a week plus 1000-1200 mg ribavirin per day for 48 weeks; 3 MU interferon alpha 2b three times a week plus 1000-1200 mg ribavirin per day for 24 weeks; or 3 MU interferon alpha 2b three times a week and placebo for 48 weeks. All patients were assessed for safety, tolerance, and efficacy at the end of weeks 1, 2, 4, 6, and 8, and every 4 weeks during treatment. After treatment was completed patients were followed up on weeks 4, 8, 12, and 24. The primary endpoint was loss of detectable HCV-RNA (serum HCV-RNA <100 copies/mL) at week 24 after treatment. Findings Sustained virological response at 24 weeks after treatment, was found in 119 (43%) of the 277 patients treated for 48 weeks with the combination regimen, 97 (35%) of the 277 patients treated for 24 weeks with the combination regimen (p=0.055), and 53 (19%) of the 278 patients treated for 48 weeks with interferon alone (p<0.001 vs both combination regimens, intention-to-treat analysis). Logistic regression identified five independent factors significantly associated with response: genotype 2 or 3, viral load less than 2 million copies/mL, age 40 years or less, minimal fibrosis stage, and female sex. Among patients with fewer than three of these factors the odds ratio of sustained response was 2.6 (95% CI 1.4-4.8; p=0.002) for the 48 week combination regimen compared with 24 weeks of the combination regimen. Discontinuation of therapy for adverse events was more frequent with combination (19%) and monotherapy (13%) given for 48 weeks than combination therapy given for 24 weeks (8%). Interpretation An interferon alpha 2b plus ribavirin combination is more effective than 48 weeks of interferon alpha 2b monotherapy and has an acceptable safety profile. Patients with few favourable factors benefit more from extending the duration of combination therapy to 48 weeks.	Univ Paris 06, Fac Pitie Salpetriere, Grp Hosp, CNRS,URA 1484, Paris, France; Hop Beaujon, Clichy, France; Univ Calgary, Calgary, AB T2N 1N4, Canada; Univ Dusseldorf, MNR Kliniken, Dusseldorf, Germany; Univ Manitoba, Winnipeg, MB, Canada; Osped Niguarda Ca Granda, Milan, Italy; Univ Alberta, Edmonton, AB T6G 2M7, Canada; Toronto Hosp, Toronto, ON M5T 2S8, Canada; Univ Frankfurt Klinikum, D-6000 Frankfurt, Germany; Hop Hotel Dieu, F-69288 Lyon, France; Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Calgary; Heinrich Heine University Dusseldorf; University of Manitoba; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; University of Alberta; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Goethe University Frankfurt; Goethe University Frankfurt Hospital; CHU Lyon; Merck & Company; Schering Plough Corporation	Poynard, T (corresponding author), Grp Hosp Pitie Salpetriere, Serv Hepatogastroenterol, 47-83 Blvd Hop, F-75651 Paris 13, France.	tpoynard@teaser.fr	Zeuzem, Stefan/AAE-7435-2019; Poynard, Thierry/C-1355-2010	Poynard, Thierry/0000-0002-3726-7230; Poynard, Thierry/0000-0002-2050-640X				Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; BEDOSSA P, 1994, HEPATOLOGY, V20, P15; Bodenheimer HC, 1997, HEPATOLOGY, V26, P473, DOI 10.1002/hep.510260231; Camma C, 1997, J HEPATOL, V26, P1187, DOI 10.1016/S0168-8278(97)80451-5; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; DAVIS G, IN PRESS N ENGL J ME; DETRE KM, 1996, VIRAL HEPATITIS REV, V2, P219; DIBISCEGLIE AM, 1992, HEPATOLOGY, V16, P649, DOI 10.1002/hep.1840160307; Dusheiko G, 1996, J HEPATOL, V25, P591, DOI 10.1016/S0168-8278(96)80225-X; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; LIN R, 1995, J HEPATOL, V23, P487, DOI 10.1016/0168-8278(95)80052-2; Lindsay KL, 1997, HEPATOLOGY, V26, pS71, DOI 10.1002/hep.510260713; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; Ning Q, 1998, J IMMUNOL, V160, P3487; PATTERSON JL, 1990, REV INFECT DIS, V12, P1139; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; Poynard T, 1996, HEPATOLOGY, V24, P778; Reichard O, 1998, LANCET, V351, P83, DOI 10.1016/S0140-6736(97)06088-1; REICHARD O, 1997, J HEPATOL S1, V26, P1085; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHINDO M, 1992, HEPATOLOGY, V15, P1013, DOI 10.1002/hep.1840150607; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TONG MJ, 1994, J GASTROEN HEPATOL, V9, P587, DOI 10.1111/j.1440-1746.1994.tb01566.x; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P341	27	2020	2131	0	31	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 31	1998	352	9138					1426	1432		10.1016/S0140-6736(98)07124-4	http://dx.doi.org/10.1016/S0140-6736(98)07124-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9807989				2022-12-28	WOS:000076719500009
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1923: Frederick G Banting (1891-1941), John J R Macleod (1876-1935)	LANCET			English	Biographical-Item									Univ Chicago, Chicago, IL 60637 USA	University of Chicago	Raju, TNK (corresponding author), Univ Chicago, Chicago, IL 60637 USA.								0	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1482	1482		10.1016/S0140-6736(05)61319-0	http://dx.doi.org/10.1016/S0140-6736(05)61319-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9808029				2022-12-28	WOS:000076719500070
J	Garry, DJ; Ordway, GA; Lorenz, LN; Radford, NB; Chin, ER; Grange, RW; Bassel-Duby, R; Williams, RS				Garry, DJ; Ordway, GA; Lorenz, LN; Radford, NB; Chin, ER; Grange, RW; Bassel-Duby, R; Williams, RS			Mice without myoglobin	NATURE			English	Article							MUSCLE; EXPRESSION; GENE; OXYGEN; HEART	Myoglobin, an intracellular haemoprotein expressed in the heart and oxidative skeletal myofibres of vertebrates, binds molecular oxygen and may facilitate oxygen transport from erythrocytes to mitochondria, thereby maintaining cellular respiration during periods of high physiological demand(1-10). Here we show, however, that mice without myoglobin, generated by gene-knockout techhnology, are fertile and exhibit normal exercise capacity and a normal ventilatory response to low oxygen levels (hypoxia). Heart and soleus muscles from these animals are depigmented, but function normally in standard assays of muscle performance in vitro across a range of work conditions and oxygen availability. These data show that myoglobin is not required to meet the metabolic requirements of pregnancy or exercise in a terrestrial mammal, and raise new questions about oxygen transport and metabolic regulation in working muscles.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Biol Oncol, Dallas, TX 75235 USA; Univ Cincinnati, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University System of Ohio; University of Cincinnati	Williams, RS (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA.			Grange, Robert/0000-0002-8288-2793; Radford, Nina/0000-0003-0847-9514				DOELLER JE, 1991, AM J PHYSIOL, V261, pH53, DOI 10.1152/ajpheart.1991.261.1.H53; Fewell JG, 1997, AM J PHYSIOL-HEART C, V273, pH1595, DOI 10.1152/ajpheart.1997.273.3.H1595; Garry DJ, 1996, DEV GENET, V19, P146, DOI 10.1002/(SICI)1520-6408(1996)19:2<146::AID-DVG6>3.0.CO;2-9; GIMENEZ M, 1977, RESPIRATION, V34, P171, DOI 10.1159/000193811; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; GUYTON GP, 1995, J APPL PHYSIOL, V79, P1148, DOI 10.1152/jappl.1995.79.4.1148; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Ho CS, 1997, P NATL ACAD SCI USA, V94, P1533, DOI 10.1073/pnas.94.4.1533; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; PARSONS WJ, 1993, P NATL ACAD SCI USA, V90, P1726, DOI 10.1073/pnas.90.5.1726; Sidell BD, 1997, P NATL ACAD SCI USA, V94, P3420, DOI 10.1073/pnas.94.7.3420; Terrados N., 1992, INT J SPORTS MED S, V13, P206; UNDERWOOD LE, 1987, AM J PHYSIOL, V252, pC450, DOI 10.1152/ajpcell.1987.252.4.C450; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; WITTENBERG JB, 1970, PHYSIOL REV, V50, P559, DOI 10.1152/physrev.1970.50.4.559	17	212	214	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1998	395	6705					905	908		10.1038/27681	http://dx.doi.org/10.1038/27681			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804424				2022-12-28	WOS:000076713400058
J	Forette, F; Seux, ML; Staessen, JA; Thijs, L; Birkenhager, WH; Babarskiene, MR; Babeanu, S; Bossini, A; Gil-Extremera, B; Girerd, X; Laks, T; Lilov, E; Moisseyev, V; Tuomilehto, J; Vanhanen, H; Webster, J; Yodfat, Y; Fagard, R				Forette, F; Seux, ML; Staessen, JA; Thijs, L; Birkenhager, WH; Babarskiene, MR; Babeanu, S; Bossini, A; Gil-Extremera, B; Girerd, X; Laks, T; Lilov, E; Moisseyev, V; Tuomilehto, J; Vanhanen, H; Webster, J; Yodfat, Y; Fagard, R		Syst-Eur Investigators	Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial	LANCET			English	Article							CEREBRAL BLOOD-FLOW; MINI-MENTAL-STATE; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; DIAGNOSTIC-CRITERIA; PREVALENCE	Background Systolic hypertension increases the risk of dementia in elderly people. The vascular dementia project, set up in the framework of the double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial, investigated whether antihypertensive drug treatment could reduce the incidence of dementia. Methods Eligible patients had no dementia, were at least 60 years old, and had a blood pressure when seated of 160-219 mm Hg systolic and below 95 mm Hg diastolic. Active treatment consisted of nitrendipine (10-40 mg/day) with the possible addition of enalapril (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs, titrated or combined to reduce the systolic blood pressure by at least 20 mm Hg to reach a value below 150 mm Hg. Cognitive function was assessed by the mini mental state examination (MMSE). If the MMSE score was 23 or less, diagnostic tests for dementia were done (DSM- III-R criteria). The cause of dementia was established by the modified ischaemic score with brain imaging or the Hachinski score. Findings Median follow-up by intention to treat was 2.0 years. Compared with placebo (n=1180), active treatment (n=1238) reduced the incidence of dementia by 50% from 7.7 to 3.8 cases per 1000 patient-years (21 vs 11 patients, p=0.05). The median MMSE score at randomisation was 29 in both treatment groups. At the last available assessment, systolic and diastolic blood pressure were, respectively, 8.3 mm Hg and 3.8 mm Hg lower (p<0.001) in the active-treatment group, but on average the MMSE scores did not change in either group. In the control patients, however, the MMSE decreased (p=0.04) with decreasing diastolic blood pressure, whereas in the active-treatment group MMSE scores improved slightly (p=0.01) with greater reduction in diastolic blood pressure (p=0.002 for between-group difference). Interpretation In elderly people with isolated systolic hypertension, antihypertensive treatment was associated with a lower incidence of dementia. If 1000 hypertensive patients were treated with antihypertensive drugs for 5 years 19 cases of dementia might be prevented.	Univ Paris 05, CHU Cochin, Hop Broca, Dept Geriatr, F-75013 Paris, France; Univ Louvain, Dept Mol & Cardiovasc Res, Louvain, Belgium; Erasmus Univ, Rotterdam, Netherlands; Inst Cardiol, Kaunas, Lithuania; Natl Inst Ana Aslan, Bucharest, Romania; Policlin Umberto 1, Ctr Ipertens, Rome, Italy; Univ Granada, Fac Med, Granada, Spain; Univ Paris 05, Broussais Hosp, Dept Internal Med, Paris, France; Tallinn Cent Hosp, Tallinn, Estonia; Reg Hlth Ctr, Vidin, Bulgaria; Moscow Municipal Clin Hosp, Dept Internal Dis, Moscow, Russia; Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland; Univ Aberdeen, Aberdeen Royal Hosp, Aberdeen, Scotland; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Family Med, IL-91010 Jerusalem, Israel	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Broca - APHP; Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Erasmus University Rotterdam; National Institute of Gerontology & Geriatrics "Ana Aslan"; Sapienza University Rome; University Hospital Sapienza Rome; University of Granada; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital; University of Aberdeen; Hebrew University of Jerusalem	Forette, F (corresponding author), Univ Paris 05, CHU Cochin, Hop Broca, Dept Geriatr, 54-56 Rue Pascal, F-75013 Paris, France.	francoise.forette@brc.ap-hop-paris.fr	Staessen, Jan A/A-1065-2011; QQ, Simon/D-3888-2014	Staessen, Jan A/0000-0002-3026-1637; Thijs, Lutgarde/0000-0002-8108-2356				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Amery A, 1991, Aging (Milano), V3, P287; [Anonymous], 1991, JAMA, V265, P3255; CHUI HC, 1992, NEUROLOGY, V42, P473, DOI 10.1212/WNL.42.3.473; Erkinjuntti T, 1997, NEW ENGL J MED, V337, P1667, DOI 10.1056/NEJM199712043372306; FOLSTEIN M, 1985, J AM GERIATR SOC, V33, P228, DOI 10.1111/j.1532-5415.1985.tb07109.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forette F, 1991, Aging (Milano), V3, P373; FORETTE F, 1991, AM J MED, V90, pS14, DOI 10.1016/0002-9343(91)90430-6; GAGNON M, 1990, NEUROEPIDEMIOLOGY, V9, P143, DOI 10.1159/000110764; GOULD RJ, 1985, BRAIN RES, V330, P217, DOI 10.1016/0006-8993(85)90680-8; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; Heckbert SR, 1997, J AM GERIATR SOC, V45, P1423, DOI 10.1111/j.1532-5415.1997.tb03191.x; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; HONG YL, 1987, INT J CLIN PHARM TH, V25, P589; LAUNER LJ, 1992, NEUROEPIDEMIOLOGY, V11, P2, DOI 10.1159/000110954; LETENNEUR L, 1994, INT J EPIDEMIOL, V23, P1256, DOI 10.1093/ije/23.6.1256; LOEB C, 1983, STROKE, V14, P399, DOI 10.1161/01.STR.14.3.399; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Morich FJ, 1996, CLIN DRUG INVEST, V11, P185, DOI 10.2165/00044011-199611040-00001; Ott A, 1997, ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, P3; Parnetti L, 1997, DRUGS, V53, P752, DOI 10.2165/00003495-199753050-00003; ROGERS RL, 1986, NEUROLOGY, V36, P1; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Staessen J, 1997, LANCET, V350, P1636; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; THOMPSON LT, 1992, ADV BEHAV BIOL, V40, P241	28	1004	1064	1	120	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	1998	352	9137					1347	1351		10.1016/S0140-6736(98)03086-4	http://dx.doi.org/10.1016/S0140-6736(98)03086-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802273				2022-12-28	WOS:000076691700013
J	Beecham, L				Beecham, L			Review body agrees to its revised remit	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1531	1531						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831603				2022-12-28	WOS:000077338300080
J	Beecham, L				Beecham, L			GMC to consult on guidance for medical managers	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1459	1459						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822420				2022-12-28	WOS:000077202200070
J	Somers, DE; Devlin, PF; Kay, SA				Somers, DE; Devlin, PF; Kay, SA			Phytochromes and cryptochromes in the entrainment of the Arabidopsis circadian clock	SCIENCE			English	Article							LIGHT; PERIOD; PHOTORECEPTORS; TRANSCRIPTION; PHENOTYPE; RHYTHMS; MUTANTS; SYSTEM; RED	Circadian clocks are synchronized by environmental cues such as light. Photoreceptor-deficient Arabidopsis thaliana mutants were used to measure the effect of light fluence Fate on circadian period in plants. Phytochrome B is the primary high-intensity red Light photoreceptor for circadian control, and phytochrome A acts under Low-intensity red Light. Cryptochrome 1 and phytochrome A both act to transmit low-fluence blue Light to the clock. Cryptochrome 1 mediates high-intensity blue light signals for period Length control. The presence of cryptochromes in both plants and animals suggests that circadian input pathways have been conserved throughout evolution.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92307 USA; Scripps Res Inst, Natl Sci Fdn Ctr Biol Timing, La Jolla, CA 92307 USA	Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Scripps Research Institute	Kay, SA (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92307 USA.	stevek@scripps.edu	Somers, David E/A-9209-2010; Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878; Devlin, Paul/0000-0002-0168-3793	NIGMS NIH HHS [GM56006] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; ASCHOFF J, 1979, Z TIERPSYCHOL, V49, P225; Casal JJ, 1998, PLANT PHYSIOL, V118, P19, DOI 10.1104/pp.118.1.19; Cashmore AR, 1997, PLANT CELL ENVIRON, V20, P764, DOI 10.1046/j.1365-3040.1997.d01-125.x; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HARRIS PJC, 1976, PLANTA, V129, P253, DOI 10.1007/BF00398267; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; JOHNSON CH, 1995, CRC HDB ORGANIC PHOT, P1602; KENDRICH RE, 1994, PHOTOMORPHOGENESIS P; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; Mathews S, 1997, PLANT CELL ENVIRON, V20, P666, DOI 10.1046/j.1365-3040.1997.d01-117.x; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; Millar AJ, 1992, PLANT MOL BIOL REP, V10, P324, DOI 10.1007/BF02668909; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; NAGATANI A, 1993, PLANT PHYSIOL, V102, P269, DOI 10.1104/pp.102.1.269; Neff MM, 1998, PLANT PHYSIOL, V118, P27, DOI 10.1104/pp.118.1.27; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; ROENNEBERG T, 1988, NATURWISSENSCHAFTEN, V75, P206, DOI 10.1007/BF00735584; Roenneberg T, 1997, PLANTA, V202, P494, DOI 10.1007/s004250050154; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; Somers DE, 1998, DEVELOPMENT, V125, P485; SOMERS DE, 1998, GENETICS, V149, P523; WAGNER D, 1991, PLANT CELL, V3, P1275, DOI 10.1105/tpc.3.12.1275; Weller JL, 1997, PLANT PHYSIOL, V114, P1225, DOI 10.1104/pp.114.4.1225; Whitelam GC, 1997, PLANT CELL ENVIRON, V20, P752, DOI 10.1046/j.1365-3040.1997.d01-100.x; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135	32	587	628	5	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1488	1490		10.1126/science.282.5393.1488	http://dx.doi.org/10.1126/science.282.5393.1488			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822379				2022-12-28	WOS:000077110800054
J	Goodare, H				Goodare, H			Herbal remedies - Patient heal thyself	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1377	1377		10.1136/bmj.317.7169.1377	http://dx.doi.org/10.1136/bmj.317.7169.1377			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812942	Green Published			2022-12-28	WOS:000077081600030
J	Williamson, C				Williamson, C			The rise of doctor-patient working groups	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; QUALITY		Consumers Eth Res, London N16 0BW, England		Williamson, C (corresponding author), Consumers Eth Res, POB 1365, London N16 0BW, England.							Bates T, 1995, REPORT INDEPENDENT R; Blumenthal D, 1996, NEW ENGL J MED, V335, P1328, DOI 10.1056/NEJM199610243351721; Blumenthal D, 1996, NEW ENGL J MED, V335, P891, DOI 10.1056/NEJM199609193351213; Borkman T, 1997, HEALTH SOC CARE COMM, V5, P357, DOI 10.1111/j.1365-2524.1997.tb00133.x; DELBANCO TL, 1992, ANN INTERN MED, V116, P414, DOI 10.7326/0003-4819-116-5-414; EDWARDS N, 1997, ASS IMPROVMENTS MATE, V8, P11; Fletcher G, 1997, VOICES PROJECT TRAIN; Gerteis M., 1993, PATIENTS EYES UNDERS; HOGG C, IN PRESS PATIENTS PO; HUTCHINSON M, 1992, TRAINING USER INVOLV; Irvine D, 1997, BRIT MED J, V314, P1540, DOI 10.1136/bmj.314.7093.1540; JOULE N, 1997, CHOICE OPPORTUNITIES; KELSON M, 1996, CONSUMER INVOLVEMENT; LEWTHWAITE J, 1997, PATIENTS INFLUENCING; Milne R, 1996, INT J QUAL HEALTH C, V8, P439, DOI 10.1093/intqhc/8.5.439; PRITCHARD P, 1993, PARTNERSHIP PATIENTS; *RAD ACT GROUP EXP, 1997, RAGE RESP REP IND RE; REISER SJ, 1993, JAMA-J AM MED ASSOC, V269, P1012, DOI 10.1001/jama.269.8.1012; ROBINSON J, 1988, PATIENT VOICE GMC; *ROYAL COLL GEN PR, 1997, WORK YOUR DOCT REP P; *ROYAL COLL GEN PR, 1997, YOU YOUR GP DAY; *ROYAL COLL GEN PR, 1997, REM PAT GPS LISTS GU; *SALF ROYAL HOSP N, 1996, CLIN AUD BOARD ANN R; SHEKELLE PG, 1993, USING APPROPRIATENES; TAYLOR D, 1997, BRIT MED J, V314, P626; TAYLOR P, 1995, CONSUMER INVOLVEMENT; Thornton H, 1998, BRIT MED J, V316, P148; WILKIE P, 1996, P R COL PHYS EDINBUR, V26, P576; WILLIAMSON C, 1993, BRIT MED J, V307, P742; WILLIAMSON C, 1995, HLTH SERVICE J, V105, P28; Williamson C., 1992, WHOSE STANDARDS CONS	31	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1374	1377		10.1136/bmj.317.7169.1374	http://dx.doi.org/10.1136/bmj.317.7169.1374			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812941	Green Published			2022-12-28	WOS:000077081600029
J	Sternberg, PW; Alberola-Ila, J				Sternberg, PW; Alberola-Ila, J			Conspiracy theory: RAS and RAF do not act alone	CELL			English	Review							ACTIVATION; PROTEIN		CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Sternberg, PW (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.			alberola-ila, Jose/0000-0003-2439-553X				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Bredt DS, 1998, CELL, V94, P691, DOI 10.1016/S0092-8674(00)81727-4; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Gutch MJ, 1998, GENE DEV, V12, P571, DOI 10.1101/gad.12.4.571; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Rommel C, 1998, CURR OPIN GENET DEV, V8, P412, DOI 10.1016/S0959-437X(98)80111-1; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Selfors LM, 1998, P NATL ACAD SCI USA, V95, P6903, DOI 10.1073/pnas.95.12.6903; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Vincent S, 1998, MOL CELL, V2, P515, DOI 10.1016/S1097-2765(00)80151-3; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	17	61	67	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1998	95	4					447	450		10.1016/S0092-8674(00)81612-8	http://dx.doi.org/10.1016/S0092-8674(00)81612-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827797	Bronze			2022-12-28	WOS:000077049400003
J	Frank, KM; Sekiguchi, JM; Seidl, KJ; Swat, W; Rathbun, GA; Cheng, HL; Davidson, L; Kangaloo, L; Alt, FW				Frank, KM; Sekiguchi, JM; Seidl, KJ; Swat, W; Rathbun, GA; Cheng, HL; Davidson, L; Kangaloo, L; Alt, FW			Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV	NATURE			English	Article							STRAND BREAK REPAIR; KU86-DEFICIENT MICE; SIGNAL; GROWTH; DEFECT; CELLS	The DNA-end-joining reactions used for repair of double-strand breaks in DNA and for V(D)J recombination, the process by which immunoglobulin and T-cell antigen-receptor genes are assembled from multiple gene segments, use common factors. These factors include components of DNA-dependent protein kinase (DNA-PK), namely DNA-PE;cs and the Ku heterodimer, Ku70-Ku80, and XRCC4 (ref. 1). The precise function of XRCC4 is unknown, but it interacts with DNA ligase IV. Ligase IV is one of the three known mammalian DNA ligases(2); however, the in vivo functions of these Ligases have not been determined unequivocally. Here we show that inactivation of the ligase IV gene in mice leads to late embryonic lethality. Lymphopoiesis in these mice is blocked and V(D)I joining does not occur. Ligase IV-deficient embryonic fibroblasts also show marked sensitivity to ionizing radiation, growth defects and premature senescence. All of these phenotypic characteristics, except embryonic lethality, resemble those associated with Ku70 and Ku80 deficiencies(3-6), indicating that they may result from an impaired end-joining process that involves both Ku subunits and ligase N. However, Ku-deficient mice are viable, so ligase TV must also be required for processes and/or in cell types in which Ku is dispensable.	Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Alt, FW (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA.			Sekiguchi, JoAnn/0000-0002-7178-4258				Bogue MA, 1997, IMMUNITY, V7, P37, DOI 10.1016/S1074-7613(00)80508-7; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gorman JR, 1996, IMMUNITY, V5, P241, DOI 10.1016/S1074-7613(00)80319-2; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Herrmann G, 1998, EMBO J, V17, P4188, DOI 10.1093/emboj/17.14.4188; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; Mizuta R, 1997, INT IMMUNOL, V9, P1607, DOI 10.1093/intimm/9.10.1607; MOGAN B, 1994, MANIPULATING MOUSE E; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; Schatz D G, 1997, Semin Immunol, V9, P149, DOI 10.1006/smim.1997.0068; Smider V, 1997, Semin Immunol, V9, P189, DOI 10.1006/smim.1997.0070; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; WEI YF, 1995, MOL CELL BIOL, V15, P3206; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	28	450	465	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1998	396	6707					173	177		10.1038/24172	http://dx.doi.org/10.1038/24172			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823897				2022-12-28	WOS:000077013300053
J	Garfinkel, MS; Singhal, A; Katz, WA; Allan, DA; Reshetar, R; Schumacher, HR				Garfinkel, MS; Singhal, A; Katz, WA; Allan, DA; Reshetar, R; Schumacher, HR			Yoga-based intervention for carpal tunnel syndrome - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Carpal tunnel syndrome is a common complication of repetitive activities and causes significant morbidity, Objective.-To determine the effectiveness of a yoga-based regimen for relieving symptoms of carpal tunnel syndrome. Design.-Randomized, single-blind, controlled trial. Setting.-A geriatric center and an industrial site in 1994-1995. Patients.-Forty-two employed or retired individuals with carpal tunnel syndrome (median age, 52 years; range, 24-77 years). Intervention.-Subjects assigned to the yoga group received a yoga-based intervention consisting of 11 yoga postures designed for strengthening, stretching, and balancing each joint in the upper body along with relaxation given twice weekly for 8 weeks. Patients in the control group were offered a wrist splint to supplement their current treatment. Main Outcome Measures.-Changes from baseline to 8 weeks in grip strength, pain intensity, sleep disturbance, Phalen sign, and Tinel sign, and in median nerve motor and sensory conduction time. Results.-Subjects in the yoga groups had significant improvement in grip strength (increased from 162 to 187 mm Hg; P = .009) and pain reduction (decreased from 5.0 to 2.9 mm; P = .02), but changes in grip strength and pain were not significant for control subjects. The yoga group had significantly more improvement in Phalen sign (12 improved vs 2 in control group; P = .008), but no significant differences were found in sleep disturbance, Tinel sign, and median nerve motor and sensory conduction time. Conclusion.-In this preliminary study, a yoga-based regimen was more effective than wrist splinting or no treatment in relieving some symptoms and signs of carpal tunnel syndrome.	Univ Penn, Sch Med, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA; Vet Affairs Med Ctr, Arthrit Immunol Ctr, Philadelphia, PA USA; Univ Penn, Presbyterian Med Ctr, Philadelphia, PA 19104 USA; Amer Board Internal Med, Philadelphia, PA USA	University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; Pennsylvania Presbyterian Medical Center; American Board of Internal Medicine	Garfinkel, MS (corresponding author), 2301 Cherry St,16F, Philadelphia, PA 19103 USA.							Atroshi I, 1996, J HAND SURG-AM, V21A, P651, DOI 10.1016/S0363-5023(96)80020-7; GARFINKEL MS, 1994, J RHEUMATOL, V21, P2341; GARFINKEL MS, 1992, EFFECT YOGA RELAXATI; HUSKISSON EC, 1982, J RHEUMATOL, V9, P768; IYENGAR BKS, 1966, LIGHT YOGA, P544; MOSSMAN SS, 1987, BRIT MED J, V294, P680, DOI 10.1136/bmj.294.6573.680; PASCARELLI E, 1994, REPETITIVE STRAIN IN, P55; PHALEN GS, 1966, J BONE JOINT SURG AM, VA 48, P211, DOI 10.2106/00004623-196648020-00001; STEINBERG DR, 1992, J HAND SURG-AM, V17A, P77, DOI 10.1016/0363-5023(92)90117-8; THOMPSON R, 1992, NATIONS BUS, V80, P1	10	172	172	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1601	1603		10.1001/jama.280.18.1601	http://dx.doi.org/10.1001/jama.280.18.1601			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820263	Bronze			2022-12-28	WOS:000076852000028
J	Beecham, L				Beecham, L			BMA chairman speaks out on clinical governance	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1325	1325						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804740				2022-12-28	WOS:000076963800065
J	Salo, H; Hanninen, J				Salo, H; Hanninen, J			Neptune's partial rings: Action of Galatea on self-gravitating arc particles	SCIENCE			English	Article								Numerical simulations of Neptune's arcs show that self-gravity between macroscopic are particles can prevent interparticle impacts and thereby stabilize their resonant confinement by Galatea, a satellite of Neptune, Stable subkilometer are particles provide a source for replenishing the observed dust and explain the clumpy substructure seen in arcs, A few confining kilometer-sized particles between the major are components can account for the observed are widths spanning several resonance sites. The modeled distribution of dust is consistent with observations and helps to explain how embedded satellites may affect the structure and evolution of planetary ring systems.	Univ Oulu, Dept Phys Sci, Div Astron, FIN-90570 Oulu, Finland	University of Oulu	Salo, H (corresponding author), Univ Oulu, Dept Phys Sci, Div Astron, FIN-90570 Oulu, Finland.	hsalo@sun3.oulu.fi						COLWELL JE, 1990, GEOPHYS RES LETT, V17, P1741, DOI 10.1029/GL017i010p01741; FERRARI C, 1994, ICARUS, V111, P193, DOI 10.1006/icar.1994.1140; Foryta DW, 1996, ICARUS, V123, P129, DOI 10.1006/icar.1996.0146; GOLDREICH P, 1986, ASTRON J, V92, P490, DOI 10.1086/114178; Hanninen J, 1997, ICARUS, V126, P1, DOI 10.1006/icar.1996.5613; HARTMANN WK, 1985, ICARUS, V63, P69, DOI 10.1016/0019-1035(85)90021-1; Porco CC, 1995, SPACE SCI S, P703; PORCO CC, 1991, SCIENCE, V253, P995, DOI 10.1126/science.253.5023.995; SALO H, 1988, ASTRON ASTROPHYS, V205, P309; SICARDY B, 1991, ICARUS, V89, P220, DOI 10.1016/0019-1035(91)90175-S; SMITH BA, 1989, SCIENCE, V246, P1422, DOI 10.1126/science.246.4936.1422; YODER CF, 1983, ICARUS, V53, P431, DOI 10.1016/0019-1035(83)90207-5	12	11	11	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1102	1104		10.1126/science.282.5391.1102	http://dx.doi.org/10.1126/science.282.5391.1102			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804544				2022-12-28	WOS:000076887700044
J	Fisher, RS; Parkman, HP				Fisher, RS; Parkman, HP			Management of nonulcer dyspepsia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HELICOBACTER-PYLORI INFECTION; PEPTIC-ULCER DISEASE; FUNCTIONAL DYSPEPSIA; INTRAGASTRIC DISTRIBUTION; GASTRIC-CANCER; DUODENAL-ULCER; DOUBLE-BLIND; ENDOSCOPY; SYMPTOMS; GASTROPARESIS		Temple Univ, Hlth Sci Ctr, Sch Med, Dept Med,Gastroenterol Sect, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Fisher, RS (corresponding author), Temple Univ, Hlth Sci Ctr, Sch Med, Dept Med,Gastroenterol Sect, Parkinson Pavil,8th Fl,3401 N Broad St, Philadelphia, PA 19140 USA.							Armstrong D, 1996, SCAND J GASTROENTERO, V31, P38, DOI 10.3109/00365529609094532; Axon ATR, 1997, GASTROENTEROLOGY, V112, P1376, DOI 10.1016/S0016-5085(97)70153-7; BARBARA L, 1989, DIGEST DIS SCI, V34, P1272, DOI 10.1007/BF01537277; BOST R, 1990, DIGEST DIS SCI, V35, P193, DOI 10.1007/BF01536762; BROWN C, 1990, BRIT MED J, V300, P829, DOI 10.1136/bmj.300.6728.829; BYTZER P, 1994, LANCET, V343, P811, DOI 10.1016/S0140-6736(94)92023-0; Camilleri M, 1996, MAYO CLIN PROC, V71, P614, DOI 10.4065/71.6.614; CARLSSON R, 1996, GASTROENTEROLOGY S, V110, pA76; Christie J, 1997, GUT, V41, P513, DOI 10.1136/gut.41.4.513; CLOUSE RE, 1994, DIGEST DIS SCI, V39, P2352, DOI 10.1007/BF02087651; DOBRILLA G, 1989, J CLIN GASTROENTEROL, V11, P169, DOI 10.1097/00004836-198904000-00011; FENDRICK AM, 1995, ANN INTERN MED, V123, P260, DOI 10.7326/0003-4819-123-4-199508150-00003; FRAITAG B, 1994, DIGEST DIS SCI, V39, P1072, DOI 10.1007/BF02087560; HALTER F, 1994, SCAND J GASTROENTERO, V29, P618, DOI 10.3109/00365529409092482; HOGAN WJ, 1988, ENDOSCOPY, V20, P179, DOI 10.1055/s-2007-1018172; JOHANNESSEN T, 1990, SCAND J GASTROENTERO, V25, P689, DOI 10.3109/00365529008997594; JOHNSEN R, 1991, BRIT MED J, V302, P749, DOI 10.1136/bmj.302.6779.749; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; JONES R, 1988, PRACTITIONER, V232, P75; KOCH KL, 1989, AM J GASTROENTEROL, V84, P1069; MALAGELADA JR, 1985, GASTROENTEROLOGY, V88, P1223, DOI 10.1016/S0016-5085(85)80083-4; Malagelada JR, 1996, GASTROENTEROL CLIN N, V25, P103, DOI 10.1016/S0889-8553(05)70367-8; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MAYER EA, 1990, GASTROENTEROLOGY, V99, P1688, DOI 10.1016/0016-5085(90)90475-G; McColl KEL, 1997, GUT, V40, P302, DOI 10.1136/gut.40.3.302; MCQUAID K, 1998, SLEISENGER FORDTRANS, V1, P105; MEARIN F, 1991, GASTROENTEROLOGY, V101, P999, DOI 10.1016/0016-5085(91)90726-2; MEINECHESCHMIDT V, 1995, GASTROENTEROLOGY, V108, pA165, DOI 10.1016/0016-5085(95)23320-2; MILNE R, 1995, GUT, V37, P314, DOI 10.1136/gut.37.3.314; NYREN O, 1986, J CLIN GASTROENTEROL, V8, P339, DOI 10.1097/00004836-198606002-00004; NYREN O, 1986, NEW ENGL J MED, V314, P339, DOI 10.1056/NEJM198602063140603; Ofman JJ, 1997, ANN INTERN MED, V126, P280, DOI 10.7326/0003-4819-126-4-199702150-00004; OH JJ, 1990, MAYO CLIN PROC, V65, P636, DOI 10.1016/S0025-6196(12)65125-8; OMorain C, 1996, SCAND J GASTROENTERO, V31, P28, DOI 10.3109/00365529609094512; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; RICHTER JE, 1991, SCAND J GASTROENTERO, V26, P11, DOI 10.3109/00365529109109531; RICHTER JE, 1991, SCAND J GASTROENTERO, V26, P40, DOI 10.3109/00365529109109536; SCOTT AM, 1993, DIGEST DIS SCI, V38, P2247, DOI 10.1007/BF01299904; Silverstein MD, 1996, GASTROENTEROLOGY, V110, P72, DOI 10.1053/gast.1996.v110.pm8536890; SIRCUS W, 1985, Q J MED, V56, P593; SMALL PK, 1995, GUT, V36, P189, DOI 10.1136/gut.36.2.189; SPIRO HM, 1974, NEW ENGL J MED, V291, P567, DOI 10.1056/NEJM197409122911107; Stanghellini V, 1996, GASTROENTEROLOGY, V110, P1036, DOI 10.1053/gast.1996.v110.pm8612991; Talley N, 1991, GASTROENTEROL INT, V4, P145; TALLEY NJ, 1988, ANN INTERN MED, V108, P865, DOI 10.7326/0003-4819-108-6-865; TALLEY NJ, 1994, GASTROENTEROLOGY, V106, P1174, DOI 10.1016/0016-5085(94)90007-8; TALLEY NJ, 1992, GASTROENTEROLOGY, V102, P1259; Talley NJ, 1998, GASTROENTEROLOGY, V114, P582, DOI 10.1016/S0016-5085(98)70542-6; TALLEY NJ, 1995, ALIMENT PHARM THER, V9, P107; TOSKES PP, 1991, SEMIN GASTROINTEST D, V2, P188; TRONCON LEA, 1994, GUT, V35, P327, DOI 10.1136/gut.35.3.327; TYTGAT GNJ, 1991, SCAND J GASTROENTERO, V26, P33, DOI 10.3109/00365529109109535; Tytgat GNJ, 1996, SCAND J GASTROENTERO, V31, P70, DOI 10.3109/00365529609094540; vanZanten SJOV, 1996, AM J GASTROENTEROL, V91, P660; VANZANTEN SJOV, 1994, CAN MED ASSOC J, V150, P177; WALSH JH, 1995, NEW ENGL J MED, V333, P984, DOI 10.1056/NEJM199510123331508; WHITE LJ, 1985, ANN INTERN MED, V102, P266, DOI 10.7326/0003-4819-102-2-266; WILLIAMS B, 1988, LANCET, V2, P1349; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	59	87	98	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1998	339	19					1376	1381		10.1056/NEJM199811053391907	http://dx.doi.org/10.1056/NEJM199811053391907			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135BN	9801400				2022-12-28	WOS:000076780200007
J	Junghans, RP				Junghans, RP			Bone marrow involvement in acute leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Beth Israel Deacones Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Junghans, RP (corresponding author), Beth Israel Deacones Med Ctr, Boston, MA 02215 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1998	339	19					1375	1375		10.1056/NEJM199811053391906	http://dx.doi.org/10.1056/NEJM199811053391906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135BN	9801399				2022-12-28	WOS:000076780200006
J	Testa, MA; Simonson, DC				Testa, MA; Simonson, DC			Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus - A randomized, controlled, double-blind trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE; ANTIHYPERTENSIVE THERAPY; HYPOGLYCEMIA; HYPERGLYCEMIA; COMPLICATIONS; SYMPTOMS; MODEL; NIDDM; IDDM	Context.-Although the long-term health benefits of good glycemic control in patients with diabetes are well documented, shorter-term quality of life (QOL) and economic savings generally have been reported to be minimal or absent. Objective.-To examine short-term outcomes of glycemic control in type 2 diabetes mellitus (DM). Design.-Double-blind, randomized, placebo-controlled, parallel trial. Setting.-Sixty-two sites in the United States. Participants.-A total of 569 male and female volunteers with type 2 DNI. Intervention.-After a 3-week, single-blind placebo-washout period, participants were randomized to diet and titration with either 5 to 20 mg of glipizide gastrointestinal therapeutic system (GITS) (n=377) or placebo (n=192) for 12 weeks. Main Outcome Measures.-Change from baseline in glucose and hemoglobin A(1c) (HbA(1c)) levels and symptom distress, QOL, and health economic indicators by questionnaires and diaries. Results.-After 12 weeks, mean (+/-SE) HbA(1c) and fasting blood glucose levels decreased with active therapy (glipizide GITS) vs placebo (7.5%+/-0.1% vs 9.3%+/-0.1% and 7.0+/-0.1 mmol/L [126+/-2 mg/dL] vs 9.3 +/- 0.2 mmol/L [168 +/- 4 mg/dL], respectively; P<.001), Quality-of-life treatment differences (SD units) for symptom distress (+0.59; P<.001), general perceived health (+0.36, P=.004), cognitive functioning (+0.34, P=.005), and the overall visual analog scale (VAS) (+0.24; P=.04) were significantly more favorable for active therapy. Subscales of acuity (+0.38, P=.002), VAS emotional health (+0.35; P=.003), general health (+0.27; P=.01), sleep (+0.26, P=.04), depression (+0.25; P=.05), disorientation and detach ment (+0.23, P=.05), and vitality (+0.22, P=.04) were most affected. Favorable health economic outcomes for glipizide GITS included higher retained employment (97% vs 85%; P<.001), greater productive capacity (99% vs 87%; P<.001), less absenteeism (losses=$24 vs $115 per worker per month; P<.001), fewer bed-days (losses=$1539 vs $1843 per 1000 person-days; P=.05), and fewer restricted-activity days (losses=$2660 vs $4275 per 1000 person-days; P=.01). Conclusions.-Improved glycemic control of type 2 DM is associated with substantial short-term symptomatic, QOL, and health economic benefits.	Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Joslin Diabet Ctr,Dept Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.	Testa, MA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Biostat, 655 Huntington Ave, Boston, MA 02115 USA.	testa@sdac.harvard.edu	Testa, Marianna/L-9768-2019		AHRQ HHS [R01 HS07767] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM DIAB ASS, 1993, DIR IND COSTS DIAB U, P27; BAGNE CA, 1995, QUAL LIFE RES, V4, P392; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; CRYER PE, 1992, DIABETES, V41, P255, DOI 10.2337/diabetes.41.3.255; CRYER PE, 1989, DIABETES, V38, P1193, DOI 10.2337/diabetes.38.9.1193; DIABET CONTROL COMPLICATIONS TRIAL RES GRP, 1995, DIABETES CARE, V18, P1468; Diabet Control Complications Trial Res Grp, 1996, DIABETES CARE, V19, P195; DRAELOS MT, 1995, AM J MED, V98, P135, DOI 10.1016/S0002-9343(99)80397-0; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; Eastman RC, 1997, DIABETES CARE, V20, P725, DOI 10.2337/diacare.20.5.725; GONDERFREDERICK LA, 1990, NEUROPSYCHOLOGICAL B, P155; Graue M, 1995, QUAL LIFE RES, V4, P436; HARRIS MI, 1994, DIABETES CARE, V17, P761, DOI 10.2337/diacare.17.7.761; KATZ JN, 1992, MED CARE, V30, P917, DOI 10.1097/00005650-199210000-00004; Nathan DM, 1996, JAMA-J AM MED ASSOC, V276, P1409; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIEGEL JE, 1992, J AM SOC NEPHROL, V3, pS111; TESTA MA, 1994, ANNU REV PUBL HEALTH, V15, P535; TESTA MA, 1991, AM J HYPERTENS, V4, P363, DOI 10.1093/ajh/4.4.363; TESTA MA, 1993, NEW ENGL J MED, V328, P907, DOI 10.1056/NEJM199304013281302; Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306; TESTA MA, 1988, POSTGRAD MED J, V64, P50; United Kingdom Prospective Diabetes Study (UKPDS), 1995, BMJ-BRIT MED J, V310, P83, DOI DOI 10.1136/BMJ.310.6972.83; *US BUR CENS, 1995, 1995 STAT ABSTR US; VanderDoes FEE, 1996, DIABETES CARE, V19, P204, DOI 10.2337/diacare.19.3.204; WEINBERGER M, 1994, MED CARE, V32, P1173, DOI 10.1097/00005650-199412000-00002; WEINGER K, 1995, AM J MED, V98, P22, DOI 10.1016/S0002-9343(99)80077-1; *WINW SOL INC, 1996, WINW SOL PROF DIAS V	28	290	298	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1490	1496		10.1001/jama.280.17.1490	http://dx.doi.org/10.1001/jama.280.17.1490			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	134RR	9809729	Bronze			2022-12-28	WOS:000076757200022
J	Sohl, JL; Jaswal, SS; Agard, DA				Sohl, JL; Jaswal, SS; Agard, DA			Unfolded conformations of alpha-lytic protease are more stable than its native state	NATURE			English	Article							PRO-REGION; FOLDING REACTION; DOMAIN	alpha-Lytic protease (alpha LP), an extracellular bacterial protease, is synthesized with a large amino-terminal pro-region that is essential for its folding in vivo and in vitro(1,2). In the absence of the proregion, the protease folds to an inactive, partially folded state, designated 'I'. The pro-region catalyses protease folding by directly stabilizing the folding transition state (>26 kcal mol(-1)) which separates the native state 'N' from I-1,I-3. Although a basic tenet of protein folding is that the native state of a protein is at the minimum free energy(4), we show here that both the I and fully unfolded states of alpha LP we lower in free energy than the native state. Native alpha LP is thus metastable: its apparent stability derives from a large barrier to unfolding. Consequently the evolution of alpha LP has been distinct from most other proteins: it has not been constrained by the free-energy difference between the native and unfolded states, but instead by the size of its unfolding barrier.	Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Agard, DA (corresponding author), Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA.							BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; Clark AC, 1997, BIOCHEMISTRY-US, V36, P1891, DOI 10.1021/bi962477m; DAquino JA, 1996, PROTEINS, V25, P143, DOI 10.1002/(SICI)1097-0134(199606)25:2<143::AID-PROT1>3.0.CO;2-J; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; FUJINAGA M, 1985, J MOL BIOL, V184, P479, DOI 10.1016/0022-2836(85)90296-7; Harrison PM, 1997, CURR OPIN STRUC BIOL, V7, P53, DOI 10.1016/S0959-440X(97)80007-3; MACE JE, 1995, J MOL BIOL, V254, P720, DOI 10.1006/jmbi.1995.0650; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Peters RJ, 1998, BIOCHEMISTRY-US, V37, P12058, DOI 10.1021/bi980883v; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; Sohl JL, 1997, BIOCHEMISTRY-US, V36, P3894, DOI 10.1021/bi962341o; Wang ZL, 1996, BIOCHEMISTRY-US, V35, P16443, DOI 10.1021/bi961214p	17	181	183	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1998	395	6704					817	819		10.1038/27470	http://dx.doi.org/10.1038/27470			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AL	9796818				2022-12-28	WOS:000076607400061
J	Whitehead, H				Whitehead, H			Cultural selection and genetic diversity in matrilineal whales	SCIENCE			English	Article							D-LOOP REGION; POPULATION-STRUCTURE; HUMPBACK WHALES; ORCINUS-ORCA; SPERM WHALES; EVOLUTION; WATERS; BEHAVIOR	Low diversities of mitochondrial DNA (mtDNA) have recently been found in four species of matrilineal whale. No satisfactory explanation for this apparent anomaly has been previously suggested. Culture seems to be an important part of the Lives of matrilineal whales. The selection of matrilineally transmitted cultural traits, upon which neutral mtDNA alleles "hitchhike," has the potential to strongly reduce genetic variation. Thus, in contrast to other nonhuman mammals, culture may be an important evolutionary force for the matrilineal whales.	Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada	Dalhousie University	Whitehead, H (corresponding author), Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada.	hwhitehe@is.dal.ca						Amos Bill, 1996, Report of the International Whaling Commission, V46, P657; ARCHER I, 1996, THESIS U CALIFORNIA; BAKER CS, 1993, P NATL ACAD SCI USA, V90, P8239, DOI 10.1073/pnas.90.17.8239; Bakke I, 1996, MAR BIOL, V125, P1, DOI 10.1007/BF00350755; BARLOW J, 1995, FISH B-NOAA, V93, P1; BIRKY CW, 1983, GENETICS, V103, P513; Boyd R., 1985, CULTURE EVOLUTIONARY; BRAULT S, 1993, ECOLOGY, V74, P1444, DOI 10.2307/1940073; Buckland S.T., 1993, Reports of the International Whaling Commission Special Issue, V14, P33; Connor RC, 1998, TRENDS ECOL EVOL, V13, P228, DOI 10.1016/S0169-5347(98)01326-3; DILLON MC, 1993, MOL BIOL EVOL, V10, P296; Dillon MC, 1996, THESIS DALHOUSIE U H; DIZON AE, 1994, CAL COOP OCEAN FISH, V35, P61; FORD JKB, 1991, CAN J ZOOL, V69, P1454, DOI 10.1139/z91-206; Gladden JGB, 1997, MOL ECOL, V6, P1033, DOI 10.1046/j.1365-294X.1997.00275.x; HELMLICHBORAN JR, IN PRESS S ZOOL SOC; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Hoelzel A. R., 1991, REPORTS INT WHALING, V13, P225; HOELZEL AR, 1991, MOL BIOL EVOL, V8, P475; Hoelzel AR, 1998, J HERED, V89, P121, DOI 10.1093/jhered/89.2.121; Janik VM, 1997, ADV STUD BEHAV, V26, P59, DOI 10.1016/S0065-3454(08)60377-0; JEFFRSON TA, 1994, HDB MARINE MAMMALS, V5, P355; KAPLAN NL, 1989, GENETICS, V123, P887; Klinowska M., 1991, DOLPHINS PORPOISES W; LALAND KN, 1992, ETHOL SOCIOBIOL, V13, P87, DOI 10.1016/0162-3095(92)90020-5; Lux C.A., 1997, Report of the International Whaling Commission, V47, P645; Lyrholm T, 1998, P ROY SOC B-BIOL SCI, V265, P1679, DOI 10.1098/rspb.1998.0488; MARTIN AP, 1993, P NATL ACAD SCI USA, V90, P4087, DOI 10.1073/pnas.90.9.4087; Palsboll PJ, 1997, HEREDITY, V78, P284; PALSBOLL PJ, 1995, MAR ECOL PROG SER, V116, P1, DOI 10.3354/meps116001; Pichler FB, 1998, CONSERV BIOL, V12, P676, DOI 10.1046/j.1523-1739.1998.96390.x; RICHERSON PJ, IN PRESS IDEOLOGY WA; ROPER TJ, 1986, SCI PROG, V70, P571; ROSEL PE, 1994, MAR BIOL, V119, P159, DOI 10.1007/BF00349552; ROSEL PE, 1995, CAN J FISH AQUAT SCI, V52, P1210, DOI 10.1139/f95-118; Siemann LA, 1994, THESIS MIT CAMBRIDGE; TAJIMA F, 1989, GENETICS, V123, P585; Wade P.R., 1992, Report of the International Whaling Commission, V42, P533; Whitehead H, 1996, J ANIM ECOL, V65, P429, DOI 10.2307/5778; WHITEHEAD H, 1991, BEHAV ECOL SOCIOBIOL, V29, P385, DOI 10.1007/BF00165964; Whitehead H, 1998, J ANIM ECOL, V67, P253, DOI 10.1046/j.1365-2656.1998.00187.x; WHITEHEAD H, IN PRESS CETACEAN SO; WU CI, 1985, P NATL ACAD SCI USA, V82, P1741, DOI 10.1073/pnas.82.6.1741	43	149	150	1	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 27	1998	282	5394					1708	1711		10.1126/science.282.5394.1708	http://dx.doi.org/10.1126/science.282.5394.1708			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831562				2022-12-28	WOS:000077246600047
J	Beecham, L				Beecham, L			Government amends review body's remit	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1459	1459						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822420				2022-12-28	WOS:000077202200069
J	Nurmikko, TJ; Nash, TP; Wiles, JR				Nurmikko, TJ; Nash, TP; Wiles, JR			Recent advances - Control of chronic pain	BRITISH MEDICAL JOURNAL			English	Review							SPINAL-CORD STIMULATION; REFRACTORY ANGINA-PECTORIS; CONTROLLED CROSSOVER TRIAL; DOUBLE-BLIND; NEUROPATHIC PAIN; BLOOD-FLOW; LONG-TERM; TRANSDERMAL FENTANYL; CLINICAL-EXPERIENCE; COST-EFFECTIVENESS		Walton Ctr Neurol & Neurosurg NHS Trust, Liverpool L9 1AE, Merseyside, England	Walton Centre	Nurmikko, TJ (corresponding author), Walton Ctr Neurol & Neurosurg NHS Trust, Liverpool L9 1AE, Merseyside, England.		Nurmikko, Turo/J-2917-2017	Nurmikko, Turo/0000-0003-1252-6256				BACKONJA M, 1997, P 16 ANN M AM PAIN S; Bell GK, 1997, J PAIN SYMPTOM MANAG, V13, P286, DOI 10.1016/S0885-3924(96)00323-5; BELLAMY N, 1995, J RHEUMATOL, V22, P915; Burchiel KJ, 1996, SPINE, V21, P2786, DOI 10.1097/00007632-199612010-00015; Canavero S, 1996, PAIN, V68, P179, DOI 10.1016/S0304-3959(96)03168-5; Croom JE, 1997, NEUROSURGERY, V40, P565, DOI 10.1097/00006123-199703000-00027; Dellemijn PLI, 1997, LANCET, V349, P753, DOI 10.1016/S0140-6736(96)09024-1; DELLEMIJN PLI, IN PRESS J PAIN SYMP; DICKENSON A, 1995, RAIN REV, V2, P1; DONOFRIO P, 1991, ARCH INTERN MED, V151, P2225; Dray A, 1996, ANNU REV PHARMACOL, V36, P253; Eliasson T, 1996, PAIN, V65, P169, DOI 10.1016/0304-3959(95)00238-3; ENGELHARDT G, 1995, INFLAMM RES, V44, P423, DOI 10.1007/BF01757699; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; GUI JG, 1997, PAIN, V73, P87; Hautvast RWM, 1997, EUR J NEUROSCI, V9, P1178, DOI 10.1111/j.1460-9568.1997.tb01472.x; Hautvast RWM, 1996, AM J CARDIOL, V77, P462, DOI 10.1016/S0002-9149(97)89338-1; Hill PA, 1996, PAIN CLINIC, V9, P181; Huskisson EC, 1996, BRIT J RHEUMATOL, V35, P29; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; JIVEGARD LEH, 1995, EUR J VASC ENDOVASC, V9, P421, DOI 10.1016/S1078-5884(05)80010-3; Katz WA, 1996, DRUGS, V52, P39, DOI 10.2165/00003495-199600523-00007; Kumar K, 1997, J NEUROSURG, V86, P662, DOI 10.3171/jns.1997.86.4.0662; LEE CR, 1993, DRUGS, V46, P313, DOI 10.2165/00003495-199346020-00008; LINDEROTH B, 1995, NEUROSURGERY, V37, P266, DOI 10.1227/00006123-199508000-00011; LOW PA, 1995, PAIN, V62, P163, DOI 10.1016/0304-3959(94)00261-C; Lundeberg T, 1996, LANCET, V348, P1672, DOI 10.1016/S0140-6736(05)65815-1; Mannheimer C, 1998, CIRCULATION, V97, P1157, DOI 10.1161/01.CIR.97.12.1157; NAKAMURACRAIG M, 1992, BRIT J PHARMACOL, V107, pP337; Noble S, 1996, DRUGS, V51, P424, DOI 10.2165/00003495-199651030-00007; Patoia L, 1996, BRIT J RHEUMATOL, V35, P61; Rosner H, 1996, CLIN J PAIN, V12, P56, DOI 10.1097/00002508-199603000-00010; ROTH SH, 1994, J RHEUMATOL, V21, P1118; Tesfaye S, 1996, LANCET, V348, P1698, DOI 10.1016/S0140-6736(96)02467-1; TURNER JA, 1995, NEUROSURGERY, V37, P1088, DOI 10.1227/00006123-199512000-00008; WALL PD, 1995, BRIT J ANAESTH, V75, P123; WATSON CPN, 1989, PAIN, V38, P177, DOI 10.1016/0304-3959(89)90236-4; WATSON CPN, 1993, CLIN THER, V15, P510; Williams ACD, 1996, PAIN, V66, P13, DOI 10.1016/0304-3959(96)02996-X; Zakrzewska JM, 1997, PAIN, V73, P223, DOI 10.1016/S0304-3959(97)00104-8	40	17	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1438	1441		10.1136/bmj.317.7170.1438	http://dx.doi.org/10.1136/bmj.317.7170.1438			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822403	Green Published			2022-12-28	WOS:000077202200028
J	Ting, CT; Tsaur, SC; Wu, ML; Wu, CI				Ting, CT; Tsaur, SC; Wu, ML; Wu, CI			A rapidly evolving homeobox at the site of a hybrid sterility gene	SCIENCE			English	Article							DROSOPHILA-SIMULANS CLADE; C-ELEGANS UNC-4; REPRODUCTIVE ISOLATION; POSITIVE SELECTION; HOMEODOMAIN PROTEIN; FUSHI-TARAZU; EVOLUTION; EXPRESSION; SEQUENCE; COMPLEX	The homeodomain is a DNA binding motif that is usually conserved among diverse taxa, Rapidly evolving homeodomains are thus of interest because their divergence may be associated with speciation, The exact site of the Odysseus (Ods) locus of hybrid male sterility in Drosophila contains such a homeobox gene. In the past half million years, this homeodomain has experienced more amino acid substitutions than it did in the preceding 700 million years; during this period, it has also evolved faster than other parts of the protein or even the introns. Such rapid sequence divergence is driven by positive selection and may contribute to reproductive isolation.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Wu, CI (corresponding author), Univ Chicago, Dept Ecol & Evolut, 940 E 57Th St, Chicago, IL 60637 USA.	ciwu@uchicago.edu		SHUN-CHERN, TSAUR/0000-0001-8358-2015; Ting, Chau-Ti/0000-0003-1802-8864				Averof M, 1997, NATURE, V388, P682, DOI 10.1038/41786; AYALA FJ, 1993, MOL BIOL EVOL, V10, P1030; Burglin T.R, 1994, EVOLUTION HOMEOBOX G, P27; CABOT EL, 1994, GENETICS, V137, P175; Caccone A, 1996, MOL BIOL EVOL, V13, P1224, DOI 10.1093/oxfordjournals.molbev.a025688; CARROLL SB, 1994, DEVELOPMENT, P217; Civetta A, 1998, MOL BIOL EVOL, V15, P901, DOI 10.1093/oxfordjournals.molbev.a025994; DAWES R, 1994, DEVELOPMENT, V120, P1561; Eberhard W.G., 1985, SEXUAL SELECTION ANI; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; Hayward DC, 1995, DEV BIOL, V172, P452, DOI 10.1006/dbio.1995.8030; HEY J, 1993, MOL BIOL EVOL, V10, P804; Hollocher H, 1996, GENETICS, V143, P1243; Jukes T.H., 1969, MAMMALIAN PROTEIN ME; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; LEE YH, 1995, MOL BIOL EVOL, V12, P231; Lemeunier F., 1986, GENETICS BIOL DROSOP, P148; Maiti S, 1996, GENOMICS, V34, P304, DOI 10.1006/geno.1996.0291; Mansouri A, 1997, DEV DYNAM, V210, P53, DOI 10.1002/(SICI)1097-0177(199709)210:1<53::AID-AJA6>3.0.CO;2-0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Metz EC, 1996, MOL BIOL EVOL, V13, P397, DOI 10.1093/oxfordjournals.molbev.a025598; MILLER DM, 1992, NATURE, V355, P841, DOI 10.1038/355841a0; MUNOZMARMOL AM, Y10299 GENB; PALOPOLI MF, 1994, GENETICS, V138, P329; PEREZ DE, 1993, GENETICS, V134, P261; PEREZ DE, 1995, GENETICS, V140, P201; PEREZ DE, 1995, THESIS U CHICAGO; Saito T, 1996, DEV BIOL, V180, P143, DOI 10.1006/dbio.1996.0291; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; Swanson WJ, 1998, SCIENCE, V281, P710, DOI 10.1126/science.281.5377.710; TABUCHI K, 1998, 39 ANN DROS RES C WA, pC545; True JR, 1996, GENETICS, V142, P819; Tsaur SC, 1997, MOL BIOL EVOL, V14, P544, DOI 10.1093/oxfordjournals.molbev.a025791; Tsaur SC, 1998, MOL BIOL EVOL, V15, P1040, DOI 10.1093/oxfordjournals.molbev.a026002; WU CI, 1994, ANNU REV GENET, V28, P283, DOI 10.1146/annurev.ge.28.120194.001435; Wu CI, 1996, TRENDS ECOL EVOL, V11, P281, DOI 10.1016/0169-5347(96)10033-1; Zhang JZ, 1998, P NATL ACAD SCI USA, V95, P3708, DOI 10.1073/pnas.95.7.3708	37	404	410	3	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1501	1504		10.1126/science.282.5393.1501	http://dx.doi.org/10.1126/science.282.5393.1501			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822383				2022-12-28	WOS:000077110800058
J	McColl, A; Roderick, P; Gabbay, J; Smith, H; Moore, M				McColl, A; Roderick, P; Gabbay, J; Smith, H; Moore, M			Performance indicators for primary care groups: an evidence based approach	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; GENERAL-PRACTICE; RANDOMIZED TRIALS; CARDIAC-SURGERY; PREVENTION; MORTALITY; EFFICACY		Univ Southampton, Wessex Inst Hlth Res & Dev, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England; Univ Southampton, Southampton SO16 5ST, Hants, England; Three Swans Surg, Salisbury ST1 1DX, Wilts, England	University of Southampton; University of Southampton	McColl, A (corresponding author), Univ Southampton, Wessex Inst Hlth Res & Dev, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England.	a.mccoll@soton.ac.uk	Smith, Helen E/M-2449-2016; Moore, Michael/C-3447-2011	Smith, Helen E/0000-0003-1883-6124; Moore, Michael/0000-0002-5127-4509				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1430, DOI 10.1136/bmj.316.7142.1430; CAMPBELL SM, IN PRESS J PUBLIC HL; *COCHR COLL, 1997, COCHR LIB; Davies HTO, 1998, BRIT MED J, V316, P989, DOI 10.1136/bmj.316.7136.989; Fahey T, 1998, BRIT J GEN PRACT, V48, P1173; FREEMANTLE N, 1993, BRIEF INTERVENTIONS; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Ghali WA, 1997, JAMA-J AM MED ASSOC, V277, P379, DOI 10.1001/jama.277.5.379; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GRIFFIN S, 1997, COCHRANE DATABASE SY; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; Haines A, 1998, BMJ-BRIT MED J, V317, P72, DOI 10.1136/bmj.317.7150.72; HMSO, 1996, IMM INF DIS; *JOINT COMM ACCR H, 1997, NAT LIB HEALTHC IND; *JOINT HLTH SURV U, 1997, HLTH SURV ENGL 1995, V1; Langenberg M, 1996, BRIT MED J, V313, P1534, DOI 10.1136/bmj.313.7071.1534; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Leyland AH, 1998, LANCET, V351, P555, DOI 10.1016/S0140-6736(97)09362-8; Majeed A, 1997, BRIT MED J, V315, P1515, DOI 10.1136/bmj.315.7121.1515; MAJEED FA, 1995, BRIT MED J, V311, P209, DOI 10.1136/bmj.311.6999.209; MANT J, 1995, BMJ-BRIT MED J, V311, P493; McDonagh TA, 1997, LANCET, V350, P829, DOI 10.1016/S0140-6736(97)03033-X; McKee M, 1998, BRIT MED J, V316, P322, DOI 10.1136/bmj.316.7128.322; Moher M, 1997, BMJ-BRIT MED J, V315, P69, DOI 10.1136/bmj.315.7100.69; MULROW C, 1997, COCHRANE DATABASE SY; *NAT WORK GROUP R, 1997, R D PRIM CAR; Newrick DC, 1996, BMJ-BRIT MED J, V312, P33, DOI 10.1136/bmj.312.7022.33; *NHS EX, 1998, NEW NHS MOD DEP NAT; *NHS EX, 1997, STAND MED ADV COMM S; *OFF NAT STAT, 1997, NAT POP PROJ PP2, V20; PEDERSEN TR, 1994, LANCET, V344, P1383; Sackett D. L., 1997, EVIDENCE BASED MED P; Schneider EC, 1996, NEW ENGL J MED, V335, P251, DOI 10.1056/NEJM199607253350406; *SECR STAT HLTH, 1997, NEW NHS; Secretary of State for Health, 1998, OUR HEALTH NAT; SHANKS J, 1997, IMPROVING HLTH OUTCO, V2, P155; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STEIN K, 1997, IMPROVING HLTH OUTCO, V2, P167; *U YORK NHS CTR RE, 1997, EFFECTIVE HLTH CARE, V3, P1; van der Weijden T, 1998, BMJ-BRIT MED J, V316, P1400, DOI 10.1136/bmj.316.7142.1400	43	87	91	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	1998	317	7169					1354	1360		10.1136/bmj.317.7169.1354	http://dx.doi.org/10.1136/bmj.317.7169.1354			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812935	Bronze, Green Published, Green Accepted, Green Submitted			2022-12-28	WOS:000077081600023
J	Takekawa, M; Saito, H				Takekawa, M; Saito, H			A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK	CELL			English	Article							ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; GAMMA-RADIATION; EXCISION-REPAIR; KINASE CASCADES; LEUKEMIA CELLS; CHOP GADD153; GENE MYD118	The stress-responsive p38 and JNK MAPK pathways regulate cell cycle and apoptosis. A human MAPKKK, MTK1 (= MEKK4), mediates activation of both p38 and JNK in response to environmental stresses. Using a yeast two-hybrid method, three related proteins, GADD45 alpha (= GADD45), GADD45 beta (= MyD118), and GADD45 gamma, were identified that bound to an N-terminal domain of MTK1. These proteins activated MTK1 kinase activity, both in vivo and in vitro. The GADD45-like genes are induced by environmental stresses, including MMS, UV, and gamma irradiation. Expression of the GADD45-like genes induces p38/JNK activation and apoptosis, which can be partially suppressed by coexpression of a dominant inhibitory MTK1 mutant protein. We propose that the GADD45-like proteins mediate activation of the p38/JNK pathway, via MTK1/MEKK4, in response to environmental stresses.	Dana Farber Canc Inst, Div Tumor Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Saito, H (corresponding author), Dana Farber Canc Inst, Div Tumor Immunol, 44 Binney St, Boston, MA 02115 USA.	haruo_saito@dfci.harvard.edu	Saito, Haruo/AAF-6113-2019	Saito, Haruo/0000-0001-7891-1689; Takekawa, Mutsuhiro/0000-0002-8027-3847	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056699, R01GM050909] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50909, GM56699] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ARTUSO M, 1995, ONCOGENE, V11, P1427; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAZANTSEV A, 1995, SCIENCE, V270, P1003, DOI 10.1126/science.270.5238.1003; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KEARSEY JM, 1995, SCIENCE, V270, P1004; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Vairapandi M, 1996, ONCOGENE, V12, P2579; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; ZENKE BW, 1996, CURR BIOL, V6, P606; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	49	573	600	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 13	1998	95	4					521	530		10.1016/S0092-8674(00)81619-0	http://dx.doi.org/10.1016/S0092-8674(00)81619-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827804	Bronze			2022-12-28	WOS:000077049400010
J	Paetzel, M; Dalbey, RE; Strynadka, NCJ				Paetzel, M; Dalbey, RE; Strynadka, NCJ			Crystal structure of a bacterial signal peptidase in complex with a beta-lactam inhibitor	NATURE			English	Article							COLI LEADER PEPTIDASE; CATALYTICALLY ACTIVE FORM; ESCHERICHIA-COLI; PROTEIN; REQUIREMENT; DETERGENT	The signal peptidase (SPase) from Escherichia coli is a membrane-bound endopeptidase with two amino-terminal transmembrane segments and a carboxy-terminal catalytic region which resides in the periplasmic space(1). SPase functions to release proteins that have been translocated into the inner membrane from the cell interior, by cleaving off their signal peptides(1). We report here the X-ray crystal structure of a catalytically active soluble fragment of E. coli SPase (SPase Delta 2-75)(2,3). We have determined this structure at 1.9 Angstrom resolution in a complex with an inhibitor, a beta-lactam (5S,6S penem)(4,5), which is covalently bound as an acyl-enzyme intermediate to the gamma-oxygen of a serine residue at position 90, demonstrating that this residue acts as the nucleophile in the hydrolytic mechanism of signal-peptide cleavage. The structure is consistent with the use by SPase of Lys 145 as a general base in the activation of the nucleophilic Ser90, explains the specificity requirement at the signal-peptide cleavage site, and reveals a large exposed hydrophobic surface which could be a site for an intimate association with the membrane. As enzymes that are essential for cell viability, bacterial SPases present a feasible antibacterial target(4-6): our determination of the SPase structure therefore provides a template for the rational design of antibiotic compounds.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Ohio State Univ, Dept Chem, Columbus, OH 43210 USA	University of British Columbia; University System of Ohio; Ohio State University	Strynadka, NCJ (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada.	natalie@byron.biochem.ubc.ca		Paetzel, Mark/0000-0002-7408-5487				ALLSOP AE, 1997, RECENT ADV CHEM STRU, P61; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Black MT, 1998, CURR PHARM DESIGN, V4, P133; BRUNGER AT, 1987, XPLOR SYSTEM XRAY CR; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; DATE T, 1983, J BACTERIOL, V154, P76, DOI 10.1128/JB.154.1.76-83.1983; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM YT, 1995, EUR J BIOCHEM, V234, P358, DOI 10.1111/j.1432-1033.1995.358_c.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO DW, 1993, ARCH BIOCHEM BIOPHYS, V303, P274, DOI 10.1006/abbi.1993.1283; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; MANARD R, 1992, BIOL CHEM HOPPESEYLE, V373, P393; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicolas A, 1996, BIOCHEMISTRY-US, V35, P398, DOI 10.1021/bi9515578; Paetzel M, 1997, J BIOL CHEM, V272, P9994; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; PAETZEL M, 1995, PROTEINS, V23, P122, DOI 10.1002/prot.340230115; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; TSCHANTZ WR, 1995, BIOCHEMISTRY-US, V34, P3935, DOI 10.1021/bi00012a010; van Klompenburg W, 1998, FEBS LETT, V431, P75, DOI 10.1016/S0014-5793(98)00733-9; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WHITLEY P, 1993, FEBS LETT, V332, P49, DOI 10.1016/0014-5793(93)80481-9; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; [No title captured]	29	262	272	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	1998	396	6707					186	190		10.1038/24196	http://dx.doi.org/10.1038/24196			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823901				2022-12-28	WOS:000077013300057
J	Cardini, F; Huang, WX				Cardini, F; Huang, WX			Moxibustion for correction of breech presentation - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VERTEX-PRESENTATION; CEPHALIC VERSION; GESTATIONAL-AGE; HUMAN-FETUS; PREGNANCY; POSITION; BIRTH	Context.-Traditional Chinese medicine uses moxibustion (burning herbs to stimulate acupuncture points) of acupoint BL 67 (Zhiyin, located beside the outer corner of the fifth toenail), to promote version of fetuses in breech presentation. Its effect may be through increasing fetal activity. However, no randomized controlled trial has evaluated the efficacy of this therapy. Objective.-To evaluate the efficacy and safety of moxibustion on acupoint BL 67 to increase fetal activity and correct breech presentation. Design.-Randomized, controlled, open clinical trial. Setting.-Outpatient departments of the Women's Hospital of Jiangxi Province, Nanchang, and Jiujiang Women's and Children's Hospital in the People's Republic of China. Patients.-Primigravidas in the 33rd week of gestation with normal pregnancy and an ultrasound diagnosis of breech presentation. Interventions.-The 130 subjects randomized to the intervention group received stimulation of acupoint BL 67 by moxa (Japanese term for Artemisia vulgaris) rolls for 7 days, with treatment for an additional 7 days if the fetus persisted in the breech presentation. The 130 subjects randomized to the control group received routine care but no interventions for breech presentation. Subjects with persistent breech presentation after 2 weeks of treatment could undergo external cephalic version anytime between 35 weeks' gestation and delivery. Main Outcome Measures.-Fetal movements counted by the mother during 1 hour each day for 1 week; number of cephalic presentations during the 35th week and at delivery. Results.-The intervention group experienced a mean of 48.45 fetal movements vs 35.35 in the control group (P < .001; 95% confidence interval [CI] for difference, 10.56-15.60). During the 35th week of gestation, 98 (75.4%) of 130 fetuses in the intervention group were cephalic vs 62 (47.7%) of 130 fetuses in the control group (P < .001; relative risk [RR], 1.58; 95% CI, 1.29-1.94). Despite the fact that 24 subjects in the control group and 1 subject in the intervention group underwent external cephalic version, 98 (75.4%) of the 130 fetuses in the intervention group were cephalic at birth vs 81 (62.3%) of the 130 fetuses in the control group (P = .02; RR, 1.21; 95% CI, 1.02-1.43). Conclusion.-Among primigravidas with breech presentation during the 33rd week of gestation, moxibustion for 1 to 2 weeks increased fetal activity during the treatment period and cephalic presentation after the treatment period and at delivery.	Jiangxi Womens Hosp, Nanchang, Peoples R China		Cardini, F (corresponding author), Via Risorgimento 15, I-37126 Verona, Italy.							BABKIN PS, 1994, ZH NEVROPATOL PSIKH, V94, P19; Bartlett D, 1997, EARLY HUM DEV, V48, P261, DOI 10.1016/S0378-3782(97)01865-3; BARTLETT D, 1994, DEV MED CHILD NEUROL, V36, P833; BOOS R, 1987, GEBURTSH FRAUENHEILK, V47, P341, DOI 10.1055/s-2008-1035833; CARDINI F, 1993, AM J CHINESE MED, V21, P133, DOI 10.1142/S0192415X93000169; CARDINI F, 1991, AM J CHINESE MED, V19, P105, DOI 10.1142/S0192415X9100017X; *COOP RES GROUP MO, 1984, 2 NAT S AC MOX AC AN; ENGEL K, 1992, GEBURTSH FRAUENHEILK, V52, P241, DOI 10.1055/s-2007-1026138; GOTTLICHER S, 1985, GEBURTSH FRAUENHEILK, V45, P534, DOI 10.1055/s-2008-1036364; GOTTLICHER S, 1989, GEBURTSH FRAUENHEILK, V49, P363, DOI 10.1055/s-2008-1026601; HICKOK DE, 1992, AM J OBSTET GYNECOL, V166, P851, DOI 10.1016/0002-9378(92)91347-D; HILL LM, 1990, AM J PERINAT, V7, P92, DOI 10.1055/s-2007-999455; HOFMEYR GJ, 1998, COCHRANE LIBRARY PRE; HUGHEY MJ, 1985, AM J OBSTET GYNECOL, V153, P885, DOI 10.1016/S0002-9378(85)80276-3; Rayl J, 1996, AM J OBSTET GYNECOL, V174, P28, DOI 10.1016/S0002-9378(96)70368-X; SCHEER K, 1976, AM J OBSTET GYNECOL, V125, P269, DOI 10.1016/0002-9378(76)90609-8; SIVAL DA, 1993, EARLY HUM DEV, V34, P13, DOI 10.1016/0378-3782(93)90036-T; THORP JM, 1991, OBSTET GYNECOL, V78, P394; WENG J, 1984, 2 NAT S AC MOX AC AN; WESTGREN M, 1985, BRIT J OBSTET GYNAEC, V92, P19, DOI 10.1111/j.1471-0528.1985.tb01043.x; *WHO REG OFF W PAC, 1995, WHO W PAC SER, V15; XIANGTONG Z, 1980, RES ACUPUNCTURE MOXI, P810	22	125	134	3	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1580	1584		10.1001/jama.280.18.1580	http://dx.doi.org/10.1001/jama.280.18.1580			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820259				2022-12-28	WOS:000076852000024
J	Ebers, GC; Rice, G; Lesaux, J; Paty, D; Oger, J; Li, DKB; Beall, S; Devonshire, V; Hashimoto, S; Hooge, J; Kastrukoff, L; Krieger, C; Mezei, M; Seland, P; Vorobeychi, G; Morrison, W; Nelson, J; Freedman, MS; Chrisie, S; Nelson, R; Rabinovitch, H; Freedman, C; Hartung, HP; Rieckmann, P; Archelos, J; Jung, S; Weilbach, F; Flachenecke, P; Sauer, J; Hommes, O; Jongen, P; Brouwer, S; McLeod, J; Pollard, J; Ng, R; Sandberg-Wollheim, M; Kallen, K; Nilsson, P; Ekberg, R; Lundgren, A; Jadback, G; Wikstrom, J; Multanen, J; Valjakka, M; Carton, H; Lissoir, F; Declerq, I; Vieren, M; Peeters, E; Dubois, B; Dekeersmaeker, E; Van Herle, A; Hughes, RAC; Sharrack, B; Soudain, S; Panelius, M; Eralinna, J; Soilu-Hanninen, M; Murto, S; Medaer, R; Broeckx, J; Vanroose, E; Bogaers, A; Blumhardt, LD; Edwards, S; Liu, C; Orpe, V; Barnes, D; Schwartz, M; Stoy, N; Harraghy, C; Bertelsmann, F; Uitdehaag, B; Nasseri, K; Chofflon, M; Roth, S; Kappos, L; Huber, S; Bellaiche, Y; Senn, C; King, J; Jubert, J; Whitten, S; Newsom-Davis, JM; Palace, J; Lee, M; Evangelou, N; Pinto, A; Cavey, A; Sindic, CJM; Monteyne, P; Verougstraete, D; Van Doorn, PA; Moll, W; Visser, L; Willems, M; Martina, I; Buljevac, D; Loman, L; Bates, D; Pandit, D; Irving, J; Rhodes, B; Riddehough, A; Zhao, GJ; Wang, X; Cheng, Y; Ammoury, N; Dupont, F; Galazka, A; Hyde, R; Olson, M; Pernin, MO; Abdul-Ahad, AK; Hommes, O; Noseworthy, J; Borden, E; O'Brien, P; Wolinsky, J				Ebers, GC; Rice, G; Lesaux, J; Paty, D; Oger, J; Li, DKB; Beall, S; Devonshire, V; Hashimoto, S; Hooge, J; Kastrukoff, L; Krieger, C; Mezei, M; Seland, P; Vorobeychi, G; Morrison, W; Nelson, J; Freedman, MS; Chrisie, S; Nelson, R; Rabinovitch, H; Freedman, C; Hartung, HP; Rieckmann, P; Archelos, J; Jung, S; Weilbach, F; Flachenecke, P; Sauer, J; Hommes, O; Jongen, P; Brouwer, S; McLeod, J; Pollard, J; Ng, R; Sandberg-Wollheim, M; Kallen, K; Nilsson, P; Ekberg, R; Lundgren, A; Jadback, G; Wikstrom, J; Multanen, J; Valjakka, M; Carton, H; Lissoir, F; Declerq, I; Vieren, M; Peeters, E; Dubois, B; Dekeersmaeker, E; Van Herle, A; Hughes, RAC; Sharrack, B; Soudain, S; Panelius, M; Eralinna, J; Soilu-Hanninen, M; Murto, S; Medaer, R; Broeckx, J; Vanroose, E; Bogaers, A; Blumhardt, LD; Edwards, S; Liu, C; Orpe, V; Barnes, D; Schwartz, M; Stoy, N; Harraghy, C; Bertelsmann, F; Uitdehaag, B; Nasseri, K; Chofflon, M; Roth, S; Kappos, L; Huber, S; Bellaiche, Y; Senn, C; King, J; Jubert, J; Whitten, S; Newsom-Davis, JM; Palace, J; Lee, M; Evangelou, N; Pinto, A; Cavey, A; Sindic, CJM; Monteyne, P; Verougstraete, D; Van Doorn, PA; Moll, W; Visser, L; Willems, M; Martina, I; Buljevac, D; Loman, L; Bates, D; Pandit, D; Irving, J; Rhodes, B; Riddehough, A; Zhao, GJ; Wang, X; Cheng, Y; Ammoury, N; Dupont, F; Galazka, A; Hyde, R; Olson, M; Pernin, MO; Abdul-Ahad, AK; Hommes, O; Noseworthy, J; Borden, E; O'Brien, P; Wolinsky, J		PRISMS Study Grp	Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis	LANCET			English	Article							STATUS SCALE EDSS; NATURAL-HISTORY; CONTROLLED TRIAL; DISABILITY; MULTICENTER; GUIDELINES	Background Previous trials of interferon beta in multiple sclerosis (MS) have shown efficacy, but the degree of clinical benefit remains uncertain, and the optimum dose is not known. We undertook a double-blind, placebo-controlled study in relapsing/remitting MS to investigate the effects of subcutaneous interferon beta-1a. Methods 560 patients with Kurtzke expanded disability status scale (EDSS) scores of 0-5.0, from 22 centres in nine countries, were randomly assigned subcutaneous recombinant interferon beta-1a 22 mu g (n=189), or 44 mu g (n=184), or placebo (n=187) three times a week for 2 years. Neurological examinations were done every 3 months. All patients had MRI twice yearly and 205 had monthly scans in the first 9 months of treatment. Analysis was by intention to treat. Findings Clinical data on 533 (95%) patients were available at 2 years. The relapse rate was significantly lower at 1 and 2 years with both doses of interferon beta-1a than with placebo (mean number per patient 1.82 for 22 mu g group, 1.73 for 44 mu g group vs 2.56 for placebo group: risk reductions 27% [95% CI 14-39] and 33 [21-44]). Time to first relapse was prolonged by 3 and 5 months in the 22 mu g and 44 mu g groups respectively, and the proportion of relapse-free patients was significantly increased (p < 0.05). Interferon beta-1a delayed progression in disability, and decreased accumulated disability during the study. The accumulation of burden of disease and number of active lesions on MRI was lower in both treatment groups than in the placebo group. Interpretation Subcutaneous interferon beta-1a is an effective treatment for relapsing/remitting MS in terms of relapse rate, defined disability, and all MRI outcome measures in a dose-related manner, and it is well tolerated. Longer-term benefits may become clearer with further follow-up and investigation.	London Hlth Sci Ctr, Div Neurol, London, ON N6A 5A5, Canada; Univ Western Ontario, Univ Hosp, London, ON N6A 5A5, Canada; Vancouver Hosp, Vancouver, BC, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Ottawa Gen Hosp, Ottawa, ON K1H 8L6, Canada; Univ Wurzburg, Kopfklinikum, Neurol Klin & Poliklin, Wurzburg, Germany; Stichting MS Centrum, Nijmegen, Netherlands; Univ Sydney, Sydney, NSW 2006, Australia; Univ Lund Hosp, S-22185 Lund, Sweden; Univ Helsinki, Cent Hosp, Helsinki, Finland; Catholic Univ Louvain, Hosp Gasthuisberg, B-3000 Louvain, Belgium; Guys Hosp, London SE1 9RT, England; Turku Univ, Cent Hosp, FIN-20520 Turku, Finland; Univ Diepenbeek, Dr Willems Inst, Diepenbeek, Belgium; Univ Hosp, Queens Med Ctr, Nottingham, England; Atkinson Morleys Hosp, London, England; Free Univ Amsterdam Hosp, Amsterdam, Netherlands; Hop Cantonal Univ Geneva, CH-1211 Geneva, Switzerland; Univ Kliniken, Kantonsspital Basel, Basel, Switzerland; Royal Melbourne Hosp, Melbourne, Vic, Australia; Univ Oxford, Radcliffe Infirm, Oxford OX2 6HE, England; Clin Univ St Luc, B-1200 Brussels, Belgium; Acad Ziekenhuis Dijkzigt, Rotterdam, Netherlands; Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ British Columbia, MS MRI Anal Res Grp, Vancouver, BC V5Z 1M9, Canada; Ares Serono Int SA, Geneva, Switzerland	London Health Sciences Centre; Western University (University of Western Ontario); University of British Columbia; University of British Columbia; University of Ottawa; Ottawa Hospital Research Institute; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg; University of Sydney; Lund University; Skane University Hospital; University of Helsinki; Helsinki University Central Hospital; Universite Catholique Louvain; Guy's & St Thomas' NHS Foundation Trust; University of Turku; Hasselt University; Nottingham University Hospital NHS Trust; University of Nottingham; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Geneva; Royal Melbourne Hospital; Radcliffe Infirmary; University of Oxford; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Erasmus University Rotterdam; Erasmus MC; Newcastle University - UK; University of British Columbia; Merck & Company; Serono International S.A.	Ebers, GC (corresponding author), London Hlth Sci Ctr, Div Neurol, 339 Windermere Rd, London, ON N6A 5A5, Canada.		Macedo, Ana/L-9912-2018; Dubois, Benedicte/A-4338-2019	Macedo, Ana/0000-0002-6978-8989; Ebers, George/0000-0003-4771-4177; Dubois, Benedicte/0000-0003-0604-8702; evangelou, nikos/0000-0003-2871-0672				Barnes D, 1997, LANCET, V349, P902, DOI 10.1016/S0140-6736(96)06453-7; CHERNAJOVSKY Y, 1984, DNA-J MOLEC CELL BIO, V3, P297, DOI 10.1089/dna.1.1984.3.297; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Duquette P, 1996, NEUROLOGY, V47, P889; EBERS GC, 1994, LANCET, V343, P275, DOI 10.1016/S0140-6736(94)91119-3; Ebers GC, 1998, EUR J NEUROL, V5, pS7; EBERS GC, 1997, MULT SCLER, P192; Fazekas F, 1997, LANCET, V349, P589, DOI 10.1016/S0140-6736(96)09377-4; GOODKIN DE, 1992, NEUROLOGY, V42, P859, DOI 10.1212/WNL.42.4.859; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; JACOBS L, 1994, ARCH NEUROL-CHICAGO, V51, P1245, DOI 10.1001/archneur.1994.00540240089022; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; JOHNSON K P, 1990, Neurology, V40, P261; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Khan OA, 1998, NEUROLOGY, V51, P738, DOI 10.1212/WNL.51.3.738; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Liu C, 1998, J NEUROL NEUROSUR PS, V64, P726, DOI 10.1136/jnnp.64.6.726; MILLER DH, 1988, BRAIN, V111, P927, DOI 10.1093/brain/111.4.927; Miller DH, 1996, ANN NEUROL, V39, P6, DOI 10.1002/ana.410390104; Munafo A, 1998, EUR J NEUROL, V5, P187, DOI 10.1046/j.1468-1331.1998.520187.x; NOSEWORTHY JH, 1989, NEUROLOGY, V39, P977, DOI 10.1212/WNL.39.7.977; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Pozzilli C, 1996, J NEUROL NEUROSUR PS, V61, P251, DOI 10.1136/jnnp.61.3.251; Reder A. T., 1997, INTERFERON THER MULT, V352, P1; RICE GPA, 1997, MULT SCLER, V3, P232; RICE GPA, 1998, IN PRESS ARCH NEUROL; ROITT IM, 1993, IMMUNOLOGY 94, P1; RUNMARKER B, 1993, BRAIN, V116, P117, DOI 10.1093/brain/116.1.117; Sandberg-Wollheim M, 1995, Mult Scler, V1 Suppl 1, pS48; SCHUMACHER GA, 1965, ANN NY ACAD SCI, V122, P552; Simon JH, 1998, ANN NEUROL, V43, P79, DOI 10.1002/ana.410430114; Thompson AJ, 1996, CURR OPIN NEUROL, V9, P187, DOI 10.1097/00019052-199606000-00006; WEINSHENKER BG, 1991, BRAIN, V114, P1057, DOI 10.1093/brain/114.2.1057; WEINSHENKER BG, 1995, NEUROL CLIN, V13, P119, DOI 10.1016/S0733-8619(18)30064-1; WEINSHENKER BG, 1989, BRAIN, V112, P1419, DOI 10.1093/brain/112.6.1419; WEINSHENKER BG, 1989, BRAIN, V112, P133, DOI 10.1093/brain/112.1.133; YOUNG IR, 1981, LANCET, V2, P1063, DOI 10.1016/S0140-6736(81)91273-3	39	1729	1772	1	56	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1498	1504		10.1016/S0140-6736(98)03334-0	http://dx.doi.org/10.1016/S0140-6736(98)03334-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820297				2022-12-28	WOS:000076862300007
J	Karanjawala, ZE; Collins, FS				Karanjawala, ZE; Collins, FS			Genetics in the context of medical practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ So Calif, Sch Med, Los Angeles, CA 90089 USA; NIH, Natl Human Genome Res Inst, Bethesda, MD 20892 USA	University of Southern California; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Karanjawala, ZE (corresponding author), Univ So Calif, Sch Med, Los Angeles, CA 90089 USA.							COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; HUDSON KL, 1995, SCIENCE, V270, P391, DOI 10.1126/science.270.5235.391; MITKA M, 1998, AM MED NEWS     0406; *NAT HUM GEN RES I, 1998, NAT COAL HLTH PROF E; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; STRASS E, 1995, AM J HUM GENET, V56, P535; *TASK FORC GEN TES, 1998, PROM SAF EFF GEN TES; *US DEP HHS, 1990, UND OUR GEN INH US G	10	13	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1533	1534		10.1001/jama.280.17.1533	http://dx.doi.org/10.1001/jama.280.17.1533			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809738	hybrid			2022-12-28	WOS:000076757200031
J	Therrien, M; Wong, AM; Rubin, GM				Therrien, M; Wong, AM; Rubin, GM			CNK, a RAF-binding multidomain protein required for RAS signaling	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; DEVELOPING DROSOPHILA EYE; KSR-1 GENE ENCODES; TYROSINE KINASE; SEVENLESS PROTEIN; EGF RECEPTOR; C-ELEGANS; DOMAINS; TRANSDUCTION; ACTIVATION	Kinase suppressor of ras (ksr) is required for efficient signal transmission within the RAS/MAPK cascade. A screen for mutations that modify a ksr-dependent phenotype identified a novel gene, connector enhancer of ksr (cnk), that functions upstream or in parallel to RAF in the RAS pathway, cnk encodes a protein containing several protein-protein interaction domains, suggesting that it brings different signaling molecules together. CNK is required in multiple receptor tyrosine kinase pathways where it appears to be a tyrosine phosphorylation target. Finally, CNK physically interacts with RAF and appears to localize to cell-cell contact regions. Together, these findings suggest that CNK is a novel component of a PAS-dependent signaling pathway that regulates RAF function and/or targets RAF to a specific subcellular compartment upon RAS activation.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Rubin, GM (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.	gerry@fruitfly.berkeley.edu		Rubin, Gerald/0000-0001-8762-8703				ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GOLEMIS E, 1994, CURRENT PROTOCOL MOL; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Karim FD, 1996, GENETICS, V143, P315; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KIRKPATRICK C, 1995, CURR OPIN GENET DEV, V5, P56, DOI 10.1016/S0959-437X(95)90054-3; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; LONGLEY RL, 1995, DEV BIOL, V171, P415, DOI 10.1006/dbio.1995.1292; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; MELNICK MB, 1993, DEVELOPMENT, V118, P127; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Schultz J, 1997, PROTEIN SCI, V6, P249; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; XU T, 1993, DEVELOPMENT, V117, P1223; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	52	136	140	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1998	95	3					343	353		10.1016/S0092-8674(00)81766-3	http://dx.doi.org/10.1016/S0092-8674(00)81766-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814705	Bronze			2022-12-28	WOS:000076789600008
J	von der Emde, G; Schwarz, S; Gomez, L; Budelli, R; Grant, K				von der Emde, G; Schwarz, S; Gomez, L; Budelli, R; Grant, K			Electric fish measure distance in the dark	NATURE			English	Article							OBJECTS; FIELD; CUES	Distance determination in animals can be achieved by visual or non-visual cues(1). Weakly electric fish use active electrolocation for orientation in the dark(2). By perceiving self-produced electric signals with epidermal electroreceptors, fish can detect, locate and analyse nearby objects. Distance discrimination, however, was thought to be hardly possible because it was assumed that confusing ambiguity could arise with objects of unknown sizes and materials(3-5). Here we show that during electrolocation electric fish can measure the distance of most objects accurately, independently of size, shape and material, Measurements of the 'electric image' projected onto the skin surface during electrolocation(6-8) revealed only one parameter combination that was unambiguously related to object distance: the ratio between maximal image slope and maximal image amplitude. However, slope-to-amplitude ratios for spheres were always smaller than those for other objects. As predicted, these objects were erroneously judged by the fish to be further away than all other objects at an identical distance. Our results suggest a novel mechanism for depth perception that can be achieved with a single, stationary two-dimensional array of detectors.	Univ Bonn, Inst Zool, D-53115 Bonn, Germany; CNRS, Inst Alfred Fessard, F-91198 Gif Sur Yvette, France; Univ Republ Uruguay, Fac Sci, Dept Biomath, Montevideo, Uruguay	University of Bonn; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Universidad de la Republica, Uruguay	von der Emde, G (corresponding author), Univ Bonn, Inst Zool, Poppelsdorfer Schloss, D-53115 Bonn, Germany.		Gomez-Sena, Leonel/ABA-9531-2020	Gomez-Sena, Leonel/0000-0002-3076-762X				Atema J, 1996, BIOL BULL, V191, P129, DOI 10.2307/1543074; BASTIAN J, 1989, COMP PERCEPTION, P35; Bleckmann H., 1989, P501; Bleckmann H, 1994, RECEPTION HYDRODYNAM; Caputi AA, 1998, J EXP BIOL, V201, P2115; Ciali S, 1997, J FISH BIOL, V50, P1074, DOI 10.1006/jfbi.1996.0372; COLLETT T, 1977, NATURE, V267, P349, DOI 10.1038/267349a0; Collett T.S., 1982, P111; DEAR SP, 1993, NATURE, V364, P620, DOI 10.1038/364620a0; HARKNESS L, 1977, NATURE, V267, P346, DOI 10.1038/267346a0; Hassan E.S., 1989, P217; HEILIGENBERG W, 1973, J COMP PHYSIOL, V87, P137, DOI 10.1007/BF01352158; HOERL AE, 1954, CHEM BUSINESS HDB, P20; HOPKINS CD, 1986, BRAIN BEHAV EVOLUT, V28, P43, DOI 10.1159/000118691; Howard IP, 1995, BINOCULAR VISION STE; Kral K, 1997, J INSECT BEHAV, V10, P145, DOI 10.1007/BF02765480; LEHRER M, 1988, NATURE, V332, P356, DOI 10.1038/332356a0; LISSMANN HW, 1958, J EXP BIOL, V35, P451; MOLLER P, 1979, BEHAV ECOL SOCIOBIOL, V4, P357, DOI 10.1007/BF00303242; Rasnow B, 1996, J COMP PHYSIOL A, V178, P397; Schnitzler H.-U., 1985, P180; SCHUIJF A, 1983, NATURE, V302, P143, DOI 10.1038/302143a0; SCHWARZ S, 1997, THESIS U BONN; SUGA N, 1995, ACTIVE HEARING, P13; Von der Emde G, 1998, J EXP BIOL, V201, P969; von der Emde Gerhard, 1998, P313; VONDEREMDE G, 1993, J EXP BIOL, V181, P157; WAGNER H, 1982, NATURE, V297, P147, DOI 10.1038/297147a0; Zar JH., 1999, BIOSTAT ANAL; [No title captured]	30	146	152	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1998	395	6705					890	894		10.1038/27655	http://dx.doi.org/10.1038/27655			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804420				2022-12-28	WOS:000076713400054
J	Frank, E				Frank, E			Breastfeeding and maternal employment: two rights don't make a wrong	LANCET			English	Editorial Material									Emory Univ, Sch Med, Dept Family & Prevent Med, Atlanta, GA 30303 USA	Emory University	Frank, E (corresponding author), Emory Univ, Sch Med, Dept Family & Prevent Med, Atlanta, GA 30303 USA.			Frank, Erica/0000-0001-7159-5417				Fein SB, 1998, AM J PUBLIC HEALTH, V88, P1042, DOI 10.2105/AJPH.88.7.1042; Gartner LM, 1997, PEDIATRICS, V100, P1035, DOI 10.1542/peds.100.6.1035; Scariati PD, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.6.e5; SPANGLER A, 1995, BREASTFEEDING PARENT; *US DEP HHS, 1990, US DEP HLTH HUM SERV, P379	5	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 3	1998	352	9134					1083	1084		10.1016/S0140-6736(05)79752-X	http://dx.doi.org/10.1016/S0140-6736(05)79752-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	125PP	9798580				2022-12-28	WOS:000076246400005
J	Thomson, AJ; Lunan, CB; Ledingham, M; Howat, RCL; Cameron, IT; Greer, IA; Norman, JE				Thomson, AJ; Lunan, CB; Ledingham, M; Howat, RCL; Cameron, IT; Greer, IA; Norman, JE			Randomised trial of nitric oxide donor versus prostaglandin for cervical ripening before first-trimester termination of pregnancy	LANCET			English	Article							CURETTAGE ABORTION; VACUUM ASPIRATION; UTERINE ARTERY; MISOPROSTOL; GEMEPROST; DILATATION; SUCTION; LABOR; NITROGLYCERIN; PREECLAMPSIA	Background Vaginal administration of the nitric oxide donor isosorbide mononitrate can induce effective ripening of the human cervix. We investigated whether this drug is associated with fewer side-effects than prostaglandins when used to ripen the cervix before first-trimester surgical termination of pregnancy, and assessed whether the extent of cervical ripening it induces is clinically sufficient. Methods 66 primigravid women scheduled for surgical termination were assigned to receive before surgery, per vaginam, isosorbide mononitrate 40 mg or 80 mg, or the prostaglandin analogue gemeprost 1 mg. The primary measured outcome was onset of new symptoms before termination of pregnancy. Findings More women remained symptom-free after isosorbide mononitrate than after gemeprost (28/44 [64%] vs 3/22 [14%], p<0.005). Pretreatment with gemeprost resulted in abdominal pain in 73% of women and vaginal bleeding in 32% compared with 3% and 0%, respectively, after isosorbide mononitrate, whereas, more women developed headache after isosorbide mononitrate (27%) than after gemeprost (0%). Cervical resistance and measured intraoperative blood loss were lowest after pretreatment with gemeprost, The measured cervical resistance and intraoperative blood loss with either dose of isosorbide mononitrate did not differ from those in a comparison group of 22 parous women not in the randomised trial. Interpretation Pretreatment with isosorbide mononitrate to ripen the cervix before first-trimester termination of pregnancy is associated with fewer side-effects than gemeprost treatment and adequately decreases cervical resistance. Isosorbide mononitrate could be used as an alternative to gemeprost for this indication.	Univ Glasgow, Dept Obstet & Gynaecol, Glasgow G31 2ER, Lanark, Scotland	University of Glasgow	Thomson, AJ (corresponding author), Univ Glasgow, Dept Obstet & Gynaecol, Glasgow G31 2ER, Lanark, Scotland.		Norman, Jane/B-2347-2010	Norman, Jane/0000-0001-6031-6953				ALI M, 1995, J SOC GYNECOL INVEST, V2, P80; Altman DG., 1982, STATISTICS PRACTICE, P6; Angaard E., 1994, LANCET, V343, P1199; ANTHONY GS, 1982, BRIT J OBSTET GYNAEC, V89, P913, DOI 10.1111/j.1471-0528.1982.tb05056.x; Buhimschi I, 1996, HUM REPROD, V11, P1755; Bulletti C, 1997, HUM REPROD, V12, P1073; Chwalisz K, 1997, HUM REPROD, V12, P2093, DOI 10.1093/humrep/12.10.2093; COTTON DB, 1986, AM J OBSTET GYNECOL, V154, P1053, DOI 10.1016/0002-9378(86)90749-0; ELREFAEY H, 1994, LANCET, V343, P1207, DOI 10.1016/S0140-6736(94)92406-6; GREER IA, 1992, EUR J OBSTET GYN R B, V47, P1, DOI 10.1016/0028-2243(92)90207-F; GRIMES DA, 1984, JAMA-J AM MED ASSOC, V251, P2108, DOI 10.1001/jama.251.16.2108; GRUNEWALD C, 1995, OBSTET GYNECOL, V86, P600, DOI 10.1016/0029-7844(95)00197-Y; HELM CW, 1988, BRIT J OBSTET GYNAEC, V95, P911, DOI 10.1111/j.1471-0528.1988.tb06579.x; HENSHAW RC, 1991, BRIT J OBSTET GYNAEC, V98, P1025, DOI 10.1111/j.1471-0528.1991.tb15341.x; Lawrie A, 1996, BRIT J OBSTET GYNAEC, V103, P1117, DOI 10.1111/j.1471-0528.1996.tb09593.x; LEES C, 1994, LANCET, V343, P1325, DOI 10.1016/S0140-6736(94)92468-6; MACKENZIE IZ, 1981, BRIT J OBSTET GYNAEC, V88, P1033, DOI 10.1111/j.1471-0528.1981.tb01693.x; Ngai SW, 1996, BRIT J OBSTET GYNAEC, V103, P1120, DOI 10.1111/j.1471-0528.1996.tb09594.x; Norman J, 1996, PHARMACOL THERAPEUT, V70, P91, DOI 10.1016/0163-7258(96)00004-6; Norman JE, 1998, HUM REPROD, V13, P251, DOI 10.1093/humrep/13.2.251; RAMSAY B, 1994, EUR J CLIN INVEST, V24, P76, DOI 10.1111/j.1365-2362.1994.tb02064.x; RICHARDSON W, 1989, J MED ENG TECHNOL, V13, P220, DOI 10.3109/03091908909015410; Robertson RM, 1995, GOODMAN GILMANS PHAR, P759; *ROYAL COLL OBST G, 1997, IND AB; SCHULZ KF, 1983, LANCET, V1, P1182; Thaler I, 1996, OBSTET GYNECOL, V88, P838, DOI 10.1016/0029-7844(96)00297-9; Thomson AJ, 1997, BRIT J OBSTET GYNAEC, V104, P1054, DOI 10.1111/j.1471-0528.1997.tb12066.x; VANLOOK PFA, 1990, BRIT J OBSTET GYNAEC, V97, P260; WING DA, 1995, AM J OBSTET GYNECOL, V172, P1804, DOI 10.1016/0002-9378(95)91415-3	29	64	64	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 3	1998	352	9134					1093	1096		10.1016/S0140-6736(98)01289-6	http://dx.doi.org/10.1016/S0140-6736(98)01289-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798584				2022-12-28	WOS:000076246400009
J	Duijm, LEM; Guit, GL; Hendriks, JHCL; Zaat, JOM; Mali, WPTM				Duijm, LEM; Guit, GL; Hendriks, JHCL; Zaat, JOM; Mali, WPTM			Value of breast imaging in women with painful breasts: observational follow up study	BRITISH MEDICAL JOURNAL			English	Article							MAMMOGRAPHY; CANCER; MANAGEMENT; MORTALITY; PUNCTURE; LESIONS; TRIALS; CYSTS	Objectives To determine the value of breast imaging in patients with localised or diffuse pain in the breast in whom physical examination shows no abnormalities. Design Observational follow up study. Setting Radiology department of a teaching hospital in the Netherlands. Subjects Altogether 987 women referred for radiological breast imaging because of pain alone and a control group of 987 asymptomatic women referred for a screening mammogram. Main outcome measures Correlation of the radiological findings rath clinical and pathological findings over two years of follow up. Results Radiological examination of the painful breast(s) showed the following: normal findings in 854 (86.5%) women, benign abnormalities in 85 (8.6%; mainly small cysts or mastopathy), abnormalities that were probably benign in 36 (3.6%), suspicious findings in 8 (0.8%), and malignancy in 4 (0.4%), Biopsy of the painful area was performed in 10 of the 939 women with normal findings or benign abnormalities, in two of 36 women with radiological abnormalities that were probably benign, and in all women with suspicious or malignant findings. Only the four lesions that had been classified radiologically as malignant were found to be malignant at surgery, The prevalence of breast cancer was similar in symptomatic and control women. Conclusions Breast imaging in women who present with pain alone is of value only in providing reassurance-no abnormalities are usually found in the painful area, radiological abnormalities classified as benign do not generally have any clinical consequences, and the prevalence of cancer is low in these women, Biopsy of the painful area should be performed only where radiological findings are suspicious.	Kennemer Gasthuis Locatie Elisabeth Gasthuis, Dept Radiol, NL-2035 RC Haarlem, Netherlands; Radboud Univ Hosp, Dept Radiol, NL-6500 HB Nijmegen, Netherlands; Free Univ Amsterdam, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands; Univ Utrecht Hosp, Dept Radiol, NL-3584 CX Utrecht, Netherlands	Spaarne Hospital; Radboud University Nijmegen; Vrije Universiteit Amsterdam; Utrecht University; Utrecht University Medical Center	Duijm, LEM (corresponding author), Catharina Hosp, Dept Radiol, NL-5602 ZA Eindhoven, Netherlands.		Mali, Willem PThM/I-1123-2014	Mali, Willem PThM/0000-0003-4391-0904				ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; BRENNER RJ, 1994, RADIOLOGY, V193, P365, DOI 10.1148/radiology.193.2.7972744; DEKONING HJ, 1995, JNCI-J NATL CANCER I, V87, P1217; Duijm LEM, 1997, BRIT J CANCER, V76, P377, DOI 10.1038/bjc.1997.393; Duijm LEM, 1998, BRIT J GEN PRACT, V48, P1421; Fracheboud J, 1998, INT J CANCER, V75, P694, DOI 10.1002/(SICI)1097-0215(19980302)75:5<694::AID-IJC6>3.0.CO;2-U; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; HERMANSEN C, 1987, CANCER, V60, P1866, DOI 10.1002/1097-0142(19871015)60:8<1866::AID-CNCR2820600832>3.0.CO;2-Z; JACKSON VP, 1995, RADIOL CLIN N AM, V33, P1161; LOCKER AP, 1989, LANCET, V1, P887; NAB HW, 1993, EUR J CANCER, V29A, P1557, DOI 10.1016/0959-8049(93)90294-P; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; SICKLES EA, 1995, RADIOL CLIN N AM, V33, P1123; Smith DN, 1997, RADIOLOGY, V204, P149, DOI 10.1148/radiology.204.1.9205237; TABAR L, 1981, RADIOLOGY, V141, P659, DOI 10.1148/radiology.141.3.7302219; Tilanus-Linthorst M M, 1995, Ned Tijdschr Geneeskd, V139, P445; VANOORD JC, 1991, ROFO FORTSCHR RONTG, V155, P63, DOI 10.1055/s-2008-1033220; VARAS X, 1992, RADIOLOGY, V184, P409, DOI 10.1148/radiology.184.2.1620838; WARWICK DJ, 1988, BRIT J SURG, V75, P243, DOI 10.1002/bjs.1800750319; [No title captured]	20	60	63	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1492	1495		10.1136/bmj.317.7171.1492	http://dx.doi.org/10.1136/bmj.317.7171.1492			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831579	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000077338300028
J	Beecham, L				Beecham, L			Extra GPs needed for primary care gap	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1459	1459						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822420				2022-12-28	WOS:000077202200068
J	Greenhalgh, T				Greenhalgh, T			Getting about	BRITISH MEDICAL JOURNAL			English	Editorial Material													Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088					0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1397	1397		10.1136/bmj.317.7169.1397	http://dx.doi.org/10.1136/bmj.317.7169.1397			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812964	Green Published			2022-12-28	WOS:000077081600069
J	Jacobson, B; Bygdeman, M				Jacobson, B; Bygdeman, M			Obstetric care and proneness of offspring to suicide as adults: case-control study	BRITISH MEDICAL JOURNAL			English	Article							ADDICTION	Objective To investigate any long term effects of traumatic birth and obstetric procedures in relation to suicide by violent means in offspring as adults. Design Prospective case-control study. Setting Stockholm, Sweden. Subjects 242 adults who committed suicide by violent means from 1978 to 1995, and who were born in one of seven hospitals in Stockholm during 1945-80, matched with 403 biological siblings born during the same period and at the same group of hospitals. Main outcome measures Adverse and beneficial perinatal factors expressed as relative risks (odds ratios) and 95% confidence intervals, derived from logistic regression of cases matched with their siblings. Results For multiple birth trauma the estimated relative risks of offspring subsequently committing suicide by violent means were 4.9 (95% confidence interval 1.8 to 13) for men and 1.04 (0.2 to 4.6) for women. In mothers who received multiple opiate treatment during delivery, the estimated relative risk of offspring subsequently committing suicide was equal for both sexes (0.26, 0.09 to 0.69). Conclusion Minimising pain and discomfort to the infant during birth seems to be of importance in reducing the risk of committing suicide by violent means as an adult.	Huddinge Univ Hosp, Dept Med Engn, SE-14186 Huddinge, Sweden; Karolinska Hosp, Dept Obstet & Gynaecol, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Jacobson, B (corresponding author), Huddinge Univ Hosp, Dept Med Engn, F60 Novum, SE-14186 Huddinge, Sweden.							Breslow NE, 1980, IARC SCI PUBL, V32, P248; GRONBLADH L, 1990, ACTA PSYCHIAT SCAND, V82, P223, DOI 10.1111/j.1600-0447.1990.tb03057.x; JACOBSON B, 1990, BRIT MED J, V301, P1067, DOI 10.1136/bmj.301.6760.1067; JACOBSON B, 1987, ACTA PSYCHIAT SCAND, V76, P364, DOI 10.1111/j.1600-0447.1987.tb05620.x; JAMES H., 1962, ANIMAL BEHAVIOUR, V10, P341, DOI 10.1016/0003-3472(62)90057-X; Nyberg K, 1993, Paediatr Perinat Epidemiol, V7, P23, DOI 10.1111/j.1365-3016.1993.tb00598.x; SALK L, 1985, LANCET, V1, P624; WALTER SD, 1975, BIOMETRIKA, V62, P371, DOI 10.1093/biomet/62.2.371	8	30	30	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1346	1349		10.1136/bmj.317.7169.1346	http://dx.doi.org/10.1136/bmj.317.7169.1346			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812930	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000077081600018
J	Broun, P; Shanklin, J; Whittle, E; Somerville, C				Broun, P; Shanklin, J; Whittle, E; Somerville, C			Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids	SCIENCE			English	Article							CARRIER-PROTEIN DESATURASE; ARABIDOPSIS-THALIANA; DIIRON; HYDROXYLATION; MOSSBAUER	Higher plants exhibit extensive diversity in the composition of seed storage fatty acids. This is Largely due to the presence of various combinations of double or triple bonds and hydroxyl or epoxy groups, which are synthesized by a family of structurally similar enzymes. As few as four amino acid substitutions can convert an oleate 12-desaturase to a hydroxylase and as few as six result in conversion of a hydroxylase;to a desaturase. These results illustrate how catalytic plasticity of these diiron enzymes has contributed to the evolution of the chemical diversity found in higher plants.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; Carnegie Institution for Science	Shanklin, J (corresponding author), Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA.		Somerville, Christopher R/A-4048-2009	Somerville, Christopher R/0000-0003-4647-0094; Shanklin, John/0000-0002-6774-8043				Babbitt PC, 1997, J BIOL CHEM, V272, P30591, DOI 10.1074/jbc.272.49.30591; BOUCHEZ D, 1993, CR ACAD SCI III-VIE, V316, P1188; Broun P, 1998, PLANT J, V13, P201, DOI 10.1046/j.1365-313X.1998.00023.x; BROUN P, UNPUB; Buist PH, 1998, J AM CHEM SOC, V120, P871, DOI 10.1021/ja971362i; Covello PS, 1996, PLANT PHYSIOL, V111, P223, DOI 10.1104/pp.111.1.223; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Kim C, 1997, J AM CHEM SOC, V119, P3635, DOI 10.1021/ja963578a; Lee M, 1998, SCIENCE, V280, P915, DOI 10.1126/science.280.5365.915; Lindqvist Y, 1996, EMBO J, V15, P4081, DOI 10.1002/j.1460-2075.1996.tb00783.x; MIQUEL M, 1992, J BIOL CHEM, V267, P1502; MOREAU RA, 1981, PLANT PHYSIOL, V67, P672, DOI 10.1104/pp.67.4.672; Pikus JD, 1996, BIOCHEMISTRY-US, V35, P9106, DOI 10.1021/bi960456m; QUE L, 1991, SCIENCE, V253, P273, DOI 10.1126/science.1857963; SHANKLIN J, 1991, P NATL ACAD SCI USA, V88, P2510, DOI 10.1073/pnas.88.6.2510; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; Shanklin J, 1997, P NATL ACAD SCI USA, V94, P2981, DOI 10.1073/pnas.94.7.2981; SUZUKI M, 1991, J BACTERIOL, V173, P1690, DOI 10.1128/jb.173.5.1690-1695.1991; VANDELOO F, 1993, PLANT LIPIDS, P91; VANDELOO FJ, 1995, P NATL ACAD SCI USA, V92, P6743, DOI 10.1073/pnas.92.15.6743	20	197	695	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1315	1317		10.1126/science.282.5392.1315	http://dx.doi.org/10.1126/science.282.5392.1315			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812895				2022-12-28	WOS:000076982200044
J	Bunker, JP; Houghton, J; Baum, M				Bunker, JP; Houghton, J; Baum, M			Putting the risk of breast cancer in perspective	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MAMMOGRAPHY; MORTALITY		UCL, Sch Med, Canc Res CAmpaign & UCL Canc Trials Ctr, London W1P 8AN, England; UCL, Middlesex Hosp Trust, Dept Surg, London W1P 7LD, England	University of London; University College London; UCL Medical School; University of London; University College London	Bunker, JP (corresponding author), UCL, Sch Med, Canc Res CAmpaign & UCL Canc Trials Ctr, London W1P 8AN, England.							[Anonymous], 1997, LANCET, V350, P1563; FAHEY T, 1995, BRIT MED J, V311, P1056, DOI 10.1136/bmj.311.7012.1056; FEUER EJ, 1992, AM J EPIDEMIOL, V136, P1423, DOI 10.1093/oxfordjournals.aje.a116463; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; LONGNECKER MP, 1988, JAMA-J AM MED ASSOC, V260, P652; McColl A, 1998, BRIT MED J, V316, P361, DOI 10.1136/bmj.316.7128.361; *OFF NAT STAT, 1997, 1995 MORT STAT C DH2, V22; *OFF NAT STAT, 1997, 1991 CANC STAT R MB1, V24; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; PILOTE L, 1995, AM HEART J, V129, P1237, DOI 10.1016/0002-8703(95)90426-3; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; Westhoff CL, 1996, CONTRACEPTION, V54, P1, DOI 10.1016/0010-7824(96)00111-4	12	33	34	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 7	1998	317	7168					1307	1309		10.1136/bmj.317.7168.1307	http://dx.doi.org/10.1136/bmj.317.7168.1307			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804725	Green Published			2022-12-28	WOS:000076963800034
J	Baukrowitz, T; Schulte, U; Oliver, D; Herlitze, S; Krauter, T; Tucker, SJ; Ruppersberg, JP; Fakler, B				Baukrowitz, T; Schulte, U; Oliver, D; Herlitze, S; Krauter, T; Tucker, SJ; Ruppersberg, JP; Fakler, B			PIP2 and PIP as determinants for ATP inhibition of K-ATP channels	SCIENCE			English	Article							SENSITIVE POTASSIUM CHANNELS; SULFONYLUREA RECEPTOR; DIAZOXIDE; PROTEIN	Adenosine triphosphate (ATP)-sensitive potassium (K-ATP) channels couple electrical activity to Cellular metabolism through their inhibition by intracellular ATP. ATP inhibition of K-ATP channels varies among tissues and is affected by the metabolic and regulatory state of individual cells, suggesting involvement of endogenous factors. It is reported here that phosphatidylinositol-4,5-bisphosphate (PIP2) and phosphatidylinositol-4-phosphate (PIP) controlled ATP inhibition of cloned K-ATP channels (K(ir)6.2 and SUR1). These phospholipids acted on the K(ir)6.2 subunit and shifted ATP sensitivity by several orders of magnitude. Receptor-mediated activation of phospholipase C resulted in inhibition of K-ATP-mediated currents. These results represent a mechanism for control of excitability through phospholipids.	Univ Tubingen, Dept Physiol 2, D-72076 Tubingen, Germany; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	Eberhard Karls University of Tubingen; University of Oxford	Fakler, B (corresponding author), Univ Tubingen, Dept Physiol 2, Gmelinstr 5, D-72076 Tubingen, Germany.	bernd.fakler@uni-tuebingen.de	Tucker, Stephen J./ABE-7468-2020; Oliver, Dominik/F-5845-2013	Tucker, Stephen J./0000-0001-8996-2000; Oliver, Dominik/0000-0002-8368-0923; Baukrowitz, Thomas/0000-0003-4562-0505				Alekseev AE, 1998, J GEN PHYSIOL, V111, P381, DOI 10.1085/jgp.111.2.381; BORDIN S, 1995, J MEMBRANE BIOL, V148, P177; Burnstock G, 1996, CIBA F SYMP, V198, P1; CAMERON JS, 1994, CARDIOVASC RES, V28, P788, DOI 10.1093/cvr/28.6.788; EDWARDS G, 1995, CARDIOVASC DRUG THER, V9, P185, DOI 10.1007/BF00878465; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FOSSET M, 1988, FEBS LETT, V242, P94, DOI 10.1016/0014-5793(88)80992-X; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; HENRY P, 1994, CARDIOVASC RES, V28, P754, DOI 10.1093/cvr/28.6.754; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; King BF, 1996, J PHYSIOL-LONDON, V494, P17, DOI 10.1113/jphysiol.1996.sp021472; MOSBACHER J, IN PRESS FEBS LETT; Oliver D, 1998, BIOPHYS J, V74, P2318, DOI 10.1016/S0006-3495(98)77941-X; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; TERZIC A, 1994, NEURON, V12, P885, DOI 10.1016/0896-6273(94)90340-9; Tricarico D, 1997, EUR J PHARMACOL, V321, P369, DOI 10.1016/S0014-2999(96)00965-X; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Zawalich WS, 1996, AM J PHYSIOL-ENDOC M, V271, pE409, DOI 10.1152/ajpendo.1996.271.3.E409	22	429	435	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1141	1144		10.1126/science.282.5391.1141	http://dx.doi.org/10.1126/science.282.5391.1141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804555				2022-12-28	WOS:000076887700055
J	Meier, P; Evan, G				Meier, P; Evan, G			Dying like flies	CELL			English	Review							PROGRAMMED CELL-DEATH; GENETIC-CONTROL; DROSOPHILA; SURVIVAL		Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Meier, P (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.			Meier, Pascal/0000-0003-2760-6523				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; DAMS JM, 1998, SCIENCE, V281, P1322; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Freeman M, 1997, DEVELOPMENT, V124, P261; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319	18	51	50	1	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 30	1998	95	3					295	298		10.1016/S0092-8674(00)81760-2	http://dx.doi.org/10.1016/S0092-8674(00)81760-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814699	Bronze			2022-12-28	WOS:000076789600002
J	Barbone, F; McMahon, AD; Davey, PG; Morris, AD; Reid, IC; McDevitt, DG; MacDonald, TM				Barbone, F; McMahon, AD; Davey, PG; Morris, AD; Reid, IC; McDevitt, DG; MacDonald, TM			Association of road-traffic accidents with benzodiazepine use	LANCET			English	Article							MOTOR-VEHICLE COLLISIONS; PRIMARY-CARE; PSYCHOACTIVE-DRUGS; RISK; ANTIDEPRESSANTS; DEPRESSION; DRIVERS; DESIGN	Background Psychomotor studies suggest that commonly prescribed psychoactive drugs impair driving skills. We have examined the association between the use of psychoactive drugs and road-traffic accidents. Methods We used dispensed prescribing as a measure of exposure in a within-person case-crossover study of drivers aged 18 years and over, resident in Tayside, UK, who experienced a first road-traffic accident between Aug 1, 1992, and June 30, 1995, and had used a psychoactive drug (tricyclic antidepressant, benzodiazepine, selective serotonin-reuptake inhibitor, or other psychoactive drug [mainly major tranquillisers]) between Aug 1, 1992, and the date of the accident. For each driver, the risks of having a road-traffic accident while exposed and not exposed to a drug were compared. Findings 19 386 drivers were involved in a first road-traffic accident during the study period. 1731 were users of any study drug. On the day of the accident, 189 individuals were taking tricyclic antidepressants (within-patient exposure odds ratio for an accident 0.93 [95% CI 0.72-1.21]), 84 selective serotonin-reuptake inhibitors (0.85 [0.55-1.33]), 235 benzodiazepines (1.62 [1.24-2.12]), and 47 other psychoactive drugs (0.88 [0.62-1.25]). The risk associated with benzodiazepine use decreased with increasing driver's age and was greater when the breath test for alcohol was positive. A dose-response relation was evident with benzodiazepines. The increased risk with benzodiazepines was significant for long-half-life drugs, used as anxiolytics, and for short-half-life hypnotics (all zopiclone). Interpretation Users of anxiolytic benzodiazepines and zopiclone were at increased risk of experiencing a road-traffic accident. Users of anxiolytic benzodiazepines and zopiclone should be advised not to drive.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Med Monitoring Unit, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Psychiat, Dundee DD1 9SY, Scotland; Univ Udine, Dipartimento Patol & Med Sperimentale & Clin, Unit Hyg & Epidemiol, I-33100 Udine, Italy	University of Dundee; University of Dundee; University of Udine	MacDonald, TM (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Med Monitoring Unit, Dundee DD1 9SY, Scotland.		Barbone, Fabio/K-1755-2014; Morris, Andrew D/C-2837-2009; McMahon, Alex D/C-4304-2008; Reid, Ian C/B-8326-2008	Barbone, Fabio/0000-0001-8795-9959; Barbone, Fabio/0000-0003-1337-5111; MacDonald, Thomas/0000-0001-5189-6669				ALVAREZ FJ, 1994, LANCET, V344, P282; *AM PSYCH TASK FOR, 1990, AM PSYCH TASK FORC B; BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; Borkenstein R.F., 1974, BLUTALKOHOL S, V11, P7; *BRIT MED ASS BOAR, 1996, DRIV IMP ALC OTH DRU; *BRIT MED ASS ROYA, 1995, BRIT NAT FORM; CURRIE D, 1995, OCCUP MED-OXFORD, V45, P323, DOI 10.1093/occmed/45.6.323; DEGIER JJ, 1993, 9339 IHP U LIMB; *DEP ENV TRANSP RE, 1997, ROAD ACC GREAT BRIT; Donoghue J. M., 1996, British Journal of Psychiatry, V168, P164, DOI 10.1192/bjp.168.2.164; EDWARDS JG, 1995, BRIT MED J, V311, P887; Evans J. M. M., 1995, Pharmaceutical Medicine (London), V9, P177; Hemmelgarn B, 1997, JAMA-J AM MED ASSOC, V278, P27, DOI 10.1001/jama.278.1.27; HINDMARCH I, 1986, DRUGS DRIVING, P71; HOBBS WR, 1996, GOODMAN GILMANS PHAR, P361; HONAKANEN R, 1980, BRIT MED J, V281, P1309; LEVEILLE SG, 1994, EPIDEMIOLOGY, V5, P591, DOI 10.1097/00001648-199411000-00006; LUNDBERG GD, 1986, JAMA-J AM MED ASSOC, V255, P529, DOI 10.1001/jama.255.4.529; MacDonald TM, 1996, BRIT MED J, V313, P860; MACDONALD TM, 1994, PHARMACOEPIDEM DR S, P245; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; Neutel CI, 1997, ANN EPIDEMIOL, V7, P568, DOI 10.1016/S1047-2797(97)00126-9; RAMAEKERS JG, 1995, BRIT J CLIN PHARMACO, V39, P397, DOI 10.1111/j.1365-2125.1995.tb04468.x; RAY WA, 1992, AM J EPIDEMIOL, V136, P873, DOI 10.1093/aje/136.7.873; Redelmeier DA, 1997, NEW ENGL J MED, V336, P453, DOI 10.1056/NEJM199702133360701; Rothman K. J., 1998, MODERN EPIDEMIOLOGY, P147; SKEGG DCG, 1979, BRIT MED J, V1, P917, DOI 10.1136/bmj.1.6168.917; SUISSA S, 1995, EPIDEMIOLOGY, V6, P248, DOI 10.1097/00001648-199505000-00010; VANDERWAALS FW, 1993, BRIT MED J, V307, P363, DOI 10.1136/bmj.307.6900.363; Volkerts ER, 1988, J DRUG THER RES, V13, P111; WOODS JH, 1992, PHARMACOL REV, V44, P151	31	391	407	0	24	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 24	1998	352	9137					1331	1336		10.1016/S0140-6736(98)04087-2	http://dx.doi.org/10.1016/S0140-6736(98)04087-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802269				2022-12-28	WOS:000076691700009
J	Partonen, T; Lonnqvist, J				Partonen, T; Lonnqvist, J			Seasonal affective disorder	LANCET			English	Article							NONSEASONAL MOOD DISORDERS; REST-ACTIVITY DISTURBANCES; EVENING LIGHT TREATMENT; CEREBRAL BLOOD-FLOW; WINTER DEPRESSION; FOLLOW-UP; BRIGHT-LIGHT; CIRCADIAN PHASE; MELATONIN SUPPRESSION; PERSONALITY-DISORDERS	Seasonal affective disorder (SAD) is a form of recurrent depressive or bipolar disorder, with episodes that vary in severity. Seasonal patterns of depressive episodes are common, but SAD seems to be less common than such patterns suggest. SAD was at first believed to be related to abnormal melatonin metabolism, but later findings did not support this hypothesis. Studies of brain serotonin function support the hypothesis of disturbed activity. The short-allele polymorphism for serotonin transporter is more common in patients with SAD than in healthy people. Atypical depressive symptoms commonly precede impaired functioning, and somatic symptoms are frequently the presenting complaint at visits to family physicians, The best treatment regimens include 2500 Ix of artificial light exposure in the morning. When patients seem to have no response or to prefer another treatment, antidepressants should be considered.	Univ Helsinki, Dept Psychiat, FIN-00300 Helsinki, Finland; Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, FIN-00300 Helsinki, Finland	University of Helsinki; Finland National Institute for Health & Welfare	Partonen, T (corresponding author), Univ Helsinki, Dept Psychiat, FIN-00300 Helsinki, Finland.	timo.partonen@ktl.fi	Partonen, Timo/G-1105-2012	Partonen, Timo/0000-0003-1951-2455				ALLEN JM, 1993, AM J PSYCHIAT, V150, P443; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDERSON JL, 1994, J PSYCHOSOM RES, V38, P323, DOI 10.1016/0022-3999(94)90037-X; Arbisi PA, 1996, PSYCHIAT RES, V59, P171, DOI 10.1016/0165-1781(95)02816-1; Avery DH, 1997, BIOL PSYCHIAT, V41, P1109, DOI 10.1016/S0006-3223(96)00210-7; BERMAN K, 1993, J AFFECT DISORDERS, V29, P219, DOI 10.1016/0165-0327(93)90011-8; Blacker CVR, 1997, J AFFECT DISORDERS, V43, P41, DOI 10.1016/S0165-0327(96)00102-4; Blazer DG, 1998, BRIT J PSYCHIAT, V172, P164, DOI 10.1192/bjp.172.2.164; BOOKER JM, 1992, AM J PSYCHIAT, V149, P1176; BOUHUYS AL, 1994, J AFFECT DISORDERS, V31, P39, DOI 10.1016/0165-0327(94)90125-2; Brunner DP, 1996, BIOL PSYCHIAT, V40, P485, DOI 10.1016/0006-3223(95)00656-7; CHECKLEY SA, 1993, BRIT J PSYCHIAT, V163, P332, DOI 10.1192/bjp.163.3.332; COHEN RM, 1992, ARCH GEN PSYCHIAT, V49, P545; COIRO V, 1993, PSYCHONEUROENDOCRINO, V18, P551, DOI 10.1016/0306-4530(93)90032-G; Eagles JM, 1998, J AFFECT DISORDERS, V49, P1, DOI 10.1016/S0165-0327(97)00177-8; Eagles JM, 1997, BRIT J PSYCHIAT, V171, P53, DOI 10.1192/bjp.171.1.53; FAEDDA GL, 1993, ARCH GEN PSYCHIAT, V50, P17; GALLIN PF, 1995, AM J OPHTHALMOL, V119, P202, DOI 10.1016/S0002-9394(14)73874-7; GLAST PA, 1990, BIOL PSYCHIAT, V28, P989; Glod CA, 1997, J AM ACAD CHILD PSY, V36, P188, DOI 10.1097/00004583-199702000-00009; Graw P, 1998, J AFFECT DISORDERS, V48, P69, DOI 10.1016/S0165-0327(97)00142-0; Graw P, 1997, PSYCHOPATHOLOGY, V30, P208, DOI 10.1159/000285049; JACOBSEN FM, 1987, ARCH GEN PSYCHIAT, V44, P1086; Jang KL, 1997, PSYCHIAT RES, V70, P145, DOI 10.1016/S0165-1781(97)00030-9; JOSEPHVANDERPOOL JR, 1991, J CLIN ENDOCR METAB, V72, P1382, DOI 10.1210/jcem-72-6-1382; JOSEPHVANDERPOOL JR, 1993, BIOL PSYCHIAT, V33, P496, DOI 10.1016/0006-3223(93)90003-V; KASPER S, 1989, ARCH GEN PSYCHIAT, V46, P823; Kogan AO, 1998, AM J PSYCHIAT, V155, P293; KRAUCHI K, 1993, PSYCHIAT RES, V46, P107, DOI 10.1016/0165-1781(93)90013-7; Krauchi K, 1997, COMPR PSYCHIAT, V38, P80, DOI 10.1016/S0010-440X(97)90085-7; LABBATE LA, 1994, J CLIN PSYCHIAT, V55, P189; LAM RW, 1995, AM J PSYCHIAT, V152, P1765; LAM RW, 1991, COMPR PSYCHIAT, V32, P552, DOI 10.1016/0010-440X(91)90034-A; LEONHARDT G, 1994, COMPR PSYCHIAT, V35, P457, DOI 10.1016/0010-440X(94)90229-1; Levitan RD, 1998, AM J PSYCHIAT, V155, P428, DOI 10.1176/ajp.155.3.428; Levitan RD, 1998, ARCH GEN PSYCHIAT, V55, P244, DOI 10.1001/archpsyc.55.3.244; LEVITT AJ, 1993, J AFFECT DISORDERS, V28, P51, DOI 10.1016/0165-0327(93)90076-V; LEWY AJ, 1987, SCIENCE, V235, P352, DOI 10.1126/science.3798117; LINGJAERDE O, 1993, ACTA PSYCHIAT SCAND, V88, P372, DOI 10.1111/j.1600-0447.1993.tb03476.x; Madden PAF, 1996, ARCH GEN PSYCHIAT, V53, P47; MAGNUSSON A, 1993, ARCH GEN PSYCHIAT, V50, P947; MEESTERS Y, 1993, J AFFECT DISORDERS, V28, P165, DOI 10.1016/0165-0327(93)90102-P; Michalon M, 1997, J PSYCHIATR NEUROSCI, V22, P19; Molin J, 1996, J AFFECT DISORDERS, V37, P151, DOI 10.1016/0165-0327(95)00090-9; MURASE S, 1995, ACTA PSYCHIAT SCAND, V92, P51, DOI 10.1111/j.1600-0447.1995.tb09542.x; MURPHY DGM, 1993, BRIT J PSYCHIAT, V163, P327, DOI 10.1192/bjp.163.3.327; Nayyar K, 1996, BRIT J PSYCHIAT, V168, P627, DOI 10.1192/bjp.168.5.627; Neumeister A, 1998, ARCH GEN PSYCHIAT, V55, P524, DOI 10.1001/archpsyc.55.6.524; Neumeister A, 1997, AM J PSYCHIAT, V154, P1153; Neumeister A, 1998, PSYCHOL MED, V28, P257, DOI 10.1017/S0033291797006375; OBRIEN JT, 1993, BRIT J PSYCHIAT, V163, P338, DOI 10.1192/bjp.163.3.338; OREN DA, 1994, AM J PSYCHIAT, V151, P591; Oren DA, 1993, DEPRESSION, V1, P29; Ozaki N, 1996, BIOL PSYCHIAT, V40, P1267, DOI 10.1016/0006-3223(95)00649-4; Ozaki N, 1995, PSYCHIAT RES, V59, P151, DOI 10.1016/0165-1781(95)02788-2; Partonen T, 1997, BIOL PSYCHIAT, V42, P509, DOI 10.1016/S0006-3223(96)00376-9; Partonen T, 1996, PSYCHOL MED, V26, P1075, DOI 10.1017/S003329170003539X; Partonen T, 1996, J AFFECT DISORDERS, V41, P93, DOI 10.1016/S0165-0327(96)00073-0; Raheja SK, 1996, J AFFECT DISORDERS, V41, P193, DOI 10.1016/S0165-0327(96)00087-0; ReichbornKjennerud T, 1996, J AFFECT DISORDERS, V41, P101, DOI 10.1016/S0165-0327(96)00076-6; REICHBORNKJENNERUD T, 1994, ACTA PSYCHIAT SCAND, V90, P413, DOI 10.1111/j.1600-0447.1994.tb01616.x; ROSENTHAL NE, 1984, ARCH GEN PSYCHIAT, V41, P72; Rosenthal NE, 1998, MOL PSYCHIATR, V3, P175, DOI 10.1038/sj.mp.4000360; ROSENTHAL NE, 1989, BIOL PSYCHIAT, V25, P1029, DOI 10.1016/0006-3223(89)90291-6; SACK RL, 1990, ARCH GEN PSYCHIAT, V47, P343; SAKAMOTO K, 1993, ACTA PSYCHIAT SCAND, V87, P258, DOI 10.1111/j.1600-0447.1993.tb03368.x; SAKAMOTO K, 1995, AM J PSYCHIAT, V152, P862; Schwartz PJ, 1996, AM J PSYCHIAT, V153, P1028; Schwartz PJ, 1997, ARCH GEN PSYCHIAT, V54, P375; Schwartz PJ, 1997, BIOL PSYCHIAT, V42, P122, DOI 10.1016/S0006-3223(96)00332-0; SWEDO SE, 1995, AM J PSYCHIAT, V152, P1016; Swedo SE, 1997, J AM ACAD CHILD PSY, V36, P816, DOI 10.1097/00004583-199706000-00019; Tam EM, 1997, J AFFECT DISORDERS, V44, P39, DOI 10.1016/S0165-0327(97)01447-X; Teicher MH, 1997, ARCH GEN PSYCHIAT, V54, P124; Terman M, 1996, AM J PSYCHIAT, V153, P1423; TERMAN M, 1989, NEUROPSYCHOPHARMACOL, V2, P1, DOI 10.1016/0893-133X(89)90002-X; THALEN BE, 1995, ACTA PSYCHIAT SCAND, V92, P274, DOI 10.1111/j.1600-0447.1995.tb09583.x; THALEN BE, 1995, ACTA PSYCHIAT SCAND, V91, P352, DOI 10.1111/j.1600-0447.1995.tb09794.x; Thalen BE, 1997, ACTA PSYCHIAT SCAND, V96, P385, DOI 10.1111/j.1600-0447.1997.tb09934.x; THOMPSON C, 1995, BRIT J PSYCHIAT, V167, P380, DOI 10.1192/bjp.167.3.380; THOMPSON C, 1990, LANCET, V336, P703, DOI 10.1016/0140-6736(90)92202-S; Thompson C, 1997, BRIT J PSYCHIAT, V170, P431, DOI 10.1192/bjp.170.5.431; Vasile RG, 1997, BIOL PSYCHIAT, V42, P1000, DOI 10.1016/S0006-3223(97)00155-8; WEHR TA, 1986, ARCH GEN PSYCHIAT, V43, P870; WHO, 1993, ICD 10 CLASS MENT BE; WICKI W, 1992, EUR ARCH PSY CLIN N, V241, P301, DOI 10.1007/BF02195980; WINTON F, 1989, PSYCHOL MED, V19, P585, DOI 10.1017/S0033291700024181; WIRZJUSTICE A, 1993, ARCH GEN PSYCHIAT, V50, P929; Yatham LN, 1997, BIOL PSYCHIAT, V42, P24, DOI 10.1016/S0006-3223(96)00243-0; YOUNG MA, 1991, J AFFECT DISORDERS, V22, P191, DOI 10.1016/0165-0327(91)90065-Z	90	134	137	3	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	1998	352	9137					1369	1374		10.1016/S0140-6736(98)01015-0	http://dx.doi.org/10.1016/S0140-6736(98)01015-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	133NB	9802288				2022-12-28	WOS:000076691700047
J	Fink, Y; Winn, JN; Fan, SH; Chen, CP; Michel, J; Joannopoulos, JD; Thomas, EL				Fink, Y; Winn, JN; Fan, SH; Chen, CP; Michel, J; Joannopoulos, JD; Thomas, EL			A dielectric omnidirectional reflector	SCIENCE			English	Article								A design criterion that permits truly omnidirectional reflectivity for all polarizations of incident light over a wide selectable range of frequencies was used in fabricating an all-dielectric omnidirectional reflector consisting of multilayer films. The reflector was simply constructed as a stack of nine alternating micrometer-thick layers of polystyrene and tellurium and demonstrates om nidirectional reflection over the wavelength range from 10 to 15 micrometers. Because the omnidirectionality criterion is general, it can be used to design omnidirectional reflectors in many frequency ranges of interest. Potential uses depend on the geometry of the system. For example, coating of an enclosure will result in an optical cavity. A hollow tube will produce a Low-Loss, broadband;;waveguide, whereas a planar film could be used as an efficient radiative heat barrier or collector in thermoelectric devices.	MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; MIT, Plasma Sci & Fus Ctr, Cambridge, MA 02139 USA; MIT, Dept Phys, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Thomas, EL (corresponding author), MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.		Fan, Shanhui/B-4659-2012; Joannopoulos, John D/E-6401-2013	Thomas, Edwin/0000-0001-5911-6524				Abeles F., 1950, ANN PHYS-PARIS, V12, P706; BORN M, 1980, PRINCIPLES OPTICS, P67; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS MO; JOHN S, 1987, PHYS REV LETT, V58, P2486, DOI 10.1103/PhysRevLett.58.2486; POUCHERT CJ, 1985, ALDRICH LIBRARY FT I, V2, pB1204; Winn JN, 1998, OPT LETT, V23, P1573, DOI 10.1364/OL.23.001573; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; YEH P, 1977, J OPT SOC AM, V67, P423, DOI 10.1364/JOSA.67.000423	8	1169	1317	11	249	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1679	1682		10.1126/science.282.5394.1679	http://dx.doi.org/10.1126/science.282.5394.1679			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831553				2022-12-28	WOS:000077246600038
J	Hensch, TK; Fagiolini, M; Mataga, N; Stryker, MP; Baekkeskov, S; Kash, SF				Hensch, TK; Fagiolini, M; Mataga, N; Stryker, MP; Baekkeskov, S; Kash, SF			Local GABA circuit control of experience-dependent plasticity in developing visual cortex	SCIENCE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; GAMMA-AMINOBUTYRIC-ACID; INHIBITORY POSTSYNAPTIC POTENTIALS; OCULAR DOMINANCE PLASTICITY; KITTEN STRIATE CORTEX; GABAERGIC CELL SUBTYPES; LONG-TERM POTENTIATION; SYNAPTIC RELEASE SITES; MONOCULAR DEPRIVATION; HIPPOCAMPAL-NEURONS	Sensory experience in early life shapes the mammalian brain. An impairment in the activity-dependent refinement of functional connections within developing visual cortex was identified here in a mouse model. Gene-targeted disruption of one isoform of glutamic acid decarboxylase prevented the competitive loss of responsiveness to an eye briefly deprived of vision, without affecting cooperative mechanisms of synapse modification in vitro. Selective, use-dependent enhancement of fast intracortical inhibitory transmission with benzodiazepines restored plasticity in vivo, rescuing the genetic defect. Specific networks of inhibitory interneurons intrinsic to visual cortex may detect perturbations in sensory input to drive experience-dependent plasticity during development.	RIKEN, Brain Sci Inst, Lab Neuronal Circuit Dev, Wako, Saitama 3510198, Japan; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Hormone Res Inst, Dept Med & Microbiol Immunol, San Francisco, CA 94143 USA	RIKEN; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hensch, TK (corresponding author), RIKEN, Brain Sci Inst, Lab Neuronal Circuit Dev, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	hensch@postman.riken.go.jp	Mataga, Nobuko/N-5531-2015; Hensch, Takao/L-4182-2019	Mataga, Nobuko/0000-0003-0991-4354; fagiolini, michela/0000-0003-2807-803X; Stryker, Michael/0000-0003-1546-5831; Baekkeskov, Steinunn/0000-0003-0878-3188	NATIONAL EYE INSTITUTE [R37EY002874] Funding Source: NIH RePORTER; NEI NIH HHS [R37 EY002874, R37 EY002874-20] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; Asada H, 1996, BIOCHEM BIOPH RES CO, V229, P891, DOI 10.1006/bbrc.1996.1898; Asada H, 1997, P NATL ACAD SCI USA, V94, P6496, DOI 10.1073/pnas.94.12.6496; Bear M F, 1993, Curr Opin Neurobiol, V3, P197, DOI 10.1016/0959-4388(93)90210-P; BENARDO LS, 1994, J PHYSIOL-LONDON, V476, P203, DOI 10.1113/jphysiol.1994.sp020124; BERRUETA LA, 1992, J PHARMACEUT BIOMED, V10, P109, DOI 10.1016/0731-7085(92)80019-J; BLAKEMORE C, 1982, J PHYSIOL-LONDON, V327, P463, DOI 10.1113/jphysiol.1982.sp014243; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Carder RK, 1996, CEREB CORTEX, V6, P271, DOI 10.1093/cercor/6.2.271; Costa E, 1998, ANNU REV PHARMACOL, V38, P321, DOI 10.1146/annurev.pharmtox.38.1.321; DEFELIPE J, 1993, CEREB CORTEX, V3, P273, DOI 10.1093/cercor/3.4.273; Dudek SM, 1996, NEURON, V16, P1097, DOI 10.1016/S0896-6273(00)80136-1; DUFFY FH, 1976, NATURE, V260, P256, DOI 10.1038/260256a0; Eghbali M, 1997, NATURE, V388, P71, DOI 10.1038/40404; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; FELDBLUM S, 1993, J NEUROSCI RES, V34, P689, DOI 10.1002/jnr.490340612; Fukuda T, 1998, J COMP NEUROL, V395, P177, DOI 10.1002/(SICI)1096-9861(19980601)395:2<177::AID-CNE3>3.0.CO;2-#; Gonchar Y, 1997, CEREB CORTEX, V7, P347, DOI 10.1093/cercor/7.4.347; Gordon JA, 1996, J NEUROSCI, V16, P3274; GREIF KF, 1991, NEUROCHEM RES, V16, P235, DOI 10.1007/BF00966086; GULYAS AI, 1993, EUR J NEUROSCI, V5, P1729, DOI 10.1111/j.1460-9568.1993.tb00240.x; Guo YH, 1997, DEV BRAIN RES, V103, P127, DOI 10.1016/S0165-3806(97)81789-0; HATA Y, 1994, SCIENCE, V265, P1732, DOI 10.1126/science.8085163; Hensch TK, 1996, SCIENCE, V272, P554, DOI 10.1126/science.272.5261.554; Kaczmarek L, 1997, BRAIN RES REV, V23, P237, DOI 10.1016/S0165-0173(97)00005-2; KANG YN, 1994, J NEUROPHYSIOL, V71, P280, DOI 10.1152/jn.1994.71.1.280; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KAUFMAN DL, 1991, J NEUROCHEM, V56, P720, DOI 10.1111/j.1471-4159.1991.tb08211.x; KAWAGUCHI Y, 1992, EXP BRAIN RES, V88, P33, DOI 10.1007/BF02259126; Kawaguchi Y, 1998, J NEUROSCI, V18, P6963; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; Kawaguchi Y, 1997, J NEUROPHYSIOL, V78, P1743, DOI 10.1152/jn.1997.78.3.1743; Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0; KOMATSU Y, 1983, DEV BRAIN RES, V8, P136, DOI 10.1016/0165-3806(83)90165-7; KRATZ KE, 1976, J NEUROPHYSIOL, V39, P501, DOI 10.1152/jn.1976.39.3.501; LUHMANN HJ, 1991, J NEUROPHYSIOL, V65, P247, DOI 10.1152/jn.1991.65.2.247; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Mataga N, 1996, NEUROSCI LETT, V218, P149, DOI 10.1016/S0304-3940(96)13139-6; MATAGA N, 1991, BRAIN RES, V551, P64, DOI 10.1016/0006-8993(91)90914-H; McAllister AK, 1996, NEURON, V17, P1057, DOI 10.1016/S0896-6273(00)80239-1; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; Miller KD, 1996, NEURON, V17, P371, DOI 10.1016/S0896-6273(00)80169-5; MOWER GD, 1989, DEV BRAIN RES, V45, P211, DOI 10.1016/0165-3806(89)90040-0; OLSON CR, 1975, J NEUROPHYSIOL, V38, P26, DOI 10.1152/jn.1975.38.1.26; Parra P, 1998, NEURON, V20, P983, DOI 10.1016/S0896-6273(00)80479-1; RAMOA AS, 1988, EXP BRAIN RES, V73, P285; RAUSCHECKER JP, 1991, PHYSIOL REV, V71, P587, DOI 10.1152/physrev.1991.71.2.587; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; ROGERS CJ, 1994, J PHYSIOL-LONDON, V475, P69, DOI 10.1113/jphysiol.1994.sp020050; Rutherford LC, 1998, NEURON, V21, P521, DOI 10.1016/S0896-6273(00)80563-2; Sala R, 1998, EUR J NEUROSCI, V10, P2185, DOI 10.1046/j.1460-9568.1998.00227.x; SEGAL M, 1990, BRAIN RES, V511, P163, DOI 10.1016/0006-8993(90)90236-5; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHAW C, 1987, DEV BRAIN RES, V37, P67, DOI 10.1016/0165-3806(87)90229-X; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SILLITO AM, 1981, NATURE, V291, P318, DOI 10.1038/291318a0; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; STUDY RE, 1981, P NATL ACAD SCI-BIOL, V78, P7180, DOI 10.1073/pnas.78.11.7180; SUGITA S, 1992, NEUROSCI LETT, V134, P207, DOI 10.1016/0304-3940(92)90518-C; TALLMAN JF, 1985, ANNU REV NEUROSCI, V8, P21, DOI 10.1146/annurev.ne.08.030185.000321; Tamas G, 1997, J PHYSIOL-LONDON, V500, P715, DOI 10.1113/jphysiol.1997.sp022054; Tamas G, 1998, J NEUROSCI, V18, P4255; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; THOMSON AM, 1997, SOC NEUR ABSTR, V23; TSUMOTO T, 1992, PROG NEUROBIOL, V39, P209, DOI 10.1016/0301-0082(92)90011-3; VANBREDERODE JFM, 1995, J NEUROPHYSIOL, V74, P1149, DOI 10.1152/jn.1995.74.3.1149; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; Xiang ZX, 1998, SCIENCE, V281, P985, DOI 10.1126/science.281.5379.985; Xiang ZX, 1998, J PHYSIOL-LONDON, V506, P715, DOI 10.1111/j.1469-7793.1998.715bv.x; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037	75	692	700	6	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1504	1508		10.1126/science.282.5393.1504	http://dx.doi.org/10.1126/science.282.5393.1504			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822384	Green Accepted			2022-12-28	WOS:000077110800059
J	Mulvey, MA; Lopez-Boado, YS; Wilson, CL; Roth, R; Parks, WC; Heuser, J; Hultgren, SJ				Mulvey, MA; Lopez-Boado, YS; Wilson, CL; Roth, R; Parks, WC; Heuser, J; Hultgren, SJ			Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli	SCIENCE			English	Article							URINARY-TRACT INFECTION; FIMH-ADHESIN; PILI; PATHOGENESIS; APOPTOSIS; BLADDER; PENETRATION; EXPRESSION; EPITHELIUM; PREVENTION	Virtually all uropathogenic strains of Escherichia coli encode filamentous surface adhesive organelles called type 1 pili. High-resolution electron microscopy of infected mouse bladders revealed that type 1 pilus tips interacted directly with the Lumenal surface of the bladder, which is embedded with hexagonal arrays of integral membrane glycoproteins known as uroplakins. Attached pill were shortened and facilitated intimate contact of the bacteria with the uroplakin-coated host cells. Bacterial attachment resulted in exfoliation of host bladder epithelial cells as part of an innate host defense system. Exfoliation occurred through a rapid apoptosis-like mechanism involving caspase activation and host DNA fragmentation. Bacteria resisted clearance in the face of host defenses within the bladder by invading into the epithelium.	Washington Univ, Sch Med, Dept Mol Microbiol & Microbial Pathogenesis, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Hultgren, SJ (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol & Microbial Pathogenesis, Box 8230,660 S Euclid Ave, St Louis, MO 63110 USA.	hultgren@borcim.wustl.edu	Parks, William C./AAH-6786-2021	Mulvey, Matthew/0000-0002-6016-7510	NIAID NIH HHS [AI09787, R01AI29549] Funding Source: Medline; NIDDK NIH HHS [R01DK51406] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051406] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barinaga M, 1998, SCIENCE, V280, P32, DOI 10.1126/science.280.5360.32; BLOMFIELD IC, 1991, MOL MICROBIOL, V5, P1439, DOI 10.1111/j.1365-2958.1991.tb00790.x; BRADLEY DE, 1972, J GEN MICROBIOL, V72, P303, DOI 10.1099/00221287-72-2-303; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; CLEGG S, 1982, INFECT IMMUN, V38, P739, DOI 10.1128/IAI.38.2.739-744.1982; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Connell H, 1996, P NATL ACAD SCI USA, V93, P9827, DOI 10.1073/pnas.93.18.9827; DAVIS CP, 1978, SCANNING ELECTRON MI, V2, P315; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; ELLIOTT TSJ, 1985, J INFECTION, V11, P191, DOI 10.1016/S0163-4453(85)92997-4; FOXMAN B, 1995, J INFECT DIS, V172, P1536, DOI 10.1093/infdis/172.6.1536; FUKUSHI Y, 1979, INVEST UROL, V17, P61; HEUSER JE, 1987, J MUSCLE RES CELL M, V8, P303, DOI 10.1007/BF01568887; HICKS RM, 1975, BIOL REV, V50, P215, DOI 10.1111/j.1469-185X.1975.tb01057.x; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; HULTGREN SJ, 1990, MOL MICROBIOL, V4, P1311, DOI 10.1111/j.1365-2958.1990.tb00710.x; Ikaheimo R, 1996, CLIN INFECT DIS, V22, P91, DOI 10.1093/clinids/22.1.91; Jones CH, 1997, EMBO J, V16, P6394, DOI 10.1093/emboj/16.21.6394; JONES CH, 1995, P NATL ACAD SCI USA, V92, P2081, DOI 10.1073/pnas.92.6.2081; LANGENAUR C, 1977, J BACTERIOL, V131, P340; Langermann S, 1997, SCIENCE, V276, P607, DOI 10.1126/science.276.5312.607; MCTAGGART LA, 1990, J MED MICROBIOL, V32, P135, DOI 10.1099/00222615-32-2-135; MINION FC, 1986, J BACTERIOL, V165, P1033, DOI 10.1128/jb.165.3.1033-1036.1986; Mittler R, 1996, TRENDS MICROBIOL, V4, P10, DOI 10.1016/0966-842X(96)81499-5; MULVEY MA, UNPUB; NOVOTNY CP, 1974, J BACTERIOL, V117, P1306, DOI 10.1128/JB.117.3.1306-1311.1974; ORIKASA S, 1977, INVEST UROL, V15, P185; ORNDORFF PE, 1984, J BACTERIOL, V159, P736, DOI 10.1128/JB.159.2.736-744.1984; ROMANTSCHUK M, 1985, J GEN VIROL, V66, P2461, DOI 10.1099/0022-1317-66-11-2461; Stapleton A, 1997, INFECT DIS CLIN N AM, V11, P719, DOI 10.1016/S0891-5520(05)70382-2; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; Thankavel K, 1997, J CLIN INVEST, V100, P1123, DOI 10.1172/JCI119623; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WALZ T, 1995, J MOL BIOL, V248, P887, DOI 10.1006/jmbi.1995.0269; WONG YC, 1977, AM J ANAT, V150, P237, DOI 10.1002/aja.1001500203; WU XR, 1995, J BIOL CHEM, V270, P29752; Wu XR, 1996, P NATL ACAD SCI USA, V93, P9630, DOI 10.1073/pnas.93.18.9630; Zychlinsky A, 1997, J CLIN INVEST, V100, P493, DOI 10.1172/JCI119557	38	727	743	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1494	1497		10.1126/science.282.5393.1494	http://dx.doi.org/10.1126/science.282.5393.1494			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822381				2022-12-28	WOS:000077110800056
J	Palmer, MR; Pearson, PN; Cobb, SJ				Palmer, MR; Pearson, PN; Cobb, SJ			Reconstructing past ocean pH-depth profiles	SCIENCE			English	Article							BORON ISOTOPES; PLANKTONIC-FORAMINIFERA; EQUATORIAL PACIFIC; GLACIAL OCEAN; DEEP-WATER; SEAWATER; FRACTIONATION; CARBON; TESTS; SEA	Measurement of boron isotope compositions in species of planktonic foraminifera that calcified their tests at different depths in the water column are used to reconstruct the pH profile of the upper water column of the tropical ocean. Results for five time windows from the middle Miocene to the late Pleistocene indicate pH-depth profiles similar to that of the modern ocean in this area, which suggests that this method may greatly aid in our understanding of the global carbon cycle.	Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England	University of Bristol	Palmer, MR (corresponding author), Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England.		Palmer, Martin R/I-6765-2012; Pearson, Paul N/B-2276-2009	Palmer, Martin R/0000-0003-1660-3714; Pearson, Paul N/0000-0003-4628-9818				AGGARWAL JK, 1995, ANALYST, V120, P1301, DOI 10.1039/an9952001301; BOYLE EA, 1988, NATURE, V331, P55, DOI 10.1038/331055a0; BREWER PG, 1995, J GEOPHYS RES-OCEANS, V100, P8761, DOI 10.1029/95JC00306; Broecker W. S., 1982, TRACERS SEA, P690; CLAYTON TD, 1993, DEEP-SEA RES PT I, V40, P2115, DOI 10.1016/0967-0637(93)90048-8; DEUSER WG, 1987, J FORAMIN RES, V17, P14, DOI 10.2113/gsjfr.17.1.14; DICKSON AG, 1990, DEEP-SEA RES, V37, P755, DOI 10.1016/0198-0149(90)90004-F; ELDERFIELD H, 1986, PALAEOGEOGR PALAEOCL, V57, P71, DOI 10.1016/0031-0182(86)90007-6; EREZ J, 1981, PALAEOGEOGR PALAEOCL, V33, P193; FAIRBANKS RG, 1982, NATURE, V298, P841, DOI 10.1038/298841a0; GASPERI JT, 1993, MAR MICROPALEONTOL, V22, P235, DOI 10.1016/0377-8398(93)90046-Z; GIESKES JM, 1974, SEA, V5, P123; HAGGERTY JA, 1995, P OCEAN DRILLING PRO, P144; HAY WW, 1988, GEOL SOC AM BULL, V100, P1934, DOI 10.1130/0016-7606(1988)100<1934:PARFTG>2.3.CO;2; Hemleben C., 1989, MODERN PLANKTONIC FO, DOI [DOI 10.1016/S0016-6995(89)80108-1, DOI 10.1007/978-1-4612-3544-6_2]; HEMMING NG, 1994, CHEM GEOL, V114, P147, DOI 10.1016/0009-2541(94)90048-5; HEMMING NG, 1992, GEOCHIM COSMOCHIM AC, V56, P537, DOI 10.1016/0016-7037(92)90151-8; KAKIHANA H, 1977, B CHEM SOC JPN, V50, P158, DOI 10.1246/bcsj.50.158; KELLER G, 1985, GEOL SOC AM MEM, V163, P177; MACKENSEN A, 1993, PALEOCEANOGRAPHY, V8, P587, DOI 10.1029/93PA01291; Opdyke Bradley N., 1995, Proceedings of the Ocean Drilling Program Scientific Results, V144, P993; PEAROSN PN, 1995, P OCEAN DRILLING PRO, P21; Pearson Paul N., 1995, Proceedings of the Ocean Drilling Program Scientific Results, V144, P401; Sanyal A, 1997, GLOBAL BIOGEOCHEM CY, V11, P125, DOI 10.1029/97GB00223; SANYAL A, 1995, NATURE, V373, P234, DOI 10.1038/373234a0; SHACKLETON NJ, 1978, MAR MICROPALEONTOL, V3, P1, DOI 10.1016/0377-8398(78)90008-7; SPIVACK AJ, 1993, NATURE, V363, P149, DOI 10.1038/363149a0; SPIVACK AJ, 1986, THESIS MIT; Watkins JM, 1998, MAR MICROPALEONTOL, V33, P157, DOI 10.1016/S0377-8398(97)00036-4	29	114	130	3	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1468	1471		10.1126/science.282.5393.1468	http://dx.doi.org/10.1126/science.282.5393.1468			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822372				2022-12-28	WOS:000077110800047
J	Brunner, D; Staehelin, J; Jeker, D				Brunner, D; Staehelin, J; Jeker, D			Large-scale nitrogen oxide plumes in the tropopause region and implications for ozone	SCIENCE			English	Article							NOX; TROPOSPHERE; DISTRIBUTIONS; ATMOSPHERE; EMISSIONS; ATLANTIC	Continuous measurements of nitrogen oxide and ozone were performed from a commercial airliner during 1 year at cruising altitudes below and above the tropopause, The upper tropospheric nitrogen oxides distribution was found to be strongly influenced by large-scale plumes extending about 100 to 1300 kilometers along the flight track. The plumes were frequently observed downwind of thunderstorms and frontal systems, which most probably caused;upward transport of polluted air from the continental boundary layer or nitrogen oxide production in lightning strokes, or both, Particularly in summer, average ozone concentrations in the plumes were enhanced compared to the tropospheric background Levels.	ETH Honggerberg HPP, Inst Atmospher Sci, CH-8093 Zurich, Switzerland; Royal Netherlands Meteorol Inst, Atmospher Composit Res Div, NL-3730 AE De Bilt, Netherlands	Swiss Federal Institutes of Technology Domain; ETH Zurich; Royal Netherlands Meteorological Institute	Staehelin, J (corresponding author), ETH Honggerberg HPP, Inst Atmospher Sci, CH-8093 Zurich, Switzerland.		Brunner, Dominik/A-1255-2009; Brunner, Dominik/GSI-5449-2022; Brunner, Dominik/P-9520-2019	Brunner, Dominik/0000-0002-4007-6902; Brunner, Dominik/0000-0002-4007-6902; 				Brasseur GP, 1996, J GEOPHYS RES-ATMOS, V101, P1423, DOI 10.1029/95JD02363; Brasseur GP, 1998, ATMOS ENVIRON, V32, P2329, DOI 10.1016/S1352-2310(97)00486-X; BRUNNER D, 1998, THESIS ETH ZURICH ZU; CRUTZEN PJ, 1971, J GEOPHYS RES, V76, P7311, DOI 10.1029/JC076i030p07311; Davis DD, 1996, J GEOPHYS RES-ATMOS, V101, P2111, DOI 10.1029/95JD02755; Dias-Lalcaca P, 1998, ENVIRON SCI TECHNOL, V32, P3228, DOI 10.1021/es980119w; DICKERSON RR, 1987, SCIENCE, V235, P460, DOI 10.1126/science.235.4787.460; Emmons LK, 1997, ATMOS ENVIRON, V31, P1851, DOI 10.1016/S1352-2310(96)00334-2; Flatoy F, 1997, J GEOPHYS RES-ATMOS, V102, P21373, DOI 10.1029/97JD01308; Friedl R. R., 1997, NASA REFERENCE PUBLI, V1400; Houghton JT., 1995, CLIMATE CHANGE 1994; LACIS AA, 1990, J GEOPHYS RES-ATMOS, V95, P9971, DOI 10.1029/JD095iD07p09971; Lee DS, 1997, ATMOS ENVIRON, V31, P1735, DOI 10.1016/S1352-2310(96)00327-5; LELIEVELD J, 1994, SCIENCE, V264, P1759, DOI 10.1126/science.264.5166.1759; LIU SC, 1987, J GEOPHYS RES-ATMOS, V92, P4191, DOI 10.1029/JD092iD04p04191; LUKE WT, 1992, J GEOPHYS RES-ATMOS, V97, P20647, DOI 10.1029/92JD02127; PARRISH DD, 1993, J GEOPHYS RES-ATMOS, V98, P2927, DOI 10.1029/92JD02384; PICKERING KE, 1990, J GEOPHYS RES-ATMOS, V95, P14049, DOI 10.1029/JD095iD09p14049; Price C, 1997, J GEOPHYS RES-ATMOS, V102, P5929, DOI 10.1029/96JD03504; Schlager H, 1997, J GEOPHYS RES-ATMOS, V102, P10739, DOI 10.1029/96JD03748; Schumann U, 1997, ATMOS ENVIRON, V31, P1723, DOI 10.1016/S1352-2310(96)00326-3; SCHUMANN U, 1996, PUBLICATION EUR; SCHUMANN U, 1996, ATMOS ENV; Smyth SB, 1996, J GEOPHYS RES-ATMOS, V101, P24165, DOI 10.1029/96JD00224; Wennberg PO, 1998, SCIENCE, V279, P49, DOI 10.1126/science.279.5347.49	25	61	64	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1305	1309		10.1126/science.282.5392.1305	http://dx.doi.org/10.1126/science.282.5392.1305			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812892				2022-12-28	WOS:000076982200041
J	Choi, BG; Huss, GR; Wasserburg, GJ; Gallino, R				Choi, BG; Huss, GR; Wasserburg, GJ; Gallino, R			Presolar corundum and spinel in ordinary chondrites: Origins from AGB stars and a supernova	SCIENCE			English	Article							SILICON-CARBIDE GRAINS; ISOTOPIC ABUNDANCES; INTERSTELLAR GRAINS; OXIDE GRAINS; METEORITES; OXYGEN; CARBON; AL2O3; NUCLEOSYNTHESIS; MAGNESIUM	On the basis of anomalous isotopic compositions of oxygen and magnesium, 14 oxide grains from two primitive meteorites (Bishunpur and Semarkona) have been identified as circumstellar condensates. One corundum grain has a high (18)O/(16)O ratio and isotopic compositions of magnesium, calcium, and titanium that are compatible with a formation in ejecta of a type II supernova that was about 15 times the mass of the sun, The other grains have oxygen, magnesium, and titanium compositions that are consistent with a formation around asymptotic giant branch (AGB) stars with a range of mass and initial composition. The large range of aluminum/magnesium in circumstellar corundum and spinel is considered to reflect various stages of back-reaction between condensed corundum and gaseous magnesium in cooling stellar ejecta.	CALTECH, Div Geol & Planetary Sci, Lunat Asylum, Pasadena, CA 91125 USA; Univ Turin, Dipartimento Fis Gen, I-10125 Turin, Italy	California Institute of Technology; University of Turin	Choi, BG (corresponding author), CALTECH, Div Geol & Planetary Sci, Lunat Asylum, Pasadena, CA 91125 USA.	bchoi@gps.caltech.edu	WASSERBURG, GERALD J/F-6247-2011	Huss, Gary/0000-0003-4281-7839				Arnould M, 1997, AIP CONF PROC, P179, DOI 10.1063/1.53328; BOOTHROYD AI, 1994, ASTROPHYS J, V430, pL77, DOI 10.1086/187442; BOOTHROYD AI, 1993, ASTROPHYS J, V416, P762, DOI 10.1086/173275; BOOTHROYD AI, 1995, ASTROPHYS J, V442, pL21, DOI 10.1086/187806; CATANZAR.EJ, 1966, J RES NBS A PHYS CH, VA 70, P453, DOI 10.6028/jres.070A.037; Collier MR, 1998, J GEOPHYS RES-SPACE, V103, P7, DOI 10.1029/97JA02245; EDVARDSSON B, 1993, ASTRON ASTROPHYS, V275, P101; FORESTINI M, 1991, ASTRON ASTROPHYS, V252, P597; GALLINO R, 1994, ASTROPHYS J, V430, P858, DOI 10.1086/174457; HALLSTEDT B, 1992, J AM CERAM SOC, V75, P1497, DOI 10.1111/j.1151-2916.1992.tb04216.x; HEINRICH M, 1998, LUNAR PLANET, V29, P1715; Holmden C, 1997, GEOCHIM COSMOCHIM AC, V61, P2253, DOI 10.1016/S0016-7037(97)00057-4; HOPPE P, 1994, ASTROPHYS J, V430, P870, DOI 10.1086/174458; HUSS GR, 1994, ASTROPHYS J, V430, pL81, DOI 10.1086/187443; HUSS GR, 1994, METEORITICS, V29, P475; Huss GR, 1997, GEOCHIM COSMOCHIM AC, V61, P5117, DOI 10.1016/S0016-7037(97)00299-8; HUSS GR, 1992, LUNAR PLANET SCI, V23, P563; HUTCHEON ID, 1994, ASTROPHYS J, V425, pL97, DOI 10.1086/187319; Kallenbach R, 1998, ASTROPHYS J, V498, pL75, DOI 10.1086/311296; Lattanzio JC, 1997, AIP CONF PROC, P85, DOI 10.1063/1.53325; LATTIMER JM, 1978, ASTROPHYS J, V219, P230, DOI 10.1086/155771; LEE T, 1976, GEOPHYS RES LETT, V3, P109, DOI 10.1029/GL003i002p00109; LUGARO M, UNPUB, P34312; MEYER BS, 1995, METEORITICS, V30, P325, DOI 10.1111/j.1945-5100.1995.tb01131.x; NIEDERER FR, 1984, GEOCHIM COSMOCHIM AC, V48, P1279, DOI 10.1016/0016-7037(84)90062-0; NIEDERER FR, 1985, GEOCHIM COSMOCHIM AC, V49, P835, DOI 10.1016/0016-7037(85)90176-0; Nittler LR, 1997, ASTROPHYS J, V483, P475, DOI 10.1086/304234; NITTLER LR, 1994, NATURE, V370, P443, DOI 10.1038/370443a0; Nittler LR, 1997, AIP CONF PROC, P59, DOI 10.1063/1.51767; Nittler LR, 1997, PHYS REV LETT, V78, P175, DOI 10.1103/PhysRevLett.78.175; OTT U, 1993, NATURE, V364, P25, DOI 10.1038/364025a0; SELESNICK RS, 1993, ASTRPHYS J, V41, pL45; STREBEL R, 1996, METEORIT PLANET SCI, V31, pA136; TIMMES FX, 1995, ASTROPHYS J SUPPL S, V98, P617, DOI 10.1086/192172; TRAVAGLIO C, IN PRESS ASTROPHYS J; WANNIER PG, 1989, IAU SYMP, V136, P107; Wasserburg GJ, 1998, ASTROPHYS J, V500, pL189, DOI 10.1086/311414; WASSERBURG GJ, 1995, ASTROPHYS J, V447, pL37, DOI 10.1086/309555; WOOSLEY SE, 1995, ASTROPHYS J SUPPL S, V101, P181, DOI 10.1086/192237; WOOSLEY SE, 1997, NUCL COSMOS, V4, P445; Zinner E, 1997, AIP CONF PROC, P3, DOI 10.1063/1.53326	41	147	150	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1284	1289		10.1126/science.282.5392.1284	http://dx.doi.org/10.1126/science.282.5392.1284			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812886				2022-12-28	WOS:000076982200035
J	Delbanco, T				Delbanco, T			Leeches, spiders, and astrology: Predilections and predictions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DEPRESSION; PLACEBO											Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; BROWN WA, 1994, NEUROPSYCHOPHARMACOL, V10, P265, DOI 10.1038/npp.1994.53; DELBANCO TL, 1994, ANN INTERN MED, V121, P803, DOI 10.7326/0003-4819-121-10-199411150-00011; DELBANCO TL, 1994, NEUROPSYCHOPHARMACOL, V10, P279, DOI 10.1038/npp.1994.57; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Gevitz N., 1988, OTHER HEALERS UNORTH, P124; Hart Julian Tudor, 1998, Health Expect, V1, P3, DOI 10.1046/j.1369-6513.1998.00001.x; TYLE L, 1998, FATHER SPIN E BERNAY	8	12	12	1	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1560	1562		10.1001/jama.280.18.1560	http://dx.doi.org/10.1001/jama.280.18.1560			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820247				2022-12-28	WOS:000076852000011
J	Eisenberg, DM; Davis, RB; Ettner, SL; Appel, S; Wilkey, S; van Rompay, M; Kessler, RC				Eisenberg, DM; Davis, RB; Ettner, SL; Appel, S; Wilkey, S; van Rompay, M; Kessler, RC			Trends in alternative medicine use in the United States, 1990-1997 - Results of a follow-up national survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLEMENTARY MEDICINE; ADVERSE REACTIONS; HERBAL MEDICINES; PREVALENCE; THERAPIES; COST	Context.-A prior national survey documented the high prevalence and costs of alternative medicine use in the United States in 1990. Objective.-To document trends in alternative medicine use in the United States between 1990 and 1997, Design.-Nationally representative random household telephone surveys using comparable key questions were conducted in 1991 and 1997 measuring utilization in 1990 and 1997, respectively. Participants.-A total of 1539 adults in 1991 and 2055 in 1997. Main Outcomes Measures.-Prevalence, estimated costs, and disclosure of alternative therapies to physicians. Results.-Use of at least 1 of 16 alternative therapies during the previous year increased from 33.8% in 1990 to 42.1% in 1997 (P less than or equal to.001). The therapies increasing the most included herbal medicine, massage, megavitamins, self-help groups, folk remedies, energy healing, and homeopathy. The probability of users visiting an alternative medicine practitioner increased from 36.3% to 46.3% (P = .002), In both surveys alternative therapies were used most frequently for chronic conditions, including back problems, anxiety, depression, and headaches. There was no significant change in disclosure rates between the 2 survey years; 39.8% of alternative therapies were disclosed to physicians in 1990 vs 38.5% in 1997, The percentage of users paying entirely out-of-pocket for services provided by alternative medicine practitioners did not change significantly between 1990 (64.0%) and 1997 (58.3%) (P = .36). Extrapolations to the US population suggest a 47.3% increase in total visits to alternative medicine practitioners, from 427 million in 1990 to 629 million in 1997, thereby exceeding total visits to all US primary care physicians. An estimated 15 million adults in 1997 took prescription medications concurrently with herbal remedies and/or high-dose vitamins (18.4% of all prescription users). Estimated expenditures for alternative medicine professional services increased 45.2% between 1990 and 1997 and were conservatively estimated at $21.2 billion in 1997, with at least $12.2 billion paid out-of-pocket. This exceeds the 1997 out-of-pocket expenditures for all US hospitalizations. Total 1997 out-of-pocket expenditures relating to alternative therapies were conservatively estimated at $27.0 billion, which is comparable with the projected 1997 out-of-pocket expenditures for all US physician services. Conclusions.-Alternative medicine use and expenditures increased substantially between 1990 and 1997, attributable primarily to an increase in the proportion of the population seeking alternative therapies, rather than increased visits per patient.	Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res & Educ, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Eisenberg, DM (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res & Educ, Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.		Van Rompay, Maria/G-9452-2012		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U24 AR43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bouchayer F., 1990, COMPLEMENT MED RES, V4, P4; DARCY PF, 1991, ADVERSE DRUG REACT T, V10, P189; DARCY PF, 1993, ADVERSE DRUG REACT T, V12, P147; De Smet P., 1996, MECH DRUG INTERACTIO, P327, DOI [10.1007/978-3-642-61015-8_12, DOI 10.1007/978-3-642-61015-8_12]; DESMET PAGM, 1995, DRUG SAFETY, V13, P81, DOI 10.2165/00002018-199513020-00003; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Ernst E, 1998, AM J MED, V104, P170, DOI 10.1016/S0002-9343(97)00397-5; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; GoldbeckWood S, 1996, BRIT MED J, V313, P131, DOI 10.1136/bmj.313.7050.131a; GROVES RM, 1998, NONRESPONSE HOUSEHOL, P159; *HLTH CAR FIN ADM, NAT HLTH CAR EXP PRO; *LANDM HEALTHC, 1998, LANDM REP PUBL PERC; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; *MED INC, CUST REP MED BILL CO; Millar WJ, 1997, CAN J PUBLIC HEALTH, V88, P154, DOI 10.1007/BF03403879; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; Pelletier KR, 1997, AM J HEALTH PROMOT, V12, P112, DOI 10.4278/0890-1171-12.2.112; PIEL E, 1991, THERAPEUTIKON, V5, P549; RASMUSSEN NK, 1990, COMPLEMENT MED RES, V4, P16; *RES TRIANGL I, 1997, SUDAAN PROF SOFTW SU; SCHAPPERT SM, 1992, ADV DATA VITAL HLTH, V2213, P1; SERMEUS G, 1990, COMPLEMENTARY MED RE, V4, P9; Shekelle PG, 1996, MED CARE, V34, P863, DOI 10.1097/00005650-199609000-00001; *US BUR CENS, 1990, US POP EST AG SEX RA; *US BUR LAB STAT D, 1998, CONS PRIC IND ALL UR; VASKILAMPI T, 1993, CLIN RES METHODOLOGY, P204; Wetzel MS, 1998, JAMA-J AM MED ASSOC, V280, P784, DOI 10.1001/jama.280.9.784; Woodwell D A, 1997, Adv Data, P1	29	4679	4788	9	271	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1569	1575		10.1001/jama.280.18.1569	http://dx.doi.org/10.1001/jama.280.18.1569			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	136GX	9820257	Bronze			2022-12-28	WOS:000076852000022
J	Wright, P; Jansen, C; Wyatt, JC				Wright, P; Jansen, C; Wyatt, JC			How to limit clinical errors in interpretation of data	LANCET			English	Article							INFORMATION; MANAGEMENT; DECISIONS; RECORD	We all assume that we can understand and correctly interpret what we read. However, interpretation is a collection of subtle processes that are easily influenced by poor presentation or wording of information. This article examines how evidence-based principles of information design can be applied to medical records to enhance clinical understanding and accuracy in interpretation of the detailed data that they contain.	Cardiff Univ, Sch Psychol, Cardiff CF1 3YG, S Glam, Wales; Univ Nijmegen, Nijmegen, Netherlands; UCL, Sch Publ Policy, London, England	Cardiff University; Radboud University Nijmegen; University of London; University College London	Wright, P (corresponding author), Cardiff Univ, Sch Psychol, POB 90, Cardiff CF1 3YG, S Glam, Wales.	WrightP1@cardiff.ac.uk	Wyatt, Jeremy/F-8160-2010	Wyatt, Jeremy/0000-0001-7008-1473				Aberson Dieuwke, 1997, J RES READ, V20, P184, DOI [10.1111/1467-9817.00032, DOI 10.1111/1467-9817.00032]; BRANSFORD JD, 1972, J VERB LEARN VERB BE, V11, P717, DOI 10.1016/S0022-5371(72)80006-9; CARTMILL RSV, 1992, LANCET, V339, P1520, DOI 10.1016/0140-6736(92)91275-D; Cranney M, 1996, BRIT J GEN PRACT, V46, P661; DRAZEN E, 1988, J ELECTROCARDIOL, V21, pS98, DOI 10.1016/0022-0736(88)90068-4; EHRENBERG ASC, 1977, J R STAT SOC A STAT, V140, P277, DOI 10.2307/2344922; FRIES JF, 1974, MED CARE, V12, P871, DOI 10.1097/00005650-197410000-00006; Furnas G.W., 1986, P SIGCHI C HUM FACT, V17, P16, DOI [DOI 10.1145/22627.22342, DOI 10.1145/22339.22342]; HEATHFIELD HA, 1993, METHOD INFORM MED, V32, P1; JANSEN C, 1992, J TECH WRIT COMMUN, V22, P179, DOI 10.2190/GA16-7X9P-NRNN-R388; MAAT HP, 1994, J TECH WRIT COMMUN, V24, P389, DOI 10.2190/LEK9-VUJP-L3B9-V2LD; Maylor EA, 1996, PSYCHOLOGIST, V9, P456; Nygren E, 1998, LANCET, V352, P1462, DOI 10.1016/S0140-6736(97)08307-4; POULTON EC, 1965, J APPL PSYCHOL, V49, P358, DOI 10.1037/h0022461; POWSNER SM, 1994, LANCET, V344, P386, DOI 10.1016/S0140-6736(94)91406-0; REDISH JC, 1985, WRITING NONACADEMIC, P129; Sunderland A, 1984, EVERYDAY MEMORY ACTI, P191; TANGE HJ, 1995, COMPUT METH PROG BIO, V48, P127, DOI 10.1016/0169-2607(95)01672-G; Tay SK, 1996, AUST NZ J OBSTET GYN, V36, P395, DOI 10.1111/j.1479-828X.1996.tb02179.x; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; WAINER H, 1984, AM STAT, V38, P137, DOI 10.2307/2683253; WASON PC, 1965, J VERB LEARN VERB BE, V4, P7, DOI 10.1016/S0022-5371(65)80060-3; WILLEMS JL, 1991, NEW ENGL J MED, V325, P1767, DOI 10.1056/NEJM199112193252503; WRIGHT P, 1973, VISIBLE LANG, V7, P351; WRIGHT P, 1980, J RES COMMUN STUD, V2, P99; WRIGHT P, 1975, J APPL PSYCHOL, V60, P606, DOI 10.1037/0021-9010.60.5.606; WYATT JC, 1995, BMJ-BRIT MED J, V311, P1539, DOI 10.1136/bmj.311.7019.1539; [No title captured]; [No title captured]; [No title captured]; [No title captured]	31	31	31	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1539	1543		10.1016/S0140-6736(98)08308-1	http://dx.doi.org/10.1016/S0140-6736(98)08308-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820319	Green Submitted			2022-12-28	WOS:000076862300040
J	Zreda, M; Noller, JS				Zreda, M; Noller, JS			Ages of prehistoric earthquakes revealed by cosmogenic chlorine-36 in a bedrock fault scarp at Hebgen Lake	SCIENCE			English	Article							CL-36 PRODUCTION-RATES; TERRESTRIAL ROCKS; ACCUMULATION	Cosmogenic chlorine-36 reveals dates of the multiple prehistoric earthquakes that have produced a scarp on the Hebgen Lake fault. Apparent chlorine-36 ages are stratigraphically correct, follow a predicted theoretical pattern, and produce geologically reasonable model ages of 24, 20, 7.0, 2.6, 1.7, and 0.4 thousand years ago. This result demonstrates the feasibility of using cosmogenic chlorine-36 to extract paleoearthquake records from bedrock fault scarps.	Univ Arizona, Dept Hydrol & Water Resources, Tucson, AZ 85721 USA; Vanderbilt Univ, Dept Geol, Nashville, TN 37235 USA	University of Arizona; Vanderbilt University	Zreda, M (corresponding author), Univ Arizona, Dept Hydrol & Water Resources, Tucson, AZ 85721 USA.			Noller, Jay/0000-0002-6968-4813				ARUSCAVAGE PJ, 1983, TALANTA, V30, P745, DOI 10.1016/0039-9140(83)80171-4; CRONE AJ, 1990, GEOL SOC AM BULL, V102, P1, DOI 10.1130/0016-7606(1990)102<0001:SATOHS>2.3.CO;2; Davis R. J., 1955, ANN NY ACAD SCI, V62, P105; ELMORE D, 1979, NATURE, V277, P22, DOI 10.1038/277022a0; Fabryka-Martin J. T., 1988, THESIS U ARIZONA; LAL D, 1991, EARTH PLANET SC LETT, V104, P424, DOI 10.1016/0012-821X(91)90220-C; LIU BL, 1994, WATER RESOUR RES, V30, P3115, DOI 10.1029/94WR00761; MCCALPIN JP, 1996, INT GEOPHYSICS SERIE, V62; MYERS WB, 1964, US GEOL SURV PROF PA, V435, P58; NASH DB, 1984, GEOL SOC AM BULL, V95, P1413, DOI 10.1130/0016-7606(1984)95<1413:MDOFTS>2.0.CO;2; NOLLER JS, QUATERNARY GEOCHRONO; Phillips F.M., 1996, RADIOCARBON, V38, P98; Phillips FM, 1997, GEOL SOC AM BULL, V109, P1453, DOI 10.1130/0016-7606(1997)109<1453:CCABAO>2.3.CO;2; Phillips FM, 1996, GEOPHYS RES LETT, V23, P949, DOI 10.1029/96GL00960; PHILLIPS FM, 1986, SCIENCE, V231, P41, DOI 10.1126/science.231.4733.41; Stone JOH, 1998, GEOCHIM COSMOCHIM AC, V62, P433, DOI 10.1016/S0016-7037(97)00369-4; WALLACE RE, 1984, J GEOPHYS RES, V89, P5763, DOI 10.1029/JB089iB07p05763; WALLACE RE, 1987, SEISMOL SOC AM B, V74, P301; WITKIND IJ, 1964, US GEOL SURV PROF PA, V435, P37; Zreda M. G., 1994, DATING EXPOSED SURFA, P161; ZREDA MG, 1991, EARTH PLANET SC LETT, V105, P94, DOI 10.1016/0012-821X(91)90123-Y; ZREDA MG, 1994, THESIS NEW MEXICO I; ZREDA MG, 1990, 901 NEW MEX I MIN TE	23	63	77	4	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1097	1099		10.1126/science.282.5391.1097	http://dx.doi.org/10.1126/science.282.5391.1097			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804542				2022-12-28	WOS:000076887700042
J	Kiyono, T; Foster, SA; Koop, JI; McDougall, JK; Galloway, DA; Klingelhutz, AJ				Kiyono, T; Foster, SA; Koop, JI; McDougall, JK; Galloway, DA; Klingelhutz, AJ			Both Rb/p16(INK4a) inactivation and telomerase activity are required to immortalize human epithelial cells	NATURE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN FIBROBLASTS; E6; KERATINOCYTES; P53; E7; ONCOPROTEINS; DEGRADATION; SENESCENCE; INDUCTION	Normal human cells undergo a limited number of divisions in; culture and enter a non-dividing state called replicative senescence(1). Senescence is accompanied by several changes, including an increase in inhibitors of cyclin-dependent kinases(2,3) and telomere shortening(4). The mechanisms by which viral oncogenes reverse these processes are not fully understood, although a general requirement for oncoproteins such as human papillomavirus E6 and E7 has suggested that the p53 and Rb pathways are targeted. Expression of the catalytic component of telomerase, hTERT, alone significantly extends the lifespan of human fibroblasts(5). Here we show that telomerase activity is not sufficient for immortalization of human keratinocyte or mammary epithelial cells: we find that neither addition of hTERT nor induction of telomerase activity by E6, both of which are active in maintaining telomere length, results in immortalization. Inactivation of the Rb/p16 pathway by E7 or downregulation of p16 expression, in combination with telomerase activity, however, is able to immortalize epithelial cells efficiently. Elimination of p53 and of the DNA-damage-induced G1 checkpoint is not necessary for immortalization, neither is elimination of p19ARF.	Fred Hutchinson Canc Res Ctr, Canc Biol Program, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Galloway, DA (corresponding author), Fred Hutchinson Canc Res Ctr, Canc Biol Program, 1100 Fairview Ave N,Cl-015,POB 19024, Seattle, WA 98109 USA.		Kiyono, Tohru/H-5834-2011; Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; Foster SA, 1996, ONCOGENE, V12, P1773; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Halbert CL, 1991, J VIROL, V65, P474; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HULBREGTSE JM, 1993, MOL CELL BIOL, V13, P775; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Krupp G, 1997, NUCLEIC ACIDS RES, V25, P919, DOI 10.1093/nar/25.4.919; Loughran O, 1997, ONCOGENE, V14, P1955, DOI 10.1038/sj.onc.1201028; MUNGER K, 1989, J VIROL, V63, P4417; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1993, ONCOGENE, V8, P1407; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	30	1005	1060	2	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1998	396	6706					84	88		10.1038/23962	http://dx.doi.org/10.1038/23962			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136HE	9817205				2022-12-28	WOS:000076852700059
J	Kim, HN				Kim, HN			Prescription for prophecy: Confronting the ambiguity of susceptibility testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUNTINGTON DISEASE; ATTITUDES; RISK		Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kim, HN (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.							ANDREWSL B, 1994, ASSESSING GENETIC RI, P146; BIESECKER BB, 1997, J AM MED WOMEN ASSOC, V51, P22; Croyle RT, 1997, HEALTH PSYCHOL, V16, P63, DOI 10.1037/0278-6133.16.1.63; KESSLER S, 1987, AM J MED GENET, V26, P259, DOI 10.1002/ajmg.1320260204; MARKEL DS, 1987, AM J MED GENET, V26, P295, DOI 10.1002/ajmg.1320260207; QUAID K, 1994, GENES HUMAN SELF KNO, P5; WEXLER NS, 1992, FASEB J, V6, P2820, DOI 10.1096/fasebj.6.10.1386047	7	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1535	1536		10.1001/jama.280.17.1535	http://dx.doi.org/10.1001/jama.280.17.1535			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809739	hybrid			2022-12-28	WOS:000076757200032
J	Sharp, D				Sharp, D			Through the eyes of the journals	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Sharp, D (corresponding author), Lancet, 42 Bedford Sq, London WC1B 3SL, England.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					48	48		10.1016/S0140-6736(05)79538-6	http://dx.doi.org/10.1016/S0140-6736(05)79538-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800761				2022-12-28	WOS:000074608600044
J	Bertin, PJ				Bertin, PJ			Memorable patients - Continued need for special treatment	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1495	1495		10.1136/bmj.317.7171.1495	http://dx.doi.org/10.1136/bmj.317.7171.1495			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831580	Green Published			2022-12-28	WOS:000077338300029
J	Reid, AJC; Whitney, CJM; Ayles, HM; Jennings, RM; Bovill, BA; Felton, JM; Behrens, RH; Bryceson, ADM; Mabey, DCW				Reid, AJC; Whitney, CJM; Ayles, HM; Jennings, RM; Bovill, BA; Felton, JM; Behrens, RH; Bryceson, ADM; Mabey, DCW			Malaria at Christmas: risks of prophylaxis versus risks of malaria	BRITISH MEDICAL JOURNAL			English	Article							ANTIMALARIAL PROPHYLAXIS; MEFLOQUINE; TRAVELERS; PREVENTION		Hosp Trop Dis, London NW1 0PE, England	University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine	Mabey, DCW (corresponding author), Hosp Trop Dis, London NW1 0PE, England.		Whitty, Christopher/C-7740-2012	Mabey, David/0000-0002-0031-8276; Whitty, Christopher/0000-0002-6076-5027; Behrens, Ron/0000-0002-8166-2633; Ayles, Helen/0000-0003-4108-2842				ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; Barrett PJ, 1996, BRIT MED J, V313, P525, DOI 10.1136/bmj.313.7056.525; BEHRENS RH, 1993, BRIT MED BULL, V49, P363, DOI 10.1093/oxfordjournals.bmb.a072615; BRADLEY DJ, 1997, COMMUNICABLE DIS REV, V7, pR138; *CDR, 1998, COMMUN DIS REP CDR W, V8, P177; Croft AMJ, 1997, T ROY SOC TROP MED H, V91, P199, DOI 10.1016/S0035-9203(97)90223-6; Goodyer L, 1998, AM J TROP MED HYG, V59, P323, DOI 10.4269/ajtmh.1998.59.323; LEWIS SJ, 1992, BMJ-BRIT MED J, V305, P741, DOI 10.1136/bmj.305.6856.741; LOBEL HO, 1993, LANCET, V341, P848, DOI 10.1016/0140-6736(93)93058-9; Lobel HO, 1997, JAMA-J AM MED ASSOC, V278, P1767, DOI 10.1001/jama.278.21.1767; PHILLIPSHOWARD PA, 1990, BMJ-BRIT MED J, V300, P499, DOI 10.1136/bmj.300.6723.499; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W; White NJ, 1998, LANCET, V352, P594, DOI 10.1016/S0140-6736(05)79572-6; World Health Organization, 1997, Weekly Epidemiological Record, V72, P269	14	28	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1506	1508		10.1136/bmj.317.7171.1506	http://dx.doi.org/10.1136/bmj.317.7171.1506			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831584	Green Published			2022-12-28	WOS:000077338300036
J	Bunz, F; Dutriaux, A; Lengauer, C; Waldman, T; Zhou, S; Brown, JP; Sedivy, JM; Kinzler, KW; Vogelstein, B				Bunz, F; Dutriaux, A; Lengauer, C; Waldman, T; Zhou, S; Brown, JP; Sedivy, JM; Kinzler, KW; Vogelstein, B			Requirement for p53 and p21 to sustain G(2) arrest after DNA damage	SCIENCE			English	Article							CELL-CYCLE; HUMAN FIBROBLASTS; CHECKPOINT CONTROL; S-PHASE; KINASE; EXPRESSION; INHIBITOR; MITOSIS; GROWTH; CANCER	After DNA damage, many cells appear to enter a sustained arrest in the G(2) phase of the cell cycle. It is shown here that this arrest could be sustained only when p53 was present in the cell and capable of transcriptionally activating the cyclin-dependent kinase inhibitor p21. After disruption of either the p53 or the p21 gene, gamma radiated cells progressed into mitosis and exhibited a G(2) DNA content only because of a failure of cytokinesis. Thus, p53 and p21 appear to be essential for maintaining the G(2) checkpoint in human cells.	Johns Hopkins Oncol Ctr, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Brown Univ, Dept Biochem Mol Biol & Cell Biol, Div Biol & Med, Providence, RI 02912 USA; Johns Hopkins Univ, Sch Med, Program Human Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Brown University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Vogelstein, B (corresponding author), Johns Hopkins Oncol Ctr, Howard Hughes Med Inst, 424 N Bond St, Baltimore, MD 21231 USA.			Dutriaux, Annie/0000-0002-4398-4850	NATIONAL CANCER INSTITUTE [R01CA043460, R01CA057345, R37CA057345, P50CA062924, R37CA043460] Funding Source: NIH RePORTER; NCI NIH HHS [CA 62924, CA 43460, CA 57345] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUNZ F, UNPUB; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FAN SJ, 1995, CANCER RES, V55, P1649; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; KASTAN MB, 1991, CANCER RES, V51, P6304; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; Khan SH, 1998, CANCER RES, V58, P396; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Laskey RA, 1996, EXP CELL RES, V229, P204, DOI 10.1006/excr.1996.0361; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI Y, 1994, ONCOGENE, V9, P2261; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; MICHIELI P, 1994, CANCER RES, V54, P3391; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Olive PL, 1996, RADIAT RES, V146, P595, DOI 10.2307/3579374; Paoletti A, 1997, Prog Cell Cycle Res, V3, P285; PAULES RS, 1995, CANCER RES, V55, P17563; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POWELL SN, 1995, CANCER RES, V55, P1643; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STEWART N, 1995, ONCOGENE, V10, P109; SU TT, 1995, CELL, V81, P825, DOI 10.1016/0092-8674(95)90000-4; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang BB, 1996, BIOCHEM J, V314, P313, DOI 10.1042/bj3140313; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	48	2493	2570	1	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1497	1501		10.1126/science.282.5393.1497	http://dx.doi.org/10.1126/science.282.5393.1497			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822382				2022-12-28	WOS:000077110800057
J	Liu, SP; Widom, J; Kemp, CW; Crews, CM; Clardy, J				Liu, SP; Widom, J; Kemp, CW; Crews, CM; Clardy, J			Structure of human methionine aminopeptidase-2 complexed with fumagillin	SCIENCE			English	Article							ANGIOGENESIS INHIBITOR TNP-470; TUMOR-GROWTH; IN-VIVO; METASTASIS; CANCER; AGENT; REFINEMENT; CARCINOMA; PROGRAM	The fungal metabolite fumagillin suppresses the formation of new blood vessels, and a fumagillin analog is currently in clinical trials as an anticancer agent. The molecular target of fumagillin is methionine aminopeptidase-2 (MetAP-2). A 1.8 Angstrom resolution crystal structure of free and inhibited human MetAP-2 shows a covalent bond formed between a reactive epoxide of fumagillin and histidine-231 in the active site of MetAP-2. Extensive hydrophobic and water-mediated polar interactions with other parts of fumagillin provide additional affinity. Fumagillin-based drugs inhibit MetAP-2 but not MetAP-1, and the three-dimensional structure also indicates the likely determinants of this specificity. The structural basis for fumagillin's potency and specificity forms the starting point for structure-based drug design.	Cornell Univ, Baker Lab, Dept Chem & Chem Biol, Ithaca, NY 14853 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Kemp Biotechnol Inc, Frederick, MD 21704 USA	Cornell University; Yale University	Clardy, J (corresponding author), Cornell Univ, Baker Lab, Dept Chem & Chem Biol, Ithaca, NY 14853 USA.		Crews, Craig M./ABH-9346-2020	Crews, Craig M./0000-0002-8456-2005	NCI NIH HHS [CA24487, CA59021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059021, R01CA024487] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Dezube BJ, 1998, J CLIN ONCOL, V16, P1444, DOI 10.1200/JCO.1998.16.4.1444; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; HANSON FR, 1949, J BACTERIOL, V58, P527, DOI 10.1128/JB.58.4.527-529.1949; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawarada Y, 1997, PANCREAS, V15, P251, DOI 10.1097/00006676-199710000-00006; KENDALL RL, 1992, J BIOL CHEM, V267, P20667; Konno H, 1996, CANCER-AM CANCER SOC, V77, P1736; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; MCCOWEN MC, 1951, SCIENCE, V113, P202, DOI 10.1126/science.113.2930.202; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ohta Y, 1997, BRIT J CANCER, V75, P512, DOI 10.1038/bjc.1997.89; RODERICK SL, 1993, BIOCHEMISTRY-US, V32, P3907, DOI 10.1021/bi00066a009; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Singh Y, 1997, BREAST CANCER RES TR, V45, P15, DOI 10.1023/A:1005826129756; Tahirov TH, 1998, J STRUCT BIOL, V121, P68, DOI 10.1006/jsbi.1997.3940; Twardowski Przemyslaw, 1997, Current Opinion in Oncology, V9, P584, DOI 10.1097/00001622-199711000-00015; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang Jieyi, 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P98; Wassberg E, 1997, EUR J CANCER, V33, P2020, DOI 10.1016/S0959-8049(97)00337-7; Xia JL, 1997, J CANCER RES CLIN, V123, P383, DOI 10.1007/BF01240121	28	371	405	2	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1324	1327		10.1126/science.282.5392.1324	http://dx.doi.org/10.1126/science.282.5392.1324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812898				2022-12-28	WOS:000076982200047
J	Beecham, L				Beecham, L			Suspension procedures for doctors to be reviewed	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1325	1325						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804740				2022-12-28	WOS:000076963800063
J	DeLeo, VA				DeLeo, VA			Skin testing in systemic cutaneous drug reactions	LANCET			English	Editorial Material									St Lukes Roosevelt Hosp Ctr, Dept Dermatol, New York, NY 10025 USA	Mount Sinai St. Luke's; Mount Sinai West	DeLeo, VA (corresponding author), St Lukes Roosevelt Hosp Ctr, Dept Dermatol, New York, NY 10025 USA.							ADKINSON NF, 1989, ALLERGY PRINCIPLES P, P1212; Barbaud A, 1998, BRIT J DERMATOL, V139, P49; Breathnach S M, 1995, Australas J Dermatol, V36, P121, DOI 10.1111/j.1440-0960.1995.tb00953.x; Markss JG, 1997, CONTACT OCCUPATIONAL; ROUGEAU JC, 1994, NEW ENGL J MED, V331, P1272; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9	6	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1488	1490		10.1016/S0140-6736(05)60323-6	http://dx.doi.org/10.1016/S0140-6736(05)60323-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820294				2022-12-28	WOS:000076862300004
J	Florence, SL; Taub, HB; Kaas, JH				Florence, SL; Taub, HB; Kaas, JH			Large-scale sprouting of cortical connections after peripheral injury in adult macaque monkeys	SCIENCE			English	Article							SOMATOSENSORY CORTEX; PERCEPTUAL PLASTICITY; LIMB AMPUTATION; STRIATE CORTEX; REORGANIZATION; REPRESENTATIONS; DEAFFERENTATION; AREA-3B; HAND; CAT	Distributions of thalamic and cortical connections were investigated in four macaque monkeys with long-standing, accidental trauma to a forelimb, to determine whether the growth of new connections plays a role in the reorganization. of somatosensory cortex that occurs after major alterations in peripheral somatosensory inputs, In each monkey, microelectrode recordings of cortical areas 3b and 1 demonstrated massive reorganizations of the cortex related to the affected limb. injections of tracers in area 1 of these monkeys revealed normal patterns of thalamocortical connections, but markedly expanded lateral connections in areas 3b and 1. Thus, the growth of intracortical but not thalamocortical connections could account for much of the reorganization of the sensory maps in cortex.	Vanderbilt Univ, Dept Psychol, Nashville, TN 37240 USA	Vanderbilt University	Florence, SL (corresponding author), Vanderbilt Univ, Dept Psychol, 301 Wilson Hall, Nashville, TN 37240 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD015052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036469, R01NS016446] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BURTON H, 1995, J COMP NEUROL, V355, P508, DOI 10.1002/cne.903550404; DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Florence SL, 1995, J NEUROSCI, V15, P8083; GARRAGHTY PE, 1994, SOMATOSENS MOT RES, V11, P109, DOI 10.3109/08990229409028864; HALLIGAN PW, 1993, NEUROREPORT, V4, P233, DOI 10.1097/00001756-199303000-00001; HALLIGAN PW, 1994, NEUROREPORT, V5, P1341, DOI 10.1097/00001756-199406000-00012; Jain N, 1997, NATURE, V386, P495, DOI 10.1038/386495a0; KRUBITZER LA, 1990, J NEUROSCI, V10, P952; NELSON RJ, 1981, J COMP NEUROL, V199, P29, DOI 10.1002/cne.901990104; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; PONS TP, 1987, SOMATOSENS MOT RES, V4, P309, DOI 10.3109/07367228709144612; RAMACHANDRAN VS, 1992, SCIENCE, V258, P1159, DOI 10.1126/science.1439826; RAMACHANDRAN VS, 1993, P NATL ACAD SCI USA, V90, P10413, DOI 10.1073/pnas.90.22.10413	16	342	348	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1117	1121		10.1126/science.282.5391.1117	http://dx.doi.org/10.1126/science.282.5391.1117			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804549				2022-12-28	WOS:000076887700049
J	Ginzberg, E				Ginzberg, E			US health system reform in the early 21st century	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Columbia Univ, Eisenhower Ctr Conservat Human Resources, New York, NY 10115 USA	Columbia University	Ginzberg, E (corresponding author), Columbia Univ, Eisenhower Ctr Conservat Human Resources, 475 Riverside Dr,Suite 248, New York, NY 10115 USA.							*C BUDG OFF, 1997, AN PRES BUDG PROP FI; *HLTH SYST RES INC, 1997, DEV CAP RAT MED MAN; Reinhardt UE, 1997, JAMA-J AM MED ASSOC, V278, P1446, DOI 10.1001/jama.278.17.1446	3	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1539	1539		10.1001/jama.280.17.1539	http://dx.doi.org/10.1001/jama.280.17.1539			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809741				2022-12-28	WOS:000076757200035
J	Nightingale, SL				Nightingale, SL			New drug to treat HIV/AIDS approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	34	37	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1472	1472		10.1001/jama.280.17.1472-b	http://dx.doi.org/10.1001/jama.280.17.1472-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809716				2022-12-28	WOS:000076757200004
J	McCann, UD; Szabo, Z; Scheffel, U; Dannals, RF; Ricaurte, GA				McCann, UD; Szabo, Z; Scheffel, U; Dannals, RF; Ricaurte, GA			Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings	LANCET			English	Article							UPTAKE SITES; (+/-)3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; METHYLENEDIOXYMETHAMPHETAMINE MDMA; NONHUMAN-PRIMATES; BABOON BRAIN; RAT-BRAIN; NEUROTOXICITY; TERMINALS; PET; 3,4-METHYLENEDIOXYMETHAMPHETAMINE	Background. (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy") is, a popular recreational drug that selectively damages brain. serotonin (5-HT) neurons in animals at doses' that closely approach those used by humans. We investigated the status of brain 5-HT neurons in MDMA users. Methods We enrolled 14 previous users of MDMA who were currently abstaining from use and 15 controls who had never used MDMA. We used positron emission tomography (PET) with the radioligand carbon-11-labelled McN-5652, which selectively labels the 5-HT transporter. We analysed whether there were differences in 5-HT transporter binding between abstinent MDMA users and participants in the control group. Blood and urine samples were taken and tested to check for abstinence. Findings MDMA users showed decreased global and regional brain BHT transporter binding compared with controls. Decreases in 5-HT transporter binding positively correlated with the extent of previous MDMA use. Interpretation Quantitative PET studies with a ligand selective for 5-HT transporters can be used to assess the status of 5-HT neurons in the living human brain. We show direct evidence of a decrease in a structural component of brain 5-HT neurons in human MDMA users.	Johns Hopkins Med Inst, Dept Neurol, Baltimore, MD 21224 USA; NIMH, Biol Psychiat Branch, Bethesda, MD 20892 USA; Johns Hopkins Med Inst, Dept Radiol, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Johns Hopkins University; Johns Hopkins Medicine	Ricaurte, GA (corresponding author), Johns Hopkins Med Inst, Dept Neurol, Baltimore, MD 21224 USA.				NIDA NIH HHS [DA06275, DA05938, DA10217] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005938, R01DA010217, R01DA006275] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BATTAGLIA G, 1987, J PHARMACOL EXP THER, V242, P911; BERGSTROM M, 1983, J COMPUT ASSIST TOMO, V7, P42, DOI 10.1097/00004728-198302000-00008; BREWERTON TD, 1988, PSYCHIAT RES, V23, P257, DOI 10.1016/0165-1781(88)90016-9; Chappell W., 1991, ADV DRUG RES, P1; COCCARO EF, 1990, SEROTONIN MAJOR PSYC; COMMINS DL, 1987, J PHARMACOL EXP THER, V241, P338; Dannals Robert F., 1995, Medicinal Chemistry Research, V5, P228; EISNER B, 1989, ECTASY MDMA STORY; FISCHER C, 1995, J NEUROSCI, V15, P5476; Frey KA, 1996, ANN NEUROL, V40, P873, DOI 10.1002/ana.410400609; INSEL TR, 1989, J PHARMACOL EXP THER, V249, P713; Koeppe RA, 1996, J CEREBR BLOOD F MET, V16, P1288, DOI 10.1097/00004647-199611000-00025; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MCCANN UD, 1994, NEUROPSYCHOPHARMACOL, V10, P129, DOI 10.1038/npp.1994.15; MOLLIVER ME, 1990, ANN NY ACAD SCI, V600, P640; Muzik O, 1997, J CEREBR BLOOD F MET, V17, P659; OHEARN E, 1988, J NEUROSCI, V8, P2788; Press W. H., 1986, ART SCI COMPUTING; Ricaurte G A, 1989, NIDA Res Monogr, V94, P306; RICAURTE GA, 1988, BRAIN RES, V474, P359, DOI 10.1016/0006-8993(88)90451-9; RICAURTE GA, 1988, JAMA-J AM MED ASSOC, V260, P51, DOI 10.1001/jama.260.1.51; RICAURTE GA, 1988, BRAIN RES, V446, P165, DOI 10.1016/0006-8993(88)91309-1; RICAURTE GA, 1992, J PHARMACOL EXP THER, V261, P616; RICAURTE GA, 1990, ANN NY ACAD SCI, V600, P699; SANDLER M, 1991, 5 HYDROXYTRYPTAMINE; Scheffel U, 1996, SYNAPSE, V24, P395, DOI 10.1002/(SICI)1098-2396(199612)24:4<395::AID-SYN6>3.0.CO;2-8; Scheffel U, 1998, SYNAPSE, V29, P183, DOI 10.1002/(SICI)1098-2396(199806)29:2<183::AID-SYN9>3.0.CO;2-3; Scheffel U., 1997, Society for Neuroscience Abstracts, V23, P558; SCHMIDT CJ, 1987, J PHARMACOL EXP THER, V240, P1; SLIKKER W, 1988, TOXICOL APPL PHARM, V94, P448, DOI 10.1016/0041-008X(88)90285-2; SUEHIRO M, 1992, J LABELLED COMPD RAD, V31, P841, DOI 10.1002/jlcr.2580311015; SUEHIRO M, 1993, J NUCL MED, V34, P120; SZABO Z, 1995, SYNAPSE, V20, P37, DOI 10.1002/syn.890200107; SZABO Z, 1995, J CEREBR BLOOD F MET, V15, P798, DOI 10.1038/jcbfm.1995.100	34	491	496	0	55	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 31	1998	352	9138					1433	1437		10.1016/S0140-6736(98)04329-3	http://dx.doi.org/10.1016/S0140-6736(98)04329-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9807990	hybrid			2022-12-28	WOS:000076719500010
J	Block, JA				Block, JA			Prevalence of arthroplasty during the course of rheumatoid arthritis	LANCET			English	Editorial Material									Rush Presbyterian St Lukes Med Ctr, Rheumatol Sect, Chicago, IL 60612 USA	Rush University	Block, JA (corresponding author), Rush Presbyterian St Lukes Med Ctr, Rheumatol Sect, 1653 W Congress Pkwy, Chicago, IL 60612 USA.			Block, Joel/0000-0002-0330-7353				AbdelNasser AM, 1997, SEMIN ARTHRITIS RHEU, V27, P123, DOI 10.1016/S0049-0172(97)80012-1; HAKALA M, 1994, J RHEUMATOL, V21, P1432; Pincus T, 1995, BRIT J RHEUMATOL, V34, P59; SHERRER YS, 1986, ARTHRITIS RHEUM, V29, P494, DOI 10.1002/art.1780290406; VANDERHEIJDE MFM, 1988, SEMIN ARTHRITIS RHEU, V17, P284, DOI 10.1016/0049-0172(88)90013-3; Wolfe F, 1998, ARTHRITIS RHEUM, V41, P1072, DOI 10.1002/1529-0131(199806)41:6<1072::AID-ART14>3.0.CO;2-G; WOLFE F, 1985, J RHEUMATOL, V12, P254	7	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 3	1998	352	9134					1086	1086		10.1016/S0140-6736(05)79754-3	http://dx.doi.org/10.1016/S0140-6736(05)79754-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798582				2022-12-28	WOS:000076246400007
J	Beecham, L				Beecham, L			BMA juniors will meet in Bath	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1531	1531						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831603				2022-12-28	WOS:000077338300081
J	Christie, JM; Reymond, P; Powell, GK; Bernasconi, P; Raibekas, AA; Liscum, E; Briggs, WR				Christie, JM; Reymond, P; Powell, GK; Bernasconi, P; Raibekas, AA; Liscum, E; Briggs, WR			Arabidopsis NPH1: A flavoprotein with the properties of a photoreceptor for phototropism	SCIENCE			English	Article							PLASMA-MEMBRANE PROTEIN; BLUE-LIGHT RECEPTOR; HIGHER-PLANTS; PHOSPHORYLATION; THALIANA; SEEDLINGS; IDENTIFICATION; TRANSDUCTION; PERCEPTION; KINASE	The NPH1 gene of Arabidopsis thaliana encodes a 120-kilodalton serine-threonine protein kinase hypothesized ta function as a photoreceptor for phototropism. When expressed in insect cells, the NPH1 protein is phosphorylated in response to blue Light irradiation. The biochemical and photochemical properties of the photosensitive protein reflect those of the native protein in microsomal membranes. Recombinant NPH1 noncovalently binds flavin mononucleotide, a likely chromophore for Light-dependent autophosphorylation. The fluorescence excitation spectrum of the recombinant protein is similar to the action spectrum for phototropism, consistent with the conclusion that NPH1 is an autophosphorylating flavoprotein photoreceptor mediating phototropic responses in higher plants.	Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA; Univ Lausanne, Inst Biol & Physiol Vegetales, CH-1015 Lausanne, Switzerland; Novartis Agribusiness Biotechnol Res Inc, Res Triangle Pk, NC 27709 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	Carnegie Institution for Science; University of Lausanne; Novartis; University of Michigan System; University of Michigan; University of Missouri System; University of Missouri Columbia	Briggs, WR (corresponding author), Carnegie Inst Sci, Dept Plant Biol, 260 Panama St, Stanford, CA 94305 USA.	briggs@andrew.stanford.edu	Reymond, Philippe/ABG-2385-2020; Reymond, Philippe/ABG-2852-2020; Raibekas, Andrei A/A-8555-2009	Reymond, Philippe/0000-0002-3341-6200; Liscum, Emmanuel/0000-0002-8672-9315; Christie, John/0000-0002-9976-0055				Ahmad M, 1998, PLANT CELL, V10, P197, DOI 10.1105/tpc.10.2.197; Ahmad M, 1998, NATURE, V392, P720, DOI 10.1038/33701; Ahmad M, 1996, PLANT MOL BIOL, V30, P851, DOI 10.1007/BF00020798; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BASKIN TI, 1987, PHOTOCHEM PHOTOBIOL, V46, P127, DOI 10.1111/j.1751-1097.1987.tb04746.x; Bibikov SI, 1997, J BACTERIOL, V179, P4075, DOI 10.1128/jb.179.12.4075-4079.1997; Briggs W. R., 1997, Signal transduction in plants., P107; BRIGGS WR, 1983, PHILOS T ROY SOC B, V303, P347, DOI 10.1098/rstb.1983.0098; GALLAND P, 1988, PHOTOCHEM PHOTOBIOL, V48, P811, DOI 10.1111/j.1751-1097.1988.tb02896.x; GALSTON AW, 1949, HDB PLANZENPHYSIOLOG, V17, P492; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; Hill S, 1996, P NATL ACAD SCI USA, V93, P2143, DOI 10.1073/pnas.93.5.2143; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; Janoudi AK, 1997, PHYSIOL PLANTARUM, V101, P278, DOI 10.1034/j.1399-3054.1997.1010204.x; KONJEVIC R, 1989, P NATL ACAD SCI USA, V86, P9876, DOI 10.1073/pnas.86.24.9876; Lin C., 1996, PLANT PHYSIOL, V110, P1047; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; LISCUM E, 1995, PLANT CELL, V7, P473, DOI 10.1105/tpc.7.4.473; LORENZI R, 1994, PHYTOCHEMISTRY, V36, P599, DOI 10.1016/S0031-9422(00)89781-2; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; OLNEY MA, UNPUB; PALMER JM, 1993, PLANT PHYSIOL, V102, P1211, DOI 10.1104/pp.102.4.1211; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; RAIBEKAS AA, 1991, J BIOLUM CHEMILUM, V6, P169, DOI 10.1002/bio.1170060306; REYMOND P, 1992, PLANT PHYSIOL, V100, P655, DOI 10.1104/pp.100.2.655; Salomon M, 1997, PLANT PHYSIOL, V115, P493, DOI 10.1104/pp.115.2.493; SHORT TW, 1990, PLANT PHYSIOL, V92, P179, DOI 10.1104/pp.92.1.179; SHORT TW, 1992, PHOTOCHEM PHOTOBIOL, V55, P773; SHORT TW, 1994, ANNU REV PLANT PHYS, V45, P143, DOI 10.1146/annurev.pp.45.060194.001043; Wald G, 1936, Science, V84, P247, DOI 10.1126/science.84.2176.247-a; Zeiger E, 1998, J EXP BOT, V49, P433, DOI 10.1093/jexbot/49.suppl_1.433	32	493	513	2	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 27	1998	282	5394					1698	1701		10.1126/science.282.5394.1698	http://dx.doi.org/10.1126/science.282.5394.1698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831559				2022-12-28	WOS:000077246600044
J	Huang, HF; Chopra, R; Verdine, GL; Harrison, SC				Huang, HF; Chopra, R; Verdine, GL; Harrison, SC			Structure of a covalently trapped catalytic complex of HIV-I reverse transcriptase: Implications for drug resistance	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; POL GENE-MUTATIONS; CRYSTAL-STRUCTURE; NONNUCLEOSIDE INHIBITORS; ANGSTROM RESOLUTION; COMBINATION THERAPY; MINOR-GROOVE; ZIDOVUDINE; SENSITIVITY; MECHANISM	A combinatorial disulfide cross-linking strategy was used to prepare a stalled complex of human immunodeficiency virus-type 1 (HIV-1) reverse transcriptase with a DNA template:primer and a deoxynucleoside triphosphate (dNTP), and the crystal structure of the complex was determined at a resolution of 3.2 angstroms. The presence of a dideoxynucleotide at the 3'-primer terminus allows capture of a state in which the substrates are poised for attack on the dNTP. Conformational changes that accompany formation of the catalytic complex produce distinct clusters of the residues that are altered in viruses resistant to nucleoside analog drugs. The positioning of these residues in the neighborhood of the dNTP helps to resolve some Long-standing puzzles about the molecular basis of resistance. The resistance mutations are Likely to influence binding or reactivity of the inhibitors, relative to normal dNTPs, and the clustering of the mutations correlates with the chemical structure of the drug.	Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA	Harvard University; Harvard University; Harvard University; Howard Hughes Medical Institute	Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.	verdine@glviris.harvard.edu; schadmin@crystal.harvard.edu			NIGMS NIH HHS [GM-39589, GM-18621, GM-44853] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044853, P01GM039589] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARROLL SS, 1994, BIOCHEMISTRY-US, V33, P2113, DOI 10.1021/bi00174a018; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; Erlanson DA, 1997, J AM CHEM SOC, V119, P6927, DOI 10.1021/ja9710666; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; GEORGIADIS MM, 1995, STRUCTURE, V3, P879, DOI 10.1016/S0969-2126(01)00223-4; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; Hostomsky Z., 1993, NUCLEASES, V2nd, P341; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JAGER J, 1994, STRUCTURE, V2, P869, DOI 10.1016/S0969-2126(94)00087-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LACEY SF, 1992, J BIOL CHEM, V267, P15789; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; Richman DD, 1996, ADV EXP MED BIOL, V394, P383; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722; SHIRASAKA T, 1993, P NATL ACAD SCI USA, V90, P562, DOI 10.1073/pnas.90.2.562; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; Tisdale M, 1997, ANTIMICROB AGENTS CH, V41, P1094, DOI 10.1128/AAC.41.5.1094; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; ZHANG D, 1994, ANTIMICROB AGENTS CH, V38, P282, DOI 10.1128/AAC.38.2.282	48	1271	1309	0	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 27	1998	282	5394					1669	1675		10.1126/science.282.5394.1669	http://dx.doi.org/10.1126/science.282.5394.1669			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831551				2022-12-28	WOS:000077246600036
J	Bonadeo, NH; Erland, J; Gammon, D; Park, D; Katzer, DS; Steel, DG				Bonadeo, NH; Erland, J; Gammon, D; Park, D; Katzer, DS; Steel, DG			Coherent optical control of the quantum state of a single quantum dot	SCIENCE			English	Article							ELECTRON GASES; SPECTROSCOPY; SCATTERING; EXCITONS; PULSES; INTERFERENCE; RELAXATION; TRANSIENTS; SEQUENCES; DYNAMICS	Picosecond optical excitation was used to coherently control the excitation in a single quantum dot on a time scale that is short compared with the time scale for loss of quantum coherence. The excitonic wave function was manipulated by controlling the optical phase of the two-pulse sequence through timing and polarization. Wave function engineering techniques, developed in atomic and molecular systems, were used to monitor and control a nonstationary quantum mechanical state composed of a superposition of eigenstates. The results extend the concept of coherent control in semiconductors to the limit of a single quantum system in a zero-dimensional quantum dot.	Univ Michigan, Harrison M Randall Lab Phys, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Ultrafast Opt Sci, Ann Arbor, MI 48109 USA; USN, Res Lab, Washington, DC 20375 USA; Univ Michigan, Dept Elect Engn & Comp Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; United States Department of Defense; United States Navy; Naval Research Laboratory; University of Michigan System; University of Michigan	Steel, DG (corresponding author), Univ Michigan, Harrison M Randall Lab Phys, Ann Arbor, MI 48109 USA.		Katzer, D. Scott/N-7841-2013					Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; BARENCO A, 1995, PHYS REV LETT, V74, P4083, DOI 10.1103/PhysRevLett.74.4083; Blanchet V, 1997, PHYS REV LETT, V78, P2716, DOI 10.1103/PhysRevLett.78.2716; BOCKELMANN U, 1993, PHYS REV B, V48, P17637, DOI 10.1103/PhysRevB.48.17637; BOCKELMANN U, 1990, PHYS REV B, V42, P8947, DOI 10.1103/PhysRevB.42.8947; Bonadeo NH, 1998, PHYS REV LETT, V81, P2759, DOI 10.1103/PhysRevLett.81.2759; BRUNNER K, 1994, PHYS REV LETT, V73, P1138, DOI 10.1103/PhysRevLett.73.1138; CITRIN DS, 1993, PHYS REV B, V47, P3832, DOI 10.1103/PhysRevB.47.3832; Dekel E, 1998, PHYS REV LETT, V80, P4991, DOI 10.1103/PhysRevLett.80.4991; Ekert A, 1996, REV MOD PHYS, V68, P733, DOI 10.1103/RevModPhys.68.733; Empedocles SA, 1997, SCIENCE, V278, P2114, DOI 10.1126/science.278.5346.2114; GAMMON D, 1995, APPL PHYS LETT, V67, P2391, DOI 10.1063/1.114557; Gammon D, 1997, SCIENCE, V277, P85, DOI 10.1126/science.277.5322.85; Gammon D, 1996, SCIENCE, V273, P87, DOI 10.1126/science.273.5271.87; Gammon D, 1996, PHYS REV LETT, V76, P3005, DOI 10.1103/PhysRevLett.76.3005; Gupalov SV, 1998, J EXP THEOR PHYS+, V86, P388, DOI 10.1134/1.558441; Hache A, 1997, PHYS REV LETT, V78, P306, DOI 10.1103/PhysRevLett.78.306; Hasen J, 1997, NATURE, V390, P54, DOI 10.1038/36299; HEBERLE AP, 1995, PHYS REV LETT, V75, P2598, DOI 10.1103/PhysRevLett.75.2598; HESS HF, 1994, SCIENCE, V264, P1740, DOI 10.1126/science.264.5166.1740; Huggard PG, 1997, APPL PHYS LETT, V71, P2647, DOI 10.1063/1.120167; Kikkawa JM, 1997, SCIENCE, V277, P1284, DOI 10.1126/science.277.5330.1284; Kikkawa JM, 1998, PHYS REV LETT, V80, P4313, DOI 10.1103/PhysRevLett.80.4313; Landin L, 1998, SCIENCE, V280, P262, DOI 10.1126/science.280.5361.262; LLOYD S, 1993, SCIENCE, V261, P1569, DOI 10.1126/science.261.5128.1569; Meekhof DM, 1996, PHYS REV LETT, V76, P1796, DOI 10.1103/PhysRevLett.76.1796; METIU H, 1990, J OPT SOC AM B, V7, P1709, DOI 10.1364/JOSAB.7.001709; MOSSBERG T, 1979, PHYS REV LETT, V42, P1665, DOI 10.1103/PhysRevLett.42.1665; PLANKEN PCM, 1993, PHYS REV B, V48, P4903, DOI 10.1103/PhysRevB.48.4903; SALOUR MM, 1977, PHYS REV LETT, V38, P757, DOI 10.1103/PhysRevLett.38.757; Schedelbeck G, 1997, SCIENCE, V278, P1792, DOI 10.1126/science.278.5344.1792; SCHERER NF, 1991, J CHEM PHYS, V95, P1487, DOI 10.1063/1.461064; SPANO F, 1987, CHEM PHYS LETT, V135, P97, DOI 10.1016/0009-2614(87)87224-X; Wang F, 1996, PHYS REV LETT, V77, P2416, DOI 10.1103/PhysRevLett.77.2416; WARREN WS, 1993, SCIENCE, V259, P1581, DOI 10.1126/science.259.5101.1581; WEHNER MU, 1998, IN PRESS NATURE, P1992; Weinacht TC, 1998, PHYS REV LETT, V80, P5508, DOI 10.1103/PhysRevLett.80.5508; WEINACHT TC, IN PRESS NATURE; YEAZELL JA, 1988, PHYS REV LETT, V60, P1494, DOI 10.1103/PhysRevLett.60.1494; Young B., 1997, ATOM INTERFEROMETRY, V1st; Zare RN, 1998, SCIENCE, V279, P1875, DOI 10.1126/science.279.5358.1875	41	555	567	4	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1473	1476		10.1126/science.282.5393.1473	http://dx.doi.org/10.1126/science.282.5393.1473			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822374				2022-12-28	WOS:000077110800049
J	Harbury, PB; Plecs, JJ; Tidor, B; Alber, T; Kim, PS				Harbury, PB; Plecs, JJ; Tidor, B; Alber, T; Kim, PS			High-resolution protein design with backbone freedom	SCIENCE			English	Article							AUTOMATED SEQUENCE SELECTION; DE-NOVO DESIGN; COILED-COILS; ALPHA-HELIX; HYDROGEN-EXCHANGE; ENERGY; CONFORMATION; OPTIMIZATION; PREDICTION; DYNAMICS	Recent advances in computational techniques have allowed the design of precise side-chain packing in proteins with predetermined, naturally occurring backbone structures. Because these methods do not model protein main-chain flexibility, they lack the breadth to explore novel backbone conformations. Here the de novo design of a family of or-helical bundle proteins with a right-handed superhelical twist is described. In the design, the overall protein fold was specified by hydrophobic-polar residue patterning, whereas the bundle oligomerization state, detailed main-chain conformation, and interior side-chain rotamers were engineered by computational enumerations of packing in alternate backbone structures. Main-chain flexibility was incorporated through an algebraic parameterization of the backbone. The designed peptides form ct-helical dimers, trimers, and tetramers in accord with the design goals. The crystal structure of the tetramer matches the designed structure in atomic detail.	Whitehead Inst Biomed Res, Howard Hughes Med Inst, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; MIT, Dept Chem, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Massachusetts Institute of Technology (MIT)	Kim, PS (corresponding author), Whitehead Inst Biomed Res, Howard Hughes Med Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	dvorak@wi.mit.edu		/0000-0002-3320-3969	NIGMS NIH HHS [GM55758, GM44162, GM48598] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048598, R01GM044162] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1988, SCIENCE, V239, P631, DOI 10.1126/science.3277275; Aurora R, 1997, J BIOL CHEM, V272, P1413, DOI 10.1074/jbc.272.3.1413; BALDWIN EP, 1993, SCIENCE, V262, P1715, DOI 10.1126/science.8259514; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; BEVERIDGE DL, 1989, ANNU REV BIOPHYS BIO, V18, P431, DOI 10.1146/annurev.bb.18.060189.002243; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Bryson JW, 1998, PROTEIN SCI, V7, P1404, DOI 10.1002/pro.5560070617; Cordes MHJ, 1996, CURR OPIN STRUC BIOL, V6, P3, DOI 10.1016/S0959-440X(96)80088-1; CORREA PE, 1990, PROTEINS, V7, P366, DOI 10.1002/prot.340070408; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P685, DOI 10.1107/S0365110X53001952; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Dahiyat BI, 1997, J MOL BIOL, V273, P789, DOI 10.1006/jmbi.1997.1341; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; DeGrado WF, 1991, CURR OPIN STRUC BIOL, V1, P984, DOI 10.1016/0959-440X(91)90095-B; DESJARLAIS JR, 1995, PROTEIN SCI, V4, P2006, DOI 10.1002/pro.5560041006; DESMET J, 1992, NATURE, V356, P539, DOI 10.1038/356539a0; DREXLER KE, 1981, P NATL ACAD SCI USA, V78, P5275, DOI 10.1073/pnas.78.9.5275; DURE L, 1993, PLANT J, V3, P363, DOI 10.1046/j.1365-313X.1993.t01-18-00999.x; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Englander SW, 1996, CURR OPIN STRUC BIOL, V6, P18, DOI 10.1016/S0959-440X(96)80090-X; ENGLANDER SW, 1972, ANNU REV BIOCHEM, V41, P903, DOI 10.1146/annurev.bi.41.070172.004351; HARBURY PB, 1995, P NATL ACAD SCI USA, V92, P8408, DOI 10.1073/pnas.92.18.8408; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hellinga HW, 1998, NAT STRUCT BIOL, V5, P525, DOI 10.1038/776; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOEHL P, 1994, J MOL BIOL, V239, P249, DOI 10.1006/jmbi.1994.1366; Lazar GA, 1997, PROTEIN SCI, V6, P1167, DOI 10.1002/pro.5560060605; LEE C, 1991, J MOL BIOL, V217, P373, DOI 10.1016/0022-2836(91)90550-P; LEE C, 1994, J MOL BIOL, V236, P918, DOI 10.1006/jmbi.1994.1198; LOCKHART DJ, 1992, SCIENCE, V257, P947, DOI 10.1126/science.1502559; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Malakauskas SM, 1998, NAT STRUCT BIOL, V5, P470, DOI 10.1038/nsb0698-470; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; MURZIN AG, 1994, J MOL BIOL, V236, P1369, DOI 10.1016/0022-2836(94)90064-7; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; Peters J, 1996, J MOL BIOL, V257, P1031, DOI 10.1006/jmbi.1996.0221; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; Schafmeister CE, 1997, NAT STRUCT BIOL, V4, P1039, DOI 10.1038/nsb1297-1039; TEMBE BL, 1984, COMPUT CHEM, V8, P281, DOI 10.1016/0097-8485(84)85020-2; TUFFERY P, 1991, J BIOMOL STRUCT DYN, V8, P1267, DOI 10.1080/07391102.1991.10507882; [No title captured]	52	377	395	0	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1462	1467		10.1126/science.282.5393.1462	http://dx.doi.org/10.1126/science.282.5393.1462			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822371				2022-12-28	WOS:000077110800046
J	Bishop, PC; Elwood, PC				Bishop, PC; Elwood, PC			Chylous effusion in Hodgkin's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Bishop, PC (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.								0	5	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1998	339	21					1515	1515		10.1056/NEJM199811193392105	http://dx.doi.org/10.1056/NEJM199811193392105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VT	9819450				2022-12-28	WOS:000077051800005
J	Heymsfield, SB; Allison, DB; Vasselli, JR; Pietrobelli, A; Greenfield, D; Nunez, C				Heymsfield, SB; Allison, DB; Vasselli, JR; Pietrobelli, A; Greenfield, D; Nunez, C			Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Hydroxycitric acid, the active ingredient in the herbal compound Garcinia cambogia, competitively inhibits the extramitochondrial enzyme adenosine triphosphate-citrate (pro-3S)-lyase. As a citrate cleavage enzyme that may play an essential role in de novo lipogenesis inhibition, G cambogia is claimed to lower body weight and reduce fat mass in humans. Objective.-To evaluate the efficacy of G cambogia for body weight and fat mass loss in overweight human subjects. Design.-Twelve-week randomized, double-blind, placebo-controlled trial. Setting.-Outpatient weight control research unit. Participants.-Overweight men and women subjects (mean body mass index [weight in kilograms divided by the square of height in meters], approximately 32 kg/m(2)). Intervention.-Subjects were randomized to receive either active herbal compound (1500 mg of hydroxycitric acid per day) or placebo, and both groups were prescribed a high-fiber, low-energy diet. The treatment period was 12 weeks. Body weight was evaluated every other week and fat mass was measured at weeks 0 and 12. Main Outcome Measures.-Body weight change and fat mass change. Results.-A total of 135 subjects were randomized to either active hydroxycitric acid (n = 66) or placebo (n = 69); 42 (64%) in the active hydroxycitric acid group and 42 (61%) in the placebo group completed 12 weeks of treatment (P = .74). Patients in both groups lost a significant amount of weight during the 12-week treatment period (P < .001); however, between-group weight loss differences were not statistically significant (mean [SD], 3.2 [3.3] kg vs 4.1 [3.9] kg; P = .14). There were no significant differences in estimated percentage of body fat mass loss between treatment groups, and the fraction of subject weight loss as fat was not influenced by treatment group. Conclusions.-Garcinia cambogia failed to produce significant weight loss and fat mass loss beyond that observed with placebo.	Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp, Obes Res Ctr,Dept Med, New York, NY 10025 USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West	Heymsfield, SB (corresponding author), Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp, Obes Res Ctr,Dept Med, 1090 Amsterdam Ave,14th Floor, New York, NY 10025 USA.	sbh2@columbia.edu	Heymsfield, Steven B/N-1968-2017	Heymsfield, Steven B/0000-0003-1127-9425; Allison, David/0000-0003-3566-9399	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026687] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00645] Funding Source: Medline; NIDDK NIH HHS [P30DK26687] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Badmaev V., 1995, NUTR 1995 NUTR DIET; BRAY GA, 1993, ANN INTERN MED, V119, P707, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00016; Burstein L., 1989, MULTILEVEL INVESTIGA; *COMM PROP MED PRO, 1997, NOT GUID CLIN INV DR; Conte A.A., 1993, AM J BARIATR MED SUM, P17; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DRAO RN, 1988, NUTR RES, V8, P209; GIROLA M, 1996, ACTA TOXICOL THER, V17, P25; Graham J W, 1994, NIDA Res Monogr, V142, P13; Heymsfield S. B., 1996, HUMAN BODY COMPOSITI, P129; Heymsfield SB, 1996, AM J CLIN NUTR, V64, P478, DOI 10.1093/ajcn/64.3.478S; Heymsfield SB., 1992, MODERN NUTR HLTH DIS, V8, P812; HOBBS LS, 1994, NEW DIET PILLS, P161; Lewis Y. S., 1965, PHYTOCHEMISTRY, V4, P610; LOWENSTEIN JM, 1971, J BIOL CHEM, V246, P629; Martius C., 1941, Z PHYSL CHEM, V269, P33; *NIH, 1992, AM J CLIN NUTR, V55, pS487; Niklson IA, 1997, PSYCHOPHARMACOL BULL, V33, P41; Pietrobelli A, 1997, INT J OBESITY, V21, P110, DOI 10.1038/sj.ijo.0800374; Pietrobelli A, 1996, AM J PHYSIOL-ENDOC M, V271, pE941, DOI 10.1152/ajpendo.1996.271.6.E941; RUSSELLAULET M, 1991, J BONE MINER RES, V6, P411; SULLIVAN AC, 1974, LIPIDS, V9, P129, DOI 10.1007/BF02532137; SULLIVAN AC, 1972, ARCH BIOCHEM BIOPHYS, V150, P183, DOI 10.1016/0003-9861(72)90025-2; SULLIVAN AC, 1974, LIPIDS, V9, P121, DOI 10.1007/BF02532136; SULLIVAN AC, 1974, FED PROC, V33, P656; Thom E, 1996, INT J OBES S4, V20, P48; Vasselli JR, 1998, FASEB J, V12, pA505; VONLIPPMANN EO, 1983, BER DTSCH CHEM GES, V16, P1078; WATSON JA, 1969, ARCH BIOCHEM BIOPHYS, V135, P209, DOI 10.1016/0003-9861(69)90532-3; WEBSTER JD, 1984, HUM NUTR-CLIN NUTR, V38C, P299; Yanovski SZ, 1996, JAMA-J AM MED ASSOC, V276, P1907, DOI 10.1001/jama.276.23.1907	31	222	237	2	57	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1596	1600		10.1001/jama.280.18.1596	http://dx.doi.org/10.1001/jama.280.18.1596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820262	Bronze			2022-12-28	WOS:000076852000027
J	Bundred, N; Maguire, P; Reynolds, J; Grimshaw, J; Morris, J; Thomson, L; Barr, L; Baildam, A				Bundred, N; Maguire, P; Reynolds, J; Grimshaw, J; Morris, J; Thomson, L; Barr, L; Baildam, A			Randomised controlled trial of effects of early discharge after surgery for breast cancer	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine the effect of early discharge from hospital after surgery for breast cancer on physical and psychological illness. Design Randomised controlled trial comparing discharge two days after surgery (before removal of drain) with standard management (discharge after removal of drain). Setting Regional breast unit. Subjects 100 women with early breast cancer undergoing mastectomy and axillary node clearance (20) or breast conservation surgery (80). Main outcome measures Physical illness (infection seroma formation, shoulder movement) and psychological illness (checklist of concerns, Rotterdam symptom questionnaire, hospital anxiety and depression scale) preoperatively and at one month and three months postoperatively. Results Women discharged early had greater shoulder movement (odds ratio 0.28 (95% confidence interval 0.08 to 0.95); P = 0.042) and less wound pain (odds ratio 0.28 (0.10 to 0.79); P = 0.016) three months after surgery compared with women given standard management. One month after surgery scores were significantly lower on the Rotterdam symptom questionnaire in patients who were discharged early (ratio of geometric mean scores 0.73 (0.55 to 0.98); P = 0.035), but rates of psychological illness generally did not differ between groups. Conclusions Increased rates of physical or psychological illness did not result from early discharge after surgery for breast cancer. This policy can be recommended for patients with support at home.	Univ S Manchester Hosp, Dept Surg, Manchester M20 8LR, Lancs, England; Univ S Manchester Hosp, Dept Med Stat, Manchester M20 8LR, Lancs, England; Christie Hosp NHS Trust, Canc Res Campaign, Psychol Med Grp, Manchester M20 4BX, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Christie NHS Foundation Trust; Christie Hospital	Bundred, N (corresponding author), Univ S Manchester Hosp, Dept Surg, Nell Lane, Manchester M20 8LR, Lancs, England.	bundredn@fs1.with.man.ac.uk		Barr, Lester/0000-0003-4030-8192; Grimshaw, Jeremy/0000-0001-8015-8243				BALL ABS, 1992, ANN ROY COLL SURG, V74, P126; Bonnema J, 1998, BRIT MED J, V316, P1267, DOI 10.1136/bmj.316.7140.1267; COHEN AM, 1986, AM J SURG, V151, P465, DOI 10.1016/0002-9610(86)90104-2; DEHAES JCJM, 1990, BRIT J CANCER, V62, P1034, DOI 10.1038/bjc.1990.434; Devlen JL., 1984, THESIS U MANCHESTER; EDWARDS MJ, 1988, ANN SURG, V208, P330, DOI 10.1097/00000658-198809000-00010; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; Funnel IC, 1992, ANN R COLL SURG ENGL, V4, P178; Holcombe C, 1995, Eur J Surg Oncol, V21, P604, DOI 10.1016/S0748-7983(95)95133-4; IBBOTSON T, 1994, EUR J CANCER, V30A, P37, DOI 10.1016/S0959-8049(05)80015-2; Pannuti F, 1992, J Palliat Care, V8, P11; [No title captured]	12	87	88	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1275	1279		10.1136/bmj.317.7168.1275	http://dx.doi.org/10.1136/bmj.317.7168.1275			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804712	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000076963800021
J	Dickey, W; Bodkin, S				Dickey, W; Bodkin, S			Prospective study of body mass index in patients with coeliac disease	BRITISH MEDICAL JOURNAL			English	Article							CELIAC-DISEASE		Altnagelvin Hosp, Londonderry BT47 1SB, North Ireland		Dickey, W (corresponding author), Altnagelvin Hosp, Londonderry BT47 1SB, North Ireland.							CIACCI C, 1995, SCAND J GASTROENTERO, V30, P1077, DOI 10.3109/00365529509101610; GARROW JS, 1992, LANCET, V340, P409, DOI 10.1016/0140-6736(92)91481-M; GRODZINSKY E, 1992, ANN ALLERGY, V69, P66; JOHNSTON SD, 1996, ACTA PAEDIATR, V412, P61; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P	5	33	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1290	1290		10.1136/bmj.317.7168.1290	http://dx.doi.org/10.1136/bmj.317.7168.1290			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804717	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000076963800026
J	Bergmann, A; Agapite, J; McCall, K; Steller, H				Bergmann, A; Agapite, J; McCall, K; Steller, H			The Drosophila gene hid is a direct molecular target of Ras-dependent survival signaling	CELL			English	Article							PROGRAMMED CELL-DEATH; RECEPTOR TYROSINE KINASE; ACTIVATED PROTEIN-KINASE; EYE DEVELOPMENT; MAP KINASE; TRANSDUCTION PATHWAY; GROWTH-FACTOR; INSECT CELLS; APOPTOSIS; EXPRESSION	Extracellular growth factors are required for the survival of most animal cells. They often signal through the activation of the Ras pathway. However, the molecular mechanisms by which Ras signaling inhibits the intrinsic cell death machinery are not well understood. Here, we present evidence that in Drosophila, activation of the Has pathway specifically inhibits the proapoptotic activity of the gene head involution defective (hid). By using transgenic animals and cultured cells, we show that MAPK phosphorylation sites in Hid are critical for this response. These findings define a novel mechanism by which growth factor signaling directly inactivates a critical component of the intrinsic cell death machinery. These studies provide further insights into the function of ras as an oncogene.	MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Steller, H (corresponding author), MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA.							ABRAMS JM, 1993, DEVELOPMENT, V117, P29; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BARRES BA, 1993, DEVELOPMENT, V118, P283; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BOS JL, 1989, CANCER RES, V49, P4682; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Dickson BJ, 1996, GENETICS, V142, P163; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; ELLIS MC, 1993, DEVELOPMENT, V119, P855; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; Freeman M, 1997, DEVELOPMENT, V124, P261; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; GRETHER ME, 1994, THESIS MIT CAMBRIDGE; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; Jarvis DL, 1996, PROTEIN EXPRES PURIF, V8, P191, DOI 10.1006/prep.1996.0092; Karim FD, 1998, DEVELOPMENT, V125, P1; Karim FD, 1996, GENETICS, V143, P315; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; McCall K, 1997, TRENDS GENET, V13, P222, DOI 10.1016/S0168-9525(97)01126-8; Miller DT, 1998, DEVELOPMENT, V125, P2327; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OKANO H, 1992, DIFFERENTIATION, V52, P1, DOI 10.1111/j.1432-0436.1992.tb00494.x; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peverali FA, 1996, EMBO J, V15, P3943, DOI 10.1002/j.1460-2075.1996.tb00768.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Robinow S, 1997, DEV BIOL, V190, P206, DOI 10.1006/dbio.1997.8696; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sawamoto K, 1998, CELL DEATH DIFFER, V5, P262, DOI 10.1038/sj.cdd.4400342; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WASSARMAN DA, 1997, ADV DEV BIO, V5, P1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamada M, 1997, PROG NEUROBIOL, V51, P19, DOI 10.1016/S0301-0082(96)00046-9; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	60	391	398	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 30	1998	95	3					331	341		10.1016/S0092-8674(00)81765-1	http://dx.doi.org/10.1016/S0092-8674(00)81765-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814704	Bronze			2022-12-28	WOS:000076789600007
J	Nguyen, T; Chin, WC; Verdugo, P				Nguyen, T; Chin, WC; Verdugo, P			Role of Ca2+/K+ ion exchange in intracellular storage and release of Ca2+	NATURE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; ENDOPLASMIC-RETICULUM; SECRETORY GRANULES; CALCIUM RELEASE; ZYMOGEN GRANULES; CELLS; BINDING; TRISPHOSPHATE; GONADOTROPES; PROTEIN	Although fluctuations in cytosolic Ca2+ concentration have a crucial role in relaying intracellular messages in the cell(1), the dynamics of Ca2+ storage in and release from intracellular sequestering compartments remains poorly understood. The rapid release of stored Ca2+ requires large concentration gradients that had been thought to result from low-affinity buffering of Ca2+ by the polyanionic matrices within Ca2+ sequestering organelles(2). However, our results here show that resting luminal free Ca2+ concentration inside the endoplasmic reticulum and in the mucin granules remains at low levels (20-35 mu M) But after stimulation, the free luminal [Ca2+] increases, undergoing large oscillations, leading to corresponding oscillations of Ca2+ release to the cytosol, These remarkable dynamics of luminal [Ca2+] result from a fast and highly cooperative Ca2+/K+ ion-exchange process rather than from Ca2+ transport into the lumen. This common paradigm for Ca2+ storage and release, found in two different Ca2+-sequestering organelles, requires the functional interaction of three molecular components: a polyanionic matrix that functions as a Ca2+/K+ ion exchanger, and two Ca2+-sensitive channels, one to import K+ into the Ca2+-sequestering compartments, the other to release Ca2+ to the cytosol.	Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Univ Washington, Dept Internal Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Verdugo, P (corresponding author), Univ Washington, Dept Bioengn, Box 357962, Seattle, WA 98195 USA.	verdugo@bioeng.washington.edu	Chin, Wei-Chun/A-6068-2008	Chin, Wei-Chun/0000-0003-4881-9085				AITKEN ML, 1995, EXP LUNG RES, V21, P1, DOI 10.3109/01902149509031741; Belan PV, 1996, PFLUG ARCH EUR J PHY, V433, P200, DOI 10.1007/s004240050268; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; BLONDEL O, 1995, TRENDS NEUROSCI, V18, P157, DOI 10.1016/0166-2236(95)93894-4; BRECKENRIDGE LJ, 1987, P NATL ACAD SCI USA, V84, P1945, DOI 10.1073/pnas.84.7.1945; Davis C. W., 1997, AIRWAY MUCUS BASIC M, P149; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FORSTNER JF, 1975, BIOCHIM BIOPHYS ACTA, V386, P283, DOI 10.1016/0005-2795(75)90270-6; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; Hehl S, 1996, CELL CALCIUM, V20, P515, DOI 10.1016/S0143-4160(96)90094-9; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; JOSEPH SK, 1986, J BIOL CHEM, V261, P4658; KAO JPY, 1994, PRACTICAL GUIDE STUD, P155; KOCH GLE, 1990, BIOESSAYS, V12, P527, DOI 10.1002/bies.950121105; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LOREZ HP, 1978, EXPERIENTIA, V34, P663, DOI 10.1007/BF01937020; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Marszalek PE, 1997, BIOPHYS J, V73, P1169, DOI 10.1016/S0006-3495(97)78149-9; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; MONCK JR, 1992, J CELL BIOL, V116, P745, DOI 10.1083/jcb.116.3.745; OROURKE F, 1994, BIOCHEM J, V300, P673, DOI 10.1042/bj3000673; Sasaki S, 1996, PFLUG ARCH EUR J PHY, V432, P538, DOI 10.1007/s004240050167; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; vandePut FHMM, 1997, J BIOL CHEM, V272, P27764, DOI 10.1074/jbc.272.44.27764; VERDUGO P, 1980, NATURE, V283, P764, DOI 10.1038/283764a0; VERDUGO P, 1994, AIRWAY SECRETION, P101; Yule DI, 1997, J BIOL CHEM, V272, P9093	30	167	168	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 29	1998	395	6705					908	912		10.1038/27686	http://dx.doi.org/10.1038/27686			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804425				2022-12-28	WOS:000076713400059
J	Daley, J; Hartman, EE				Daley, J; Hartman, EE			A 52-year-old woman with diabetes and claudication, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Daley J, 1998, JAMA-J AM MED ASSOC, V279, P615, DOI 10.1001/jama.279.8.615	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	1998	280	16					1439	1439		10.1001/jama.280.16.1439	http://dx.doi.org/10.1001/jama.280.16.1439			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130YA	9801005				2022-12-28	WOS:000076546900040
J	Ristinen, E; Mamtani, R				Ristinen, E; Mamtani, R			Ethics of transmission of hepatitis B virus by health-care workers	LANCET			English	Editorial Material							ANTIGEN; INFECTION; RISK		New York Med Coll, Dept Community & Prevent Med, Valhalla, NY 10595 USA	New York Medical College	Ristinen, E (corresponding author), New York Med Coll, Dept Community & Prevent Med, Valhalla, NY 10595 USA.							ALTER HJ, 1975, NEW ENGL J MED, V292, P454, DOI 10.1056/NEJM197502272920904; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; ARNOLD RM, 1995, ENCY BIOETHICS, P1250; Beekmann SE, 1997, INFECT DIS CLIN N AM, V11, P313, DOI 10.1016/S0891-5520(05)70358-5; Boxall EH, 1997, BRIT MED J, V314, P144, DOI 10.1136/bmj.314.7074.144; Calman KC, 1996, BRIT MED J, V313, P799; FRIEDE A, 1997, RECOMMENDATIONS PREV, P281; GOLLAN JL, 1966, INTENSIVE REV INTERN, P591; Halle M, 1996, BRIT MED J, V313, P576; Harpaz R, 1996, NEW ENGL J MED, V334, P549, DOI 10.1056/NEJM199602293340901; Henderson DK, 1997, INFECT CONT HOSP EP, V18, P349; *INC INV TEAMS OTH, 1997, NEW ENGL J MED, V336, P176; KATZ J, 1995, ENCY BIOETHICS, P1255; Koziol DE, 1996, HOSP EPIDEMIOLOGY IN, P829; Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406; Poole CJM, 1997, LANCET, V350, P218, DOI 10.1016/S0140-6736(05)62384-7; REISSLEVY EA, 1994, MED J AUSTRALIA, V160, P524	17	11	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 24	1998	352	9137					1381	1383		10.1016/S0140-6736(98)03095-5	http://dx.doi.org/10.1016/S0140-6736(98)03095-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802291				2022-12-28	WOS:000076691700050
J	Kon, OM; Sihra, BS; Compton, CH; Leonard, TB; Kay, AB; Barnes, NC				Kon, OM; Sihra, BS; Compton, CH; Leonard, TB; Kay, AB; Barnes, NC			Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma	LANCET			English	Article							CORTICOSTEROID-DEPENDENT ASTHMA; ANTI-CD4 MONOCLONAL-ANTIBODY; DISEASE SEVERITY; ATOPIC ASTHMA; LYMPHOCYTE-T; DOUBLE-BLIND; CELLS; EOSINOPHILIA; ARTHRITIS; SYMPTOMS	Background There is substantial circumstantial evidence that CD4 lymphocytes have a role in the pathogenesis of chronic asthma. We investigated the efficacy and safety in severe corticosteroid-dependent asthma of a single intravenous infusion of keliximab (IDEC CE9.1), a chimeric monoclonal antibody to CD4. Methods 22 patients were recruited from two asthma clinics. In an ascending-dose design, the first eight patients were assigned 0.5 mg/kg keliximab (six) or placebo (two); the next seven were assigned 1.5 mg/kg (five) or placebo (two); and the last seven were assigned 3.0 mg/kg (five) or placebo (two), Masked data on safety for each dose group were assessed before progression to the next dose. Patients kept a daily symptom diary and measured morning and evening peak expiratory flow (PEF) at home. PEF and forced expiratory volume in 1 s (FEV1) were measured at follow-up clinic visits. Findings Patients given 0.5 mg/kg or 1.5 mg/kg keliximab and placebo recipients did not differ in change from baseline of PEF, FEV1, or symptom score. Those given 3.0 mg/kg keliximab differed significantly from placebo recipients in change in morning PEF (median area under curve [AUC] 445 vs -82.5, p=0.005) and evening PEF (median AUC 548 vs -85, p=0.014). Symptom score showed the same pattern (though differences did not achieve significance), but there was no difference in clinic FEV1. There were no serious adverse effects related to treatment. Two patients had mild exacerbations of eczema and one developed a transient maculopapular rash. All doses of keliximab were associated with a reduction from baseline in CD4 count. Interpretation Our findings raise the possibility that T-cell-directed treatment may be an alternative approach to the treatment of severe asthma.	London Chest Hosp, Dept Resp Med, London E2 9JX, England; Natl Heart & Lung Inst, Imperial Coll Sch Med, London, England; SmithKline Beecham Pharmaceut, Harlow CM19 5AD, Essex, England	University of London; Queen Mary University London; Imperial College London; GlaxoSmithKline	Barnes, NC (corresponding author), London Chest Hosp, Dept Resp Med, London E2 9JX, England.			Kon, Onn Min/0000-0003-2647-4688				AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Bernstein IL, 1996, J ALLERGY CLIN IMMUN, V98, P317, DOI 10.1016/S0091-6749(96)70156-2; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CHOY EHS, 1993, ARTHRITIS RHEUM, V36, P723, DOI 10.1002/art.1780360523; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; HERZOG C, 1987, LANCET, V2, P1461; JEYARAJAH DR, 1993, TRANSPLANT P, V25, P16; Lock SH, 1996, AM J RESP CRIT CARE, V153, P509, DOI 10.1164/ajrccm.153.2.8564089; LUCEY DR, 1989, J EXP MED, V169, P327, DOI 10.1084/jem.169.1.327; MORELAND LW, 1994, ARTHRITIS RHEUM, V37, P834, DOI 10.1002/art.1780370610; NEWMAN R, 1992, BIO-TECHNOL, V10, P1455, DOI 10.1038/nbt1192-1455; Pearson MG, 1997, THORAX, V52, pS1; PRINZ J, 1991, LANCET, V338, P320, DOI 10.1016/0140-6736(91)90464-Z; REINKE P, 1991, LANCET, V338, P702, DOI 10.1016/0140-6736(91)91285-3; ROBINSON DS, 1993, THORAX, V48, P26, DOI 10.1136/thx.48.1.26; Rosenzwajg M, 1996, BLOOD, V87, P535, DOI 10.1182/blood.V87.2.535.bloodjournal872535; SHINER RJ, 1990, LANCET, V336, P137, DOI 10.1016/0140-6736(90)91659-X; STEWART SJ, 1986, J IMMUNOL, V136, P3773; TILL S, 1995, EUR J IMMUNOL, V25, P2727, DOI 10.1002/eji.1830251002; WALKER C, 1991, J IMMUNOL, V146, P1829; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WALLS AF, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb00106.x; Wofsy D, 1990, Semin Immunol, V2, P419; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	24	116	124	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 3	1998	352	9134					1109	1113		10.1016/S0140-6736(97)12261-9	http://dx.doi.org/10.1016/S0140-6736(97)12261-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798587				2022-12-28	WOS:000076246400012
J	Wigley, TML; Smith, RL; Santer, BD				Wigley, TML; Smith, RL; Santer, BD			Anthropogenic influence on the autocorrelation structure of hemispheric-mean temperatures	SCIENCE			English	Article							CLIMATE-CHANGE; ATMOSPHERE; MODEL; VARIABILITY; TREND	It is shown that Lagged correlations for and cross-correlations between observed hemispheric-mean temperature data differ markedly from those for unforced (control-run) climate model simulations. The differences can be explained adequately by assuming that the observed data contain a significant externally forced component involving both natural (solar) and anthropogenic influences and that the global climate sensitivity is in the commonly accepted range. Solar forcing alone cannot reconcile the differences in autocorrelation structure between observations and model control-run data.	Natl Ctr Atmospher Res, Boulder, CO 80307 USA; Univ N Carolina, Dept Stat, Chapel Hill, NC 27599 USA; Univ Calif Lawrence Livermore Natl Lab, PCMDI, Livermore, CA 94550 USA	National Center Atmospheric Research (NCAR) - USA; University of North Carolina; University of North Carolina Chapel Hill; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Wigley, TML (corresponding author), Natl Ctr Atmospher Res, Pob 3000, Boulder, CO 80307 USA.	wigley@ucar.edu	Santer, Ben/ABA-1099-2021; Santer, Benjamin D/F-9781-2011; Way, James Douglas/A-9408-2010; Wigley, Tom M.L./B-4705-2008	Way, James Douglas/0000-0001-9612-8508; 				[Anonymous], 1996, INTRO STAT TIME SERI; BARNETT TP, 1987, J GEOPHYS RES-ATMOS, V92, P14772, DOI 10.1029/JD092iD12p14772; Folland CK, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P195; Folland CK., 1992, CLIMATE CHANGE 1992, P135; Hegerl GC, 1996, J CLIMATE, V9, P2281, DOI 10.1175/1520-0442(1996)009<2281:DGGICC>2.0.CO;2; HOYT DV, 1993, J GEOPHYS RES-SPACE, V98, P18895, DOI 10.1029/93JA01944; Johns TC, 1997, CLIM DYNAM, V13, P103, DOI 10.1007/s003820050155; JONES PD, 1988, CLIMATE MONITOR, V17, P80; Kattenberg A., 1996, CLIMATE CHANGE 1995, P285; Kaufmann RK, 1997, NATURE, V388, P39, DOI 10.1038/40332; LEAN J, 1995, GEOPHYS RES LETT, V22, P3195, DOI 10.1029/95GL03093; LEGGETT A, 1992, CLIMATE CHANGE 1992, P69; MADDEN RA, 1980, SCIENCE, V209, P763, DOI 10.1126/science.209.4458.763; Manabe S, 1996, J CLIMATE, V9, P376, DOI 10.1175/1520-0442(1996)009<0376:LFVOSA>2.0.CO;2; Meehl G.A., 1997, EOS T AM GEOPHYS UN, V78, P445, DOI [10.1029/97EO00276, DOI 10.1029/97EO00276]; Mitchell JFB, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P131; Mitchell JFB, 1997, J CLIMATE, V10, P245, DOI 10.1175/1520-0442(1997)010&lt;0245:OMOGWB&gt;2.0.CO;2; NICHOLLS N, 1996, CLIMATE CHANGE 1995, P133; Raper S.C.B., 1996, SEA LEVEL RISE COAST, P11, DOI DOI 10.1007/978-94-015-8719-8_2; Santer BD, 1996, NATURE, V382, P39, DOI 10.1038/382039a0; SANTER BD, 1993, CLIM DYNAM, V8, P265, DOI 10.1007/BF00209666; Santer BD, 1995, CLIM DYNAM, V12, P77, DOI 10.1007/BF00223722; Tett SFB, 1997, CLIM DYNAM, V13, P303, DOI 10.1007/s003820050168; TOL RSJ, 1994, THEOR APPL CLIMATOL, V49, P91, DOI 10.1007/BF00868194; Wigley TML, 1997, P NATL ACAD SCI USA, V94, P8314, DOI 10.1073/pnas.94.16.8314; Wigley TML, 1998, GEOPHYS RES LETT, V25, P2285, DOI 10.1029/98GL01855; WIGLEY TML, 1992, NATURE, V357, P293, DOI 10.1038/357293a0; WOODWARD WA, 1995, J CLIMATE, V8, P1929, DOI 10.1175/1520-0442(1995)008<1929:SAMFDT>2.0.CO;2; WOODWARD WA, 1993, J CLIMATE, V6, P953, DOI 10.1175/1520-0442(1993)006&lt;0953:GWATPO&gt;2.0.CO;2	29	73	73	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1676	1679		10.1126/science.282.5394.1676	http://dx.doi.org/10.1126/science.282.5394.1676			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831552				2022-12-28	WOS:000077246600037
J	Rubinstein, P; Carrier, C; Scaradavou, A; Kurtzberg, J; Adamson, J; Migliaccio, AR; Berkowitz, RL; Cabbad, M; Dobrila, NL; Taylor, PE; Rosenfield, RE; Stevens, CE				Rubinstein, P; Carrier, C; Scaradavou, A; Kurtzberg, J; Adamson, J; Migliaccio, AR; Berkowitz, RL; Cabbad, M; Dobrila, NL; Taylor, PE; Rosenfield, RE; Stevens, CE			Outcomes among 562 recipients of placental-blood transplants from unrelated donors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UMBILICAL-CORD-BLOOD; BONE-MARROW TRANSPLANTATION; HLA-IDENTICAL SIBLINGS; VERSUS-HOST DISEASE; MONOCLONAL ORIGIN; STEM-CELLS; LEUKEMIA; RECONSTITUTION; CHILDREN; ENGRAFTMENT	Background A program for banking, characterizing, and distributing placental blood, also called umbilical-cord blood, for transplantation provided grafts for 562 patients between August 24, 1992, and January 30, 1998. We evaluated this experience. Methods Placental blood was stored under liquid nitrogen and selected for specific patients on the basis of HLA type and leukocyte content. Patients were prepared for the transplantation of allogeneic hematopoietic cells in the placental blood and received prophylaxis against graft-versus-host disease (GVHD) according to routine procedures at each center. Results Outcomes at 100 days after transplantation were known for all 562 patients, and outcomes at 1 year for 94 percent of eligible recipients. The cumulative rates of engraftment among the recipients, according to actuarial analysis, were 81 percent by day 42 for neutrophils (median time to engraftment, 28 days) and 85 percent by day 180 for platelets (median, day 90). The speed of myeloid engraftment was associated primarily with the leukocyte content of the graft, whereas transplantation-related events were associated with the patient's underlying disease and age, the number of leukocytes in the graft, the degree of HLA disparity, and the transplantation center. After engraftment, age, HLA disparity, and center were the primary predictors of outcome. Severe acute GVHD (grade III or IV) occurred in 23 percent of patients, and chronic GVHD occurred in 25 percent. The rate of relapse among recipients with leukemia was 9 percent within the first 100 days, 17 percent within 6 months, and 26 percent by 1 year. These rates were associated with the severity of GVHD, type of leukemia, and stage of the disease. Conclusions Placental blood is a useful source of allogeneic hematopoietic stem cells for bone marrow reconstitution. (N Engl J Med 1998;339:1565-77) (C)1998, Massachusetts Medical Society.	New York Blood Ctr, Allen Lab Immunogenet, New York, NY 10021 USA; New York Blood Ctr, Hematopoiet Growth Factors Lab, New York, NY 10021 USA; New York Blood Ctr, Wolf Szmuness Lab Epidemiol, New York, NY 10021 USA; Duke Univ, Med Ctr, Pediat Bone Marrow Transplant Unit, Durham, NC USA; Mt Sinai Med Ctr, Dept Obstet Gynecol & Reprod Med, New York, NY USA; Brooklyn Hosp Med Ctr, Dept Obstet & Gynecol, Brooklyn, NY USA	New York Blood Center; New York Blood Center; New York Blood Center; Duke University; Icahn School of Medicine at Mount Sinai; Brooklyn Hospital Center	Rubinstein, P (corresponding author), New York Blood Ctr, Allen Lab Immunogenet, 310 E 67th St, New York, NY 10021 USA.		Migliaccio, Anna Rita/GWZ-9323-2022	FRANCO MIGLIACCIO, ANNA RITA/0000-0003-1800-271X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R18HL048031] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48031] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANASETTI C, 1989, NEW ENGL J MED, V320, P197, DOI 10.1056/NEJM198901263200401; BALCAREK KB, 1993, J INFECT DIS, V167, P1433, DOI 10.1093/infdis/167.6.1433; BALDUZZI A, 1995, BLOOD, V86, P3247; COX DR, 1972, J R STAT SOC B, V34, P187; Emerson SG, 1996, BLOOD, V87, P3082, DOI 10.1182/blood.V87.8.3082.bloodjournal8783082; Ford AM, 1997, BLOOD, V89, P281, DOI 10.1182/blood.V89.1.281.281_281_285; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; GLUCKMAN E, 1909, NEW ENGL J MED, V337, P373; Hongeng S, 1997, LANCET, V350, P767, DOI 10.1016/S0140-6736(97)03098-5; HOROWITZ MM, 1990, BLOOD, V75, P555; *INT CORD BLOOD FD, 1997, CORD BLOOD MAK INF C; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; KURTZBERG J, 1994, BLOOD CELLS, V20, P275; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; MAHMOUD HH, 1995, MED PEDIATR ONCOL, V24, P77, DOI 10.1002/mpo.2950240203; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Rowley JD, 1998, NAT MED, V4, P150, DOI 10.1038/nm0298-150; RUBINSTEIN P, 1986, TISSUE ANTIGENS, V27, P209; RUBINSTEIN P, 1995, P NATL ACAD SCI USA, V92, P10119, DOI 10.1073/pnas.92.22.10119; RUBINSTEIN P, 1994, BLOOD CELLS, V20, P587; Rubinstein P, 1993, J Hematother, V2, P207, DOI 10.1089/scd.1.1993.2.207; SULLIVAN, 1989, BLOOD, V74, P1180; SULLIVAN KM, 1989, BLOOD, V73, P1720; Szydlo R, 1997, J CLIN ONCOL, V15, P1767, DOI 10.1200/JCO.1997.15.5.1767; WAGNER JE, 1995, LANCET, V346, P214, DOI 10.1016/S0140-6736(95)91268-1; Wagner JE, 1996, BLOOD, V88, P795	28	1066	1143	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 26	1998	339	22					1565	1577		10.1056/NEJM199811263392201	http://dx.doi.org/10.1056/NEJM199811263392201			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZU	9828244				2022-12-28	WOS:000077176100001
J	Simcic, KJ; Moreno, AJ				Simcic, KJ; Moreno, AJ			Tumors of the pituitary, pancreas, and parathyroid glands in a patient with multiple endocrine neoplasia type 1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA; William Beaumont Army Med Ctr, El Paso, TX 79920 USA	San Antonio Military Medical Center; United States Department of Defense; United States Army; William Beaumont Army Medical Center	Simcic, KJ (corresponding author), Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 26	1998	339	22					1602	1602		10.1056/NEJM199811263392205	http://dx.doi.org/10.1056/NEJM199811263392205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZU	9828248				2022-12-28	WOS:000077176100005
J	Grumbach, K; Osmond, D; Vranizan, K; Jaffe, D; Bindman, AB				Grumbach, K; Osmond, D; Vranizan, K; Jaffe, D; Bindman, AB			Primary care physicians' experience of financial incentives in managed-care systems	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLANS; RISK	Background Managed-care organizations' use of financial incentives to influence the practice of primary care physicians is controversial. We studied the prevalence and effects of these incentives. Methods We surveyed a probability sample of primary care physicians practicing in the largest urban counties in California in 1996. The physicians were asked about the types of incentives they encountered, the amount of income that was keyed to incentives, their experience of pressure in their practices, and the ways in which such pressure affected patient care. Results Data were analyzed for 766 physicians involved in managed-care systems. Thirty-eight percent of these physicians reported that their arrangements with the managed-care system included some type of incentive in the form of a bonus. Fifty-seven percent of the physicians reported that they felt pressure from the managed-care organization to limit referrals (17 percent said they believed such pressure compromised patient care), and 75 percent felt pressure to see more patients per day (24 percent believed such pressure compromised patient care). The physicians who reported that their financial arrangements included an incentive based on referrals were more likely than others to have felt pressure to limit referrals in a manner that compromised care (adjusted odds ratio, 2.5; 95 percent confidence interval, 1.2 to 5.0), and physicians with an incentive based on productivity were more likely to have felt a pressure to see more patients that they believed compromised care (adjusted odds ratio, 2.1; 95 percent confidence interval, 1.2 to 3.8). The physicians whose health care systems used incentives keyed to productivity were less likely than others to be very satisfied with their practices (adjusted odds ratio, 0.4; 95 percent confidence interval, 0.2 to 0.6), whereas those whose systems included incentives related to the quality of care or patients' satisfaction were more likely to be very satisfied (adjusted odds ratio, 1.8; 95 percent confidence interval, 1.1 to 3.0). Conclusions Many managed-care organizations include financial incentives for primary care physicians that are indexed to various measures of performance. Incentives that depend on limiting referrals or on greater productivity apply selective pressure to physicians in ways that are believed to compromise care. Incentives that depend on the quality of care and patients' satisfaction are associated with greater job satisfaction among physicians. (N Engl J Med 1998;339:1516-21.) (C) 1998, Massachusetts Medical Society.	Univ Calif San Francisco, Primary Care Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Calif Hlth Workforce Studies, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	Grumbach, K (corresponding author), Univ Calif San Francisco, Primary Care Res Ctr, Box 1364, San Francisco, CA 94143 USA.		Grumbach, Kevin/L-9222-2016		BHP HRSA HHS [1U76-MB-1001] Funding Source: Medline	BHP HRSA HHS		Bindman AB, 1998, JAMA-J AM MED ASSOC, V279, P675, DOI 10.1001/jama.279.9.675; Bodenheimer TS, 1996, JAMA-J AM MED ASSOC, V276, P1025, DOI 10.1001/jama.276.13.1025; Conrad DA, 1998, JAMA-J AM MED ASSOC, V279, P853, DOI 10.1001/jama.279.11.853; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; Grumbach K, 1998, HEALTH AFFAIR, V17, P227, DOI 10.1377/hlthaff.17.3.227; Hellinger FJ, 1996, MED CARE RES REV, V53, P294, DOI 10.1177/107755879605300305; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; Remler DK, 1997, INQUIRY-J HEALTH CAR, V34, P196; Simon CJ, 1997, HEALTH AFFAIR, V16, P120, DOI 10.1377/hlthaff.16.3.120; WOOLHANDLER S, 1995, NEW ENGL J MED, V333, P1706, DOI 10.1056/NEJM199512213332510	12	219	220	1	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1998	339	21					1516	1521		10.1056/NEJM199811193392106	http://dx.doi.org/10.1056/NEJM199811193392106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	139VT	9819451				2022-12-28	WOS:000077051800006
J	Neul, JL; Ferguson, EL				Neul, JL; Ferguson, EL			Spatially restricted activation of the SAX receptor by SCW modulates DPP/TKV signaling in Drosophila dorsal-ventral patterning	CELL			English	Article							TGF-BETA RECEPTOR; SHORT GASTRULATION GENE; THICK VEINS; I RECEPTORS; ACTIVITY GRADIENT; EMBRYO; DPP; XENOPUS; FAMILY; REQUIREMENT	Dorsal-ventral patterning within the embryonic ectoderm of Drosophila requires two TGF beta ligands, DPP and SCW, and two type I TGF beta receptors, TKV and SAX. In embryos lacking dpp signaling, increasing the level of TKV activity promotes progressively more dorsal cell types, while activation of SAX alone has no phenotypic consequences. However, SAX activity synergizes with TKV activity to promote dorsal development. Functional experiments suggest the two receptors have different ligands: DPP acts through TKV, and SCW acts through SAX. Furthermore, SOG, a negative regulator of this patterning process, preferentially blocks SCW activity. We propose that spatial regulation of the SAX pathway modulates TKV signaling to create positional information over the embryonic ectoderm.	Univ Chicago, Comm Dev Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Ferguson, EL (corresponding author), Univ Chicago, Comm Dev Biol, Chicago, IL 60637 USA.		Neul, Jeffrey/AAF-5324-2020	Ferguson, Edwin/0000-0003-4125-4253; Neul, Jeffrey/0000-0002-5628-5872	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050838] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50838] Funding Source: Medline; OHS HRSA HHS [ST32GM07281] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OHS HRSA HHS		ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; Bier E, 1997, CELL, V89, P681, DOI 10.1016/S0092-8674(00)80250-0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Das P, 1998, DEVELOPMENT, V125, P1519; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Haerry TE, 1998, DEVELOPMENT, V125, P3977; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; Hudson JB, 1998, DEVELOPMENT, V125, P1407; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; Khalsa O, 1998, DEVELOPMENT, V125, P2723; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Newfeld SJ, 1997, DEVELOPMENT, V124, P3167; Nguyen VH, 1998, DEV BIOL, V199, P93, DOI 10.1006/dbio.1998.8927; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TERRACOL R, 1994, GENETICS, V138, P165; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; Vincent S, 1997, DEVELOPMENT, V124, P2741; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	53	81	85	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 13	1998	95	4					483	494		10.1016/S0092-8674(00)81616-5	http://dx.doi.org/10.1016/S0092-8674(00)81616-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827801	Bronze			2022-12-28	WOS:000077049400007
J	Gardner, MJ; Tettelin, H; Carucci, DJ; Cummings, LM; Aravind, L; Koonin, EV; Shallom, S; Mason, T; Yu, K; Fujii, C; Pederson, J; Shen, K; Jing, JP; Aston, C; Lai, ZW; Schwartz, DC; Pertea, M; Salzberg, S; Zhou, LX; Sutton, GG; Clayton, R; White, O; Smith, HO; Fraser, CM; Adams, MD; Venter, JC; Hoffman, SL				Gardner, MJ; Tettelin, H; Carucci, DJ; Cummings, LM; Aravind, L; Koonin, EV; Shallom, S; Mason, T; Yu, K; Fujii, C; Pederson, J; Shen, K; Jing, JP; Aston, C; Lai, ZW; Schwartz, DC; Pertea, M; Salzberg, S; Zhou, LX; Sutton, GG; Clayton, R; White, O; Smith, HO; Fraser, CM; Adams, MD; Venter, JC; Hoffman, SL			Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum	SCIENCE			English	Article							COMPLETE GENOME SEQUENCE; ERYTHROCYTE SURFACE-ANTIGEN; BLOOD STAGE ANTIGEN; MOLECULAR-CLONING; MEMBRANE PROTEIN; GENETIC-ANALYSIS; SERINE-STRETCH; REPETITIVE DNA; SERA GENE; DOMAINS	Chromosome 2 of Plasmodium falciparum was sequenced; this sequence contains 947,103 base pairs and encodes 210 predicted genes. In comparison with the Saccharomyces cerevisiae genome, chromosome 2 has a lower gene density, introns are more frequent, and proteins are markedly enriched in nonglobular domains. A family of surface proteins, rifins, that may play a role in antigenic variation was identified. The complete sequencing of chromosome 2 has shown that sequencing of the A + T-rich P. falciparum genome is technically feasible.	USN, Med Res Inst, Malari Program, Rockville, MD 20852 USA; Inst Genome Res, Rockville, MD 20850 USA; Texas A&M Univ, Dept Biol, College Stn, TX USA; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA; NYU, Dept Chem, Lab Biomol Imaging, New York, NY 10003 USA; Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA; Inst Genom Res, Rockville, MD 20850 USA; Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; J. Craig Venter Institute; Texas A&M University System; Texas A&M University College Station; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); New York University; Johns Hopkins University; J. Craig Venter Institute; Johns Hopkins University	Hoffman, SL (corresponding author), USN, Med Res Inst, Malari Program, 12300 Washington Ave, Rockville, MD 20852 USA.		Pertea, Mihaela/AAT-2705-2021; Salzberg, Steven L/F-6162-2011; Salzberg, Steven/Q-6514-2019	Pertea, Mihaela/0000-0003-0762-8637; Salzberg, Steven L/0000-0002-8859-7432; Salzberg, Steven/0000-0002-8859-7432; Gardner, Malcolm/0000-0003-2180-5089	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040125] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI40125-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAVIND L, UNPUB; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BLACKMAN MJ, 1991, MOL BIOCHEM PARASIT, V49, P29, DOI 10.1016/0166-6851(91)90127-R; Bonnefoy S, 1997, MOL BIOCHEM PARASIT, V87, P1, DOI 10.1016/S0166-6851(97)00033-9; BORK P, 1992, TRENDS BIOCHEM SCI, V17, P129, DOI 10.1016/0968-0004(92)90319-5; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; COPPEL RL, 1984, NATURE, V310, P789, DOI 10.1038/310789a0; CUMMINGS LJ, UNPUB; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Dame JB, 1996, MOL BIOCHEM PARASIT, V79, P1, DOI 10.1016/0166-6851(96)02641-2; DEVINE SE, 1994, NUCLEIC ACIDS RES, V22, P3765, DOI 10.1093/nar/22.18.3765; DUFFY PE, 1993, J EXP MED, V177, P505, DOI 10.1084/jem.177.2.505; duSart D, 1997, NAT GENET, V16, P144; EAKIN AE, 1989, NATURE, V342, P132, DOI 10.1038/342132b0; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FOLEY M, 1994, EXP PARASITOL, V79, P340, DOI 10.1006/expr.1994.1096; FOSTER J, 1995, PARASITOL TODAY, V11, P1, DOI 10.1016/0169-4758(95)80092-1; FOX BA, 1994, MOL BIOCHEM PARASIT, V68, P133, DOI 10.1016/0166-6851(94)00162-6; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GARDNER MJ, 1991, MOL BIOCHEM PARASIT, V44, P115, DOI 10.1016/0166-6851(91)90227-W; Haucke V, 1997, TRENDS CELL BIOL, V7, P103, DOI 10.1016/S0962-8924(96)10052-0; HernandezRivas R, 1997, MOL CELL BIOL, V17, P604, DOI 10.1128/MCB.17.2.604; HIGGINS DG, 1989, NATURE, V340, P604, DOI 10.1038/340604a0; Jing J., UNPUB; KASLOW DC, 1988, NATURE, V333, P74, DOI 10.1038/333074a0; KEMP DJ, 1985, NATURE, V315, P347, DOI 10.1038/315347a0; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KNAPP B, 1989, MOL BIOCHEM PARASIT, V32, P73, DOI 10.1016/0166-6851(89)90131-X; KNAPP B, 1991, MOL BIOCHEM PARASIT, V44, P1, DOI 10.1016/0166-6851(91)90215-R; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; KUZIO J, 1996, METHOD ENZYMOL, V266, P554; LANZER M, 1993, NATURE, V361, P654, DOI 10.1038/361654a0; Lechner J, 1996, FEBS LETT, V389, P70, DOI 10.1016/0014-5793(96)00563-7; LI WB, 1989, MOL BIOCHEM PARASIT, V33, P13, DOI 10.1016/0166-6851(89)90037-6; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Mahtani MM, 1998, GENOME RES, V8, P100, DOI 10.1101/gr.8.2.100; Marshall VM, 1997, INFECT IMMUN, V65, P4460, DOI 10.1128/IAI.65.11.4460-4467.1997; Marshall VM, 1998, MOL BIOCHEM PARASIT, V94, P13, DOI 10.1016/S0166-6851(98)00045-0; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; NEUWALD AF, 1995, PROTEIN SCI, V4, P1618, DOI 10.1002/pro.5560040820; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OQUENDO P, 1986, MOL BIOCHEM PARASIT, V18, P89, DOI 10.1016/0166-6851(86)90053-8; QUAKYI IA, 1989, INFECT IMMUN, V57, P833, DOI 10.1128/IAI.57.3.833-839.1989; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROST B, 1995, PROTEIN SCI, V4, P521; Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888; Saitoh S, 1997, CELL, V90, P131, DOI 10.1016/S0092-8674(00)80320-7; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; SLABAS AR, 1992, PLANT MOL BIOL, V19, P169, DOI 10.1007/BF00015613; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Smith MM, 1996, MOL CELL BIOL, V16, P1017; SU Z, 1995, CELL, V82, P89; SUPLICK K, 1988, MOL BIOCHEM PARASIT, V30, P289, DOI 10.1016/0166-6851(88)90098-9; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TRAGER W, 1978, NATURE, V273, P621, DOI 10.1038/273621a0; VERNICK KD, 1988, MOL BIOCHEM PARASIT, V28, P85, DOI 10.1016/0166-6851(88)90055-2; WALKER DR, 1997, INTELL SYST MOL BIOL, V5, P333; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; Watanabe J, 1997, MOL BIOCHEM PARASIT, V88, P253, DOI 10.1016/S0166-6851(97)00073-X; WEBER JL, 1988, MOL BIOCHEM PARASIT, V29, P117, DOI 10.1016/0166-6851(88)90066-7; WILSON RJM, 1991, PARASITOL TODAY, V7, P134, DOI 10.1016/0169-4758(91)90276-T; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; World Health Organization, 1997, Weekly Epidemiological Record, V72, P269	73	403	430	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1126	1132		10.1126/science.282.5391.1126	http://dx.doi.org/10.1126/science.282.5391.1126			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804551				2022-12-28	WOS:000076887700051
J	Welch, HG; Burke, W				Welch, HG; Burke, W			Uncertainties in genetic testing for chronic disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							FOLLOW-UP CARE; INHERITED PREDISPOSITION; INFORMED CONSENT; CANCER; BRCA1; RISKS; RECOMMENDATIONS; INDIVIDUALS; MUTATIONS; SAMPLES		Dept Vet Affairs Med Ctr, White River Jct, VT USA; Univ Washington, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Welch, HG (corresponding author), VA Outcomes Grp IIIB, White River Jct, VT 05009 USA.	gilbert.welch@dartmouth.edu						[Anonymous], 1989, NEW ENGL J MED, V321, P406; Bacon BR, 1997, GASTROENTEROLOGY, V113, P995, DOI 10.1016/S0016-5085(97)70196-3; BAIRD PA, 1995, PERSPECT BIOL MED, V38, P159; Black WC, 1997, AM J ROENTGENOL, V168, P3, DOI 10.2214/ajr.168.1.8976910; *BREAST CANC INF C, OP ACC ON LIN BREAST; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; CLAYTON EW, 1995, JAMA-J AM MED ASSOC, V274, P1786, DOI 10.1001/jama.274.22.1786; COLLINS F, 1997, ACAD PHYSICIAN SC JU, P6; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; EZZAT S, 1994, ARCH INTERN MED, V154, P1838; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Geller G, 1997, JAMA-J AM MED ASSOC, V277, P1467, DOI 10.1001/jama.277.18.1467; HARPER PS, 1993, LANCET, V341, P224, DOI 10.1016/0140-6736(93)90080-Z; Healy B, 1997, NEW ENGL J MED, V336, P1448, DOI 10.1056/NEJM199705153362009; HENIG RM, 1997, WASHINGTON POST 1013, P23; Jonsen AR, 1996, NAT MED, V2, P622, DOI 10.1038/nm0696-622; KNOPPERS BM, 1995, JAMA-J AM MED ASSOC, V274, P1806, DOI 10.1001/jama.274.22.1806; MEADOR CK, 1994, NEW ENGL J MED, V330, P440, DOI 10.1056/NEJM199402103300618; Pauker SG, 1997, NEW ENGL J MED, V336, P1243, DOI 10.1056/NEJM199704243361708; Price DT, 1997, ANN INTERN MED, V127, P895, DOI 10.7326/0003-4819-127-10-199711150-00007; Rex DK, 1997, GASTROENTEROLOGY, V112, P24, DOI 10.1016/S0016-5085(97)70214-2; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; WAGENER DK, 1995, ENVIRON HEALTH PERSP, V103, P75, DOI 10.2307/3432564; Welch HG, 1996, ANN INTERN MED, V124, P577, DOI 10.7326/0003-4819-124-6-199603150-00007; Welch HG, 1997, J GEN INTERN MED, V12, P118, DOI 10.1046/j.1525-1497.1997.00017.x	27	42	42	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1525	1527		10.1001/jama.280.17.1525	http://dx.doi.org/10.1001/jama.280.17.1525			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809734				2022-12-28	WOS:000076757200027
J	Woodall, J				Woodall, J			Medical aid and human rights in Kosovo	LANCET			English	Editorial Material									Harvard Med Sch, Boston, MA 02124 USA	Harvard University; Harvard Medical School	Woodall, J (corresponding author), Harvard Med Sch, 60 Ocean St, Boston, MA 02124 USA.								0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1467	1467		10.1016/S0140-6736(98)09404-5	http://dx.doi.org/10.1016/S0140-6736(98)09404-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9808010				2022-12-28	WOS:000076719500043
J	Tong, JK; Hassig, CA; Schnitzler, GR; Kingston, RE; Schreiber, SL				Tong, JK; Hassig, CA; Schnitzler, GR; Kingston, RE; Schreiber, SL			Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex	NATURE			English	Article							MI-2 AUTOANTIGEN; TRANSCRIPTION; PROTEINS	The dynamic assembly and remodelling of eukaryotic chromosomes facilitate fundamental cellular processes such as DNA replication and gene transcription. The repeating unit of eukaryotic chromosomes is the nucleosome fore, consisting of DNA wound about a defined octamer of histone proteins(1). Two enzymatic processes that regulate transcription by targeting elements of the nucleosome include ATP-dependent nucleosome remodelling and reversible histone acetylation(2,3). The histone deacetylases, however, are unable to deacetylate oligonucleosomal histones in vitro(4). The protein complexes that mediate ATP-dependent nucleosome remodelling and histone acetylation/deacetylation in the regulation of transcription were considered to be different, although it has recently been suggested that these activities might be coupled(5). We report here the identification and functional characterization of a novel ATP-dependent nucleosome remodelling activity that is part of an endogenous human histone deacetylase complex This activity is derived from the CHD3 and CHD4 proteins which contain helicase/ATPase domains found in SWI2-related chromatin remodelling factors, and facilitates the deacetylation of oligonucleosomal histones in vitro. We refer to this complex as the nucleosome remodelling and deacetylating (NRD) complex. Our results establish a physical and functional link between the distinct chromatin-modifying activities of histone deacetylases and nucleosome remodelling proteins.	Harvard Univ, Howard Hughes Med Inst, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital	Schreiber, SL (corresponding author), Harvard Univ, Howard Hughes Med Inst, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.							Cote J, 1995, METH MOL G, P108, DOI [10.1016/S1067-2389(06)80009-9, DOI 10.1016/S1067-2389(06)80009-9]; DeRubertis F, 1996, NATURE, V384, P589; ELGIN SCR, 1995, CHROMATIN STRUCTURE; GE Q, 1995, J CLIN INVEST, V96, P1730, DOI 10.1172/JCI118218; Hartzog GA, 1997, CURR OPIN GENET DEV, V7, P192, DOI 10.1016/S0959-437X(97)80128-1; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; Tavladoraki P, 1998, FEBS LETT, V426, P62, DOI 10.1016/S0014-5793(98)00311-1; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472	14	535	557	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1998	395	6705					917	921		10.1038/27699	http://dx.doi.org/10.1038/27699			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804427				2022-12-28	WOS:000076713400061
J	Shine, KI				Shine, KI			Encouraging clinical research by physician scientists	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Natl Acad Sci, Inst Med, Washington, DC 20418 USA	National Academies of Sciences, Engineering & Medicine	Shine, KI (corresponding author), Natl Acad Sci, Inst Med, 2101 Constitut Ave NW, Washington, DC 20418 USA.							Nathan DG, 1998, JAMA-J AM MED ASSOC, V280, P1427, DOI 10.1001/jama.280.16.1427; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303; [No title captured]	3	25	25	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	1998	280	16					1442	1444		10.1001/jama.280.16.1442	http://dx.doi.org/10.1001/jama.280.16.1442			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130YA	9801007				2022-12-28	WOS:000076546900042
J	O'Neill, D				O'Neill, D			Benzodiazepines and driver safety	LANCET			English	Editorial Material							VEHICLE		Adelaide & Meath Hosp, Ctr Mobil Enhancement, Dublin 24, Ireland	Trinity College Dublin	O'Neill, D (corresponding author), Adelaide & Meath Hosp, Ctr Mobil Enhancement, Dublin 24, Ireland.		O'Neill, Desmond/D-1486-2013	O'Neill, Desmond/0000-0002-5542-9897				Coren S, 1996, NEW ENGL J MED, V334, P924, DOI 10.1056/NEJM199604043341416; Evans L., 1991, TRAFFIC SAFETY DRIVE; Hemmelgarn B, 1997, JAMA-J AM MED ASSOC, V278, P27, DOI 10.1001/jama.278.1.27; RANNEY TA, 1994, ACCIDENT ANAL PREV, V26, P733, DOI 10.1016/0001-4575(94)90051-5; RAY WA, 1992, J CLIN PSYCHOPHARM, V12, P386; Redelmeier DA, 1997, NEW ENGL J MED, V336, P453, DOI 10.1056/NEJM199702133360701; SACKS J, 1994, PREV MED, V23, P27	7	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 24	1998	352	9137					1324	1325		10.1016/S0140-6736(98)00045-2	http://dx.doi.org/10.1016/S0140-6736(98)00045-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802262				2022-12-28	WOS:000076691700002
J	Black, JA				Black, JA			A consultant's view	LANCET			English	Editorial Material											Black, JA (corresponding author), Victoria Mill House,Victoria Mill Rd, Woodbridge IP13 9EG, Suffolk, England.								0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					50	51		10.1016/S0140-6736(98)02466-0	http://dx.doi.org/10.1016/S0140-6736(98)02466-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800763				2022-12-28	WOS:000074608600046
J	Knight, JC; Broeng, J; Birks, TA; Russel, PSJ				Knight, JC; Broeng, J; Birks, TA; Russel, PSJ			Photonic band cap guidance in optical fibers	SCIENCE			English	Article							GAP STRUCTURES	A fundamentally different type of optical waveguide structure is demonstrated, in which light is confined to the vicinity of a Low-index region by a two-dimensional photonic band gap crystal, The waveguide consists of an extra air hole in an otherwise regular honeycomb pattern of holes running down the length of a fine silica glass fiber. Optical fibers based on this waveguide mechanism support guided modes with extraordinary properties.	Univ Bath, Dept Phys, Optoelect Grp, Bath BA2 7AY, Avon, England	University of Bath	Knight, JC (corresponding author), Univ Bath, Dept Phys, Optoelect Grp, Claverton Down, Bath BA2 7AY, Avon, England.		Birks, Tim A/GNW-3099-2022; Knight, Jonathan C/D-3879-2011; Russell, Philip St.J./G-5132-2012	Knight, Jonathan C/0000-0002-0802-8804; Russell, Philip St.J./0000-0002-8972-2477; Broeng, Jes/0000-0003-1018-2779				Birks TA, 1997, OPT LETT, V22, P961, DOI 10.1364/OL.22.000961; BIRKS TA, 1995, ELECTRON LETT, V31, P1941, DOI 10.1049/el:19951306; Broeng J, 1998, OPT COMMUN, V156, P240, DOI 10.1016/S0030-4018(98)00470-2; Cassagne D, 1996, PHYS REV B, V53, P7134, DOI 10.1103/PhysRevB.53.7134; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS MO; Knight JC, 1998, ELECTRON LETT, V34, P1347, DOI 10.1049/el:19980965; Knight JC, 1998, J OPT SOC AM A, V15, P748, DOI 10.1364/JOSAA.15.000748; Knight JC, 1996, OPT LETT, V21, P1547, DOI 10.1364/OL.21.001547; Russell PSTJ, 1996, NATO ADV SCI I E-APP, V324, P203; TONUCCI RJ, 1992, SCIENCE, V258, P783, DOI 10.1126/science.258.5083.783; YABLONOVITCH E, 1993, J OPT SOC AM B, V10, P283, DOI 10.1364/JOSAB.10.000283	11	1132	1234	13	241	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1476	1478		10.1126/science.282.5393.1476	http://dx.doi.org/10.1126/science.282.5393.1476			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822375				2022-12-28	WOS:000077110800050
J	Lemon, KP; Grossman, AD				Lemon, KP; Grossman, AD			Localization of bacterial DNA polymerase: Evidence for a factory model of replication	SCIENCE			English	Article							GREEN FLUORESCENT PROTEIN; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; GENE-EXPRESSION; BIPOLAR LOCALIZATION; SPORULATION; CHROMOSOME; IMMUNOFLUORESCENCE; VISUALIZATION; ORGANIZATION	Two general models have been proposed for DNA replication. In one model, DNA polymerase moves along the DNA (Like a train on a track); in the other model, the polymerase is stationary (Like a factory), and DNA is pulled through. To distinguish between these models, we visualized DNA polymerase of the bacterium Bacillus subtilis in living cells by the creation of a fusion protein containing the catalytic subunit (PolC) and green fluorescent protein (GFP). PolC-GFP was Localized at discrete intracellular positions, predominantly at or near midcell, rather than being distributed randomly. These results suggest that the polymerase is anchored in place and thus support the model in which the DNA template moves through the polymerase.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Grossman, AD (corresponding author), MIT, Dept Biol, Bldg 68-530, Cambridge, MA 02139 USA.		Lemon, Katherine P/AGS-8572-2022		NIGMS NIH HHS [GM41934] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041934] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BENSON AK, 1993, J BACTERIOL, V175, P2347, DOI 10.1128/JB.175.8.2347-2356.1993; Boye E, 1996, P NATL ACAD SCI USA, V93, P12206, DOI 10.1073/pnas.93.22.12206; Britton RA, 1998, GENE DEV, V12, P1254, DOI 10.1101/gad.12.9.1254; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Glaser P, 1997, GENE DEV, V11, P1160, DOI 10.1101/gad.11.9.1160; Gordon GS, 1997, CELL, V90, P1113, DOI 10.1016/S0092-8674(00)80377-3; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; HELMSTETTER CE, 1996, CELLULAR MOL BIOL, V2, P1627; HENNER DJ, 1990, METHOD ENZYMOL, V185, P223; Hiraga S, 1998, MOL CELL, V1, P381, DOI 10.1016/S1097-2765(00)80038-6; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KORNBERG A, 1992, DNA REPLICATOIN; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lewis PJ, 1997, MOL MICROBIOL, V25, P945, DOI 10.1111/j.1365-2958.1997.mmi530.x; Lin DCH, 1998, CELL, V92, P675, DOI 10.1016/S0092-8674(00)81135-6; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; Newport J, 1996, CURR OPIN CELL BIOL, V8, P365, DOI 10.1016/S0955-0674(96)80011-1; Niki H, 1998, GENE DEV, V12, P1036, DOI 10.1101/gad.12.7.1036; OGASAWARA N, 1985, EMBO J, V4, P3345, DOI 10.1002/j.1460-2075.1985.tb04087.x; POGLIANO K, 1995, MOL MICROBIOL, V18, P459, DOI 10.1111/j.1365-2958.1995.mmi_18030459.x; SLATER S, 1995, CELL, V82, P927, DOI 10.1016/0092-8674(95)90272-4; Trun NJ, 1998, ASM NEWS, V64, P276; VASANTHA N, 1980, J BACTERIOL, V144, P1119, DOI 10.1128/JB.144.3.1119-1125.1980; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; WEBB CD, 1995, J BACTERIOL, V177, P5906, DOI 10.1128/jb.177.20.5906-5911.1995; Webb CD, 1998, MOL MICROBIOL, V28, P883, DOI 10.1046/j.1365-2958.1998.00808.x; YANSURA DG, 1984, P NATL ACAD SCI-BIOL, V81, P439, DOI 10.1073/pnas.81.2.439; Yoshiakwa H., 1993, P507	30	417	428	3	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1516	1519		10.1126/science.282.5393.1516	http://dx.doi.org/10.1126/science.282.5393.1516			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822387				2022-12-28	WOS:000077110800062
J	Nair, KV				Nair, KV			A memorable interview - Saved by the chaplain	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1384	1384		10.1136/bmj.317.7169.1384	http://dx.doi.org/10.1136/bmj.317.7169.1384			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812945	Green Published			2022-12-28	WOS:000077081600033
J	Guadagno, TM; Ferrell, JE				Guadagno, TM; Ferrell, JE			Requirement for MAPK activation for normal mitotic progression in Xenopus egg extracts	SCIENCE			English	Article							SPINDLE ASSEMBLY CHECKPOINT; CELL-CYCLE EXTRACTS; PROTEIN-KINASE; DNA-REPLICATION; IN-VITRO; MOS; OOCYTES; VIVO	The p42 mitogen-activated protein kinase (MAPK) is required for progression through meiotic M phase in Xenopus oocytes. This report examines whether it also plays a role in normal mitotic progression. MAPK was transiently activated during mitosis in cycling Xenopus egg extracts after activation of the cyclin-dependent kinase Cdc2-cyclin B. Interference with MAPK activation by immunodepletion of its activator MEK, or by addition of the MEK inhibitor PD98059, caused precocious termination of mitosis and interfered with production of normal mitotic microtubules. Sustained activation of MAPK arrested extracts in mitosis in the absence of active Cdc2-cyclin B. These findings identify a role for MEK and MAPK in maintaining the mitotic state.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Ferrell, JE (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.				NIGMS NIH HHS [GM46383] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bitangcol JC, 1998, MOL BIOL CELL, V9, P451, DOI 10.1091/mbc.9.2.451; Chiri S, 1998, J CELL SCI, V111, P2519; Cross DAE, 1998, EXP CELL RES, V241, P12, DOI 10.1006/excr.1998.4023; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GUADAGNO TM, UNPUB; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Murakami MS, 1998, DEVELOPMENT, V125, P237; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Philipova R, 1998, J CELL SCI, V111, P2497; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Verlhac MH, 1996, DEVELOPMENT, V122, P815; Walter SA, 1997, MOL BIOL CELL, V8, P2157, DOI 10.1091/mbc.8.11.2157; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	29	82	82	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1312	1315		10.1126/science.282.5392.1312	http://dx.doi.org/10.1126/science.282.5392.1312			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812894				2022-12-28	WOS:000076982200043
J	Swinscow, D; Smith, T				Swinscow, D; Smith, T			Martin Ware - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1323	1323		10.1136/bmj.317.7168.1323	http://dx.doi.org/10.1136/bmj.317.7168.1323			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804739	Green Published			2022-12-28	WOS:000076963800055
J	Price, DL; Sisodia, SS; Borchelt, DR				Price, DL; Sisodia, SS; Borchelt, DR			Genetic neurodegenerative diseases: The human illness and transgenic models	SCIENCE			English	Review							AMYOTROPHIC-LATERAL-SCLEROSIS; AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; PAIRED HELICAL FILAMENTS; MOTOR-NEURON DISEASE; CU,ZN SUPEROXIDE-DISMUTASE; CARBOXYL-TERMINAL FRAGMENT; BETA-PEPTIDE DEPOSITION; APOPTOTIC CELL-DEATH; APOLIPOPROTEIN-E	The neurodegenerative disorders, a heterogeneous group of chronic progressive diseases, are among the most puzzling and devastating illnesses in medicine. Some of these disorders, such as Alzheimer's disease, amyotrophic lateral sclerosis, the prion diseases, and Parkinson's disease, can occur sporadically and, in some instances, are caused by inheritance of gene mutations. Huntington's disease is acquired in an entirely genetic manner. Transgenic mice that express disease-causing genes recapitulate many features of these diseases. This review provides an overview of transgenic mouse models of familiar amyotrophic lateral sclerosis, familiar Alzheimer's disease, and Huntington's disease and the emerging insights relevant to the underlying molecular mechanisms of these diseases.	Johns Hopkins Univ, Sch Med, Div Neuropathol, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Neuropathol Lab, Baltimore, MD 21205 USA; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Chicago	Price, DL (corresponding author), Johns Hopkins Univ, Sch Med, Div Neuropathol, Dept Pathol, 558 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	dlprice@welchlink.welch.jhu.edu			NINDS NIH HHS [NS 20471, NS 10580, NS 37145] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037145, P50NS020471, P01NS020471] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BLACKER D, IN PRESS NATURE GENE; Borchelt DR, 1998, NEUROBIOL DIS, V5, P27, DOI 10.1006/nbdi.1998.0178; BORCHELT DR, 1995, J BIOL CHEM, V270, P3234, DOI 10.1074/jbc.270.7.3234; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BRAAK H, 1994, NEURODEGENER DIS, P585; Brown RH, 1997, ARCH NEUROL-CHICAGO, V54, P1246, DOI 10.1001/archneur.1997.00550220050013; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; BUXBAUM JD, 1993, BIOCHEM BIOPH RES CO, V197, P639, DOI 10.1006/bbrc.1993.2527; CARPENTER S, 1968, NEUROLOGY, V18, P841, DOI 10.1212/WNL.18.9.841; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DALCANTO MC, 1994, AM J PATHOL, V145, P1271; DalCanto MC, 1997, ACTA NEUROPATHOL, V93, P537; Delacourte A, 1998, ANN NEUROL, V43, P193, DOI 10.1002/ana.410430209; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Dickson DW, 1997, ANN NEUROL, V42, P541, DOI 10.1002/ana.410420403; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Eyer J, 1998, NATURE, V391, P584, DOI 10.1038/35378; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; Feany MB, 1996, ANN NEUROL, V40, P139, DOI 10.1002/ana.410400204; Francis Paul T., 1994, P247; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Geula Changiz, 1994, P263; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GomezIsla T, 1996, ANN NEUROL, V39, P62, DOI 10.1002/ana.410390110; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; GUMEY ME, 1994, SCIENCE, V264, P1772; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HIGGINS LS, 1994, ANN NEUROL, V35, P598, DOI 10.1002/ana.410350514; Hirano A, 1996, NEUROLOGY, V47, pS63, DOI 10.1212/WNL.47.4_Suppl_2.63S; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hottinger AF, 1997, EUR J NEUROSCI, V9, P1548, DOI 10.1111/j.1460-9568.1997.tb01511.x; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; IKEUCHI T, 1995, ANN NEUROL, V37, P769, DOI 10.1002/ana.410370610; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Junck L, 1996, NEUROLOGY, V46, P4, DOI 10.1212/WNL.46.1.4; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Koshy BT, 1997, BRAIN PATHOL, V7, P927, DOI 10.1111/j.1750-3639.1997.tb00894.x; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; Lamb BT, 1997, HUM MOL GENET, V6, P1535, DOI 10.1093/hmg/6.9.1535; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; Mann DMA, 1997, ANN NEUROL, V41, P52, DOI 10.1002/ana.410410110; MASLIAH E, 1992, J NEUROPATH EXP NEUR, V51, P404, DOI 10.1097/00005072-199207000-00003; Masliah E, 1996, J NEUROSCI, V16, P5795; MASLIAH E, 1998, NEUROSCI NEWS, V1, P14; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mayeux R, 1998, NEW ENGL J MED, V338, P506, DOI 10.1056/NEJM199802193380804; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORAN PM, 1995, P NATL ACAD SCI USA, V92, P5341, DOI 10.1073/pnas.92.12.5341; Morrison BM, 1996, J COMP NEUROL, V373, P619, DOI 10.1002/(SICI)1096-9861(19960930)373:4<619::AID-CNE9>3.0.CO;2-4; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; NEVE RL, 1992, P NATL ACAD SCI USA, V89, P3448, DOI 10.1073/pnas.89.8.3448; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; PRICE DL, IN PRESS ANN REV GEN; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; Robitaille Y, 1997, BRAIN PATHOL, V7, P901, DOI 10.1111/j.1750-3639.1997.tb00893.x; ROHER A, 1986, P NATL ACAD SCI USA, V83, P2662, DOI 10.1073/pnas.83.8.2662; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; ROWLAND LP, 1994, NEURODEGENER DIS, P507; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Sharp AH, 1996, NEUROBIOL DIS, V3, P3, DOI 10.1006/nbdi.1996.0002; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Sze CI, 1997, J NEUROPATH EXP NEUR, V56, P933, DOI 10.1097/00005072-199708000-00011; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; WEISGRABER KH, 1994, CURR OPIN STRUC BIOL, V4, P507, DOI 10.1016/S0959-440X(94)90212-7; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Young Anne B., 1994, P293	111	217	233	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 6	1998	282	5391					1079	1083		10.1126/science.282.5391.1079	http://dx.doi.org/10.1126/science.282.5391.1079			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804539				2022-12-28	WOS:000076887700039
J	Griffith, MJ; Gammage, MD				Griffith, MJ; Gammage, MD			Radiofrequency ablation of macro re-entrant arrhythmias: cure or adjunctive therapy?	LANCET			English	Editorial Material							TYPE-1 ATRIAL-FLUTTER; CATHETER ABLATION; TACHYCARDIA; PATHWAY		Queen Elizabeth Hosp, Univ Hosp Birmingham NHS Trust, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Div Med Sci, Birmingham B15 2TH, W Midlands, England	University of Birmingham; University of Birmingham	Griffith, MJ (corresponding author), Queen Elizabeth Hosp, Univ Hosp Birmingham NHS Trust, Birmingham B15 2TH, W Midlands, England.							BORGGREFE M, 1987, J AM COLL CARDIOL, V10, P576, DOI 10.1016/S0735-1097(87)80200-0; Brignole M, 1997, CIRCULATION, V96, P2617, DOI 10.1161/01.CIR.96.8.2617; Cauchemez B, 1996, CIRCULATION, V93, P284, DOI 10.1161/01.CIR.93.2.284; FELD GK, 1992, CIRCULATION, V86, P1233, DOI 10.1161/01.CIR.86.4.1233; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; HAISSAGUERRE M, 1992, CIRCULATION, V85, P1262; JACKMAN WM, 1991, NEW ENGL J MED, V324, P1605, DOI 10.1056/NEJM199106063242301; JACKMAN WM, 1992, NEW ENGL J MED, V327, P313, DOI 10.1056/NEJM199207303270504; LESH MD, 1994, CIRCULATION, V89, P1074, DOI 10.1161/01.CIR.89.3.1074; Marshall HJ, 1998, HEART, V79, P543, DOI 10.1136/hrt.79.6.543; MORADY F, 1993, CIRCULATION, V87, P363, DOI 10.1161/01.CIR.87.2.363; Paydak H, 1998, CIRCULATION, V98, P315, DOI 10.1161/01.CIR.98.4.315; POTY H, 1995, CIRCULATION, V92, P1389; Stevenson WG, 1998, CIRCULATION, V98, P308, DOI 10.1161/01.CIR.98.4.308	14	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1404	1405		10.1016/S0140-6736(05)61259-7	http://dx.doi.org/10.1016/S0140-6736(05)61259-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9807984				2022-12-28	WOS:000076719500004
J	Henderson, RA; Pocock, SJ; Sharp, SJ; Nanchahal, K; Sculpher, MJ; Buxton, MJ; Hampton, JR				Henderson, RA; Pocock, SJ; Sharp, SJ; Nanchahal, K; Sculpher, MJ; Buxton, MJ; Hampton, JR		Randomised Intervention Treatment Angina RITA	Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting	LANCET			English	Article							RANDOMIZED INTERVENTION TREATMENT; INTERNAL MAMMARY ARTERY; QUALITY-OF-LIFE; BALLOON ANGIOPLASTY; FOLLOW-UP; SURGERY; DISEASE; ANGINA; REVASCULARIZATION	Background Percutaneous transluminal coronary angioplasty (PTCA) and coronary-artery bypass grafting (CABG) are both effective intervention strategies for patients with coronary heart disease. We report comparative long-term clinical and health-service cost findings for these interventions in the first Randomised Intervention Treatment of Angina (RITA-1) trial. Methods 1011 patients with coronary heart disease (45% single-vessel, 55%;multivessel) were randomly assigned initial treatment strategies of PTCA or CABG. Information on clinical events, subsequent intervention, symptomatic status, exercise testing, and use of health-care resources is available for a median 6.5 years of follow-up. Analyses were by intention to treat. Findings The predefined primary endpoint of death or nonfatal myocardial infarction occurred in 87 (17%) PTCA-group patients and 80 (16%) CABG-group patients (p=0.64). Similarly, there was no significant treatment difference in deaths alone (39 PTCA, 45 CABG), of which 46% were cardiac related. In both groups, the risk of cardiac death or myocardial infarction was more than five times higher in the first year than in subsequent years of follow-up. 26% of patients assigned PTCA subsequently also had CABG, and a further 19% required additional non-randomised PTCA. Most of these reinterventions occurred within a year of randomisation, and from 3 years onwards the reintervention rate averaged 4% per year. In the CABG group the reintervention rate averaged 2% per year. The prevalence of angina was consistently higher in the PTCA group, with an absolute average 10% excess compared with the CABG group (p<0.001). Total health-service costs over 5 years showed no significant difference between initial strategies of PTCA and CABG (mean difference pound 426 [95% CI -pound 383 to pound 1235]; p=0.30). The clinical and cost comparisons showed similar patterns for patients with single-vessel and multivessel disease. Interpretation Initial strategies of PTCA and CABG led to similar long-term results in terms of survival and avoidance of myocardial infarction and to similar long-term healthcare costs. Choice of approach, therefore, rests on weighing the more invasive nature of CABG against the greater risk of recurrent angina and reintervention over many years after PTCA.	Univ Nottingham Hosp, Dept Cardiovasc Med, Nottingham NG7 2UH, England; London Sch Hyg & Trop Med, Med Stat Unit, London WC1, England; Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England	University of Nottingham; University of London; London School of Hygiene & Tropical Medicine; Brunel University	Henderson, RA (corresponding author), Univ Nottingham Hosp, Dept Cardiovasc Med, D Floor,South Block, Nottingham NG7 2UH, England.			Nanchahal, Kiran/0000-0001-8812-7628; Sculpher, Mark/0000-0003-3746-9913				Alderman E, 1997, CIRCULATION, V96, P1761, DOI 10.1161/01.CIR.96.6.1761; Alderman EL, 1997, JAMA-J AM MED ASSOC, V277, P715; Alderman EL, 1996, NEW ENGL J MED, V335, P217; Aronson D, 1996, J AM COLL CARDIOL, V27, P528, DOI 10.1016/0735-1097(95)00496-3; BERTRAND ME, 1995, 68 SCI SESS AN NOV 1; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Campeau L, 1997, NEW ENGL J MED, V336, P153; *CAN COORD OFF HLT, 1997, COR STENTS CLIN EXP; Carrie D, 1997, CIRCULATION, V96, P1; Detre KM, 1996, J AM COLL CARDIOL, V28, P609, DOI 10.1016/0735-1097(96)00216-1; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; FITZGIBBON GM, 1991, J AM COLL CARDIOL, V17, P1075, DOI 10.1016/0735-1097(91)90834-V; GOY JJ, 1994, LANCET, V343, P1449, DOI 10.1016/S0140-6736(94)92579-8; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; HENDERSON RA, 1989, BRIT HEART J, V62, P411; HENDERSON RA, 1995, QJM-INT J MED, V88, P167; Hlatky MA, 1997, NEW ENGL J MED, V336, P92, DOI 10.1056/NEJM199701093360203; *HM TREAS, 1991, EC APPR CENTR GOV TE; HUEB W, 1995, J AM COLL CARDIOL, V25, P1600; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; King SB, 1997, CIRCULATION, V96, P2121; KOSINSKI AS, 1995, CIRCULATION S1, V92, P543; LYTLE BW, 1985, J THORAC CARDIOV SUR, V89, P248; Macaya C, 1996, J AM COLL CARDIOL, V27, P255, DOI 10.1016/0735-1097(95)00473-4; *NHS EX, 1997, HLTH SERV COST IND; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; RICKARDS AF, 1995, LANCET, V346, P1179; Rodriguez A, 1996, J AM COLL CARDIOL, V27, P1178, DOI 10.1016/0735-1097(95)00592-7; SCULPHER MJ, 1994, LANCET, V344, P927, DOI 10.1016/S0140-6736(94)92274-8; Serruys PW, 1998, LANCET, V352, P673, DOI 10.1016/S0140-6736(97)11128-X; SHEFFIELD LT, 1972, EXERCISE TESTING TRA, P35; Topol EJ, 1997, JAMA-J AM MED ASSOC, V278, P479, DOI 10.1001/jama.278.6.479; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; WEINTRAUB WS, 1995, CIRCULATION, V92, P2831, DOI 10.1161/01.CIR.92.10.2831; WEINTRAUB WS, 1994, NEW ENGL J MED, V331, P1332	36	171	180	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1419	1425		10.1016/S0140-6736(98)03358-3	http://dx.doi.org/10.1016/S0140-6736(98)03358-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9807988				2022-12-28	WOS:000076719500008
J	Montelius, S; Maasho, K; Pratlong, F; Lebbad, M; Gregory, L; Akuffo, H				Montelius, S; Maasho, K; Pratlong, F; Lebbad, M; Gregory, L; Akuffo, H			Skin rash for 15 years	LANCET			English	Article							LEISHMANIASIS		Karolinska Inst, Microbiol & Tumour Biol Ctr, MTC, S-17177 Stockholm, Sweden; Malarsjukhuset Eskilstuna, Dept Infect Dis, Eskilstuna, Sweden; Karolinska Inst, Swedish Inst Infect Dis Control, S-17177 Stockholm, Sweden; Malarsjukhuset Eskilstuna, Dept Infect Dis, Eskilstuna, Sweden	Karolinska Institutet; Karolinska Institutet; Swedish Institute for Infectious Disease Control	Akuffo, H (corresponding author), Karolinska Inst, Microbiol & Tumour Biol Ctr, MTC, Box 280, S-17177 Stockholm, Sweden.		Lebbad, Marianne/AAF-5541-2020	Akuffo, Hannah/0000-0003-1854-3591				GRADONI L, 1995, B WORLD HEALTH ORGAN, V73, P191; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; JIMENEZ M, 1995, FEMS MICROBIOL LETT, V131, P197, DOI 10.1016/0378-1097(95)00259-8; RIOUX JA, 1990, ANN PARASIT HUM COMP, V65, P111, DOI 10.1051/parasite/1990653111	4	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1438	1438		10.1016/S0140-6736(98)06498-8	http://dx.doi.org/10.1016/S0140-6736(98)06498-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9807991				2022-12-28	WOS:000076719500011
J	Gralton, E; Wildgoose, J; Donovan, WM; Wilkie, J				Gralton, E; Wildgoose, J; Donovan, WM; Wilkie, J			Excentric exercise and neuroleptic malignant syndrome	LANCET			English	Article									Longdon Hosp, Butler Clin, Forens Psychiat Serv, Dawlish EX7 0NR, Devon, England		Wilkie, J (corresponding author), Longdon Hosp, Butler Clin, Forens Psychiat Serv, Dawlish EX7 0NR, Devon, England.							BUCKLEY PF, 1995, J NEUROL NEUROSUR PS, V58, P271, DOI 10.1136/jnnp.58.3.271; EBBELING CB, 1989, SPORTS MED, V7, P207, DOI 10.2165/00007256-198907040-00001; LISHMAN W, 1998, ORGANIC PSYCHIAT, P626; *SECR STAT HLTH, 1998, OUR HLTH NAT, P20; WILHELM K, 1994, AUST NZ J PSYCHIAT, V28, P453, DOI 10.3109/00048679409075873	5	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 3	1998	352	9134					1114	1114		10.1016/S0140-6736(98)08029-5	http://dx.doi.org/10.1016/S0140-6736(98)08029-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	125PP	9798588				2022-12-28	WOS:000076246400013
J	Kilmartin, DJ; Forrester, JV; Dick, AD				Kilmartin, DJ; Forrester, JV; Dick, AD			Rescue therapy with mycophenolate mofetil in refractory uveitis	LANCET			English	Article									Univ Aberdeen, Sch Med, Dept Ophthalmol, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Dick, AD (corresponding author), Univ Aberdeen, Sch Med, Dept Ophthalmol, Aberdeen AB25 2ZD, Scotland.			Dick, Andrew/0000-0002-0742-3159				BENEZRA D, 1992, UVEITIS SCORING SYST, P1; CHANAUD NP, 1995, EXP EYE RES, V61, P429, DOI 10.1016/S0014-4835(05)80138-1; Dick AD, 1997, BRIT J OPHTHALMOL, V81, P1107, DOI 10.1136/bjo.81.12.1107; Lipsky JJ, 1996, LANCET, V348, P1357, DOI 10.1016/S0140-6736(96)10310-X; SuttorpSchulten MSA, 1996, BRIT J OPHTHALMOL, V80, P844, DOI 10.1136/bjo.80.9.844	5	83	89	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					35	36		10.1016/S0140-6736(05)79515-5	http://dx.doi.org/10.1016/S0140-6736(05)79515-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800750				2022-12-28	WOS:000074608600021
J	Kandela, P				Kandela, P			Road-traffic accidents	LANCET			English	Editorial Material											Kandela, P (corresponding author), 29 Greenlands Rd, Staines TW18 4LR, Middx, England.							1912, LANCET          0720, P166; 1896, LANCET          1121, P1484; 1912, LANCET          0210, P396; 1913, LANCET          1025, P1227; 1902, LANCET          1213, P1641; 1866, LANCET          0407, P376; 1902, LANCET          0705, P46; 1896, LANCET          0425, P1143	8	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1483	1483		10.1016/S0140-6736(05)61321-9	http://dx.doi.org/10.1016/S0140-6736(05)61321-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9841274				2022-12-28	WOS:000076719500071
